<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000031.pub4" GROUP_ID="TOBACCO" ID="090499071913353636" MERGED_FROM="" MODIFIED="2016-06-15 09:46:24 +0100" MODIFIED_BY="Nicola Lindson-Hawley" REVIEW_NO="7" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="19.0">
<COVER_SHEET MODIFIED="2016-06-15 09:46:15 +0100" MODIFIED_BY="Nicola Lindson-Hawley">
<TITLE>Antidepressants for smoking cessation</TITLE>
<CONTACT MODIFIED="2016-06-15 09:46:15 +0100" MODIFIED_BY="Nicola Lindson-Hawley"><PERSON ID="19829" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><EMAIL_1>john.hughes@uvm.edu</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Psychiatry</DEPARTMENT><ORGANISATION>University of Vermont</ORGANISATION><ADDRESS_1>UHC Campus, OH3 Stop # 482</ADDRESS_1><ADDRESS_2>1 South Prospect Street</ADDRESS_2><CITY>Burlington</CITY><ZIP>05401</ZIP><REGION>Vermont</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 802 656 9610</PHONE_1><FAX_1>+1 802 847 1446</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-06-15 09:46:15 +0100" MODIFIED_BY="Nicola Lindson-Hawley"><PERSON ID="19829" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><EMAIL_1>john.hughes@uvm.edu</EMAIL_1><ADDRESS><DEPARTMENT>Dept of Psychiatry</DEPARTMENT><ORGANISATION>University of Vermont</ORGANISATION><ADDRESS_1>UHC Campus, OH3 Stop # 482</ADDRESS_1><ADDRESS_2>1 South Prospect Street</ADDRESS_2><CITY>Burlington</CITY><ZIP>05401</ZIP><REGION>Vermont</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 802 656 9610</PHONE_1><FAX_1>+1 802 847 1446</FAX_1></ADDRESS></PERSON><PERSON ID="8169" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Lindsay</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Stead</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>lindsay.stead@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="18610660923872414930120124130151" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Jamie</FIRST_NAME><LAST_NAME>Hartmann-Boyce</LAST_NAME><EMAIL_1>jamie.hartmann-boyce@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865289206</PHONE_1><FAX_1>01865289287</FAX_1></ADDRESS></PERSON><PERSON ID="11120" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Kate</FIRST_NAME><LAST_NAME>Cahill</LAST_NAME><POSITION>Cochrane Tobacco Addiction Group</POSITION><EMAIL_1>kate.cahill@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289284</PHONE_1><PHONE_2>+44 1865 377427</PHONE_2><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="7767" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tim</FIRST_NAME><LAST_NAME>Lancaster</LAST_NAME><POSITION>Co-ordinating Editor,  Cochrane Tobacco Addiction Group</POSITION><EMAIL_1>tim.lancaster@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289285</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-06-14 15:07:19 +0100" MODIFIED_BY="Nicola Lindson-Hawley" NOTES="&lt;p&gt;Minor update: 10/12/06&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 10/12/06&lt;/p&gt;&lt;p&gt;Conclusions changed: 10/12/06&lt;/p&gt;&lt;p&gt;Feedback added: 12/21/05&lt;/p&gt;&lt;p&gt;Response to feedback added: 12/21/05&lt;/p&gt;&lt;p&gt;Reformatted: 7/21/99&lt;/p&gt;" NOTES_MODIFIED="2016-06-14 15:07:19 +0100" NOTES_MODIFIED_BY="Nicola Lindson-Hawley">
<UP_TO_DATE>
<DATE DAY="4" MONTH="10" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="7" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2016-06-15 09:25:47 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-06-14 15:13:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>Corrected typographical error in Abstract results. Risk Ratio for buproprion + NRT (12 trials) changed from 1.9 to 1.19. Now matches meta-analysis 1.5</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-06-15 09:25:47 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-06-15 09:25:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Updated with 24 new included studies. Studies of S-Adenosyl-L-Methionine and St John's wort included for the first time. Meta-analyses of serious adverse events added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-06-15 09:25:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Conclusions largely unchanged. Efficacy findings unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-07-24 16:23:35 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="22" MONTH="6" YEAR="2011"/>
<DESCRIPTION>
<P>Additional table converted to appendix to correct pdf format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-06-22 10:02:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Correction to excluded studies table, detail for Carrão 2007</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-10-05 14:08:07 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="30" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Updated with 13 new included trials including 3 of selegiline, not previously covered. No substantial change to effects, main conclusions not altered</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-05 16:33:54 +0100" MODIFIED_BY="Lindsay Stead">
<DATE DAY="17" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-08-06 13:38:57 +0100" MODIFIED_BY="Kate Cahill">
<DATE DAY="11" MONTH="10" YEAR="2006"/>
<DESCRIPTION>
<P>Seventeen new trials were added to the review for issue 1, 2007. There were no major changes to the reviewers' conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-07-24 17:29:44 +0100" MODIFIED_BY="L S">
<DATE DAY="16" MONTH="7" YEAR="2004"/>
<DESCRIPTION>
<P>New trials of bupropion, nortriptyline and fluoxetine were added for issue 4, 2004, and additional information on adverse effects was included. There were no major changes to the reviewers' conclusions.</P>
<P>
<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-06-17 12:15:06 +0100" MODIFIED_BY="L S">
<DATE DAY="8" MONTH="1" YEAR="2003"/>
<DESCRIPTION>
<P>New trials of bupropion and nortriptyline were added to the review in Issue 2 2003. There were no major changes to the reviewers' conclusions</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-07-24 17:30:09 +0100" MODIFIED_BY="L S">
<DATE DAY="19" MONTH="9" YEAR="2001"/>
<DESCRIPTION>
<P>Four new studies on bupropion, and one each on nortriptyline and paroxetine were added to the review in Issue 1 2002. In press data from a trial of fluoxetine are included which differ from unpublished data previously used. The reviewers' conclusions about the efficacy of bupropion and nortriptyline were not changed substantively.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-07-24 17:30:35 +0100" MODIFIED_BY="L S">
<DATE DAY="28" MONTH="8" YEAR="2000"/>
<DESCRIPTION>
<P>Updates the earlier Cochrane review 'Anxiolytics and antidepressants for smoking cessation'. Anxiolytics are evaluated in a separate review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-11-26 15:04:31 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-11-26 15:04:31 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-11-26 15:04:02 +0000" MODIFIED_BY="[Empty name]">
<NAME>Department of Primary Health Care, Oxford University</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Editorial base for the Cochrane Tobacco Addiction Group</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2013-11-26 15:04:31 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research School for Primary Care Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Support for the Department of Primary Health Care, Oxford University</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Institute on Drug Abuse (NIDA)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Research and Development Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-06-14 15:11:05 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-12-04 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-08-12 11:07:51 +0100" MODIFIED_BY="[Empty name]">Do medications used to treat depression help smokers who are trying to quit</TITLE>
<SUMMARY_BODY MODIFIED="2013-12-04 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Background and review questions</B>
</P>
<P>Some medications and supplements that have been used to treat depression (antidepressants) have been tested to see whether they also help people who are trying to stop smoking. Two antidepressants, bupropion (Zyban) and nortriptyline, are sometimes prescribed to help with quitting smoking. This review set out to determine if using antidepressants increased people's likelihood of successfully quitting smoking at six months or longer and to determine the safety of using these medications to help quit smoking.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence is current to July 2013. This update includes 24 new studies, and this review includes 90 studies overall. The studies included people who smoked and people who had recently quit smoking. There were 65 trials of bupropion, which is licensed for use as a smoking cessation medication under the trade name 'Zyban'. There were ten trials of nortriptyline which is a tricyclic antidepressant which is not licensed specifically for smoking cessation. We only included studies which measured long term quitting (whether or not people had quit smoking at six months or longer from the start of the study).</P>
<P>
<B>Key results and quality of evidence</B>
</P>
<P>Trials of bupropion (Zyban) for smoking cessation show high quality evidence that it increases the likelihood of a quit attempt being successful after at least six months (44 trials, over 13,000 participants). The side effects of bupropion include insomnia, dry mouth and nausea and rarely (1:1000) seizures and perhaps psychiatric problems, but the last is unclear. There is also moderate quality evidence, limited by a relatively small number of included studies and participants, that the antidepressant nortriptyline increases quit rates (six trials, 975 participants). The side effects of this medication include dry mouth, constipation, nausea, and sedation, and it can be dangerous in overdose. Selective serotonin reuptake inhibitor antidepressants (for example, fluoxetine), monoamine oxidase inhibitor antidepressants (for example, selegiline), and the antidepressant venlaxafine have not been shown to help smoking cessation, nor has the herbal therapy St John's wort, or S-Adenosyl-L-Methionine (SAMe), a dietary supplement that is thought to have antidepressant properties.</P>
<P>
<B>Discussion and considerations</B>
</P>
<P>The way in which bupropion and nortriptyline might work is not fully understood. Both appear to help people quit smoking whether or not they have a history of depression, or have depressive symptoms when they stop smoking. The likelihood of quitting using bupropion or nortriptyline appears to be similar to that for nicotine replacement therapy, but the likelihood of quitting using bupropion appears to be lower than the likelihood of quitting using varenicline. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-06-14 15:11:05 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-11-26 15:47:12 +0000" MODIFIED_BY="Lindsay Stead">
<P>There are at least three reasons to believe antidepressants might help in smoking cessation. Firstly, nicotine withdrawal may produce depressive symptoms or precipitate a major depressive episode and antidepressants may relieve these. Secondly, nicotine may have antidepressant effects that maintain smoking, and antidepressants may substitute for this effect. Finally, some antidepressants may have a specific effect on neural pathways (e.g. inhibiting monoamine oxidase) or receptors (e.g. blockade of nicotinic-cholinergic receptors) underlying nicotine addiction.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-12-03 16:55:50 +0000" MODIFIED_BY="Lindsay Stead">
<P>The aim of this review is to assess the effect and safety of antidepressant medications to aid long-term smoking cessation. The medications include bupropion; doxepin; fluoxetine; imipramine; lazabemide; moclobemide; nortriptyline; paroxetine; S-Adenosyl-L-Methionine (SAMe); selegiline; sertraline; St. John's wort; tryptophan; venlafaxine; and zimeledine.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-11-26 15:47:51 +0000" MODIFIED_BY="Monaz Mehta">
<P>We searched the Cochrane Tobacco Addiction Group Specialised Register which includes reports of trials indexed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and PsycINFO, and other reviews and meeting abstracts, in July 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-10-17 12:31:37 +0100" MODIFIED_BY="[Empty name]">
<P>We considered randomized trials comparing antidepressant medications to placebo or an alternative pharmacotherapy for smoking cessation. We also included trials comparing different doses, using pharmacotherapy to prevent relapse or re-initiate smoking cessation or to help smokers reduce cigarette consumption. We excluded trials with less than six months follow-up.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-11-26 15:48:16 +0000" MODIFIED_BY="Lindsay Stead">
<P>We extracted data and assessed risk of bias using standard methodological procedures expected by the Cochrane Collaboration.</P>
<P>The main outcome measure was abstinence from smoking after at least six months follow-up in patients smoking at baseline, expressed as a risk ratio (RR). We used the most rigorous definition of abstinence available in each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis using a fixed-effect model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-06-14 15:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-four new trials were identified since the 2009 update, bringing the total number of included trials to 90. There were 65 trials of bupropion and ten trials of nortriptyline, with the majority at low or unclear risk of bias. There was high quality evidence that, when used as the sole pharmacotherapy, bupropion significantly increased long-term cessation (44 trials, N = 13,728, risk ratio [RR] 1.62, 95% confidence interval [CI] 1.49 to 1.76). There was moderate quality evidence, limited by a relatively small number of trials and participants, that nortriptyline also significantly increased long-term cessation when used as the sole pharmacotherapy (six trials, N = 975, RR 2.03, 95% CI 1.48 to 2.78). There is insufficient evidence that adding bupropion (12 trials, N = 3487, RR 1.19, 95% CI 0.94 to 1.51) or nortriptyline (4 trials, N = 1644, RR 1.21, 95% CI 0.94 to 1.55) to nicotine replacement therapy (NRT) provides an additional long-term benefit. Based on a limited amount of data from direct comparisons, bupropion and nortriptyline appear to be equally effective and of similar efficacy to NRT (bupropion versus nortriptyline 3 trials, N = 417, RR 1.30, 95% CI 0.93 to 1.82; bupropion versus NRT 8 trials, N = 4096, RR 0.96, 95% CI 0.85 to 1.09; no direct comparisons between nortriptyline and NRT). Pooled results from four trials comparing bupropion to varenicline showed significantly lower quitting with bupropion than with varenicline (N = 1810, RR 0.68, 95% CI 0.56 to 0.83). Meta-analyses did not detect a significant increase in the rate of serious adverse events amongst participants taking bupropion, though the confidence interval only narrowly missed statistical significance (33 trials, N = 9631, RR 1.30, 95% CI 1.00 to 1.69). There is a risk of about 1 in 1000 of seizures associated with bupropion use. Bupropion has been associated with suicide risk, but whether this is causal is unclear. Nortriptyline has the potential for serious side-effects, but none have been seen in the few small trials for smoking cessation.</P>
<P>There was no evidence of a significant effect for selective serotonin reuptake inhibitors on their own (RR 0.93, 95% CI 0.71 to 1.22, N = 1594; 2 trials fluoxetine, 1 paroxetine, 1 sertraline) or as an adjunct to NRT (3 trials of fluoxetine, N = 466, RR 0.70, 95% CI 0.64 to 1.82). Significant effects were also not detected for monoamine oxidase inhibitors (RR 1.29, 95% CI 0.93 to 1.79, N = 827; 1 trial moclobemide, 5 selegiline), the atypical antidepressant venlafaxine (1 trial, N = 147, RR 1.22, 95% CI 0.64 to 2.32), the herbal therapy St John's wort (hypericum) (2 trials, N = 261, RR 0.81, 95% CI 0.26 to 2.53), or the dietary supplement SAMe (1 trial, N = 120, RR 0.70, 95% CI 0.24 to 2.07).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-11-26 15:56:14 +0000" MODIFIED_BY="Lindsay Stead">
<P>The antidepressants bupropion and nortriptyline aid long-term smoking cessation. Adverse events with either medication appear to rarely be serious or lead to stopping medication. Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement. Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding. Evidence suggests that neither selective serotonin reuptake inhibitors (e.g. fluoxetine) nor monoamine oxidase inhibitors aid cessation.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-04 10:16:18 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-12-03 17:08:00 +0000" MODIFIED_BY="Lindsay Stead">
<P>Whilst nicotine replacement is the most widely used pharmacotherapy for smoking cessation, some people prefer a treatment that does not use nicotine. Others require alternative treatments having failed to quit with nicotine replacement. Observations that a history of depression is found more frequently amongst smokers than nonsmokers, that cessation may precipitate depression, that nicotine may have antidepressant effects, and that antidepressants influence the neurotransmitters and receptors involved in nicotine addiction provided a rationale for the study of antidepressant medications for smoking cessation (<LINK REF="REF-Benowitz-2000" TYPE="REFERENCE">Benowitz 2000</LINK>; <LINK REF="REF-Kotlyar-2001" TYPE="REFERENCE">Kotlyar 2001</LINK>).</P>
<INTERVENTION MODIFIED="2013-12-03 17:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>The following medications and substances regarded as having antidepressant properties have been investigated for their effect on smoking behaviour in at least one study:</P>
<UL>
<LI>the tricyclic antidepressants (TCAs) doxepin, imipramine and nortriptyline</LI>
<LI>the monoamine oxidase inhibitors (MAOI) moclobemide, selegiline, lazabemide, and EVT302</LI>
<LI>the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, paroxetine, sertraline, citalopram, and zimeledine</LI>
<LI>the atypical antidepressants bupropion, tryptophan, venlafaxine, imipramine, and doxepin</LI>
<LI>extracts of St. John's wort (<I>Hypericum perforatum</I> L.)</LI>
<LI>the dietary supplement S-Adenosyl-L-Methionine (SAMe)</LI>
</UL>
<P>Of the antidepressants tested for smoking cessation, the most commonly used medication is bupropion. This antidepressant has both dopaminergic and adrenergic actions, and appears to be an antagonist at the nicotinic acetylcholinergic receptor (<LINK REF="REF-Fryer-1999" TYPE="REFERENCE">Fryer 1999</LINK>). It may work by blocking nicotine effects, relieving withdrawal (<LINK REF="REF-Cryan-2003" TYPE="REFERENCE">Cryan 2003</LINK>; <LINK REF="REF-West-2008" TYPE="REFERENCE">West 2008</LINK>), or reducing depressed mood (<LINK REF="REF-Lerman-2002a" TYPE="REFERENCE">Lerman 2002a</LINK>). It has been licensed as a prescription aid to smoking cessation in many countries. The usual dose for smoking cessation is 150 mg once a day for three days increasing to 150 mg twice a day continued for 7 to 12 weeks, and the quit attempt is generally initiated a week after starting pharmacotherapy.</P>
<P>Following bupropion, the second most commonly tested medication for smoking cessation is the tricyclic antidepressant nortriptyline. Its presumed mechanism of action is increased noradrenergic activity. It is sometimes prescribed when first-line treatments have been unsuccessful, and is licensed for smoking cessation in New Zealand. The recommended regimen is 10 to 28 days of titration before the quit attempt, followed by a 12-week dose of 75 to 100 mg daily (<LINK REF="REF-Cahill-2013" TYPE="REFERENCE">Cahill 2013</LINK>).</P>
<P>No other antidepressants are currently licensed for use as smoking cessation aids, though others have been tested for possible use. It has been hypothesized that MOAIs may aid smoking cessation because they could substitute for the ability of smoking to act as a monoamine oxidase-A (MOA) inhibitor. Inhibiting MOA increases dopamine and noradrenaline and hence it has been hypothesized that it should decrease negative affect and make quitting smoking easier. It has been hypothesised that SSRIs might be helpful because they increase serotonin which is also associated with improving negative affect. Other antidepressants including doxepin, tryptophan, and venlafaxine, and alternative therapies for depression such as St. John's wort and SAMe, may help with smoking cessation through similar biological mechanisms. Whether antidepressants work mostly due to reducing negative affect, reducing urges to smoke or withdrawal symptoms, or by acting as nicotine blockers is unclear.</P>
<P>The focus of this review and meta-analysis is on trials that provide evidence for an effect of antidepressants on long-term smoking cessation. We describe these in the <LINK TAG="INTERVENTION_EFFECTS" TYPE="SECTION">Effects of interventions</LINK> section. For pharmacotherapies for which there is still a lack of long-term data, we briefly describe results from excluded short-term trials in the <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies </LINK>section.</P>
</INTERVENTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-11-26 16:01:56 +0000" MODIFIED_BY="Lindsay Stead">
<P>To assess the evidence for the efficacy and safety of medications with antidepressant properties in assisting long-term smoking cessation, including: bupropion; citalopram; doxepin; fluoxetine; imipramine; lazabemide; moclobemide; nortriptyline; paroxetine; tryptophan; SAMe; selegiline; sertraline; St John's wort; venlafaxine; and zimeledine.</P>
<P>For each medication identified as having been used in a smoking cessation trial we evaluated whether it was more effective than placebo or an alternative treatment in achieving long-term smoking cessation.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-04 10:16:18 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-03 17:08:19 +0000" MODIFIED_BY="Lindsay Stead">
<CRIT_STUDIES MODIFIED="2013-12-03 17:08:14 +0000" MODIFIED_BY="[Empty name]">
<P>For efficacy, we examined randomized trials comparing antidepressant with placebo or with an alternative therapeutic control, or comparing different dosages of an antidepressant, that reported six-month or longer follow-ups. For safety, we examined data from randomized controlled trials comparing antidepressant with placebo or no pharmacotherapy controls, and also considered observational data. Studies were included irrespective of their publication status and language of publication.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-03 17:08:19 +0000" MODIFIED_BY="[Empty name]">
<P>Current cigarette smokers, or recent quitters (for trials of relapse prevention).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-04 16:13:05 +0100" MODIFIED_BY="Lindsay Stead">
<P>Treatment with any medication with antidepressant properties to aid a smoking cessation attempt or to prevent relapse, or to reduce the number of cigarettes smoked and aid subsequent cessation. Trials in which all participants received the same pharmacotherapy regimen but different behavioural support were not included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-17 13:21:21 +0100" MODIFIED_BY="Lindsay Stead">
<P>Efficacy was measured via a) abstinence from smoking or b) incidence of reducing cigarette consumption to 50% or less of baseline, both assessed at follow-up at least six months from start of treatment. Safety was assessed by incidence of serious and other adverse events, and drop-outs due to adverse events.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-04 10:16:18 +0000" MODIFIED_BY="Lindsay Stead">
<P>We identified studies from the Cochrane Tobacco Addiction Group's Specialised Register. At the time of the updated search in July 2013, the Register included the results of searches of the Cochrane Central Register of Controlled trials (CENTRAL), issue 5, 2013; MEDLINE (via OVID) to update 20130607; EMBASE (via OVID) to week 201324; and PsycINFO (via OVID) to update 20130610. See the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/TOBACCO/frame.html">Tobacco Addiction Group Module</A> in the Cochrane Library for full search strategies and a list of other resources searched. We searched the Register for reports of studies evaluating bupropion, nortriptyline or any other pharmacotherapy generally classified as having an antidepressant effect. Search terms included relevant individual drug names or antidepressant* or antidepressive*. We checked the citation lists of these studies, recent reviews of non-nicotine pharmacotherapy, and abstracts from the meetings of the Society for Research on Nicotine and Tobacco. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the register search strategy.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-12-04 10:02:29 +0000" MODIFIED_BY="[Empty name]">
<P>One author (LS) conducted the searches, screened titles and abstracts for relevance, and obtained full text of reports of eligible or possibly eligible studies. For conference abstracts reporting potentially eligible studies, attempts were made to contact study investigators to obtain additional data. Papers that reported secondary analyses from eligible studies were listed as additional references under the main study identifier. Two authors (LS and TL or JHB) independently extracted study data and compared the findings. Any discrepancies were resolved by mutual consent. Where available, the following information is recorded in the <A HREF="http://archie.cochrane.org/sections/documents/view?document=621C1BB482E26AA2002F6AEA0D40E3C1&amp;format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES">Characteristics of included studies</A> table:</P>
<UL>
<LI>Type of antidepressant</LI>
<LI>Country and setting</LI>
<LI>Recruitment method</LI>
<LI>Definition of smoker used</LI>
<LI>Participant demographics (i.e. average age, gender, average cigarettes per day)</LI>
<LI>Intervention and control description (including dose, schedule, and behavioural support common to all arms)</LI>
<LI>Outcome(s) used in meta-analysis, including length of follow-up, definition of abstinence, and biochemical validation of smoking cessation</LI>
<LI>Sources of funding</LI>
</UL>
<QUALITY_ASSESSMENT MODIFIED="2013-12-03 17:09:51 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed included studies for risks of selection bias (method of random sequence generation and allocation concealment), performance and detection bias (the presence or absence of blinding), attrition bias (levels and reporting of loss to follow-up), and any other threats to study validity.</P>
<P>Studies were considered at high risk of performance and detection bias where there was no blinding of participants or personnel or where there was evidence of unblinding, at unclear risk if insufficient information was available with which to judge, and at low risk if the study reported blinding of participants and personnel in detail and there was no evidence of unblinding. Studies were considered to be at low risk of attrition bias where over half of the participants were followed up at the longest follow-up and where numbers followed up were similar across arms (difference &lt; 20%).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-12-04 10:02:07 +0000" MODIFIED_BY="[Empty name]">
<P>In each study, we used the strictest available criteria to define cessation, so we used the longest reported follow-up and extracted figures for sustained abstinence in preference to point prevalence where both were presented. In studies that used biochemical validation of cessation, only those subjects meeting the criteria for biochemically confirmed abstinence were regarded as having stopped smoking. As far as possible, we used an intention-to-treat analysis with people who dropped out or were lost to follow-up treated as continuing smokers. Where subjects appeared to have been randomized but were not included in the data presented by the author we noted this in the study description (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Assuming that people lost to follow-up were smokers will ensure that actual quit rates are conservative, but may not necessarily lead to conservative relative treatment effects (e.g. risk ratios) if loss to follow-up is higher in the control group than in the intervention group (<LINK REF="REF-Hall-2001" TYPE="REFERENCE">Hall 2001</LINK>). Some studies now use alternative methods to model effects of missing data (<LINK REF="REF-Hall-2001" TYPE="REFERENCE">Hall 2001</LINK>; <LINK REF="STD-Niaura-2002" TYPE="STUDY">Niaura 2002</LINK>). Where differential results using alternative models were reported we considered whether the results of the meta-analysis were sensitive to the use of different denominators. </P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-12-04 10:02:25 +0000" MODIFIED_BY="[Empty name]">
<P>To investigate statistical heterogeneity we use the I² statistic, given by the formula [(Q - df)/Q] x 100%, where Q is the Chi² statistic and df is its degrees of freedom (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). We used threshold values of 25% and 50% as suggesting moderate and substantial heterogeneity respectively. Although we give a summary statistic, the conclusions that can be drawn from it must be cautious. Where trials are small and few in number the confidence intervals will be wide.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-10-17 13:46:29 +0100" MODIFIED_BY="[Empty name]">
<P>The derivation of the summary statistic implicitly assumes that data from all randomized trials are available without any bias due to non-publication of unpromising results or to exclusion of randomized individuals. There is evidence that publication bias occurs in the field of smoking cessation research (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>), and this issue is discussed further in the Cochrane review of nicotine replacement therapy (NRT) (<LINK REF="REF-Stead-2012" TYPE="REFERENCE">Stead 2012</LINK>). Thus, we included unpublished studies or studies found only as abstracts where sufficient detail was available. We contacted authors for further data if necessary. Where sufficient data were available (ten or more studies in a comparison), we used funnel plots to investigate publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-12-04 10:02:29 +0000" MODIFIED_BY="[Empty name]">
<P>We summarized individual study results as a risk ratio (RR), calculated as: (number of quitters in intervention group/ number randomized to intervention group) / (number of quitters in control group/ number randomized to control group). A risk ratio greater than 1.0 indicates a higher rate of quitting in the treatment group than in the control group. For each type of medication where more than one eligible trial was identified, we performed meta-analysis using a Mantel-Haenszel fixed-effect method to estimate a pooled risk ratio with 95% confidence intervals (<LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>). Where studies contributed more than one intervention arm to a pooled analysis, we split the control arm to avoid double counting. We created summary of findings tables for the efficacy of bupropion and nortriptyline, using standard Cochrane methodology.</P>
<P>Throughout, when we discuss effect we are referring to risk ratios, and not to absolute quit rates.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-12-03 10:00:44 +0000" MODIFIED_BY="[Empty name]">
<P>We distinguished between trials testing an antidepressant as a single pharmacotherapy and those testing an antidepressant as an adjunct to NRT for initial cessation. We also distinguished between cessation trials and those where the intervention addressed relapse prevention or reduction in number of cigarettes smoked. For trials of bupropion, we have included subgroup analyses by length of follow-up, recruitment method (clinical/community), and level of behavioural support. For the subgroup analysis based on level of additional support, we used the same criteria applied in the Cochrane NRT review (<LINK REF="REF-Stead-2012" TYPE="REFERENCE">Stead 2012</LINK>); low intensity support was regarded as part of the provision of routine care, so the duration of time spent with the smoker (including assessment for the trial) had to be less than 30 minutes at the initial consultation, with no more than two further assessment and reinforcement visits.</P>
<P>Where reported, we also extracted data from analyses evaluating a potential interaction between current depression or past history of depression and quit rates. We relied upon the definition of depression used by study authors, which included both formal diagnoses and scores on validated depression scales.</P>
<P>None of the trials located were specifically designed to directly compare antidepressant pharmacotherapy with non-pharmacological therapies.</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Tables in the results section summarize the adverse events reported in clinical trials for smoking cessation for medications which have shown evidence of efficacy (bupropion and nortriptyline). These tables include all studies of bupropion and nortriptyline in which one arm received the pharmacotherapy and the other arm did not.</P>
<P>In addition, for this update we have created meta-analyses for serious adverse events (SAEs) for bupropion and nortriptyline. As per the definition provided by the U.S. Food and Drug Adminstration, SAEs were defined as any event that was life-threatening, resulted in hospitalization, death, disability, or permanent damage, or required intervention to prevent one of the above outcomes (<A HREF="http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm">FDA definition</A>). Studies had to meet three criteria to be included in SAE analyses:</P>
<UL>
<LI>the active treatment was compared to a placebo or no pharmacotherapy control;</LI>
<LI>neither arm received additional pharmacotherapy above the antidepressant being tested; and</LI>
<LI>SAEs were reported during or within 30 days of active drug treatment.</LI>
</UL>
<P>We differentiate between studies which stated that no SAEs occurred (included in the analyses) and those that did not report on SAEs, in which it is possible that no events occurred, but not explicitly made clear (excluded from analyses and recorded in AE tables). In addition to screening included studies, we also screened excluded studies of nortriptyline and bupropion where the reason for exclusion was short-term follow-up. Where these studies met the above three criteria, they were included in the SAE meta-analysis.</P>
<P>As with smoking cessation meta-analyses, we used number randomized as the denominator and calculated risk ratios for each comparison, calculated as (number of events in the treatment group/number randomized to the treatment group)/(number of events in the control group/number randomized to the control group). For nortriptyline and bupropion, we used any SAE as the outcome of interest. Due to concerns about specific adverse effects of bupropion, we also analysed psychiatric and cardiovascular SAEs separately for bupropion studies.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-04 10:03:20 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-12-04 10:02:44 +0000" MODIFIED_BY="[Empty name]">
<P>We identified twenty-four additional trials for this update, yielding a total of 90 included trials. The new trials were of bupropion (<LINK REF="STD-Cinciripini-2013" TYPE="STUDY">Cinciripini 2013</LINK>; <LINK REF="STD-Cox-2012" TYPE="STUDY">Cox 2012</LINK>; <LINK REF="STD-Eisenberg-2013" TYPE="STUDY">Eisenberg 2013</LINK>; <LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK>; <LINK REF="STD-Hall-2011" TYPE="STUDY">Hall 2011</LINK>; <LINK REF="STD-Hays-2009" TYPE="STUDY">Hays 2009</LINK>; <LINK REF="STD-Kalman-2011" TYPE="STUDY">Kalman 2011</LINK>; <LINK REF="STD-Levine-2010" TYPE="STUDY">Levine 2010</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Planer-2011" TYPE="STUDY">Planer 2011</LINK>; <LINK REF="STD-Rose-2013" TYPE="STUDY">Rose 2013</LINK>; <LINK REF="STD-Rovina-2009" TYPE="STUDY">Rovina 2009</LINK>; <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK> (previously in 'awaiting classification' as Schnoll 2005) <LINK REF="STD-Siddiqi-2013" TYPE="STUDY">Siddiqi 2013</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>), fluoxetine (<LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK>), nortriptyline (<LINK REF="STD-Richmond-2013" TYPE="STUDY">Richmond 2013</LINK>), SAMe (<LINK REF="STD-Sood-2012" TYPE="STUDY">Sood 2012</LINK>, not previously covered in this review), selegiline ( <LINK REF="STD-Kahn-2012" TYPE="STUDY">Kahn 2012</LINK>; <LINK REF="STD-Killen-2010" TYPE="STUDY">Killen 2010</LINK>), and St John's wort (<LINK REF="STD-Parsons-2009" TYPE="STUDY">Parsons 2009</LINK>; <LINK REF="STD-Sood-2010" TYPE="STUDY">Sood 2010</LINK>, not previously covered in this review). One study previously included based on unpublished data is now published (<LINK REF="STD-Weinberger-2010" TYPE="STUDY">Weinberger 2010</LINK>). There were sixty-six trials of bupropion, including seven testing the medication for relapse prevention (<LINK REF="STD-Covey-2007" TYPE="STUDY">Covey 2007</LINK>; <LINK REF="STD-Croghan-2007" TYPE="STUDY">Croghan 2007</LINK>; <LINK REF="STD-Hall-2011" TYPE="STUDY">Hall 2011</LINK>; <LINK REF="STD-Hays-2001" TYPE="STUDY">Hays 2001</LINK>; <LINK REF="STD-Hays-2009" TYPE="STUDY">Hays 2009</LINK>; <LINK REF="STD-Hurt-2003" TYPE="STUDY">Hurt 2003</LINK>; <LINK REF="STD-Killen-2006" TYPE="STUDY">Killen 2006</LINK>) and one for reduction (<LINK REF="STD-Hatsukami-2004" TYPE="STUDY">Hatsukami 2004</LINK>). Eight of the bupropion trials allowed a direct comparison with nicotine replacement therapy (<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK>; <LINK REF="STD-G_x00f3_recka-2003" TYPE="STUDY">Górecka 2003</LINK>; <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>; <LINK REF="STD-Uyar-2007" TYPE="STUDY">Uyar 2007</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>), and four a direct comparison with the nicotine receptor partial agonist varenicline (<LINK REF="STD-Cinciripini-2013" TYPE="STUDY">Cinciripini 2013</LINK>; <LINK REF="STD-Gonzales-2006" TYPE="STUDY">Gonzales 2006</LINK>; <LINK REF="STD-Jorenby-2006" TYPE="STUDY">Jorenby 2006</LINK>; <LINK REF="STD-Nides-2006" TYPE="STUDY">Nides 2006</LINK>). Ten trials used nortriptyline including three which also used bupropion (<LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>; <LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>). There were five trials of fluoxetine (<LINK REF="STD-Blondal-1999" TYPE="STUDY">Blondal 1999</LINK>; <LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK>; <LINK REF="STD-Niaura-2002" TYPE="STUDY">Niaura 2002</LINK>; <LINK REF="STD-Saules-2004" TYPE="STUDY">Saules 2004</LINK>; <LINK REF="STD-Spring-2007" TYPE="STUDY">Spring 2007</LINK>), five of selegiline (<LINK REF="STD-Biberman-2003" TYPE="STUDY">Biberman 2003</LINK>; <LINK REF="STD-George-2003" TYPE="STUDY">George 2003</LINK>; <LINK REF="STD-Kahn-2012" TYPE="STUDY">Kahn 2012</LINK>; <LINK REF="STD-Killen-2010" TYPE="STUDY">Killen 2010</LINK>; <LINK REF="STD-Weinberger-2010" TYPE="STUDY">Weinberger 2010</LINK>), two of St John's wort (<LINK REF="STD-Parsons-2009" TYPE="STUDY">Parsons 2009</LINK>; <LINK REF="STD-Sood-2010" TYPE="STUDY">Sood 2010</LINK>), one of paroxetine (<LINK REF="STD-Killen-2000" TYPE="STUDY">Killen 2000</LINK>), one of sertraline (<LINK REF="STD-Covey-2002" TYPE="STUDY">Covey 2002</LINK>), one of venlafaxine (<LINK REF="STD-Cinciripini-2005" TYPE="STUDY">Cinciripini 2005</LINK>), and one of SAMe (<LINK REF="STD-Sood-2012" TYPE="STUDY">Sood 2012</LINK>). One study included only patients with current depression (<LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK>). All other studies but two (<LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK>; <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>) excluded smokers with current depression but almost all included smokers with a past history of depression. Further details of the study designs are given in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
<P>We list 80 excluded studies. Most of these were short-term or laboratory-based studies. For medications where there is little or no evidence from long-term studies we briefly describe the results of the excluded short-term trials. The reasons for exclusion are given in the table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'. Two placebo-controlled trials studied the use of bupropion for smokeless tobacco cessation (<LINK REF="STD-Dale-2002" TYPE="STUDY">Dale 2002</LINK>; <LINK REF="STD-Glover-2002" TYPE="STUDY">Glover 2002</LINK>). These trials are excluded from the present review but are covered in the Cochrane review of interventions for smokeless tobacco cessation (<LINK REF="REF-Ebbert-2011" TYPE="REFERENCE">Ebbert 2011</LINK>). Papers reporting additional outcomes or subgroup analyses from included studies are listed as references under the study identifier. One further study is potentially relevant but did not have sufficient data to assess for inclusion at the time of publication (<LINK REF="STD-Rose-2013a" TYPE="STUDY">Rose 2013a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Bupropion</HEADING>
<P>Sixty-six studies of bupropion with long-term follow-up are included. Outcomes for four studies are based on conference abstracts or pharmaceutical company data (<LINK REF="STD-Ferry-1992" TYPE="STUDY">Ferry 1992</LINK>; <LINK REF="STD-Ferry-1994" TYPE="STUDY">Ferry 1994</LINK>; <LINK REF="STD-Selby-2003" TYPE="STUDY">Selby 2003</LINK>; <LINK REF="STD-SMK20001" TYPE="STUDY">SMK20001</LINK>).</P>
<P>The majority of trials were conducted in North America but studies are also included from Europe (<LINK REF="STD-Aubin-2004" TYPE="STUDY">Aubin 2004</LINK>; <LINK REF="STD-Dalsgar_x00f0_-2004" TYPE="STUDY">Dalsgarð 2004</LINK>; <LINK REF="STD-Fossati-2007" TYPE="STUDY">Fossati 2007</LINK>; <LINK REF="STD-G_x00f3_recka-2003" TYPE="STUDY">Górecka 2003</LINK>; <LINK REF="STD-Rovina-2009" TYPE="STUDY">Rovina 2009</LINK>; <LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>; <LINK REF="STD-Zellweger-2005" TYPE="STUDY">Zellweger 2005</LINK> ); Brazil (<LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>); Australia (<LINK REF="STD-Myles-2004" TYPE="STUDY">Myles 2004</LINK>); Israel (<LINK REF="STD-Planer-2011" TYPE="STUDY">Planer 2011</LINK>); New Zealand (<LINK REF="STD-Holt-2005" TYPE="STUDY">Holt 2005</LINK>); Pakistan (<LINK REF="STD-Siddiqi-2013" TYPE="STUDY">Siddiqi 2013</LINK>); Turkey (<LINK REF="STD-Uyar-2007" TYPE="STUDY">Uyar 2007</LINK>); and two multi-continent studies (<LINK REF="STD-Tonnesen-2003" TYPE="STUDY">Tonnesen 2003</LINK>; <LINK REF="STD-Tonstad-2003" TYPE="STUDY">Tonstad 2003</LINK>). Special populations recruited include smokers with the following conditions: chronic obstructive pulmonary disease (<LINK REF="STD-G_x00f3_recka-2003" TYPE="STUDY">Górecka 2003</LINK>; <LINK REF="STD-Tashkin-2001" TYPE="STUDY">Tashkin 2001</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>); schizophrenia (<LINK REF="STD-Evins-2001" TYPE="STUDY">Evins 2001</LINK>; <LINK REF="STD-Evins-2005" TYPE="STUDY">Evins 2005</LINK>; <LINK REF="STD-Evins-2007" TYPE="STUDY">Evins 2007</LINK>; <LINK REF="STD-George-2002" TYPE="STUDY">George 2002</LINK>; <LINK REF="STD-George-2008" TYPE="STUDY">George 2008</LINK>); post traumatic stress disorder (<LINK REF="STD-Hertzberg-2001" TYPE="STUDY">Hertzberg 2001</LINK>); cancer (<LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>); suspected tuberculosis (<LINK REF="STD-Siddiqi-2013" TYPE="STUDY">Siddiqi 2013</LINK>); alcoholism (<LINK REF="STD-Grant-2007" TYPE="STUDY">Grant 2007</LINK>; <LINK REF="STD-Hays-2009" TYPE="STUDY">Hays 2009</LINK>); and cardiovascular disease (<LINK REF="STD-Eisenberg-2013" TYPE="STUDY">Eisenberg 2013</LINK>; <LINK REF="STD-Planer-2011" TYPE="STUDY">Planer 2011</LINK>; <LINK REF="STD-Rigotti-2006" TYPE="STUDY">Rigotti 2006</LINK>; <LINK REF="STD-Tonstad-2003" TYPE="STUDY">Tonstad 2003</LINK>). Three of the studies in patients with cardiovascular disease, and one other, enrolled hospital inpatients (<LINK REF="STD-Eisenberg-2013" TYPE="STUDY">Eisenberg 2013</LINK>; <LINK REF="STD-Planer-2011" TYPE="STUDY">Planer 2011</LINK>; <LINK REF="STD-Rigotti-2006" TYPE="STUDY">Rigotti 2006;</LINK> <LINK REF="STD-Simon-2009" TYPE="STUDY">Simon 2009</LINK>). Other populations included adolescents (<LINK REF="STD-Killen-2004" TYPE="STUDY">Killen 2004</LINK>; <LINK REF="STD-Muramoto-2007" TYPE="STUDY">Muramoto 2007</LINK>); smokers awaiting surgery (<LINK REF="STD-Myles-2004" TYPE="STUDY">Myles 2004</LINK>); hospital staff (<LINK REF="STD-Dalsgar_x00f0_-2004" TYPE="STUDY">Dalsgarð 2004</LINK>); healthcare workers (<LINK REF="STD-Zellweger-2005" TYPE="STUDY">Zellweger 2005</LINK>); African-Americans (<LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK>; <LINK REF="STD-Cox-2012" TYPE="STUDY">Cox 2012</LINK>); and Maori (<LINK REF="STD-Holt-2005" TYPE="STUDY">Holt 2005</LINK>). Two studies recruited smokers who had previously failed to quit smoking using bupropion (<LINK REF="STD-Gonzales-2001" TYPE="STUDY">Gonzales 2001</LINK>; <LINK REF="STD-Selby-2003" TYPE="STUDY">Selby 2003</LINK>), and two included smokers who had just failed to quit using NRT (<LINK REF="STD-Hurt-2003" TYPE="STUDY">Hurt 2003</LINK>; <LINK REF="STD-Rose-2013" TYPE="STUDY">Rose 2013</LINK>).</P>
<P>More than half the bupropion studies followed participants for at least 12 months from the start of treatment or the target quit day. Twenty-six studies (40%) had only six months-follow-up (<LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK>; <LINK REF="STD-Aubin-2004" TYPE="STUDY">Aubin 2004</LINK>; <LINK REF="STD-Cinciripini-2013" TYPE="STUDY">Cinciripini 2013</LINK>; <LINK REF="STD-Collins-2004" TYPE="STUDY">Collins 2004</LINK>; <LINK REF="STD-Cox-2012" TYPE="STUDY">Cox 2012</LINK>; <LINK REF="STD-Dalsgar_x00f0_-2004" TYPE="STUDY">Dalsgarð 2004</LINK>; <LINK REF="STD-Evins-2001" TYPE="STUDY">Evins 2001</LINK>; <LINK REF="STD-Evins-2005" TYPE="STUDY">Evins 2005</LINK>; <LINK REF="STD-George-2002" TYPE="STUDY">George 2002</LINK>; <LINK REF="STD-George-2008" TYPE="STUDY">George 2008</LINK>; <LINK REF="STD-Grant-2007" TYPE="STUDY">Grant 2007</LINK>; <LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>; <LINK REF="STD-Hatsukami-2004" TYPE="STUDY">Hatsukami 2004</LINK>; <LINK REF="STD-Hertzberg-2001" TYPE="STUDY">Hertzberg 2001</LINK>; <LINK REF="STD-Kalman-2011" TYPE="STUDY">Kalman 2011</LINK>; <LINK REF="STD-Killen-2004" TYPE="STUDY">Killen 2004</LINK>; <LINK REF="STD-Muramoto-2007" TYPE="STUDY">Muramoto 2007</LINK>; <LINK REF="STD-Myles-2004" TYPE="STUDY">Myles 2004</LINK>; <LINK REF="STD-Rose-2013" TYPE="STUDY">Rose 2013</LINK>; <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>; <LINK REF="STD-Siddiqi-2013" TYPE="STUDY">Siddiqi 2013</LINK>; <LINK REF="STD-Simon-2009" TYPE="STUDY">Simon 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>; <LINK REF="STD-Uyar-2007" TYPE="STUDY">Uyar 2007</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>). The majority of studies reported an outcome of sustained abstinence. In 18 (28%) only point prevalence rates were given, or the definition of abstinence was unclear (<LINK REF="STD-Cox-2012" TYPE="STUDY">Cox 2012</LINK>; <LINK REF="STD-Evins-2005" TYPE="STUDY">Evins 2005</LINK>; <LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK>; <LINK REF="STD-George-2002" TYPE="STUDY">George 2002</LINK>; <LINK REF="STD-George-2008" TYPE="STUDY">George 2008</LINK>; <LINK REF="STD-Grant-2007" TYPE="STUDY">Grant 2007</LINK>; <LINK REF="STD-Hall-2011" TYPE="STUDY">Hall 2011</LINK>; <LINK REF="STD-Killen-2004" TYPE="STUDY">Killen 2004</LINK>; <LINK REF="STD-Muramoto-2007" TYPE="STUDY">Muramoto 2007</LINK>; <LINK REF="STD-Myles-2004" TYPE="STUDY">Myles 2004</LINK>; <LINK REF="STD-Piper-2007" TYPE="STUDY">Piper 2007</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Schmitz-2007" TYPE="STUDY">Schmitz 2007</LINK>; <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>; <LINK REF="STD-Selby-2003" TYPE="STUDY">Selby 2003</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Swan-2003" TYPE="STUDY">Swan 2003</LINK>; <LINK REF="STD-Uyar-2007" TYPE="STUDY">Uyar 2007</LINK>).</P>
<P>Forty-four trials evaluated bupropion as a single pharmacotherapy to assist initial cessation. Twelve trials that tested bupropion as an adjunct to nicotine replacement therapy are pooled separately (<LINK REF="STD-Evins-2007" TYPE="STUDY">Evins 2007</LINK>; <LINK REF="STD-Kalman-2011" TYPE="STUDY">Kalman 2011</LINK>; <LINK REF="STD-Killen-2004" TYPE="STUDY">Killen 2004</LINK>; <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (part); <LINK REF="STD-George-2008" TYPE="STUDY">George 2008</LINK>; <LINK REF="STD-Grant-2007" TYPE="STUDY">Grant 2007</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Rose-2013" TYPE="STUDY">Rose 2013</LINK>; <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>; <LINK REF="STD-Simon-2004" TYPE="STUDY">Simon 2004</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>), as are the eight trials making direct comparisons between bupropion and nicotine replacement therapy (<LINK REF="STD-Gariti-2009" TYPE="STUDY">Gariti 2009</LINK>; <LINK REF="STD-G_x00f3_recka-2003" TYPE="STUDY">Górecka 2003</LINK>; <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>; <LINK REF="STD-Uyar-2007" TYPE="STUDY">Uyar 2007</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>), three comparing bupropion and nortriptyline (<LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>; <LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>), and four comparing bupropion and varenicline (<LINK REF="STD-Cinciripini-2013" TYPE="STUDY">Cinciripini 2013</LINK>; <LINK REF="STD-Gonzales-2006" TYPE="STUDY">Gonzales 2006</LINK>, <LINK REF="STD-Jorenby-2006" TYPE="STUDY">Jorenby 2006</LINK>; <LINK REF="STD-Nides-2006" TYPE="STUDY">Nides 2006</LINK>). Trials testing the extended use of bupropion for relapse prevention (<LINK REF="STD-Covey-2007" TYPE="STUDY">Covey 2007</LINK>; <LINK REF="STD-Croghan-2007" TYPE="STUDY">Croghan 2007</LINK>; <LINK REF="STD-Hall-2011" TYPE="STUDY">Hall 2011</LINK>; <LINK REF="STD-Hays-2001" TYPE="STUDY">Hays 2001</LINK>; <LINK REF="STD-Hays-2009" TYPE="STUDY">Hays 2009</LINK>; <LINK REF="STD-Hurt-2003" TYPE="STUDY">Hurt 2003</LINK>; <LINK REF="STD-Killen-2006" TYPE="STUDY">Killen 2006</LINK>) and its use for assisting in reducing the amount smoked (<LINK REF="STD-Hatsukami-2004" TYPE="STUDY">Hatsukami 2004</LINK>) are pooled separately.</P>
<P>The seven studies that evaluated bupropion SR for relapse prevention each had slightly different designs. These studies also contribute to a separate Cochrane review on interventions for relapse prevention (<LINK REF="REF-Hajek-2013" TYPE="REFERENCE">Hajek 2013</LINK>).</P>
<P>One study evaluated bupropion for reducing smoking in people not wanting to make a quit attempt but interested in reducing smoking (<LINK REF="STD-Hatsukami-2004" TYPE="STUDY">Hatsukami 2004</LINK>). During treatment, if participants decided they wanted to try to quit, they were enrolled in a cessation programme during which they continued to use bupropion and were then followed up for 19 weeks.</P>
<P>Most of the bupropion trials excluded participants with current depression but not those with a history of depression. Two studies did include participants with current depression (<LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK>; <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>). Two studies explicitly excluded participants with a past history of major depression (<LINK REF="STD-Dalsgar_x00f0_-2004" TYPE="STUDY">Dalsgarð 2004</LINK>) or any psychiatric disorder (<LINK REF="STD-Collins-2004" TYPE="STUDY">Collins 2004</LINK>). Amongst the studies recording the prevalence of a past history of depression at baseline, the proportion ranged from 6% (<LINK REF="STD-Hatsukami-2004" TYPE="STUDY">Hatsukami 2004</LINK>) to 44% (<LINK REF="STD-Swan-2003" TYPE="STUDY">Swan 2003</LINK>), but was typically 20 to 30%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Nortriptyline</HEADING>
<P>Ten published studies of the tricyclic antidepressant nortriptyline are included. <LINK REF="STD-Richmond-2013" TYPE="STUDY">Richmond 2013</LINK> is new since the last review, and was conducted in prisoners. Hall and colleagues conducted three trials, and Prochazka and colleagues two, both in the USA. Two studies were conducted in Brazil (<LINK REF="STD-Da-Costa-2002" TYPE="STUDY">Da Costa 2002</LINK>; <LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>), one in the Netherlands (<LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>), one in the UK (<LINK REF="STD-Aveyard-2008" TYPE="STUDY">Aveyard 2008</LINK>), and one in Australia (<LINK REF="STD-Richmond-2013" TYPE="STUDY">Richmond 2013</LINK>). Eight studies excluded participants with current depression but most of these included people with a history of depression. All studies were placebo controlled and used doses of 75 to 100 mg/day or titrated doses to serum levels recommended for depression during the week prior to the quit date. Treatment duration ranged from 12 to 14 weeks. All studies used a definition of cessation based on a sustained period of abstinence. The three studies by Hall and colleagues, <LINK REF="STD-Aveyard-2008" TYPE="STUDY">Aveyard 2008</LINK>, and <LINK REF="STD-Richmond-2013" TYPE="STUDY">Richmond 2013</LINK> reported outcomes after 12 months of follow-up and the other five studies had six months of follow-up.</P>
<P>The three studies by Hall and colleagues (<LINK REF="STD-Hall-1998" TYPE="STUDY">Hall 1998</LINK>; <LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>; <LINK REF="STD-Hall-2004" TYPE="STUDY">Hall 2004</LINK>) used factorial designs to test nortriptyline versus placebo crossed with different intensities of behavioural support, whereas the remaining studies provided a set amount of behavioural support to all participants, ranging from brief behavioural counselling to repeated group and individual sessions. Four studies tested nortriptyline as an adjunct to NRT (<LINK REF="STD-Aveyard-2008" TYPE="STUDY">Aveyard 2008</LINK>; <LINK REF="STD-Hall-2004" TYPE="STUDY">Hall 2004</LINK>; <LINK REF="STD-Prochazka-2004" TYPE="STUDY">Prochazka 2004</LINK>; <LINK REF="STD-Richmond-2013" TYPE="STUDY">Richmond 2013</LINK>) and six tested nortriptyline on its own (<LINK REF="STD-Da-Costa-2002" TYPE="STUDY">Da Costa 2002</LINK>; <LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>; <LINK REF="STD-Hall-1998" TYPE="STUDY">Hall 1998</LINK>; <LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>; <LINK REF="STD-Prochazka-1998" TYPE="STUDY">Prochazka 1998</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selective Serotonin Reuptake Inhibitors (SSRIs)</HEADING>
<P>One new study of an SSRI has been added since the last update of this review (<LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK>, evaluating fluoxetine).</P>
<SUBSECTION>
<HEADING LEVEL="4">Fluoxetine</HEADING>
<P>Five trials with long-term follow-up are included. Two studies used fluoxetine as the only pharmacotherapy and had six months follow-up: a multicentre trial compared 30 mg daily, 60 mg daily, or placebo for 10 weeks (<LINK REF="STD-Niaura-2002" TYPE="STUDY">Niaura 2002</LINK>) and a single-site study used 60 mg or placebo for 12 weeks (<LINK REF="STD-Spring-2007" TYPE="STUDY">Spring 2007</LINK>). Three trials provided NRT to all participants and evaluated the addition of fluoxetine over 12 months follow-up: <LINK REF="STD-Blondal-1999" TYPE="STUDY">Blondal 1999</LINK> used 20 mg/day or placebo for three months as an adjunct to nicotine inhaler; <LINK REF="STD-Saules-2004" TYPE="STUDY">Saules 2004</LINK> used 20 or 40 mg/day or placebo for 10 weeks as an adjunct to nicotine patch; and <LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK> compared 10 weeks of fluoxetine, 16 weeks of fluoxetine, or no additional treatment in participants using nicotine patch for eight weeks. <LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK> was conducted in smokers with elevated depressive symptoms. Participants in all other trials were not currently depressed but may have had a past history of depression. <LINK REF="STD-Spring-2007" TYPE="STUDY">Spring 2007</LINK> stratified by history of depression.</P>
<P>We list as excluded other short-term studies, one with three month abstinence outcomes (<LINK REF="STD-Spring-1995" TYPE="STUDY">Spring 1995</LINK>) and others which reported outcomes other than abstinence (<LINK REF="STD-Cornelius-1997" TYPE="STUDY">Cornelius 1997</LINK>; <LINK REF="STD-Cornelius-1997" TYPE="STUDY">Cornelius 1997</LINK>; <LINK REF="STD-Dalack-1995" TYPE="STUDY">Dalack 1995</LINK>; <LINK REF="STD-Naranjo-1990" TYPE="STUDY">Naranjo 1990</LINK>; <LINK REF="STD-Pomerleau-1991" TYPE="STUDY">Pomerleau 1991</LINK>; <LINK REF="STD-Stein-1993" TYPE="STUDY">Stein 1993</LINK>). Another pharmaceutical company-sponsored multicentre trial was completed but its results were never presented or published (<I>personal communication</I>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Paroxetine</HEADING>
<P>One trial with six-month follow-up assessed paroxetine (40 mg, 20 mg, or placebo) for nine weeks as an adjunct to nicotine patch (<LINK REF="STD-Killen-2000" TYPE="STUDY">Killen 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sertraline</HEADING>
<P>One trial with six-month follow-up assessed sertraline (200 mg/day) for 11 weeks versus placebo in conjunction with six individual counselling sessions. There were 134 participants, all current smokers with a past history of major depression (<LINK REF="STD-Covey-2002" TYPE="STUDY">Covey 2002</LINK>). One trial that combined sertraline with buspirone was excluded because the specific effect of sertraline could not be evaluated (<LINK REF="STD-Carr_x00e3_o-2007" TYPE="STUDY">Carrão 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Citalopram/zimelidine</HEADING>
<P>There were no long-term studies of citalopram or zimelidine. One short-term study used a crossover design to investigate the effect of the SSRIs citalopram or zimelidine on the smoking behaviour of heavy drinkers who were not attempting to stop smoking. Their cigarette use did not change significantly between active medication and placebo periods (<LINK REF="STD-Sellers-1987" TYPE="STUDY">Sellers 1987</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Monoamine oxidase inhibitors</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Moclobemide</HEADING>
<P>Moclobemide has been tested for smoking cessation in one long-term placebo-controlled trial in France (<LINK REF="STD-Berlin-1995" TYPE="STUDY">Berlin 1995</LINK>). Treatment with 400 mg/day began one week before quit day and continued for two months, reducing to 200 mg/day for a further month. No behavioural counselling was provided. Final follow-up was at 12 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selegiline</HEADING>
<P>Five long-term trials have been published. Three used 10 mg/day oral treatment (<LINK REF="STD-Biberman-2003" TYPE="STUDY">Biberman 2003</LINK>; <LINK REF="STD-George-2003" TYPE="STUDY">George 2003</LINK>; <LINK REF="STD-Weinberger-2010" TYPE="STUDY">Weinberger 2010</LINK>) and two used 6 mg/day patch treatment (<LINK REF="STD-Kahn-2012" TYPE="STUDY">Kahn 2012</LINK>; <LINK REF="STD-Killen-2010" TYPE="STUDY">Killen 2010</LINK>). Three had treatment durations of nine weeks (<LINK REF="STD-George-2003" TYPE="STUDY">George 2003</LINK>; <LINK REF="STD-Kahn-2012" TYPE="STUDY">Kahn 2012</LINK>; <LINK REF="STD-Weinberger-2010" TYPE="STUDY">Weinberger 2010</LINK>), one had a treatment duration of eight weeks (<LINK REF="STD-Killen-2010" TYPE="STUDY">Killen 2010</LINK>), and one continued therapy for 26 weeks (<LINK REF="STD-Biberman-2003" TYPE="STUDY">Biberman 2003</LINK>). One excluded study was terminated early due to lack of efficacy and reported results to nine weeks only (<LINK REF="STD-Le-Foll-2009" TYPE="STUDY">Le Foll 2009</LINK>). One other short-term study (<LINK REF="STD-Houtsmuller-2002" TYPE="STUDY">Houtsmuller 2002</LINK>) and one reporting only preliminary short-term data (<LINK REF="STD-Brauer-2000" TYPE="STUDY">Brauer 2000</LINK>) are also excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lazabemide</HEADING>
<P>There were no long-term studies of this selective MAO-B inhibitor. It was evaluated in an eight-week, dose finding, exploratory study (<LINK REF="STD-Berlin-2002" TYPE="STUDY">Berlin 2002</LINK>). The trial was halted early due to liver toxicity observed in trials of the medications for other indications, and lazabemide is not being developed further. Continuous four-week quit rates at the end of treatment, including all drop-outs as treatment failures, were 17% (18/108) for 200 mg/day, 11% (12/108) for 100 mg/day, and 9% (10/114) for placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">EVT302</HEADING>
<P>There are no long-term studies of this selective reversible MAO-B inhibitor. It has been evaluated in an eight-week placebo controlled study (<LINK REF="STD-Berlin-2012" TYPE="STUDY">Berlin 2012</LINK>), excluded due to short follow-up. There was no evidence of clinical benefit and no significant difference between active and placebo groups. Continuous four-week quit rates at the end of treatment, including all drop-outs as treatment failures were 17.2% (25/145) for EVT302, 15.2 % (22/145) for placebo, 32.8 % (22/61) for EVT302 plus nicotine patch, and 26.8 % (17/61) for placebo plus nicotine patch.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other antidepressants</HEADING>
<P>Three studies of other antidepressants have been included since the last review: two studies of St John's wort (<LINK REF="STD-Parsons-2009" TYPE="STUDY">Parsons 2009</LINK>; <LINK REF="STD-Sood-2010" TYPE="STUDY">Sood 2010</LINK>) and one trial of the dietary supplement SAMe (<LINK REF="STD-Sood-2012" TYPE="STUDY">Sood 2012</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Venlafaxine</HEADING>
<P>One long-term trial with 147 participants compared venlafaxine at a dose of up to 225 mg/day with placebo. All participants also received nicotine patches and nine brief individual counselling sessions; follow-up was for 12 months (<LINK REF="STD-Cinciripini-2005" TYPE="STUDY">Cinciripini 2005</LINK>). An unpublished short-term study (<LINK REF="STD-Frederick-1997" TYPE="STUDY">Frederick 1997</LINK>) reported no difference in abstinence rates at eight weeks, and frequent side effects in the treatment group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hypericum (St John's wort)</HEADING>
<P>Two studies with long-term follow-up are included (<LINK REF="STD-Parsons-2009" TYPE="STUDY">Parsons 2009</LINK>; <LINK REF="STD-Sood-2010" TYPE="STUDY">Sood 2010</LINK>). Both reported prolonged abstinence at six months. <LINK REF="STD-Parsons-2009" TYPE="STUDY">Parsons 2009</LINK> compared 14 weeks of 900 mg/day St John's wort to placebo and <LINK REF="STD-Sood-2010" TYPE="STUDY">Sood 2010</LINK> compared 900 mg/day, 1800 mg/day, and placebo for 12 weeks.</P>
<P>Two studies are excluded. One unpublished study of an oral spray and placebo control with 45 participants detected no difference in abstinence at one month follow-up (<LINK REF="STD-Becker-2003" TYPE="STUDY">Becker 2003</LINK>). <LINK REF="STD-Barnes-2006" TYPE="STUDY">Barnes 2006</LINK> compared two doses for smoking cessation in an open randomized study with no placebo control. Quit rates were low and did not differ between dose levels. No participants maintained abstinence for 12 months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">S-Adenosyl-L-Methionine (SAMe)</HEADING>
<P>One long-term trial with 120 participants compared 1600 mg/day or 800 mg/day SAMe to placebo for 8 weeks with follow-up at six months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Doxepin</HEADING>
<P>There are no long-term studies of this serotonergic tricyclic antidepressant. It has been evaluated in a single small trial with short-term follow-up (<LINK REF="STD-Edwards-1989" TYPE="STUDY">Edwards 1989</LINK>). Treatment was with 150 mg doxepin daily for three weeks prior to quit day and four weeks afterwards. Subjects forfeited a US$135 deposit if they failed to stop smoking for seven days. Two months after cessation, 78% (7/9) of the doxepin group and 10% (1/10) of the placebo group reported abstinence, a statistically significant difference (P &lt; 0.02). However one week post-cessation abstinence rates using stringent validated abstinence criteria failed to show a statistically significant difference. Among withdrawal symptoms, there was a significant group difference only for craving.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Imipramine</HEADING>
<P>There are no long-term studies of this noradrenergic tricyclic antidepressant. One trial (<LINK REF="STD-Jacobs-1971" TYPE="STUDY">Jacobs 1971</LINK>) compared imipramine (25 mg 3 times/day) with lobeline, dextroamphetamine, placebo and a no-medication control. Some participants attended group support sessions. After three months, success rates, which included a reduction in smoking to less than 10% of baseline, were 56% (10/18) for imipramine, 40% (6/15) for placebo, and 69% (27/39) for the no-medications control. These differences were not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tryptophan</HEADING>
<P>There have been no long-term studies reported. Bowen and colleagues postulated that this serotonin-enhancing action in conjunction with a high carbohydrate (CHO) diet might relieve the negative affect of cigarette withdrawal. Oral l-tryptophan (50mg/kg/day) and instructions to follow a high CHO, low-protein diet were compared with placebo pills and instructions for a low-carbohydrate diet (<LINK REF="STD-Bowen-1991" TYPE="STUDY">Bowen 1991</LINK>). Participants in both groups also received four two-hour weekly multi-component group therapy sessions. Two weeks following the target cessation date 75% (12/16) of the tryptophan and high CHO diet group were abstinent versus 47% (7/15) of the placebo and low CHO diet group. This difference was not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-12-03 17:15:10 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of studies were judged to be at unclear risk for selection, performance and detection bias and at low risk for attrition bias. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> displays risk of bias judgements across each domain.</P>
<P>Risk of bias in each area is summarized below. Additional details about the methodology of individual trials are given in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Consistent with Cochrane methods, we included some trials that have only been published as abstracts, which have limited information on methodological issues (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). For some studies we have obtained additional information from authors, or from the pharmaceutical company funding the study. Use of unpublished data in the meta-analysis is noted in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<ALLOCATION MODIFIED="2013-11-26 17:09:31 +0000" MODIFIED_BY="[Empty name]">
<P>All of the trials were described as randomized, but most failed to report randomization and concealment methods in detail. Twenty-nine studies (32%) reported a method of sequence generation and allocation concealment judged to place the results at low risk of selection bias. One study was judged to be at high risk of selection bias due to a lack of allocation concealment (<LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>). All other trials were judged to be at unclear risk of selection bias because the method of sequence generation or allocation was not described in sufficient detail.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-10-23 15:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-seven trials (30%) provided sufficient information on blinding to be judged to be at low risk of performance and detection bias. These trials were placebo controlled, with both participants and personnel blinded to treatment allocation. Thirteen studies either did not blind participants or personnel or reported evidence suggesting unblinding, and were hence judged to be at high risk of performance and detection bias. The remaining studies did not provide sufficient information on blinding with which to judge risk of bias. For the most part, these trials reported that they were "double-blind" but provided no additional detail on the nature of the blinding used.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-11-26 17:09:55 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of studies (63%, 57 trials) reported low losses to follow-up and were judged to be at low risk of attrition bias. Eight studies reported high (&gt; 50%) or differential (&gt; 20% difference between arms) loss to follow-up and were judged to be at high risk of bias for this domain. The remaining 25 studies did not report the number or percentage of participants lost to follow-up in each arm, and were hence judged to be at unclear risk for attrition bias.</P>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2013-10-23 15:18:59 +0100" MODIFIED_BY="[Empty name]">
<P>One cluster-randomized trial (<LINK REF="STD-Siddiqi-2013" TYPE="STUDY">Siddiqi 2013</LINK>) was judged to be at high risk of other bias. In this trial, despite adequate reported methods of sequence generation and allocation concealment, the authors found substantial heterogeneity of program effects across clusters and a baseline imbalance in cigarette smoking behaviour (20% of participants in the control arm smoked only waterpipes (no cigarettes) compared to 4% in the intervention arm). </P>
<SUBSECTION>
<HEADING LEVEL="3">Definition of abstinence</HEADING>
<P>The definition of abstinence was not always explicit and biochemical validation of self-reported smoking status was not always used. However, all but four of the bupropion studies (<LINK REF="STD-Planer-2011" TYPE="STUDY">Planer 2011</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>; <LINK REF="STD-Swan-2003" TYPE="STUDY">Swan 2003</LINK>; <LINK REF="STD-Wittchen-2011" TYPE="STUDY">Wittchen 2011</LINK>) and all but one of the nortriptyline studies (<LINK REF="STD-Da-Costa-2002" TYPE="STUDY">Da Costa 2002</LINK>) used biochemical verification for most self-reported quitters at some assessment points. In a small number of studies we were able to obtain a sustained outcome that was not given in the published report. Most of the sustained abstinence rates are based on self-reported slip-free abstinence from the start of the third week after the target quit date (TQD) onward and validated at intermediate and final follow-ups.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-04 10:03:20 +0000" MODIFIED_BY="[Empty name]">
<P>(Selected analyses are displayed as Figures in the text. Other analyses are shown in the <LINK TAG="ANALYSES_AND_DATA" TYPE="SECTION">Data and analyses</LINK> section online and full PDF versions of the review.)</P>
<SUBSECTION>
<HEADING LEVEL="3">Smoking cessation</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Bupropion</HEADING>
<P>We distinguish between the subgroup of trials where bupropion was tested as the only pharmacotherapy, and those trials that assessed the effect of bupropion when added to NRT. Two trials contributed arms to both subgroups (<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Compared to placebo or no pharmacotherapy control, no other pharmacotherapy</HEADING>
<P>There were 44 trials in which bupropion was the sole pharmacotherapy, with over 13,000 participants. The pooled risk ratio [RR] was 1.62 (95% confidence interval [CI] 1.49 to 1.76) with little evidence of heterogeneity (I² = 18%), see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. The control group quit rates ranged from 0% to 33%, with a weighted average of 9%. Intervention group quit rates ranged from 4% to 43% with a weighted average of 18%. A sensitivity analysis did not suggest that results were sensitive to the exclusion of studies at high or unclear risk of bias across any domains. One cluster randomized trial of bupropion versus no pharmacotherapy was not included in the meta-analysis due to substantial heterogeneity of program effects across clusters. It detected no significant difference between groups at any follow-up point (adjusted RR 1.1, 95% CI 0.5 to 2.3) (<LINK REF="STD-Siddiqi-2013" TYPE="STUDY">Siddiqi 2013</LINK>). A funnel plot (<I>not shown</I>) did not suggest the presence of publication bias.</P>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity to length of follow-up</HEADING>
<P>Of the 44 trials of bupropion included in the main analysis, 27 had 12-month follow-up and 17 had six months. The estimated RR for the 12-month follow-up group was 1.59 (95% CI 1.44 to 1.76, I² = 39%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1) which was not substantially different than that for trials with only six months (RR 1.69, 95% CI 1.45 to 1.97, I² = 0%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity to clinical setting</HEADING>
<P>In a post hoc subgroup analysis we distinguished between trials that recruited community volunteers and trials that recruited patients in healthcare settings or with specific diagnoses. Whilst the estimated effect was marginally smaller amongst trials that recruited community volunteers than those recruiting in health care settings, the confidence intervals overlapped and effects were significant in both groups (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Effect of level of behavioural support</HEADING>
<P>Three trials compared bupropion and placebo in factorial designs varying the behavioural support. There was no evidence from any that the efficacy of bupropion differed between lower and higher levels of behavioural support (<LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>; <LINK REF="STD-McCarthy-2008" TYPE="STUDY">McCarthy 2008</LINK>) or by type of counselling approach used (<LINK REF="STD-Schmitz-2007" TYPE="STUDY">Schmitz 2007</LINK>). Other studies have compared different levels of behavioural support for people prescribed bupropion. These did not include placebo arms so do not provide evidence about within-study interactions between behavioural interventions and pharmacotherapy. We also explored a between-study subgroup analysis of the possible interaction with behavioural support using the classification into low and high intensity used in the Cochrane NRT review (<LINK REF="REF-Stead-2012" TYPE="REFERENCE">Stead 2012</LINK>). Low intensity was less than 30 minutes at the initial consultation, with no more than two further assessment and reinforcement visits. Only one of the included trials had such low intensity support (<LINK REF="STD-Myles-2004" TYPE="STUDY">Myles 2004</LINK>) and it was too small to draw conclusions from. <LINK REF="STD-Fossati-2007" TYPE="STUDY">Fossati 2007</LINK> (in a primary care setting) and part of <LINK REF="STD-McCarthy-2008" TYPE="STUDY">McCarthy 2008</LINK> had limited behavioural support but in both cases there were more than three visits. We also examined, within the more intensive therapy trials, evidence of a different effect of bupropion versus placebo in ten trials that provided group-based behavioural interventions compared to the majority (30) where individual therapy was provided. We found no evidence of a difference between subgroups (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). (This subgroup analysis was based on the trials contributing to <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> but excludes four trials where the level of support could not be classified and one factorial trial where data were not provided in a usable manner.)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Effect of dose</HEADING>
<P>In the first multi-dose study (<LINK REF="STD-Hurt-1997" TYPE="STUDY">Hurt 1997</LINK>), cessation rate was linearly related to dose (100 mg versus 150 mg versus 300 mg) through the end of treatment, consistent with pharmacological efficacy, although the difference between 300 mg and 150 mg doses was not significant at long-term follow-up. A larger study compared 150 mg and 300 mg daily doses, without a placebo group, and reported similar 12-month point prevalence quit rates for both doses (<LINK REF="STD-Swan-2003" TYPE="STUDY">Swan 2003</LINK>). A study in adolescents also included 150 mg and 300 mg doses (<LINK REF="STD-Muramoto-2007" TYPE="STUDY">Muramoto 2007</LINK>), with higher quit rates in the larger does group. Doses above 300 mg have not been tested. Pooling the three studies and comparing 300 mg versus 150 mg shows no evidence of a significant difference in abstinence (RR 1.08, 95% CI 0.93 to 1.26, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), with moderate statistical heterogeneity (I<SUP>2</SUP> = 49%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined bupropion and nicotine replacement therapy compared to NRT alone</HEADING>
<P>There was substantial statistical heterogeneity in the results of twelve studies adding bupropion to NRT (I² = 52%). Although two studies detected a clinically and statistically significant benefit of adding bupropion, the two studies contributing the largest weights to the analysis had point estimates very close to 1. Pooling using a fixed effect model does suggest a small benefit (RR 1.19, 95% CI 1.05 to 1.36, <I>analysis not shown</I>), but the level of heterogeneity makes a more conservative random-effects model more appropriate. This does not alter the point estimate but the wider confidence intervals no longer exclude no effect (RR 1.19, 95% CI 0.94 to 1.51, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>), although neither do they exclude a benefit that would be clinically useful. A funnel plot (<I>not shown</I>) did not suggest the presence of publication bias. Of the twelve trials, five recruited people who were potentially hard to treat: adolescents (<LINK REF="STD-Killen-2004" TYPE="STUDY">Killen 2004</LINK>); smokers with schizophrenia (<LINK REF="STD-Evins-2007" TYPE="STUDY">Evins 2007</LINK>; <LINK REF="STD-George-2008" TYPE="STUDY">George 2008</LINK>); smokers in treatment for alcohol dependence (<LINK REF="STD-Grant-2007" TYPE="STUDY">Grant 2007</LINK>); and smokers who had failed to quit using NRT alone (<LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>). <LINK REF="STD-George-2008" TYPE="STUDY">George 2008</LINK> was a small study with no quitters at all in the control group. The significant benefit seen in one trial (<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>) may be due in part to the unusually poor results from nicotine patch alone in this study. Most studies used nicotine patch but two studies provided nicotine lozenge (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>) and one offered a choice of NRT (<LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>); this does not explain the heterogeneity, nor does the exclusion of studies that did not use a bupropion placebo in the control arm.</P>
<P>One relapse prevention study (<LINK REF="STD-Croghan-2007" TYPE="STUDY">Croghan 2007</LINK>) compared nicotine inhaler, bupropion or both combined as initial therapy for cessation. In this open label phase, the combination had higher quit rates than either single therapy. After 12 weeks there was a second phase of randomization, so long-term effects cannot be compared.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion for relapse prevention</HEADING>
<P>Seven trials have evaluated extended use of bupropion for preventing relapse in people who have already stopped smoking. Pooling studies suggests the possibility of a small benefit but confidence intervals just include 1 (RR 1.15, 95% CI 1.00 to 1.33, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>
<I>).</I> The studies were heterogeneous with respect to the length of initial abstinence, the period of pharmacotherapy and the length of post treatment follow-up. The results of these studies are discussed in more detail in a Cochrane review of relapse prevention interventions (<LINK REF="REF-Hajek-2013" TYPE="REFERENCE">Hajek 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion and depression</HEADING>
<P>Most studies did not report outcomes separately for participants with and without a history of depression, current depression, or depressive symptoms, even if any were enrolled. A separate Cochrane review on smoking cessation interventions for smokers with current or past depression has identified a small number of studies with data for these subgroups (<LINK REF="REF-van-der-Meer-2013" TYPE="REFERENCE">van der Meer 2013</LINK>). They identified data from five trials that included a total of 410 participants with current depressive symptoms (<LINK REF="STD-Brown-2007" TYPE="STUDY">Brown 2007</LINK>; <LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK> (reported in <LINK REF="REF-Catley-2005" TYPE="REFERENCE">Catley 2005</LINK>); <LINK REF="STD-Levine-2010" TYPE="STUDY">Levine 2010</LINK>; <LINK REF="STD-Rigotti-2006" TYPE="STUDY">Rigotti 2006</LINK> (reported in <LINK REF="REF-Thorndike-2008" TYPE="REFERENCE">Thorndike 2008</LINK>); <LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>). When pooled the effect was non-significant but the confidence intervals did not rule out a benefit in this population (RR 1.37, 95% CI 0.83 to 2.27). In five trials with a total of 404 participants with a past history of depression (<LINK REF="STD-Brown-2007" TYPE="STUDY">Brown 2007</LINK>; <LINK REF="STD-Hurt-1997" TYPE="STUDY">Hurt 1997</LINK> (reported in <LINK REF="REF-Hayford-1999" TYPE="REFERENCE">Hayford 1999</LINK>); <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (reported in <LINK REF="REF-Smith-2003" TYPE="REFERENCE">Smith 2003</LINK>)), there was evidence of benefit (RR 2.04, 95% CI 1.31 to 3.18) although the review authors note the small number of participants and the post hoc nature of the subgroup analyses. Some study reports have noted a lack of evidence for any interaction between depression and treatment effect (<LINK REF="REF-Hurt-2002" TYPE="REFERENCE">Hurt 2002</LINK> &amp; <LINK REF="REF-Cox-2004" TYPE="REFERENCE">Cox 2004</LINK> subgroup analyses of <LINK REF="STD-Hays-2001" TYPE="STUDY">Hays 2001</LINK>; <LINK REF="STD-Kalman-2011" TYPE="STUDY">Kalman 2011</LINK>). However, in a within trial analysis of a recent study comparing bupropion with NRT, a significant interaction was detected between participants with a past history of depression and treatment with bupropion, which suggested that bupropion was more effective than NRT for those with a past history of depression (<LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>).</P>
<P>Bupropion may alleviate some subclinical symptoms of depression during treatment (<LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK>; <LINK REF="REF-Catley-2005" TYPE="REFERENCE">Catley 2005</LINK>; <LINK REF="REF-Lerman-2002a" TYPE="REFERENCE">Lerman 2002a</LINK>), but although this may facilitate smoking cessation, other mechanisms are probably more important (<LINK REF="REF-Catley-2005" TYPE="REFERENCE">Catley 2005</LINK>). In one trial (<LINK REF="STD-Collins-2004" TYPE="STUDY">Collins 2004</LINK> reported in <LINK REF="REF-Lerman-2004" TYPE="REFERENCE">Lerman 2004</LINK>), there was an interaction between nicotine dependence and treatment on post-cessation depression symptoms. Most smokers showed a reduction in depression symptoms during the treatment phase, whether they received bupropion or placebo. The reduction was maintained during follow-up. However highly dependent smokers showed a greater reduction in depression scores whilst receiving bupropion than whilst receiving placebo, and an increase when treatment ended.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Gender/age differences with bupropion</HEADING>
<P>Too few of the studies have published data on long-term quit rates by gender for it to be possible to conduct a definitive subgroup meta-analysis. A meta-analysis of mainly short-term outcomes and including 12 trials with 4421 participants showed no evidence of a treatment-gender interaction (<LINK REF="REF-Scharf-2004" TYPE="REFERENCE">Scharf 2004</LINK>). In these trials, women were less successful at quitting than men overall, but bupropion was equally beneficial in men and women. A subgroup analysis of long-term data from one study (<LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>, reported in <LINK REF="REF-Smith-2003" TYPE="REFERENCE">Smith 2003</LINK>) did report an interaction such that women appeared to benefit relatively more from medication. A more recent study reported a significant gender by smoking rate by treatment group interaction, such that bupropion seemed to benefit male heavy smokers and female light smokers but not others (<LINK REF="STD-Collins-2004" TYPE="STUDY">Collins 2004</LINK>). This study also showed an interaction among treatment effect, gender, and genotype (<LINK REF="REF-Lerman-2002b" TYPE="REFERENCE">Lerman 2002b</LINK>). At the end of treatment, women with a variant CYP2B6 gene had significantly higher quit rates when treated with bupropion than on placebo. The bupropion treatment effect was not significant for the other three gender/genotype subgroups. A study in smokers with chronic obstructive pulmonary disease (COPD) noted a larger treatment effect for women (ORs 2.7 versus 1.7), although the statistical significance of this interaction was not tested (<LINK REF="STD-Tashkin-2001" TYPE="STUDY">Tashkin 2001</LINK>). One study has reported a larger treatment effect for four- to seven-week abstinence in males (<LINK REF="STD-Gonzales-2001" TYPE="STUDY">Gonzales 2001</LINK>). This was a study re-treating smokers who had already failed to quit with bupropion. In the <LINK REF="STD-Hays-2001" TYPE="STUDY">Hays 2001</LINK> relapse prevention study, there were no significant gender effects (<LINK REF="REF-Gonzales-2002a" TYPE="REFERENCE">Gonzales 2002a</LINK>) and in a recent analysis of data from two included studies comparing bupropion with NRT and with placebo (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Smith-2009" TYPE="STUDY">Smith 2009</LINK>), there were also no significant gender effects (<LINK REF="REF-Piper-2010" TYPE="REFERENCE">Piper 2010</LINK>). In summary, gender does not appear to consistently influence the efficacy of bupropion.<BR/>
<BR/>Whilst most reports have not indicated any difference in treatment effects between older and younger smokers, subgroup analyses of two trials, <LINK REF="STD-Hays-2001" TYPE="STUDY">Hays 2001</LINK> (reported in <LINK REF="REF-Hurt-2002" TYPE="REFERENCE">Hurt 2002</LINK>) and <LINK REF="STD-Hurt-1997" TYPE="STUDY">Hurt 1997</LINK> (reported in <LINK REF="REF-Dale-2001" TYPE="REFERENCE">Dale 2001</LINK>), found evidence of an interaction, with a larger treatment effect for older smokers. One study in adolescents did not show evidence of an effect for bupropion over nicotine patch alone (<LINK REF="STD-Killen-2004" TYPE="STUDY">Killen 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion as second treatment</HEADING>
<P>One trial, included in the analysis of combined bupropion and NRT versus NRT alone, randomized participants immediately after failing to quit using NRT alone or lapsing within one week of quitting using NRT. More participants successfully quit in the combined arm than in the NRT alone arm, although the result was not statistically significant (<LINK REF="STD-Rose-2013" TYPE="STUDY">Rose 2013</LINK>, RR 1.89, 95% CI 0.94 to 3.81). In addition, one relapse prevention trial described above (<LINK REF="STD-Hurt-2003" TYPE="STUDY">Hurt 2003</LINK>) also randomized 194 smokers who had not quit successfully using nicotine patch therapy to bupropion or placebo as a second line treatment. Only one person, in the bupropion group, quit and sustained abstinence at six months. This is consistent with the results of some other studies, which find low overall success rates in smokers offered further pharmacotherapy soon after treatment failure (e.g. <LINK REF="REF-Gourlay-1995" TYPE="REFERENCE">Gourlay 1995</LINK>; <LINK REF="REF-Tonnesen-1993" TYPE="REFERENCE">Tonnesen 1993</LINK>), though <LINK REF="STD-Rose-2013" TYPE="STUDY">Rose 2013</LINK> detected somewhat higher rates (six month continuous abstinence: 14% combined arm; 11% NRT only). In addition, a subgroup analysis of <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK> (reported in <LINK REF="REF-Durcan-2002" TYPE="REFERENCE">Durcan 2002</LINK>) suggested that bupropion was equally effective in smokers with and without a past history of failure with NRT. In this trial, the gap between the previous failed attempt and the second attempt at cessation would have been longer.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion versus NRT</HEADING>
<P>Eight studies provided direct comparisons between bupropion and NRT, some comparing more than one type. Six allowed a comparison with the patch. Pooled results for all forms of NRT did not detect a significant difference between the two types of pharmacotherapy (RR 0.96, 95% CI 0.85 to 1.09, I<SUP>2</SUP> = 27%, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). No single type of NRT (patch, lozenge or a choice) showed a significant difference with bupropion, but two studies included a comparison with combination nicotine patch and lozenge and when these are pooled the combination is more effective than bupropion (RR 0.74, 95% CI 0.55 to 0.98). This is consistent with evidence that using two types of NRT is more effective than using the patch alone (<LINK REF="REF-Fiore-2008" TYPE="REFERENCE">Fiore 2008</LINK>; <LINK REF="REF-Stead-2012" TYPE="REFERENCE">Stead 2012</LINK>). Statistical heterogeneity was low within all subgroups, with the exception of patch (I<SUP>2</SUP> = 48%). All of the statistical heterogeneity in this subgroup can be attributed to <LINK REF="STD-Jorenby-1999" TYPE="STUDY">Jorenby 1999</LINK>, which, unlike the other studies, detected a significant effect in favour of bupropion. However, nicotine patch itself was not efficacious in this particular study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion versus varenicline</HEADING>
<P>Four studies there directly compared bupropion and varenicline (<LINK REF="STD-Cinciripini-2013" TYPE="STUDY">Cinciripini 2013</LINK>; <LINK REF="STD-Gonzales-2006" TYPE="STUDY">Gonzales 2006</LINK>; <LINK REF="STD-Jorenby-2006" TYPE="STUDY">Jorenby 2006</LINK>; <LINK REF="STD-Nides-2006" TYPE="STUDY">Nides 2006</LINK>). The pooled estimate showed a significantly lower rate of quitting with bupropion than varenicline (N = 1810, RR 0.68, 95% CI 0.56 to 0.83, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), with no evidence of heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion for smoking reduction</HEADING>
<P>One study offered bupropion to smokers not wishing to quit (<LINK REF="STD-Hatsukami-2004" TYPE="STUDY">Hatsukami 2004</LINK>). There were no significant differences in reduced cigarettes/day, cotinine, or cessation (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nortriptyline</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Compared to placebo control, no other pharmacotherapy</HEADING>
<P>Pooling six trials using nortriptyline as the only pharmacotherapy shows evidence of a significant benefit of nortriptyline over placebo (N = 975, RR 2.03, 95% CI 1.48 to 2.78, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) without evidence of statistical heterogeneity (I² = 7%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined nortriptyline and nicotine replacement therapy compared to NRT alone</HEADING>
<P>Pooling four trials (one with a factorial design entered in two parts) using nortriptyline as an adjunct to nicotine patch therapy does not show evidence of an additional benefit from nortriptyline (N = 1644, RR 1.21, 95% CI 0.94 to 1.55, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), with moderate heterogeneity (I² = 26%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup and sensitivity analyses</HEADING>
<P>There were too few trials of nortriptyline to examine effect of duration of follow-up, past depression, or amount of behavioural therapy between subgroups of trials. In one within-study comparison, a past history of depression did not appear to moderate the efficacy of nortriptyline, but subgroup numbers were small (<LINK REF="STD-Hall-1998" TYPE="STUDY">Hall 1998</LINK>). In two within-study comparisons, the intensity of adjunctive behaviour therapy did not influence the active versus placebo effect (<LINK REF="STD-Hall-1998" TYPE="STUDY">Hall 1998</LINK>; <LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>). In the study by Hall and colleagues of extended treatment (longer duration of both nortriptyline and behaviour therapy) versus brief treatment (similar to other nortriptyline trials), the confidence intervals for nortriptyline versus placebo included 1.0 (i.e. no evidence of an effect) for each treatment. The extended treatment increased absolute rates of abstinence and the relative effect for nortriptyline (RR 1.34 versus 0.62) but this was not statistically significant. Dose-response studies with nortriptyline have not been reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Bupropion versus nortriptyline</HEADING>
<P>Three trials included a direct comparison between bupropion and nortriptyline (<LINK REF="STD-Haggstr_x00e4_m-2006" TYPE="STUDY">Haggsträm 2006</LINK>; <LINK REF="STD-Hall-2002" TYPE="STUDY">Hall 2002</LINK>; <LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>). In each study, the comparison favoured bupropion but none showed significant differences. There was no evidence of heterogeneity. When pooled the difference remained non-significant, but does not exclude a clinically useful difference in favour of bupropion (N = 417, RR 1.30, 95% CI 0.93 to 1.82, <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective serotonin reuptake inhibitors (SSRIs)</HEADING>
<P>Seven trials of SSRIs were included. Four compared an SSRI to control (two fluoxetine: <LINK REF="STD-Niaura-2002" TYPE="STUDY">Niaura 2002</LINK>; <LINK REF="STD-Spring-2007" TYPE="STUDY">Spring 2007</LINK>; one paroxetine: <LINK REF="STD-Killen-2000" TYPE="STUDY">Killen 2000</LINK>; one sertraline: <LINK REF="STD-Covey-2002" TYPE="STUDY">Covey 2002</LINK>). Pooled, they did not detect a significant effect (N = 1546, RR 0.93, 95% CI 0.71 to 1.22, I<SUP>2</SUP> = 0%, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), nor did any of the individual therapies. Three trials which evaluated fluoxetine as an adjunct to NRT (<LINK REF="STD-Blondal-1999" TYPE="STUDY">Blondal 1999</LINK>; <LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK>; <LINK REF="STD-Saules-2004" TYPE="STUDY">Saules 2004</LINK>) also did not detect a significant effect (N = 466, RR 0.70, 95% CI 0.48 to 1.03, I<SUP>2</SUP> = 0%, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Monoamine oxidase inhibitors (MAOIs)</HEADING>
<P>One trial of moclobemide (<LINK REF="STD-Berlin-1995" TYPE="STUDY">Berlin 1995</LINK>) and five of selegiline (<LINK REF="STD-Biberman-2003" TYPE="STUDY">Biberman 2003</LINK>; <LINK REF="STD-George-2003" TYPE="STUDY">George 2003</LINK>; <LINK REF="STD-Kahn-2012" TYPE="STUDY">Kahn 2012</LINK>; <LINK REF="STD-Killen-2010" TYPE="STUDY">Killen 2010</LINK>; <LINK REF="STD-Weinberger-2010" TYPE="STUDY">Weinberger 2010</LINK>) were included. When pooled, there was no evidence of benefit (N = 827, RR 1.29, 95% CI 0.93 to 1.79, I² = 9%, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) and the two contributing the highest weights reported higher quit rates in the placebo group (<LINK REF="STD-Killen-2010" TYPE="STUDY">Killen 2010</LINK>; <LINK REF="STD-Weinberger-2010" TYPE="STUDY">Weinberger 2010</LINK>).</P>
<P>One trial of befloxatone showed no effect on cessation but data are unpublished (<LINK REF="STD-Berlin-2005" TYPE="STUDY">Berlin 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Venlafaxine</HEADING>
<P>One trial of venlafaxine (<LINK REF="STD-Cinciripini-2005" TYPE="STUDY">Cinciripini 2005</LINK>) failed to detect a significant increase in 12-month quit rates compared to nicotine patch and counselling alone, but confidence intervals do not exclude a clinically useful effect (RR 1.22, 95% CI 0.64 to 2.32, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>). Post hoc subgroup analyses suggested that there might be greater evidence for an effect amongst lighter smokers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">St John's wort</HEADING>
<P>Neither of the two small trials of St John's wort detected a significant effect (<LINK REF="STD-Parsons-2009" TYPE="STUDY">Parsons 2009</LINK>; <LINK REF="STD-Sood-2010" TYPE="STUDY">Sood 2010</LINK>). In one, more participants quit in the placebo than in the intervention arm. The pooled result was not significant, with some evidence of heterogeneity (N = 261, RR 0.81, 95% CI 0.26 to 2.53, I<SUP>2</SUP> = 29%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">S-Adenosyl-L-Methionine (SAMe)</HEADING>
<P>One trial of SAMe (<LINK REF="STD-Sood-2012" TYPE="STUDY">Sood 2012</LINK>) had lower quit rates in the active than control groups. The trial tested two doses which had similar outcomes and are pooled in the analysis (RR 0.70, 95% CI 0.24, 2.07, <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>). The authors concluded that further clinical trials were not justified.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse Events</HEADING>
<P>We summarize all adverse events (AEs) reported in trials of bupropion (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and nortriptyline (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). In this update, we also conducted meta-analyses of serious adverse events (SAEs) that occurred during treatment for studies in which bupropion or nortriptyline were compared with placebo or no pharmacotherapy controls. We also consider findings from recent large observational studies. A summary of historic data on bupropion from national surveillance schemes in the United Kingdom (UK), Australia and Canada is given in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>Assessing AEs in smoking cessation medications is difficult because any AEs may be due, not to the medication, but to nicotine withdrawal (i.e., physical dependence).  In addition, given smokers are more likely to have several medical and psychiatric illnesses, some "new" AEs may be exacerbations of pre-existing illnesses (<LINK REF="REF-Hughes-2008" TYPE="REFERENCE">Hughes 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Adverse affects of bupropion</HEADING>
<P>The most common side effects of bupropion are insomnia, occurring in 30% to 40% of patients, dry mouth (10%), and nausea (<LINK REF="REF-GlaxoSmithKline" TYPE="REFERENCE">GlaxoSmithKline</LINK>; <LINK REF="REF-Goldstein-1998" TYPE="REFERENCE">Goldstein 1998</LINK>). Typical drop-out rates due to adverse events range from 7% to 12%, but in one study 31% of those on 300 mg and 26% on 150 mg discontinued medication (<LINK REF="STD-Swan-2003" TYPE="STUDY">Swan 2003</LINK>) and in a second small study testing the 300 mg dose in alcoholic smokers, 33% of those receiving active medication withdrew due to adverse events (compared to 11% on placebo) (<LINK REF="STD-Grant-2007" TYPE="STUDY">Grant 2007</LINK>). In a pragmatic, non-blinded effectiveness trial, 20% of abstinent participants who had been allocated to bupropion at baseline switched to NRT due to adverse events (<LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>).</P>
<P>Allergic reactions have also been reported with bupropion. These include pruritus, hives, angioedema and dyspnoea. Symptoms of this type requiring medical treatment have been reported at a rate of about 1 to 3 per thousand in clinical trials (<LINK REF="REF-GlaxoSmithKline" TYPE="REFERENCE">GlaxoSmithKline</LINK>), and this is approximately the level at which they are being reported in the national surveillance schemes. Hypersensitivity reactions are listed as possible rare (occurring at rates less than 1 per 1000) adverse effects in the product data.</P>
<P>Bupropion is also an inhibitor of CYP2D6 so care is needed when starting or stopping bupropion use in patients taking other medication metabolized by this route (<LINK REF="REF-Kotlyar-2005" TYPE="REFERENCE">Kotlyar 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Serious adverse events</HEADING>
<P>For this update, we conducted meta-analyses of SAEs reported in the studies of bupropion versus placebo or a no pharmacotherapy control (including studies that were excluded from efficacy analyses due to short length of follow-up). Meta-analyses of the 33 trials in which SAEs whilst on treatment were measured and reported found a marginal and statistically non-significant excess of any SAE in the bupropion groups compared with the control groups (RR 1.30, 95% CI 1.00 to 1.69, 9631 participants, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), with event rates of 2.1% for bupropion and 1.9% for placebo users. Of the 33 trials, 11 reported no SAEs in either arm during the period of interest. Subgroup analysis of psychiatric SAEs detected no difference between the bupropion and placebo arms, with an RR of 0.60 (95% CI 0.28 to 1.28, 19 trials, <I>analysis not shown</I>). The event rates were 0.4% and 0.7%, respectively. Subgroup analysis of cardiovascular events also detected no difference between the two groups, with an RR of 1.16 (95% CI 0.65 to 2.06, 25 trials, <I>analysis not shown</I>) and event rates of 0.5% for bupropion and 0.4% for placebo.</P>
<SUBSECTION>
<HEADING LEVEL="6">Seizures</HEADING>
<P>Early trials of bupropion as a treatment for depression using the immediate release formulation and often doses greater than 300 mg/day suggested it increased the risk of seizures in those with a prior history of alcohol withdrawal, anorexia, or head trauma. This led to the development of the slow release (SR) preparation licensed for smoking cessation (and used in all but the earliest of the included studies of bupropion). Using this preparation in doses of 300 mg/day or less, and excluding those at risk of seizures, no seizures had been reported in any of the smoking cessation trials until the study in physicians and nurses in Europe (<LINK REF="STD-Zellweger-2005" TYPE="STUDY">Zellweger 2005</LINK>). In this study there were two seizures amongst 502 people randomized to bupropion, one of whom had a familial history (data from GlaxoSmithKline). Since then two seizures have been reported in a study in which 126 participants received bupropion (<LINK REF="STD-Nides-2006" TYPE="STUDY">Nides 2006</LINK>), one in a study with 329 treated (<LINK REF="STD-Gonzales-2006" TYPE="STUDY">Gonzales 2006</LINK>), one in a study with 289 treated (<LINK REF="STD-Covey-2007" TYPE="STUDY">Covey 2007</LINK>), one in a study with 362 treated (<LINK REF="STD-Killen-2006" TYPE="STUDY">Killen 2006</LINK>), and one in a study with 264 treated (<LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>). Two seizures were also reported in an unpublished study with 100 participants prescribed bupropion (<LINK REF="STD-Strayer-2004" TYPE="STUDY">Strayer 2004</LINK>, <I>personal communication</I>). This gives a total of 10 seizures amongst over 13,000 people exposed in clinical trials, so despite these reports the overall seizure rate remains similar to the rate of 1:1000 given in product safety data. The figure of 1:1000 derives from a large, open, uncontrolled observational safety surveillance study conducted by the manufacturers (<LINK REF="REF-Dunner-1998" TYPE="REFERENCE">Dunner 1998</LINK>) which examined 3100 adult patients using slow release bupropion for eight weeks for treatment of depression (not smoking cessation). Treatment was extended if necessary to a year, at a maximum dose of 150 mg twice daily. Patients with a history of eating disorder, or a personal or family history of epilepsy were excluded. Three participants (i.e. 1:1000) had a seizure considered to be related to the therapeutic use of bupropion.</P>
<P>The evidence on seizure risk from trials is consistent with findings from large observational studies of use of bupropion SR for smoking cessation. <LINK REF="REF-Boshier-2003" TYPE="REFERENCE">Boshier 2003</LINK> reported on a cohort of 11,753 English patients who had been dispensed bupropion. Eleven seizures were reported for a rate of 1 in 1000; four of these were associated with a past history of seizure. <LINK REF="REF-Hubbard-2005" TYPE="REFERENCE">Hubbard 2005</LINK> used a UK general practice database to estimate the relative incidence of death or seizure in 9329 individuals over a mean (SD) follow-up of 1.9 (0.9) years comparing each individual during a 'high risk' period following prescription of bupropion with him/herself outside this period. High risk periods of either 28 or 63 days were evaluated. The reported seizure rates were non-significantly higher during the high risk periods (28 days: 3.62, 95% CI 0.87 to 15.09; 63 days: 2.38, 95% CI 0.72 to 7.93). A total of 45 seizures in 28 people were reported but only two occurred in the first 28 days of treatment, in one individual with no previous history of epilepsy. Of note in this study was that 12 people had been prescribed bupropion despite previous diagnoses of seizure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Psychiatric adverse events</HEADING>
<P>In 2009, the US Food and Drug Administration (FDA) added new warnings about the risk of serious mental health events including changes in behaviour, depressed mood, hostility, and suicidal thoughts in patients using bupropion for smoking cessation (<LINK REF="REF-US-FDA-2009a" TYPE="REFERENCE">US FDA 2009a</LINK>; <LINK REF="REF-US-FDA-2009b" TYPE="REFERENCE">US FDA 2009b</LINK>). The added warnings were based on the continued review of postmarketing adverse event reports for varenicline (a more recently licensed smoking cessation treatment, see <LINK REF="REF-Cahill-2012" TYPE="REFERENCE">Cahill 2012</LINK>) and bupropion received by the FDA. There were 46 reports of suicidal ideation and 29 of suicidal behaviour for bupropion to November 27 2007 (<LINK REF="REF-US-FDA-2009a" TYPE="REFERENCE">US FDA 2009a</LINK>). Prior to this, a review of the safety of bupropion had been undertaken by the European Agency for the Evaluation of Medicines for Human Use (<LINK REF="REF-EMEA-2002" TYPE="REFERENCE">EMEA 2002</LINK>) which had stated that there was neither a pharmacological nor a clinical reason for suspecting bupropion to be causally associated with depression or suicide. Suicidal ideation had been observed in six out of a total of 4067 participants in clinical trials for smoking cessation, a rate of 1: 677. The rate of suicidal ideation with bupropion was stated to be low compared with the rates found in the general population but no data were presented. The EMEA review committee concluded that the benefit/risk balance remained favourable, but made recommendations to strengthen warnings on hypersensitivity and depression by advising clinicians to be aware of the possible emergence of significant depressive symptoms in patients undergoing a smoking cessation attempt.</P>
<P>Since the last update, three new observational analyses of psychiatric events in people using bupropion for smoking cessation have been published. All three compared bupropion with varenicline and two also included comparisons with NRT. A registry-based cohort study in Denmark evaluated risk of psychiatric adverse events in people prescribed bupropion or varenicline over a period of three years. In propensity score-matched analyses, there was no significant difference in psychiatric adverse events between participants receiving varenicline and participants receiving bupropion (hazard ratio 0.85, 95% CI 0.55 to 1.30) (<LINK REF="REF-Pasternak-2013" TYPE="REFERENCE">Pasternak 2013</LINK>). Similarly, in an analysis of five years of data from general practices in the UK, no differences in rates of depression, suicide and non-fatal self-harm were detected between people prescribed varenicline, bupropion or NRT for smoking cessation (bupropion versus NRT hazard ratio for fatal and non-fatal self-harm 0.83, 95% CI 0.30 to 2.31; for treated depression 0.63, 95% CI 0.46 to 0.87) (<LINK REF="REF-Thomas-2013" TYPE="REFERENCE">Thomas 2013</LINK>). Conversely, an analysis based on US data comparing suicidal behaviour and depression in people prescribed bupropion,varenicline or NRT for smoking cessation did detect significant between group differences. Using NRT as a reference group, bupropion showed a statistically significant increased risk of suicidal behaviour and depression (OR 2.9, 95% CI 2.3 to 3.7), and varenicline showed statistically significant increased risk substantially higher than that of bupropion (OR 8.4, 95% CI 6.8 to 10.4) (<LINK REF="REF-Moore-2011" TYPE="REFERENCE">Moore 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Overdoses and deaths</HEADING>
<P>Although no patient is reported to have died while taking bupropion in trials for smoking cessation, some have died while taking bupropion prescribed for smoking cessation in routine practice. There has been no formal epidemiological analysis of these deaths, but no national reporting scheme has concluded that bupropion caused these deaths. In a self-controlled case series analysis (<LINK REF="REF-Hubbard-2005" TYPE="REFERENCE">Hubbard 2005</LINK>), death rates were non-significantly lower during the high risk period (28 days after being prescribed bupropion) compared to the period before taking bupropion and after 28 days of being prescribed bupropion (0.5, 95% CI 0.12 to 2.05; 63 days: 0.47, 95% CI 0.18 to 1.19).</P>
<P>Bupropion may cause adverse effects in overdose. A review of bupropion-only non-therapeutic exposures reported to the US Toxic Exposure Surveillance System for 1998-1999 identified 3755 exposures to Wellbutrin SR, 2184 to Wellbutrin, and 1409 to Zyban (<LINK REF="REF-Belson-2002" TYPE="REFERENCE">Belson 2002</LINK>). Non-therapeutic exposures included intentional overdose and unintentional ingestion as well as reports of adverse reactions. Of those exposed to Zyban who showed any symptoms,13% developed a seizure. There were no deaths associated with Zyban.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bupropion in pregnancy</HEADING>
<P>A follow-up of 136 women exposed to bupropion prescribed for smoking cessation or depression during the first trimester of pregnancy suggested that bupropion does not increase the rates of major malformations, but there were significantly more spontaneous abortions (<LINK REF="REF-Chun_x002d_Fai_x002d_Chan-2005" TYPE="REFERENCE">Chun-Fai-Chan 2005</LINK>). An assessment of potential infant exposure to bupropion and active metabolites in breast milk suggests that the exposure of an infant whose mother was taking a therapeutic dose would be small (<LINK REF="REF-Haas-2004" TYPE="REFERENCE">Haas 2004</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects of nortriptyline</HEADING>
<P>Five studies comparing nortriptyline to placebo or to a no pharmacotherapy control measured and reported SAEs occurring during treatment only. However, no SAEs occurred whilst on treatment in any arms of these trials, meaning we were unable to calculate an RR for SAEs whilst on nortriptyline. The only serious adverse event in someone treated with nortriptyline was collapse/palpitations thought possibly caused by treatment (<LINK REF="STD-Aveyard-2008" TYPE="STUDY">Aveyard 2008</LINK>). The other adverse events reported included the well known tricyclic effects of dry mouth, drowsiness, light-headedness and constipation observed in studies treating depression in which doses were often <U>&gt;</U> 150 mg (<LINK REF="REF-Khawam-2006" TYPE="REFERENCE">Khawam 2006</LINK>). When used at 75 to 150 mg doses in smokers, drop-out rates in the trials reporting this outcome have ranged from 4% to 12%, with one exception (<LINK REF="STD-Wagena-2005" TYPE="STUDY">Wagena 2005</LINK>). This rate is similar to that for bupropion and NRT. Nortriptyline can be lethal in overdoses. Studies of nortriptyline used for depression suggest it may have the potential for more serious adverse events than those reported in trials of nortriptyline for smoking cessation. Since nortriptyline is not approved for smoking cessation in any country, we are unaware of any observational data.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-12-03 17:20:44 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Bupropion and nortriptyline</HEADING>
<P>Forty-four trials now provide a large, high quality evidence base confirming the benefit from bupropion used as single pharmacotherapy for smoking cessation (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). There is no substantial statistical heterogeneity evident and the pooled estimate suggests that bupropion increased long-term quitting success by relative factor of 1.5 to 1.8. Treatment effects appear to be comparable in a range of populations, settings and types of behavioural support and in smokers with and without a past history of depression. Clear evidence of an additional benefit from adding bupropion to NRT was not demonstrated.</P>
<P>Meta-analysis of the three bupropion trials that compared the recommended dose of 300 mg/day (150 mg twice daily) with a dose of only 150 mg failed to show a significant long-term benefit of the higher dose. Whilst the power of the comparison is not sufficient to establish equivalence, for people with troubling side effects such as insomnia, a reduction in dose to 150 mg in the morning would be an alternative to discontinuing pharmacotherapy altogether.</P>
<P>Evidence from eight head-to-head trials did not detect a significant difference between bupropion and NRT. This is consistent with a recent network meta-analysis which found that, in indirect, across-study comparison, the efficacy was similar, suggesting no advantage for one treatment over the other (<LINK REF="REF-Cahill-2013" TYPE="REFERENCE">Cahill 2013</LINK>). The choice between these two therapies will depend on patient preferences, including a consideration of the risks of adverse events.</P>
<P>Pooled results from four trials found that participants treated with bupropion were significantly less likely to quit than  those treated with varenicline, a partial nicotinic agonist. This is also consistent with results from the recent network meta-analysis (<LINK REF="REF-Cahill-2013" TYPE="REFERENCE">Cahill 2013</LINK>). Although this suggests varenicline should be preferred over bupropion as a first line therapy, further study is warranted for several reasons. First, the number of studies is still small. Second, the trials used very similar optimal samples, settings and procedures. Whether the same degree of superiority for varenicline would occur in a more real-world setting is unclear. Finally, given that both bupropion and varenicline block nicotine receptors and increase dopamine, a  biological explanation for superior efficacy for varenicline has not been proposed. The evidence for efficacy of varenicline is covered by another Cochrane review (<LINK REF="REF-Cahill-2012" TYPE="REFERENCE">Cahill 2012</LINK>).</P>
<P>Two further trials of extended therapy with bupropion for individuals who have recently quit bring the number included to seven, and the pooled estimate narrowly misses statistical significance (RR 1.15, 95% CI 1.00 to 1.33) but the clinical importance of any effect seems likely to be small. Preventing relapse remains a major challenge.</P>
<P>Nortriptyline has also been shown to assist cessation; there is a moderate evidence base, limited by a relatively small number of trials and total number of participants (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). As with bupropion, there is no evidence that the combination of nortriptyline and NRT is more effective than NRT alone.</P>
<P>There are no direct comparisons of nortriptyline with NRT or varenicline. Head-to-head comparison with bupropion in three trials favour bupropion but do not show a significant difference. The pooled risk ratios of efficacy of nortriptyline and bupropion appear broadly similar. One argument for considering nortriptyline as a first line therapy is its lower cost when compared to licensed therapies (<LINK REF="REF-Wagena-2005a" TYPE="REFERENCE">Wagena 2005a</LINK>). The main argument against this is based on the potential for serious adverse effects (<LINK REF="REF-Hughes-2005" TYPE="REFERENCE">Hughes 2005</LINK>).</P>
<P>Data from two included studies new to this update suggest there may be a significant interaction between bupropion and current or past history of depression, with bupropion appearing more effective in participants with a history of depression (<LINK REF="STD-Schnoll-2010" TYPE="STUDY">Schnoll 2010</LINK>) or with current depression (<LINK REF="STD-Stapleton-2013" TYPE="STUDY">Stapleton 2013</LINK>). This contrasts with previous versions of this review which found that, although not widely tested, the efficacy of bupropion and nortriptyline appeared to be independent of a past history of depression (<LINK REF="STD-Hall-1998" TYPE="STUDY">Hall 1998</LINK>; <LINK REF="REF-Hayford-1999" TYPE="REFERENCE">Hayford 1999</LINK>; <LINK REF="REF-Hurt-2002" TYPE="REFERENCE">Hurt 2002</LINK>) and post-cessation depression (<LINK REF="REF-Catley-2005" TYPE="REFERENCE">Catley 2005</LINK>, reporting an analysis of <LINK REF="STD-Ahluwalia-2002" TYPE="STUDY">Ahluwalia 2002</LINK>). These data suggested that their efficacy is not due to a traditional antidepressant effect and that they benefit those with no history of depression. Although the pharmacological mechanism of action of bupropion is still unclear, animal studies suggest that it may act as an antagonist at the nicotine receptor (<LINK REF="REF-Cryan-2003" TYPE="REFERENCE">Cryan 2003</LINK>; <LINK REF="REF-Wiley-2002" TYPE="REFERENCE">Wiley 2002</LINK>, <LINK REF="REF-Young-2002" TYPE="REFERENCE">Young 2002</LINK>). How nortriptyline increases cessation is unclear. Regardless of relative efficacy, both treatments have been shown to be effective in people with no history of depression.</P>
<P>Although there is considerable research interest in genetic differences that could help predict response to pharmacotherapy (<LINK REF="REF-Uhl-2008" TYPE="REFERENCE">Uhl 2008</LINK>), there is currently no genetic test that can be used for treatment matching in a clinical setting, and a recent analysis concluded that a single gene test to aid choice of treatment was not the most cost effective approach (<LINK REF="REF-Welton-2008" TYPE="REFERENCE">Welton 2008</LINK>). There is preliminary evidence that smokers with normal dopamine receptor availability and function might respond better to bupropion than to NRT (<LINK REF="REF-David-2005" TYPE="REFERENCE">David 2005</LINK>; <LINK REF="REF-Lerman-2006" TYPE="REFERENCE">Lerman 2006</LINK>) whilst genotypes that are associated with impaired dopaminergic systems could have relatively better outcomes with NRT (<LINK REF="REF-Johnstone-2004" TYPE="REFERENCE">Johnstone 2004</LINK>). It is also possible that gender may moderate the interaction between bupropion and genotype (<LINK REF="REF-Swan-2005" TYPE="REFERENCE">Swan 2005</LINK>). The rate of metabolism of nicotine has also been suggested as a moderator of treatment effect (<LINK REF="STD-Collins-2004" TYPE="STUDY">Collins 2004</LINK>, reported in <LINK REF="REF-Patterson-2008" TYPE="REFERENCE">Patterson 2008</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects</HEADING>
<P>No seizures were reported in the first large studies of bupropion for smoking cessation but more recently seven studies (<LINK REF="STD-Covey-2007" TYPE="STUDY">Covey 2007</LINK>; <LINK REF="STD-Gonzales-2006" TYPE="STUDY">Gonzales 2006</LINK>; <LINK REF="STD-Killen-2006" TYPE="STUDY">Killen 2006</LINK>; <LINK REF="STD-Nides-2006" TYPE="STUDY">Nides 2006</LINK>; <LINK REF="STD-Piper-2009" TYPE="STUDY">Piper 2009</LINK>; <LINK REF="STD-Strayer-2004" TYPE="STUDY">Strayer 2004</LINK>; <LINK REF="STD-Zellweger-2005" TYPE="STUDY">Zellweger 2005</LINK>) report a total of ten seizures. Since about 13,000 people have been exposed to the slow release formulation of bupropion in the cessation studies included in this review, the averaged rate is still less than the 1:1000 estimated risk used in product safety information, although the clustering of seizures in a few small studies is unexpected. Some suicides and deaths while taking bupropion have been reported. Currently, like many other antidepressants and varenicline, bupropion has a warning about the possibility of serious mood and behavioural changes.  However, it remains unclear whether these outcomes were caused by bupropion effects. Meta-analyses did not detect any difference between bupropion and placebo or no pharmacotherapy controls in rate of psychiatric or cardiovascular SAEs, and detected a marginal and non-statistically significant increased rate of any SAEs in people randomized to bupropion.</P>
<P>In studies in depressed patients, nortriptyline sometimes caused sedation, constipation, urinary retention and cardiac problems, and when taken as an overdose could be fatal. Based on the rate of significant adverse events when used to treat depression, nortriptyline would be expected to have higher rate of drop-outs in smoking cessation studies. This has not been the case in the relatively small number of subjects receiving nortriptyline in the existing studies (about 1300), perhaps because the dose of nortriptyline used (75 to 150 mg) is generally smaller than that used for depression and smokers are not acutely ill. No SAEs were reported in any trials comparing nortriptyline to placebo or a no pharmacotherapy control. However, given the small sample size, the safety of these doses of nortriptyline for smoking cessation is still unclear.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Other antidepressants</HEADING>
<P>The seven long-term trials of selective serotonin reuptake inhibitors (SSRIs) (fluoxetine, paroxetine and sertraline) and other short-term trials have, somewhat surprisingly, failed to show that this class of antidepressants helps smoking cessation. Some studies have found SSRIs effective in post hoc-determined subgroups (<LINK REF="REF-Borrelli-2004" TYPE="REFERENCE">Borrelli 2004</LINK>; <LINK REF="REF-Swan-1999" TYPE="REFERENCE">Swan 1999</LINK>) but this requires verification. The most recent trial of fluoxetine alone (<LINK REF="STD-Spring-2007" TYPE="STUDY">Spring 2007</LINK>) found that although fluoxetine initially increased cessation amongst smokers with a history of depressive disorder, by the end of the study it impaired cessation regardless of depressive history. A recent study of fluoxetine as an adjunct to NRT in people with elevated symptoms of depression (<LINK REF="STD-Brown-2013" TYPE="STUDY">Brown 2013</LINK>) found it significantly impaired cessation in the group receiving 10 weeks of treatment, and did not have a significant effect on the group receiving 16 weeks of treatment, though again less people quit in the group receiving fluoxetine.</P>
<P>There is no evidence of long-term efficacy for monoamine oxidase inhibitors. Two early trials of selegiline suggested a possible benefit but the more recent trials do not support this.</P>
<P>This update saw the inclusion of studies of alternative therapies for depression. Two studies of St John's wort did not detect a significant effect, with conflicting results and low quit rates across all arms. The one study of the dietary supplement SAMe also did not detect a significant effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Mechanism of action of antidepressants</HEADING>
<P>Whether the efficacy of bupropion and nortriptyline is specific to the unique pharmacology of these medications or whether it would occur in all antidepressants has not been completely resolved. The SSRI antidepressants appear not to be efficacious. This suggests serotonin modulation is not important, leaving the dopaminergic or noradrenergic effects of nortriptyline and bupropion to account for their efficacy. Although the efficacy of bupropion was initially thought to be due to its dopaminergic actions, nortriptyline, which is also effective, has relatively weak dopaminergic activity. In addition, bupropion has as much noradrenergic activity as dopaminergic activity. Another possibility, at least for bupropion, is that it acts as a nicotinic receptor blocker (<LINK REF="REF-Warner-2005" TYPE="REFERENCE">Warner 2005</LINK>). Whether the same is true for nortriptyline is not clear (<LINK REF="REF-Gambassi-1999" TYPE="REFERENCE">Gambassi 1999</LINK>). If noradrenergic effects are important in treatments for smoking, then monoamine oxidase inhibitors and other tricyclic antidepressants should be effective; however, the six small trials of these present conflicting results.</P>
</SUBSECTION>
<AGREEMENT MODIFIED="2013-12-03 17:20:44 +0000" MODIFIED_BY="[Empty name]">
<P>The findings of this review are in agreement with the conclusions of other reviews and guidelines (<LINK REF="REF-Aubin-2002" TYPE="REFERENCE">Aubin 2002</LINK>; <LINK REF="REF-Haustein-2003" TYPE="REFERENCE">Haustein 2003</LINK>; <LINK REF="REF-Hughes-2005" TYPE="REFERENCE">Hughes 2005</LINK>; <LINK REF="REF-Jorenby-2002" TYPE="REFERENCE">Jorenby 2002</LINK>; <LINK REF="REF-Martinez_x002d_Raga-2003" TYPE="REFERENCE">Martinez-Raga 2003</LINK>; <LINK REF="REF-McRobbie-2005" TYPE="REFERENCE">McRobbie 2005</LINK>; <LINK REF="REF-RCP-2000" TYPE="REFERENCE">RCP 2000</LINK>; <LINK REF="REF-Tonstad-2002" TYPE="REFERENCE">Tonstad 2002</LINK>; <LINK REF="REF-Tracey-2002" TYPE="REFERENCE">Tracey 2002</LINK>; <LINK REF="REF-West-2000" TYPE="REFERENCE">West 2000</LINK>; <LINK REF="REF-West-2003" TYPE="REFERENCE">West 2003</LINK>). US smoking cessation guidelines (<LINK REF="REF-Fiore-2008" TYPE="REFERENCE">Fiore 2008</LINK>) continue to recommend bupropion as a first line therapy and nortriptyline as a second-line therapy due to possible adverse events. Open uncontrolled trials and observational studies of bupropion have shown real-life quit rates comparable to those found in clinical trials (<LINK REF="REF-Holmes-2004" TYPE="REFERENCE">Holmes 2004</LINK>; <LINK REF="STD-Paluck-2006" TYPE="STUDY">Paluck 2006</LINK>; <LINK REF="REF-Wilkes-2005" TYPE="REFERENCE">Wilkes 2005</LINK>). Studies of cost-effectiveness also support the utility of bupropion (<LINK REF="REF-Bolin-2006" TYPE="REFERENCE">Bolin 2006</LINK>; <LINK REF="REF-Javitz-2004" TYPE="REFERENCE">Javitz 2004</LINK>; <LINK REF="REF-Welton-2008" TYPE="REFERENCE">Welton 2008</LINK>) and nortriptyline (<LINK REF="REF-Hall-2005" TYPE="REFERENCE">Hall 2005</LINK>). Findings regarding the efficacy of bupropion in smokers with current or past depression are consistent with those from a separate Cochrane review evaluating smoking cessation treatments exclusively in these populations (<LINK REF="REF-van-der-Meer-2013" TYPE="REFERENCE">van der Meer 2013</LINK>).</P>
<P>However, our findings on the effectiveness of bupropion as an adjunct to NRT differ from the results of the USPHS clinical practice guideline. Whereas we did not detect a significant difference, the US guideline reported an odds ratio of 1.3 (95% CI 1.0 to 1.8) for a combination versus nicotine patch alone (<LINK REF="REF-Fiore-2008" TYPE="REFERENCE">Fiore 2008</LINK> table 6.28). The difference in meta-analytic outcomes may be because the current analysis included several studies of hard-to-treat populations not included in the USPHS analysis. Also, it could be because the Cochrane analysis was a collation of 12 within-study randomized comparisons whereas the USPS was an across-study comparison of the results from the combination arm in three trials and the results from the patch alone arm in 32 studies.</P>
<P>Similar to our findings, other systematic reviews looking at the serious adverse events profile of bupropion remain inconclusive. A meta-analysis of suicidality in placebo-controlled trials of bupropion detected no significant difference between bupropion and placebo groups (<LINK REF="REF-Wightman-2010" TYPE="REFERENCE">Wightman 2010</LINK>) and a review of trials in which bupropion was prescribed to hospitalised patients with cardiovascular disease highlighted the need for larger randomized controlled trials to determine the long-term safety of bupropion in this population (<LINK REF="REF-Grandi-2011a" TYPE="REFERENCE">Grandi 2011a</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-12-03 17:21:17 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-12-03 17:21:01 +0000" MODIFIED_BY="Lindsay Stead">
<P>The existing evidence supports a role for bupropion and nortriptyline in clinical practice. Nicotine replacement therapy has proven efficacy in over 100 studies (<LINK REF="REF-Stead-2012" TYPE="REFERENCE">Stead 2012</LINK>) and has a very benign side-effect profile. There is insufficient published evidence to conclude either bupropion or nortriptyline has superior efficacy to NRT or vice versa. The confidence intervals around the efficacy estimates for bupropion, nortriptyline and NRT overlap. Nortriptyline appears equally effective in smokers with and without a history of depression. Data are conflicting on whether there is an interaction between bupropion and current or past depression, though efficacy has been established for all groups. The efficacy of bupropion and nortriptyline does not appear to be mediated by improving post-cessation depression. Whether smokers with a previous history of depression or mild current depression would do better with bupropion or nortriptyline than NRT has not been tested. Whether bupropion prevents depressive symptoms or relapse to depression better than NRT has also not been studied. Patient preferences, cost, availability, and side-effect profile will all need to be taken into account in choosing among medications. Bupropion and nortriptyline may be helpful in those who fail on NRT. Studies comparing bupropion with varenicline have shown higher quit rates with varenicline.</P>
<P>All smoking cessation medications can produce clinically significant adverse effects. When people are initially screened for potential adverse effects, however, fewer than 10% of those on antidepressants for smoking cessation stop taking the medications due to adverse effects. Although bupropion use has been associated with deaths in lay public reports, currently there is insufficient evidence to state that bupropion caused these deaths. There has also been concern about antidepressants such as bupropion being associated with psychiatric disorders including suicidal ideation and suicide attempts. Again, it is not clear that there is a causal relationship. Smoking cessation may also precipitate depression (<LINK REF="REF-Hughes-2007" TYPE="REFERENCE">Hughes 2007</LINK>). Also, although nortriptyline is associated with more side effects when used for depression, in the doses used for smoking cessation this may not be true.</P>
<P>Slow release bupropion, under the name Zyban, is licensed for smoking cessation in many parts of the world, including North America, Australia, and Europe, but is not available in many other countries. Often, bupropion is available in these countries under the name Wellbutrin SR as a treatment for depression. Nortriptyline is marketed as an antidepressant in many countries but is not currently marketed as a smoking cessation aid in any country. In almost all countries, bupropion and nortriptyline are available only as prescription medications.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-12-03 17:21:17 +0000" MODIFIED_BY="[Empty name]">
<P>More research is needed with different antidepressants to determine which antidepressants or classes of antidepressant are effective in smoking cessation. Determining this could provide insight not only into the mechanism of action of antidepressant efficacy but also into the biological factors controlling nicotine dependence and smoking. Antidepressants of the SSRI category are not effective, which suggests serotonin may not be an important factor. However, it is unclear whether dopaminergic, noradrenergic, or nicotinic-cholinergic monoaminergic activity or blockage of nicotine receptors is most important for cessation efficacy. Similarly, the suggestive findings that genotype might moderate antidepressant treatment efficacy deserve follow-up.  Research on the biological and behavioural mediators of the efficacy of bupropion and nortriptyline is needed; e.g. how much of their efficacy is due to craving or withdrawal relief, blocking nicotine reinforcement, or preventing lapses from becoming relapses. Knowledge of whether NRT or antidepressants have more efficacy in decreasing depression post-cessation would help decide whether smokers with a past history of depression should prefer antidepressants over NRT.</P>
<P>Given the concern by some about deaths and psychiatric disorders from antidepressants used for smoking cessation, continued monitoring is indicated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-15 18:51:26 +0000" MODIFIED_BY="Lindsay Stead">
<P>Our thanks to Drs Niaura, Borrelli, Spring, Fiore, Hurt, Mizes, Ferry, Schuh, Cinciripini, Hays, Prochazka, Ahluwalia, Mayo, Collins, Novotny, Brown, David, Evins, Le Foll, Glover &amp; Piper for assistance with additional information or data on studies.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-11-12 15:46:42 +0000" MODIFIED_BY="[Empty name]">
<P>JR Hughes has received consultancy fees from many pharmaceutical companies that provide tobacco related services or products or are developing new products, including Pfizer (the maker of NRTs and varenicline) and GlaxoSmithKline (the makers of bupropion and NRTs).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-28 09:36:50 +0100" MODIFIED_BY="[Empty name]">
<P>All authors contribute to the text of the review. LS and TL extracted study data, and JHB also extracted data for the 2013 update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>This review was first published as part of the review 'Anxiolytics and antidepressants for smoking cessation'. From Issue 4 2000 the classes of drugs are reviewed separately.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-06-15 09:46:24 +0100" MODIFIED_BY="Nicola Lindson-Hawley">
<STUDIES MODIFIED="2013-12-03 14:21:53 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-03 14:21:53 +0000" MODIFIED_BY="Lindsay Stead">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahluwalia-2002" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Ahluwalia 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;New 2003&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS</AU>
<TI>Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>468-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269953"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boardman T, Catley D, Mayo MS, Ahluwalia JS</AU>
<TI>Self-efficacy and motivation to quit during participation in a smoking cessation program</TI>
<SO>International Journal of Behavioral Medicine</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>266-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269954"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catley D, Harris KJ, Okuyemi KS, Mayo MS, Pankey E, Ahluwalia JS</AU>
<TI>The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>859-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269955"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris KJ, Ahluwalia JS, Catley D, Okuyemi KS, Mayo MS, Resnicow K</AU>
<TI>Successful recruitment of minorities into clinical trials: the Kick It at Swope project</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>575-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269956"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris KJ, Okuyemi KS, Catley D, Mayo MS, Ge B, Ahluwalia JS</AU>
<TI>Predictors of smoking cessation among African-Americans enrolled in a randomized controlled trial of bupropion</TI>
<SO>Preventive Medicine</SO>
<YR>2004</YR>
<VL>38</VL>
<PG>498-502</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269957"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okuyemi KS, Ahluwalia JS, Ebersole Robinson M, Catley D, Mayo MS, Resnicow K</AU>
<TI>Does menthol attenuate the effect of bupropion among African American smokers?</TI>
<SO>Addiction</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>1387-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269958"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas JL, Guo H, Lynam IM, Powell JN, Okuyemi KS, Bronars CA, et al</AU>
<TI>The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1361-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269959"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269952"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aubin-2004" NAME="Aubin 2004" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Added as primary reference 2006&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aubin HJ, Lebargy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G</AU>
<TI>Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>1206-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269961"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lebargy F, Aubin HJ, Lagrue G, Bidaut-Mazel C, Chemali-Hudry J, Poulain L</AU>
<TI>A placebo-controlled, double-blind study of Zyban LP: An effective and well-tolerated aid to smoking cessation - preliminary results (POS4-69)</TI>
<SO>Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19-22 New Orleans, Louisiana</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269962"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269960"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aveyard-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Aveyard 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 14:15:07 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aveyard P, Johnson C, Fillingham S, Parsons A, Murphy M</AU>
<TI>Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7655</NO>
<PG>1223-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269964"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aveyard P, Johnson C, Murphy M, Johnstone E, Walton R, Fillingham S, et al</AU>
<TI>A pragmatic randomised controlled trial to test the efficacy of nortriptyline plus nicotine replacement therapy (NRT) versus a placebo plus NRT in helping smokers to stop and testing the role of noradrenergic and dopaminergic genetic variants in smoking cessation [PI-TS-02]</TI>
<SO>Society for Research on Nicotine and Tobacco 8th European Meeting, September 2006; Kusadasi, Turkey</SO>
<YR>2006</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269965"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269963"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlin-1995" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Berlin 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Said S, Spreux Varoquaux O, Launay JM, Olivares R, Millet V, et al</AU>
<TI>A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1995</YR>
<VL>58</VL>
<PG>444-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269967"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added 2004&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Spreux Varoquaux O, Said S, Launay JM</AU>
<TI>Effects of past history of major depression on smoking characteristics, monoamine oxidase-A and -B activities and withdrawal symptoms in dependent smokers</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>31-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269968"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269966"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biberman-2003" MODIFIED="2009-07-28 13:44:43 +0100" MODIFIED_BY="Lindsay Stead" NAME="Biberman 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-23 11:20:46 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biberman R, Neumann R, Katzir I, Gerber Y</AU>
<TI>A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation</TI>
<SO>Addiction</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>1403-07</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269970"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269969"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blondal-1999" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Blondal 1999" YEAR="">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, et al</AU>
<TI>The effects of fluoxetine combined with nicotine inhalers in smoking cessation - a randomized trial</TI>
<SO>Addiction</SO>
<YR>1999</YR>
<VL>94</VL>
<PG>1007-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269972"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269971"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Brown 2007" YEAR="2005">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abrantes AM, Strong DR, Lloyd-Richardson EE, Niaura R, Kahler CW, Brown RA</AU>
<TI>Regular exercise as a protective factor in relapse following smoking cessation treatment</TI>
<SO>American Journal on Addictions</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>1</NO>
<PG>100-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269974"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al</AU>
<TI>Bupropion and cognitive-behavioral treatment for depression in smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>721-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269975"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, et al</AU>
<TI>Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>821-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269976"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, et al</AU>
<TI>Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>935-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269977"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SP, Strong DR, Munafo MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, et al</AU>
<TI>Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>12</NO>
<PG>1251-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269978"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Linked to Brown 2007&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leventhal AM, David SP, Brightman M, Strong D, McGeary JE, Brown RA, et al</AU>
<TI>Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation</TI>
<SO>Pharmacogenomics Journal</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>1</NO>
<PG>86-92</PG>
<PB>Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012694"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269979"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:31:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links distantly to Lerman 2002 and Brown 2007&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:31:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li Y, Wileyto EP, Heitjan DF</AU>
<TI>Modeling smoking cessation data with alternating states and a cure fraction using frailty models</TI>
<SO>Statistics in Medicine</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>6</NO>
<PG>627-38</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005712"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269980"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:50:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Okun ML, Levine MD, Houck P, Perkins KA, Marcus MD</AU>
<TI>Subjective sleep disturbance during a smoking cessation program: associations with relapse</TI>
<SO>Addictive Behaviors</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>8</NO>
<PG>861-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011571"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269981"/><IDENTIFIER TYPE="OTHER" VALUE="9400123000011571"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="OTHER">
<AU>Strong DR, Kahler CW, Leventhal AM, Abrantes AM, Lloyd-Richardson E, Niaura R, et al</AU>
<TI>Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1142-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005451"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269982"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al</AU>
<TI>Molecular genetics of successful smoking cessation: convergent genome-wide association study results</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>6</NO>
<PG>683-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269983"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269973"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Brown-2013" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Brown 2013" NOTES="&lt;p&gt;Before publication check if article published in Nicotine and Tobacco Research - if so remove unpublished tag, unpublished ref, and add in new ref&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" YEAR="2011">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brown RA, Abrantes AM, Strong DR, Niaura R, Kahler CW, Miller IW, et al</AU>
<TI>Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2013</YR>
<VL>epub Sep 20</VL>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269985"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Conference abstract. Not NRT. In depression as ongoing; / Sent to RvdM 23/10/2012&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brown RA, Strong DR, Abrantes AM, Miller IW, Kahler CW, Niaura R, et al</AU>
<TI>Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers</TI>
<SO>Society for Research on Nicotine &amp; Tobacco 17th Annual Meeting, February 2011, Toronto</SO>
<YR>2011</YR>
<PG>28S</PG>
<IDENTIFIERS MODIFIED="2013-08-22 11:39:26 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006076"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269986"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-19 15:47:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brown RA, Strong DR, Miller IW, Kahler CW, Niaura R, Price LH</AU>
<TI>Efficacy of sequential vs. concurrent use of fluoxetine in smoking cessation for elevated depressive symptom smokers (SYM8D)</TI>
<SO>Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas</SO>
<YR>2007</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269987"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269984"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cinciripini-2005" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Cinciripini 2005" YEAR="1999">
<REFERENCE MODIFIED="2009-07-28 13:46:44 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cinciripini PM, Tsoh JY, Friedman K, Wetter D, Cinciripini LG, Skaar KL</AU>
<TI>A placebo controlled evaluation of venlafaxine for smoking cessation: preliminary findings [Abstract A18]</TI>
<SO>Society for Research on Nicotine and Tobacco Annual Meeting; Mar 27-29 1998; New Orleans, Louisiana</SO>
<YR>1998</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269989"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Became primary reference with change of study ID in 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Tsoh JY, Wetter DW, Lam C, de Moor C, Cinciripini L, et al</AU>
<TI>Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation</TI>
<SO>Experimental and Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>13</VL>
<PG>282-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269990"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cinciripini PM, Wetter D, Minna J, et al</AU>
<TI>The effects of brief counseling, transdermal nicotine replacement and antidepressant therapy on smoking cessation among smokers carrying the DRD2 A1 allele (PA3A)</TI>
<SO>Society for Research on Nicotine and Tobacco Annual Meeting; Mar 5-7 1999; San Diego, California</SO>
<YR>1999</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Wetter DW, Tomlinson GE, Tsoh JY, de Moor CA, Cinciripini LG, et al</AU>
<TI>The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>229-39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269992"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269988"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cinciripini-2013" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Cinciripini 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Previously lised as ongoing NCT00507728 in varenicline. Allows head to head comparison Originally included nortriptyline rather than varenicline but no data reported for small numbers enrolled&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al</AU>
<TI>Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal</TI>
<SO>JAMA Psychiatry</SO>
<YR>2013</YR>
<VL>70</VL>
<NO>5</NO>
<PG>522-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400107000000437"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269994"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-03 15:18:30 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269993"/><IDENTIFIER MODIFIED="2013-09-03 15:18:30 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00507728"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collins-2004" MODIFIED="2013-12-03 14:17:50 +0000" MODIFIED_BY="Lindsay Stead" NAME="Collins 2004" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, et al</AU>
<TI>Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence</TI>
<SO>Biological Psychiatry</SO>
<YR>2007</YR>
<VL>61</VL>
<NO>1</NO>
<PG>111-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269996"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added 2004, replaces Lerman 2002 as primary reference&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collins B, Wileyto P, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, et al</AU>
<TI>Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>27-37</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269997"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conti DV, Lee W, Li D, Liu J, Van Den BD, Thomas PD, et al</AU>
<TI>Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation</TI>
<SO>Human Molecular Genetics</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>18</NO>
<PG>2834-48</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269998"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SP, Strong DR, Munafo MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, et al</AU>
<TI>Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>12</NO>
<PG>1251-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3269999"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:28:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to a bupropion trial ?Lerman&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:28:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gold AB, Wileyto EP, Jepson C, Lori A, Cubells JF, Lerman C</AU>
<TI>Galanin receptor 1 (GALR1) SNP is associated with craving and smoking relapse</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2011</YR>
<VL>36</VL>
<PG>S378</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012457"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270000"/><IDENTIFIER TYPE="OTHER" VALUE="9400123000012457"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-22 12:39:05 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Links to Lerman trials. Seen in Central 2012 issue 11&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 12:39:05 +0100" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C</AU>
<TI>Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>7</NO>
<PG>1683-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000014652"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270001"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu J, Redden DT, Berrettini WH, Shields PG, Restine SL, Pinto A, et al</AU>
<TI>No evidence for a major role of polymorphisms during bupropion treatment</TI>
<SO>Obesity</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1863-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270002"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:17:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Javitz HS, Swan GE, Lerman C</AU>
<TI>The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>10</NO>
<PG>1835-45</PG>
<IDENTIFIERS MODIFIED="2013-12-03 14:17:50 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011869"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270003"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al</AU>
<TI>CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>6</NO>
<PG>635-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270004"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al</AU>
<TI>Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>231-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270005"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Niaura R, Collins BN, Wileyto P, Audrain MJ, Pinto A, et al</AU>
<TI>Effect of bupropion on depression symptoms in a smoking cessation clinical trial</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>362-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270006"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lerman confirmed that this is an interim analysis of same study. Also listed in excluded studies.&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu AY, et al</AU>
<TI>Mediating mechanisms for the impact of bupropion in smoking cessation treatment</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2002</YR>
<VL>67</VL>
<PG>219-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270007"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, et al</AU>
<TI>Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial</TI>
<SO>Health Psychology</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>541-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270008"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, et al</AU>
<TI>Pharmacogenetic investigation of smoking cessation treatment</TI>
<SO>Pharmacogenetics</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>627-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270009"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al</AU>
<TI>Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>84</VL>
<PG>320-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270010"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnoll RA, Epstein L, Audrain J, Niaura R, Hawk L, Shields PG, et al</AU>
<TI>Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>2</NO>
<PG>234-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al</AU>
<TI>Molecular genetics of successful smoking cessation: convergent genome-wide association study results</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>6</NO>
<PG>683-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270012"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wileyto EP, Patterson F, Niaura R, Epstein LH, Brown RA, Audrain-McGovern J, et al</AU>
<TI>Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>257-68</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270013"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wileyto P, Patterson F, Niaura R, Epstein L, Brown R, Audrain-McGovern J, et al</AU>
<TI>Do small lapses predict relapse to smoking behavior under bupropion treatment?</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>357-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 17:37:05 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3269995"/><IDENTIFIER MODIFIED="2013-08-27 17:37:05 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00322205"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covey-2002" MODIFIED="2013-12-03 14:18:12 +0000" MODIFIED_BY="[Empty name]" NAME="Covey 2002" YEAR="2000">
<REFERENCE MODIFIED="2013-12-03 14:18:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Berlin I, Chen H, Covey LS</AU>
<TI>Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit date</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>12</NO>
<PG>2209-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005900"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270016"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;added as main reference 2003/2 update&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Covey LS, Glassman AH, Stetner F, Rivelli S, Stage K</AU>
<TI>A randomized trial of sertraline as a cessation aid for smokers with a history of major depression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>159</VL>
<PG>1731-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270017"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Covey LS, Glassman AH, Stetner F, Rivelli S</AU>
<TI>A trial of sertraline for smokers with past major depression</TI>
<SO>Society for Research on Nicotine and Tobacco Meeting. Arlington, VA (http://www.srnt.org/events/abstracts99/index.htm)</SO>
<YR>2000</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270018"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270015"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covey-2007" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Covey 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Covey LS, Botello-Harbaum M, Glassman AH, Masmela J, LoDuca C, Salzman V, et al</AU>
<TI>Smokers' response to combination bupropion, nicotine patch, and counseling treatment by race/ethnicity</TI>
<SO>Ethnicity &amp; Disease</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>59-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270020"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al</AU>
<TI>A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse</TI>
<SO>Addiction</SO>
<YR>2007</YR>
<VL>102</VL>
<PG>1292-302</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270021"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 17:05:57 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270019"/><IDENTIFIER MODIFIED="2013-08-27 17:05:57 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00063323"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-2012" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Cox 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Probably links to Ahluwalia 2006 bupropion study. Not rel to Combined or behav adj. Tagged RCT 15/02/12 Conference abstract. 35th Annual Meeting American Society of Preventive Oncology, ASPO&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan TS, Cox LS, Nollen NL, Thomas JL, Berg CJ, Mayo MS, et al</AU>
<TI>Perceived treatment assignment and smoking cessation in a clinical trial of bupropion</TI>
<SO>Cancer Epidemiology, Biomarkers &amp; Prevention</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>4</NO>
<PG>721</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011648"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270023"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Results presented at SRNT 2011, Published 2012&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cox LS, Faseru B, Mayo MS, Krebill R, Snow TS, Bronars CA, et al</AU>
<TI>Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data</TI>
<SO>Trials</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005878"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270024"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al</AU>
<TI>Bupropion for smoking cessation in African American light smokers: a randomized controlled trial</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2012</YR>
<VL>104</VL>
<NO>4</NO>
<PG>290-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270025"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Yet another paper linked to Ahluwalia 2006 bupropion trial. Not rel to Combined&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="OTHER">
<AU>Faseru B, Choi WS, Krebill R, Mayo MS, Nollen NL, Okuyemi KS, et al</AU>
<TI>Factors associated with smoking menthol cigarettes among treatment-seeking African American light smokers</TI>
<SO>Addictive Behaviors</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>12</NO>
<PG>1321-4</PG>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011663"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faseru B, Nollen NL, Mayo MS, Krebill R, Choi WS, Benowitz NL, et al</AU>
<TI>Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial</TI>
<SO>Addictive Behaviors</SO>
<YR>2013</YR>
<VL>38</VL>
<NO>3</NO>
<PG>1796-803</PG>
<IDENTIFIERS MODIFIED="2013-08-22 13:55:02 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER MODIFIED="2013-08-22 13:55:02 +0100" MODIFIED_BY="Lindsay Stead" OTHERTYPE="CRS" TYPE="OTHER" VALUE="9400107000000930"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270027"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Proabbly links to a trial&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al</AU>
<TI>CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2012</YR>
<VL>92</VL>
<NO>6</NO>
<PG>771-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000017581"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270028"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-20 15:30:57 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270022"/><IDENTIFIER MODIFIED="2013-08-20 15:30:57 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00666978"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croghan-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Croghan 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark MM, Hurt RD, Croghan IT, Patten CA, Novotny P, Sloan JA, et al</AU>
<TI>The prevalence of weight concerns in a smoking abstinence clinical trial</TI>
<SO>Addictive Behaviors</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>1144-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270030"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 17:00:36 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croghan IT, Hurt RD, Croghan GA, Sloan JA</AU>
<TI>Comparing nicotine inhaler, bupropion and nicotine inhaler plus bupropion in treating tobacco dependence [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>680-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270031"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, et al</AU>
<TI>Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2007</YR>
<VL>82</VL>
<PG>186-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270032"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Croghan Mayo Clin Proc 2007 trial. Added to refs for NRT 2011 update. Not Combined; no non pharma control&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Croghan IT, Hurt RD, Ebbert JO, Croghan GA, Polk Jr OD, Stella PJ, et al</AU>
<TI>Racial differences in smoking abstinence rates in a multicenter, randomized, open-label trial in the United States</TI>
<SO>Journal of Public Health</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>1</NO>
<PG>59-68</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006023"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270033"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 13:58:38 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270029"/><IDENTIFIER MODIFIED="2013-08-27 13:58:38 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00033592"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Da-Costa-2002" NAME="Da Costa 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Added 2004, on CCTR&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa C, Younes R, Lourenco M</AU>
<TI>Smoking cessation: A randomized double-blind study comparing nortriptyline to placebo [abstract]</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2001</YR>
<VL>163</VL>
<NO>5 Suppl</NO>
<PG>A354</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270035"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New 2003&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>da Costa CL, Younes RN, Lourenco MT-C</AU>
<TI>Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<PG>403-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270034"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalsgar_x00f0_-2004" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Dalsgarð 2004" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New 2003, ID changed and based on publication from 2004.&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dalsgarð OJ, Hansen NC, Søes-Petersen U, Evald T, Høegholm A, Barber J, et al</AU>
<TI>A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2004</YR>
<VL>6</VL>
<PG>55-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270038"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dalsgarð OJ, Vestbo J</AU>
<TI>A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking cessation (ZYB30009). Poster and oral presentation</TI>
<SO>European Congress on Tobacco or Health, Warsaw, Poland, 20-22 June 2002</SO>
<YR>2002</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270039"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270037"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisenberg-2013" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Eisenberg 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-08-22 09:28:26 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Comment on Eisenberg&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 09:28:26 +0100" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benowitz NL, Prochaska JJ</AU>
<TI>Smoking cessation after acute myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>5</NO>
<PG>533-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000017824"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270041"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Not found in time for hospital update. Main publication 2013 similar title&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisenberg MJ, Grandi SM, Gervais A, Joseph L, O'Loughlin J, Paradis G, et al</AU>
<TI>Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: A randomized, placebo-controlled trial</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>5 SUPPL 1</NO>
<PG>S344</PG>
<IDENTIFIERS MODIFIED="2013-08-22 09:28:03 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012454"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270042"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eisenberg MJ, Grandi SM, Gervais A, O'Loughlin J, Paradis G, Rinfret S, et al</AU>
<TI>Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: A randomized, placebo-controlled trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>5</NO>
<PG>524-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000017546"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270043"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Conference abstract&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Grandi SM, Filion KB, Gervais A, Joseph L, O'Loughlin J, Paradis G, et al</AU>
<TI>The effect of smoking cessation on weight at 12 months in patients post-myocardial infarction [abstract]</TI>
<SO>Circulation</SO>
<YR>2012</YR>
<VL>10 Suppl</VL>
<PG>P090</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000018293"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-20 14:52:23 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270040"/><IDENTIFIER MODIFIED="2013-08-20 14:52:23 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00689611"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evins-2001" MODIFIED="2013-12-03 14:19:04 +0000" MODIFIED_BY="[Empty name]" NAME="Evins 2001" YEAR="2000">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm Shipman CM, et al</AU>
<TI>Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<PG>307-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270046"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:19:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New 2003&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:19:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC</AU>
<TI>A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>397-403</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270047"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270045"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evins-2005" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Evins 2005" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Cather C, Culhane M, Freudenreich O, Rigotti NA, Goff DC</AU>
<TI>Smoking cessation in schizophrenia: A double blind placebo controlled trial of bupropion SR added to cognitive behavioral therapy</TI>
<SO>Biological Psychiatry</SO>
<YR>2004</YR>
<VL>55</VL>
<PG>806</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270049"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al</AU>
<TI>A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<PG>218-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270050"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, et al</AU>
<TI>Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>1184-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270051"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270048"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evins-2007" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Evins 2007" YEAR="2006">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Evins AE, Cather C, Culhane M, Birnbaum AS, Horowitz J, Hsieh E, et al</AU>
<TI>A placebo-controlled study of bupropion SR added to high dose nicotine replacement therapy for smoking cessation or reduction in schizophrenia (POS2-104)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting; February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270053"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al</AU>
<TI>A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>380-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270054"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 13:42:16 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270052"/><IDENTIFIER MODIFIED="2013-08-27 13:42:16 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00307203"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ferry-1992" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Ferry 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferry LH, Robbins AS, Scariati PD, et al</AU>
<TI>Enhancement of smoking cessation using the antidepressant bupropion hydrochloride [abstract 2670]</TI>
<SO>Circulation</SO>
<YR>1992</YR>
<VL>86</VL>
<NO>4 Suppl 1</NO>
<PG>I-671</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270056"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270055"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ferry-1994" NAME="Ferry 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferry LH, Burchette RJ</AU>
<TI>Efficacy of bupropion for smoking cessation in non depressed smokers [Abstract]</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>4</NO>
<PG>249</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270058"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270057"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fossati-2007" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Fossati 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 17:02:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferketich AK, Fossati R, Apolone G</AU>
<TI>An evaluation of the Italian version of the Fagerstrom Test for Nicotine Dependence</TI>
<SO>Psychological Reports</SO>
<YR>2008</YR>
<VL>102</VL>
<PG>687-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270060"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fossati R, Apolone G, Negri E, Compagnoni A, La Vecchia C, Mangano S, et al</AU>
<TI>A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2007</YR>
<VL>167</VL>
<PG>1791-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270061"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270059"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gariti-2009" MODIFIED="2013-08-27 16:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Gariti 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-26 11:13:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Data extracted for behavioural adjunct review&lt;br&gt;Compares NRT &amp;amp; bupropion. Check whether head to head comparisons go into NRT review or only into antidepressants?&lt;br&gt;2 &amp;#194;&amp;#382; 2 double-blind, double-dummy design for the medication component of the study. Participants were randomized to receive one of two levels of counseling intensity in combination with one of two pharmacotherapies. Master's level nurse practitioners or nursing clinical specialists were assigned to each model and delivered all sessions.&lt;br&gt;Sent to Gareth H 22/06/11&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:13:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K</AU>
<TI>Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>3</NO>
<PG>247-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005384"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270063"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:23:52 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270062"/><IDENTIFIER MODIFIED="2013-08-27 16:23:52 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00086411"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-2002" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="George 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;New 2003&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al</AU>
<TI>A placebo controlled trial of bupropion for smoking cessation in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2002</YR>
<VL>52</VL>
<PG>53-61</PG>
<IDENTIFIERS MODIFIED="2013-08-22 09:30:28 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270065"/><IDENTIFIER MODIFIED="2013-08-22 09:30:28 +0100" MODIFIED_BY="Lindsay Stead" TYPE="OTHER" VALUE="9400123000002832"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270064"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-2003" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="George 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-08-22 10:20:13 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS</AU>
<TI>A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation</TI>
<SO>Biological Psychiatry</SO>
<YR>2003</YR>
<VL>53</VL>
<NO>2</NO>
<PG>136-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270067"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;results reported for 39 people. 6m f-up planned. Added to ongoing studies for 2002/1 7790 28/1/03 Probably published Jan 2003 as George, et al in Biological Psychiatry, look for ref&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lara XD, Vessicchio JC, Termine A, Kosten TR, O'Malley SS, George TP</AU>
<TI>Selegiline versus placebo for smoking cessation in nicotine dependent refractory smokers (PO2 02)</TI>
<SO>Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23-23 Seattle Washington</SO>
<YR>2001</YR>
<PG>53</PG>
<IDENTIFIERS MODIFIED="2013-08-22 10:20:18 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000002571"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-George-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="George 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al</AU>
<TI>A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>11</NO>
<PG>1092-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270070"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 16:37:59 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>George TP, Vessicchio JC, Weinberger AH, Sacco KA</AU>
<TI>Sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia (SYM11C)</TI>
<SO>Society for Research on Nicotine and Tobacco 13th Annual Meeting February 21-24, Austin, Texas</SO>
<YR>2007</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270071"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:33:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Used In Schizophrenia background, but substudy of George 2008, linked in CRS not added as reference in review&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:33:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Moss TG, Sacco KA, Allen TM, Weinberger AH, Vessicchio JC, George TP</AU>
<TI>Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>1-2</NO>
<PG>94-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005367"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270072"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-20 15:32:32 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270069"/><IDENTIFIER MODIFIED="2013-08-20 15:32:32 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00124683"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzales-2001" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Gonzales 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Gonzales D, Nides M, Ferry LH, Segall N, Herrero L, Modell J, et al</AU>
<TI>Retreatment with bupropion SR: results from 12-month follow-up (RP-83)</TI>
<SO>Rapid Communication Poster Abstracts. Society for Research on Nicotine and Tobacco 8th Annual Meeting, February 20-23 Savannah, Georgia</SO>
<YR>2002</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270074"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, et al</AU>
<TI>Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo-controlled study</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>69</VL>
<PG>438-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270075"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270073"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzales-2006" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Gonzales 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;2006&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al</AU>
<TI>Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<PG>47-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270077"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:53:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sent to Gareth H 22/06/11&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:53:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hays JT, Leischow SJ, Lawrence D, Lee TC</AU>
<TI>Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>574-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005608"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270078"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson KC, Nahoopii R, Said Q, Dirani R, Brixner D</AU>
<TI>An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation</TI>
<SO>Journal of Occupational &amp; Environmental Medicine</SO>
<YR>2007</YR>
<VL>49</VL>
<NO>4</NO>
<PG>453-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270079"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Uses data from Jorenby 2006, Gonzales 2006, Oncken 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al</AU>
<TI>Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>3</NO>
<PG>641-50</PG>
<PB>Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012713"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270080"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:35:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comment on Hays 2010 article, which uses data from Jorenby 2006 and Gonzalez 2006&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:35:51 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Prignot J</AU>
<TI>Care for adherence to treatment for tobacco dependence</TI>
<SO>Breathe</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>3</NO>
<PG>291</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011702"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270081"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 16:54:59 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West R, Baker CL, Cappelleri JC, Bushmakin AG</AU>
<TI>Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt</TI>
<SO>Psychopharmacology</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>3</NO>
<PG>371-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270082"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 17:13:31 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270076"/><IDENTIFIER MODIFIED="2013-08-27 17:13:31 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00141206"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-G_x00f3_recka-2003" NAME="Górecka 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;2004 found too late to include. 15052977&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Górecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J</AU>
<TI>Effect of treatment for nicotine dependence in patients with COPD</TI>
<TO>Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc</TO>
<SO>Pneumonologia i Alergologia Polska</SO>
<YR>2003</YR>
<VL>71</VL>
<PG>411-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270084"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270083"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grant-2007" MODIFIED="2013-08-27 16:02:51 +0100" MODIFIED_BY="Lindsay Stead" NAME="Grant 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ</AU>
<TI>Bupropion and nicotine patch as smoking cessation aids in alcoholics</TI>
<SO>Alcohol</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>5</NO>
<PG>381-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270086"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:02:51 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270085"/><IDENTIFIER MODIFIED="2013-08-27 16:02:51 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00044434"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haggstr_x00e4_m-2006" NAME="Haggsträm 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;New 2006&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haggsträm FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC</AU>
<TI>A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results</TI>
<SO>Pulmonary Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>19</VL>
<PG>205-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270088"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270087"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1998" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Hall 1998" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas AL, Munoz RF, Humfleet GL, Reus VI, Hall SM</AU>
<TI>Influences of mood, depression history, and treatment modality on outcomes in smoking cessation</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<PG>563-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270090"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 16:41:38 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Gorecki JA, Reus VI, Humfleet GL, Munoz RF</AU>
<TI>Belief about drug assignment and abstinence in treatment of cigarette smoking using nortriptyline</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>4</NO>
<PG>467-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270091"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, et al</AU>
<TI>Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55</VL>
<PG>683-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270092"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mooney ME, Reus VI, Gorecki J, Hall SM, Humfleet GL, Munoz RF, et al</AU>
<TI>Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>83</VL>
<PG>436-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270093"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270089"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2002" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Hall 2002" YEAR="2001">
<REFERENCE MODIFIED="2009-07-28 16:41:39 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Gorecki JA, Reus VI, Humfleet GL, Munoz RF</AU>
<TI>Belief about drug assignment and abstinence in treatment of cigarette smoking using nortriptyline</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>4</NO>
<PG>467-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270095"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hall SM, Humfleet G, Maude-Griffin R, Reus VI, Munoz R, Hartz DT</AU>
<TI>Nortriptyline versus bupropion and medical management versus psychological intervention in smoking treatment (PA 5A)</TI>
<SO>Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23-23 Seattle, Washington</SO>
<YR>2001</YR>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270096"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New 2003&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R</AU>
<TI>Psychological intervention and antidepressant treatment in smoking cessation</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2002</YR>
<VL>59</VL>
<PG>930-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270097"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Lightwood JM, Humfleet GL, Bostrom A, Reus VI, Munoz R</AU>
<TI>Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation</TI>
<SO>Journal of Behavioral Health Services &amp; Research</SO>
<YR>2005</YR>
<VL>32</VL>
<PG>381-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270098"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mooney ME, Reus VI, Gorecki J, Hall SM, Humfleet GL, Munoz RF, et al</AU>
<TI>Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>83</VL>
<PG>436-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270099"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2004" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Hall 2004" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Humfleet GL, Reus VI, Munoz RF, Cullen J</AU>
<TI>Extended nortriptyline and psychological treatment for cigarette smoking</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<VL>161</VL>
<PG>2100-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270101"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mooney ME, Reus VI, Gorecki J, Hall SM, Humfleet GL, Munoz RF, et al</AU>
<TI>Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>83</VL>
<PG>436-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270102"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270100"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2011" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hall 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-08-21 09:47:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;List as excl for antidepressants. Listed as excl for combined &amp;amp; behav adj. Reason for excl in behav adj; 'Similar design to Hall 2004: Factorial trial crossing extended behavioural support (CBT) with medical management only, and bupropion or placebo, as adjunct to nicotine patch and 5 group support sessions over 11 weeks. As with Hall 2004, placebo arms could have been compared, but no other trials confounded behavioural support with placebo, and the support common to all conditions was also much more intensive than in other trials&lt;/p&gt;" NOTES_MODIFIED="2013-08-21 09:47:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Hall SM, Humfleet GL, Munoz RF, Reus VI, Prochaska JJ, Robbins JA</AU>
<TI>Using extended cognitive behavioral treatment and medication to treat dependent smokers</TI>
<SO>American Journal of Public Health</SO>
<YR>2011</YR>
<VL>101</VL>
<NO>12</NO>
<PG>2349-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011870"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270104"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exercise component confounded with other Rp components&lt;br&gt;Links to Hall 2011 trial of bupropion but no info to include in RP update. Not NRT&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Prochaska JJ, Hall SM, Humfleet G, Munoz RF, Reus V, Gorecki J, et al</AU>
<TI>Physical activity as a strategy for maintaining tobacco abstinence: a randomized trial</TI>
<SO>Preventive Medicine</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>2</NO>
<PG>215-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000004887"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270105"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 11:32:56 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270103"/><IDENTIFIER MODIFIED="2013-09-04 11:32:56 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00087880"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hatsukami-2004" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hatsukami 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, et al</AU>
<TI>Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>116</VL>
<PG>151-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270107"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;added to refs 2001&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rennard S, Hatsukami D, Malcolm R E, Patel MK, Jamerson BD, Dozier G</AU>
<TI>Zyban (bupropion HCL SR) vs placebo as an aid to smoking reduction among smokers unwilling and unable to quit smoking (PO4 77)</TI>
<SO>Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23-23 Seattle, Washington</SO>
<YR>2001</YR>
<PG>117</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270108"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hays-2001" MODIFIED="2013-12-03 14:20:12 +0000" MODIFIED_BY="[Empty name]" NAME="Hays 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-03 14:20:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abel GA, Hays JT, Decker PA, Croghan GA, Kuter DJ, Rigotti NA</AU>
<TI>Effects of biochemically confirmed smoking cessation on white blood cell count</TI>
<SO>Mayo Clin Proceedings</SO>
<YR>2005</YR>
<VL>80</VL>
<PG>1022-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270110"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox LS, Patten CA, Niaura RS, Decker PA, Rigotti N, Sachs DPL, et al</AU>
<TI>Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>828-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270111"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, et al</AU>
<TI>The effect of bupropion sustained-release on cigarette craving after smoking cessation</TI>
<SO>Clinical Therapeutics</SO>
<YR>2002</YR>
<VL>24</VL>
<PG>540-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270112"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durcan MJ, Johnston JA, White J, Gonzales D, Sachs DP, Rigotti N, Niaura R</AU>
<TI>Bupropion SR for relapse prevention: a "slips-allowed" analysis</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>5</NO>
<PG>456-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270113"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales D, Bjornson W, Durcan MJ, White JD, Johnston JA, Buist AS, et al</AU>
<TI>Effects of gender on relapse prevention in smokers treated with bupropion SR</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>234-39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270114"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Published article cited 2002/1, changed from Hays 2000 to Hays 2001&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al</AU>
<TI>Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<PG>423-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270115"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ, et al</AU>
<TI>Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome</TI>
<SO>Addictive Behaviors</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>4</NO>
<PG>493-507</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270116"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rigotti N, Thorndike AN, Durcan MJ, White JD, Johnston AJ, Niaura R, et al</AU>
<TI>Attenuation of post-cessation weight gain in smokers taking bupropion: The effect of gender</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 6th Annual Meeting; Feb 18-20 2000; Arlington VA</SO>
<YR>2000</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270117"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270109"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hays-2009" MODIFIED="2013-08-27 15:13:21 +0100" MODIFIED_BY="[Empty name]" NAME="Hays 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-21 15:25:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;List as excl from antidepressants. NRT for all participants&lt;/p&gt;" NOTES_MODIFIED="2013-08-21 15:25:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA</AU>
<TI>A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>7</NO>
<PG>859-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005366"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270119"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 15:13:21 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270118"/><IDENTIFIER MODIFIED="2013-08-27 15:13:21 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00000457"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hertzberg-2001" NAME="Hertzberg 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hertzberg MA, Moore SD, Feldman ME, Beckham JC</AU>
<TI>A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>94-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270121"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270120"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holt-2005" NAME="Holt 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R</AU>
<TI>Efficacy of bupropion in the indigenous Maori population in New Zealand</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<PG>120-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270123"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270122"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hurt-1997" MODIFIED="2013-12-03 14:20:36 +0000" MODIFIED_BY="L S" NAME="Hurt 1997" YEAR="1996">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added to references for Hurt 1997 for 2001/4 update&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, et al</AU>
<TI>Bupropion for smoking cessation: predictors of successful outcome</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<PG>1357-1364</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270125"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Glaxo Wellcome. Presentation for FDA approval of Bupropion sustained release for smoking cessation, Dr J. Andrew Johnston. December 10 1996.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Glaxo Wellcome</AU>
<TI>Presentation for FDA approval of Bupropion sustained release for smoking cessation</TI>
<SO>Dr J. Andrew Johnston</SO>
<YR>December 10 1996</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270126"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, et al</AU>
<TI>Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>174</VL>
<PG>173-8</PG>
<IDENTIFIERS MODIFIED="2008-06-17 12:59:24 +0100" MODIFIED_BY="L S"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270127"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Glover ED, Sachs DPL, et al</AU>
<TI>Bupropion for smoking cessation: A double-blind, placebo-controlled dose response trial [Abstract]</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>137</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270128"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, et al</AU>
<TI>A comparison of sustained-release bupropion and placebo for smoking cessation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>1195-202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270129"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:20:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added to study refs 2001&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:20:36 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J</AU>
<TI>Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>131-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270130"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hurt-2003" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hurt 2003" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hurt RD, Croghan GA, Sloan JA, Krook JE, Silberstein PT</AU>
<TI>Bupropion for relapse prevention after nicotine patch therapy [PA 5B abstract ]</TI>
<SO>Society for Research on Nicotine and Tobacco 7th Annual Meeting, March 23-23 2001, Seattle, Washington</SO>
<YR>2001</YR>
<PG>32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270132"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added as main ref 2004 JRH suggests not worrying about second arm. 17/5/04&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al</AU>
<TI>Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>914-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270133"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270131"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorenby-1999" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="L S" NAME="Jorenby 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, et al</AU>
<TI>Impact of prior nicotine replacement therapy on smoking cessation efficacy</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2002</YR>
<VL>26</VL>
<PG>213-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270135"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ref added to study 2001&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, et al</AU>
<TI>Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo</TI>
<SO>Clinical Therapeutics</SO>
<YR>2001</YR>
<VL>23</VL>
<PG>744-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270136"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al</AU>
<TI>A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>685-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270137"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-17 12:59:43 +0100" MODIFIED_BY="L S" NOTES="&lt;p&gt;Added to refs 2002/1 update&lt;/p&gt;" NOTES_MODIFIED="2008-06-17 12:59:43 +0100" NOTES_MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen K, Fiore MC</AU>
<TI>Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation</TI>
<SO>Preventive Medicine</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>209-216</PG>
<IDENTIFIERS MODIFIED="2008-06-17 12:59:43 +0100" MODIFIED_BY="L S"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270138"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston AJ, et al</AU>
<TI>Targeting smokers at increased risk for relapse: treating women and those with a history of depression</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>99-109</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270139"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270134"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorenby-2006" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Jorenby 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-08-20 16:26:52 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="OTHER">
<AU>Hays JT, Leischow SJ, Lawrence D, Lee TC</AU>
<TI>Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>574-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005608"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;New 2006&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al</AU>
<TI>Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<PG>56-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270142"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Uses data from Jorenby 2006, Gonzales 2006, Oncken 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al</AU>
<TI>Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>3</NO>
<PG>641-50</PG>
<PB>Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012713"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270143"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 16:55:22 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West R, Baker CL, Cappelleri JC, Bushmakin AG</AU>
<TI>Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt</TI>
<SO>Psychopharmacology</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>3</NO>
<PG>371-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 17:16:40 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270140"/><IDENTIFIER MODIFIED="2013-08-27 17:16:40 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00143364"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahn-2012" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kahn 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Test of selegiline. All participants had behavioural support&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, et al</AU>
<TI>Selegiline transdermal system (STS) as an aid for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2012</YR>
<VL>14</VL>
<NO>3</NO>
<PG>377-82</PG>
<PB>Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom)</PB>
<CY>United Kingdom</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000014198"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270146"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-16 14:38:59 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270145"/><IDENTIFIER MODIFIED="2013-07-16 14:38:59 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00439413"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalman-2011" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kalman 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;All participants received NRT&lt;br&gt;Check for training 14/3/12&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al</AU>
<TI>Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2011</YR>
<VL>118</VL>
<NO>2-3</NO>
<PG>111-8</PG>
<CY>Ireland</CY>
<IDENTIFIERS MODIFIED="2013-07-16 13:40:52 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011678"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270148"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 09:50:45 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not a cessation study&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 09:50:45 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Madden GJ, Kalman D</AU>
<TI>Effects of bupropion on simulated demand for cigarettes and the subjective effects of smoking</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>4</NO>
<PG>416-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005651"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270149"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-16 13:40:19 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D</AU>
<TI>Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: Preliminary results using an aggregate genetic risk score</TI>
<SO>Substance Abuse : Research and Treatment</SO>
<YR>2012</YR>
<VL>6</VL>
<NO>1</NO>
<PG>107-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-16 13:17:13 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270147"/><IDENTIFIER MODIFIED="2013-07-16 13:17:13 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00304707"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-2000" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Killen 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A</AU>
<TI>Onset of major depression during treatment for nicotine dependence</TI>
<SO>Addictive Behaviors</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>461-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270152"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, et al</AU>
<TI>Nicotine patch and paroxetine for smoking cessation</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2000</YR>
<VL>68</VL>
<PG>883-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270151"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-2004" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NAME="Killen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Samuels D</AU>
<TI>Major depression among adolescent smokers undergoing treatment for nicotine dependence</TI>
<SO>Addictive Behaviors</SO>
<YR>2004</YR>
<VL>29</VL>
<PG>1517-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270155"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New for 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, et al</AU>
<TI>Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<PG>729-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270156"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-2006" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Killen 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New for 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Arredondo C, Cromp D, et al</AU>
<TI>Extended treatment with Bupropion SR for cigarette smoking cessation</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2006</YR>
<VL>74</VL>
<NO>2</NO>
<PG>286-94</PG>
<IDENTIFIERS MODIFIED="2013-11-14 14:08:35 +0000" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270158"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to two studies, neither tests of NRT? Not relevant to NRT or Combined/Adj (though parent stuies might be)&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al</AU>
<TI>Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy</TI>
<SO>American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics</SO>
<YR>2011</YR>
<VL>156</VL>
<NO>3</NO>
<PG>275-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006100"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270159"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 15:56:03 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270157"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killen-2010" MODIFIED="2013-12-03 14:21:18 +0000" MODIFIED_BY="[Empty name]" NAME="Killen 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-03 14:21:18 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sent to Gareth H 22/06/11. Not combined, trial of pharma&lt;br&gt;Check for training&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:21:18 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Killen JD, Fortmann SP, Murphy GMJ, Hayward C, Fong D, Lowenthal K, et al</AU>
<TI>Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>9</NO>
<PG>1660-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005871"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270161"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-16 14:48:17 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270160"/><IDENTIFIER MODIFIED="2013-07-16 14:48:16 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00218647"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2010" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Levine 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sent to RvdM 15/12/10. Behavioural interventions were matched for intensity, specifically tested a weight related intervention. No minimal intensity control&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, et al</AU>
<TI>Bupropion and cognitive behavioural therapy for weight-concerned women smokers</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2010</YR>
<VL>170</VL>
<NO>6</NO>
<PG>543-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005577"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270163"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-07-16 14:42:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Levine 2010 Bupropion and cognitive behavioral therapy for weight-concerned women smokers.  Not group format&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 14:42:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Okun ML, Levine MD, Houck P, Perkins KA, Marcus MD</AU>
<TI>Subjective sleep disturbance during a smoking cessation program: associations with relapse</TI>
<SO>Addictive Behaviors</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>8</NO>
<PG>861-4</PG>
<IDENTIFIERS MODIFIED="2013-07-16 14:42:52 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011571"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270164"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:31:44 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270162"/><IDENTIFIER MODIFIED="2013-08-27 16:31:44 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00006170"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarthy-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="McCarthy 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 11:28:15 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to McCarthy NTR 2008&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:28:15 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McCarthy DE, Piasecki TM, Jorenby DE, Lawrence DL, Shiffman S, Baker TB</AU>
<TI>A multi-level analysis of non-significant counseling effects in a randomized smoking cessation trial</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>12</NO>
<PG>2195-208</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005902"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270166"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB</AU>
<TI>Psychological mediators of bupropion sustained-release treatment for smoking cessation</TI>
<SO>Addiction</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>9</NO>
<PG>1521-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270167"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al</AU>
<TI>A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2008</YR>
<VL>10</VL>
<PG>717-29</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270168"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-06-18 14:58:27 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarthy DE</AU>
<TI>Mechanisms of tobacco cessation treatment: Self-report mediators of counseling and bupropion sustained release treatment</TI>
<SO>Dissertation Abstracts International: Section B: The Sciences and Engineering</SO>
<YR>2007</YR>
<VL>67</VL>
<NO>9-B</NO>
<PG>5414</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270169"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 11:56:38 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McCarthy DE. Piasecki TM, Lawrence DL, Fiore MC, Baker TB</AU>
<TI>Efficacy of bupropion SR and individual counseling among adults attempting to quit smoking (POS1-041)</TI>
<SO>Society for Research on Nicotine and Tobacco 10th Annual Meeting February 18-21, Phoenix, Arizona</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270170"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-03 14:57:59 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270165"/><IDENTIFIER MODIFIED="2013-09-03 14:57:59 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT01621009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muramoto-2007" MODIFIED="2013-08-20 16:10:43 +0100" MODIFIED_BY="Lindsay Stead" NAME="Muramoto 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-06-26 11:21:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Commentary on Muramoto 2007. Tagged Feb 2012&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:21:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Best D</AU>
<TI>Bupropion assists with tobacco cessation in adolescents but relapse is high</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>152</VL>
<NO>5</NO>
<PG>738-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011733"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270172"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 17:07:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer LJ</AU>
<TI>Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation</TI>
<SO>Archives of Pediatrics &amp; Adolescent Medicine</SO>
<YR>2007</YR>
<VL>161</VL>
<PG>1068-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270173"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Taren D, Fankem S, Muramoto M</AU>
<TI>Weight loss in adolescents who quit smoking with bupropion [RP-071]</TI>
<SO>Society for Research on Nicotine and Tobacco 11th annual meeting, March 2005; Prague, Czech Republic. Rapid Communications posters</SO>
<YR>2005</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270174"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-20 16:10:43 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270171"/><IDENTIFIER MODIFIED="2013-08-20 16:10:43 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00344695"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myles-2004" NAME="Myles 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;New for 2006&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myles PS, Leslie K, Angliss M, Mezzavia P, Lee L</AU>
<TI>Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial</TI>
<SO>Anaesthesia</SO>
<YR>2004</YR>
<VL>59</VL>
<PG>1053-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270176"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270175"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niaura-2002" MODIFIED="2013-12-03 14:21:38 +0000" MODIFIED_BY="L S" NAME="Niaura 2002" YEAR="1997">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Moved from excluded study list 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, Depue JD, Murphy C, et al</AU>
<TI>Development of major depressive disorder during smoking-cessation treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<PG>534-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270178"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrelli B, Papandonatos G, Spring B, Hitsman B, Niaura R</AU>
<TI>Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>378-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270179"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrelli B, Spring B, Niaura R, Hitsman B, Papandonatos G</AU>
<TI>Influences of gender and weight gain on short-term relapse to smoking in a cessation trial</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2001</YR>
<VL>69</VL>
<PG>511-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270180"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-17 13:00:01 +0100" MODIFIED_BY="L S" NOTES="&lt;p&gt;Moved from excluded studies 2004&lt;/p&gt;" NOTES_MODIFIED="2008-06-17 13:00:01 +0100" NOTES_MODIFIED_BY="L S" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borrelli B, Spring B, Niaura R, Kristeller J, Ockene JK, Keuthen NJ</AU>
<TI>Weight suppression and weight rebound in ex-smokers treated with fluoxetine</TI>
<SO>Journal of Consulting and Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>67</VL>
<PG>124-31</PG>
<IDENTIFIERS MODIFIED="2008-06-17 13:00:01 +0100" MODIFIED_BY="L S"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270181"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cook JW, Spring B, McChargue DE, Borrelli B, Hitsman B, Niaura R, et al</AU>
<TI>Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial</TI>
<SO>Psychopharmacology</SO>
<YR>2004</YR>
<VL>173</VL>
<PG>153-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270182"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doran N, Spring B, Borrelli B, McChargue D, Hitsman B, Niaura R, Hedeker D</AU>
<TI>Elevated positive mood: a mixed blessing for abstinence</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>36-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270183"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:21:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ref added 2004&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:21:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hitsman B, Spring B, Borrelli B, Niaura R, Papandonatos GD</AU>
<TI>Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine</TI>
<SO>Experimental &amp; Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>9</VL>
<PG>355-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270184"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Moved to Niaura refs 2004. Previously a separate excluded study&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mizes JS, Sloan DM, Segraves K, Spring B, Pingatore R, Kristeller J</AU>
<TI>Fluoxetine and weight-gain in smoking cessation - examination of actual weight-gain and fear of weight-gain [abstract]</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<PG>491</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270185"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Original reference for unpublished data&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Niaura R, Goldstein M, Spring B, Keuthen N, Kristeller J, DePue J, et al</AU>
<TI>Fluoxetine for smoking cessation: A multicenter randomized double blind dose response study</TI>
<SO>Society for Behavioral Medicine Annual Meeting; April 18 1997; San Francisco, CA</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270186"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;updated with published details 2003/2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Niaura R, Spring B, Borrelli B, Hedeker D, Goldstein MG, Keuthen N, et al</AU>
<TI>Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2002</YR>
<VL>70</VL>
<PG>887-96</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270187"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Jack LM, Niaura R, Borrelli B, Spring B</AU>
<TI>Subgroups of smokers with different success rates after treatment with fluoxetine for smoking cessation [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>281</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270177"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nides-2006" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Nides 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al</AU>
<TI>Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<PG>1561-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270190"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Oncken C, Watsky E, Reeves K, Anziano R</AU>
<TI>Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo- and bupropion-controlled trial</TI>
<SO>Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005, Prague, Czech Republic</SO>
<YR>2005</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270191"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 16:10:06 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270189"/><IDENTIFIER MODIFIED="2013-09-04 16:10:06 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00150241"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parsons-2009" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Parsons 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Parsons A, Ingram J, Inglis J, Aveyard P, Johnstone E, Brown K, et al</AU>
<TI>A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2009</YR>
<VL>102</VL>
<NO>1-3</NO>
<PG>116-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005315"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270193"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 16:18:31 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270192"/><IDENTIFIER MODIFIED="2013-09-04 16:18:31 +0100" MODIFIED_BY="Lindsay Stead" TYPE="ISRCTN" VALUE=" ISRCTN31302738"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piper-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Piper 2007" YEAR="2004">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al</AU>
<TI>Efficacy of bupropion alone and in combination with nicotine gum</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>947-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270195"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to a trial but JHB searched and not sure which one - numbers don't match up with Piper papers&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al</AU>
<TI>Mediators of bupropion treatment effects (SYM 2C)</TI>
<SO>Society for Research on Nicotine and Tobacco 14th Annual Meeting February 26-March 1, Portland, Oregon</SO>
<YR>2008</YR>
<PG>31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005187"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270196"/><IDENTIFIER TYPE="OTHER" VALUE="9400123000005187"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 17:08:50 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Piper ME, Federman EB, Smith SS, Fiore MC, Baker TB</AU>
<TI>Efficacy of bupropion SR alone and combined with 4-mg gum (PA2-2)</TI>
<SO>Society for Research on Nicotine and Tobacco 10th Annual Meeting February 18-21, Phoenix, Arizona</SO>
<YR>2004</YR>
<PG>18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270197"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Federmen EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al</AU>
<TI>Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>2008</YR>
<VL>117</VL>
<PG>94-105</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270198"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 17:10:58 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME</AU>
<TI>Bupropion alone and in combination with nicotine gum: Efficacy, mediation and moderation</TI>
<SO>Dissertation Abstracts International: Section B: The Sciences and Engineering</SO>
<YR>2007</YR>
<VL>67</VL>
<NO>9-B</NO>
<PG>5418</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270199"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:59:55 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270194"/><IDENTIFIER MODIFIED="2013-08-27 16:59:54 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT01621022"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Piper-2009" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Piper 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-26 11:57:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Piper 2009 trial comparing multiple pharmacotherapies&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:57:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Asthana A, Johnson HM, Piper ME, Fiore MC, Baker TB, Stein JH</AU>
<TI>Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers</TI>
<SO>American Heart Journal</SO>
<YR>2010</YR>
<VL>160</VL>
<NO>3</NO>
<PG>458-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005744"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270201"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:54:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Piper 2009 is main trial report&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:54:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gepner AD, Piper ME, Johnson HM, Fiore MC, Baker TB, Stein JH</AU>
<TI>Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial</TI>
<SO>American Heart Journal</SO>
<YR>2011</YR>
<VL>161</VL>
<NO>1</NO>
<PG>145-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005846"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270202"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Piper 2009, main trial report&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC, et al</AU>
<TI>Smoker characteristics and smoking-cessation milestones</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2011</YR>
<VL>40</VL>
<NO>3</NO>
<PG>286-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006012"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270203"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:53:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Piper 2009 is main trial report&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:53:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB</AU>
<TI>The effect of five smoking cessation pharmacotherapies on smoking cessation milestones</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2011</YR>
<VL>79</VL>
<NO>1</NO>
<PG>34-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006131"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270204"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 11:30:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Piper 2009 is main trial report. Comes up on schizophrenia search, check&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:30:03 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB</AU>
<TI>Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment</TI>
<SO>Addiction</SO>
<YR>2011</YR>
<VL>106</VL>
<NO>2</NO>
<PG>418-27</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005906"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270205"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Links to Smith 2009 &amp;amp; Piper 2009&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, et al</AU>
<TI>Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>647-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005794"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270206"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:34:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Linked to Piper 2009&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:34:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Piper ME, Kenford S, Fiore MC, Baker TB</AU>
<TI>Smoking cessation and quality of life: changes in life satisfaction over 3 years following a quit attempt</TI>
<SO>Annals of Behavioral Medicine</SO>
<YR>2012</YR>
<VL>43</VL>
<NO>2</NO>
<PG>262-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012954"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270207"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Links to one of the trials of 5 meds - Piper, et al. Add to refs. Not Combined&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Schlam TR, Cook JW, Sheffer MA, Smith SS, Loh WY, et al</AU>
<TI>Tobacco withdrawal components and their relations with cessation success</TI>
<SO>Psychopharmacology</SO>
<YR>2011</YR>
<VL>216</VL>
<NO>4</NO>
<PG>569-78</PG>
<IDENTIFIERS MODIFIED="2013-08-22 13:40:12 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011701"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270208"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Very similar to Smith 2009 but this is an efficacy study and compares to placebo.&lt;br&gt;[Erratum appears in Arch Gen Psychiatry. 2010 Jan;67(1):77 Note: Dosage error in article text]&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al</AU>
<TI>A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1253-62</PG>
<IDENTIFIERS MODIFIED="2013-08-22 13:36:54 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005399"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270209"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 16:54:42 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270200"/><IDENTIFIER MODIFIED="2013-09-04 16:54:42 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00332644"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Planer-2011" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Planer 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;LS added to hospital RevMan file 20/12/11. Exclude from nursing since common to both conditions. No need to list as excl from TC&lt;br&gt;Added to RevMan nursing file 20/12/11&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al</AU>
<TI>Bupropion for smoking cessation in patients with acute coronary syndrome</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2011</YR>
<VL>171</VL>
<NO>12</NO>
<PG>1055-60</PG>
<IDENTIFIERS MODIFIED="2013-08-22 13:41:54 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000010561"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270211"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270210"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prochazka-1998" NAME="Prochazka 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D</AU>
<TI>A randomized trial of nortriptyline for smoking cessation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>2035-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270213"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270212"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prochazka-2004" MODIFIED="2013-09-04 16:08:26 +0100" MODIFIED_BY="Lindsay Stead" NAME="Prochazka 2004" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Reference &amp;amp; ID changed to published study 2006&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prochazka AV, Kick S, Steinbrunn C, Miyoshi T, Fryer GE</AU>
<TI>A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<PG>2229-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270215"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New study based on abstract 2002/1&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Prochazka AV, Reyes R, Steinbrunn C, Miyoshi T</AU>
<TI>Randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation (PO3 26)</TI>
<SO>Society for Research on Nicotine and Tobacco 7th Annual Meeting, March 23-23 2001, Seattle, Washington</SO>
<YR>2001</YR>
<PG>73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270216"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 16:08:26 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270214"/><IDENTIFIER MODIFIED="2013-09-04 16:08:26 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00018148"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richmond-2013" MODIFIED="2013-10-17 15:56:42 +0100" MODIFIED_BY="[Empty name]" NAME="Richmond 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-08-13 11:40:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richmond R, Indig D, Butler T, Wilhelm K, Archer V and Wodak A</AU>
<TI>A randomized controlled trial of a smoking cessation intervention conducted among prisoners</TI>
<SO>Addiction</SO>
<YR>2013</YR>
<VL>108</VL>
<NO>5</NO>
<PG>966-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-10-17 15:56:42 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270217"/><IDENTIFIER MODIFIED="2013-10-17 15:56:42 +0100" MODIFIED_BY="Lindsay Stead" TYPE="OTHER" VALUE="Australian New Zealand Clinical Trials Registry #12606000229572."/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rigotti-2006" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Rigotti 2006" YEAR="2005">
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rigotti N, Thorndike A, Regan S, Pasternak R, Chang Y, McKool K, et al</AU>
<TI>Safety and efficacy of bupropion for smokers hospitalized with acute cardiovascular disease [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>682</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270220"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;New 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rigotti NA., Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al</AU>
<TI>Bupropion for smokers hospitalized with acute cardiovascular disease</TI>
<SO>American Journal of Medicine</SO>
<YR>2006</YR>
<VL>119</VL>
<PG>1080-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270221"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thorndike AN, Regan S, McKool K, Pasternak RC, Swartz S, Torres-Finnerty N, et al</AU>
<TI>Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2008</YR>
<VL>168</VL>
<NO>2</NO>
<PG>186-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270222"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 09:42:40 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270219"/><IDENTIFIER MODIFIED="2013-09-04 09:42:40 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00181818"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-2013" MODIFIED="2013-09-18 15:29:53 +0100" MODIFIED_BY="Lindsay Stead" NAME="Rose 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-09-18 15:29:53 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Hand entered. Get full Medline record&lt;/p&gt;" NOTES_MODIFIED="2013-09-18 15:29:53 +0100" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Behm FM</AU>
<TI>Adapting smoking cessation treatment according to initial response to precessation nicotine patch</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2013</YR>
<VL>170</VL>
<PG>860-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400107000001313"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270224"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 12:16:04 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270223"/><IDENTIFIER MODIFIED="2013-08-27 12:16:04 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00894166"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rovina-2009" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Rovina 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not combined, all participants had some intervention&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rovina N, Nikoloutsou I, Katsani G, Dima E, Fransis K, Roussos C, et al</AU>
<TI>Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice</TI>
<SO>Therapeutic Advances in Respiratory Disease</SO>
<YR>2009</YR>
<VL>3</VL>
<NO>6</NO>
<PG>279-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005487"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270226"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270225"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Saules-2004" MODIFIED="2009-07-30 11:12:14 +0100" MODIFIED_BY="Lindsay Stead" NAME="Saules 2004" NOTES="&lt;p&gt;The reference is incorrect as it appears. It should be volume 13.&lt;/p&gt;" NOTES_MODIFIED="2009-07-30 11:12:14 +0100" NOTES_MODIFIED_BY="Lindsay Stead" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;New 2006 (Previously Schuh excluded)&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Saules KK, Schuh LM, Arfken CL, Reed K, Kilbey MM, Schuster CR</AU>
<TI>Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy</TI>
<SO>American Journal on Addictions</SO>
<YR>2004</YR>
<VL>14</VL>
<PG>438-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270228"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Schuh 2000 in excluded studies until 2004&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Schuh LM, Downey KK, Hopper JA, Tancer M, Schuster CR</AU>
<TI>Fluoxetine in smoking cessation treatment</TI>
<SO>College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270229"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270227"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2007" MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" NAME="Schmitz 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Stotts AL, Mooney ME, Delaune KA, Moeller GF</AU>
<TI>Bupropion and cognitive-behavioral therapy for smoking cessation in women.[erratum appears in Nicotine Tob Res. 2007 Jul;9(7):785]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>6</NO>
<PG>699-709</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270231"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270230"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnoll-2010" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Schnoll 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Schnoll Cancer Causes Control 2010. Not rel to NRT&lt;br&gt;All patients receive behavioral counseling, nicotine replacement therapy (NRT; the transdermal patch), and are randomized to receive either Zyban (bupropion SR) or placebo for 9 weeks&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Martinez E, Tatum KL, Weber DM, Kuzla N, Pendley A, Campbell K, et al</AU>
<TI>Issues related to implementing a smoking cessation clinical trial for cancer patients</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2009</YR>
<VL>20</VL>
<NO>1</NO>
<PG>97-104</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005109"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270233"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-26 11:15:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schnoll R, Lazev A, Sobel M, Tatum K, Butler D, Lerman C</AU>
<TI>Preliminary results from a randomized trial of bupropion for smoking cessation among cancer patients</TI>
<SO>Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March, Prague, Czech Republic</SO>
<YR>2005</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270234"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 11:31:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Schnoll Cancer Causes Control 2010. Marginal to be relevant to depression. Trial used bupropion&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:31:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schnoll RA, Martinez E, Langer C, Miyamoto C, Leone F</AU>
<TI>Predictors of smoking cessation among cancer patients enrolled in a smoking cessation program</TI>
<SO>Acta Oncologica</SO>
<YR>2011</YR>
<VL>50</VL>
<NO>5</NO>
<PG>678-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006110"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270235"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Full pub of Schnoll 2005 SRNT presentation which is in AWAC section of antidepressants. Sent to RvdM 15/12/10&lt;br&gt;Sent to Gareth H 22/06/11&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Schnoll RA, Martinez E, Tatum KL, Weber DM, Kuzla N, Glass M, et al</AU>
<TI>A bupropion smoking cessation clinical trial for cancer patients</TI>
<SO>Cancer Causes &amp; Control</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>6</NO>
<PG>811-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005737"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270236"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270232"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Selby-2003" MODIFIED="2013-08-12 12:00:28 +0100" MODIFIED_BY="[Empty name]" NAME="Selby 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline Clinical Trials Register</AU>
<TI>Study No: ZYB40001. A randomized, double-blind, placebo-controlled, 12-week smoking cessation trial of Zyban (150 mg bid) in adult smokers previously treated with Zyban</TI>
<SO>http--ctr.glaxowellcome.co.uk-Summary-bupropion-IV_ZYB40001.pdf</SO>
<YR>(accessed 23rd August 2006)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270238"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selby P, Ainslie M, Stepner N, Roberts J</AU>
<TI>Sustained-release bupropion (Zybanr) is effective in the re-treatment of relapsed adult smokers</TI>
<SO>Am J Respir Crit Care Med</SO>
<YR>2003</YR>
<VL>167</VL>
<NO>7</NO>
<PG>A47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270239"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Included 2006&lt;/p&gt;" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Selby P, Brands B, Stepner N</AU>
<TI>Retreatment with ZYban SR: 52 week follow-up of a Canadian Multicentre trial (POS3-63)</TI>
<SO>Society for Research on Nicotine and Tobacco 9th Annual Meeting, February 19-22, New Orleans</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270240"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Selby P, Brosky G, Baker R, Lertzman M, Dakin P, Roberts J</AU>
<TI>Zyban is effective in the retreatment of relapsed adult smokers (PO4 68)</TI>
<SO>Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23-23 Seattle Washington</SO>
<YR>2001</YR>
<PG>114</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270241"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270237"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siddiqi-2013" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Siddiqi 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al</AU>
<TI>Action to stop smoking in suspected tuberculosis (assist) in Pakistan: A cluster randomized, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2013</YR>
<VL>158</VL>
<NO>9</NO>
<PG>667-75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400107000000417"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270243"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-22 13:50:23 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Published 2013&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 13:50:23 +0100" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siddiqi K, Khan A, Ahmad M, Shafiq-ur-Rehman</AU>
<TI>An intervention to stop smoking among patients suspected of TB--evaluation of an integrated approach</TI>
<SO>BMC Public Health</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>160</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011594"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270244"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270242"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-2004" MODIFIED="2009-07-28 17:41:24 +0100" MODIFIED_BY="Lindsay Stead" NAME="Simon 2004" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caplan BJ</AU>
<TI>The "bupropion for smoking cessation" trial from a family practice perspective</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<PG>470</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270246"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Published trial added and reference changed 2006&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Simon JA, Duncan C, Carmody TP, Hudes ES</AU>
<TI>Bupropion for smoking cessation: a randomized trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<PG>1797-803</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270247"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon JA, Duncan C, Carmody TP, Hudes ES</AU>
<TI>Bupropion plus nicotine replacement no better than replacement alone</TI>
<SO>Journal of Family Practice</SO>
<YR>2004</YR>
<VL>53</VL>
<PG>953-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270248"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270245"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-2009" MODIFIED="2013-08-27 13:14:01 +0100" MODIFIED_BY="Lindsay Stead" NAME="Simon 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP</AU>
<TI>Sustained-release bupropion for hospital-based smoking cessation: a randomized trial</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>6</NO>
<PG>663-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270250"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 13:14:01 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270249"/><IDENTIFIER MODIFIED="2013-08-27 13:14:01 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00261170"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-2009" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Links to Smith 2009 &amp;amp; Piper 2009&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, et al</AU>
<TI>Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>647-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005794"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270252"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Very similar to Piper 2009 but this is an effectiveness study NCT00296647. LS removed incorrect link to AD Piper 2009. Created new study. Unclear why there is no study link from NRT review&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al</AU>
<TI>Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>22</NO>
<PG>2148-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005493"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270253"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270251"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-SMK20001" MODIFIED="2013-12-03 14:21:53 +0000" MODIFIED_BY="Lindsay Stead" NAME="SMK20001" NOTES="&lt;p&gt;Link updated 2009&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:21:53 +0000" NOTES_MODIFIED_BY="Lindsay Stead" YEAR="2001">
<REFERENCE MODIFIED="2013-12-03 14:21:53 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline Clinical Trials Register</AU>
<TI>Study No: SMK 20001. A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation</TI>
<SO>http://www.gsk-clinicalstudyregister.com/files/pdf/812.pdf</SO>
<YR>(accessed 4th August 2009)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270255"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270254"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sood-2010" MODIFIED="2013-12-03 11:32:39 +0000" MODIFIED_BY="[Empty name]" NAME="Sood 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-03 11:32:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;In antidepressants as ongoing&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:32:39 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR</AU>
<TI>A randomized clinical trial of St. John's wort for smoking cessation</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>7</NO>
<PG>761-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005770"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270257"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-16 12:01:47 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270256"/><IDENTIFIER MODIFIED="2013-07-16 12:01:47 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00405912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sood-2012" MODIFIED="2013-12-03 11:32:54 +0000" MODIFIED_BY="[Empty name]" NAME="Sood 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-03 11:32:54 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Supplement was adjunct to behavioural support. Wait for Medline record&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:32:54 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sood A, Prasad K, Croghan IT, Schroeder DR, Ehlers SL, Ebbert JO</AU>
<TI>S-Adenosyl-L-methionine (SAMe) for smoking abstinence: A randomized clinical trial</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>9</NO>
<PG>854-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000015738"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-21 10:08:00 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270258"/><IDENTIFIER MODIFIED="2013-08-21 10:08:00 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00722124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spring-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Spring 2007" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Carrington A, Doran N, Spring B</AU>
<TI>Fluoxetine moderates the association between trait-anxiety and smoking status following behavioral treatment for smoking cessation (POS4-81)</TI>
<SO>Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19-22 New Orleans, Louisiana</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270261"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spring B, Doran N, Pagoto S, McChargue D, Cook JW, Bailey K, et al</AU>
<TI>Fluoxetine, smoking, and history of major depression: A randomized controlled trial</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>2007</YR>
<VL>75</VL>
<PG>85-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270262"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;New 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Spring B, Doran N, Pagoto S, McChargue DE, Cook JW, Bailey K, et al</AU>
<TI>Reduced abstinence for smokers previously treated with fluoxetine (PA1-1)</TI>
<SO>Society for Research on Nicotine and Tobacco 10th Annual Meeting February 18-21, Phoenix, Arizona</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270263"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 15:30:21 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270260"/><IDENTIFIER MODIFIED="2013-09-04 15:30:21 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00018174"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stapleton-2013" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Stapleton 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al</AU>
<TI>Randomized trial of NRT, bupropion, and NRT plus bupropion for smoking cessation: effectiveness in clinical practice</TI>
<SO>Addiction</SO>
<YR>2013</YR>
<VL>108</VL>
<NO>12</NO>
<PG>2193-201</PG>
<IDENTIFIERS MODIFIED="2013-09-16 11:23:29 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270265"/><IDENTIFIER MODIFIED="2013-09-16 11:23:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/add.12304"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-16 11:22:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270264"/><IDENTIFIER MODIFIED="2013-09-16 11:22:05 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="91464711"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swan-2003" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Swan 2003" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Catz S, Jack LM, Swan GE, McClure J</AU>
<TI>Adherence to bupropion SR in a smoking cessation effectiveness trial (POS2-77)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270267"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jack LM, Swan GE, Thompson E, Curry SJ, McAfee T, Dacey S, Bergman K</AU>
<TI>Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting</TI>
<SO>Preventive Medicine</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>585-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270268"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Javitz HS, Swan GE, Zbikowski SM, Curry SJ, McAfee TA, Decker DL, et al</AU>
<TI>Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective</TI>
<SO>American Journal of Managed Care</SO>
<YR>2004</YR>
<VL>10</VL>
<PG>217-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270269"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McAfee T, Zbikowski SM, Bush T, McClure J, Swan G, Jack LM, Curry S</AU>
<TI>The effectiveness of bupropion SR and phone counseling for light and heavy smokers (PA2-1)</TI>
<SO>Society for Research on Nicotine and Tobacco 10th Annual Meeting February 18-21, Phoenix, Arizona</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270270"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Jack LM, Curry S, Chorost M, Javitz H, McAfee T, Dacey S</AU>
<TI>Bupropion SR and counseling for smoking cessation in actual practice: Predictors of outcome</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>911-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270271"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Jack LM, Javitz HS, McAfee T, McClure JB</AU>
<TI>Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation</TI>
<SO>Central Nervous System Drugs</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>3</NO>
<PG>239-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270272"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, et al</AU>
<TI>Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR</TI>
<SO>Health Psychology</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>361-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270273"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T</AU>
<TI>Heterogeneity in 12-month outcome among female and male smokers</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>237-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270274"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as main reference 2004&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, Bergman K</AU>
<TI>Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<PG>2337-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270275"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al</AU>
<TI>Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR</TI>
<SO>Pharmacogenomics Journal</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>21-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270276"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270266"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tashkin-2001" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="L S" NAME="Tashkin 2001" YEAR="2000">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Patel MK, Tashkin DP, Kanner RE, Bailey WC, Buist A, Anderson PJ, et al</AU>
<TI>A multicenter evaluation of the effects of bupropion hydrochloride sustained release tablets (Bup SR) versus placebo in a population of smokers with chronic obstructive pulmonary disease (PO130)</TI>
<SO>11th World Conference on Tobacco or Health; Aug 6-11 2000; Chicago, ILL</SO>
<YR>2000</YR>
<VL>1</VL>
<PG>118</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270278"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="L S" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al</AU>
<TI>Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1571-75</PG>
<IDENTIFIERS MODIFIED="2008-06-17 12:56:30 +0100" MODIFIED_BY="L S"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270277"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonnesen-2003" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Tonnesen 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolliger CT, Gilljam H, Lebargy F, van Spiegel PI, Edwards J, Hider A, et al</AU>
<TI>Bupropion hydrochloride (Zyban) is effective and well tolerated as an aid to smoking cessation - a multicountry study. Abstract and presentation at 11th Annual meeting of European Respiratory Society, Berlin, September 22-26 2001</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18 (Suppl 33)</VL>
<PG>12s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270281"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added as primary ref and ID changed 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Tonstad S, Hjalmarson A, Lebargy F, van Spiegel PI, Hider A, et al</AU>
<TI>A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2003</YR>
<VL>254</VL>
<PG>184-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270282"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Used as primary ref until 2004&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tonstad S, Aaserud E, Hjalmarson A, Peiffer G, van der Molen T, Hider A, et al</AU>
<TI>Zyban is an effective and well tolerated aid to smoking cessation in a general smoking population - a multi-country study</TI>
<SO>Society for Research on Nicotine and Tobacco 3rd Europe Conference, September 19-22 2001, Paris, France</SO>
<YR>2001</YR>
<PG>46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270283"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tonstad-2003" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Tonstad 2003" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Some abstracts presented by Tonstad at European Cardiology Soc meetings not included. This was primary ref and ID until 2004&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McRobbie H, Brath H, Astbury C, Hider A, Sweet R</AU>
<TI>Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease 12 month follow-up phase data (ZYB40014)</TI>
<SO>Abstract and presentation at European Respiratory Society meeting, 14-18 September 2002, Stockholm, Sweden</SO>
<YR>2002</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270285"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added as primary ref 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al</AU>
<TI>Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study</TI>
<SO>European Heart Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<PG>946-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270286"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 11:37:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Spiegel PI, Lewis K, Seinost G, Astbury C, Hider A, Sweet R</AU>
<TI>Bupropion hydrochloride (Zyban) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease - a multicountry study. Abstract and presentation at 11th Annual meeting of European Respiratory Society, Berlin, September 22-26</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>Suppl 33</NO>
<PG>13s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270284"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uyar-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Uyar 2007" YEAR="2005">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uyar M, Bayram N, Filiz A, Elbek O, Topçu A, Dikensoy O, et al</AU>
<TI>Comparison of nicotine patch and bupropion in treating tobacco dependence</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>388s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270289"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Uyar M, Filiz A, Bayram N, Elbek O, Herken H, Topcu A, et al</AU>
<TI>A randomized trial of smoking cessation. Medication versus motivation</TI>
<SO>Saudi Medical Journal</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>6</NO>
<PG>922-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270290"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wagena-2005" MODIFIED="2013-12-03 11:38:17 +0000" MODIFIED_BY="[Empty name]" NAME="Wagena 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-03 11:38:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to earlier study report&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:38:03 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Quaak M, van Schayck Constant P, Postma Dirkje S, Wagena Edwin J, van Schooten Frederik J</AU>
<TI>Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation</TI>
<SO>Addiction</SO>
<YR>2012</YR>
<VL>107</VL>
<NO>1</NO>
<PG>178-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000013216"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270292"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-22 11:19:35 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;abstract only, published 2005, don't include citation in antidepressants review&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 11:19:35 +0100" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wagena EJ, Knipschild PG, Huibers MJH, Wouters EFM, Schayck CPR</AU>
<TI>Efficacy of bupropion and nortriptyline for smoking cessation among people who are at risk for or have chronic obstructive pulmonary disease: Results from a randomized, placebo-controlled trial</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>4</NO>
<PG>683-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000004372"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270293"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 11:38:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to previous study report - Wagena 2005, already in antidepressants. Ref needs adding&lt;br&gt;Sent to RvdM 15/12/10&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 11:38:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>van Schayck CP, Kaper J, Wagena EJ, Wouters EF, Severens JL</AU>
<TI>The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients</TI>
<SO>Addiction</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>12</NO>
<PG>2110-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005573"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270294"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270291"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Weinberger-2010" MODIFIED="2013-08-29 10:28:41 +0100" MODIFIED_BY="Lindsay Stead" NAME="Weinberger 2010" YEAR="2009">
<REFERENCE MODIFIED="2013-08-16 11:25:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Weinberger 2010&lt;/p&gt;" NOTES_MODIFIED="2013-08-16 11:25:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Weinberger AH, George TP, Mckee SA</AU>
<TI>Differences in smoking expectancies in smokers with and without a history of major depression</TI>
<SO>Addictive Behaviors</SO>
<YR>2011</YR>
<VL>36</VL>
<NO>4</NO>
<PG>434-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005996"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270296"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-16 11:25:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to a Selegiline trial&lt;br&gt;Check for training&lt;/p&gt;" NOTES_MODIFIED="2013-08-16 11:25:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Weinberger AH, Mckee SA, George TP</AU>
<TI>Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>9</NO>
<PG>937-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005825"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270297"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-16 11:26:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sent to Gareth H 22/06/11&lt;/p&gt;" NOTES_MODIFIED="2013-08-16 11:26:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Weinberger AH, Reutenauer EL, Jatlow PI, O'Malley SS, Potenza MN, George TP</AU>
<TI>A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2010</YR>
<VL>107</VL>
<NO>2-3</NO>
<PG>188-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005586"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270298"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-04 14:46:11 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Weinberger AH, Reutenauer EL, O'Malley SS, Potenza MN, George TP</AU>
<TI>A randomized placebo-controlled clinical trial of selegiline for smoking cessation: Preliminary results (POS5-29)</TI>
<SO>Society for Research on Nicotine and Tobacco 15th Annual Meeting April 27-30, 2009, Dublin, Ireland</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270299"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-16 11:27:05 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Weinberger AH, Reutenauer EL, Solorzano M, O'Malley SS, Potenza MN, George TP</AU>
<TI>A randomized placebo controlled clinical trial of selegiline for smoking cessation (abstract 653)</TI>
<SO>CPDD 71st Annual Meeting, June 20-25 2009, Reno Nevada</SO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270300"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-29 10:25:49 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270295"/><IDENTIFIER MODIFIED="2013-08-29 10:25:49 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00129311"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wittchen-2011" MODIFIED="2013-11-26 15:42:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wittchen 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-26 15:42:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not Combined/Adjunct - Pharmacotherapy and BT not combined. Only MI arm would be physician advice&lt;br&gt;Check for training; / Prelim refs to MM for group update - Counselling offered in individual rather than group format. More intensive intervention than just physician advice. Add as excluded for physician advice?&lt;/p&gt;" NOTES_MODIFIED="2013-11-26 15:42:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wittchen HU, Hoch E, Klotsche J, Muehlig S</AU>
<TI>Smoking cessation in primary care - a randomized controlled trial of bupropion, nicotine replacements, CBT and a minimal intervention</TI>
<SO>International Journal of Methods in Psychiatric Research</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>1</NO>
<PG>28-39</PG>
<IDENTIFIERS MODIFIED="2013-08-22 13:52:05 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000009843"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270302"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270301"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zellweger-2005" NAME="Zellweger 2005" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Puska P, Brath H, Astbury C, Hider AE</AU>
<TI>Zyban is an effective and well tolerated aid to smoking cessation in a healthcare professionals population - a multi-country study</TI>
<SO>Society for Research on Nicotine and Tobacco 3rd European Conference, September 2001, Paris, France</SO>
<YR>2001</YR>
<PG>45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270304"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;New 2003 (abstract)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zellweger JP, Blaziene A, Astbury C, Hider A, Hogue S</AU>
<TI>Bupropion hydrochloride sustained release is an effective and well tolerated aid to smoking cessation in a healthcare professionals population - a multicountry study. Abstract and presentation at 11th Annual meeting of European Respiratory Society, Berlin, September 22-26 2001</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>18 (Suppl 33)</VL>
<PG>166s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270305"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Became main reference in 2006&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ</AU>
<TI>Bupropion SR vs placebo for smoking cessation in health care professionals</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2005</YR>
<VL>29</VL>
<PG>240-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270306"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270303"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akbarpour-2010" MODIFIED="2013-06-26 10:17:26 +0100" MODIFIED_BY="[Empty name]" NAME="Akbarpour 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-26 10:17:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not hospital as psychiatric inpatients. Short term study, list as excl from antidepressants&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:17:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Akbarpour F, Rezaei O, Khodaie-Ardakani MR, Sheikhvatan M, Goodarzi H, Dolatshahi B</AU>
<TI>A double-blind placebo-controlled trial of bupropion for smoking abstinence and cognition improvement in schizophrenia</TI>
<SO>Minerva Psichiatrica</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>4</NO>
<PG>263-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000016548"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270308"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270307"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banham-2010" MODIFIED="2013-12-03 13:32:44 +0000" MODIFIED_BY="[Empty name]" NAME="Banham 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-03 13:32:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Systematic Review, removed from Central 04/12/12&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 13:32:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Banham L, Gilbody S</AU>
<TI>Smoking cessation in severe mental illness: What works?</TI>
<SO>Addiction</SO>
<YR>2010</YR>
<VL>105</VL>
<NO>7</NO>
<PG>1176-89</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270310"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270309"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-2006" MODIFIED="2009-07-28 13:44:12 +0100" MODIFIED_BY="Lindsay Stead" NAME="Barnes 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-28 13:44:12 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes J, Barber N, Wheatley D, Williamson EM</AU>
<TI>A pilot randomised, open, uncontrolled, clinical study of two dosages of St John's wort (Hypericum perforatum) herb extract (LI-160) as an aid to motivational/behavioural support in smoking cessation</TI>
<SO>Planta Medica</SO>
<YR>2006</YR>
<VL>72</VL>
<NO>4</NO>
<PG>378-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270312"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270311"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Becker-2003" MODIFIED="2013-08-29 11:42:53 +0100" MODIFIED_BY="Lindsay Stead" NAME="Becker 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-08-29 11:42:51 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Becker B, Bock B, Carmona-Barros R</AU>
<TI>St. John's Wort oral spray reduces withdrawal symptoms during quitting smoking (POS4-82)</TI>
<SO>Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19-22 New Orleans, Louisiana</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270314"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270313"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlin-2002" NAME="Berlin 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G</AU>
<TI>Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation</TI>
<SO>Addiction</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>1347-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270316"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270315"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlin-2005" NAME="Berlin 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Covey LS, Jiang HP, Hamer D</AU>
<TI>Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>725-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270318"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270317"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berlin-2012" MODIFIED="2013-11-20 16:49:56 +0000" MODIFIED_BY="[Empty name]" NAME="Berlin 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-11-20 16:49:56 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Need to check what drug type this is&lt;/p&gt;" NOTES_MODIFIED="2013-11-20 16:49:56 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berlin I, Hunneyball IM, Greiling D, Jones SP, Fuder H, Stahl HD</AU>
<TI>A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch</TI>
<SO>Psychopharmacology</SO>
<YR>2012</YR>
<VL>223</VL>
<NO>1</NO>
<PG>89-98</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000015756"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270320"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-20 16:49:51 +0000" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270319"/><IDENTIFIER MODIFIED="2013-11-20 16:49:51 +0000" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00738595"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloch-2010" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Bloch 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to trial of bupropion for smoking reduction in people with schizophrenia&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bloch B, Reshef A, Cohen T, Tafla A, Gathas S, Israel S, et al</AU>
<TI>Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia</TI>
<SO>Psychiatry Research</SO>
<YR>2010</YR>
<VL>175</VL>
<NO>1-2</NO>
<PG>38-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005445"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270322"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270321"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowen-1991" NAME="Bowen 1991" YEAR="1991`">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowen DJ, Spring B, Fox E</AU>
<TI>Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy</TI>
<SO>Journal of Behavioral Medicine</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>2</NO>
<PG>97-110</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270324"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270323"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Brauer-2000" NAME="Brauer 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Brauer LH, Paxton DA, Stock CT, Rose JE</AU>
<TI>Selegiline and transdermal nicotine for smoking cessation</TI>
<SO>Society for Research on Nicotine and Tobacco Annual Conference; 2000 Feb 18-20; Arlington VA (http://www.srnt.org/events/abstracts99/index.htm)</SO>
<YR>2000</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270326"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270325"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breitling-2008" MODIFIED="2009-07-28 17:44:07 +0100" MODIFIED_BY="Lindsay Stead" NAME="Breitling 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-28 17:44:07 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breitling LP, Twardella D, Brenner H</AU>
<TI>High effectiveness of short treatment with bupropion for smoking cessation in general care</TI>
<SO>Thorax</SO>
<YR>2008</YR>
<VL>63</VL>
<PG>476-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270328"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270327"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carr_x00e3_o-2007" MODIFIED="2009-07-28 17:44:20 +0100" MODIFIED_BY="Lindsay Stead" NAME="Carrão 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 17:44:20 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carrao JL, Moreira LB, Fuchs FD</AU>
<TI>The efficacy of the combination of sertraline with buspirone for smoking cessation. A randomized clinical trial in nondepressed smokers</TI>
<SO>European Archives of Psychiatry &amp; Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>257</VL>
<PG>383-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270330"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270329"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2005" MODIFIED="2009-07-28 17:44:29 +0100" MODIFIED_BY="Lindsay Stead" NAME="Chan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-07-28 17:44:29 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan B, Einarson A, Koren G</AU>
<TI>Effectiveness of bupropion for smoking cessation during pregnancy</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>2</NO>
<PG>19-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270332"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270331"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornelius-1997" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Cornelius 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Black A, et al</AU>
<TI>Double-blind fluoxetine in depressed alcoholic smokers</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1997</YR>
<VL>33</VL>
<PG>165-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270334"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270333"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornelius-1999" MODIFIED="2009-07-28 17:44:33 +0100" MODIFIED_BY="Lindsay Stead" NAME="Cornelius 1999" YEAR="1996">
<REFERENCE MODIFIED="2009-07-28 17:44:33 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Perkins KA, Salloum IM, Thase ME, Moss HB</AU>
<TI>Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients [letter]</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>183-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270336"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270335"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalack-1995" NAME="Dalack 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalack GW, Glassman AH, Rivelli S, Covey LS, Stetner F</AU>
<TI>Mood, major depression, and fluoxetine response in cigarette smokers</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>398-403</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270338"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270337"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dale-2002" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Dale 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dale LC, Ebbert JO, Schroeder DR, Croghan IT, Rasmussen DF, Trautman JA, et al</AU>
<TI>Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study</TI>
<SO>Nicotine Tobacco Research</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>3</NO>
<PG>267-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270340"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270339"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dale-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Dale 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, et al</AU>
<TI>Bupropion SR for the treatment of smokeless tobacco use</TI>
<SO>Drug &amp; Alcohol Dependence</SO>
<YR>2007</YR>
<VL>90</VL>
<NO>1</NO>
<PG>56-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270342"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 16:47:56 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas JL, Ebbert JO, Patten CA, Dale LC, Bronars CA, Schroeder DR</AU>
<TI>Measuring nicotine dependence among smokeless tobacco users</TI>
<SO>Addictive Behaviors</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>9</NO>
<PG>1511-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270343"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270341"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniela-2008" MODIFIED="2013-08-22 10:15:52 +0100" MODIFIED_BY="[Empty name]" NAME="Daniela 2008" NOTES="&lt;p&gt;First author surname is probably Ionescu&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 10:15:52 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2008">
<REFERENCE MODIFIED="2013-06-26 10:23:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniela I, Carmen C</AU>
<TI>The combination of sertraline with buspirone for smoking cessation process - The effectiveness and adverse events</TI>
<SO>Toxicology Letters</SO>
<YR>2008</YR>
<VL>180</VL>
<NO>Suppl 1</NO>
<PG>S130</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270345"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270344"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1989" NAME="Edwards 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL</AU>
<TI>Doxepin as an adjunct to smoking cessation: a double-blind pilot study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>3</NO>
<PG>373-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270347"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy JK, Edwards NB, Downs AD, Ackerman BJ, Rosenthal TL</AU>
<TI>Effects of doxepin on withdrawal symptoms in smoking cessation</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>10</NO>
<PG>1353-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270348"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270346"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elsasser-2002" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Elsasser 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Elsasser GN, Guck TP, Destache CJ, Daher PM, Frey DR, Jones J, et al</AU>
<TI>Sustained release bupropion in the treatment of nicotine addiction among teenage smokers (RP-32)</TI>
<SO>Rapid Communication Poster Abstracts. Society for Research on Nicotine and Tobacco 8th Annual Meeting, February 20-23 Savannah, Georgia</SO>
<YR>2002</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270350"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270349"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evins-2008" MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" NAME="Evins 2008" NOTES="&lt;p&gt;2005 abstract originally included as a separate excluded paper&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:40 +0000" NOTES_MODIFIED_BY="Lindsay Stead" YEAR="2008">
<REFERENCE MODIFIED="2013-08-27 13:33:58 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Alpert JE, Pava J, Petersen TJ, Farabaugh AH, Fava M</AU>
<TI>A double blind placebo controlled trial of bupropion added to nicotine patch and cognitive behavioral therapy in smokers with current or past unipolar depressive disorder</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30 Suppl 1</VL>
<PG>S91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270352"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh, A, et al</AU>
<TI>A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<PG>660-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270353"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-20 15:08:48 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270351"/><IDENTIFIER MODIFIED="2013-08-20 15:08:48 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00142831"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fatemi-2005" NAME="Fatemi 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fatemi SH, Stary JM, Hatsukami DK, Murphy SE</AU>
<TI>A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>2-3</NO>
<PG>353-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270355"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270354"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frederick-1997" NAME="Frederick 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frederick SL, Hall SM, Sees KL</AU>
<TI>The effect of venlafaxine on smoking cessation in subjects with and without a history of depression</TI>
<SO>NIDA Research Monograph</SO>
<YR>1997</YR>
<VL>174</VL>
<PG>208</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270357"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270356"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gawin-1989" NAME="Gawin 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gawin F, Compton M, Byck R</AU>
<TI>Buspirone reduces smoking [letter]</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>3</NO>
<PG>288-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270359"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270358"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gifford-2011" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Gifford 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;All participants got bupropion; / Prelim refs to MM for group update. Should have been considered for adjunct review although very specialised intervention. Had both individual and group components; 'counseling participants attended one group and one individual session per week for 10 weeks, with treatment delivered according to individual and group treatment manuals&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gifford EV, Kohlenberg BS, Hayes SC, Pierson HM, Piasecki MP, Antonuccio DO, et al</AU>
<TI>Does acceptance and relationship focused behavior therapy contribute to bupropion outcomes? A randomized controlled trial of functional analytic psychotherapy and acceptance and commitment therapy for smoking cessation</TI>
<SO>Behavior Therapy</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>4</NO>
<PG>700-15</PG>
<IDENTIFIERS MODIFIED="2013-08-22 10:11:54 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012398"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270360"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glover-2002" MODIFIED="2013-12-03 13:34:53 +0000" MODIFIED_BY="Lindsay Stead" NAME="Glover 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 13:34:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glover ED, Glover PN, Sullivan CR, Cerullo CL, Hobbs G</AU>
<TI>A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>5</NO>
<PG>386-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270363"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270362"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-2002" NAME="Gold 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold PB, Rubey RN, Harvey RT</AU>
<TI>Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care</TI>
<SO>American Journal of Addiction</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>4</NO>
<PG>315-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270365"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270364"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grandi-2011" MODIFIED="2013-06-26 10:18:21 +0100" MODIFIED_BY="[Empty name]" NAME="Grandi 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-06-26 10:18:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Review&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:18:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Grandi S, Shimony A, Eisenberg MJ</AU>
<TI>The efficacy and safety of bupropion started in-hospital for smoking cessation in patients with cardiovascular disease: A systematic review and meta-analysis</TI>
<SO>Circulation</SO>
<YR>2011</YR>
<VL>124</VL>
<NO>21 SUPPL 1</NO>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000012459"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270367"/><IDENTIFIER TYPE="OTHER" VALUE="9400123000012459"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270366"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grassi-2009" MODIFIED="2013-06-26 10:18:29 +0100" MODIFIED_BY="[Empty name]" NAME="Grassi 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-26 10:18:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not randomised, self selected treament&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:18:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Grassi MC, Enea D, Ferketich AK, Lu B, Nencini P</AU>
<TI>A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>9</NO>
<PG>1114-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005435"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270369"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270368"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gray-2011" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Gray 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-06-26 11:55:54 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Linked. Main trial report is Gray 2011.&lt;br&gt;'Data for the present analysis come from a larger randomized clinical trial (N = 134) which examined placebo-controlled bupropion +/- contingency management (2 &amp;#194;&amp;#382; 2 design) for adolescent smoking cessation (results forthcoming).&lt;br&gt;Sent to AS &amp;amp; GG 29/03/12&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 11:55:54 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Carpenter MJ, Baker NL, Gray KM, Upadhyaya HP</AU>
<TI>Assessment of nicotine dependence among adolescent and young adult smokers: A comparison of measures</TI>
<SO>Addictive Behaviors</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>11</NO>
<PG>977-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005998"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270371"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Only 12 week follow-up. List as excl for antidepressants. Not relevant to Combined review&lt;br&gt;Sent to Gareth H 22/06/11. Sent to AS &amp;amp; GG 29/03/12&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Gray KM, Carpenter MJ, Baker NL, Hartwell KJ, Lewis AL, Hiott DW, et al</AU>
<TI>Bupropion SR and contingency management for adolescent smoking cessation</TI>
<SO>Journal of Substance Abuse Treatment</SO>
<YR>2011</YR>
<VL>40</VL>
<NO>1</NO>
<PG>77-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005880"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270372"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gray KM, Carpenter MJ, Baker NL, Klintworth EM, Leinbach AS, Upadhyaya HP, et al</AU>
<TI>Bupropion SR and contingency management in adolescent smokers: main findings</TI>
<SO>College on Problems of Drug Dependence 71st Annual Meeting</SO>
<YR>2009</YR>
<PG>74</PG>
<CY>Reno/Sparks, Nevada</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270373"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 10:04:15 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270370"/><IDENTIFIER MODIFIED="2013-09-04 10:04:15 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00330187"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-2009" MODIFIED="2013-08-22 13:09:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hall 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-22 13:09:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not antidepressants as all received bupropion, not Combined as no minimal treatment arm - all had pharma and counselling&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 13:09:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hall SM, Humfleet GL, Muñoz RF, Reus VI, Robbins JA, Prochaska JJ</AU>
<TI>Extended treatment of older cigarette smokers</TI>
<SO>Addiction</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>6</NO>
<PG>1043-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005370"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270375"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270374"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hawk-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Hawk 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hawk LW, Mahoney MC, Ashare RL, Rhodes JD, Oliver JA, Cummings KM, et al</AU>
<TI>Preliminary evidence of extinction of smoking behavior with bupropion (PA9-4)</TI>
<SO>Society for Research on Nicotine and Tobacco 14th Annual Meeting February 26-March 1, Portland, Oregon</SO>
<YR>2008</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270377"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270376"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilberink-2005" MODIFIED="2013-08-27 16:08:46 +0100" MODIFIED_BY="[Empty name]" NAME="Hilberink 2005" YEAR="2011">
<REFERENCE MODIFIED="2013-06-26 10:19:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Links to Hilberink 2005, which had 6 month results. Not NRT or Combined; low use of NRT and bupropion, main component was advice. Data extracted to add to nursing. Earlier paper did not mention bupropion arm. List as excl for antidepressants?&lt;br&gt;LS checked for Training, not relevant&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:19:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hilberink SR, Jacobs JE, Breteler MHM, de Vries H, Grol RPTM</AU>
<TI>General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: Impact after 1 year of two complex interventions</TI>
<SO>Patient Education and Counseling</SO>
<YR>2011</YR>
<VL>83</VL>
<NO>1</NO>
<PG>120-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005920"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270379"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:08:46 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270378"/><IDENTIFIER MODIFIED="2013-08-27 16:08:46 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00628225"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hitsman-1999" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hitsman 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hitsman B, Pingitore R, Spring B, Mahableshwarkar A, Mizes JS, Segraves KA, et al</AU>
<TI>Antidepressant pharmacotherapy helps some cigarette smokers more than others</TI>
<SO>Journal of Consulting and Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>67</VL>
<PG>547-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270381"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Hitsman B, Spring B, Borrelli B, Niaura R, Papandonatos G</AU>
<TI>Adherence to medication versus behavioral therapy as predictors of smoking cessation in combined treatment involving fluoxetine [abstract]</TI>
<SO>Society for Research on Nicotine and Tobacco Annual Conference; 2000 Feb 18-20; Arlington VA</SO>
<YR>2000</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270382"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270380"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houtsmuller-2002" MODIFIED="2009-07-28 17:46:10 +0100" MODIFIED_BY="Lindsay Stead" NAME="Houtsmuller 2002" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Houtsmuller EJ, Stitzer ML</AU>
<TI>Selegiline effects on smoking and abstinence [abstract]</TI>
<SO>CPDD Annual Meeting; 1998; Scottsdale, AZ</SO>
<YR>1998</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270384"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Added as main reference 2003/2 update&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Houtsmuller EJ, Thornton JA, Stitzer ML</AU>
<TI>Effects of selegiline (l-deprenyl) during smoking and short-term abstinence</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2002</YR>
<VL>163</VL>
<PG>213-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270385"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270383"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hussain-2010" MODIFIED="2013-06-26 10:19:32 +0100" MODIFIED_BY="[Empty name]" NAME="Hussain 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-26 10:19:32 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;List as excl for antidepressants&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:19:32 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hussain S, Zawertailo L, Busto U, Zack M, Farvolden P, Selby P</AU>
<TI>The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: a randomized controlled trial in unmotivated smokers</TI>
<SO>Addictive Behaviors</SO>
<YR>2010</YR>
<VL>35</VL>
<NO>2</NO>
<PG>164-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005919"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270387"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270386"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-1971" NAME="Jacobs 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs MA, Spilken AZ, Norman MM, Wohlberg GW, Knapp PH</AU>
<TI>Interaction of personality and treatment conditions associated with success in a smoking control program</TI>
<SO>Psychosomatic Medicine</SO>
<YR>1971</YR>
<VL>33</VL>
<NO>6</NO>
<PG>545-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270389"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270388"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kalman-2004" NAME="Kalman 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Added 2004&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kalman D, Engler P, Monti P</AU>
<TI>Preliminary findings from a pilot treatment study of smokers in early alcohol recovery (POS1-072)</TI>
<SO>Society for Research on Nicotine and Tobacco 10th Annual Meeting February 18-21, Phoenix, Arizona</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270391"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270390"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karam_x002d_Hage-2011" MODIFIED="2013-08-22 11:50:15 +0100" MODIFIED_BY="Lindsay Stead" NAME="Karam-Hage 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-08-22 11:50:15 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;List as excl from antidepressants, short f-up&lt;/p&gt;" NOTES_MODIFIED="2013-08-22 11:50:15 +0100" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karam-Hage M, Strobbe S, Robinson JD, Brower KJ</AU>
<TI>Bupropion-SR for smoking cessation in early recovery from alcohol dependence: a placebo-controlled, double-blind pilot study</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>2011</YR>
<VL>37</VL>
<NO>6</NO>
<PG>487-90</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2013-08-22 11:50:15 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011679"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270393"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270392"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotz-2009" MODIFIED="2009-07-28 17:48:11 +0100" MODIFIED_BY="Lindsay Stead" NAME="Kotz 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-28 17:48:11 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotz D, Wesseling G, Huibers MJ, van Schayck OC</AU>
<TI>Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial</TI>
<SO>BMC Public Health</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>332</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270395"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 17:46:44 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kotz D, Wesseling G, Huibers MJH, van Schayck OCP</AU>
<TI>Efficacy of confronting smokers with airflow limitation for smoking cessation</TI>
<SO>European Respiratory Journal</SO>
<YR>2009</YR>
<VL>33</VL>
<PG>754-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270396"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270394"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kras-2010" MODIFIED="2013-06-26 10:19:39 +0100" MODIFIED_BY="[Empty name]" NAME="Kras 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-26 10:19:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Only 10 week follow-up. List as excl from antidepressants&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:19:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kras M, Stough C, Scholey A, Kure C, Camfield D</AU>
<TI>Hypericum perforatum, nicotine patches and combination hypericum perforatum/nicotine patches for smoking cessation</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<PG>S608-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006088"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270398"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270397"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawvere-2006" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Lawvere 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-04 14:18:49 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lawvere S, Mahoney MC, Cummings KM, Hyland AJ</AU>
<TI>St John's Wort for smoking cessation: twelve months post cessation</TI>
<SO>Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic</SO>
<YR>2005</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270400"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lawvere S, Mahoney MC, Cummings KM, Kepner JL, Hyland A, Lawrence DD, et al</AU>
<TI>A Phase II study of St. John's Wort for smoking cessation</TI>
<SO>Complementary Therapies in Medicine</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>3</NO>
<PG>175-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270401"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270399"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Le-Foll-2009" MODIFIED="2013-07-16 17:33:58 +0100" MODIFIED_BY="[Empty name]" NAME="Le Foll 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-26 11:06:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Foll, B</AU>
<TI>Testing a full substitution therapy approach as treatment of tobacco dependence (NCT00390923)</TI>
<SO>Clinicaltrials.gov</SO>
<YR>2009</YR>
<PG>http://clinicaltrials.gov/show/NCT00390923, accessed on 25 June 2013</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270403"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-07-16 17:33:58 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270402"/><IDENTIFIER MODIFIED="2013-07-16 17:33:58 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00390923"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2009" MODIFIED="2013-12-03 13:36:54 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-03 13:36:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Found by Daniel Tsoi, hand entered. Chinese text http://en.cnki.com.cn/Article_en/CJFDTOTAL-XYYL200903022.htm&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 13:36:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li J, Zhang T, Wang B, Li X</AU>
<TI>An efficacy analysis of bupropion for smoking cessation in schizophrenia</TI>
<SO>Zhongguo Xinyao Yu Linchuang Zazhi (Chinese Journal of New Drugs and Clinical Remedies)</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>3</NO>
<PG>231-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000016534"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270405"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2003" MODIFIED="2013-09-03 14:22:03 +0100" MODIFIED_BY="Lindsay Stead" NAME="Miller 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller H, Ranger-Moore J, Hingten M</AU>
<TI>Bupropion SR for smoking cessation in pregnancy: a pilot study [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>189</VL>
<NO>6</NO>
<PG>S133</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270407"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-03 14:22:03 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270406"/><IDENTIFIER MODIFIED="2013-09-03 14:22:03 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT01875172"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monuteaux-2007" MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" NAME="Monuteaux 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J</AU>
<TI>A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>7</NO>
<PG>1094-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270409"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270408"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mooney-2008" MODIFIED="2009-08-12 11:24:18 +0100" MODIFIED_BY="[Empty name]" NAME="Mooney 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-28 16:46:21 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mooney ME, Poling J, Gonzalez G, Gonsai K, Kosten T, Sofuoglu M</AU>
<TI>Preliminary study of buprenorphine and bupropion for opioid-dependent smokers</TI>
<SO>American Journal on Addictions</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>4</NO>
<PG>287-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270411"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-08-12 11:24:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sofuoglu M, Mooney M, Gonzalez G, Gonsai K, Poling J, Kosten T</AU>
<TI>Buprenorphine and bupropion combination for opioid-dependent smokers</TI>
<SO>68th Annual Scientific Meeting of the College on Problems of Drug Dependence</SO>
<YR>2006</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270412"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naranjo-1990" NAME="Naranjo 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naranjo CA, Kadlec KE, Sanhueza P, Woodley Remus D, Sellers EM</AU>
<TI>Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1990</YR>
<VL>47</VL>
<PG>490-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270414"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270413"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Neumann-2000" MODIFIED="2013-12-03 13:37:31 +0000" MODIFIED_BY="Lindsay Stead" NAME="Neumann 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann JK, Peeples B, East J, Ellis AR</AU>
<TI>Nicotine reduction: effectiveness of bupropion</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>177</VL>
<PG>87-88</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270416"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270415"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumann-2002" NAME="Neumann 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumann JK, Peeples B, Seneker A</AU>
<TI>Nicotine reduction and bupropion</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>121</VL>
<PG>1378</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270418"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270417"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niederhofer-2004" NAME="Niederhofer 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niederhofer H, Huber M</AU>
<TI>Bupropion may support psychosocial treatment of nicotine- dependent adolescents: Preliminary results</TI>
<SO>Pharmacotherapy</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1524-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270420"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270419"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olmstead-1999" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Olmstead 1999" YEAR="">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Added 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Olmstead R, Kelly J, Chin C, Iwamoto-Schaap PN, Madsen DC, Huerta L, et al</AU>
<TI>Combined bupropion and mecamylamine treatment for smoking cessation: a pilot trial</TI>
<SO>Society for Research on Nicotine and Tobacco Fifth Annual Meeting March 5-7 San Diego CA</SO>
<YR>1999</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270422"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270421"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paluck-2006" NAME="Paluck 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paluck EC, McCormack JP, Ensom MH, Levine M, Soon JA, Fielding DW</AU>
<TI>Outcomes of bupropion therapy for smoking cessation during routine clinical use</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2996</YR>
<VL>40</VL>
<NO>2</NO>
<PG>185-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270424"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270423"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomerleau-1991" NAME="Pomerleau 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pomerleau OF, Pomerleau CS, Morrell EM, Lowenbergh JM</AU>
<TI>Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1991</YR>
<VL>16</VL>
<PG>433-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270426"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270425"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raynor-2005" NAME="Raynor 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raynor DA</AU>
<TI>Adherence to pharmacological smoking cessation treatment among weight-concerned women</TI>
<SO>Dissertation Abstracts International: Section B: The Sciences and Engineering</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>8-B</NO>
<PG>4301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270428"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270427"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1991" NAME="Robinson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson MD, Smith WA, Cederstrom EA, Sutherland DE</AU>
<TI>Buspirone effect on tobacco withdrawal symptoms: a pilot study</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>2</NO>
<PG>89-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270430"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270429"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rovina-2003" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Rovina 2003" NOTES="&lt;p&gt;Nothing further found in 2009&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" YEAR="2003">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gratziou C, Rovina N, Athanassa Z, Francis K, Evangelou E, Chiotis D, et al</AU>
<TI>Evaluation of prolonged bupropion treatment as an aid in smoking cessation [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20 Suppl 38</VL>
<PG>611s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270432"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-30 14:27:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rovina N, Gratziou C, Nikoloutsou I, Athanassa Z, Francis K, Roussos C</AU>
<TI>Ideal duration of therapy with bupropion HCL: Comparison between short and long treatment</TI>
<SO>Society for Research on Nicotine and Tobacco 5th European Meeting November 20-22 2003 Padua: Abstract book</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270433"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-30 14:27:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rovina N, Gratziou C, Nikoloutsou I, Athanassa Z, Francis K, Roussos C</AU>
<TI>Short or prolonged treatment with bupropion HCL in smoking cessation therapy</TI>
<SO>European Respiratory Journal</SO>
<YR>2003</YR>
<VL>22 Suppl 45</VL>
<PG>165s</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270434"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270431"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Schepis-2006" MODIFIED="2013-08-30 14:27:45 +0100" MODIFIED_BY="[Empty name]" NAME="Schepis 2006" NOTES="&lt;p&gt;Nothing further found 2009&lt;/p&gt;" NOTES_MODIFIED="2013-08-30 14:27:45 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="2006">
<REFERENCE MODIFIED="2013-08-30 14:27:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schepis TS, Warren KA, Rao U</AU>
<TI>Evaluation of a cognitive-behavioral smoking cessation treatment for adolescents and young adults (POS2-53)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270436"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270435"/><IDENTIFIER TYPE="CTG" VALUE="NCT00129272"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sellers-1987" NAME="Sellers 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sellers EM, Naranjo CA, Kadlec K</AU>
<TI>Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<PG>417-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270438"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270437"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2013" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Sheng 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Needs medline&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng LX, Tang YL, Jiang ZN, Yao CH, Gao JY, Xu GZ, et al</AU>
<TI>Sustained-release bupropion for smoking cessation in a Chinese sample: a double-blind, placebo-controlled, randomized trial</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2013</YR>
<VL>15</VL>
<NO>2</NO>
<PG>320-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000018059"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270440"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270439"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherman-2008" MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" NAME="Sherman 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman SE, Aldana I, Estrada M, York L</AU>
<TI>Comparing the tolerability and effectiveness of two treatment regimens in a smoking clinic</TI>
<SO>Military Medicine</SO>
<YR>2008</YR>
<VL>173</VL>
<NO>6</NO>
<PG>550-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270442"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270441"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiffman-2000" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Shiffman 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, et al</AU>
<TI>The effect of bupropion on nicotine craving and withdrawal</TI>
<SO>Psychopharmacology</SO>
<YR>2000</YR>
<VL>148</VL>
<PG>33-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270444"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270443"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoptaw-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Shoptaw 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al</AU>
<TI>Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>96</VL>
<NO>3</NO>
<PG>222-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270446"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270445"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-2010" MODIFIED="2013-06-26 10:21:15 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-26 10:21:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Small study with only 16 weeks follow up. List as excl from antidepressants&lt;/p&gt;" NOTES_MODIFIED="2013-06-26 10:21:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Singh P, Kumar R</AU>
<TI>Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation</TI>
<SO>Lung India</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>1</NO>
<PG>11-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006043"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270448"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270447"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sittipunt-2007" MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" NAME="Sittipunt 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sittipunt C, Kawkitinarong K, Wongtim S, Udompanich V</AU>
<TI>The effectiveness of nortriptyline plus brief motivation counseling for the treatment of smoking cessation in Thai active smokers [Abstract]</TI>
<SO>Respirology</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>Suppl 4</NO>
<PG>A223</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270450"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270449"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sonntag-2003" MODIFIED="2013-08-30 14:27:48 +0100" MODIFIED_BY="[Empty name]" NAME="Sonntag 2003" NOTES="&lt;p&gt;Nothing else found in 2009&lt;/p&gt;" NOTES_MODIFIED="2013-08-30 14:27:48 +0100" NOTES_MODIFIED_BY="[Empty name]" YEAR="">
<REFERENCE MODIFIED="2013-08-30 14:27:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hoch E, Wittchen HU</AU>
<TI>Population health perspective on smoking cessation: A randomized controlled trial of different methods in primary health care (RPOS 3-71)</TI>
<SO>Society for Research on Nicotine and Tobacco 12th Annual Meeting February 15-18, Orlando, Florida</SO>
<YR>2006</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270452"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-30 14:27:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sonntag H, Hoch E, Jahn B, Spiegel B, Pfister H, Wittchen HU</AU>
<TI>Smoking cessation in primary care: implementation effectiveness and optimized allocation</TI>
<SO>Suchtmedizin in Forschung und Praxis</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>137-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270453"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270451"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spring-1995" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Spring 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spring B, Wurtman J, Wurtman R, el Khoury A, Goldberg H, McDermott J, et al</AU>
<TI>Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1995</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1181-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270455"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270454"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1993" NAME="Stein 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein RA, Jarvik ME, Gorelick DA</AU>
<TI>Impairment of memory by fluoxetine in smokers</TI>
<SO>Experimental and Clinical Psychopharmacology</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>188-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270457"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270456"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinberg-2009" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Steinberg 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al</AU>
<TI>Triple-combination pharmacotherapy for medically ill smokers: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2009</YR>
<VL>150</VL>
<NO>7</NO>
<PG>447-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270459"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-04 10:34:22 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270458"/><IDENTIFIER MODIFIED="2013-09-04 10:34:22 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00770666"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Strayer-2004" MODIFIED="2013-12-03 13:41:29 +0000" MODIFIED_BY="[Empty name]" NAME="Strayer 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-03 13:41:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 13:41:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Strayer SM, Flusche A, Hodge J, Martindale JR</AU>
<TI>Effectiveness trial of Zyban for smoking cessation in the outpatient setting (POS1-044)</TI>
<SO>Abstract Book. Society for Research on Nicotine and Tobacco 10th Annual Meeting February 18-21, Phoenix, Arizona</SO>
<YR>2004</YR>
<PG>45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270461"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270460"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swanson-2003" NAME="Swanson 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Citation corrected - bupropion is in fact misspelt in original paper&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swanson NA, Burroughs CC, Long MA, Lee RW</AU>
<TI>Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release bupropion, or both</TI>
<SO>Military Medicine</SO>
<YR>2003</YR>
<VL>168</VL>
<PG>830-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270463"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270462"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tidey-2009" MODIFIED="2013-08-27 16:21:16 +0100" MODIFIED_BY="Lindsay Stead" NAME="Tidey 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tidey JW, Rohsenow DJ</AU>
<TI>Intention to quit moderates the effect of bupropion on smoking urge</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>3</NO>
<PG>308-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270465"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:21:16 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270464"/><IDENTIFIER MODIFIED="2013-08-27 16:21:16 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00218231"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toll-2007" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Toll 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jatlow P, Toll BA, Leary V, Krishnan-Sarin S, O'Malley SS</AU>
<TI>Comparison of expired carbon monoxide and plasma cotinine as markers of cigarette abstinence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>98</VL>
<NO>3</NO>
<PG>203-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270467"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leeman RF, Mckee SA, Toll BA, Krishnan-Sarin S, Cooney JL, Makuch RW, et al</AU>
<TI>Risk factors for treatment failure in smokers: Relationship to alcohol use and to lifetime history of an alcohol use disorder</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>12</NO>
<PG>1793-809</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270468"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Toll BA, O'Malley SS, Katulak NA, Wu R, Dubin JA, Latimer A, et al</AU>
<TI>Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>4</NO>
<PG>534-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270469"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toll BA, Salovey P, O'Malley SS, Mazure CM, Latimer A, Mckee SA</AU>
<TI>Message framing for smoking cessation: the interaction of risk perceptions and gender</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>1</NO>
<PG>195-200</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270470"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 15:28:11 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270466"/><IDENTIFIER MODIFIED="2013-08-27 15:28:11 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00104598"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinberger-2008" MODIFIED="2013-08-27 15:14:33 +0100" MODIFIED_BY="Lindsay Stead" NAME="Weinberger 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinberger AH, Vessicchio JC, Sacco KA, Creeden CL, Chengappa KN, George TP</AU>
<TI>A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>5</NO>
<PG>584-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270472"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 15:14:33 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270471"/><IDENTIFIER MODIFIED="2013-08-27 15:14:33 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00593099"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiner-2001" NAME="Weiner 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiner E, Ball MP, Summerfelt A, Gold J, Buchanan RW</AU>
<TI>Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>4</NO>
<PG>635-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270474"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270473"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiner-2012" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Weiner 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-06-26 11:52:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Mann-Wrobel MC, Bennett ME, Weiner EE, Buchanan RW, Ball MP</AU>
<TI>Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program</TI>
<SO>Schizophrenia Research</SO>
<YR>2011</YR>
<VL>126</VL>
<NO>1-3</NO>
<PG>277-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006008"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270476"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Less than 6 months follow-up. List as excl for antidepressants. Probably same study as already included as Weiner 2007 conference abstract; / Sent to RvdM 23/10/2012&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Weiner E, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon RP, et al</AU>
<TI>Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2012</YR>
<VL>73</VL>
<NO>1</NO>
<PG>95-102</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000011967"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270477"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 13:23:11 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270475"/><IDENTIFIER MODIFIED="2013-08-27 13:23:11 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00176449"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-2005" NAME="White 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;new for 2006&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White WD, Crockford D, Patten S, el Guebaly N</AU>
<TI>A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>5</NO>
<PG>809-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270479"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270478"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zernig-2008" MODIFIED="2013-08-27 16:56:43 +0100" MODIFIED_BY="Lindsay Stead" NAME="Zernig 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-28 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A</AU>
<TI>A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation</TI>
<SO>Addiction</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>12</NO>
<PG>2024-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270481"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-27 16:56:43 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270480"/><IDENTIFIER MODIFIED="2013-08-27 16:56:43 +0100" MODIFIED_BY="Lindsay Stead" TYPE="CTG" VALUE="NCT00484692"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ZYB30011-2002" MODIFIED="2013-12-03 13:43:05 +0000" MODIFIED_BY="Lindsay Stead" NAME="ZYB30011 2002" NOTES="&lt;p&gt;Link updated 2009&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 13:43:05 +0000" NOTES_MODIFIED_BY="Lindsay Stead" YEAR="2002">
<REFERENCE MODIFIED="2013-12-03 13:43:05 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Added 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 13:43:05 +0000" NOTES_MODIFIED_BY="Lindsay Stead" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>GlaxoSmithKline Clinical Trials Register</AU>
<TI>A multicentre, randomised, double- blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor</TI>
<SO>http://www.gsk-clinicalstudyregister.com/files/pdf/730.pdf</SO>
<YR>(accessed 4th August 2009)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270483"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270482"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-08-30 14:27:48 +0100" MODIFIED_BY="Lindsay Stead"/>
<ONGOING_STUDIES MODIFIED="2013-12-03 13:43:20 +0000" MODIFIED_BY="Lindsay Stead">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rose-2013a" MODIFIED="2013-12-03 13:43:20 +0000" MODIFIED_BY="[Empty name]" NAME="Rose 2013a" YEAR="">
<REFERENCE MODIFIED="2013-09-18 15:29:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hand search for antidep.&lt;/p&gt;" NOTES_MODIFIED="2013-09-18 15:29:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose JE, Behm FM</AU>
<TI>Combination varenicline/bupropion treatment benefits male NRT-Nonresponders</TI>
<SO>Society for Research on Nicotine and Tobacco 19th Annual Meeting March 13-16 Boston MA</SO>
<YR>2013</YR>
<PG>261</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400107000001311"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3270485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-09-18 15:40:06 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3270484"/><IDENTIFIER MODIFIED="2013-09-18 15:40:06 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01303861"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Monaz Mehta">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Kate Cahill">
<REFERENCE ID="REF-Aubin-2002" NAME="Aubin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Aubin HJ</AU>
<TI>Tolerability and safety of sustained-release bupropion in the management of smoking cessation</TI>
<SO>Drugs</SO>
<YR>2002</YR>
<VL>62 Suppl 2</VL>
<PG>45-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belson-2002" MODIFIED="2013-12-03 13:43:32 +0000" MODIFIED_BY="[Empty name]" NAME="Belson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Belson MG, Kelley TR</AU>
<TI>Bupropion exposures: clinical manifestations and medical outcome</TI>
<SO>Journal of Emergency Medicine</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>223-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benowitz-2000" NAME="Benowitz 2000" NOTES="&lt;p&gt;Added to list of reviews checked 2003/2.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Benowitz NL, Peng MW</AU>
<TI>Non-nicotine pharmacotherapy for smoking cessation</TI>
<SO>CNS Drugs</SO>
<YR>2000</YR>
<VL>13</VL>
<PG>265-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beyens-2008" MODIFIED="2013-12-03 13:43:56 +0000" MODIFIED_BY="Lindsay Stead" NAME="Beyens 2008" TYPE="JOURNAL_ARTICLE">
<AU>Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M</AU>
<TI>Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004</TI>
<SO>Drug Safety</SO>
<YR>2008</YR>
<VL>31</VL>
<PG>1017-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bolin-2006" NAME="Bolin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bolin K, Lindgren B, Willers S</AU>
<TI>The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden</TI>
<SO>Chest</SO>
<YR>2006</YR>
<VL>129</VL>
<PG>651-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borrelli-2004" NAME="Borrelli 2004" TYPE="JOURNAL_ARTICLE">
<AU>Borrelli B, Papandonatos G, Spring B, Hitsman B, Niaura R</AU>
<TI>Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>378-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boshier-2003" NAME="Boshier 2003" TYPE="JOURNAL_ARTICLE">
<AU>Boshier A, Wilton LV, Shakir SA</AU>
<TI>Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>2003</YR>
<VL>59</VL>
<NO>10</NO>
<PG>767-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cahill-2012" MODIFIED="2013-10-07 11:35:54 +0100" MODIFIED_BY="Lindsay Stead" NAME="Cahill 2012" TYPE="COCHRANE_REVIEW">
<AU>Cahill K, Stead LF, Lancaster T</AU>
<TI>Nicotine receptor partial agonists for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-10-07 11:35:54 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER MODIFIED="2013-10-07 11:35:54 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD006103.pub6"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cahill-2013" MODIFIED="2013-10-07 09:48:26 +0100" MODIFIED_BY="[Empty name]" NAME="Cahill 2013" TYPE="COCHRANE_REVIEW">
<AU>Cahill K, Stevens S, Perera R, Lancaster T</AU>
<TI>Pharmacological interventions for smoking cessation: an overview and network meta-analysis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2013-10-07 09:48:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-10-07 09:48:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009329.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Catley-2005" NAME="Catley 2005" TYPE="JOURNAL_ARTICLE">
<AU>Catley D, Harris KJ, Okuyemi KS, Mayo MS, Pankey E, Ahluwalia JS</AU>
<TI>The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>6</NO>
<PG>859-870</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chun_x002d_Fai_x002d_Chan-2005" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Chun-Fai-Chan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al</AU>
<TI>Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>3</NO>
<PG>932-936</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-2004" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Cox 2004" NOTES="&lt;p&gt;Hays 2001 Added 2006&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Cox LS, Patten CA, Niaura RS, Decker PA, Rigotti N, Sachs DPL, et al</AU>
<TI>Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>828-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cryan-2003" MODIFIED="2013-12-03 13:46:34 +0000" MODIFIED_BY="[Empty name]" NAME="Cryan 2003" NOTES="&lt;p&gt;Added 2004&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 13:46:34 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Cryan JF, Bruijnzeel AW, Skjei KL, Markou A</AU>
<TI>Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>168</VL>
<PG>347-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dale-2001" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Dale 2001" NOTES="&lt;p&gt;Added to references for Hurt 1997 for 2001/4 update&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, et al</AU>
<TI>Bupropion for smoking cessation: predictors of successful outcome</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<PG>1357-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-David-2005" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="David 2005" TYPE="JOURNAL_ARTICLE">
<AU>David SP, Papandonatos GD, Munafo MR, McCaffery JM, Lerman C, Lloyd-Richardson EE, et al</AU>
<TI>DRD2-TAQ1A genotypic moderation of bupropion treatment efficacy for smoking cessation at 6-month follow-up [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>704</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunner-1998" NAME="Dunner 1998" TYPE="JOURNAL_ARTICLE">
<AU>Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA</AU>
<TI>A prospective safety surveillance study for bupropion sustained-release in the treatment of depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<PG>366-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Durcan-2002" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Durcan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Durcan MJ, White J, Jorenby DE, Fiore MC, Rennard SI, Leischow SJ, et al</AU>
<TI>Impact of prior nicotine replacement therapy on smoking cessation efficacy</TI>
<SO>American Journal of Health Behavior</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>3</NO>
<PG>213-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebbert-2011" MODIFIED="2013-12-03 14:14:05 +0000" MODIFIED_BY="[Empty name]" NAME="Ebbert 2011" TYPE="COCHRANE_REVIEW">
<AU>Ebbert J, Montori VM, Erwin PJ, Stead LF</AU>
<TI>Interventions for smokeless tobacco use cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-12-03 13:48:30 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-12-03 13:48:30 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004306.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-634</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-2002" NAME="EMEA 2002" TYPE="OTHER">
<AU>European Agency for the Evaluation of Medicines for Human Use</AU>
<TI>Committee for Proprietary Medicinal Products. Opinion following an article 36 referral. Bupropion hydrochloride</TI>
<SO>http://www.emea.eu.int/pdfs/human/referral/2761002en.pdf</SO>
<YR>Accessed 29 April 2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiore-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Fiore 2008" TYPE="BOOK">
<AU>Fiore MC, Jaén CR, Baker TB, et al</AU>
<SO>Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. AHRQ publication No. 00-0032</SO>
<YR>May 2008</YR>
<PB>US Dept of Health and Human Services. Public Health Services</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fryer-1999" NAME="Fryer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fryer JD, Lukas RJ</AU>
<TI>Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1999</YR>
<VL>288</VL>
<PG>88-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gambassi-1999" NAME="Gambassi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gambassi G, Bernabei R</AU>
<TI>Antidepressants and smoking cessation [Comment]</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<PG>1257-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GlaxoSmithKline" NAME="GlaxoSmithKline" TYPE="OTHER">
<AU>GlaxoSmithKline</AU>
<TI>Zyban(R) bupropion hydrochloride Sustained-Release Tablets. Product Information</TI>
<SO>www.gsk.com/products/assets/us_zyban.pdf</SO>
<YR>(accessed 15/11/2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1998" NAME="Goldstein 1998" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein MG</AU>
<TI>Bupropion sustained release and smoking cessation</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59 suppl 4</VL>
<PG>66-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzales-2002a" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Gonzales 2002a" NOTES="&lt;p&gt;Ref added 2004, in 2003 omitted in error&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales D, Bjornson W, Durcan MJ, White JD, Johnston JA, Buist AS, et al</AU>
<TI>Effects of gender on relapse prevention in smokers treated with bupropion SR</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>4</NO>
<PG>234-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gourlay-1995" NAME="Gourlay 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ</AU>
<TI>Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grandi-2011a" MODIFIED="2013-12-03 14:10:32 +0000" MODIFIED_BY="[Empty name]" NAME="Grandi 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Grandi S, Shimony A, Eisenberg MJ</AU>
<TI>The efficacy and safety of bupropion started in-hospital for smoking cessation in patients with cardiovascular disease: A systematic review and meta-analysis</TI>
<SO>Circulation</SO>
<YR>2011</YR>
<VL>124</VL>
<NO>21</NO>
<PG>Suppl 1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haas-2004" NAME="Haas 2004" TYPE="JOURNAL_ARTICLE">
<AU>Haas JS, Kaplan CP, Barenboim D, Jacob P, Benowitz NL</AU>
<TI>Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use</TI>
<SO>Tobacco Control</SO>
<YR>2004</YR>
<VL>13</VL>
<PG>52-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hajek-2013" MODIFIED="2013-10-07 11:36:52 +0100" MODIFIED_BY="Lindsay Stead" NAME="Hajek 2013" TYPE="COCHRANE_REVIEW">
<AU>Hajek P, Stead LF, West R, Jarvis M, Hartmann-Boyce J, Lancaster T</AU>
<TI>Relapse prevention interventions for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-10-07 11:36:52 +0100" MODIFIED_BY="Lindsay Stead"><IDENTIFIER MODIFIED="2013-10-07 11:36:52 +0100" MODIFIED_BY="Lindsay Stead" TYPE="DOI" VALUE="10.1002/14651858.CD003999.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hall-2001" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hall 2001" NOTES="&lt;p&gt;added 2004&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Delucchi KL, Velicer WF, Kahler CW, Ranger-Moore J, Hedeker D, et al</AU>
<TI>Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2005" NAME="Hall 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hall SM, Lightwood JM, Humfleet GL, Bostrom A, Reus VI, Munoz R</AU>
<TI>Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation</TI>
<SO>Journal of Behavioral Health Services &amp; Research</SO>
<YR>2005</YR>
<VL>32</VL>
<PG>381-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haustein-2003" NAME="Haustein 2003" NOTES="&lt;p&gt;Added 2004&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Haustein KO</AU>
<TI>Bupropion: pharmacological and clinical profile in smoking cessation</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>56-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayford-1999" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hayford 1999" NOTES="&lt;p&gt;Hurt 1997 trial&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, et al</AU>
<TI>Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>174</VL>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" NOTES="&lt;p&gt;added with description of I2 statistic 2004&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2013-12-03 14:11:31 +0000" MODIFIED_BY="Kate Cahill" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<PB>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS MODIFIED="2009-08-04 16:46:51 +0100" MODIFIED_BY="Lindsay Stead"/>
</REFERENCE>
<REFERENCE ID="REF-Holmes-2004" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Holmes 2004" TYPE="JOURNAL_ARTICLE">
<AU>Holmes S, Zwar N, Jimenez-Ruiz CA, Ryan PJ, Browning D, Bergmann L, et al</AU>
<TI>Bupropion as an aid to smoking cessation: a review of real-life effectiveness</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>3</NO>
<PG>285-291</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hubbard-2005" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hubbard 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, et al</AU>
<TI>Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>10</NO>
<PG>848-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2005" NAME="Hughes 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Nortriptyline for smoking cessation: A review</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>491-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007" MODIFIED="2009-08-05 16:18:40 +0100" MODIFIED_BY="Lindsay Stead" NAME="Hughes 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR</AU>
<TI>Depression during tobacco abstinence</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>443-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2008" MODIFIED="2009-08-05 14:11:50 +0100" MODIFIED_BY="Lindsay Stead" NAME="Hughes 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR</AU>
<TI>Smoking and suicide: A brief overview</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2008</YR>
<VL>198</VL>
<PG>169-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurt-2002" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Hurt 2002" NOTES="&lt;p&gt;Hays 2001&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ, et al</AU>
<TI>Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome</TI>
<SO>Addictive Behaviors</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>4</NO>
<PG>493-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Javitz-2004" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Javitz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Javitz HS, Swan GE, Zbikowski SM, Curry SJ, McAfee TA, Decker DL, et al</AU>
<TI>Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective</TI>
<SO>American Journal of Managed Care</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>3</NO>
<PG>217-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnstone-2004" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Johnstone 2004" TYPE="JOURNAL_ARTICLE">
<AU>Johnstone EC, Yudkin Pl, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al</AU>
<TI>Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch</TI>
<SO>Pharmacogenetics</SO>
<YR>2004</YR>
<VL>14</VL>
<PG>83-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorenby-2002" NAME="Jorenby 2002" NOTES="&lt;p&gt;Added 2004&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Joreby D</AU>
<TI>Clinical efficacy of bupropion in the management of smoking cessation</TI>
<SO>Drugs</SO>
<YR>2002</YR>
<VL>62 Suppl 2</VL>
<PG>25-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khawam-2006" NAME="Khawam 2006" TYPE="JOURNAL_ARTICLE">
<AU>Khawam EA, Laurencic G, Malone DA</AU>
<TI>Side effects of antidepressants: An overview</TI>
<SO>Cleveland Clinic Journal of Medicine</SO>
<YR>2006</YR>
<VL>73</VL>
<PG>351-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kotlyar-2001" NAME="Kotlyar 2001" NOTES="&lt;p&gt;Added to list of reviews checked 2003/2. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kotlyar M, Golding M, Hatsukami DK, Jamerson BD</AU>
<TI>Effect of nonnicotine pharmacotherapy on smoking behavior</TI>
<SO>Pharmacotherapy</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>1530-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kotlyar-2005" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kotlyar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, et al</AU>
<TI>Inhibition of CYP2D6 activity by bupropion</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<PG>226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lerman-2002a" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Lerman 2002a" NOTES="&lt;p&gt;Lerman confirmed that this is an interim analysis of same study (Collins).&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu AY, et al</AU>
<TI>Mediating mechanisms for the impact of bupropion in smoking cessation treatment</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2002</YR>
<VL>67</VL>
<PG>219-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lerman-2002b" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Lerman 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, et al</AU>
<TI>Pharmacogenetic investigation of smoking cessation treatment</TI>
<SO>Pharmacogenetics</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>627-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lerman-2004" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Lerman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Niaura R, Collins BN, Wileyto P, Audrain MJ, Pinto A, et al</AU>
<TI>Effect of bupropion on depression symptoms in a smoking cessation clinical trial</TI>
<SO>Psychology of Addictive Behaviors</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>362-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lerman-2006" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Lerman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al</AU>
<TI>Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>231-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" NAME="Mantel 1959" NOTES="&lt;p&gt;Added 2003/2 Ref most commonly used by other groups&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from retrospective studies of disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1959</YR>
<VL>22</VL>
<PG>719-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martinez_x002d_Raga-2003" NAME="Martinez-Raga 2003" NOTES="&lt;p&gt;Added 2004&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Martinez-Raga J, Keaney F, Sutherland G, Perez Galvez B, Strang J</AU>
<TI>Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile</TI>
<SO>Addiction Biology</SO>
<YR>2003</YR>
<VL>8</VL>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McRobbie-2005" NAME="McRobbie 2005" TYPE="JOURNAL_ARTICLE">
<AU>McRobbie H, Lee M, Juniper Z</AU>
<TI>Non-nicotine pharmacotherapies for smoking cessation</TI>
<SO>Respiratory Medicine</SO>
<YR>2005</YR>
<VL>99</VL>
<PG>1202-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2011" MODIFIED="2013-12-03 14:12:49 +0000" MODIFIED_BY="Lindsay Stead" NAME="Moore 2011" NOTES="&lt;p&gt;Adverse events&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:12:49 +0000" NOTES_MODIFIED_BY="Lindsay Stead" TYPE="JOURNAL_ARTICLE">
<AU>Moore TJ, Furberg CD, GJ, Maltsberger JT, Singh S</AU>
<TI>Suicidal behavior and depression in smoking cessation treatments</TI>
<SO>PloS One</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>11</NO>
<PG>e27016</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000013260"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pasternak-2013" MODIFIED="2013-10-07 14:33:28 +0100" MODIFIED_BY="[Empty name]" NAME="Pasternak 2013" TYPE="JOURNAL_ARTICLE">
<AU>Pasternak B, Svanström H, Hviid A</AU>
<TI>Use of varenicline versus bupropion and risk of psychiatric adverse events</TI>
<SO>Addiction</SO>
<YR>2013</YR>
<VL>108</VL>
<NO>7</NO>
<PG>1336-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patterson-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Patterson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al</AU>
<TI>Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>84</VL>
<PG>320-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piper-2010" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Piper 2010" NOTES="&lt;p&gt;Links to Smith 2009 &amp;amp; Piper 2009&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:16:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Bolt DM, et al</AU>
<TI>Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>6</NO>
<PG>647-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000005794"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RCP-2000" NAME="RCP 2000" TYPE="BOOK_SECTION">
<AU>Working party of the Royal College of Physicians of London</AU>
<TI>Non-nicotine medications for treating nicotine addiction</TI>
<SO>Nicotine Addiction in Britain</SO>
<YR>2000</YR>
<PG>147-151</PG>
<PB>Royal College of Physicians</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scharf-2004" NAME="Scharf 2004" TYPE="JOURNAL_ARTICLE">
<AU>Scharf D, Shiffman S</AU>
<TI>Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>1462-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2003" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Smith 2003" TYPE="JOURNAL_ARTICLE">
<AU>Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston AJ, et al</AU>
<TI>Targeting smokers at increased risk for relapse: treating women and those with a history of depression</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>99-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stead-2012" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Stead 2012" TYPE="COCHRANE_REVIEW">
<AU>Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al</AU>
<TI>Nicotine replacement therapy for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2013-10-07 11:38:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-10-07 11:38:22 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000146.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Swan-1999" NAME="Swan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Jack LM, Niaura R, Borrelli B, Spring B</AU>
<TI>Subgroups of smokers with different success rates after treatment with fluoxetine for smoking cessation [abstract]</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>1999</YR>
<VL>1</VL>
<NO>3</NO>
<PG>281</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swan-2005" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="[Empty name]" NAME="Swan 2005" TYPE="JOURNAL_ARTICLE">
<AU>Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, et al</AU>
<TI>Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR</TI>
<SO>Pharmacogenomics Journal</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>21-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2013" MODIFIED="2013-10-23 09:49:29 +0100" MODIFIED_BY="[Empty name]" NAME="Thomas 2013" TYPE="JOURNAL_ARTICLE">
<AU>Thomas KH, Martin RM, Davies NM, Metcalfe C, Windmeijer F, Gunnell D</AU>
<TI>Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study</TI>
<SO>BMJ</SO>
<YR>2013</YR>
<VL>347</VL>
<PG>f5704</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorndike-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Thorndike 2008" TYPE="JOURNAL_ARTICLE">
<AU>Thorndike AN, Regan S, McKool K, Pasternak RC, Swartz S, Torres-Finnerty N, et al</AU>
<TI>Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2008</YR>
<VL>168</VL>
<NO>2</NO>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tonnesen-1993" NAME="Tonnesen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Tonnesen P, Norregaard J, Sawe U, Simonsen K</AU>
<TI>Recycling with nicotine patches in smoking cessation</TI>
<SO>Addiction</SO>
<YR>1993</YR>
<VL>88</VL>
<PG>533-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tonstad-2002" NAME="Tonstad 2002" NOTES="&lt;p&gt;Added 2004&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tonstad S</AU>
<TI>Use of sustained-release bupropion in specific patient populations for smoking cessation</TI>
<SO>Drugs</SO>
<YR>2002</YR>
<VL>2 Suppl 2</VL>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tracey-2002" NAME="Tracey 2002" NOTES="&lt;p&gt;added 2004&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tracey JA</AU>
<TI>Zyban - is there a cause for concern?</TI>
<SO>Expert Opinion on Drug Safety</SO>
<YR>2002</YR>
<VL>1</VL>
<PG>303-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Uhl-2008" MODIFIED="2013-12-03 14:16:55 +0000" MODIFIED_BY="Lindsay Stead" NAME="Uhl 2008" TYPE="JOURNAL_ARTICLE">
<AU>Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al</AU>
<TI>Molecular genetics of successful smoking cessation: convergent genome-wide association study results</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>6</NO>
<PG>683-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-US-FDA-2009a" MODIFIED="2009-08-05 14:22:40 +0100" MODIFIED_BY="Lindsay Stead" NAME="US FDA 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Varenicline and bupropion. Reports of suicidality associated with used of varenicline (marketed as CHANTIX) and bupropion (marketed as Zyban and generics)</TI>
<SO>FDA Drug Safety Newsletter</SO>
<YR>2009</YR>
<VL>2</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-US-FDA-2009b" MODIFIED="2013-11-20 18:18:06 +0000" MODIFIED_BY="Lindsay Stead" NAME="US FDA 2009b" TYPE="OTHER">
<TI>Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm169988.htm accessed 20th November 2013</SO>
<IDENTIFIERS MODIFIED="2009-07-30 17:54:19 +0100" MODIFIED_BY="Lindsay Stead"/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Meer-2013" MODIFIED="2013-09-23 11:17:43 +0100" MODIFIED_BY="[Empty name]" NAME="van der Meer 2013" TYPE="COCHRANE_REVIEW">
<AU>van der Meer RM, Willemsen MC, Smit F, Cuijpers P</AU>
<TI>Smoking cessation interventions for smokers with current or past depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2013-09-23 11:17:43 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-09-23 11:17:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006102.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wagena-2005a" NAME="Wagena 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Wagena EJ, Knipschild P, Zeegers MP</AU>
<TI>Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>317-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warner-2005" NAME="Warner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Warner C, Shoaib M</AU>
<TI>How does bupropion work as a smoking cessation aid?</TI>
<SO>Addiction Biology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>3</NO>
<PG>219-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Welton-2008" MODIFIED="2013-12-03 14:02:45 +0000" MODIFIED_BY="[Empty name]" NAME="Welton 2008" TYPE="JOURNAL_ARTICLE">
<AU>Welton NJ, Johnstone EC, David SP, Munafò MR</AU>
<TI>A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation</TI>
<SO>Nicotine &amp; Tobacco Research</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>1</NO>
<PG>231-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2000" NAME="West 2000" TYPE="JOURNAL_ARTICLE">
<AU>West R, McNeill A, Raw M</AU>
<TI>Smoking cessation guidelines for health professionals: an update</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>12</NO>
<PG>987-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2003" NAME="West 2003" NOTES="&lt;p&gt;added 2004&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>West R</AU>
<TI>Bupropion SR for smoking cessation</TI>
<SO>Expert Opinion on Pharamcotherapy</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>533-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-West-2008" MODIFIED="2009-08-04 17:21:37 +0100" MODIFIED_BY="Lindsay Stead" NAME="West 2008" TYPE="JOURNAL_ARTICLE">
<AU>West R, Baker CL, Cappelleri JC, Bushmakin AG</AU>
<TI>Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt</TI>
<SO>Psychopharmacology</SO>
<YR>2008</YR>
<VL>197</VL>
<NO>3</NO>
<PG>371-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wightman-2010" MODIFIED="2013-12-03 14:02:59 +0000" MODIFIED_BY="Lindsay Stead" NAME="Wightman 2010" NOTES="&lt;p&gt;Review of adverse events&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 14:02:59 +0000" NOTES_MODIFIED_BY="Lindsay Stead" TYPE="JOURNAL_ARTICLE">
<AU>Wightman DS, Foster VJ, Krishen A, Richard NE, Modell JG</AU>
<TI>Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion</TI>
<SO>Primary Care Companion to the Journal of Clinical Psychiatry</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>5</NO>
<PG>e1-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="9400123000006102"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiley-2002" NAME="Wiley 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wiley JL, Lavecchia KL, Martin BR, Damaj MI</AU>
<TI>Nicotine-like discriminative stimulus effects of bupropion in rats</TI>
<SO>Experimental and Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>10</VL>
<PG>129-135</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkes-2005" MODIFIED="2013-12-03 14:03:13 +0000" MODIFIED_BY="[Empty name]" NAME="Wilkes 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wilkes S, Evans A, Henderson M, Gibson J</AU>
<TI>Pragmatic, observational study of bupropion treatment for smoking cessation in general practice</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2005</YR>
<VL>81</VL>
<PG>719-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2002" NAME="Young 2002" TYPE="JOURNAL_ARTICLE">
<AU>Young R, Glennon RA</AU>
<TI>Nicotine and bupropion share a similar discriminative stimulus effect</TI>
<SO>European Journal of Pharmacology</SO>
<YR>2002</YR>
<VL>443</VL>
<PG>113-118</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-10-07 11:56:59 +0100" MODIFIED_BY="Monaz Mehta">
<REFERENCE ID="REF-Hughes-1994" MODIFIED="2008-06-17 12:23:08 +0100" MODIFIED_BY="L S" NAME="Hughes 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hughes JR</AU>
<TI>Non-nicotine pharmacotherapies for smoking cessation</TI>
<SO>Journal of Drug Development</SO>
<YR>1994</YR>
<VL>6</VL>
<PG>197-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2000" MODIFIED="2009-08-12 13:40:50 +0100" MODIFIED_BY="Kate Cahill" NAME="Hughes 2000" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Anxiolytics and antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-08-12 13:40:50 +0100" MODIFIED_BY="Kate Cahill"/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2002" NAME="Hughes 2002" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2003" MODIFIED="2008-06-17 12:05:37 +0100" MODIFIED_BY="L S" NAME="Hughes 2003" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-06-17 12:05:37 +0100" MODIFIED_BY="L S"><IDENTIFIER MODIFIED="2008-06-17 12:05:37 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000031"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2004" MODIFIED="2013-10-07 11:56:59 +0100" MODIFIED_BY="L S" NAME="Hughes 2004" TYPE="COCHRANE_REVIEW">
<AU>Hughes J, Stead L, Lancaster T</AU>
<TI>Antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-10-07 11:56:59 +0100" MODIFIED_BY="L S"><IDENTIFIER MODIFIED="2013-10-07 11:56:59 +0100" MODIFIED_BY="L S" TYPE="DOI" VALUE="10.1002/14651858.CD000031.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007a" MODIFIED="2013-10-07 11:39:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hughes 2007a" TYPE="COCHRANE_REVIEW">
<AU>Hughes JR, Stead LF, Lancaster T</AU>
<TI>Antidepressants for smoking cessation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-10-07 11:39:58 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-10-07 11:39:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000031.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-08-22 13:54:09 +0100" MODIFIED_BY="Lindsay Stead"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-03 16:11:18 +0000" MODIFIED_BY="Lindsay Stead">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-03 16:11:18 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-12-03 15:14:45 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Ahluwalia-2002">
<CHAR_METHODS MODIFIED="2013-12-03 15:14:45 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION<BR/>Randomized controlled trial </P>
<P>Setting: community-based health care centre, USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 12:27:46 +0100" MODIFIED_BY="Lindsay Stead">
<P>600 African American smokers, &gt; 10 CPD; 70% F, av. age 44, av. CPD 17, 27% had possible clinical depression (CES-D &gt; 16)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 12:28:12 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg/day for 7 weeks<BR/>2. Placebo<BR/>Both arms: 8 sessions of in-person or telephone counselling &amp; S-H guide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 26w (prolonged) <BR/>Validation: CO &lt;= 10 ppm, discrepancies resolved with cotinine &lt;= 20 mg</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence rates shown in Figure 3 of paper. Figures obtained from authors.</P>
<P>Funding: National Cancer Institute. GlaxoSmithKline provided study medication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:15:15 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Aubin-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:15:15 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 74 cessation outpatient clinics, France<BR/>Recruitment: volunteers<BR/>Randomization: computer-generated, blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 12:29:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>504 smokers, &gt;= 10 CPD; 56% F, av age 41, av CPD NS, 16% history of MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 12:29:05 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg for 7 weeks<BR/>2. Placebo<BR/>Both arms: motivational support at clinic visits at baseline, w3, w7, w12 &amp; 3 phone calls TQD, 2-3 days later, w5, w18</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 26w (continuous from w4)<BR/>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:04:41 +0100" MODIFIED_BY="[Empty name]">
<P>First included as Lebargy 2003 based on abstract.</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:15:19 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Aveyard-2008">
<CHAR_METHODS MODIFIED="2013-12-03 15:15:19 +0000" MODIFIED_BY="Lindsay Stead">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: National Health Service stop smoking clinics, UK<BR/>Recruitment: People attending clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-17 16:55:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>901 smokers, &#8805;10/day; 46% F, av. age 43, av. CPD 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-17 16:56:56 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Nortriptyline 75 mg/day, for 8 w including tapering (max dose for 6w)<BR/>2. Placebo capsules<BR/>All participants received free NRT and had behavioural support, the majority attending group sessions run by cessation specialists</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-17 16:29:10 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12 months (prolonged from day 15 post quit)<BR/>Validation: CO at 4w, saliva cotinine (collected by post) at 6m &amp; 12m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 12:37:02 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: Cancer Research UK and National Institute for Health Research. Medication provided by King Pharmaceuticals.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:15:22 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Berlin-1995">
<CHAR_METHODS MODIFIED="2013-12-03 15:15:22 +0000" MODIFIED_BY="Lindsay Stead">
<P>MOCLOBEMIDE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, France<BR/>Recruitment: By adverts in general practices or from occupational medicine depts<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 15:29:10 +0100" MODIFIED_BY="Lindsay Stead">
<P>88 smokers, &gt;20/day and FTQ&gt;=6. No current major depression or anxiety disorders. 57% had history of MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 15:29:50 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Moclobemide 400 mg/day for 1w pre- and 2m post-TQD, 200 mg for 3rd month<BR/>2. Placebo (P)<BR/>No behavioural intervention or counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 1 year (prolonged)<BR/>Abstinence verified at all visits up to 6m by plasma cotinine &lt;= 20 ng/ml. 1 year abstinence based on telephone self report by 6m quitters.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:08:41 +0100" MODIFIED_BY="Lindsay Stead">
<P>There were no serious adverse reactions. Insomnia was more common in drug (36%) than P (7%) groups. There were 4 drop-outs for adverse effects/relapse in drug and 2 in P.</P>
<P>Funding: Roche</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:15:25 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Biberman-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:15:25 +0000" MODIFIED_BY="Lindsay Stead">
<P>SELEGILINE</P>
<P>Randomized controlled trial<BR/>Setting: 3 community-based clinic, Israel<BR/>Recruitment: mailing to members of public health service provider</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 15:37:53 +0100" MODIFIED_BY="Lindsay Stead">
<P>109 smokers (15+ CPD); 38% F, av. age 42, av. CPD 27-30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 11:21:37 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Selegiline 10 mg/day for 26 weeks, nicotine patch 21 mg for 8 weeks incl tapering<BR/>2. Placebo &amp; nicotine patch<BR/>Both arms: Behavioural support from trained family physician; weekly then fortnightly visits for 12w</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-23 11:21:45 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 52 w, continuous with validation at each visit<BR/>Validation: negative for urine nicotine, cotinine, 3-hydroxycotinine (Niccheck)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:03:36 +0100" MODIFIED_BY="Lindsay Stead">
<P>No serious AEs, no significant differences in AEs, 2 selegiline discontinuations.</P>
<P>Funding not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:15:29 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Blondal-1999">
<CHAR_METHODS MODIFIED="2013-12-03 15:15:29 +0000" MODIFIED_BY="Lindsay Stead">
<P>FLUOXETINE</P>
<P>Randomized controlled trial<BR/>Setting: cessation clinic, Iceland<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 11:04:15 +0100" MODIFIED_BY="Lindsay Stead">
<P>100 smokers (excl 5 early withdrawals), &gt; 10 CPD; 62% F, av age 41, av CPD 28, 38% fluoxetine/56% placebo had history of depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine inhaler and fluoxetine for 3m, option of continuing for 3m more. Fluoxetine 10 mg/day initiated 16 days before TQD, increased to 20 mg/day on day 6.<BR/>2. Nicotine inhaler and placebo<BR/>Both arms: 5 x 1 hr group behaviour therapy. Advised to use 6-12 inhalers/day for up to 6m.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 1 year (sustained from quit day)<BR/>Validation: CO &lt; 10 ppm at all assessments (6w, 3,6, 12 m)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:12:00 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: Oddur Olafsson Fund, Pharmacia &amp; Upjohn Consumer Health Care. Delta Pharmaceutical Company provided fluoxetine and placebo and fluoxetine analyses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:07 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Fisrt included as Brown 2006, part unpublished data&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:16:07 +0000" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:07 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION<BR/>Randomized controlled trial, 2x2 factorial design</P>
<P>Setting: 2 clinical sites (Butler Hospital, Miriam Hospital) Rhode Island, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 12:34:56 +0100" MODIFIED_BY="Lindsay Stead">
<P>524 smokers &gt;= 10 CPD; 48% F, av. age 44, av. CPD 25, 17.6% with history of MDD single episode, 3.1% recurrent MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 12:35:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>2 x 2 factorial design. Alternative psychosocial treatments were standard cessation therapy or plus CBT for depression. Both had 12 x 90 min groups twice weekly/ weekly/ monthly for 12w. TQD 5th session. Collapsed in this analysis<BR/>1. Bupropion 300 mg/day for 12 weeks<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (sustained at 4 visits)<BR/>Validation: CO &lt;= 10 ppm, saliva cotinine &lt;= 15 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:12:27 +0100" MODIFIED_BY="Lindsay Stead">
<P>First included as Brown 2006, part unpublished data. Some genotyping studies combine these participants with those reported in Collins 2004</P>
<P>Funding: National Institutes of Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:17 +0000" MODIFIED_BY="[Empty name]">
<P>FLUOXETINE</P>
<P>Randomized controlled trial</P>
<P>Setting: clinic, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-19 14:09:05 +0100" MODIFIED_BY="[Empty name]">
<P>216 smokers with elevated depressive symptoms (CES-D score &#8805; 6) smoking &#8805; 10 cpd. 38.4% F, av age 46, av cpd 21, mean FTND 5.6, mean CES-D 11.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-29 13:31:44 +0100" MODIFIED_BY="[Empty name]">
<P>1. 10 weeks of 20 mg fluoxetine (beginning 2 weeks prior to TQD)</P>
<P>2. 16 weeks of 20 mg fluoxetine (beginning 8 weeks prior to TQD)</P>
<P>3. Control (no placebo)</P>
<P>All arms: nicotine patch for 8 weeks starting on TQD (21 mg/day for 4 weeks, 14mg/day for 2 weeks, 7 mg/day for last 2 weeks), 5 sessions of brief behavioural smoking cessation treatment (in person and phone over 4 weeks, 20- 30 mins each)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 10:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence at 12m</P>
<P>Validation: salivary cotinine &lt; 10 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 10:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013.</P>
<P>Significantly higher abstinence in 16 week arm than in 10 week arm, results presented separately in meta-analysis with control divided. N abstinent not reported, extrapolated from percentages provided.</P>
<P>Funding: American Cancer Society</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:23 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;&amp;quot;Blinding of the study staff to the medication was maintained using prenumbered pill containers, assigned to each participant at randomization by the pharmacy. All study personnel with direct patient contact were blind to group assignment.&amp;quot;&lt;/p&gt;&lt;p&gt;... &amp;quot;Participants missed an average of 1.30 (SD 2.6) and 1.25 (SD 2.7) visits during treatment in the venlafaxine and placebo groups, respectively.&amp;quot;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:16:23 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Cinciripini-2005">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:23 +0000" MODIFIED_BY="Lindsay Stead">
<P>VENLAFAXINE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 11:46:52 +0100" MODIFIED_BY="Lindsay Stead">
<P>135 smokers, &gt;= 10 CPD; 50% F, av age 46, av CPD 27</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Venlafaxine titrated to max of 225 mg/day from 3w before quit day for 21w, including 2w tapering.<BR/>2. Placebo<BR/>Both arms: 6w 22 mg nicotine patch, and 9x 15 min behavioural counselling.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (PP)<BR/>Validation: CO &lt;= 10 ppm and/or saliva cotinine &lt; 15 ng/ul<BR/>Adverse events/withdrawals: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:13:13 +0100" MODIFIED_BY="[Empty name]">
<P>First included as Cinciripini 1999 based on abstract.</P>
<P>Funding: National Institutes for Health and National Institute for Drug Abuse. Medication provided free of charge by Wyeth Ayerst Laboratories.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cinciripini-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:27 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: clinic, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-22 14:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>294 smokers of &#8805; 5 cpd</P>
<P>61% M, av age 44, av cpd 20, mean FTND 4.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:46:48 +0000" MODIFIED_BY="[Empty name]">
<P>1. 12 weeks bupropion started 12-19 days before TQD (150mg/d days 1-3, 300mg/d thereafter)</P>
<P>2. 12 weeks varenicline on same schedule (0.5mg/day days 1-3, 1.0mg/day days 4-7, 2.0mg/day thereafter)</P>
<P>3. Placebo on same schedule</P>
<P>All arms: 10 individual counselling sessions (6 in person, 4 via phone, 240 mins total)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 16:46:45 +0000" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence after 2 week grace period at 6m (Other prolonged abstinence outcomes also reported)</P>
<P>Validation: CO &lt; 10 ppm or salivary cotinine &lt; 15 ng/mL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-28 09:36:02 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013</P>
<P>In less than 1% of the total cases, participants who did not attend a follow-up were coded as abstinent because they were abstinent at the following data point. All other losses to follow-up counted as smokers.</P>
<P>Author provided further detail on AE measurements via e-mail.</P>
<P>Funding: National Institute on Drug Abuse, National Cancer Institute</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:31 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Collins-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:31 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 2 clinical research sites (Georgetown University Medical Center &amp; State University of New York), USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 12:37:47 +0100" MODIFIED_BY="Lindsay Stead">
<P>555 smokers, &gt;= 10 CPD, excluding history of psychiatric disorder including MDD; 57% F, av. age 46, av. CPD 21</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 12:38:31 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg/day for 10 w begun 2 w before TQD<BR/>2. Placebo<BR/>Both arms: 7 sessions group behavioural counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (prolonged from w2, 7 consecutive days of smoking defined as relapse)<BR/>Validation: saliva cotinine &lt;= 15 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:14:17 +0100" MODIFIED_BY="Lindsay Stead">
<P>Replaces Lerman 2002 which reported subset of data. Denominators supplied by 1st author, excludes 114 who withdrew before intervention. Some study details from Lerman 2006. Some genotyping studies combine these participants with those reported in Brown 2007.</P>
<P>Funding: National Cancer Institute, National Institute on Drug Abuse, National Center for Research Resources. Treatment provided free of charge by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:35 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Covey-2002">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:35 +0000" MODIFIED_BY="Lindsay Stead">
<P>SERTRALINE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 12:32:09 +0100" MODIFIED_BY="Lindsay Stead">
<P>134 smokers with a history of past MDD; 65% F, av age 44.5, 47% had history of recurrent MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sertraline starting dose 50 mg/day, 200 mg/day by week 4 quit day. 9 day taper. Total duration 10w + 9 day taper, including 1w placebo washout prior to randomization<BR/>2. Placebo<BR/>Both arms: 9 x 45 min individual counselling sessions at clinic visits</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence 6m after end of treatment (7 day PP)<BR/>Validation: serum cotinine &lt; 25 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:16:47 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Pfizer, Inc and National Institute on Drug Abuse</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:16:57 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Covey-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:16:57 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial<BR/>Setting: Cessation clinic, USA<BR/>Recruitment: community volunteers quit after 8w bupropion &amp; nicotine patch<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-03 10:04:40 +0000" MODIFIED_BY="Lindsay Stead">
<P>289 abstainers (excludes 5 withdrawing consent before starting medication); 45% F, av. age 43, av. cpd 21<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 13:36:06 +0100" MODIFIED_BY="Lindsay Stead">
<P>Relapse prevention study. All participants received 8 w open-label bupropion &amp; nicotine patch (21mg with weaning) for 7w from TQD. Transition procedures preserved blinding for RP phase but allowed weaning from bupropion. Individual counselling including CBT techniques, 15 min x6 during open label, x4 during RP, x2 during follow up.<BR/>1. Bupropion (300 mg) &amp; nicotine gum (2 mg, use as needed to manage craving) for 16 w<BR/>2. Bupropion &amp; placebo gum<BR/>3. Nicotine gum &amp; placebo pill (150 mg bupropion for first week)<BR/>4. Double placebo (150 mg bupropion for first week)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-25 17:05:56 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence (no relapse to 7 days of smoking) for 12m (10m after randomization, 6m after EOT) (Primary outcome for study was time to relapse)<BR/>Validation: CO &#8804;8ppm at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:02:28 +0100" MODIFIED_BY="Lindsay Stead">
<P>Quit rate after open-label treatment was 52% so the final quit rate of 30% for combination therapy is equivalent to ~16% of people starting treatment</P>
<P>Funding: National Institute on Drug Abuse. GlaxoSmithKline provided medications.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cox-2012">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:02 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: urban community-based clinic, USA</P>
<P>Recruitment: volunteers, via healthcare settings and via community</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 14:07:09 +0100" MODIFIED_BY="[Empty name]">
<P>540 African American light smokers (&#8804; 10 cpd for &#8805; 2 years, smoked on &#8805;25 days in past month). 66% F, av. age 47, av. cpd 8, av. FTND 3.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>1. 300 mg bupropion for 7 weeks (150 mg 1xd for 3d, then 150 mg 2xd for remainder)</P>
<P>2. Placebo on same schedule</P>
<P>Both arms: up to 6 one-to-one 15-20 minute individual counselling sessions, self-help guide at start</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 14:09:57 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 6 months</P>
<P>Validation: salivary cotinine &lt;15 ng/mL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 14:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>SAEs only reported at week 3 (none reported), not included in SAE analysis.</P>
<P>Funding: National Cancer Institute, National Institutes of Health, National Institute for Minority Health and Disparities</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:05 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Croghan-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:05 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: clinics, USA<BR/>Recruitment: community volunteers for pharmacotherapy cessation &amp; relapse prevention trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 12:29:50 +0100" MODIFIED_BY="Lindsay Stead">
<P>405 abstainers after 3m pharmacotherapy, 74 from inhaler, 141 bupropion, 190 combination. Participant characteristics not presented at start of RP phase</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 13:36:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>Relapse prevention study. In cessation phase participants had been randomized to bupropion (300mg), nicotine inhaler (up to 16 cartridges/day) or combination. Physician advice at entry, brief (&lt;10 min) counselling at monthly study visits (total 12-18 including RP phase) &amp; S-H. Abstainers (7 day PP after 3m therapy) eligible for RP phase.<BR/>RP intervention randomized single therapy abstainers to continue cessation therapy or placebo for 9m.<BR/>Combined therapy abstainers randomized to 4 groups: combination, placebo &amp; single therapy, or double placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-25 17:08:58 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 15m (from TQD, 12m from RP start, 3m from EOT) (PP)<BR/>Validation: CO &#8804;8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:02:35 +0100" MODIFIED_BY="Lindsay Stead">
<P>All arms with bupropion combined, compared to the respective placebo arms.<BR/>Cessation rates at end of induction phase were 14% for inhaler, 26% for bupropion and 34% for combination.</P>
<P>Funding: Public Health Service</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:17 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Da-Costa-2002">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:17 +0000" MODIFIED_BY="Lindsay Stead">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: cessation clinic, Brazil<BR/>Recruitment: volunteers to a smokers' support group<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>144 smokers, &gt;= 15 CPD; 'predominantly female' , age, CPD not described, 48% had a history of depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nortriptyline max 75 mg/day for 6w incl titration period, begun 1w before start of behaviour therapy<BR/>2. Placebo<BR/>Both arms: 6 weekly group cognitive behavioural therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence 6m after end of treatment (prolonged)<BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:21:19 +0100" MODIFIED_BY="[Empty name]">
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:21 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:21 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 5 hospitals, Denmark<BR/>Recruitment: hospital staff</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 13:16:52 +0100" MODIFIED_BY="Lindsay Stead">
<P>335 smokers incl physicians, nurses, other hospital service and admin staff, &gt;= 10 CPD, no history of MDD; 75% F, av. age 43, av. CPD 19</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 13:16:35 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg/day for 7 weeks<BR/>2. Placebo<BR/>Both arms: motivational support around TQD, at w3 &amp; 7, and at 12w follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (prolonged from w4)<BR/>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eisenberg-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:24 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: 38 hospitals, Canada</P>
<P>Recruitment: hospital patients with acute myocardial infarction (AMI)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 14:48:54 +0100" MODIFIED_BY="[Empty name]">
<P>392 smokers of at least 10 cpd, hospitalized with enzyme positive AMI. 84% M, av. age 54, av. cpd 23, av. FTND NR.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:48:08 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion 300 mg/day for 9 weeks (150 mg for 3d, then 150 mg 2xd for remainder)</P>
<P>2. Placebo on same schedule</P>
<P>Both arms: 7 one-to-one counselling sessions by research nurses at baseline and all follow-ups of &lt; 20 mins (avg. 5) &#8211; mix of phone and in-person</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-29 17:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>12m continuous abstinence (7d PP also reported)</P>
<P>Validation: CO &#8804; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 16:48:17 +0000" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>Patients not allowed to smoke whilst hospitalized. SAEs reported over 12m so not included in analysis. n quit extracted from percentages provided; denominators do not include 9 deaths in bupropion and 6 deaths in placebo group, all deemed not to be related to study medication.</P>
<P>Adherence to treatment: 72.3% bupropion 82% placebo took at least 1 pill per day</P>
<P>Funding: Canadian Institutes of Health Research and Heart and Stroke Foundation of Quebec</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:28 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Evins-2001">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:28 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: outpatient clinic, USA<BR/>Recruitment: volunteers<BR/>Randomization: no details</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 smokers with stable schizophrenia (excl 1 drop-out prior to medication)<BR/>39% F, av age 45.5/42.7, av CPD 38/30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 3m. TQD after w3<BR/>2. Placebo<BR/>Both arms: 9x 1 hr weekly group CBT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m, (prolonged)<BR/>Validation: CO &lt; 9 ppm or serum cotinine &lt; 14 ng/mL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-03 14:16:40 +0000" MODIFIED_BY="Lindsay Stead">
<P>2 year follow up also reported (Evins, et al 2004). 3 additional quitters, not used in meta-analysis since additional therapy used</P>
<P>Funding: National Association for Research on Schizophrenia and Affective Disorders. Medication provided by Glaxo Wellcome Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:32 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Evins-2005">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:32 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-17 14:43:17 +0100" MODIFIED_BY="Lindsay Stead">
<P>56 smokers with schizophrenia (&gt;=10 CPD) (excl 6 drop-outs prior to medication); 27% F, av age 45, av CPD 37/26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 3m. <BR/>2. Placebo<BR/>Both arms: 12 session group CBT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (7 day PP)<BR/>Validation: CO &lt; 9 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:23:07 +0100" MODIFIED_BY="[Empty name]">
<P>There was a significant treatment effect at EOT.<BR/>Originally included as Evins 2003 based on abstracts</P>
<P>Funding: National Association for Research on Schizophrenia and Affective Disorders. Medication provided by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:36 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Evins-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:36 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: community mental health centre, USA<BR/>Recruitment: outpatients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 13:27:26 +0100" MODIFIED_BY="Lindsay Stead">
<P>51 smokers (&gt;=10 CPD) with schizophrenia; av. age 44, av. CPD 28/25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 3m, nicotine patch, 21 mg for 8w incl tapering, 2 mg nicotine gum<BR/>2. Placebo + NRT as 1.<BR/>Both arms: 12 session group CBT, TQD week 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (from TQD)<BR/>Validation: CO &lt;= 8 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-03 10:05:05 +0000" MODIFIED_BY="Lindsay Stead">
<P>First included as Evins 2006 based on unpublished data<BR/>Used in bupropion+NRT vs NRT comparison.</P>
<P>Funding: Massachusetts Department of Mental Health. Medication provided by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:17:51 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Ferry-1992">
<CHAR_METHODS MODIFIED="2013-12-03 15:17:51 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA</P>
<P>Recruitment: NS</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>42 male smokers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 3m<BR/>2. Placebo<BR/>Both arms: group smoking cessation and relapse prevention counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m from end of treatment (sustained)<BR/>Validation: saliva cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:25:50 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract with no further details</P>
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:01 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Ferry-1994">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:01 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: Veterans Medical Centre, USA</P>
<P>Recruitment: NS<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>190 smokers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 100 mg x 3/day for 12w<BR/>2. Placebo<BR/>Both arms: group smoking cessation and relapse prevention counselling; TQD within first 4w</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (prolonged from day 29)<BR/>Validation: saliva cotinine &lt;= 15 ng/ml at 6m and 12m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract with long-term abstinence data supplied by author.</P>
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:07 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Fossati-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:07 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: primary care clinics, Italy<BR/>Recruitment: patients of 71 general practitioners</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-06-18 10:04:27 +0100" MODIFIED_BY="Lindsay Stead">
<P>593 smokers, &#8805; 10 CPD; 40% F, av. age 49, av. CPD 22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 10:05:14 +0000" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg/day for 7 weeks<BR/>2. Placebo<BR/>Both arms: GP visits at enrolment &amp; 4, 7, 26 &amp; 52w, phone calls 1 day pre TQD, 3 days post TQD, 10w post enrolment. Classified as low intensity</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-18 10:10:04 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (continuous from week 4)<BR/>Validation: CO &#8804;10ppm at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:02:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: Mario Negri Institute and GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gariti-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:17 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial</P>
<P>Setting: university, USA</P>
<P>Recruitment: self-referral from community</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 14:02:42 +0100" MODIFIED_BY="[Empty name]">
<P>260 light smokers (6-15 cpd) motivated to quit</P>
<P>57% F, av.age 54, av.cpd 11, av.FTND 4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-26 14:04:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Placebo patch for 8 wks + 9 wks bupropion SR + 10 wks individualized counselling sessions</P>
<P>2. Placebo patch for 8 wks + 9 wks bupropion SR + 4x5-10min counselling sessions</P>
<P>3. Nicotine patch + 9 wks placebo bupropion + 10 wks individualized counselling sessions</P>
<P>4. Nicotine patch for 8 wks + 9 wks placebo bupropion + four 5-10min counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 14:04:43 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 12m.</P>
<P>Validation: CO&lt;10ppm; urinary cotinine &lt;200ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-26 14:17:12 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>Used in direct comparison of bupropion and NRT only, pooling 1+2 versus 3+4.</P>
<P>Funding: National Institute on Drug Abuse</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:24 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-George-2002">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:24 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: mental health clinic, USA<BR/>Recruitment: outpatients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 14:07:13 +0100" MODIFIED_BY="Lindsay Stead">
<P>32 smokers with schizophrenia motivated to quit; 44% F, av. age 41/45, av. CPD 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 14:07:21 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg/day for 9 weeks. TQD w3<BR/>2. Placebo<BR/>Both arms: 10x 60 min weekly group therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (7-day PP)<BR/>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:33:51 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: National institute on Drug Abuse, U.S. Department of Veterans Affairs, National Alliance for Research on Schizophrenia and Depression. Medication provided by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-George-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:28 +0000" MODIFIED_BY="Lindsay Stead">
<P>SELEGILINE</P>
<P>Randomized controlled trial<BR/>Setting: outpatient smoking research clinic, USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-03 10:06:25 +0000" MODIFIED_BY="Lindsay Stead">
<P>40 smokers, CO &#8805;10 ppm; 63% F, av. age 49, av. CPD 23, 25% MDD history positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 14:28:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Selegiline 10 mg/day for 9 weeks (5 mg/day in w1 &amp; w9)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-23 14:42:03 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m (7 day PP)<BR/>Validation: CO &lt; 10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>"The main side effects of SEL were anorexia, gastrointestinal symptoms, and insomnia. None of the differences in adverse event ratings were significant in the SEL compared with the PLA group, and the drug was well tolerated compared with the placebo group. Reports of anxiety/agitation in both the SEL and PLA groups during the trial were high."</P>
<P>Funding: National Institute on Drug Abuse, U.S. Department of Veteran Affairs, National Alliance for Research on Schizophrenia and Depression</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:31 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-George-2008">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:31 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: Mental Health CentreUSA<BR/>Recruitment: Outpatients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 17:17:07 +0100" MODIFIED_BY="Lindsay Stead">
<P>58 smokers with schizophrenia or schizoaffective disorder (excludes 1 receiving no study medication); 40% F, av. age 40, av. CPD ~23</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-18 12:36:39 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg/day for 9w, begun 7 days pre-TQD<BR/>2. Placebo<BR/>Both arms: Nicotine patch (21mg/24hrs) for 8w from TQD &amp; group behaviour therapy 10 weekly sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-18 12:37:48 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m, PP<BR/>Validation: CO &lt;10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:01:44 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion as adjunct to NRT</P>
<P>Funding: National Institute on Drug Abuse, National Alliance for Research on Schizophrenia and Depression</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:34 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Gonzales-2001">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:34 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 16 clinical trial centres, USA<BR/>Recruitment: volunteers who had previously failed to quit using bupropion<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 15:20:05 +0100" MODIFIED_BY="Lindsay Stead">
<P>450 smokers, &gt;= 15 CPD, who had previously used bupropion for at least 2w without adverse effects; 55% F (Placebo), 48% F (Bup); av. age 45, av. CPD not specified, no details of depression history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 12w, begun 7 days pre-TQD.<BR/>2. Placebo<BR/>Both arms: brief individual counselling at visits w1-7, 9, 12, + telephone counselling at 4 and 5m</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m, prolonged from w4<BR/>Validation: CO &lt;= 10 ppm at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>6m data published. 12m data presented in a poster used since 2003 update</P>
<P>Funding: GlaxoWellcome Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:38 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Gonzales-2006">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:38 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 19 clinical trial centres, USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 15:28:17 +0100" MODIFIED_BY="Lindsay Stead">
<P>1025 smokers of &gt;= 10 CPD (673 in relevant arms), recent MDD excluded, prior exposure to bupropion excluded; 46% F, av. age 42, av. CPD 21, no details of depression history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 12w, begun 7 days pre-TQD<BR/>2. Varenicline 2mg/day<BR/>3. Placebo<BR/>All arms: Brief (&lt;10 min) standardized individual counselling at 12 weekly visits during drug phase and 11 clinic/phone visits during follow up, problem solving and relapse prevention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 1 year (sustained from w4)<BR/>Validation: CO &lt;= 10 ppm at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:38:33 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion was an active control for varenicline.<BR/>Bupropion vs placebo and bupropion vs varenicline comparisons contribute to review.</P>
<P>Funding: Pfizer, Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:43 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Grant-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:43 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 2 substance use disorder clinics, USA<BR/>Recruitment: Alcoholics in residential or outpatient treatment programmes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 15:37:35 +0100" MODIFIED_BY="Lindsay Stead">
<P>58 alcoholic smokers (20+ CPD); 84% M, av. age 40, av. CPD 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 15:41:49 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg for 60 days + nicotine patch 21 mg for 8 weeks incl tapering<BR/>2. Placebo &amp; nicotine patch<BR/>Both arms: 1 hour cessation group (&amp; 4 weekly assessment visits)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 14:38:53 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m, 7 day PP<BR/>Validation: no biochemical val, collaterals contacted, inconsistent, adjusted rates not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:02:47 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: National Institute on Alcohol Abuse and Alocholism</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:46 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-G_x00f3_recka-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:46 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: Smokers' clinic, Poland<BR/>Recruitment: smokers with a diagnosis of COPD and failure to stop smoking with advice alone<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>70 smokers with COPD<BR/>43% F, av age 56, av CPD 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 7w<BR/>2. Nicotine patch (15mg) for 8w<BR/>Common components: support at clinic visits at baseline, 2w, EOT</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 1 year (sustained)<BR/>Validation: CO &lt; 10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:39:27 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:50 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:50 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION &amp; NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: Smoking cessation clinic, Brazil<BR/>Recruitment: community volunteers.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-03 10:06:42 +0000" MODIFIED_BY="Lindsay Stead">
<P>156 smokers, FTND at least 4; 70% F placebo &amp; nortriptyline, 59% Bup, av. age 44, av. CPD NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day for 60 days, placebo nortriptyline, TQD during week 2<BR/>2. Nortripytyline 75 mg/day for 60 days, placebo bupropion<BR/>3. Double placebo<BR/>All arms: 6x 15-min individual CBT, weekly then bi-weekly.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (continuous from TQD)<BR/>Validation: CO &lt;= 10 ppm at 3 &amp; 6m</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:42:01 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:18:55 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hall-1998">
<CHAR_METHODS MODIFIED="2013-12-03 15:18:55 +0000" MODIFIED_BY="Lindsay Stead">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: community volunteers. Exclusion criteria included MDD within 3m of baseline<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>199 smokers of &gt;= 10 CPD, 33% had history of MDD<BR/>55% F, av age 40, av CPD 21-25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>2 x 2 factorial design. Alternative psychological Rxs were 10 sessions of CBT or 5 sessions of health education control. Collapsed in this analysis<BR/>1. Nortriptyline titrated to therapeutic levels - usually 75-100 mg/day, 12w<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 1 year post-EOT, prolonged. PP rates also reported.<BR/>Validation: CO at weeks 12, 24, 39 and 64<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:45:18 +0100" MODIFIED_BY="[Empty name]">
<P>There were no significant main or intervention effects for MDD category so these are pooled.</P>
<P>Funding: National Instutute on Drug Abuse and Veterans Administration</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:06 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hall-2002">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:06 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION &amp; NORTRIPTYLINE</P>
<P>Randomized controlled trial, 3x2 factorial<BR/>Setting: cessation research centre, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 15:53:19 +0100" MODIFIED_BY="Lindsay Stead">
<P>220 smokers, &gt;= 10 CPD; 40-47% F, av. age 37-43, av. CPD 20-23, 33% had history of MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-05 17:41:05 +0100" MODIFIED_BY="Lindsay Stead">
<P>3 x 2 factorial design. Alternative psychological interventions were Medical Management (MM, physician advice, S-H, 10-20 min 1st visit, 5 minds at 2,6,11 weeks) or Psychosocial Intervention (PI, as MM plus 5x 90 min group sessions at 4,5,7,11w)<BR/>Pharmacotherapy:<BR/>1. Bupropion 300 mg/day, 12w<BR/>2. Nortriptyline titrated to therapeutic levels, 12w<BR/>3. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 1 year (47w post quit date), prolonged. PP also reported<BR/>Validation: CO &lt;= 10 ppm, urine cotinine &lt;= 60 ng/mL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-12 11:18:07 +0100" MODIFIED_BY="[Empty name]">
<P>No significant interaction between pharmacotherapy and behaviour therapy, so BT arms collapsed in main analysis. Bupropion &amp; nortriptyline compared to placebo and head-to-head. Levels of support compared for bupropion only, PP rates used. Not included in behavioural support subgroup.</P>
<P>Funding: National Institute on Drug Abuse, National Cancer Institute<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:15 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Originally treated as two separated studies but changed for 2013 as same study can be entered twice in MA and distinguished in footnotes&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:19:15 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hall-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:15 +0000" MODIFIED_BY="Lindsay Stead">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial, 2x2 factorial<BR/>Setting: clinic, USA<BR/>Recruitment: community volunteers.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-03 10:07:14 +0000" MODIFIED_BY="Lindsay Stead">
<P>160 smokers of &#8805; 10 CPD<BR/>41% F, av age ~38, av CPD ~19, 21% MDD history positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-24 12:12:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>2 x 2 factorial design. Nortriptyline vs placebo and brief vs extended treatment.</P>
<P>Brief treatment: Nicotine patch for 8w from quit date, &amp; 5 group counselling sessions, total 7.5 hrs</P>
<P>Extended treatment: First 12w as for Brief, then same dose continued to week 52 then tapered. Individual counselling every 4w, total 3-4.5 hrs. Phone counselling, total 40-80 mins.<BR/>1. Nortriptyline titrated to 50-150 ng/ml (~75-100 mg) for 12w, quit date week 5<BR/>2. Placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-24 12:21:01 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 52w, repeated PP at 24, 36, 52w.<BR/>Validation: CO &#8804; 10 ppm and urine cotinine &#8804; 50 ng/ml at each point.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 12:10:05 +0100" MODIFIED_BY="[Empty name]">
<P>Factorial design, Brief and extended treatment entered in meta-analysis separately. In the active extended treatment arm participants were still receiving nortriptyline at the time of final follow up.</P>
<P>Funding: National Institute on Drug Abuse</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hall-2011">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:25 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: Clinic, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-21 15:06:55 +0100" MODIFIED_BY="[Empty name]">
<P>406 smokers of &#8805; 10 cpd</P>
<P>39% F, av age 41, av cpd 19, mean FTND 4.9</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-21 15:16:08 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse prevention study. All arms received same cessation intervention (5 sessions group counselling, 10wks NRT and 12wks bupropion at 150 mg/d for first 3 days and 300 mg/d for remainder). After cessation treatment ended:</P>
<P>1. Bupropion for 40wks (300mg/d)</P>
<P>2. As per 1, but placebo</P>
<P>3. As per 1, plus 11 sessions of individual CBT over 40 wks</P>
<P>4. As per 3, but placebo</P>
<P>5. No further treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-21 15:08:36 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 2y</P>
<P>CO &#8804; 10 ppm and urinary cotinine &#8804; 60 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 16:50:10 +0000" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>Study report does not present absolute values for N abstinent, only adjusted ORs. N quit extrapolated from graph. Group 5 does not contribute to any analyses.</P>
<P>Funding: National Institute on Drug Abuse</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:36 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hatsukami-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:36 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 12 clinical trial sites, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-03 10:07:20 +0000" MODIFIED_BY="Lindsay Stead">
<P>594 smoker of &gt;= 20 CPD wanting to reduce amount smoked. Not quit for &gt; 3m in previous year, at least 2 failed quit attempts including 1 with NRT, not currently depressed, 6% had history of MDD. Excludes 15 who took no study medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Not a cessation trial<BR/>1. Bupropion 300 mg/day, 26w<BR/>2. Placebo<BR/>Both arms: written materials suggesting reduction techniques, monthly brief individual counselling, telephone contact 2 days, 12 days, 5w after target reduction date. Participants indicating a willingness to quit at any time were enrolled in a 7w cessation programme with weekly visits followed by 19w of follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-23 17:00:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence 6m after quit date (denominator 594; 214 entered cessation phase<BR/>Validation: urine cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:47:52 +0100" MODIFIED_BY="[Empty name]">
<P>Not used in main analysis<BR/>38% of bupropion and 34% of placebo group entered cessation phase. Median time to attempting cessation shorter in bupropion group</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:40 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hays-2001">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:40 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 5 clinical trial centres, USA<BR/>Recruitment: 784 community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 17:02:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>429 smokers of &gt;= 15 CPD who quit after 7 weeks open label bupropion; 51% F, av age 46, av CPD 26, 19% history of MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 13:36:48 +0100" MODIFIED_BY="Lindsay Stead">
<P>Relapse prevention study</P>
<P>1. Bupropion 300 mg/day for 45 weeks<BR/>2. Placebo<BR/>Both arms: physician advice, S-H materials and brief individual counselling at follow-up visits.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-23 17:03:08 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 2 years (1 year after end of pharmacotherapy), prolonged<BR/>Validation: CO &lt;= 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:48:25 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse prevention trial</P>
<P>Funding: Glaxo Wellcome Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hays-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:43 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: Clinic, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-21 15:28:46 +0100" MODIFIED_BY="[Empty name]">
<P>110 recovering alcoholic abstainers with at least 1 y continuous abstinence from alcohol and drugs, 18+ years old, smoking &#8805; 20 cpd for previous year. Quit for at least last week of 8w patch therapy</P>
<P>78% M; av age 44; av cpd 29.9 (in initial population of 195 volunteers)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-21 15:29:00 +0100" MODIFIED_BY="[Empty name]">
<P>Relapse prevention study. All participants first received brief weekly counselling sessions and nicotine patch for 8 w. Patch tailored on the basis of baseline serum cotinine concentration</P>
<P>1. Bupropion: 150 mg/day first 3 d, then 300 mg/d until w 52</P>
<P>2. Placebo on same schedule</P>
<P>Brief individual counselling (&#8804; 10 min) at each clinic visit (weekly for w 9-12, monthly for w 13-24, then at 52, 53, 64 and 76 w)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-21 15:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Abstinence at 76 w (continuous and 7 d PP)</P>
<P>Validation: CO &lt; 8 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-21 15:31:06 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>Study does not report number of participants allocated to each group or number of successful abstainers in each group; numbers obtained through extrapolation</P>
<P>Funding: National Institute on Alcohol Abuse and Alocholism</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:47 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hertzberg-2001">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:47 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: Veterans Affairs Medical Centre (VAMC), USA<BR/>Recruitment: VAMC outpatient volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15 male veterans with Post Traumatic Stress Disorder, av age 50, av CPD 33</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg/day, 12w begun at least 1w before TQD.<BR/>2. Placebo<BR/>Both arms: individual counselling pre-quit, weeks 1,2,4,8,12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m, prolonged, validated at weeks 2, 8, 12.<BR/>Validation: CO &lt;= 10ppm<BR/>Paper includes as abstinent one person with a slip at week 12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:48:56 +0100" MODIFIED_BY="[Empty name]">
<P>2 of the successful quitters were taking bupropion at 6m, prescribed after end of study.</P>
<P>Funding: Glaxo Wellcome Inc, National Cancer Institute</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:50 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Holt-2005">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:50 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: Cessation clinic, New Zealand<BR/>Recruitment: Maori community volunteers aged 16-70<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 17:38:23 +0100" MODIFIED_BY="Lindsay Stead">
<P>134 smokers, &gt;=10 CPD; 72% F, av age 42/38</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300mg/day for 7w<BR/>2. Placebo<BR/>Both arms: counselling at 3 clinic visits during medication &amp; 3 monthly follow ups, motivational phone call 1 day before &amp; 2 days after TQD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 18:23:23 +0100" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Details corrected 12m outcomes not 6m&lt;/p&gt;" NOTES_MODIFIED="2009-07-22 18:23:23 +0100" NOTES_MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (continuous, undefined)<BR/>Validation: CO at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:49:21 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:53 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hurt-1997">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:53 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: multi-centre, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 17:43:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>615 smokers, &gt; 15 CPD, without current depression; 55% F, av. age 44, av. CPD 27, 3% had a history of major depression and alcoholism, 15% depression alone, 7% alcoholism alone.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 17:43:47 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 100 mg/day for 7 weeks<BR/>2. Bupropion 150 mg/day<BR/>3. Bupropion 300 mg/day<BR/>4. Placebo<BR/>All arms: physician advice, S-H materials, and brief individual counselling by study assistant at each visit</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-23 17:43:03 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (prolonged from day 22, data provided by Glaxo Wellcome) (continuous abstinence to week 6 and 7 day PP abstinence at 12m reported in paper)<BR/>Validation: expired CO &lt;= 10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>300 mg compared with placebo in main analysis<BR/>There was no evidence that history of major depression or alcoholism interacted with treatment condition or was associated with poorer outcomes. Prolonged abstinence rates at 12m as supplied by Glaxo Wellcome: 300 mg 21; 150 mg 23; Placebo 15</P>
<P>Funding: Glaxo Wellcome</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:19:57 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Until 2009 used continuous abstinence rates obtained from authors for RP arms but changed for consistency with data in RP review.&lt;/p&gt;&lt;p&gt;12m data replaced 6m data from 2004.&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:19:57 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hurt-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:19:57 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: multi-centre 14 North Central Cancer Treatment Group sites, USA<BR/>Recruitment: community volunteers.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>578 smokers recruited to first stage of study: &gt;= 15 CPD; 57% F, av age 42, 21% history of MDD<BR/>176 smokers abstinent after 8w nicotine patch treatment randomized to relapse prevention intervention<BR/>194 non-abstinent smokers randomized to bupropion as second line therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(All participants first received nicotine patch for 8w, dose based on cig consumption)<BR/>Relapse prevention arm:<BR/>1. Bupropion for 26w<BR/>2. Placebo<BR/>Second line therapy arm:<BR/>1. Bupropion for 8w<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 17:47:28 +0100" MODIFIED_BY="Lindsay Stead">
<P>Relapse prevention arm: Abstinence at 12m, (PP, 6m after end of therapy).<BR/>Second line therapy arm: Abstinence at 6m (4m after end of therapy)<BR/>Validation: CO &lt; 8 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:50:33 +0100" MODIFIED_BY="Lindsay Stead">
<P>Does not contribute to primary analysis.<BR/>Long-term follow up for 2nd line Rx arm from authors.</P>
<P>Funding: National Cancer Institute, Public Health Service. Medication provided by Glaxo Wellcome and Elan Pharmaceutical.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:20:34 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Jorenby-1999">
<CHAR_METHODS MODIFIED="2013-12-03 15:20:34 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial<BR/>Setting: multi-centre clinical trial units, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>893 smokers, &gt; 15 CPD, no current major depressive episode, 15-20% had history of MDD<BR/>52% F, av age 43 av CPD 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine patch (24 hr, 21 mg for 6w, tapered for 2w) and sustained release bupropion 300 mg for 9w from 1w before quit day<BR/>2. Bupropion 300 mg and placebo patch<BR/>3. Nicotine patch and placebo tablets<BR/>4. Placebo patch and placebo tablets<BR/>All arms: Brief (&lt; 15 min) individual counselling session at each weekly assessment. One telephone call 3 days after quit day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m, (continuous)<BR/>Validation: Expired CO &lt; 10ppm at each clinic visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome for study was PP abstinence; this analysis uses continuous abstinence since quit day.</P>
<P>Funding: Glaxo Wellcome</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:20:52 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Jorenby-2006">
<CHAR_METHODS MODIFIED="2013-12-03 15:20:52 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: multi-centre clinical trial units, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 18:03:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>683 smokers (in relevant arms) &gt;=10 CPD, no recent treatment for MDD, prior exposure to bupropion excluded; 41% F, av. age 42, av. CPD 22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300mg for 12 w +placebo varenicline<BR/>2. Varenicline 2mg for 12 w +placebo bupropion<BR/>3. Placebo bupropion + placebo varenicline<BR/>All arms: Brief (&lt; 10 min) individual counselling at each weekly assessment for 12w &amp; 5 follow-up visits. One telephone call 3 days after quit day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m, (sustained from week 9)<BR/>Validation: Expired CO &lt; 10 ppm at each clinic visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:51:25 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion was an active control for varenicline.<BR/>Bupropion vs placebo and bupropion vs varenicline comparisons contribute to review.</P>
<P>Funding: Pfizer Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:20:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahn-2012">
<CHAR_METHODS MODIFIED="2013-12-03 15:20:56 +0000" MODIFIED_BY="[Empty name]">
<P>SELEGILINE</P>
<P>Randomized controlled trial</P>
<P>Setting: clinics, USA</P>
<P>Recruitment: community</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 15:49:49 +0100" MODIFIED_BY="[Empty name]">
<P>246 smokers of &#8805; 15 cpd in 30d prior to enrolment, smoked for past 5 years and expired CO &#8805; 9 ppm, motivated to quit. 51% M, av. age 46, av. cpd 22.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 15:50:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Selegiline patch (6mg/24hr) for 9 weeks, starting 7 days before TQD</P>
<P>2. Placebo patch on same schedule</P>
<P>Both arms: 9 weekly individual counselling sessions of approx. 10mins each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-09 10:29:25 +0100" MODIFIED_BY="[Empty name]">
<P>Prolonged abstinence at 6m (continuous from week 6 onwards)</P>
<P>Validation: CO &lt; 9 ppm </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 16:51:07 +0000" MODIFIED_BY="[Empty name]">
<P>New for 2013 update. </P>
<P>Some additional information on study characteristics provided by author.</P>
<P>Mean compliance rates 91.6% and 91.3% for the STS and placebo groups</P>
<P>Funding: National Institutes of Health, National Institute on Drug Abuse</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:20:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalman-2011">
<CHAR_METHODS MODIFIED="2013-12-03 15:20:59 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: not specified (but presumably clinic-based), USA</P>
<P>Recruitment: Veterans Administration Medical Center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 09:46:22 +0100" MODIFIED_BY="[Empty name]">
<P>143 smokers with 2 to 12 months alcohol abstinence, smoking at least 10 cpd with history of alcohol abuse or dependence. Mean age 49, 83% M, avg. cpd 20.8, mean FTND 5.9.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-13 09:41:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Bupropion (8 weeks) (started 1 week before TQD, first 3 days 150mg/day, rest of period 2 x 150 mg/day)</P>
<P>2. Placebo as above</P>
<P>Both arms: nicotine patch (7 weeks starting on TQD; 21mg weeks 1-4, 14mg weeks 5-6, 7mg week 7) and 8 weekly counselling sessions starting 1 week before TQD (one-to-one sessions based on CBT and MI)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-13 09:49:17 +0100" MODIFIED_BY="[Empty name]">
<P>Prolonged abstinence at 24 weeks (no smoking after first 2 weeks after TQD)</P>
<P>Validation: salivary cotinine &#8804; 15ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:05:13 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>N quit calculated from percentages provided.</P>
<P>Funding: National Institute of Drug Abuse, National Institute on Alcohol Abuse and Alocholism</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:03 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Killen-2000">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:03 +0000" MODIFIED_BY="Lindsay Stead">
<P>PAROXETINE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: Advertisements<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 17:37:23 +0100" MODIFIED_BY="Lindsay Stead">
<P>224 smokers, &gt; 10 CPD, no current major depression. 12-25% had history of MDD; 46% F, av age 46, av CPD 26</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nicotine patch (24 hr, 21 mg, 8w) + 40 mg paroxetine (9w incl tapering)<BR/>2. Patch as 1 + 20 mg paroxetine<BR/>3. Patch as 1 + placebo paroxetine<BR/>All arms: S-H manual and 15 min behavioural counselling at weeks 1 &amp; 4.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (7 day PP at 10 &amp; 26w)<BR/>Validation: CO &lt; 9 ppm and saliva cotinine &lt; 20 ng/ml at each visit.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:53:05 +0100" MODIFIED_BY="Lindsay Stead">
<P>40 mg &amp; 20 mg dose pooled in MA from 2009. 20/75 quit on 40mg, 15/75 on 20mg</P>
<P>Funding: University of California Tobacco-Related Disease Research Program, SmithKline Beecham</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:06 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Killen-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:06 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: continuation high schools, USA<BR/>Recruitment: adolescents at schools<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 18:04:49 +0100" MODIFIED_BY="Lindsay Stead">
<P>211 adolescent smokers, &gt;= 10 CPD, at least 1 failed quit attempt; 31% F, av. age 17, av. CPD 15</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 150mg for 9w from 1w before TQD, Nicotine patch for 8w<BR/>2. Placebo &amp; nicotine patch<BR/>Both arms: Weekly 45 min group sessions, skills training</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (7 day PP)<BR/>Validation: Saliva cotinine &lt; 20 ng/ml at 6m (CO at EOT)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:53:37 +0100" MODIFIED_BY="Lindsay Stead">
<P>Low compliance with both bupropion &amp; patch therapy</P>
<P>Funding: National Cancer Institute. GlaxoSmithKline provided medication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:10 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Killen-2006">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:10 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: clinics, USA<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:00:01 +0100" MODIFIED_BY="Lindsay Stead">
<P>362 smokers &gt;=10 CPD, no current major depression; 46% F, av age 45, av CPD 20, 25% previous bupropion use<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-06-17 12:34:27 +0100" MODIFIED_BY="L S">
<P>Extended treatment for relapse prevention after successful quitting. All received open label combination pharmacotherapy of bupropion 300 mg for 11w, nicotine patch for 10w. TQD day 7, 30 min individual relapse prevention skills training at 6 clinic visits.<BR/>1. Bupropion 150 mg for 14w<BR/>2. 2w tapering bupropion then placebo.<BR/>Both arms had 4 further clinic visits during extended therapy<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (continuous). PP and 7day relapse-free outcomes also reported.<BR/>Validation: CO (10 people not required to provide samples)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:54:09 +0100" MODIFIED_BY="Lindsay Stead">
<P>Relapse prevention, does not contribute to main analysis.<BR/>PP outcomes favour placebo but no outcomes showed significant effects</P>
<P>Funding: National Cancer Institute. Medication provided by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Killen-2010">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:13 +0000" MODIFIED_BY="[Empty name]">
<P>SELEGILINE</P>
<P>Randomized controlled trial</P>
<P>Setting: community, USA</P>
<P>Recruitment: radio, newspapers, community website and notices distributed via local organizations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 11:15:15 +0100" MODIFIED_BY="[Empty name]">
<P>243 smokers of &#8805; 10 cpd, 18-65 years old. 70% M, av age 45, av cpd 19.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:51:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Selegiline patch for 8 weeks, 6mg/24hr, starting on TQD</P>
<P>2. Identical placebo on same schedule</P>
<P>Both groups: 9 sessions of individual counselling to develop cognitive and behavioural skills to resist urges to smoke.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-13 11:16:46 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 12m</P>
<P>Validation: CO &lt; 10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>Funding: National Institute on Drug Abuse. Medication and matching placebo provided by Somerset Pharmaceuticals, Inc.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levine-2010">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:22 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial</P>
<P>Setting: not specified, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-15 12:01:10 +0100" MODIFIED_BY="[Empty name]">
<P>349 weight-concerned women smokers of &#8805; 10 cpd, motivated to quit</P>
<P>Av age 42, av cpd 21, mean FTND 5.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-15 12:02:52 +0100" MODIFIED_BY="[Empty name]">
<P>Factorial trial</P>
<P>1. Bupropion SR for 26 weeks. 150mg/d for first 2 days and 300mg/d for remainder of treatment.</P>
<P>2. Placebo on same schedule</P>
<P>Counselling conditions:</P>
<P>1. Standard cessation counselling</P>
<P>2. Standard cessation counselling + material on weight concerns</P>
<P>All arms received 12, 90 minute group counselling sessions delivered over 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-15 12:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>Prolonged abstinence at 12m (7d PP at 3, 6 and 12m)</P>
<P>Validation: CO &#8804; 8 ppm and salivary cotinine &#8804; 15 ug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-16 11:20:42 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>Counselling arms collapsed in analyses (same intensity, just differed in content). N abstinent calculated from percentages given.</P>
<P>Funding: National Institute on Drug Abuse. Medication supplied by GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:30 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-McCarthy-2008">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:30 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial<BR/>Setting: Cessation clinic, USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 18:12:54 +0100" MODIFIED_BY="Lindsay Stead">
<P>463 smokers; 50% F, av. age 36-41 across arms, av. CPD 22</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-18 15:13:00 +0100" MODIFIED_BY="Lindsay Stead">
<P>Factorial trial<BR/>1. Bupropion SR 300mg for 8 weeks<BR/>2. Placebo<BR/>Counselling conditions:<BR/>1. Counselling; 8 x10min session, 2 prequit, TQD, 5 over 4 wks<BR/>2. Psychoeducation about medication, support &amp; encouragement. Same no. of sessions, 80mins less contact time</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-29 14:46:39 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (7 day PP). Prolonged self-reported abstinence also assessed<BR/>Validation: CO &#8804;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 16:53:04 +0000" MODIFIED_BY="Lindsay Stead">
<P>Counselling conditions collapsed in main analysis, entered separately in subgroup analysis by intensity. Psychoeducation arms placed in multisession individual counselling subgroup due to high level of contact received, though not classified as counselling in paper.</P>
<P>Funding: National Cancer Institute, National Instutute on Drug Abuse. GlaxoSmithKline provided placebo medication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:33 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Muramoto-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:33 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: research clinic, USA<BR/>Recruitment: adolescent community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 16:29:17 +0100" MODIFIED_BY="Lindsay Stead">
<P>312 adolescents (14 to 17) smoking &#8805;6 CPD; 46% F, median age 16, median CPD 11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 18:18:15 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg for 7w<BR/>2. Bupropion 150 mg<BR/>3. Placebo<BR/>All arms: Brief (10-20 min) individual counselling session pre quit and at each weekly assessment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-06 11:40:06 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m (7 day PP; 30 day PP abstinence assessed but not reported)<BR/>Validation: CO &lt;10ppm (cotinine at weeks 2 &amp; 6 only)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:02:53 +0100" MODIFIED_BY="Lindsay Stead">
<P>300 mg arm contributes to main analysis. 2/105 quit in 150mg group</P>
<P>Funding: National Cancer Institute, The Robert Wood Johnson Foundation, GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:36 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;MM queried (C - Inadequate Why did LS have this as a 'no'?)- because no mention of blinding at allocation, and table of random numbers can easily be 'open'. - but probably not justified so changed!&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:21:36 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Myles-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:36 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: preoperative clinic, Australia<BR/>Recruitment: Smokers awaiting surgery<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>47 smokers expected to undergo surgery within 8-14w<BR/>34% F, av age 45/40, 49% smoked 21-30 CPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg for 7w<BR/>2. Placebo<BR/>Both arms: Advice at baseline, 1 phone call 2-4 days after TQD. Low intensity</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (28 day PP - classified as sustained)<BR/>Validation CO &lt;= 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-23 15:09:43 +0100" MODIFIED_BY="[Empty name]">
<P>More drop-outs in placebo group. Only 20 had surgery.</P>
<P>Funding: Alfred Hospital Research Trust, Glaxo Wellcome</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:40 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Niaura-2002">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:40 +0000" MODIFIED_BY="Lindsay Stead">
<P>FLUOXETINE</P>
<P>Randomized controlled trial<BR/>Setting: 16 clinical trial centres, USA<BR/>Recruitment: Community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>989 non-depressed smokers, no history of bipolar or current psychiatric disorder<BR/>61% F, av age 42 av CPD 28</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Fluoxetine 30 mg for 10w, starting 2w before TQD<BR/>2. Fluoxetine 60 mg for 10w, starting 2w before TQD<BR/>3. Placebo<BR/>All arms: 9 sessions (60-90 mins) individual CBT. Included coping skills, stimulus control techniques and relapse prevention.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 32w from TQD, multiple PP<BR/>Validation: saliva cotinine &lt; 20 ng/mL at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:57:11 +0100" MODIFIED_BY="[Empty name]">
<P>Originally based on abstract and data from authors. From 2002 based on full report. Numbers quit derived from rounded quit rates (10% quit in each group).</P>
<P>Funding: Eli Lilly and Company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:44 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Nides-2006">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:44 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 5 clinical sites, USA<BR/>Recruitment: Volunteers (phase II study)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>638 smokers (255 in relevant arms, incl 2 bupropion &amp; 4 placebo who did not start medication). No major depression in past year<BR/>51% F, av age 41, av CPD 20. 13-20% had used bupropion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 10:07:43 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion 300 mg for 7w<BR/>2. Varenicline 2 mg for 7w (other dose regimens not used in review<BR/>3. Placebo<BR/>All arms: Up to 10 mins counselling at 7 weekly clinic visits, 12 &amp; 24w.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (continuous from week 4)<BR/>Validation: CO</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:59:27 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion was an active control for varenicline.<BR/>Bupropion vs placebo and bupropion vs 2mg varenicline comparisons contribute to review.<BR/>Inclusion of 6 pretreatment drop-outs has minimal effect on RR.</P>
<P>Funding: Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 16:11:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parsons-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>ST JOHN'S WORT</P>
<P>Randomized controlled trial, 2x2 factorial</P>
<P>Setting: Smoking cessation clinic, UK</P>
<P>Recruitment: direct mail from GP, stop smoking service, newspaper advertisements</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-14 15:36:19 +0100" MODIFIED_BY="[Empty name]">
<P>143 adult smokers of at least 10 cpd, motivated to quit</P>
<P>38% M, av age 46, av cpd 21, mean FTND 5.5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 16:11:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. St John's wort 900 mg/day (300mg x 3/day) for 14 w, started 2 w prior to TWD</P>
<P>2. Placebo on same schedule</P>
<P>Both arms: 7 weekly individual behavioural support sessions in clinic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-14 15:38:08 +0100" MODIFIED_BY="[Empty name]">
<P>Prolonged abstinence at 6m</P>
<P>Validation: CO &#8804; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-09 10:55:31 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013.</P>
<P>Factorial trial - also tested the use of chromium versus placebo for weight loss. Arms collapsed for analysis; no difference detected.</P>
<P>Funding: Cancer Research UK</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:51 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Originally included as unpublished Piper 2004&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:21:51 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Piper-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:51 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: USA<BR/>Recruitment: volunteers<BR/>Randomization: method not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-23 18:44:25 +0100" MODIFIED_BY="Lindsay Stead">
<P>608 smokers of &#8805; 10 CPD; 58% F, av. age 42, av CPD 22, no details of depression history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 18:36:55 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Nicotine gum (4 mg) and bupropion (300 mg) (not used in this review)<BR/>2. Placebo gum and bupropion<BR/>3. Double placebo<BR/>All arms: 3x 10 min counselling over 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-23 18:47:27 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (PP)<BR/>Validation: CO or blood cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:00:56 +0100" MODIFIED_BY="Lindsay Stead">
<P>First included with 6m data as Piper 2004 based on abstract</P>
<P>Funding: National Institutes for Health<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:21:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piper-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:21:58 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: community, USA</P>
<P>Recruitment: volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 14:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>1504 smokers motivated to quit.</P>
<P>58% F, av.age 45, av.cpd 21.4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:55:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion SR (150 mg bid, 1 wk pre-quit, 8 wks postquit)</P>
<P>2. Bupropion + NRT (lozenge) (duration and dosage as below)</P>
<P>3. Nicotine lozenge 2 or 4 mg for 12 wks (based on dose-for-dependence level as per instructions)</P>
<P>4. Nicotine patch (24hr, 21, 14, and 7 mg titrated down over 8 wk period postquit)</P>
<P>5. Lozenge + patch (duration and dosage as above)</P>
<P>6. Placebo bupropion</P>
<P>7. Placebo bupropion + placebo lozenge</P>
<P>8. Placebo lozenge</P>
<P>9. Placebo patch</P>
<P>10. Placebo lozenge + placebo patch</P>
<P>All arms: 7 one-to-one 10-20min counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 14:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP abstinence at 6m; initial cessation.</P>
<P>Validation: CO&lt;10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 09:44:01 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>Placebo outcomes reported as a whole in published report, author provided data for individual groups. 1 versus 6 in Analyses 1.1, 1.2 and 1.3. 2 versus 3 included in Analysis 1.5. 1 versus 4 in Analysis 1.7.1, 1 versus 3 in Analysis 1.7.2 and 1 versus 5 in Analysis 1.7.3 (intervention arm split in three to avoid triple counting).</P>
<P>Majority of funding from National Institute on Drug Abuse and National Center for Research Resources. Medication provided to participants at no extra cost by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Planer-2011">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:04 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: hospitals, Jersulem, Israel</P>
<P>Recruitment: patients hospitalised for acute coronary syndrome in 2 separate campuses in Jerusalem</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 15:18:12 +0100" MODIFIED_BY="[Empty name]">
<P>151 smokers of &gt; 10 cpd with diagnosis of acute coronary syndrome, motivated to quit.</P>
<P>av. age: 51.9 yrs, 79.9% M, av. cpd 31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:57:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion 150 mg 1xday for 3 days, then 2x day for 2m</P>
<P>2. Placebo, same schedule</P>
<P>Both arms: counselling (at least 15 min of motivational support) during hospitalisation and continued after discharge (at least 2 visits with physician and nurse at 1 and 2m and weekly telephone call by nurse during first and second month, then monthly telephone calls during rest of the year)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 15:21:08 +0100" MODIFIED_BY="[Empty name]">
<P>Self-reported continuous abstinence at 12m</P>
<P>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 16:57:25 +0000" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>Study stopped early after interim analysis indicated no benefit</P>
<P>OR adjusted for age, sex, invasive procedure, risk factors, Fagerstrom score, cpd: 0.90 (95% CI 0.39-2.09)</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:07 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Prochazka-1998">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:07 +0000" MODIFIED_BY="Lindsay Stead">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: VAMC &amp; Army Medical Centre, USA<BR/>Recruitment: outpatient clinics and campus advertisements<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:01:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>214 smokers, &gt;10 CPD (Excludes 29 early drop-outs); 38% F, av age 47, av CPD 21,12% had a history of depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nortriptyline max 75 mg/day from 10 days pre-quit date to 8w after, tapered for 2w.<BR/>2. Placebo capsules.<BR/>Both arms: 2 behavioural group sessions prior to drug therapy. During treatment individual support was provided by the study nurse.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 6m (prolonged)<BR/>Validation: CO =&lt; 9 ppm at each visit and urine cotinine &lt; 50 ng/mL at 6m.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:02:19 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: Department of Veterans Affairs, US Department of Defense</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:11 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;It's not clear whether the numbers for 'relapsed to smoking' are missing to follow up data in the trial profile diagram (figure 1) . -I agree that figure 1 makes no sense for the placebo group so think we have to assume that the number randomized and quitters are correct but say that number of dropouts not specified&lt;/p&gt;&lt;p&gt;Blinding during trial: &amp;quot;An unblinded research pharmacist recommended dosage reductions for those with nortriptyline levels above the therapeutic range (150 ng/mL) and dosage increases for those whose levels were subtherapeutic (50 ng/mL).Tomaintain blinding, dosage reductions and increases on an equal number of randomly selected placebo-treated subjects were also recommended...our blinding was only partially effective. Because of the high frequency of dry mouth, the study nurse was often able to identify the active drug.&amp;quot;&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:22:11 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Prochazka-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:11 +0000" MODIFIED_BY="Lindsay Stead">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: outpatient clinic &amp; community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 09:50:21 +0100" MODIFIED_BY="Lindsay Stead">
<P>158 smokers, &gt; 10 CPD, excluding current depression; 54% F, av. CPD 22, 6% history of depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nortriptyline max 75 mg/day for 14w, from 2w before TQD tapered for 2w + nicotine patch 8w from TQD<BR/>2. Placebo capsules + active nicotine patch.<BR/>All arms: brief counselling from nurse at weekly visits</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 09:51:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m (prolonged)<BR/>Validation: CO &#8804; 9 ppm at each visit, cotinine &lt; 50 ng/ml at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:02:43 +0100" MODIFIED_BY="Lindsay Stead">
<P>First included based on unpublished data, Prochazka 2001. One fewer nortriptyline quitter in published paper</P>
<P>Funding: Department of Veterans Affairs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richmond-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:16 +0000" MODIFIED_BY="[Empty name]">
<P>NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: 18 prisons, Australia<BR/>Recruitment: referral from clinic staff, flyers and posters in prisons</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 16:57:38 +0000" MODIFIED_BY="[Empty name]">
<P>425 male prisoners aged &gt;18, incarcerated for &#8805; 1m with &#8805; 6m of current sentence remaining, FTND &#8805; 5. av age 34, av cpd 23, 83% FTND &#8805; 6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:58:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. Nortriptyline in tablet form for 13 weeks (TQD week 3. Week 1: 25 mg/day for 3 days, 50 mg/day for 4 days. Weeks 2 to 12 75 mg/day. Week 13 50 mg/day for 4 days, then 25 mg/day for 3 days)</P>
<P>2. Placebo on same schedule</P>
<P>Both groups: Two 30 minute counselling sessions with CBT. Self-help materials, access to quitline. 10 weeks NRT patch started on TQD; 21 mg weeks 1-6, 14 mg/day weeks 7-8, 7 mg/day weeks 9-10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-29 17:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence at 12m</P>
<P>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 16:58:33 +0000" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>N quit extrapolated from percentages provided</P>
<P>Funding: National Health and Medical Research Council, NSW Department of Health, Queensland Department of Health. NRT provided free of charge by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:19 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Rigotti-2006">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:19 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: hospitals, USA<BR/>Recruitment: volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>248 smokers hospitalised with cardiovascular disease (excludes 3/3 dropped prior to treatment &amp; 2 placebo deaths during follow up)<BR/>31% F, av age 56, av CPD 23/21. 30%/20% had prior use of bupropion, 54%/56% prior use of NRT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg for 12w<BR/>2. Placebo<BR/>Both arms: Multicomponent CBT cessation &amp; relapse prevention programme, motivational interviewing approach, Begun in hospital, 30-45 mins, 5 X10 min post-discharge contacts (2 days,1,3,8, 12w), S-H, chart prompt for physician. Total time 80-95 mins</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (sustained at multiple follow ups)<BR/>Validation: saliva cotinine at 12 &amp; 52w, CO at 2 &amp; 4w</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:04:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: National Heart, Lung and Blood Institute, National Institutes of Health General Clinical Research Centers Program, GlaxoSmithKline<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rose-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:22 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: clinic, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-27 11:43:10 +0100" MODIFIED_BY="[Empty name]">
<P>440 smokers of &#8805; 10cpd who did not respond successfully to cessation treatment with NRT (phase 1 = 335 participants whose smoking did not decrease by &gt;50% after 1 week NRT (prior to TQD); phase 2 = 105 participants who lapsed within one week after TQD)</P>
<P>50% M, av age 43, av cpd 22, mean FTND 5.8</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>1. 12 weeks bupropion (150 mg/day for 3 days, 300 mg/d for remainder) and nicotine patch (patch dose based on expired CO, 21 mg/day for CO &#8804; 30 ppm, 42 mg/day for CO &gt; 30 ppm)</P>
<P>2. Varenicline alone (not included in any analyses as bupropion comparison would be confounded by addition of NRT)</P>
<P>3. Nicotine patch only (dosing as above)</P>
<P>Both arms: Cessation programme with nicotine patch (discontinued after 1w in Phase 1 varenicline arm) and 4 to 6 brief (&lt;15min) counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-22 16:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence at 6m</P>
<P>Validation: CO &#8804; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-22 17:00:11 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>Phase 1 and Phase 2 combined in meta-analysis. Sensitivity analyses including both separately did not detect any significant effect on the pooled result.</P>
<P>Funding: Supported by grant to Duke University from Philip Morris USA. NRT donated by GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rovina-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:30 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: cessation clinic, Greece</P>
<P>Recruitment: Clinic attenders invited to participate</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-06-26 15:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>205 smokers of average &gt;15 cpd daily</P>
<P>40% F, av. age 45, av. cpd 37</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 16:59:54 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion 300 mg/day for 19 wks + 15 mins physician counselling</P>
<P>2. Bupropion 300 mg/day for 19 wks + nonspecific group therapy (NSGT), 1 hour weekly for 1 m, then every 3 wks until 19 wks</P>
<P>3. Bupropion 300 mg/day for 19 wks + cognitive behavioral group therapy (CBGT), same schedule</P>
<P>4. CBGT without bupropion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 15:39:46 +0100" MODIFIED_BY="[Empty name]">
<P>Abstinence at 12m after end of treatment (continuous)</P>
<P>Validation: CO &#8804; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-19 16:02:08 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>3 versus 4 used analyses, 1 and 2 not included in any analyses (effect of different counselling would confound effect of bupropion)</P>
<P>Authors do not report n abstinent, numbers included in MA extrapolated from applying percentage to overall n randomized</P>
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:36 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Saules-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:36 +0000" MODIFIED_BY="Lindsay Stead">
<P>FLUOXETINE</P>
<P>Randomized controlled trial<BR/>Setting: cessation clinic, USA<BR/>Recruitment: volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 11:11:44 +0100" MODIFIED_BY="Lindsay Stead">
<P>150 smokers, 20% history of MDD; 55% F, av. age 40</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Fluoxetine 40 mg for 14w, nicotine patch for 10w<BR/>2. Fluoxetine 20 mg for 14w, nicotine patch for 10w<BR/>3. Placebo &amp; nicotine patch<BR/>All arms: TQD end of w4, CBT 6 sessions starting 2w before TQD, 11 clinic visits</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (not defined)<BR/>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:05:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>Authors provided quit numbers by treatment group</P>
<P>Funding: National Institute on Drug Abuse, State of Michigan. Nicotine patch provided by McNeil Consumer Healthcare.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:45 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial<BR/>Setting: Research clinic, USA<BR/>Recruitment: Community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 10:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>154 women smokers &gt;20 CPD; av. age 48, av. CPD 21<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 10:08:28 +0000" MODIFIED_BY="Lindsay Stead">
<P>Factorial trial of bupropion and 2 group therapies<BR/>1. Bupropion 300 mg/day for 7 weeks<BR/>2. Placebo<BR/>Both arms: either CBT based on relapse prevention model, or group support therapy, both 7 weekly 60 min meetings, TQD morning of 1st session, 10 days after start of medications<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-28 10:08:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 12m (7 day PP)<BR/>Validation: CO &#8804; 10ppm, saliva cotinine &lt; 15ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:03:01 +0100" MODIFIED_BY="Lindsay Stead">
<P>Group therapy variants collapsed in main analysis</P>
<P>Funding: National Institute on Drug Abuse. Bupropion provided by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schnoll-2010">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:48 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: not specified (presumably clinic), USA</P>
<P>Recruitment: Patient lists from physicians treating people with cancer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-29 15:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>246 cancer patients smoking &#8805; 2 cpd</P>
<P>48% F, av age 54.8, av cpd 17.5, mean FTND 3.2. 32% had tobacco related tumours.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-16 11:13:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Bupropion for 9 weeks, started 2 weeks before TQD (150mg/d first week, 300mg/d remaining 8 weeks)           </P>
<P>2. Placebo on same schedule</P>
<P>Both arms: 8 weeks nicotine patches and 5 sessions of behavioural counselling (3 in person, 2 over phone)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-16 11:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 6m</P>
<P>Validation: CO &#8804; 10ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-16 11:15:25 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013. Previously listed as Scholl 2005 in 'Studies awaiting classification.'</P>
<P>Funding: National Cancer Institute. NRT provided free of charge from GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:22:52 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Selby-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:22:52 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 15 clinical centres, Canada<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>284 smokers previously exposed to bupropion for at least 2w, not quit for more than 24 hours in previous month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300mg for 12w<BR/>2. Placebo<BR/>Behavioural support not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (PP)<BR/>Validation: CO &lt;= 10 ppm at treatment visits</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:06:32 +0100" MODIFIED_BY="Lindsay Stead">
<P>Based on abstract</P>
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:15:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siddiqi-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:15:01 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Cluster randomized trial</P>
<P>Setting: health centres, Pakistan</P>
<P>Recruitment: patients from participating health centres with suspected pulmonary tuberculosis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-03 15:14:57 +0000" MODIFIED_BY="[Empty name]">
<P>33 health centres covering 1955 adult smokers with suspected tuberculosis (1299 included in arms relevant to this review), smoking &#8805; 1cpd or smoking hookah on a daily basis</P>
<P>95%M, av age 41, av cpd 19 (where one hookah counts as 2 cigarettes)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-22 15:34:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. 7 weeks bupropion (75mg/d first week, 150mg/d thereafter)</P>
<P>2. No pharmacotherapy</P>
<P>Both arms: 2 sessions of brief, in-person behavioural support</P>
<P>(Note, third arm received usual care only, not included in this review)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-22 15:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence at 6m</P>
<P>Validation: CO &#8804; 9 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 17:01:18 +0000" MODIFIED_BY="[Empty name]">
<P>New for 2013</P>
<P>Reported narratively only due to substantial heterogeneity of program effects across clusters. 275/659 quit intervention vs 254/640 control, adjusted RR 1.1 (0.5&#8211;2.3).</P>
<P>Funding: International Development Research Centre</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:04 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Simon-2004">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:04 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: VAMC outpatient units, USA<BR/>Recruitment: outpatients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:05:59 +0100" MODIFIED_BY="Lindsay Stead">
<P>244 smokers, 79% veterans; 5% F, av. age 50, av. CPD 24, 17% history of depression.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion 300 mg for 7w, nicotine patch for 2m<BR/>2. Placebo bupropion, nicotine patch for 2m<BR/>Both arms: 3m CBT counselling, S-H materials and telephone follow-up counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (sustained at multiple follow ups)<BR/>Validation: saliva cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:07:03 +0100" MODIFIED_BY="[Empty name]">
<P>Used in bupropion+NRT vs NRT comparison.<BR/>2 placebo &amp; 3 bupropion deaths excluded from denominators<BR/>Originally based on abstract, now uses published data and sustained quitting outcome.</P>
<P>Funding: California Tobacco-Related Disease Research Program</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:07 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Simon-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:07 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: VAMC hospital, USA<BR/>Recruitment: hospitalised volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-21 17:38:40 +0100" MODIFIED_BY="Lindsay Stead">
<P>83 inpatients smoking at least 5 CPD in previous year, smoking in week before admission, in contemplation or preparation stage of change; </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-23 19:04:02 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg for 7w<BR/>2. Placebo<BR/>Both arms: Individual cognitive behavioural 30-60 min during hospital stay + 5 phone calls at w1, w3, w5, w8, w12, recycling encouraged.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-21 18:37:25 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m, continuous at each assessment<BR/>Validation: saliva cotinine &lt;15 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:01:54 +0100" MODIFIED_BY="Lindsay Stead">
<P>1 death in bupropion, 1 in placebo excluded from analyses</P>
<P>Funding: California Tobacco-Related Disease Research Program</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-2009">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:11 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: 12 primary care clinics, USA</P>
<P>Recruitment: volunteers from primary care clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 10:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>1346 smokers of &gt;10 cpd for past 6m. 56% F, av.age 44, av.cpd 20.3, motivated to quit</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 17:01:48 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion only (up-titrated during wk pre-quitting, 150 mg bid for 8 wks postquit)</P>
<P>2. Nicotine lozenge only (4 mg lozenge if first cig of day smoked &gt;30 min after waking, 2 mg otherwise. 1 lozenge every 1-2hrs postquit wk 1-6; 1 lozenge every 2-4hrs wk 7-9; 1 lozenge every 4-8hrs wk 10-12)</P>
<P>3. Nicotine patch only (21 mg post-quit wk 1-4; 14 mg wk 5-6; 7 mg wk 7-8)</P>
<P>4. Bupropion and lozenge (dosage as above)</P>
<P>5. Patch and lozenge (dosage as above)</P>
<P>Both arms: Quitline counselling (state provided). All participants received initial session, then could elect to receive up to 4 additional calls + could call for additional support if required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 10:17:36 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 6m and number of days to relapse.</P>
<P>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 10:20:43 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>No control so does not contribute to primary analysis. 4 vs 2 used in <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>. 1 vs 3 used in <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.1, 1 vs 2 used in <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.2, and 1 vs 5 used in <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>.3 (n in 1 divided equally between subgroups to avoid triple counting).</P>
<P>Majority of funding from National Institutes of Health, National Institute on Drug Abuse, and National Cancer Institute. Medication provided to participants at no cost by GlaxoSmithKline.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:20 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-SMK20001">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:20 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 6 clinical trial centres, USA<BR/>Recruitment: volunteers for phase II trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>286 smokers &gt;=15 CPD, no prior use of bupropion<BR/>48% F, av age 42, av CPD NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-06 11:19:40 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300 mg for 7w &amp; placebo novel therapy<BR/>2. Double placebo<BR/>No information about behavioural support</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (continuous)<BR/>Validation: CO &lt;= 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:07:35 +0100" MODIFIED_BY="Lindsay Stead">
<P>Identified from GSK trials website. Also included a novel cessation aid</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sood-2010">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:26 +0000" MODIFIED_BY="[Empty name]">
<P>ST JOHN'S WORT</P>
<P>Randomized controlled trial</P>
<P>Setting: Community, USA</P>
<P>Recruitment: press releases and local advertising</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 17:02:19 +0000" MODIFIED_BY="[Empty name]">
<P>118 adult smokers of &#8805; 10 cpd, motivated to quit. </P>
<P>18% M, av age 38, av cpd 20, mean FTND 5.0.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 17:02:35 +0000" MODIFIED_BY="[Empty name]">
<P>1. St John's wort 900 mg/day (300 mg tablet 3xday for 12 weeks)</P>
<P>2. St John's wort 1800 mg/day (3 x 300 mg/day tablet first week, 3 x 600 mg/day tablet weeks 2-12)</P>
<P>3. Matched placebo on same schedule</P>
<P>Both arms:12 week behavioural intervention using Mayo Clinic &#8216;Smoke Free and Living It&#8217; manual (type and number of sessions not stated)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-29 17:34:52 +0100" MODIFIED_BY="[Empty name]">
<P>Prolonged abstinence at 24 weeks (2 week grace period following quit date) (7d PP also reported)</P>
<P>Validation: CO &#8804; 8ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>Groups 1 and 2 combined in meta-analysis; no significant difference between the two (at 24 weeks, 1/39 abstinent intervention 1, 2/40 abstinent intervention 2). </P>
<P>Funding: National Cancer Institute</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sood-2012">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:50 +0000" MODIFIED_BY="[Empty name]">
<P>S-ADENOSYL-L-METHIONINE (SAMe)</P>
<P>Randomized controlled trial</P>
<P>Setting: clinic, USA</P>
<P>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-29 15:52:25 +0100" MODIFIED_BY="[Empty name]">
<P>120 smokers of &#8805; 10 cpd motivated to quit</P>
<P>53% M, av age 40, av cpd 20, mean FTND 5.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 17:04:47 +0000" MODIFIED_BY="[Empty name]">
<P>1. SAMe 1600 mg/day (via mouth) for 8w</P>
<P>2. SAMe 800 mg/day same schedule</P>
<P>3. Placebo same schedule</P>
<P>All arms: Behavioural counselling using &#8220;Smoke Free and Living It&#8221; manual at every clinic visit (approx. 7)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-21 10:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>7d PP at 6m (prolonged abstinence measured but not reported)</P>
<P>Validation: CO &#8804; 8 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-21 10:26:39 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update.</P>
<P>SAMe is a dietary supplement used to treat depression.</P>
<P>No difference between arms 1 and 2, hence combined in meta-analysis.</P>
<P>Funding: National Institutes of Health</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:23:58 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;Included as Spring 2004 until 2009 update&lt;/p&gt;&lt;p&gt;LS has taken methods from the published paper which differed from the draft we saw originally&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:23:58 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Spring-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:23:58 +0000" MODIFIED_BY="Lindsay Stead">
<P>FLUOXETINE</P>
<P>Randomized controlled trial<BR/>Setting: clinic, USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 11:40:10 +0100" MODIFIED_BY="Lindsay Stead">
<P>247 smokers, &gt;= 10 CPD; 54% F, av. age 44, av. CPD 23, 44% history of MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-30 11:39:51 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Fluoxetine 60 mg (titrated up over 2 w) for 12 weeks<BR/>2. Placebo<BR/>Both arms: group behavioural counselling, 9 meetings over 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 15:01:03 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m (prolonged from 2 w after quit date)<BR/>Validation: CO &lt; 10 ppm, urine cotinine &lt; 20 ng/ml</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:08:18 +0100" MODIFIED_BY="Lindsay Stead">
<P>First included as Spring 2004 with unpublished data. Full publication reports sustained abstinence</P>
<P>Funding: National Institutes of Health, Veterans Affairs. Medication provided by Eli Lilly and Company.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stapleton-2013">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:01 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: Smoking cessation clinics, UK</P>
<P>Recruitment: People attending smoking cessation clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-16 11:25:37 +0100" MODIFIED_BY="[Empty name]">
<P>1071 daily smokers; 47% M, av age 41, av CPD 20, &gt;25% history of depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 17:05:39 +0000" MODIFIED_BY="[Empty name]">
<P>1. Bupropion for 8 weeks, started prior to TQD (exact period NS), 150 mg/d for first 6d, then 300 mg for remainder</P>
<P>2. Bupropion (as above) + NRT (choice of single product, 12 weeks started on TQD, dosage determined on individual basis)</P>
<P>3. NRT only (as above)</P>
<P>All groups: 7 weekly behavioural support sessions as per standard service protocol. Mainly group, 60-90 mins each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-16 11:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>Prolongued abstinence at 6m</P>
<P>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-16 11:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>Funding: Department of Health for England. Study medication provided free of charge by Pfizer UK, GSK UK and Novartis UK.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:12 +0000" MODIFIED_BY="Lindsay Stead" NOTES="&lt;p&gt;&lt;span class=&quot;marker&quot;&gt;&amp;quot;...to maintain fidelity with actual practice, the study did not include a placebo control group and was not blinded.&amp;quot; &lt;/span&gt;- this does not affect allocation concealment which can still be secure - in this case I would judge that because it was built into the database there was no opportunity for selection bias&lt;/p&gt;&lt;p&gt;MM query &lt;span class=&quot;marker&quot;&gt;see Table 1 - how can you have '21.5' people?&lt;/span&gt; - haven't had a chance to look at this!&lt;/p&gt;" NOTES_MODIFIED="2013-12-03 15:24:12 +0000" NOTES_MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Swan-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:12 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial, 2x2 factorial<BR/>Setting: HMO, USA<BR/>Recruitment: volunteers from Group Health Co-op membership<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 15:07:47 +0100" MODIFIED_BY="Lindsay Stead">
<P>1524 smokers &gt;= 10 CPD; 57% F, av age 45, av CPD 23, 44% history of depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Factorial design crossing 2 drug doses with 2 intensities of behavioural counselling:<BR/>Bupropion 300 mg/day versus 150 mg/day<BR/>Free &amp; Clear proactive telephone counselling (4 brief calls), access to quitline and S-H materials vs<BR/>Zyban Advantage Program (ZAP) tailored S-H materials, single telephone call after TQD, access to Zyban support line<BR/>Prescription was mailed. No face-to-face contact during enrolment or Rx</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (7-day PP) <BR/>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>Based on published data from 2004<BR/>No dose/behavioural treatment interaction at 12m so arms collapsed to compare 300 vs 150<BR/>Effects differed at 3 and 12m. Effect of higher dose disappeared and additional support aided recycling.</P>
<P>Funding: National Cancer Institute</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:16 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Tashkin-2001">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:16 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: multi-centre, USA<BR/>Recruitment: advertisements for volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:24:38 +0100" MODIFIED_BY="Lindsay Stead">
<P>404 smokers with mild to moderate COPD. (Excludes 7 early drop-outs who did not take any study medication); 45% F, av. age 53-54, av. CPD 28, 18% in Bupropion group and 23% in Placebo had a history of depression.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion SR 300 mg/day for 12w from 1w before TQD<BR/>2. Placebo<BR/>All participants had brief face-to-face counselling at each clinic visit (weeks 1-7, 10, 12), telephone counselling 3 days after TQD</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 52w, sustained from w4 (unpublished data from GSK, Lancet paper reports 6m data)<BR/>Validation: CO =&lt; 10 ppm at each visit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>12m unpublished data used from 2003/2.<BR/>ITT population defined as those taking at least one dose of study medication.</P>
<P>Funding: Glaxo Wellcome Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:20 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Tonnesen-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:20 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 28 clinical trial centres in 8 European countries, Australia, NZ<BR/>Recruitment: community volunteers<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:25:39 +0100" MODIFIED_BY="Lindsay Stead">
<P>710 smokers &gt;= 10 CPD; 51% F, av. age 42, median CPD 20, no details of depression history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-06-17 14:37:14 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion SR 300 mg/day for 7w<BR/>2. Placebo<BR/>Both arms: brief motivational support at weekly clinic visits and telephone support during follow up. 11 clinic visits and 10 phone calls scheduled.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 52w (prolonged from w4)<BR/>Validation: CO &lt;= 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:09:39 +0100" MODIFIED_BY="[Empty name]">
<P>First included 2003 as Tonstad 2001.<BR/>ITT population defined as those taking at least one dose of study medication excludes 3 randomized participants</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:25 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Tonstad-2003">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:25 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 28 clinical trial centres in 10 countries incl Europe, Australia, NZ<BR/>Recruitment: volunteers with CVD</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:27:03 +0100" MODIFIED_BY="Lindsay Stead">
<P>629 smokers with stable cardiovascular disease (CVD), &gt;= 10 CPD; 23% F, av. age 55, av. CPD 25, 49% had history of MI, no details of depression history<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion SR 300 mg/day for 7w, begun 1-2w before TQD<BR/>2. Placebo<BR/>Both arms: brief motivational support at weekly clinic visits and telephone support during follow up. 9 clinic visits and 10 phone calls scheduled.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 12m (prolonged from w4)<BR/>Validation: CO &lt;= 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>First included 2003 as McRobbie 2003. ITT population = 626 defined as those taking at least one dose of study medication.</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:28 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Uyar-2007">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:28 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: cessation clinic, Turkey<BR/>Recruitment: cessation clinic patients<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-06 13:28:33 +0100" MODIFIED_BY="Lindsay Stead">
<P>131 smokers; 81% M, av. age 36</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-22 09:43:26 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Bupropion 300mg for 7 weeks<BR/>2. Nicotine patch 21mg for 6 weeks incl tapering<BR/>3. Advice and follow up only<BR/>All arms: Brief counselling on consequences of smoking with follow up for 24 weeks- more than low intensity</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 24w (not defined)<BR/>Validation: CO &lt; 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:11:42 +0100" MODIFIED_BY="Lindsay Stead">
<P>First included based on abstract. Contributes to bupropion vs control and bupropion vs nicotine patch</P>
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:32 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Wagena-2005">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:32 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION &amp; NORTRIPTYLINE</P>
<P>Randomized controlled trial<BR/>Setting: university medical centre, Netherlands<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-30 10:17:19 +0100" MODIFIED_BY="Lindsay Stead">
<P>255 smokers (&gt;= 10 CPD) with or at risk of COPD; 51% F, av. age 51, av. CPD 23, 20% had possible depression, 7% previous use of bupropion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion SR 300 mg/day for 12w<BR/>2. Nortriptyline 75 mg/day for 12w<BR/>3. Placebo bupropion or placebo nortriptyline<BR/>All arms: Individual counselling 10-20 mins at baseline, 1w &amp; 3w post TQD (TQD typically day 11). Telephone support TQD, 2, 4, 6, 8, 11w.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-30 10:17:37 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 26w (prolonged puff-free from w4)<BR/>Validation: Urine cotinine &lt;= 60 ng/ml at 4, 12 &amp; 26w</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:12:39 +0100" MODIFIED_BY="Lindsay Stead">
<P>Funding: Netherlands Asthma Foundation, Netherlands Organization for Health Research and Development. Lundbeck BV provided nortriptyline free of charge.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:36 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Weinberger-2010">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:36 +0000" MODIFIED_BY="Lindsay Stead">
<P>SELEGILINE</P>
<P>Randomized controlled trial<BR/>Setting: clinics, USA<BR/>Recruitment: community volunteers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-04 14:09:02 +0100" MODIFIED_BY="Lindsay Stead">
<P>101 smokers (excludes 2 taking no medication), 50% F, av. age 47, av. CPD 22, 28% had history of MDD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-04 14:10:44 +0100" MODIFIED_BY="Lindsay Stead">
<P>1. Selegiline 10 mg/day for 9 weeks (5 mg/day in w1 &amp; w9)<BR/>2. Placebo<BR/>Both arms; brief weekly counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-04 14:11:12 +0100" MODIFIED_BY="Lindsay Stead">
<P>Abstinence at 6m (7-day PP)<BR/>Validation: CO &amp; cotinine</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-24 13:04:34 +0100" MODIFIED_BY="Lindsay Stead">
<P>Previously included as Weinberger 2009 based on unpublished data. Minor change to data based on published report in 2013 update. </P>
<P>Funding: National Institute of Drug Abuse, Veteran's Administration, Women's Health Research at Yale, NIH, University of Toronto.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wittchen-2011">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:39 +0000" MODIFIED_BY="[Empty name]">
<P>BUPROPION</P>
<P>Randomized controlled trial</P>
<P>Setting: 167 primary care clinics, Germany</P>
<P>Recruitment: patients at participating primary care clinics</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-07-02 11:19:45 +0100" MODIFIED_BY="[Empty name]">
<P>467 'current regular smokers' attending primary care clinic for any reason and willing to consider treatment in next 7d. 48% M, av.age 43, av.cpd 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-02 11:20:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Minimal intervention (not used in review)</P>
<P>2. CBT (4-5 one on one counselling sessions for 20-30min)</P>
<P>3. CBT (as above) + bupropion SR (9-12 wks, 150mg;1/d for first 6d; 2/d thereafter)</P>
<P>4. CBT (as above) + NRT for 9-12 wks, patient's choice of patch (7mg-52.5 mg), gum (2 or 4 mg) or spray (10mg/ml)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-02 11:20:38 +0100" MODIFIED_BY="[Empty name]">
<P>Abstinence at 12m (from EoT)</P>
<P>Validation: none</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-02 11:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>New for 2013 update</P>
<P>3 vs 2 included in primary analyses. 2 vs 4 included in <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> comparison of NRT with bupropion. 1 not used as results vs. bupropion would be confounded with CBT.</P>
<P>Patients covered all costs for pharmaceutical treatments.</P>
<P>Sponsored by the Federal Ministry of Education and Research; additional support provided by GlaxoSmithKline GmbH &amp; Co and Pharmacia GmbH.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-03 15:24:49 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Zellweger-2005">
<CHAR_METHODS MODIFIED="2013-12-03 15:24:49 +0000" MODIFIED_BY="Lindsay Stead">
<P>BUPROPION</P>
<P>Randomized controlled trial<BR/>Setting: 26 clinical trial centres in 12 European countries<BR/>Recruitment: volunteers, healthcare professionals (qualified practising physician or nurse)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>667 smokers (&gt;= 10 CPD) (excludes 1 centre enrolling 20 people, and 3 people who took no medication)<BR/>64% F, Av age 40, av CPD 23. 32% doctor, 68% nurse, no details of depression history</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Bupropion SR 300 mg/day for 7w<BR/>2. Placebo<BR/>Both arms: Brief (10-15 min) motivational support at weekly clinic visits and telephone support one day before TQD, 3 days after TQD, monthly during follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Abstinence at 52w (prolonged from w4)<BR/>Validation: CO &lt;= 10 ppm</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 16:14:38 +0100" MODIFIED_BY="[Empty name]">
<P>Continuous abstinence rates and information on adverse events from GlaxoSmithKline data. One centre excluded</P>
<P>Funding: GlaxoSmithKline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>av: average</P>
<P>AE: adverse event<BR/>CBT: cognitive behavioural therapy<BR/>CES-D: Center for Epidemiologic Studies Depression Scale<BR/>CO: carbon monoxide (in exhaled breath)<BR/>COPD: chronic obstructive pulmonary disease<BR/>CPD: cigarettes per day<BR/>CVD: cardiovascular disease<BR/>EOT: end of treatment<BR/>F: female<BR/>FTND: Fagerstrom Test for Nicotine Dependence<BR/>FTQ: Fagerstrom Tolerance Questionnaire<BR/>ITT: intention to treat<BR/>m: month/s<BR/>MA: meta-analysis<BR/>MDD: major depressive disorder<BR/>MI: myocardial infarction<BR/>mins: minutes</P>
<P>NRT: nicotine replacement therapy<BR/>NS: not stated<BR/>P: placebo<BR/>PP: point prevalence abstinence<BR/>RP: relapse prevention<BR/>Rx: treatment<BR/>S-H: self-help<BR/>TQD: target quit date<BR/>VAMC: Veterans Affairs Medical Center<BR/>w: week/s</P>
<P>y: year/s</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-12-03 14:04:09 +0000" MODIFIED_BY="Lindsay Stead" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:24:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akbarpour-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:24:09 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:24:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banham-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:24:34 +0100" MODIFIED_BY="[Empty name]">
<P>Not RCT - review of smoking cessation treatment for people with severe mental illness</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:41:55 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Barnes-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:41:55 +0000" MODIFIED_BY="Lindsay Stead">
<P>St John's wort - pilot study comparing two doses of St John's wort, no quitters at 12 months.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:41:58 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Becker-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:41:58 +0000" MODIFIED_BY="Lindsay Stead">
<P>St John's wort - short follow-up (1 month)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berlin-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Lazabemide (monoamine oxidase-B inhibitor) - short follow up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Berlin-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Befloxatone (reversible monoamine oxidase-B inhibitor) - data not published, treatment reported to have had no effect on abstinence rates.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 10:00:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berlin-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 10:00:33 +0000" MODIFIED_BY="[Empty name]">
<P>EVT302 (MAO-B inhibitor) - short follow-up. (No evidence of short-term benefit; 412 participants, RR 1.21, 95% CI 0.83 to 1.76)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:54:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bloch-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:54:51 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - trial in people with schizophrenia, short follow-up and cessation not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:42:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bowen-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:42:33 +0000" MODIFIED_BY="[Empty name]">
<P>Tryptophan - short follow up<BR/>Tryptophan 50 mg/kg/day, with high carbohydrate low protein diet (7/1 ratio), vs placebo and low carbohydrate high protein diet (1/1 ratio) for two weeks.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:42:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brauer-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:42:43 +0000" MODIFIED_BY="[Empty name]">
<P>Selegiline - only preliminary short-term results available. Six month follow-up planned</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-17 17:10:15 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Breitling-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-17 17:10:15 +0100" MODIFIED_BY="Lindsay Stead">
<P>Trial of practitioner education and financial incentives, or cessation drug costs reimbursement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-05 14:06:19 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Carr_x00e3_o-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-05 14:06:19 +0100" MODIFIED_BY="Lindsay Stead">
<P>Sertraline - combined with buspirone so effect of sertraline could not be isolated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chan-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion - case control study in pregnant women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornelius-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:02 +0000" MODIFIED_BY="[Empty name]">
<P>Fluoxetine - cessation not an outcome. Fluoxetine reduced the amount smoked by depressed alcoholic smokers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cornelius-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fluoxetine - short-term outcome in a study of depressed alcoholic patients not attempting to quit.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalack-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fluoxetine - refers to but does not report on a cessation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dale-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:17 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - used for smokeless tobacco cessation, not smoking cessation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 13:48:02 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Dale-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 13:48:02 +0000" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - for smokeless tobacco cessation, see <LINK REF="REF-Ebbert-2011" TYPE="REFERENCE">Ebbert 2011</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:27:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniela-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:27:12 +0100" MODIFIED_BY="[Empty name]">
<P>Sertraline and buspirone - effect of antidepressant confounded with that of anxiolytic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:31 +0000" MODIFIED_BY="[Empty name]">
<P>Doxepin - short follow-up (2 months)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elsasser-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:34 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - only 12 week follow-up reported to date. 17 teenage (14-19) smokers treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:46 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Evins-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:46 +0000" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - long-term results not presented due to high loss to follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fatemi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion - short-term crossover trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frederick-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:50 +0000" MODIFIED_BY="[Empty name]">
<P>Venlafaxine - short follow-up (8 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:43:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gawin-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:43:53 +0000" MODIFIED_BY="[Empty name]">
<P>Buspirone - open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:27:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gifford-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:27:38 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - test of behavioural therapy, all participants received bupropion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:44:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glover-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:44:05 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - used for smokeless tobacco cessation, not smoking cessation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gold-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion - non random assignment, patient preference</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-16 15:15:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;no need to list as excl?&lt;/p&gt;" NOTES_MODIFIED="2013-07-16 15:15:27 +0100" NOTES_MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grandi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:28:08 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - not RCT, review of bupropion use in patients with CVD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:28:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grassi-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:28:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not an RCT, pre-post study of influence of smoking ban on people's selection of smoking cessation treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 10:29:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gray-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 10:29:06 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-30 14:47:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hall-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-30 14:47:33 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - all participants received bupropion for quitting, test of extended CBT or NRT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:51:20 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Hawk-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:51:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - short follow-up (12 weeks). Compares 1 week to 4 week prequit use. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 11:02:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hilberink-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 11:02:54 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - test of NRT + counselling, one cluster received bupropion but is not a test of bupropion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:44:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hitsman-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:44:40 +0000" MODIFIED_BY="[Empty name]">
<P>Fluoxetine - the majority of patients in this study were also part of the multi-centre trial reported in <LINK REF="STD-Niaura-2002" TYPE="STUDY">Niaura 2002</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:44:43 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Houtsmuller-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:44:43 +0000" MODIFIED_BY="Lindsay Stead">
<P>Selegiline - short-term laboratory study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 11:03:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hussain-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 11:03:32 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up, trial in unmotivated smokers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:44:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:44:58 +0000" MODIFIED_BY="[Empty name]">
<P>Imipramine - short follow-up. Outcome was reduction in smoking to less than 10% of baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:45:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalman-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:45:13 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up (12 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:45:28 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Karam_x002d_Hage-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:45:28 +0000" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - short follow-up (to end of medication phase). Pilot study, 11 participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-17 11:55:10 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Kotz-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-17 11:55:10 +0100" MODIFIED_BY="Lindsay Stead">
<P>Nortriptyline - pharmacotherapy was confounded with additional counselling from nurse (control group 1), compared to usual care </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:45:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kras-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:45:35 +0000" MODIFIED_BY="[Empty name]">
<P>St John's wort - short follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:45:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lawvere-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:45:45 +0000" MODIFIED_BY="[Empty name]">
<P>St John's wort - uncontrolled study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-19 11:50:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Foll-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-19 11:50:22 +0100" MODIFIED_BY="[Empty name]">
<P>Selegiline - study terminated early due to lack of efficacy, results available at 9 weeks only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 11:07:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 11:07:56 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:46:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:46:30 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up (8 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:51:44 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Monuteaux-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:51:39 +0000" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - participants were adolescent non-smokers, not for cessation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:43:29 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Mooney-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:43:29 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - short follow-up, bupropion for opioid and tobacco dependence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naranjo-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fluoxetine - study of short-term smoking behaviour.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neumann-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion - smokers randomized to 1 or 2 months of medication (300 mg/day). 91/165 randomized were not included in the analysis, including some 1-month group participants who requested further medication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:52:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumann-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:52:28 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - short-term follow-up. Comparison of 300 mg and 150 mg doses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niederhofer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion - short-term. 22 adolescents followed up during 90 days of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:52:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olmstead-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:52:39 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - all participants received bupropion. Short-term follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:52:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paluck-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:52:44 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - uncontrolled prospective observational study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:52:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pomerleau-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:52:46 +0000" MODIFIED_BY="[Empty name]">
<P>Fluoxetine - no cessation data reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:52:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raynor-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:52:58 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - short (90 day) follow-up. Sub-study within a larger trial with long-term follow up, not yet published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:52:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:52:57 +0000" MODIFIED_BY="[Empty name]">
<P>Buspirone - case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-30 14:28:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rovina-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-30 14:28:38 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - abstract only, trial report not available. Insufficient information to determine inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-30 14:29:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schepis-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-30 14:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - abstract only, trial report not available. Insufficient information to determine inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:54:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sellers-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:54:58 +0000" MODIFIED_BY="[Empty name]">
<P>Zimelidine or citalopram (SSRIs) - placebo-controlled crossover design study of smoking behaviour and alcohol use in non-depressed heavy drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:55:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheng-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:55:04 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - follow-up less than 6 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-24 15:54:43 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Sherman-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-24 15:54:43 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - trial of NRT as adjunct to bupropion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:55:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiffman-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:55:09 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - placebo-controlled short-term study of effects on craving and withdrawal in patients not wanting to quit smoking permanently</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:55:25 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Shoptaw-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:55:25 +0000" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - tested for methamphetamine dependence. Reduction in smoking was a secondary outcome. Only 48/73 participants smoked, quitting not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:55:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Singh-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:55:33 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - short-term follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-02 17:57:23 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Sittipunt-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-02 17:57:23 +0100" MODIFIED_BY="Lindsay Stead">
<P>Nortriptyline - only 3-month follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-30 14:32:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sonntag-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-30 14:32:34 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - abstract only, trial report not available. Insufficient information to determine inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spring-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fluoxetine - 6-month cessation not reported. Primarily a study of post-cessation weight gain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:55:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:55:48 +0000" MODIFIED_BY="[Empty name]">
<P>Fluoxetine - does not report outcomes from a double-blind study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-17 13:42:31 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Steinberg-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-17 13:42:31 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - confounded with nicotine inhaler and treatment duration in comparison with nicotine patch alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strayer-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion - all participants prescribed bupropion. Test of behavioural interventions, not bupropion. Adverse event data from author used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Swanson-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Bupropion +/- nicotine patch. Unable to confirm correct denominators.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-17 13:16:20 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Tidey-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-17 13:16:20 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - laboratory study, outcomes included urge to smoke, not cessation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-30 16:51:21 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Toll-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-30 16:51:21 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - all participants had same pharmacotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-24 17:26:10 +0100" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Weinberger-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-24 17:26:10 +0100" MODIFIED_BY="Lindsay Stead">
<P>Bupropion for people with bipolar disorder. Short follow-up (8 weeks). Only 5 participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:56:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiner-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:56:13 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - no control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 11:10:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiner-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 11:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>Bupropion - short follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:57:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:57:39 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion versus gabapentin - Short follow-up (6 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:57:45 +0000" MODIFIED_BY="Lindsay Stead" STUDY_ID="STD-Zernig-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:57:45 +0000" MODIFIED_BY="Lindsay Stead">
<P>Bupropion - used as an active control to a psychosocial intervention, cannot estimate pharmacotherapy effect</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-03 09:58:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ZYB30011-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-03 09:58:54 +0000" MODIFIED_BY="[Empty name]">
<P>Bupropion - only follow-up to end of treatment (7 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-08-30 14:27:48 +0100" MODIFIED_BY="Lindsay Stead" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-10-24 12:01:14 +0100" MODIFIED_BY="Lindsay Stead" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-10-24 12:01:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rose-2013a">
<CHAR_STUDY_NAME MODIFIED="2013-10-24 12:01:05 +0100" MODIFIED_BY="[Empty name]">
<P>Combination varenicline/bupropion treatment for NRT-nonresponders</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-24 12:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-24 12:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>222 NRT non-responders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-24 12:01:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Varenicline and bupropion</P>
<P>2. Varenicline alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-24 12:01:09 +0100" MODIFIED_BY="[Empty name]">
<P>Abstinence at 8-11 weeks postquit and at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-24 12:01:09 +0100" MODIFIED_BY="[Empty name]">
<P>March 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-24 12:01:11 +0100" MODIFIED_BY="[Empty name]">
<P>Jed Rose, jed.rose@duke.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-24 12:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>Results at 8 to 11 weeks found significant benefit of adding bupropion for male participants, but not for female participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-12-03 10:08:42 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-26 16:51:52 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 14:52:28 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Ahluwalia-2002">
<DESCRIPTION>
<P>"Randomization codes were generated in blocks of 50 and sent to the pharmaceutical company..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 14:53:23 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Aubin-2004">
<DESCRIPTION>
<P>"The computerized randomization schedule, prepared by the sponsor, was inaccessible to the investigator who was provided with a specific set of sequential treatment numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 15:30:19 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Aveyard-2008">
<DESCRIPTION>
<P>"An independent statistician generated the randomisation<BR/>schedule in Stata. We used block randomisation,<BR/>with randomly ordered block sizes of two, four, and six,<BR/>stratified by stop smoking adviser."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlin-1995">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:52:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biberman-2003">
<DESCRIPTION>
<P>"Four hundred dice-throwing generated a randomized sequence code; 199 containers prepacked with selegiline and 201 containers prepacked with placebo were numbered accordingly." Judged adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-10 11:21:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>Computer generated randomization; part of the randomization procedure was performed by the manufacturer at another location where the code was also kept until it was broken in May 1997.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:52:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2007">
<DESCRIPTION>
<P>"Participants were randomly assigned to one of two treatment sites, where they were to receive one of two manualized group treatments ... Participants<BR/>were then randomly assigned to receive one of two medication conditions, bupropion or placebo, using the urn randomization technique."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-19 14:12:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2013">
<DESCRIPTION>
<P>Urn randomization, no further detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2005">
<DESCRIPTION>
<P>Randomization method not described. Stratification by depression history.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 14:52:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2013">
<DESCRIPTION>
<P>&#8220;Adaptive randomization,&#8221; no further detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collins-2004">
<DESCRIPTION>
<P>"Randomization was determined by a computer-generated randomization scheme operated by a senior data manager; stratification was carried out by study site" (Lerman 2006).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Covey-2002">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Covey-2007">
<DESCRIPTION>
<P>"A statistician who did not participate in the clinical phases of the study provided computer-generated randomization lists that were not accessible to the clinical staff", stratified by gender &amp; depression history.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 14:12:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cox-2012">
<DESCRIPTION>
<P>Computer generated random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Croghan-2007">
<DESCRIPTION>
<P>Randomization using a dynamic allocation procedure balancing stratification factors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Da-Costa-2002">
<DESCRIPTION>
<P>"Each patient chose a blind number from a box ...' Probably adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<DESCRIPTION>
<P>Randomization was computer generated and blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 14:55:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisenberg-2013">
<DESCRIPTION>
<P>"Randomization was done via an internet website using random blocks of 2 and 4 and was stratified by center to ensure that similar numbers of patients were randomized to the 2 arms of the study at each study center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2001">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2005">
<DESCRIPTION>
<P>Randomization method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2007">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1992">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1994">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 14:45:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fossati-2007">
<DESCRIPTION>
<P>Method of sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 14:06:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>Computerized &#8216;urn randomization&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2002">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2003">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2008">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 14:33:09 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Gonzales-2001">
<DESCRIPTION>
<P>"Participants who satisfied the inclusion criteria were randomized to the treatment phase and received either bupropion SR ... or matching placebo. Eligible participants were assigned a protocol-specific treatment number on the basis of a randomization code provided by GlaxoWellcome."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 15:27:20 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Gonzales-2006">
<DESCRIPTION>
<P>'predefined ... computer-generated randomization sequence', 1:1:1, using block size of 6, stratified by centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grant-2007">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_recka-2003">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1998">
<DESCRIPTION>
<P>Computer randomization, after stratification on history of MDD and number of cigarettes smoked.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2002">
<DESCRIPTION>
<P>"Participants were stratified by number of cigarettes smoked, sex and history of depression vs no history, and randomly assigned to 1 of the 6 experimental cells."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2004">
<DESCRIPTION>
<P>Randomization stratified on CPD, prior NRT use, MDD history; method not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 15:10:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2011">
<DESCRIPTION>
<P>&#8220;Randomly assigned,&#8221; methods not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 16:55:29 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Hatsukami-2004">
<DESCRIPTION>
<P>"Subjects were assigned randomly using a computer-generated schedule..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 14:34:38 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Hays-2001">
<DESCRIPTION>
<P>"Randomization to the placebo or bupropion groups was computer generated at a central location;..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 15:31:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hays-2009">
<DESCRIPTION>
<P>"Randomized", method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hertzberg-2001">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holt-2005">
<DESCRIPTION>
<P>Randomization using a computer generated code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1997">
<DESCRIPTION>
<P>Randomized, stratified by site, method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hurt-2003">
<DESCRIPTION>
<P>Randomized using 'dynamic allocation'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 17:46:56 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>"The subjects were randomly assigned to one of four treatments with use of an unequal-cell design...[<I>but</I>] Randomization was not balanced within sites."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 17:47:46 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Jorenby-2006">
<DESCRIPTION>
<P>"Randomization was completed centrally by using a computer-generated list and sites used an electronic system to assign participants to treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 15:52:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahn-2012">
<DESCRIPTION>
<P>"Adaptive randomization," method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 09:40:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2011">
<DESCRIPTION>
<P>"Urn randomization," no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killen-2000">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killen-2004">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2006">
<DESCRIPTION>
<P>Centrally generated pre-assigned random sequence stratified by gender, prior to open label phase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 16:51:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2010">
<DESCRIPTION>
<P>Random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-15 12:04:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-2010">
<DESCRIPTION>
<P>Blocked randomization, method of sequence generation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCarthy-2008">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muramoto-2007">
<DESCRIPTION>
<P>"Active study medication and identical-appearing placebo were prepackaged into 3 sets of identical-appearing blister cards in accordance with a computer-generated randomization list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 16:42:01 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Myles-2004">
<DESCRIPTION>
<P>Patients were randomly allocated from a table of random numbers into one of two groups: active (bupropion) or placebo (identical appearance).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-2002">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 17:56:45 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Nides-2006">
<DESCRIPTION>
<P>"...a randomization list was computer generated using a method of randomly permuted blocks and a pseudorandom number generator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:38:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parsons-2009">
<DESCRIPTION>
<P>Via computer program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:49:39 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>"Randomization was conducted in double-blind<BR/>fashion using blocked randomization within each of<BR/>the 10 [orientation session] cohorts." No further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 15:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>Method of sequence generation not specified. "Randomization was double-blind and used a block randomization scheme with sex and self-reported race as the blocking variables."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 15:22:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planer-2011">
<DESCRIPTION>
<P>"Randomized," method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:52:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prochazka-1998">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-30 10:02:38 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Prochazka-2004">
<DESCRIPTION>
<P>"Subjects were stratified by history of previous major depression and randomized by means of a computer-generated random number list that was held by the Research Pharmacy Service of the Denver Veterans Affairs Medical Center."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 12:07:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-2013">
<DESCRIPTION>
<P>&#8220;Randomization algorithm,&#8221; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-30 14:15:33 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Rigotti-2006">
<DESCRIPTION>
<P>"Using a computer program, the study statistician generated a sequence of randomly-permuted blocks of 4 within strata formed by study site and daily cigarette consumption (10 vs 10)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 16:56:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 15:39:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rovina-2009">
<DESCRIPTION>
<P>Randomised, method not stated, 3:1:1:1 ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:58:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMK20001">
<DESCRIPTION>
<P>Randomization method not specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-17 15:19:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saules-2004">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:54:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2007">
<DESCRIPTION>
<P>Urn procedure, balancing on a range of outcome-related variables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 11:15:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010">
<DESCRIPTION>
<P>Stratified by depression status. Method of sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:54:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selby-2003">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 15:35:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siddiqi-2013">
<DESCRIPTION>
<P>Computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-30 16:04:27 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Simon-2004">
<DESCRIPTION>
<P>"We assigned participants to the 2 study arms by using a computer algorithm to generate a random list of treatment assignments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:55:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simon-2009">
<DESCRIPTION>
<P>"computer algorithm to generate a random list of treatment assignments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 10:21:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>Insufficient detail with which to judge. "Smokers were randomized to the 5 treatment conditions within each clinic with blocking on sex and self-identified race."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 14:56:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sood-2010">
<DESCRIPTION>
<P>Generated centrally by Mayo Clinic Division of Biostatistics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 10:24:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-30 14:59:21 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Spring-2007">
<DESCRIPTION>
<P>"The study pharmacist stratified participants by depression history and used computer- generated random numbers to assign them to drug or placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-16 11:27:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stapleton-2013">
<DESCRIPTION>
<P>Computerized. &#8220;Randomization and packaging was organized by an independent statistician at the host site.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 14:36:57 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Swan-2003">
<DESCRIPTION>
<P>"Open-label randomized trial...The computer code for the procedure calculated probabilities of group assignment that were dynamically modified based on the number of members in each group so that final group sizes were equal. No restrictions such as stratification or blocking were used as part of the randomization process."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 13:25:00 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Tashkin-2001">
<DESCRIPTION>
<P>"Randomised as per code provided by Glaxo Wellcome, using block sizes of four stratified by centre. Within each block of four, two participants were assigned placebo and two bupropion SR. The randomisation codes were kept at the study sites during the trial and we instructed investigators to break the code only for a medical emergency."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-09 12:11:17 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Tonnesen-2003">
<DESCRIPTION>
<P>"GlaxoSmithKline created a randomization schedule in a 3 : 1 bupropion: placebo ratio. Each centre received a list with treatment numbers and subjects were consecutively assigned a treatment number at the baseline visit."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tonstad-2003">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uyar-2007">
<DESCRIPTION>
<P>'Randomly allocated', method not described, unclear why fewer in control condition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagena-2005">
<DESCRIPTION>
<P>Computer-generated by pharmacist, stratified by COPD severity, block size 33.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinberger-2010">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 11:26:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>"Generated by the study center"; used to put 4 different coloured questionnaires in random order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zellweger-2005">
<DESCRIPTION>
<P>Randomization method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-12-03 10:08:23 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-17 14:52:35 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Ahluwalia-2002">
<DESCRIPTION>
<P>Blinded drugs provided to investigator; " ... [the pharmaceutical company]... packaged the treatment and then shipped the blinded drug to the investigator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 11:37:41 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Aubin-2004">
<DESCRIPTION>
<P>"The computerized randomization schedule, prepared by the sponsor, was inaccessible to the investigator who was provided with a specific set of sequential treatment numbers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 17:48:54 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Aveyard-2008">
<DESCRIPTION>
<P>Study nurses recruited participants, and the study administrator (who had not met the participants) allocated participants in sequence against the list for each adviser. Only the administrator and the pharmacist knew the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:52:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlin-1995">
<DESCRIPTION>
<P>Double-blind, but blinding at allocation not explicit.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:52:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biberman-2003">
<DESCRIPTION>
<P>"The code was sealed, kept secretly and was revealed for the first time when the last participant finished the 12 months of follow-up. The first participant who joined the trial after the initial visit run-in phase received the first bottle from the container set number 001, the second<BR/>participant from set number 002 and so on. The trial coordinator arranged participant&#8217;s allocation." Judged adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 11:48:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>Randomization codes applied to pill boxes which were then allocated sequentially. "This part of the randomization procedure was performed by the manufacturer at another location where the code was also kept."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2007">
<DESCRIPTION>
<P>"Whereas we were able to balance the drug and placebo conditions on an individual basis, behavioral treatments were randomized by group and thus were more susceptible to fluctuations in recruitment and to the availability at both sites of pairings of a senior and a junior therapist trained in CBTD". Knowledge of behavioural assignment was probably not concealed but seems unlikely to have lead to individual selection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-19 14:12:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2013">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-06 11:46:40 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Cinciripini-2005">
<DESCRIPTION>
<P>Randomization by pharmacy, all study personnel with direct patient contact blind. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 14:52:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collins-2004">
<DESCRIPTION>
<P>Centrally generated &amp; allocation concealed from counsellors &amp; assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:08:58 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Covey-2002">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:53:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Covey-2007">
<DESCRIPTION>
<P>A research nurse who did not have direct contact with participants prepared individual medication kits based on the randomization schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 14:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 14:45:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Croghan-2007">
<DESCRIPTION>
<P>Randomization procedure makes prior knowledge of allocation unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Da-Costa-2002">
<DESCRIPTION>
<P>"... with each number corresponding to a &#8220;medication kit&#8221; that was externally undistinguishable. Patients and professionals participating in this study were blindfolded for this distribution." Potentially adequate but difference in numbers in each group not accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<DESCRIPTION>
<P>Allocation was double-blinded and bupropion and placebo tablets were identical in form and number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 14:55:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisenberg-2013">
<DESCRIPTION>
<P>Allocation performed centrally, see above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 14:31:15 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2005">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2007">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1992">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:54:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1994">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fossati-2007">
<DESCRIPTION>
<P>Stated to be double-blind, but not explicit that GPs blind to randomization code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 14:06:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 14:47:29 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-George-2002">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-09 15:30:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2003">
<DESCRIPTION>
<P>Method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-09 15:57:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2008">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-09 15:58:02 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Gonzales-2001">
<DESCRIPTION>
<P>Allocation concealment method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzales-2006">
<DESCRIPTION>
<P>Central allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 09:35:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grant-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_recka-2003">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 10:06:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1998">
<DESCRIPTION>
<P>Allocation generated at enrolment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 16:54:56 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Hall-2002">
<DESCRIPTION>
<P>"We encapsulated both drugs to maintain the patency of the bupropion formulation and to provide a blinded drug. All participants received capsules that were identical in number and appearance" but blinding of allocation not explicit.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2004">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 15:10:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2011">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hatsukami-2004">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 09:56:50 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Hays-2001">
<DESCRIPTION>
<P>Centralized (see above)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 15:31:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hays-2009">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hertzberg-2001">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 10:06:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holt-2005">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:56:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1997">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 10:16:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-2003">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:05:44 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>Allocation concealment method unclear. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-29 15:20:15 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Jorenby-2006">
<DESCRIPTION>
<P>"Folders [containing medication or placebo] for all participants (regardless of treatment assignment) were identical throughout the treatment phase including a period of dose titration (week 1) and treatment at the target dose (weeks 2-12)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 15:52:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahn-2012">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 09:40:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:14:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killen-2000">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killen-2004">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2006">
<DESCRIPTION>
<P>Centrally assigned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 11:15:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2010">
<DESCRIPTION>
<P>Participant assigned sequential ID numbers corresponding with drug &#8220;pre-packaged and labelled by ID only at an off-site location by an individual who had no association with the participants.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-15 12:04:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCarthy-2008">
<DESCRIPTION>
<P>Staff who screened and enrolled participants were unaware of the experimental condition to be assigned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:31:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muramoto-2007">
<DESCRIPTION>
<P>"... a research assistant assigned the subject the next treatment number (and associated blister cards) in sequence."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myles-2004">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:38:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-23 17:55:55 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Nides-2006">
<DESCRIPTION>
<P>"Investigators assigned medication to subjects in numerical order of acceptance into the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:38:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parsons-2009">
<DESCRIPTION>
<P>Independent statistician sent randomization codes to medication packing company, medication allocated in sequence. Researchers blind to allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:49:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 15:13:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>"Staff did not know to which type(s) of medication a participant would be assigned until the moment of randomization, and study staff were blinded to whether the medication was active or placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 15:24:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Planer-2011">
<DESCRIPTION>
<P>Method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:52:02 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Prochazka-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:53:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prochazka-2004">
<DESCRIPTION>
<P>"Once a patient was enrolled, the Research Pharmacy Service randomized the subject according to the randomization list." Judged adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-13 12:07:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-2013">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-03 10:08:23 +0000" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Rigotti-2006">
<DESCRIPTION>
<P>"The study pharmacist used this sequence, concealed from enrolment staff, to assign participants to study arm. Subjects and study personnel, except the statistician and pharmacist, were blind to treatment assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 16:56:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2013">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 15:39:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rovina-2009">
<DESCRIPTION>
<P>No details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 20:58:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMK20001">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:55:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saules-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 11:58:32 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Schmitz-2007">
<DESCRIPTION>
<P>"Investigators and research staff were blind to the randomization codes, which were kept by a faculty member independent of the<BR/>research and treatment team."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 11:15:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:54:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selby-2003">
<DESCRIPTION>
<P>No details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 15:35:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siddiqi-2013">
<DESCRIPTION>
<P>Cluster randomized trial. &#8220;A researcher who was blinded to center identity&#8221; allocated conditions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:05:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simon-2004">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:05:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simon-2009">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 10:21:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 17:04:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-2010">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 10:24:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:12:27 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Spring-2007">
<DESCRIPTION>
<P>Allocated by unblinded pharmacist, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-16 11:27:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stapleton-2013">
<DESCRIPTION>
<P>&#8220;On enrolment, participants selected their envelope from a large batch and signed it before breaking the seal to reveal their allocation.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:56:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swan-2003">
<DESCRIPTION>
<P>Procedure built into study database.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:15:25 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Tashkin-2001">
<DESCRIPTION>
<P>See above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:18:06 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Tonnesen-2003">
<DESCRIPTION>
<P>As per above. "GlaxoSmithKline supplied bupropion SR 150 mg and placebo-to-match tablets for oral administration as white, film-coated tablets."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:18:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tonstad-2003">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uyar-2007">
<DESCRIPTION>
<P>Allocation concealment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 19:57:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagena-2005">
<DESCRIPTION>
<P>Research staff blinded throughout study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:30:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinberger-2010">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-02 11:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>No concealment: "questionnaires were distributed consecutively to all attending patients on the target days by nurses. Thus, the assignment of patients was entirely dependent on the consecutive attendance of patients and the random assignment of a color. Doctors were not allowed to interfere with this study procedure." But numbers allocated to groups very uneven and discussion states: "Random checks of this procedure [randomization] and quality assurance tests by study monitors revealed that in some cases in the latter part of the study treatment was based on patient and physician preferences."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-12 12:33:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zellweger-2005">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-24 12:25:29 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:54:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahluwalia-2002">
<DESCRIPTION>
<P>Double blind. "Blinding was successful. At the end of treatment, 58% (150/259) of participants correctly guessed that they received bupropion SR, and 41% (104/253) correctly guessed they received placebo." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:54:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aubin-2004">
<DESCRIPTION>
<P>"Double-blind" "Blinding was assured by matching the placebo to the bupropion tablets..." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:54:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aveyard-2008">
<DESCRIPTION>
<P>"Advisers, participants, and study staff...were blind to allocation... tablets were encapsulated, and identical powder filled capsules provided the placebos." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:41:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berlin-1995">
<DESCRIPTION>
<P>"Double-blind" but further detail not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biberman-2003">
<DESCRIPTION>
<P>"Double-blind" (see above) "No discontinuation difference for selegiline or placebo was observed among the groups, which implies masking success." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:54:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>"Double-blind." "...pill boxes, with either fluoxetine or an identical appearing placebo containing the same ingredients except fluoxetine, were labelled with numbers ranging from 100 to 210.." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 11:54:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2007">
<DESCRIPTION>
<P>"Double-blind." Psychological condition unlikely to be blinded but unlikely to affect comparisons included in this review. "All participants and study staff were blind to medication condition." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-19 14:12:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brown-2013">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 12:02:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cinciripini-2005">
<DESCRIPTION>
<P>"Double-blind... Blinding of the study staff to the medication<BR/>was maintained using prenumbered pill containers, assigned to each participant at randomization by the pharmacy. All study personnel with direct patient contact were blind to group assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-22 14:52:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2013">
<DESCRIPTION>
<P>&#8220;Blinded&#8221; but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 12:06:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Collins-2004">
<DESCRIPTION>
<P>Placebo used but blinding procedure not described in detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 12:09:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Covey-2002">
<DESCRIPTION>
<P>"double-blind" "Medications were provided in prepared bottles that were numbered according to the randomization schedule and dispensed at each visit. All study staff at the clinic site were blinded to treatment assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 12:12:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Covey-2007">
<DESCRIPTION>
<P>"Double-blind" "Participants and clinical researchers with direct participant contact were blinded to the randomization" At end, subjects asked to guess treatment assignment; half guessed correctly and guess was not associated with treatment outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-02 14:12:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cox-2012">
<DESCRIPTION>
<P>"Both participants and investigators were blinded to the pharmacotherapy condition." No further information provided, unclear if counsellors blinded to treatment condition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:24:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Croghan-2007">
<DESCRIPTION>
<P>Placebo used, but insufficient information provided re: blinding to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:26:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Da-Costa-2002">
<DESCRIPTION>
<P>"Double-blind" but insufficient detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:29:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<DESCRIPTION>
<P>"Double-blind" Clear that participants were blinded but unclear if all staff were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-02 14:56:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eisenberg-2013">
<DESCRIPTION>
<P>"Double-blind." "All clinical end points were adjudicated by members of the Endpoints Evaluation Committee who were blinded to treatment assignment." No further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:31:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2001">
<DESCRIPTION>
<P>"Subjects were randomly assigned to 12 weeks of double-blind bupropion SR, 150 mg/day, or an identical appearing placebo tablet added to their usual medication regimen." Unclear if all staff members were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:32:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evins-2005">
<DESCRIPTION>
<P>"Double-blind" with "identical placebo tablets." No further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:35:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evins-2007">
<DESCRIPTION>
<P>"Participants and investigators remained<BR/>blind to the treatment condition (bupropion or placebo)<BR/>throughout the follow-up period." "Assessment of treatment assignment was at the level of chance for both participants and staff at Weeks 4 and 12 for both treatment assignments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:43:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1992">
<DESCRIPTION>
<P>"Double-blind," no further detail provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:40:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1994">
<DESCRIPTION>
<P>"Double-blind," no further detail provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fossati-2007">
<DESCRIPTION>
<P>"Double-blind", further detail not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 14:06:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>&#8216;double-blind, double-dummy&#8217; for medication component. 'Neither the nurses nor the participants knew which of the two formulations contained the active formulation.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-08 14:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2002">
<DESCRIPTION>
<P>"Both subjects and research staff were blinded to study medication assignment. Study medications were prepared by research pharmacists at CMHC, using encapsulation of SR bupropion tablets with blue 00 opaque capsules; placebo capsules contained only a dextrose matrix."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-09 15:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-George-2003">
<DESCRIPTION>
<P>Double-blind, adequacy of blinding tested in research staff; results suggested blinding was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-09 15:57:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-George-2008">
<DESCRIPTION>
<P>"Double blind" but no additional details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-09 16:00:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzales-2001">
<DESCRIPTION>
<P>"Even though participants and the site staff were blinded to the drug assignments and the site staff did not encourage participants to speculate on their assignments, the lower placebo abstinence rates in the current study may be attributable to the previous experiences of participants with bupropion in their previous cessation attempts." However, little difference in completion between two arms, suggesting blinding may have been successful.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:31:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gonzales-2006">
<DESCRIPTION>
<P>"Participants and investigators were blinded to drug treatment assignments[, and] ... were not encouraged to guess their treatment assignment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:36:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grant-2007">
<DESCRIPTION>
<P>"Double-blind" but unclear who was blinded, no further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:33:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-G_x00f3_recka-2003">
<DESCRIPTION>
<P>Not described but presumably no blinding, as participants will have known assignment based on patch versus pill</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<DESCRIPTION>
<P>Double blind, double dummy. "Both investigators and patients were blind to the treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:42:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-1998">
<DESCRIPTION>
<P>"Medication was placebo controlled and double blind. Placebo and active drug were identical in appearance." However, no detail on who was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:44:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hall-2002">
<DESCRIPTION>
<P>Double blind but participants informed about adverse effects of each drug and 87% of participants taking active drug guessed that they were (compared to 67% placebo group). Bupropion participants no more likely than nortriptyline participants to correctly identify which drug they had received.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:48:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hall-2004">
<DESCRIPTION>
<P>Double blind, but "participants given active drug were more likely to guess that they had received active drug (63%) than the placebo participants were to believe they were taking active drug (37%)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-21 15:10:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2011">
<DESCRIPTION>
<P>Participants blinded successfully but blinding of staff not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:56:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hatsukami-2004">
<DESCRIPTION>
<P>"Double-blind," unclear who was blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 09:57:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hays-2001">
<DESCRIPTION>
<P>Double-blind. "...the investigators did not know the patient assignments. All bupropion and placebo pills were identical in shape, size, and color."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-21 15:31:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hays-2009">
<DESCRIPTION>
<P>Described as "double-blind", placebo used, but no further information given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 10:05:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hertzberg-2001">
<DESCRIPTION>
<P>Double-blind, no further information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 10:06:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holt-2005">
<DESCRIPTION>
<P>Double-blind, "Neither the study team nor the participant was aware of which treatment had been allocated until the end of the 12 month study period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 10:14:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1997">
<DESCRIPTION>
<P>"Double-blind" but no detail given on who was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 10:16:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-2003">
<DESCRIPTION>
<P>"Double-blind," no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>"Double-blind" but no further detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:07:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-2006">
<DESCRIPTION>
<P>"in a double-blind manner," no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-02 15:52:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kahn-2012">
<DESCRIPTION>
<P>"Double-blind," no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-13 09:50:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2011">
<DESCRIPTION>
<P>"Double-blind" but no detail on who was blinded in terms of study staff, including counsellors. "Both medication groups performed at the chance level in judging medication assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:16:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killen-2000">
<DESCRIPTION>
<P>"Double-blind" but unclear who exactly was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:26:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2004">
<DESCRIPTION>
<P>"Double-blind." Though further details not provided, assessment of blind suggests it was successful (30% placebo and 31% bupropion correctly guessed assignment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:27:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2006">
<DESCRIPTION>
<P>Double-blind. Blinded drugs provided to investigator; " ... [the pharmaceutical company]... packaged the treatment and then shipped the blinded drug to the investigator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-13 11:15:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2010">
<DESCRIPTION>
<P>&#8220;Treatment assignment was concealed from staff and both research staff and participants were blind to week 52.&#8221; Assessment of blinding in participants and study staff suggests it was successful</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-15 12:04:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Levine-2010">
<DESCRIPTION>
<P>"Double-blind," no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:29:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCarthy-2008">
<DESCRIPTION>
<P>Double-blind (for medication). "Research staff who interacted with participants were blind to participants&#8217; medication condition assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:31:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muramoto-2007">
<DESCRIPTION>
<P>"Study subjects and researchers remained blind to treatment group assignment throughout the study." "9.6% in the 300 mg<BR/>group accurately guessed their treatment assignment. Across all treatment groups, there were no significant differences in the proportion of subjects who accurately guessed their treatment group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:33:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myles-2004">
<DESCRIPTION>
<P>"Double-blind," no further detail provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Niaura-2002">
<DESCRIPTION>
<P>Double-blind but further detail not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:44:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nides-2006">
<DESCRIPTION>
<P>"double-blind", "to preserve treatment blinding," no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-14 15:38:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parsons-2009">
<DESCRIPTION>
<P>&#8220;Participants, therapists, and outcome assessors were blind to the treatment allocation.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:49:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>Described as double-blind, but no further information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 15:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>"Double blind" but no further detail provided.</P>
<P>"Study staff were blinded to whether the medication was active or placebo" (Type of medication (i.e. patch, gum, pill) would have been apparent to both groups)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 15:24:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planer-2011">
<DESCRIPTION>
<P>Participants and staff blind to treatment assignment, "Numbered study bottles were supplied by the study coordinator and remained concealed from the patients and medical staff." No biochemical validation but participants blind to condition so differential misreport unlikely.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:52:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prochazka-1998">
<DESCRIPTION>
<P>"An unblinded research pharmacist recommended dosage reductions for those above the therapeutic range and dosage increases for those who were subtherapeutic. To maintain blinding, dose reductions and increases on an equal number of randomly selected placebo-treated subjects were also recommended...our blinding was only partially effective. Because of the high frequency of dry mouth, the nurse and subjects were often able to identify the active drug."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-02 10:13:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prochazka-2004">
<DESCRIPTION>
<P>Authors caution "...our blinding was only partially effective. Because of the high frequency of dry mouth, the study nurse was often able to identify the active drug."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-13 12:07:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richmond-2013">
<DESCRIPTION>
<P>Identical placebo. &#8220;Follow-up assessments were conducted&#8230; by a prison nurse research assistant who was blind to group allocation.&#8221; No further information on blinding provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:54:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rigotti-2006">
<DESCRIPTION>
<P>"Subjects and study personnel, except the statistician and pharmacist, were blind to treatment assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-22 16:56:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rose-2013">
<DESCRIPTION>
<P>"Double-blind," no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-06-26 15:39:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rovina-2009">
<DESCRIPTION>
<P>Open-label, participants and staff aware of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:09:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SMK20001">
<DESCRIPTION>
<P>Double-blind but methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:55:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saules-2004">
<DESCRIPTION>
<P>"Double-blind" but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 11:58:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2007">
<DESCRIPTION>
<P>"Double-blind," further information not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-16 11:16:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010">
<DESCRIPTION>
<P>"Double-blind," no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:02:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selby-2003">
<DESCRIPTION>
<P>No details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-22 15:35:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Siddiqi-2013">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:05:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simon-2004">
<DESCRIPTION>
<P>"All study personnel engaged in providing interventions to participants were blinded to treatment assignment." "Blinding appeared to be effective in our study; an approximately equal number of participants were able to guess what their treatment had been at the end of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:06:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Simon-2009">
<DESCRIPTION>
<P>"All study personnel engaged in providing interventions to participants were blinded to treatment assignment." "A significant<BR/>percentage of participants were able to guess correctly whether<BR/>they were taking active bupropion or placebo" but as results did not favour intervention group, authors suggest this unblinding did not bias the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-02 10:21:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-13 14:57:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-2010">
<DESCRIPTION>
<P>&#8220;Blinded&#8221; with matched placebo, no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-21 10:25:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-2012">
<DESCRIPTION>
<P>"Blinded," no further detail provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:12:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spring-2007">
<DESCRIPTION>
<P>Double blind, "Research staff and participants were blinded to medication status." "Drug assignment was guessed correctly by 59.8% of placebo and 64.6% of fluoxetine participants. Facilitators guessed correctly for 65.3% of placebo and 55.6% of fluoxetine participants."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-16 11:28:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stapleton-2013">
<DESCRIPTION>
<P>Open label, no blinding. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:14:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Swan-2003">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:16:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tashkin-2001">
<DESCRIPTION>
<P>Double-blind study, but further detail not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2003">
<DESCRIPTION>
<P>Double blind but methods not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:19:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tonstad-2003">
<DESCRIPTION>
<P>Double-blind but no further detail provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:21:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Uyar-2007">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:24:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wagena-2005">
<DESCRIPTION>
<P>Double blind but "at both time points, participants receiving active drug compared with those receiving placebo were more likely to guess that they had received bupropion SR and nortriptyline treatment (72% vs 43% , P.01; and 62% vs 37%; P=.001; respectively)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-16 11:30:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weinberger-2010">
<DESCRIPTION>
<P>"Both participants and research staff were blinded to study medication assignment," assessments of staff and participants suggest blinding was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-07-02 11:26:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>Neither participants nor providers were blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-12 12:33:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zellweger-2005">
<DESCRIPTION>
<P>Double-blind but further detail not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-12-03 10:08:42 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:51:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahluwalia-2002">
<DESCRIPTION>
<P>Approximately 32% lost to follow-up in each group; included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:51:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aubin-2004">
<DESCRIPTION>
<P>26% of the placebo and 27% of the bupropion groups lost; included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:52:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aveyard-2008">
<DESCRIPTION>
<P>12% I, 17% C lost at 12m, included as smokers. Authors note that majority of losses were already smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:36:51 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Berlin-1995">
<DESCRIPTION>
<P>Number lost to follow-up not reported. "Relapses and subjects lost from follow-up were considered treatment failures."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:04:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biberman-2003">
<DESCRIPTION>
<P>19 lost to follow-up, included as smokers in MA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:38:23 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION>
<P>Low numbers lost to follow up but reported results exclude 5 withdrawals; 3 from fluoxetine group due to adverse effects - nervousness and anxiety, 1 from fluoxetine due to pregnancy, 1 from placebo who had purchased fluoxetine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-25 16:58:29 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Brown-2007">
<DESCRIPTION>
<P>81% provided complete outcome data at all follow ups, not related to treatment condition. All participants included in ITT analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-19 14:12:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2013">
<DESCRIPTION>
<P>Over 90% followed up at 12m. Similar rates across arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:44:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2005">
<DESCRIPTION>
<P>Majority of participants followed-up (65 intervention; 63 control), participants lost to follow-up counted as smokers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 16:47:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cinciripini-2013">
<DESCRIPTION>
<P>73% followed up at 6m, similar rates across arms, all lost to follow-up known to be smokers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:44:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collins-2004">
<DESCRIPTION>
<P>6% lost to follow-up at 6 month follow-up; included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:47:04 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Covey-2002">
<DESCRIPTION>
<P>Total participants lost to follow-up at 6m not reported. "The subjects lost to follow-up after random assignment were considered treatment failures."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:48:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Covey-2007">
<DESCRIPTION>
<P>5 randomized participants withdrew before double blind phase. Less than 50% followed up in each group. Greater loss to follow up in double placebo, losses included in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-02 14:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cox-2012">
<DESCRIPTION>
<P>30% lost to follow-up at 6m, no difference between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:49:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Croghan-2007">
<DESCRIPTION>
<P>Losses to follow up post-medication were high and not enumerated by group, but all included in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:54:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Da-Costa-2002">
<DESCRIPTION>
<P>Number lost in each group not clear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<DESCRIPTION>
<P>32% of the bupropion group and 43% the placebo group discontinued treatment, included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-02 14:56:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisenberg-2013">
<DESCRIPTION>
<P>77% followed up at 12m, similar across arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-17 14:32:15 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Evins-2001">
<DESCRIPTION>
<P>"Nineteen subjects were enrolled and 18 subjects completed the 6-month smoking cessation trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:54:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evins-2005">
<DESCRIPTION>
<P>Only people taking at least one dose of study medication included in analyses in paper. 5 in each group lost to follow-up and included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:51:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evins-2007">
<DESCRIPTION>
<P>20% of the bupropion group and 18% of the placebo group were lost to follow-up at week 12; included as smokers. All other participants followed up at 12m.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1992">
<DESCRIPTION>
<P>No details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:52:53 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1994">
<DESCRIPTION>
<P>72% followed-up intervention, 61% followed up control. "The most conservative approach to analysis would reclassify all of these individuals as smokers due to protocol violation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:05:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fossati-2007">
<DESCRIPTION>
<P>15% Bupropion &amp; 17% Placebo did not attend 12m follow-up, included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 14:06:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION>
<P>Missing data included as smokers. Similar losses to follow-up across both groups. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 15:54:55 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-George-2002">
<DESCRIPTION>
<P>Number followed-up at 6m not reported."Subjects who were lost during the trial or at 6-month follow-up were counted as smokers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:06:32 +0000" MODIFIED_BY="Lindsay Stead" RESULT="NO" STUDY_ID="STD-George-2003">
<DESCRIPTION>
<P>29/40 not assessed at 6m. Greater loss to follow-up in placebo, exact data not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:55:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-George-2008">
<DESCRIPTION>
<P>6/29 intervention &amp; 10/29 control did not complete trial, included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 16:01:56 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Gonzales-2001">
<DESCRIPTION>
<P>Number of participants followed-up at 12m unclear. "...all participants who stopped participating in the study during the treatment phase were considered to be smokers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-23 15:36:21 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Gonzales-2006">
<DESCRIPTION>
<P>Loss to follow-up similar across conditions; 44% bupropion, 39.5% varenicline, 46% placebo, all included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:06:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grant-2007">
<DESCRIPTION>
<P>Higher loss in bupropion (40%) than placebo (21%) but still within 20% range of each other. ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:55:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_recka-2003">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:55:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<DESCRIPTION>
<P>Numbers lost to follow-up not reported, all included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:55:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-1998">
<DESCRIPTION>
<P>30% did not complete treatment in placebo and 17% in active groups. Analyses with missing =smoking given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:07:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-2002">
<DESCRIPTION>
<P>19% lost to follow-up at 52 w. No significant difference across conditions. Included as smokers in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:56:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hall-2004">
<DESCRIPTION>
<P>9% lost at week 52, included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-21 15:10:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hall-2011">
<DESCRIPTION>
<P>83% followed up at 2y, similar rates across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 10:10:29 +0100" MODIFIED_BY="Lindsay Stead" RESULT="NO" STUDY_ID="STD-Hatsukami-2004">
<DESCRIPTION>
<P>Very high levels of attrition (at 6 months, 43% placebo and 39% control followed up). For cessation analyses, subjects who dropped out were considered to have resumed smoking [after withdrawal date].</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-17 14:34:44 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Hays-2001">
<DESCRIPTION>
<P>"Participants who dropped out were considered to have relapsed to smoking, but information on other important factors, such as weight gain, was not collected and therefore could not be included in the analysis." Approximately 26% of the bupropion group and 27% of the placebo group did not complete the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-21 15:31:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hays-2009">
<DESCRIPTION>
<P>At w 76, similar rate of dropout in both groups (34% intervention; 37% control). Participants lost to follow-up counted as relapsed smokers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 10:11:15 +0100" MODIFIED_BY="Lindsay Stead" RESULT="NO" STUDY_ID="STD-Hertzberg-2001">
<DESCRIPTION>
<P>Uneven attrition between arms; very high percentage lost to follow-up in placebo group. 30% of the participants receiving bupropion SR did not complete the full 12-week trial; 80% of the placebo group failed to complete the trial and were considered to have resumed smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 10:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holt-2005">
<DESCRIPTION>
<P>High and uneven loss to follow-up, with less than half of placebo group followed up at 12 months. 36% lost in bupropion group and 52% in placebo at 12 months. "Participants who were lost to follow up were categorised as smokers ... often this was confirmed by family members or friends."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-17 14:45:16 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1997">
<DESCRIPTION>
<P>"Subjects who missed a follow-up visit were considered to be smoking.... The rate of completion of the study increased with the dose and was 57 percent, 65 percent, 64 percent, and 71 percent for the placebo, 100-mg, 150-mg, and 300-mg groups, respectively..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 10:19:57 +0100" MODIFIED_BY="Lindsay Stead" RESULT="UNKNOWN" STUDY_ID="STD-Hurt-2003">
<DESCRIPTION>
<P>Number of participants lost to follow-up not given. Patients lost to follow-up considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-17 14:35:51 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION>
<P>"All subjects who discontinued treatment early or who were lost to follow-up were classified as smokers." Approximately 20% left the study and provided no additional information. 15% stopped taking medication but participated in follow-up assessments.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-29 15:29:42 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Jorenby-2006">
<DESCRIPTION>
<P>Over the period of treatment and follow-up 14% of those receiving varenicline were lost to follow-up; 14% randomized to bupropion lost to follow-up; 16% of the placebo group were lost to follow-up. "Participants whose smoking status was unknown or whose carbon monoxide<BR/>level was higher than 10 ppm were classified as smoking during both the treatment phase and follow-up."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-02 15:52:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kahn-2012">
<DESCRIPTION>
<P>70% placebo and 74% STS followed up at 12 months</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-09 10:29:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalman-2011">
<DESCRIPTION>
<P>13 participants who dropped out prior to receiving medication, not included in denominators. Further 18% intervention and 14% control lost at 24 weeks,counted as smoking in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 11:17:36 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Killen-2000">
<DESCRIPTION>
<P>Number lost to follow-up not reported. "Those failing to provide confirmation [of smoking status] were reclassified as smokers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:57:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2004">
<DESCRIPTION>
<P>38% bupropion &amp; 35% placebo lost at 6 months, included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:57:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2006">
<DESCRIPTION>
<P>8% bupropion &amp; 13% placebo lost at 12 months, included in analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-13 11:15:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killen-2010">
<DESCRIPTION>
<P>87% followed up at 12m, same in both arms. Missing counted as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-15 12:04:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Levine-2010">
<DESCRIPTION>
<P>Over half lost to follow-up at 12m. 48% followed up overall, similar rates between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:57:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCarthy-2008">
<DESCRIPTION>
<P>171 (37%) failed to attend quit date visit or lost to follow up, similar across groups, included in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:07:37 +0000" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Muramoto-2007">
<DESCRIPTION>
<P>Slightly higher lost to follow-up/ declined further participation in placebo group (30%) than active arms (18%). ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 11:33:10 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Myles-2004">
<DESCRIPTION>
<P>17% lost to follow-up in the bupropion group; 9% lost to follow-up in the placebo group. "Patients lost to follow-up were assumed to still be smoking."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 11:42:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Niaura-2002">
<DESCRIPTION>
<P>Missing data in treatment phase addressed, but unclear whether missing data in follow-up phase addressed. At 12m, 42% missing data, similar across all arms; missing data counted as smokers in our analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:08:09 +0000" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Nides-2006">
<DESCRIPTION>
<P>"Subjects who dropped out for any reason were considered to be smokers at all subsequent time points." 9.5% of varenicline tartrate 0.3 mg, once daily; 7% of varenicline tartrate 1.0 mg, once daily; 11 % of varenicline tartrate 1.0 mg, twice daily; 6% of bupropion hydrochloride 150 mg, twice daily and 13% of the placebo group were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-14 15:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parsons-2009">
<DESCRIPTION>
<P>Over 90% followed up at 6m, similar between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:58:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piper-2007">
<DESCRIPTION>
<P>32% of bupropion &amp; 36% of placebo groups lost at 12 months. "Participants who could not be reached at follow-up were considered to be smoking for the purposes of follow-up analyses."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 15:14:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Piper-2009">
<DESCRIPTION>
<P>90 drop-outs (out of 1504). Analyses conducted using ITT. Individuals with missing data considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 15:22:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Planer-2011">
<DESCRIPTION>
<P>1 lost to follow-up in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 11:52:21 +0100" MODIFIED_BY="Lindsay Stead" RESULT="NO" STUDY_ID="STD-Prochazka-1998">
<DESCRIPTION>
<P>75% drop-out rate in placebo, 61% in drug group, majority classified as ineffective therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 19:53:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prochazka-2004">
<DESCRIPTION>
<P>"Subjects who dropped out were counted as smokers." Number of dropouts not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-13 12:07:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richmond-2013">
<DESCRIPTION>
<P>80% followed up at 12m, similar in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 11:53:35 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Rigotti-2006">
<DESCRIPTION>
<P>"Subjects were considered smokers if they were lost to follow-up..."; 23% lost to follow up in the bupropion group and 23% in the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 16:59:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rose-2013">
<DESCRIPTION>
<P>&lt; 50% followed up at 6m in both phases, similar rates of dropout across all arms. 27 participants censored from reported analyses, mainly for protocol violations, included a smoking here.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-26 15:51:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rovina-2009">
<DESCRIPTION>
<P>90% followed up at 12m, but authors do not specify percentage per group and do not specify how participants lost to follow-up were treated. Authors only provide percentages abstinent, so n abstinent in this review may be inflated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 20:58:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SMK20001">
<DESCRIPTION>
<P>34% lost in bupropion, 29% placebo, included as smokers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 11:57:10 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Saules-2004">
<DESCRIPTION>
<P>Numbers lost to follow up not provided by study arm but high: at six months, only 58 of 150 subjects followed-up. Subjects who dropped out of the study or lost to follow-up were considered to be smoking again.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:08:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2007">
<DESCRIPTION>
<P>14 'enrolment failures' who did not receive any treatment are excluded from analyses. Other non-completers and losses to follow up included in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 11:16:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schnoll-2010">
<DESCRIPTION>
<P>65% intervention and 72% control followed up at 6m</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:03:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Selby-2003">
<DESCRIPTION>
<P>No details given, unclear how participants lost to follow-up treated in outcome data. 70% intervention group and 50% control group completed study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-22 15:35:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siddiqi-2013">
<DESCRIPTION>
<P>No clinics dropped out post-randomization. Over 90% of participants followed up at 6m</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-01 10:17:07 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Simon-2004">
<DESCRIPTION>
<P>"Of the 244 participants enrolled, 3 (1%) were lost to follow-up (all randomized to the placebo arm)...Participants lost to follow-up were considered smokers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-03 10:08:42 +0000" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Simon-2009">
<DESCRIPTION>
<P>5 withdrawals, 1 lost to follow-up, 1 death in placebo, 2 withdrawals, 1 lost, 1 death in bupropion. All except deaths included in MA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:13:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-2009">
<DESCRIPTION>
<P>158 individuals who did not pick up study medication at first point not included in analyses; 122 withdrawals &amp; 9 deaths considered to be smoking. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-13 14:57:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sood-2010">
<DESCRIPTION>
<P>43% dropped out within first 12 weeks, unclear how many dropped out by 24 weeks. Not given by arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 17:05:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sood-2012">
<DESCRIPTION>
<P>57% followed up overall, similar rates between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 19:56:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spring-2007">
<DESCRIPTION>
<P>Withdrawals/lost to follow-up 40% for fluoxetine, 48% placebo. Authors report similar results from missing assumed smoking and GEE analyses. All participants included in MA.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-11-26 17:05:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stapleton-2013">
<DESCRIPTION>
<P>61.5% followed up at both 1 and 6m, no significant difference between groups. Prolonged abstinence only imputed for 16% of total.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:15:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Swan-2003">
<DESCRIPTION>
<P>Similar percentage lost to follow-up across all groups (approx 15%). Nonresponders treated as smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:16:10 +0100" MODIFIED_BY="Lindsay Stead" RESULT="YES" STUDY_ID="STD-Tashkin-2001">
<DESCRIPTION>
<P>64% intervention and 73% control followed up at 6m. "All participants who withdrew from the study were taken to be smokers thereafter."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-06-09 13:40:55 +0100" MODIFIED_BY="Monaz Mehta" RESULT="YES" STUDY_ID="STD-Tonnesen-2003">
<DESCRIPTION>
<P>9% of bupropion SR and 12% placebo were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:20:37 +0100" MODIFIED_BY="Monaz Mehta" RESULT="UNKNOWN" STUDY_ID="STD-Tonstad-2003">
<DESCRIPTION>
<P>Number missing follow-up in each group not provided. At 12m, 38% bupropion and 50% placebo had prematurely discontinued treatment. "Subjects with missing investigator assessments were assumed to be smokers at that visit."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:20:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uyar-2007">
<DESCRIPTION>
<P>No mention of any losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 19:57:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wagena-2005">
<DESCRIPTION>
<P>10 (12%) bupropion, 13 (16%) nortriptyline, 12 (13%) lost or withdrawn. All included in ITT analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-08-11 19:57:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weinberger-2010">
<DESCRIPTION>
<P>27.5% selegiline, 42% placebo lost at 6 months. Including all participants is less conservative.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-07-02 11:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION>
<P>Similar number of drop-outs between groups; participants lost to follow-up considered smokers for MA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-12 12:34:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zellweger-2005">
<DESCRIPTION>
<P>Number lost to follow-up not stated. Participants with missing assessments or drop-outs considered to be smoking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-10-24 12:25:29 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ahluwalia-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Aubin-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Aveyard-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Berlin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Biberman-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Blondal-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brown-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brown-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 14:52:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cinciripini-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Collins-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Covey-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Covey-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cox-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Croghan-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Da-Costa-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Eisenberg-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Evins-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Evins-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Evins-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferry-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fossati-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gariti-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-George-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-George-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-George-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gonzales-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gonzales-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Grant-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-G_x00f3_recka-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hall-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hatsukami-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hays-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 15:32:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hays-2009">
<DESCRIPTION>
<P>Discrepancy in data: at 76 w, 7 d PP less than continuous abstinence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hertzberg-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Holt-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hurt-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hurt-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jorenby-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kahn-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kalman-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Killen-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Levine-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-McCarthy-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Muramoto-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Myles-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niaura-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nides-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Parsons-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piper-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piper-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Planer-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prochazka-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prochazka-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Richmond-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rigotti-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rose-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rovina-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-SMK20001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Saules-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schnoll-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Selby-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-22 15:35:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Siddiqi-2013">
<DESCRIPTION>
<P>Substantial heterogeneity of program effects across clusters. 20% of participants in control arm smoked only hookah (no cigarettes) compared to 4% in intervention arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simon-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simon-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Smith-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sood-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sood-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Spring-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stapleton-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Swan-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tashkin-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonnesen-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tonstad-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Uyar-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wagena-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Weinberger-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wittchen-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zellweger-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-03 11:42:25 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-12-03 11:42:25 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-10-08 12:58:34 +0100" MODIFIED_BY="Grade Profiler">Bupropion for smoking cessation</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Bupropion for smoking cessation</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people who smoke<BR/>
<B>Intervention:</B> bupropion<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Bupropion</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Bupropion versus placebo/control. Abstinence</B>
<BR/>Follow-up: 6+ months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>187 per 1000</B>
<BR/>(172 to 203)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.62 </B>
<BR/>(1.49 to 1.76)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>13728<BR/>(44 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Bupropion and NRT versus NRT alone. Abstinence</B>
<BR/>Follow-up: 6+ months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>186 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>221 per 1000</B>
<BR/>(175 to 281)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.19 </B>
<BR/>(0.94 to 1.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3487<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Bupropion versus NRT. Abstinence</B>
<BR/>Follow-up: 6+ months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>254 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>244 per 1000</B>
<BR/>(216 to 277)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.85 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4086<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control risk calculated as mean across included studies<BR/>
<SUP>2</SUP> Sensitivity analyses including only those studies judged to be at low risk of bias did not impact the pooled results<BR/>
<SUP>3</SUP> Funnel plot did not show evidence of asymmetry<BR/>
<SUP>4</SUP> All but one study at unclear or high risk for selection bias<BR/>
<SUP>5</SUP> Inconsistency across pooled results (I squared = 52%)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-12-03 11:41:16 +0000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-10-08 12:58:02 +0100" MODIFIED_BY="Grade Profiler">Nortriptyline for smoking cessation</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Nortriptyline for smoking cessation</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people who smoke<BR/>
<B>Intervention:</B> nortriptyline<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nortriptyline</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Nortriptyline versus placebo. Abstinence</B>
<BR/>Follow-up: 6+ months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>99 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>201 per 1000</B>
<BR/>(147 to 275)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.03 </B>
<BR/>(1.48 to 2.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>975<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Nortriptyline and NRT versus NRT alone. Abstinence</B>
<BR/>Follow-up: 6+ months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>141 per 1000</B>
<BR/>(109 to 180)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(0.94 to 1.55)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1644<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Control risk based on average across all control groups<BR/>
<SUP>2</SUP> Though majority of studies at unclear risk of bias, sensitivity analyses suggests this is unlikely to affect the point estimate<BR/>
<SUP>3</SUP> Total number of events less than 300</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-06-22 09:45:27 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-04 10:03:59 +0000" MODIFIED_BY="Lindsay Stead">
<COMPARISON ID="CMP-001" MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="Lindsay Stead" NO="1">
<NAME>Bupropion. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="52.43583156717951" CI_END="1.7622799504654791" CI_START="1.4892044620171614" CI_STUDY="95" CI_TOTAL="95" DF="43" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6199985078871442" ESTIMABLE="YES" EVENTS_1="1507" EVENTS_2="701" I2="17.995007011742636" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.24607490026494055" LOG_CI_START="0.17295432879973113" LOG_EFFECT_SIZE="0.20951461453233583" METHOD="MH" MODIFIED="2013-11-26 15:13:24 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.15337010953741215" P_Q="0.5320644157008482" P_Z="2.8433135667755925E-29" Q="0.39044792632289893" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7646" TOTAL_2="6082" WEIGHT="100.0" Z="11.231889753858184">
<NAME>Bupropion versus placebo/control. Subgroups by length of follow-up</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bupropion</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="42.58597039149952" CI_END="1.760616846131614" CI_START="1.4396991957599858" DF="26" EFFECT_SIZE="1.5920925404690418" ESTIMABLE="YES" EVENTS_1="1024" EVENTS_2="501" I2="38.94702935972126" ID="CMP-001.01.01" LOG_CI_END="0.2456648530053211" LOG_CI_START="0.15827176204800114" LOG_EFFECT_SIZE="0.20196830752666112" MODIFIED="2013-11-14 16:10:30 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.021344115499427607" P_Z="1.3155245931269308E-19" STUDIES="27" TAU2="0.0" TOTAL_1="5444" TOTAL_2="4422" WEIGHT="70.945434086685" Z="9.059082461429066">
<NAME>Twelve month follow-up</NAME>
<DICH_DATA CI_END="2.358020456421056" CI_START="0.9347948167763013" EFFECT_SIZE="1.4846768336964415" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="27" LOG_CI_END="0.3725475683893706" LOG_CI_START="-0.029283704336819254" LOG_EFFECT_SIZE="0.17163193202627566" MODIFIED="2013-09-09 16:15:10 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1169" O_E="0.0" SE="0.23603767869624365" STUDY_ID="STD-Brown-2007" TOTAL_1="255" TOTAL_2="269" VAR="0.05571378576431116" WEIGHT="3.464378470867907"/>
<DICH_DATA CI_END="1.7250900173636334" CI_START="0.8459501412352303" EFFECT_SIZE="1.2080315160757402" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="43" LOG_CI_END="0.23681176203207296" LOG_CI_START="-0.07265523273462553" LOG_EFFECT_SIZE="0.0820782646487237" MODIFIED="2013-11-14 16:10:16 +0000" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.1817824446122887" STUDY_ID="STD-Eisenberg-2013" TOTAL_1="183" TOTAL_2="194" VAR="0.033044857169219816" WEIGHT="5.503397326723803"/>
<DICH_DATA CI_END="324.0039639094615" CI_START="1.2500329320451646" EFFECT_SIZE="20.125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5105503234580793" LOG_CI_START="0.09692145462173302" LOG_EFFECT_SIZE="1.3037358890399062" MODIFIED="2013-11-14 16:10:16 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1158" O_E="0.0" SE="1.4177775452100598" STUDY_ID="STD-Ferry-1992" TOTAL_1="23" TOTAL_2="22" VAR="2.0100931677018634" WEIGHT="0.06731875283863284"/>
<DICH_DATA CI_END="5.461809525863762" CI_START="0.8595035074391462" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.737336550562281" LOG_CI_START="-0.06575234671589476" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2013-11-14 16:10:17 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1159" O_E="0.0" SE="0.47173839361535563" STUDY_ID="STD-Ferry-1994" TOTAL_1="95" TOTAL_2="95" VAR="0.2225371120107962" WEIGHT="0.7909953458539359"/>
<DICH_DATA CI_END="2.7831017825538176" CI_START="1.2622971378888377" EFFECT_SIZE="1.874326923076923" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="26" LOG_CI_END="0.44452908947927056" LOG_CI_START="0.10116159750400144" LOG_EFFECT_SIZE="0.27284534349163597" MODIFIED="2013-11-14 16:10:17 +0000" MODIFIED_BY="Lindsay Stead" ORDER="208" O_E="0.0" SE="0.20169576448277068" STUDY_ID="STD-Fossati-2007" TOTAL_1="400" TOTAL_2="193" VAR="0.0406811814102893" WEIGHT="4.624143674469328"/>
<DICH_DATA CI_END="10.37923812074336" CI_START="1.5143758155593516" EFFECT_SIZE="3.9646017699115044" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="1.016165475660732" LOG_CI_START="0.18023366536871685" LOG_EFFECT_SIZE="0.5981995705147243" MODIFIED="2013-11-14 16:10:18 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1160" O_E="0.0" SE="0.49103048329472615" STUDY_ID="STD-Gonzales-2001" TOTAL_1="226" TOTAL_2="224" VAR="0.24111093552465232" WEIGHT="0.6620924006036649"/>
<DICH_DATA CI_END="2.9279813474837035" CI_START="1.2471322987106108" EFFECT_SIZE="1.9109108059951787" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="29" LOG_CI_END="0.466568305750185" LOG_CI_START="0.09591252689659248" LOG_EFFECT_SIZE="0.28124041632338875" MODIFIED="2013-11-14 16:10:18 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1168" O_E="0.0" SE="0.21772503927429648" STUDY_ID="STD-Gonzales-2006" TOTAL_1="329" TOTAL_2="344" VAR="0.04740419272699394" WEIGHT="3.7379329345182777"/>
<DICH_DATA CI_END="4.387275664407896" CI_START="0.7861324101006102" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6421949231603534" LOG_CI_START="-0.10450429857519355" LOG_EFFECT_SIZE="0.26884531229257996" MODIFIED="2013-11-14 16:10:19 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1161" O_E="0.0" SE="0.4386148190682198" STUDY_ID="STD-Hall-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.19238295950624718" WEIGHT="0.9228279034962585"/>
<DICH_DATA CI_END="4.975994504154581" CI_START="0.7929350590265837" EFFECT_SIZE="1.9863636363636363" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.6968798920170354" LOG_CI_START="-0.10076237972060419" LOG_EFFECT_SIZE="0.2980587561482156" MODIFIED="2013-11-14 16:10:19 +0000" MODIFIED_BY="Lindsay Stead" ORDER="549" O_E="0.0" SE="0.4685390188116135" STUDY_ID="STD-Holt-2005" TOTAL_1="88" TOTAL_2="46" VAR="0.21952881214894948" WEIGHT="0.8657660501883876"/>
<DICH_DATA CI_END="2.5625080424919373" CI_START="0.7357402222445212" EFFECT_SIZE="1.373076923076923" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.40866523710942554" LOG_CI_START="-0.133275500826675" LOG_EFFECT_SIZE="0.13769486814137524" MODIFIED="2013-11-14 16:10:21 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1162" O_E="0.0" SE="0.3183386721135834" STUDY_ID="STD-Hurt-1997" TOTAL_1="156" TOTAL_2="153" VAR="0.10133951016303956" WEIGHT="1.9966872807963432"/>
<DICH_DATA CI_END="6.519433294867828" CI_START="1.6488854099851884" EFFECT_SIZE="3.278688524590164" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="9" LOG_CI_END="0.8142098460987333" LOG_CI_START="0.21719047520769508" LOG_EFFECT_SIZE="0.5157001606532142" MODIFIED="2013-11-14 16:10:21 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1163" O_E="0.0" SE="0.3506921337549441" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.12298497267759562" WEIGHT="1.4331895870422802"/>
<DICH_DATA CI_END="2.1357628221662064" CI_START="0.9499646474393186" EFFECT_SIZE="1.4243943191311612" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" LOG_CI_END="0.3295530223529506" LOG_CI_START="-0.02229255650873887" LOG_EFFECT_SIZE="0.15363023292210584" MODIFIED="2013-11-14 16:10:22 +0000" MODIFIED_BY="[Empty name]" ORDER="1170" O_E="0.0" SE="0.20667583468706094" STUDY_ID="STD-Jorenby-2006" TOTAL_1="342" TOTAL_2="341" VAR="0.042714900643593345" WEIGHT="4.620895212236023"/>
<DICH_DATA CI_END="5.132739368440747" CI_START="1.5274494645500922" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="12" LOG_CI_END="0.710349212103786" LOG_CI_START="0.18396685058065237" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2013-11-14 16:01:06 +0000" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.30919960479340136" STUDY_ID="STD-Levine-2010" TOTAL_1="195" TOTAL_2="156" VAR="0.0956043956043956" WEIGHT="1.757767435230969"/>
<DICH_DATA CI_END="2.306149584378626" CI_START="1.018722256800146" EFFECT_SIZE="1.5327510917030567" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="32" LOG_CI_END="0.3628874736279313" LOG_CI_START="0.00805579462394092" LOG_EFFECT_SIZE="0.18547163412593606" MODIFIED="2013-11-14 16:10:22 +0000" MODIFIED_BY="Lindsay Stead" ORDER="255" O_E="0.0" SE="0.20842988469208254" STUDY_ID="STD-McCarthy-2008" TOTAL_1="229" TOTAL_2="234" VAR="0.043443016832754824" WEIGHT="4.173084157248123"/>
<DICH_DATA CI_END="3.704257040124485" CI_START="0.4724587111497075" EFFECT_SIZE="1.3229166666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5687011149522657" LOG_CI_START="-0.32563613911948874" LOG_EFFECT_SIZE="0.12153248791638847" MODIFIED="2013-11-14 16:10:23 +0000" MODIFIED_BY="[Empty name]" ORDER="1171" O_E="0.0" SE="0.5253381300825547" STUDY_ID="STD-Nides-2006" TOTAL_1="128" TOTAL_2="127" VAR="0.27598015091863515" WEIGHT="0.7940972883866965"/>
<DICH_DATA CI_END="2.2561498367461423" CI_START="0.8598945818271262" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="21" LOG_CI_END="0.3533679388889403" LOG_CI_START="-0.06555478752038037" LOG_EFFECT_SIZE="0.14390657568427997" MODIFIED="2013-11-14 16:10:24 +0000" MODIFIED_BY="Lindsay Stead" ORDER="617" O_E="0.0" SE="0.24607728319377492" STUDY_ID="STD-Piper-2007" TOTAL_1="224" TOTAL_2="156" VAR="0.060554029304029304" WEIGHT="3.263896584997293"/>
<DICH_DATA CI_END="1.4884649830088992" CI_START="0.5839043227075914" EFFECT_SIZE="0.9322666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.1727386220765351" LOG_CI_START="-0.23365830960724193" LOG_EFFECT_SIZE="-0.030459843765353416" MODIFIED="2013-11-14 16:10:24 +0000" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.23871956936830668" STUDY_ID="STD-Planer-2011" TOTAL_1="75" TOTAL_2="76" VAR="0.056987032799389783" WEIGHT="3.2739873586669535"/>
<DICH_DATA CI_END="2.6480852321048074" CI_START="0.8566714367580373" EFFECT_SIZE="1.506166982922201" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" LOG_CI_END="0.4229319593315184" LOG_CI_START="-0.06718571315654748" LOG_EFFECT_SIZE="0.17787312308748546" MODIFIED="2013-11-14 16:01:11 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1172" O_E="0.0" SE="0.28789754694109665" STUDY_ID="STD-Rigotti-2006" TOTAL_1="124" TOTAL_2="127" VAR="0.08288499753470095" WEIGHT="2.214366784940368"/>
<DICH_DATA CI_END="3.956888450351169" CI_START="0.8188252058792445" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.5973538071323893" LOG_CI_START="-0.08680879692577706" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-11-14 16:10:25 +0000" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.4018805002832764" STUDY_ID="STD-Rovina-2009" TOTAL_1="40" TOTAL_2="36" VAR="0.1615079365079365" WEIGHT="0.9713977931539564"/>
<DICH_DATA CI_END="1.2433617797885919" CI_START="0.22138584085478996" EFFECT_SIZE="0.52465483234714" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.09459751327982222" LOG_CI_START="-0.6548501586843603" LOG_EFFECT_SIZE="-0.28012632270226895" MODIFIED="2013-11-14 16:10:25 +0000" MODIFIED_BY="Lindsay Stead" ORDER="619" O_E="0.0" SE="0.44022927233756826" STUDY_ID="STD-Schmitz-2007" TOTAL_1="78" TOTAL_2="76" VAR="0.19380181222286486" WEIGHT="1.7360806941469502"/>
<DICH_DATA CI_END="3.04030364682353" CI_START="0.761201100152762" EFFECT_SIZE="1.5212765957446808" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.48291696043585847" LOG_CI_START="-0.1185005927051321" LOG_EFFECT_SIZE="0.18220818386536314" MODIFIED="2013-11-14 16:10:26 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1173" O_E="0.0" SE="0.3532756477799193" STUDY_ID="STD-Selby-2003" TOTAL_1="141" TOTAL_2="143" VAR="0.12480368331432161" WEIGHT="1.5708499121888022"/>
<DICH_DATA CI_END="2.219412315091913" CI_START="0.7614628379360018" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.3462379915222437" LOG_CI_START="-0.11835128690857019" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2013-11-14 16:10:26 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1174" O_E="0.0" SE="0.2729020419042783" STUDY_ID="STD-SMK20001" TOTAL_1="143" TOTAL_2="143" VAR="0.07447552447552448" WEIGHT="2.6366511528464533"/>
<DICH_DATA CI_END="2.226624137820237" CI_START="0.6587088379431306" EFFECT_SIZE="1.2110726643598615" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.3476469127470291" LOG_CI_START="-0.18130650955957367" LOG_EFFECT_SIZE="0.08317020159372775" MODIFIED="2013-11-14 16:10:27 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1165" O_E="0.0" SE="0.3107098586245673" STUDY_ID="STD-Tashkin-2001" TOTAL_1="204" TOTAL_2="200" VAR="0.0965406162464986" WEIGHT="2.2633431183345296"/>
<DICH_DATA CI_END="2.9582037912289705" CI_START="1.214735312614868" EFFECT_SIZE="1.8956356736242885" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="20" LOG_CI_END="0.47102808932198076" LOG_CI_START="0.08448165670489075" LOG_EFFECT_SIZE="0.2777548730134357" MODIFIED="2013-11-14 16:10:28 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1166" O_E="0.0" SE="0.22705928795497957" STUDY_ID="STD-Tonnesen-2003" TOTAL_1="527" TOTAL_2="180" VAR="0.05155592024662233" WEIGHT="3.9307359478078663"/>
<DICH_DATA CI_END="3.5172766069773567" CI_START="1.5632027342205153" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="29" LOG_CI_END="0.5462065236084376" LOG_CI_START="0.19401530600612288" LOG_EFFECT_SIZE="0.3701109148072802" MODIFIED="2013-11-14 16:10:29 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1164" O_E="0.0" SE="0.20687886459424357" STUDY_ID="STD-Tonstad-2003" TOTAL_1="313" TOTAL_2="313" VAR="0.04279886461580336" WEIGHT="3.823144171627357"/>
<DICH_DATA CI_END="2.197107992236128" CI_START="0.7934051512497178" EFFECT_SIZE="1.3203017832647461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.34185140388436785" LOG_CI_START="-0.10050498415924054" LOG_EFFECT_SIZE="0.12067320986256362" MODIFIED="2013-11-14 16:10:30 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.2598423320362514" STUDY_ID="STD-Wittchen-2011" TOTAL_1="108" TOTAL_2="175" VAR="0.06751803751803752" WEIGHT="2.7167755341697024"/>
<DICH_DATA CI_END="1.4974758638421168" CI_START="0.774368387316768" EFFECT_SIZE="1.0768463073852295" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="36" LOG_CI_END="0.17535983120514995" LOG_CI_START="-0.11105238490178249" LOG_EFFECT_SIZE="0.03215372315168373" MODIFIED="2013-09-12 10:20:03 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1167" O_E="0.0" SE="0.16823995350454723" STUDY_ID="STD-Zellweger-2005" TOTAL_1="501" TOTAL_2="166" VAR="0.02830468195521222" WEIGHT="7.129631213304142"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.11244061283116" CI_END="1.9686888497564652" CI_START="1.4475696743695123" DF="16" EFFECT_SIZE="1.6881392943643176" ESTIMABLE="YES" EVENTS_1="483" EVENTS_2="200" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.2941770815459769" LOG_CI_START="0.16063947634833764" LOG_EFFECT_SIZE="0.22740827894715726" MODIFIED="2013-11-14 16:10:41 +0000" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.9087108616164933" P_Z="2.4646881770647205E-11" STUDIES="17" TAU2="0.0" TOTAL_1="2202" TOTAL_2="1660" WEIGHT="29.054565913315002" Z="6.675453492864438">
<NAME>Six month follow-up</NAME>
<DICH_DATA CI_END="3.306872251935789" CI_START="1.1467766150002021" EFFECT_SIZE="1.9473684210526316" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="19" LOG_CI_END="0.5194174179705584" LOG_CI_START="0.05947882825777366" LOG_EFFECT_SIZE="0.28944812311416607" ORDER="1175" O_E="0.0" SE="0.2701702043300275" STUDY_ID="STD-Ahluwalia-2002" TOTAL_1="300" TOTAL_2="300" VAR="0.07299193930772879" WEIGHT="2.5048185952041306"/>
<DICH_DATA CI_END="3.0307810892493663" CI_START="1.2576927435442133" EFFECT_SIZE="1.9523809523809523" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="21" LOG_CI_END="0.4815545687779086" LOG_CI_START="0.09957455519372388" LOG_EFFECT_SIZE="0.2905645619858162" MODIFIED="2013-11-14 16:10:32 +0000" MODIFIED_BY="Lindsay Stead" ORDER="1181" O_E="0.0" SE="0.2243769508109123" STUDY_ID="STD-Aubin-2004" TOTAL_1="340" TOTAL_2="164" VAR="0.050345016055202564" WEIGHT="3.7352557998658082"/>
<DICH_DATA CI_END="2.8773076640026582" CI_START="0.8824665216372964" EFFECT_SIZE="1.5934640522875816" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4589863025002357" LOG_CI_START="-0.054301761570707104" LOG_EFFECT_SIZE="0.20234227046476427" MODIFIED="2013-11-14 16:10:32 +0000" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.3015079496521667" STUDY_ID="STD-Cinciripini-2013" TOTAL_1="102" TOTAL_2="106" VAR="0.09090704370345348" WEIGHT="1.939459742238016"/>
<DICH_DATA CI_END="2.277431411676236" CI_START="1.2605257206116747" EFFECT_SIZE="1.694331983805668" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="52" LOG_CI_END="0.3574453064006549" LOG_CI_START="0.10055171173857132" LOG_EFFECT_SIZE="0.22899850906961308" MODIFIED="2013-11-14 16:10:33 +0000" MODIFIED_BY="[Empty name]" ORDER="1180" O_E="0.0" SE="0.1509005691483103" STUDY_ID="STD-Collins-2004" TOTAL_1="285" TOTAL_2="270" VAR="0.02277098176928398" WEIGHT="7.040571186519718"/>
<DICH_DATA CI_END="2.1324815850753076" CI_START="0.8336661803881398" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" LOG_CI_END="0.32888528953020096" LOG_CI_START="-0.07900781631360113" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-11-14 16:10:33 +0000" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.23959842947608695" STUDY_ID="STD-Cox-2012" TOTAL_1="270" TOTAL_2="270" VAR="0.05740740740740741" WEIGHT="3.559479056342712"/>
<DICH_DATA CI_END="5.323541925972373" CI_START="1.249581207577302" EFFECT_SIZE="2.579185520361991" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" LOG_CI_END="0.72620067873703" LOG_CI_START="0.09676448523773143" LOG_EFFECT_SIZE="0.41148258198738075" MODIFIED="2013-11-14 16:10:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1176" O_E="0.0" SE="0.3697339358208961" STUDY_ID="STD-Dalsgar_x00f0_-2004" TOTAL_1="221" TOTAL_2="114" VAR="0.13670318329761053" WEIGHT="1.3915221606664268"/>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.1381198200435548" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649093" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-11-14 16:10:34 +0000" MODIFIED_BY="[Empty name]" ORDER="1177" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Evins-2001" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.06591627882116133"/>
<DICH_DATA CI_END="16.33411175549101" CI_START="0.07062735543059231" EFFECT_SIZE="1.0740740740740742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.21309552263898" LOG_CI_START="-1.1510270551590425" LOG_EFFECT_SIZE="0.03103423373996882" MODIFIED="2013-11-14 16:10:35 +0000" MODIFIED_BY="[Empty name]" ORDER="1183" O_E="0.0" SE="1.3886973047940554" STUDY_ID="STD-Evins-2005" TOTAL_1="27" TOTAL_2="29" VAR="1.9284802043422733" WEIGHT="0.1271242520122397"/>
<DICH_DATA CI_END="25.870086473447536" CI_START="0.3478921498479488" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4127978803933245" LOG_CI_START="-0.4585553709539996" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-11-14 16:10:35 +0000" MODIFIED_BY="[Empty name]" ORDER="1178" O_E="0.0" SE="1.0992421631894098" STUDY_ID="STD-George-2002" TOTAL_1="16" TOTAL_2="16" VAR="1.2083333333333333" WEIGHT="0.13183255764232266"/>
<DICH_DATA CI_END="3.5533668327223173" CI_START="1.0423379738493495" EFFECT_SIZE="1.9245283018867925" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.5506400443042505" LOG_CI_START="0.018008560018006436" LOG_EFFECT_SIZE="0.28432430216112853" MODIFIED="2013-11-14 16:10:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1184" O_E="0.0" SE="0.31287037043810906" STUDY_ID="STD-Haggstr_x00e4_m-2006" TOTAL_1="53" TOTAL_2="51" VAR="0.09788786869807957" WEIGHT="1.4780457904898867"/>
<DICH_DATA CI_END="10.999253275213881" CI_START="0.20455934086636887" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0413632024798651" LOG_CI_START="-0.6891806843685024" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-11-14 16:10:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1179" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Hertzberg-2001" TOTAL_1="10" TOTAL_2="5" VAR="1.0333333333333332" WEIGHT="0.17577674352309686"/>
<DICH_DATA CI_END="4.023758037840486" CI_START="0.5484770141802915" EFFECT_SIZE="1.4855769230769231" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6046318572391892" LOG_CI_START="-0.26084156831504296" LOG_EFFECT_SIZE="0.1718951444620731" MODIFIED="2013-11-14 16:10:37 +0000" MODIFIED_BY="Lindsay Stead" ORDER="387" O_E="0.0" SE="0.5083833743331065" STUDY_ID="STD-Muramoto-2007" TOTAL_1="104" TOTAL_2="103" VAR="0.2584536552983155" WEIGHT="0.7948165794087859"/>
<DICH_DATA CI_END="25.6814912287983" CI_START="0.32185144259579535" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4096202379963167" LOG_CI_START="-0.4923445399450183" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2013-11-14 16:10:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1187" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Myles-2004" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="0.13463750567726568"/>
<DICH_DATA CI_END="2.1179230501765183" CI_START="0.6902520968948512" EFFECT_SIZE="1.209090909090909" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="10" LOG_CI_END="0.3259101769750483" LOG_CI_START="-0.16099226535732686" LOG_EFFECT_SIZE="0.08245895580886071" MODIFIED="2013-11-14 16:10:39 +0000" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.28600890483199803" STUDY_ID="STD-Piper-2009" TOTAL_1="264" TOTAL_2="38" VAR="0.08180109364319892" WEIGHT="2.3048871005015354"/>
<DICH_DATA CI_END="1.7467125142740394" CI_START="0.2670096254095267" EFFECT_SIZE="0.6829268292682927" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24222143174969704" LOG_CI_START="-0.5734730825047295" LOG_EFFECT_SIZE="-0.16562582537751624" MODIFIED="2013-11-14 16:10:39 +0000" MODIFIED_BY="[Empty name]" ORDER="386" O_E="0.0" SE="0.47914299542601574" STUDY_ID="STD-Simon-2009" TOTAL_1="41" TOTAL_2="42" VAR="0.22957801006581494" WEIGHT="1.172197922169086"/>
<DICH_DATA CI_END="4.081546072323049" CI_START="0.6366567849425291" EFFECT_SIZE="1.612" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.6108247031612354" LOG_CI_START="-0.19609462822309173" LOG_EFFECT_SIZE="0.20736503746907187" MODIFIED="2013-11-14 16:10:40 +0000" MODIFIED_BY="[Empty name]" ORDER="1185" O_E="0.0" SE="0.47398840957026356" STUDY_ID="STD-Uyar-2007" TOTAL_1="50" TOTAL_2="31" VAR="0.2246650124069479" WEIGHT="0.8137812200143374"/>
<DICH_DATA CI_END="3.50362642318525" CI_START="1.041840165704785" EFFECT_SIZE="1.9105545617173525" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5445177929873354" LOG_CI_START="0.01780109662489327" LOG_EFFECT_SIZE="0.2811594448061143" MODIFIED="2013-11-14 16:10:41 +0000" MODIFIED_BY="[Empty name]" ORDER="1188" O_E="0.0" SE="0.3093959947329953" STUDY_ID="STD-Wagena-2005" TOTAL_1="86" TOTAL_2="89" VAR="0.09572588155681963" WEIGHT="1.684443422218477"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="52.435831567179505" CI_END="1.7622799504654791" CI_START="1.4892044620171614" CI_STUDY="95" CI_TOTAL="95" DF="43" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6199985078871442" ESTIMABLE="YES" EVENTS_1="1507" EVENTS_2="701" I2="17.995007011742626" I2_Q="2.4063723215713875" ID="CMP-001.02" LOG_CI_END="0.24607490026494055" LOG_CI_START="0.17295432879973113" LOG_EFFECT_SIZE="0.20951461453233583" METHOD="MH" MODIFIED="2013-11-26 15:13:46 +0000" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.1533701095374127" P_Q="0.39282276584884634" P_Z="2.8433135667756536E-29" Q="4.098628255914429" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="44" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7646" TOTAL_2="6082" WEIGHT="100.0" Z="11.231889753858182">
<NAME>Bupropion versus placebo/control. Subgroups by clinical/recruitment setting</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.521359712935446" CI_END="1.8736398644842949" CI_START="1.4914240016507918" DF="20" EFFECT_SIZE="1.6716433424452761" ESTIMABLE="YES" EVENTS_1="863" EVENTS_2="379" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.2726861180898233" LOG_CI_START="0.17360112795982216" LOG_EFFECT_SIZE="0.22314362302482277" MODIFIED="2013-08-22 14:53:43 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.48820588576679347" P_Z="1.0671185482106045E-18" STUDIES="21" TAU2="0.0" TOTAL_1="4245" TOTAL_2="3279" WEIGHT="54.311470321052056" Z="8.827844942702633">
<NAME>Community volunteers</NAME>
<DICH_DATA CI_END="3.0307810892493663" CI_START="1.2576927435442133" EFFECT_SIZE="1.9523809523809523" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="21" LOG_CI_END="0.4815545687779086" LOG_CI_START="0.09957455519372388" LOG_EFFECT_SIZE="0.2905645619858162" ORDER="1194" O_E="0.0" SE="0.2243769508109123" STUDY_ID="STD-Aubin-2004" TOTAL_1="340" TOTAL_2="164" VAR="0.050345016055202564" WEIGHT="3.7352557998658082"/>
<DICH_DATA CI_END="2.358020456421056" CI_START="0.9347948167763013" EFFECT_SIZE="1.4846768336964415" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="27" LOG_CI_END="0.3725475683893706" LOG_CI_START="-0.029283704336819254" LOG_EFFECT_SIZE="0.17163193202627566" ORDER="1198" O_E="0.0" SE="0.23603767869624365" STUDY_ID="STD-Brown-2007" TOTAL_1="255" TOTAL_2="269" VAR="0.05571378576431116" WEIGHT="3.464378470867907"/>
<DICH_DATA CI_END="2.8773076640026582" CI_START="0.8824665216372964" EFFECT_SIZE="1.5934640522875816" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4589863025002357" LOG_CI_START="-0.054301761570707104" LOG_EFFECT_SIZE="0.20234227046476427" MODIFIED="2013-08-22 14:53:43 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.3015079496521667" STUDY_ID="STD-Cinciripini-2013" TOTAL_1="102" TOTAL_2="106" VAR="0.09090704370345348" WEIGHT="1.939459742238016"/>
<DICH_DATA CI_END="2.277431411676236" CI_START="1.2605257206116747" EFFECT_SIZE="1.694331983805668" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="52" LOG_CI_END="0.3574453064006549" LOG_CI_START="0.10055171173857132" LOG_EFFECT_SIZE="0.22899850906961308" ORDER="1193" O_E="0.0" SE="0.1509005691483103" STUDY_ID="STD-Collins-2004" TOTAL_1="285" TOTAL_2="270" VAR="0.02277098176928398" WEIGHT="7.040571186519718"/>
<DICH_DATA CI_END="2.9279813474837035" CI_START="1.2471322987106108" EFFECT_SIZE="1.9109108059951787" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="29" LOG_CI_END="0.466568305750185" LOG_CI_START="0.09591252689659248" LOG_EFFECT_SIZE="0.28124041632338875" ORDER="1196" O_E="0.0" SE="0.21772503927429648" STUDY_ID="STD-Gonzales-2006" TOTAL_1="329" TOTAL_2="344" VAR="0.04740419272699394" WEIGHT="3.7379329345182777"/>
<DICH_DATA CI_END="3.5533668327223173" CI_START="1.0423379738493495" EFFECT_SIZE="1.9245283018867925" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.5506400443042505" LOG_CI_START="0.018008560018006436" LOG_EFFECT_SIZE="0.28432430216112853" ORDER="1197" O_E="0.0" SE="0.31287037043810906" STUDY_ID="STD-Haggstr_x00e4_m-2006" TOTAL_1="53" TOTAL_2="51" VAR="0.09788786869807957" WEIGHT="1.4780457904898867"/>
<DICH_DATA CI_END="4.387275664407896" CI_START="0.7861324101006102" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6421949231603534" LOG_CI_START="-0.10450429857519355" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="1191" O_E="0.0" SE="0.4386148190682198" STUDY_ID="STD-Hall-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.19238295950624718" WEIGHT="0.9228279034962585"/>
<DICH_DATA CI_END="4.975994504154581" CI_START="0.7929350590265837" EFFECT_SIZE="1.9863636363636363" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.6968798920170354" LOG_CI_START="-0.10076237972060419" LOG_EFFECT_SIZE="0.2980587561482156" ORDER="1199" O_E="0.0" SE="0.4685390188116135" STUDY_ID="STD-Holt-2005" TOTAL_1="88" TOTAL_2="46" VAR="0.21952881214894948" WEIGHT="0.8657660501883876"/>
<DICH_DATA CI_END="2.5625080424919373" CI_START="0.7357402222445212" EFFECT_SIZE="1.373076923076923" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.40866523710942554" LOG_CI_START="-0.133275500826675" LOG_EFFECT_SIZE="0.13769486814137524" ORDER="1190" O_E="0.0" SE="0.3183386721135834" STUDY_ID="STD-Hurt-1997" TOTAL_1="156" TOTAL_2="153" VAR="0.10133951016303956" WEIGHT="1.9966872807963432"/>
<DICH_DATA CI_END="6.519433294867828" CI_START="1.6488854099851884" EFFECT_SIZE="3.278688524590164" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="9" LOG_CI_END="0.8142098460987333" LOG_CI_START="0.21719047520769508" LOG_EFFECT_SIZE="0.5157001606532142" ORDER="1189" O_E="0.0" SE="0.3506921337549441" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.12298497267759562" WEIGHT="1.4331895870422802"/>
<DICH_DATA CI_END="2.1357628221662064" CI_START="0.9499646474393186" EFFECT_SIZE="1.4243943191311612" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" LOG_CI_END="0.3295530223529506" LOG_CI_START="-0.02229255650873887" LOG_EFFECT_SIZE="0.15363023292210584" ORDER="1200" O_E="0.0" SE="0.20667583468706094" STUDY_ID="STD-Jorenby-2006" TOTAL_1="342" TOTAL_2="341" VAR="0.042714900643593345" WEIGHT="4.620895212236023"/>
<DICH_DATA CI_END="5.132739368440747" CI_START="1.5274494645500922" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="12" LOG_CI_END="0.710349212103786" LOG_CI_START="0.18396685058065237" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2013-08-20 12:53:47 +0100" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.30919960479340136" STUDY_ID="STD-Levine-2010" TOTAL_1="195" TOTAL_2="156" VAR="0.0956043956043956" WEIGHT="1.757767435230969"/>
<DICH_DATA CI_END="2.306149584378626" CI_START="1.018722256800146" EFFECT_SIZE="1.5327510917030567" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="32" LOG_CI_END="0.3628874736279313" LOG_CI_START="0.00805579462394092" LOG_EFFECT_SIZE="0.18547163412593606" ORDER="256" O_E="0.0" SE="0.20842988469208254" STUDY_ID="STD-McCarthy-2008" TOTAL_1="229" TOTAL_2="234" VAR="0.043443016832754824" WEIGHT="4.173084157248123"/>
<DICH_DATA CI_END="4.023758037840486" CI_START="0.5484770141802915" EFFECT_SIZE="1.4855769230769231" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6046318572391892" LOG_CI_START="-0.26084156831504296" LOG_EFFECT_SIZE="0.1718951444620731" ORDER="389" O_E="0.0" SE="0.5083833743331065" STUDY_ID="STD-Muramoto-2007" TOTAL_1="104" TOTAL_2="103" VAR="0.2584536552983155" WEIGHT="0.7948165794087859"/>
<DICH_DATA CI_END="3.704257040124485" CI_START="0.4724587111497075" EFFECT_SIZE="1.3229166666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5687011149522657" LOG_CI_START="-0.32563613911948874" LOG_EFFECT_SIZE="0.12153248791638847" ORDER="1201" O_E="0.0" SE="0.5253381300825547" STUDY_ID="STD-Nides-2006" TOTAL_1="128" TOTAL_2="127" VAR="0.27598015091863515" WEIGHT="0.7940972883866965"/>
<DICH_DATA CI_END="2.2561498367461423" CI_START="0.8598945818271262" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="21" LOG_CI_END="0.3533679388889403" LOG_CI_START="-0.06555478752038037" LOG_EFFECT_SIZE="0.14390657568427997" MODIFIED="2009-07-23 19:00:05 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1192" O_E="0.0" SE="0.24607728319377492" STUDY_ID="STD-Piper-2007" TOTAL_1="224" TOTAL_2="156" VAR="0.060554029304029304" WEIGHT="3.263896584997293"/>
<DICH_DATA CI_END="2.1179230501765183" CI_START="0.6902520968948512" EFFECT_SIZE="1.209090909090909" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="10" LOG_CI_END="0.3259101769750483" LOG_CI_START="-0.16099226535732686" LOG_EFFECT_SIZE="0.08245895580886071" MODIFIED="2013-07-02 09:51:07 +0100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.28600890483199803" STUDY_ID="STD-Piper-2009" TOTAL_1="264" TOTAL_2="38" VAR="0.08180109364319892" WEIGHT="2.3048871005015354"/>
<DICH_DATA CI_END="1.2433617797885919" CI_START="0.22138584085478996" EFFECT_SIZE="0.52465483234714" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.09459751327982222" LOG_CI_START="-0.6548501586843603" LOG_EFFECT_SIZE="-0.28012632270226895" ORDER="620" O_E="0.0" SE="0.44022927233756826" STUDY_ID="STD-Schmitz-2007" TOTAL_1="78" TOTAL_2="76" VAR="0.19380181222286486" WEIGHT="1.7360806941469502"/>
<DICH_DATA CI_END="2.219412315091913" CI_START="0.7614628379360018" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="0.3462379915222437" LOG_CI_START="-0.11835128690857019" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="1202" O_E="0.0" SE="0.2729020419042783" STUDY_ID="STD-SMK20001" TOTAL_1="143" TOTAL_2="143" VAR="0.07447552447552448" WEIGHT="2.6366511528464533"/>
<DICH_DATA CI_END="2.9582037912289705" CI_START="1.214735312614868" EFFECT_SIZE="1.8956356736242885" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="20" LOG_CI_END="0.47102808932198076" LOG_CI_START="0.08448165670489075" LOG_EFFECT_SIZE="0.2777548730134357" ORDER="1195" O_E="0.0" SE="0.22705928795497957" STUDY_ID="STD-Tonnesen-2003" TOTAL_1="527" TOTAL_2="180" VAR="0.05155592024662233" WEIGHT="3.9307359478078663"/>
<DICH_DATA CI_END="3.50362642318525" CI_START="1.041840165704785" EFFECT_SIZE="1.9105545617173525" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5445177929873354" LOG_CI_START="0.01780109662489327" LOG_EFFECT_SIZE="0.2811594448061143" ORDER="1203" O_E="0.0" SE="0.3093959947329953" STUDY_ID="STD-Wagena-2005" TOTAL_1="86" TOTAL_2="89" VAR="0.09572588155681963" WEIGHT="1.684443422218477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.150327314156495" CI_END="1.8563605500510418" CI_START="1.3781306876996686" DF="17" EFFECT_SIZE="1.5994709880020885" ESTIMABLE="YES" EVENTS_1="413" EVENTS_2="234" I2="19.622993311212575" ID="CMP-001.02.02" LOG_CI_END="0.26866233055221206" LOG_CI_START="0.13929040353358954" LOG_EFFECT_SIZE="0.20397636704290079" MODIFIED="2013-08-16 11:18:44 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.2196383371570566" P_Z="6.393184744193572E-10" STUDIES="18" TAU2="0.0" TOTAL_1="2042" TOTAL_2="1886" WEIGHT="31.374954935842204" Z="6.18041861653434">
<NAME>People recruited from health care settings</NAME>
<DICH_DATA CI_END="3.306872251935789" CI_START="1.1467766150002021" EFFECT_SIZE="1.9473684210526316" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="19" LOG_CI_END="0.5194174179705584" LOG_CI_START="0.05947882825777366" LOG_EFFECT_SIZE="0.28944812311416607" ORDER="1210" O_E="0.0" SE="0.2701702043300275" STUDY_ID="STD-Ahluwalia-2002" TOTAL_1="300" TOTAL_2="300" VAR="0.07299193930772879" WEIGHT="2.5048185952041306"/>
<DICH_DATA CI_END="1.7250900173636334" CI_START="0.8459501412352303" EFFECT_SIZE="1.2080315160757402" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="43" LOG_CI_END="0.23681176203207296" LOG_CI_START="-0.07265523273462553" LOG_EFFECT_SIZE="0.0820782646487237" MODIFIED="2013-07-02 14:57:48 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.1817824446122887" STUDY_ID="STD-Eisenberg-2013" TOTAL_1="183" TOTAL_2="194" VAR="0.033044857169219816" WEIGHT="5.503397326723803"/>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.1381198200435548" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649093" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1206" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Evins-2001" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.06591627882116133"/>
<DICH_DATA CI_END="16.33411175549101" CI_START="0.07062735543059231" EFFECT_SIZE="1.0740740740740742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.21309552263898" LOG_CI_START="-1.1510270551590425" LOG_EFFECT_SIZE="0.03103423373996882" ORDER="1208" O_E="0.0" SE="1.3886973047940554" STUDY_ID="STD-Evins-2005" TOTAL_1="27" TOTAL_2="29" VAR="1.9284802043422733" WEIGHT="0.1271242520122397"/>
<DICH_DATA CI_END="324.0039639094615" CI_START="1.2500329320451646" EFFECT_SIZE="20.125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5105503234580793" LOG_CI_START="0.09692145462173302" LOG_EFFECT_SIZE="1.3037358890399062" ORDER="1211" O_E="0.0" SE="1.4177775452100598" STUDY_ID="STD-Ferry-1992" TOTAL_1="23" TOTAL_2="22" VAR="2.0100931677018634" WEIGHT="0.06731875283863284"/>
<DICH_DATA CI_END="5.461809525863762" CI_START="0.8595035074391462" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.737336550562281" LOG_CI_START="-0.06575234671589476" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="1212" O_E="0.0" SE="0.47173839361535563" STUDY_ID="STD-Ferry-1994" TOTAL_1="95" TOTAL_2="95" VAR="0.2225371120107962" WEIGHT="0.7909953458539359"/>
<DICH_DATA CI_END="2.7831017825538176" CI_START="1.2622971378888377" EFFECT_SIZE="1.874326923076923" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="26" LOG_CI_END="0.44452908947927056" LOG_CI_START="0.10116159750400144" LOG_EFFECT_SIZE="0.27284534349163597" ORDER="209" O_E="0.0" SE="0.20169576448277068" STUDY_ID="STD-Fossati-2007" TOTAL_1="400" TOTAL_2="193" VAR="0.0406811814102893" WEIGHT="4.624143674469328"/>
<DICH_DATA CI_END="25.870086473447536" CI_START="0.3478921498479488" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4127978803933245" LOG_CI_START="-0.4585553709539996" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1207" O_E="0.0" SE="1.0992421631894098" STUDY_ID="STD-George-2002" TOTAL_1="16" TOTAL_2="16" VAR="1.2083333333333333" WEIGHT="0.13183255764232266"/>
<DICH_DATA CI_END="10.999253275213881" CI_START="0.20455934086636887" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0413632024798651" LOG_CI_START="-0.6891806843685024" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1209" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Hertzberg-2001" TOTAL_1="10" TOTAL_2="5" VAR="1.0333333333333332" WEIGHT="0.17577674352309686"/>
<DICH_DATA CI_END="25.6814912287983" CI_START="0.32185144259579535" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4096202379963167" LOG_CI_START="-0.4923445399450183" LOG_EFFECT_SIZE="0.4586378490256493" ORDER="1213" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Myles-2004" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="0.13463750567726568"/>
<DICH_DATA CI_END="1.4884649830088992" CI_START="0.5839043227075914" EFFECT_SIZE="0.9322666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.1727386220765351" LOG_CI_START="-0.23365830960724193" LOG_EFFECT_SIZE="-0.030459843765353416" MODIFIED="2013-06-26 15:25:39 +0100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.23871956936830668" STUDY_ID="STD-Planer-2011" TOTAL_1="75" TOTAL_2="76" VAR="0.056987032799389783" WEIGHT="3.2739873586669535"/>
<DICH_DATA CI_END="2.6480852321048074" CI_START="0.8566714367580373" EFFECT_SIZE="1.506166982922201" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" LOG_CI_END="0.4229319593315184" LOG_CI_START="-0.06718571315654748" LOG_EFFECT_SIZE="0.17787312308748546" ORDER="1214" O_E="0.0" SE="0.28789754694109665" STUDY_ID="STD-Rigotti-2006" TOTAL_1="124" TOTAL_2="127" VAR="0.08288499753470095" WEIGHT="2.214366784940368"/>
<DICH_DATA CI_END="3.956888450351169" CI_START="0.8188252058792445" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.5973538071323893" LOG_CI_START="-0.08680879692577706" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-06-26 15:55:06 +0100" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.4018805002832764" STUDY_ID="STD-Rovina-2009" TOTAL_1="40" TOTAL_2="36" VAR="0.1615079365079365" WEIGHT="0.9713977931539564"/>
<DICH_DATA CI_END="1.7467125142740394" CI_START="0.2670096254095267" EFFECT_SIZE="0.6829268292682927" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24222143174969704" LOG_CI_START="-0.5734730825047295" LOG_EFFECT_SIZE="-0.16562582537751624" ORDER="388" O_E="0.0" SE="0.47914299542601574" STUDY_ID="STD-Simon-2009" TOTAL_1="41" TOTAL_2="42" VAR="0.22957801006581494" WEIGHT="1.172197922169086"/>
<DICH_DATA CI_END="2.226624137820237" CI_START="0.6587088379431306" EFFECT_SIZE="1.2110726643598615" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.3476469127470291" LOG_CI_START="-0.18130650955957367" LOG_EFFECT_SIZE="0.08317020159372775" ORDER="1204" O_E="0.0" SE="0.3107098586245673" STUDY_ID="STD-Tashkin-2001" TOTAL_1="204" TOTAL_2="200" VAR="0.0965406162464986" WEIGHT="2.2633431183345296"/>
<DICH_DATA CI_END="3.5172766069773567" CI_START="1.5632027342205153" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="29" LOG_CI_END="0.5462065236084376" LOG_CI_START="0.19401530600612288" LOG_EFFECT_SIZE="0.3701109148072802" ORDER="1205" O_E="0.0" SE="0.20687886459424357" STUDY_ID="STD-Tonstad-2003" TOTAL_1="313" TOTAL_2="313" VAR="0.04279886461580336" WEIGHT="3.823144171627357"/>
<DICH_DATA CI_END="4.081546072323049" CI_START="0.6366567849425291" EFFECT_SIZE="1.612" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.6108247031612354" LOG_CI_START="-0.19609462822309173" LOG_EFFECT_SIZE="0.20736503746907187" ORDER="1215" O_E="0.0" SE="0.47398840957026356" STUDY_ID="STD-Uyar-2007" TOTAL_1="50" TOTAL_2="31" VAR="0.2246650124069479" WEIGHT="0.8137812200143374"/>
<DICH_DATA CI_END="2.197107992236128" CI_START="0.7934051512497178" EFFECT_SIZE="1.3203017832647461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.34185140388436785" LOG_CI_START="-0.10050498415924054" LOG_EFFECT_SIZE="0.12067320986256362" MODIFIED="2013-07-02 11:30:16 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.2598423320362514" STUDY_ID="STD-Wittchen-2011" TOTAL_1="108" TOTAL_2="175" VAR="0.06751803751803752" WEIGHT="2.7167755341697024"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1324815850753076" CI_START="0.8336661803881398" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.32888528953020096" LOG_CI_START="-0.07900781631360113" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-07-02 14:14:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.22987370857651646" STUDIES="1" TAU2="0.0" TOTAL_1="270" TOTAL_2="270" WEIGHT="3.559479056342712" Z="1.20068429947907">
<NAME>Community + health care settings</NAME>
<DICH_DATA CI_END="2.1324815850753076" CI_START="0.8336661803881398" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" LOG_CI_END="0.32888528953020096" LOG_CI_START="-0.07900781631360113" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-07-02 14:14:17 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.23959842947608695" STUDY_ID="STD-Cox-2012" TOTAL_1="270" TOTAL_2="270" VAR="0.05740740740740741" WEIGHT="3.559479056342712"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.7543517617981275" CI_END="1.782711225028492" CI_START="0.9806208320713365" DF="1" EFFECT_SIZE="1.322181441720595" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="44" I2="78.96663835362082" ID="CMP-001.02.04" LOG_CI_END="0.25108099907343656" LOG_CI_START="-0.008498884945104099" LOG_EFFECT_SIZE="0.1212910570641662" MODIFIED="2013-07-02 14:14:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.029224391297925978" P_Z="0.06700776790762196" STUDIES="2" TAU2="0.0" TOTAL_1="722" TOTAL_2="280" WEIGHT="8.521153373970568" Z="1.8316219254923358">
<NAME>Health care professionals/ hospital staff</NAME>
<DICH_DATA CI_END="5.323541925972373" CI_START="1.249581207577302" EFFECT_SIZE="2.579185520361991" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" LOG_CI_END="0.72620067873703" LOG_CI_START="0.09676448523773143" LOG_EFFECT_SIZE="0.41148258198738075" ORDER="1217" O_E="0.0" SE="0.3697339358208961" STUDY_ID="STD-Dalsgar_x00f0_-2004" TOTAL_1="221" TOTAL_2="114" VAR="0.13670318329761053" WEIGHT="1.3915221606664268"/>
<DICH_DATA CI_END="1.4974758638421168" CI_START="0.774368387316768" EFFECT_SIZE="1.0768463073852295" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="36" LOG_CI_END="0.17535983120514995" LOG_CI_START="-0.11105238490178249" LOG_EFFECT_SIZE="0.03215372315168373" ORDER="1216" O_E="0.0" SE="0.16823995350454723" STUDY_ID="STD-Zellweger-2005" TOTAL_1="501" TOTAL_2="166" VAR="0.02830468195521222" WEIGHT="7.129631213304142"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.5553239425672576" CI_END="3.899468055677315" CI_START="1.2933539676453556" DF="1" EFFECT_SIZE="2.2457498706482375" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="17" I2="60.86601845888354" ID="CMP-001.02.05" LOG_CI_END="0.5910053669648101" LOG_CI_START="0.11171739971193921" LOG_EFFECT_SIZE="0.3513613833383747" MODIFIED="2013-07-02 14:14:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.10992362598708794" P_Z="0.004057437485404304" STUDIES="2" TAU2="0.0" TOTAL_1="367" TOTAL_2="367" WEIGHT="2.232942312792467" Z="2.8736613641629503">
<NAME>People with a previously unsuccessful quit attempt using bupropion</NAME>
<DICH_DATA CI_END="10.37923812074336" CI_START="1.5143758155593516" EFFECT_SIZE="3.9646017699115044" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="1.016165475660732" LOG_CI_START="0.18023366536871685" LOG_EFFECT_SIZE="0.5981995705147243" ORDER="1218" O_E="0.0" SE="0.49103048329472615" STUDY_ID="STD-Gonzales-2001" TOTAL_1="226" TOTAL_2="224" VAR="0.24111093552465232" WEIGHT="0.6620924006036649"/>
<DICH_DATA CI_END="3.04030364682353" CI_START="0.761201100152762" EFFECT_SIZE="1.5212765957446808" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.48291696043585847" LOG_CI_START="-0.1185005927051321" LOG_EFFECT_SIZE="0.18220818386536314" ORDER="1219" O_E="0.0" SE="0.3532756477799193" STUDY_ID="STD-Selby-2003" TOTAL_1="141" TOTAL_2="143" VAR="0.12480368331432161" WEIGHT="1.5708499121888022"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="52.09305659985072" CI_END="1.7748913978725724" CI_START="1.493407388604043" CI_STUDY="95" CI_TOTAL="95" DF="41" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6280773714884247" ESTIMABLE="YES" EVENTS_1="1450" EVENTS_2="662" I2="21.294693235340905" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.24917178457555705" LOG_CI_START="0.1741782956610644" LOG_EFFECT_SIZE="0.21167504011831073" METHOD="MH" MODIFIED="2013-11-26 15:14:09 +0000" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="0.11479209838203419" P_Q="0.6132950912798634" P_Z="1.869040209418911E-28" Q="0.977818311510048" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="41" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="7289" TOTAL_2="5723" WEIGHT="100.0" Z="11.06430601011242">
<NAME>Bupropion versus placebo. Subgroups by level of behavioural support</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.030124286952377" CI_END="2.157646289154012" CI_START="1.4378715394155943" DF="9" EFFECT_SIZE="1.7613682724802964" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="119" I2="35.85231452033715" ID="CMP-001.03.01" LOG_CI_END="0.33398025069943077" LOG_CI_START="0.1577200875663184" LOG_EFFECT_SIZE="0.24585016913287455" MODIFIED="2013-08-20 12:55:09 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.12125773453838484" P_Z="4.562445105752039E-8" STUDIES="10" TAU2="0.0" TOTAL_1="1023" TOTAL_2="978" WEIGHT="17.025607648857335" Z="5.467570987434234">
<NAME>Multisession group behavioural support</NAME>
<DICH_DATA CI_END="2.358020456421056" CI_START="0.9347948167763013" EFFECT_SIZE="1.4846768336964415" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="27" LOG_CI_END="0.3725475683893706" LOG_CI_START="-0.029283704336819254" LOG_EFFECT_SIZE="0.17163193202627566" ORDER="1227" O_E="0.0" SE="0.23603767869624365" STUDY_ID="STD-Brown-2007" TOTAL_1="255" TOTAL_2="269" VAR="0.05571378576431116" WEIGHT="3.651442514711057"/>
<DICH_DATA CI_END="2.277431411676236" CI_START="1.2605257206116747" EFFECT_SIZE="1.694331983805668" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="52" LOG_CI_END="0.3574453064006549" LOG_CI_START="0.10055171173857132" LOG_EFFECT_SIZE="0.22899850906961308" ORDER="1226" O_E="0.0" SE="0.1509005691483103" STUDY_ID="STD-Collins-2004" TOTAL_1="285" TOTAL_2="270" VAR="0.02277098176928398" WEIGHT="7.4207368434163214"/>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.1381198200435548" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649093" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1224" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Evins-2001" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.06947552206639775"/>
<DICH_DATA CI_END="16.33411175549101" CI_START="0.07062735543059231" EFFECT_SIZE="1.0740740740740742" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.21309552263898" LOG_CI_START="-1.1510270551590425" LOG_EFFECT_SIZE="0.03103423373996882" ORDER="1228" O_E="0.0" SE="1.3886973047940554" STUDY_ID="STD-Evins-2005" TOTAL_1="27" TOTAL_2="29" VAR="1.9284802043422733" WEIGHT="0.1339885068423385"/>
<DICH_DATA CI_END="324.0039639094615" CI_START="1.2500329320451646" EFFECT_SIZE="20.125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.5105503234580793" LOG_CI_START="0.09692145462173302" LOG_EFFECT_SIZE="1.3037358890399062" ORDER="1222" O_E="0.0" SE="1.4177775452100598" STUDY_ID="STD-Ferry-1992" TOTAL_1="23" TOTAL_2="22" VAR="2.0100931677018634" WEIGHT="0.07095372466355514"/>
<DICH_DATA CI_END="5.461809525863762" CI_START="0.8595035074391462" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.737336550562281" LOG_CI_START="-0.06575234671589476" LOG_EFFECT_SIZE="0.3357921019231931" ORDER="1223" O_E="0.0" SE="0.47173839361535563" STUDY_ID="STD-Ferry-1994" TOTAL_1="95" TOTAL_2="95" VAR="0.2225371120107962" WEIGHT="0.833706264796773"/>
<DICH_DATA CI_END="25.870086473447536" CI_START="0.3478921498479488" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4127978803933245" LOG_CI_START="-0.4585553709539996" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1225" O_E="0.0" SE="1.0992421631894098" STUDY_ID="STD-George-2002" TOTAL_1="16" TOTAL_2="16" VAR="1.2083333333333333" WEIGHT="0.1389510441327955"/>
<DICH_DATA CI_END="5.132739368440747" CI_START="1.5274494645500922" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="12" LOG_CI_END="0.710349212103786" LOG_CI_START="0.18396685058065237" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2013-08-20 12:55:09 +0100" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.30919960479340136" STUDY_ID="STD-Levine-2010" TOTAL_1="195" TOTAL_2="156" VAR="0.0956043956043956" WEIGHT="1.8526805884372732"/>
<DICH_DATA CI_END="3.956888450351169" CI_START="0.8188252058792445" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.5973538071323893" LOG_CI_START="-0.08680879692577706" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-06-26 15:55:21 +0100" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.4018805002832764" STUDY_ID="STD-Rovina-2009" TOTAL_1="40" TOTAL_2="36" VAR="0.1615079365079365" WEIGHT="1.02384979887323"/>
<DICH_DATA CI_END="1.2433617797885919" CI_START="0.22138584085478996" EFFECT_SIZE="0.52465483234714" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.09459751327982222" LOG_CI_START="-0.6548501586843603" LOG_EFFECT_SIZE="-0.28012632270226895" ORDER="621" O_E="0.0" SE="0.44022927233756826" STUDY_ID="STD-Schmitz-2007" TOTAL_1="78" TOTAL_2="76" VAR="0.19380181222286486" WEIGHT="1.8298228409175925"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="37.18942489477362" CI_END="1.7587591958431683" CI_START="1.4529240598827653" DF="30" EFFECT_SIZE="1.5985441974436" ESTIMABLE="YES" EVENTS_1="1225" EVENTS_2="542" I2="19.33190662430486" ID="CMP-001.03.02" LOG_CI_END="0.2452063811995917" LOG_CI_START="0.16224291558105716" LOG_EFFECT_SIZE="0.20372464839032442" MODIFIED="2013-09-12 11:27:39 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.17168761904396557" P_Z="6.224843392298215E-22" STUDIES="30" TAU2="0.0" TOTAL_1="6242" TOTAL_2="4722" WEIGHT="82.83248490181555" Z="9.62575443615309">
<NAME>Multisession individual counselling</NAME>
<DICH_DATA CI_END="3.306872251935789" CI_START="1.1467766150002021" EFFECT_SIZE="1.9473684210526316" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="19" LOG_CI_END="0.5194174179705584" LOG_CI_START="0.05947882825777366" LOG_EFFECT_SIZE="0.28944812311416607" ORDER="1229" O_E="0.0" SE="0.2701702043300275" STUDY_ID="STD-Ahluwalia-2002" TOTAL_1="300" TOTAL_2="300" VAR="0.07299193930772879" WEIGHT="2.6400698385231145"/>
<DICH_DATA CI_END="3.0307810892493663" CI_START="1.2576927435442133" EFFECT_SIZE="1.9523809523809523" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="21" LOG_CI_END="0.4815545687779086" LOG_CI_START="0.09957455519372388" LOG_EFFECT_SIZE="0.2905645619858162" ORDER="1232" O_E="0.0" SE="0.2243769508109123" STUDY_ID="STD-Aubin-2004" TOTAL_1="340" TOTAL_2="164" VAR="0.050345016055202564" WEIGHT="3.9369462504292057"/>
<DICH_DATA CI_END="2.8773076640026582" CI_START="0.8824665216372964" EFFECT_SIZE="1.5934640522875816" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4589863025002357" LOG_CI_START="-0.054301761570707104" LOG_EFFECT_SIZE="0.20234227046476427" MODIFIED="2013-08-22 14:53:54 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.3015079496521667" STUDY_ID="STD-Cinciripini-2013" TOTAL_1="102" TOTAL_2="106" VAR="0.09090704370345348" WEIGHT="2.044183630030549"/>
<DICH_DATA CI_END="2.1324815850753076" CI_START="0.8336661803881398" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" LOG_CI_END="0.32888528953020096" LOG_CI_START="-0.07900781631360113" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-07-02 14:14:29 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.23959842947608695" STUDY_ID="STD-Cox-2012" TOTAL_1="270" TOTAL_2="270" VAR="0.05740740740740741" WEIGHT="3.751678191585478"/>
<DICH_DATA CI_END="5.323541925972373" CI_START="1.249581207577302" EFFECT_SIZE="2.579185520361991" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="8" LOG_CI_END="0.72620067873703" LOG_CI_START="0.09676448523773143" LOG_EFFECT_SIZE="0.41148258198738075" ORDER="1230" O_E="0.0" SE="0.3697339358208961" STUDY_ID="STD-Dalsgar_x00f0_-2004" TOTAL_1="221" TOTAL_2="114" VAR="0.13670318329761053" WEIGHT="1.4666593792643727"/>
<DICH_DATA CI_END="1.7250900173636334" CI_START="0.8459501412352303" EFFECT_SIZE="1.2080315160757402" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="43" LOG_CI_END="0.23681176203207296" LOG_CI_START="-0.07265523273462553" LOG_EFFECT_SIZE="0.0820782646487237" MODIFIED="2013-07-02 14:57:59 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.1817824446122887" STUDY_ID="STD-Eisenberg-2013" TOTAL_1="183" TOTAL_2="194" VAR="0.033044857169219816" WEIGHT="5.800561094328741"/>
<DICH_DATA CI_END="2.7831017825538176" CI_START="1.2622971378888377" EFFECT_SIZE="1.874326923076923" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="26" LOG_CI_END="0.44452908947927056" LOG_CI_START="0.10116159750400144" LOG_EFFECT_SIZE="0.27284534349163597" MODIFIED="2009-07-29 15:00:49 +0100" MODIFIED_BY="Lindsay Stead" ORDER="240" O_E="0.0" SE="0.20169576448277068" STUDY_ID="STD-Fossati-2007" TOTAL_1="400" TOTAL_2="193" VAR="0.0406811814102893" WEIGHT="4.873830890324024"/>
<DICH_DATA CI_END="10.37923812074336" CI_START="1.5143758155593516" EFFECT_SIZE="3.9646017699115044" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="1.016165475660732" LOG_CI_START="0.18023366536871685" LOG_EFFECT_SIZE="0.5981995705147243" ORDER="1238" O_E="0.0" SE="0.49103048329472615" STUDY_ID="STD-Gonzales-2001" TOTAL_1="226" TOTAL_2="224" VAR="0.24111093552465232" WEIGHT="0.6978430216447062"/>
<DICH_DATA CI_END="2.9279813474837035" CI_START="1.2471322987106108" EFFECT_SIZE="1.9109108059951787" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="29" LOG_CI_END="0.466568305750185" LOG_CI_START="0.09591252689659248" LOG_EFFECT_SIZE="0.28124041632338875" ORDER="1240" O_E="0.0" SE="0.21772503927429648" STUDY_ID="STD-Gonzales-2006" TOTAL_1="329" TOTAL_2="344" VAR="0.04740419272699394" WEIGHT="3.9397679407756367"/>
<DICH_DATA CI_END="3.5533668327223173" CI_START="1.0423379738493495" EFFECT_SIZE="1.9245283018867925" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.5506400443042505" LOG_CI_START="0.018008560018006436" LOG_EFFECT_SIZE="0.28432430216112853" ORDER="1241" O_E="0.0" SE="0.31287037043810906" STUDY_ID="STD-Haggstr_x00e4_m-2006" TOTAL_1="53" TOTAL_2="51" VAR="0.09788786869807957" WEIGHT="1.557854975565765"/>
<DICH_DATA CI_END="10.999253275213881" CI_START="0.20455934086636887" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.0413632024798651" LOG_CI_START="-0.6891806843685024" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1231" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Hertzberg-2001" TOTAL_1="10" TOTAL_2="5" VAR="1.0333333333333332" WEIGHT="0.18526805884372732"/>
<DICH_DATA CI_END="4.975994504154581" CI_START="0.7929350590265837" EFFECT_SIZE="1.9863636363636363" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="0.6968798920170354" LOG_CI_START="-0.10076237972060419" LOG_EFFECT_SIZE="0.2980587561482156" ORDER="1242" O_E="0.0" SE="0.4685390188116135" STUDY_ID="STD-Holt-2005" TOTAL_1="88" TOTAL_2="46" VAR="0.21952881214894948" WEIGHT="0.91251431967806"/>
<DICH_DATA CI_END="2.5625080424919373" CI_START="0.7357402222445212" EFFECT_SIZE="1.373076923076923" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.40866523710942554" LOG_CI_START="-0.133275500826675" LOG_EFFECT_SIZE="0.13769486814137524" ORDER="1239" O_E="0.0" SE="0.3183386721135834" STUDY_ID="STD-Hurt-1997" TOTAL_1="156" TOTAL_2="153" VAR="0.10133951016303956" WEIGHT="2.1045012509433105"/>
<DICH_DATA CI_END="6.519433294867828" CI_START="1.6488854099851884" EFFECT_SIZE="3.278688524590164" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="9" LOG_CI_END="0.8142098460987333" LOG_CI_START="0.21719047520769508" LOG_EFFECT_SIZE="0.5157001606532142" ORDER="1234" O_E="0.0" SE="0.3506921337549441" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="160" VAR="0.12298497267759562" WEIGHT="1.5105766976020738"/>
<DICH_DATA CI_END="2.1357628221662064" CI_START="0.9499646474393186" EFFECT_SIZE="1.4243943191311612" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="35" LOG_CI_END="0.3295530223529506" LOG_CI_START="-0.02229255650873887" LOG_EFFECT_SIZE="0.15363023292210584" ORDER="1243" O_E="0.0" SE="0.20667583468706094" STUDY_ID="STD-Jorenby-2006" TOTAL_1="342" TOTAL_2="341" VAR="0.042714900643593345" WEIGHT="4.870407022751279"/>
<DICH_DATA CI_END="3.0967871401854534" CI_START="0.9478562195239575" EFFECT_SIZE="1.713274336283186" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" LOG_CI_END="0.49091135484987697" LOG_CI_START="-0.023257535871966602" LOG_EFFECT_SIZE="0.23382690948895515" MODIFIED="2013-09-12 11:27:20 +0100" MODIFIED_BY="Lindsay Stead" ORDER="257" O_E="0.0" SE="0.30202535158706806" STUDY_ID="STD-McCarthy-2008" TOTAL_1="113" TOTAL_2="121" VAR="0.09121931300129209" WEIGHT="2.0130087162828065">
<FOOTNOTE>Counselling arms</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.4190287455571426" CI_START="0.7818519434398581" EFFECT_SIZE="1.3752535496957403" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" LOG_CI_END="0.38364102915670045" LOG_CI_START="-0.10687547997703385" LOG_EFFECT_SIZE="0.13838277458983334" MODIFIED="2013-09-12 11:27:39 +0100" MODIFIED_BY="Lindsay Stead" ORDER="241" O_E="0.0" SE="0.2881318255610356" STUDY_ID="STD-McCarthy-2008" TOTAL_1="116" TOTAL_2="113" VAR="0.08301994890113507" WEIGHT="2.3931131793001983">
<FOOTNOTE>Pscyhoeducation arms</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.023758037840486" CI_START="0.5484770141802915" EFFECT_SIZE="1.4855769230769231" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6046318572391892" LOG_CI_START="-0.26084156831504296" LOG_EFFECT_SIZE="0.1718951444620731" ORDER="391" O_E="0.0" SE="0.5083833743331065" STUDY_ID="STD-Muramoto-2007" TOTAL_1="104" TOTAL_2="103" VAR="0.2584536552983155" WEIGHT="0.8377338312933758"/>
<DICH_DATA CI_END="3.704257040124485" CI_START="0.4724587111497075" EFFECT_SIZE="1.3229166666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5687011149522657" LOG_CI_START="-0.32563613911948874" LOG_EFFECT_SIZE="0.12153248791638847" ORDER="1244" O_E="0.0" SE="0.5253381300825547" STUDY_ID="STD-Nides-2006" TOTAL_1="128" TOTAL_2="127" VAR="0.27598015091863515" WEIGHT="0.8369757011293093"/>
<DICH_DATA CI_END="2.2561498367461423" CI_START="0.8598945818271262" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="21" LOG_CI_END="0.3533679388889403" LOG_CI_START="-0.06555478752038037" LOG_EFFECT_SIZE="0.14390657568427997" MODIFIED="2009-07-23 19:00:33 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1233" O_E="0.0" SE="0.24607728319377492" STUDY_ID="STD-Piper-2007" TOTAL_1="224" TOTAL_2="156" VAR="0.060554029304029304" WEIGHT="3.4401353242140527"/>
<DICH_DATA CI_END="2.1179230501765183" CI_START="0.6902520968948512" EFFECT_SIZE="1.209090909090909" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="10" LOG_CI_END="0.3259101769750483" LOG_CI_START="-0.16099226535732686" LOG_EFFECT_SIZE="0.08245895580886071" MODIFIED="2013-09-03 13:43:51 +0100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.28600890483199803" STUDY_ID="STD-Piper-2009" TOTAL_1="264" TOTAL_2="38" VAR="0.08180109364319892" WEIGHT="2.429342758348213"/>
<DICH_DATA CI_END="1.4884649830088992" CI_START="0.5839043227075914" EFFECT_SIZE="0.9322666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.1727386220765351" LOG_CI_START="-0.23365830960724193" LOG_EFFECT_SIZE="-0.030459843765353416" MODIFIED="2013-06-26 15:26:09 +0100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.23871956936830668" STUDY_ID="STD-Planer-2011" TOTAL_1="75" TOTAL_2="76" VAR="0.056987032799389783" WEIGHT="3.4507709635628023"/>
<DICH_DATA CI_END="2.6480852321048074" CI_START="0.8566714367580373" EFFECT_SIZE="1.506166982922201" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" LOG_CI_END="0.4229319593315184" LOG_CI_START="-0.06718571315654748" LOG_EFFECT_SIZE="0.17787312308748546" ORDER="1245" O_E="0.0" SE="0.28789754694109665" STUDY_ID="STD-Rigotti-2006" TOTAL_1="124" TOTAL_2="127" VAR="0.08288499753470095" WEIGHT="2.3339346695771543"/>
<DICH_DATA CI_END="1.7467125142740394" CI_START="0.2670096254095267" EFFECT_SIZE="0.6829268292682927" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24222143174969704" LOG_CI_START="-0.5734730825047295" LOG_EFFECT_SIZE="-0.16562582537751624" ORDER="390" O_E="0.0" SE="0.47914299542601574" STUDY_ID="STD-Simon-2009" TOTAL_1="41" TOTAL_2="42" VAR="0.22957801006581494" WEIGHT="1.2354924165060612"/>
<DICH_DATA CI_END="2.226624137820237" CI_START="0.6587088379431306" EFFECT_SIZE="1.2110726643598615" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.3476469127470291" LOG_CI_START="-0.18130650955957367" LOG_EFFECT_SIZE="0.08317020159372775" ORDER="1248" O_E="0.0" SE="0.3107098586245673" STUDY_ID="STD-Tashkin-2001" TOTAL_1="204" TOTAL_2="200" VAR="0.0965406162464986" WEIGHT="2.3855555497650234"/>
<DICH_DATA CI_END="2.9582037912289705" CI_START="1.214735312614868" EFFECT_SIZE="1.8956356736242885" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="20" LOG_CI_END="0.47102808932198076" LOG_CI_START="0.08448165670489075" LOG_EFFECT_SIZE="0.2777548730134357" ORDER="1235" O_E="0.0" SE="0.22705928795497957" STUDY_ID="STD-Tonnesen-2003" TOTAL_1="527" TOTAL_2="180" VAR="0.05155592024662233" WEIGHT="4.142981627042898"/>
<DICH_DATA CI_END="3.5172766069773567" CI_START="1.5632027342205153" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="29" LOG_CI_END="0.5462065236084376" LOG_CI_START="0.19401530600612288" LOG_EFFECT_SIZE="0.3701109148072802" ORDER="1236" O_E="0.0" SE="0.20687886459424357" STUDY_ID="STD-Tonstad-2003" TOTAL_1="313" TOTAL_2="313" VAR="0.04279886461580336" WEIGHT="4.02958027985107"/>
<DICH_DATA CI_END="4.081546072323049" CI_START="0.6366567849425291" EFFECT_SIZE="1.612" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.6108247031612354" LOG_CI_START="-0.19609462822309173" LOG_EFFECT_SIZE="0.20736503746907187" ORDER="1247" O_E="0.0" SE="0.47398840957026356" STUDY_ID="STD-Uyar-2007" TOTAL_1="50" TOTAL_2="31" VAR="0.2246650124069479" WEIGHT="0.8577224946468858"/>
<DICH_DATA CI_END="3.50362642318525" CI_START="1.041840165704785" EFFECT_SIZE="1.9105545617173525" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.5445177929873354" LOG_CI_START="0.01780109662489327" LOG_EFFECT_SIZE="0.2811594448061143" ORDER="1246" O_E="0.0" SE="0.3093959947329953" STUDY_ID="STD-Wagena-2005" TOTAL_1="86" TOTAL_2="89" VAR="0.09572588155681963" WEIGHT="1.77539734103389"/>
<DICH_DATA CI_END="2.197107992236128" CI_START="0.7934051512497178" EFFECT_SIZE="1.3203017832647461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="27" LOG_CI_END="0.34185140388436785" LOG_CI_START="-0.10050498415924054" LOG_EFFECT_SIZE="0.12067320986256362" MODIFIED="2013-07-02 11:30:35 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.2598423320362514" STUDY_ID="STD-Wittchen-2011" TOTAL_1="108" TOTAL_2="175" VAR="0.06751803751803752" WEIGHT="2.8634716939309657"/>
<DICH_DATA CI_END="1.4974758638421168" CI_START="0.774368387316768" EFFECT_SIZE="1.0768463073852295" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="36" LOG_CI_END="0.17535983120514995" LOG_CI_START="-0.11105238490178249" LOG_EFFECT_SIZE="0.03215372315168373" ORDER="1237" O_E="0.0" SE="0.16823995350454723" STUDY_ID="STD-Zellweger-2005" TOTAL_1="501" TOTAL_2="166" VAR="0.02830468195521222" WEIGHT="7.514605793040778"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.6814912287983" CI_START="0.32185144259579535" DF="0" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="1.4096202379963167" LOG_CI_START="-0.4923445399450183" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2009-07-29 15:00:51 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="1.0" P_Z="0.3445325778893604" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="23" WEIGHT="0.14190744932711027" Z="0.9452474372424133">
<NAME>Low intensity support</NAME>
<DICH_DATA CI_END="25.6814912287983" CI_START="0.32185144259579535" EFFECT_SIZE="2.875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4096202379963167" LOG_CI_START="-0.4923445399450183" LOG_EFFECT_SIZE="0.4586378490256493" MODIFIED="2009-07-29 15:00:10 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1249" O_E="0.0" SE="1.1172235254402323" STUDY_ID="STD-Myles-2004" TOTAL_1="24" TOTAL_2="23" VAR="1.2481884057971013" WEIGHT="0.14190744932711027"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9554334125682624" CI_END="1.259232571149241" CI_START="0.929200868515592" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0817023614539245" ESTIMABLE="YES" EVENTS_1="254" EVENTS_2="235" I2="49.43664090905779" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.10010594856600628" LOG_CI_START="-0.031890392940514184" LOG_EFFECT_SIZE="0.03410777781274606" METHOD="MH" MODIFIED="2009-08-05 12:14:28 +0100" MODIFIED_BY="Lindsay Stead" NO="4" P_CHI2="0.13838503306386885" P_Q="1.0" P_Z="0.3111045480032595" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1021" TOTAL_2="1021" WEIGHT="100.0" Z="1.0129071054954097">
<NAME>Bupropion dose response. 300 mg/day versus 150 mg/day</NAME>
<GROUP_LABEL_1>300 mg/day bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>150 mg/day bupropion</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 150mg dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 300mg dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5488740388606566" CI_START="0.5177266034924813" EFFECT_SIZE="0.8954849498327759" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.19001610048865528" LOG_CI_START="-0.285899518129728" LOG_EFFECT_SIZE="-0.047941708820536395" ORDER="1220" O_E="0.0" SE="0.27955519019674474" STUDY_ID="STD-Hurt-1997" TOTAL_1="156" TOTAL_2="153" VAR="0.07815110436593811" WEIGHT="9.884857719526936"/>
<DICH_DATA CI_END="20.524873219101607" CI_START="1.0056722437654078" EFFECT_SIZE="4.543269230769231" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3122804831890602" LOG_CI_START="0.0024564639039427135" LOG_EFFECT_SIZE="0.6573684735465014" MODIFIED="2009-07-21 17:26:23 +0100" MODIFIED_BY="Lindsay Stead" ORDER="384" O_E="0.0" SE="0.7693971126615416" STUDY_ID="STD-Muramoto-2007" TOTAL_1="104" TOTAL_2="105" VAR="0.5919719169719171" WEIGHT="0.8472147660588928"/>
<DICH_DATA CI_END="1.254089340148402" CI_START="0.9120291791936173" EFFECT_SIZE="1.0694699956197986" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="210" LOG_CI_END="0.09832847632834604" LOG_CI_START="-0.03999126675924361" LOG_EFFECT_SIZE="0.029168604784551216" ORDER="1221" O_E="0.0" SE="0.08124970178342104" STUDY_ID="STD-Swan-2003" TOTAL_1="761" TOTAL_2="763" VAR="0.006601514039894852" WEIGHT="89.26792751441417"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.099201062832798" CI_END="1.5069675351578786" CI_START="0.9440256159845715" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1927346543327093" ESTIMABLE="YES" EVENTS_1="360" EVENTS_2="342" I2="52.37930537043863" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.1781038963400732" LOG_CI_START="-0.025016221030521486" LOG_EFFECT_SIZE="0.07654383765477583" METHOD="MH" MODIFIED="2013-11-26 15:14:30 +0000" MODIFIED_BY="Lindsay Stead" NO="5" P_CHI2="0.017114303696831756" P_Q="0.5119058579313962" P_Z="0.13962560559367262" Q="1.3392292439595817" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06838351897855606" TOTALS="YES" TOTAL_1="1648" TOTAL_2="1839" WEIGHT="100.0" Z="1.4771866714523678">
<NAME>Bupropion and NRT versus NRT alone</NAME>
<GROUP_LABEL_1>Bupropion &amp; NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRT alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Bupropion + NRT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.00850270789176" CI_END="1.8434151553983606" CI_START="0.8350945290377626" DF="8" EFFECT_SIZE="1.2407360359957584" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="102" I2="50.02655684934097" ID="CMP-001.05.01" LOG_CI_END="0.2656231536642582" LOG_CI_START="-0.07826436150339479" LOG_EFFECT_SIZE="0.0936793960804317" MODIFIED="2013-10-23 17:14:31 +0100" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.04225860325297226" P_Z="0.2855931787668945" STUDIES="9" TAU2="0.1554769133902666" TOTAL_1="874" TOTAL_2="900" WEIGHT="51.677498242375265" Z="1.067838954965234">
<NAME>Patch alone</NAME>
<DICH_DATA CI_END="8.564008407165172" CI_START="0.284165998478458" EFFECT_SIZE="1.56" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9326770849633221" LOG_CI_START="-0.5464278882543989" LOG_EFFECT_SIZE="0.1931245983544616" MODIFIED="2013-10-23 17:08:04 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1154" O_E="0.0" SE="0.8688335829557895" STUDY_ID="STD-Evins-2007" TOTAL_1="25" TOTAL_2="26" VAR="0.7548717948717948" WEIGHT="1.7292052246204768"/>
<DICH_DATA CI_END="159.9412453779377" CI_START="0.5064359715881839" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2039604733159854" LOG_CI_START="-0.2954754544373356" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2013-10-23 17:08:05 +0100" MODIFIED_BY="Lindsay Stead" ORDER="212" O_E="0.0" SE="1.4681810363696828" STUDY_ID="STD-George-2008" TOTAL_1="29" TOTAL_2="29" VAR="2.155555555555556" WEIGHT="0.640115282926453"/>
<DICH_DATA CI_END="1.5723688678825776" CI_START="0.2164109101422309" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.19655443641957582" LOG_CI_START="-0.6647208484863117" LOG_EFFECT_SIZE="-0.23408320603336796" MODIFIED="2013-10-23 17:08:06 +0100" MODIFIED_BY="Lindsay Stead" ORDER="241" O_E="0.0" SE="0.5059173657351376" STUDY_ID="STD-Grant-2007" TOTAL_1="30" TOTAL_2="28" VAR="0.255952380952381" WEIGHT="4.389206961701522"/>
<DICH_DATA CI_END="3.563356672763342" CI_START="1.461810524950586" EFFECT_SIZE="2.2823129251700682" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="24" LOG_CI_END="0.5518592950594996" LOG_CI_START="0.16489108445417014" LOG_EFFECT_SIZE="0.3583751897568348" MODIFIED="2013-09-26 11:23:58 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1155" O_E="0.0" SE="0.22730704243310615" STUDY_ID="STD-Jorenby-1999" TOTAL_1="245" TOTAL_2="244" VAR="0.05166849153968592" WEIGHT="11.858005407500308"/>
<DICH_DATA CI_END="3.741952243903251" CI_START="0.11168409212318789" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5730982405820452" LOG_CI_START="-0.9520086818093707" LOG_EFFECT_SIZE="-0.1894552206136627" MODIFIED="2013-10-23 16:47:14 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.8958553556137386" STUDY_ID="STD-Kalman-2011" TOTAL_1="66" TOTAL_2="64" VAR="0.8025568181818181" WEIGHT="1.634529174005246"/>
<DICH_DATA CI_END="2.689820286328789" CI_START="0.40874250001073165" EFFECT_SIZE="1.0485436893203883" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.42972326466300825" LOG_CI_START="-0.38855020309945326" LOG_EFFECT_SIZE="0.02058653078177749" ORDER="1156" O_E="0.0" SE="0.48065788548266125" STUDY_ID="STD-Killen-2004" TOTAL_1="103" TOTAL_2="108" VAR="0.2310320028766631" WEIGHT="4.754521011756234"/>
<DICH_DATA CI_END="3.8113170511039858" CI_START="0.9416727544139575" EFFECT_SIZE="1.89446916719644" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.581075077824291" LOG_CI_START="-0.026099994918354297" LOG_EFFECT_SIZE="0.2774875414529684" MODIFIED="2013-09-03 11:40:56 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.35665764329411304" STUDY_ID="STD-Rose-2013" TOTAL_1="143" TOTAL_2="149" VAR="0.12720467452011078" WEIGHT="7.278442345837712"/>
<DICH_DATA CI_END="1.806684210104722" CI_START="0.6186411837856535" EFFECT_SIZE="1.05720823798627" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.2568822489670729" LOG_CI_START="-0.20856117179566566" LOG_EFFECT_SIZE="0.024160538585703634" MODIFIED="2013-08-16 11:18:56 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.27340376933812355" STUDY_ID="STD-Schnoll-2010" TOTAL_1="114" TOTAL_2="132" VAR="0.07474962108829386" WEIGHT="9.945826586643173"/>
<DICH_DATA CI_END="1.3847366376095107" CI_START="0.44977024874915716" EFFECT_SIZE="0.7891852393131166" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.14136718299694526" LOG_CI_START="-0.3470092755153307" LOG_EFFECT_SIZE="-0.10282104625919274" ORDER="1157" O_E="0.0" SE="0.2868747492325695" STUDY_ID="STD-Simon-2004" TOTAL_1="119" TOTAL_2="120" VAR="0.08229712174724962" WEIGHT="9.44764624738415"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.323605022023631" CI_END="1.8077247348468355" CI_START="0.8051314742603379" DF="1" EFFECT_SIZE="1.206422844952843" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="139" I2="76.87115277861442" ID="CMP-001.05.02" LOG_CI_END="0.25713230045441143" LOG_CI_START="-0.09413319555317674" LOG_EFFECT_SIZE="0.08149955245061737" MODIFIED="2013-10-23 17:28:09 +0100" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.037587404886272546" P_Z="0.36309166575813623" STUDIES="2" TAU2="0.06563050769685135" TOTAL_1="530" TOTAL_2="521" WEIGHT="32.38770636488553" Z="0.9094897698457263">
<NAME>Lozenge alone</NAME>
<DICH_DATA CI_END="1.2648754852773956" CI_START="0.778567619937705" EFFECT_SIZE="0.9923664122137404" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="87" LOG_CI_END="0.10204777553674808" LOG_CI_START="-0.10870366223460308" LOG_EFFECT_SIZE="-0.003327943348927497" MODIFIED="2013-10-23 17:10:08 +0100" MODIFIED_BY="Lindsay Stead" ORDER="411" O_E="0.0" SE="0.12379643778333373" STUDY_ID="STD-Piper-2009" TOTAL_1="262" TOTAL_2="260" VAR="0.01532555800784282" WEIGHT="17.0062487982982"/>
<DICH_DATA CI_END="2.0319858864149043" CI_START="1.104750040599245" EFFECT_SIZE="1.4982778415614237" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="52" LOG_CI_END="0.30792068713874504" LOG_CI_START="0.04326402619452805" LOG_EFFECT_SIZE="0.17559235666663658" MODIFIED="2013-10-23 17:28:09 +0100" MODIFIED_BY="Lindsay Stead" ORDER="219" O_E="0.0" SE="0.1554606327102333" STUDY_ID="STD-Smith-2009" TOTAL_1="268" TOTAL_2="261" VAR="0.024168008322666065" WEIGHT="15.381457566587333"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2839733580037511" CI_START="0.7279873994489061" DF="0" EFFECT_SIZE="0.9668073364713521" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="101" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.10855601236834961" LOG_CI_START="-0.13787613771604043" LOG_EFFECT_SIZE="-0.014660062673845387" MODIFIED="2013-10-23 17:28:11 +0100" MODIFIED_BY="Lindsay Stead" NO="3" P_CHI2="1.0" P_Z="0.815611108704098" STUDIES="1" TAU2="0.0" TOTAL_1="244" TOTAL_2="418" WEIGHT="15.934795392739199" Z="0.23319355726919014">
<NAME>Choice of NRT</NAME>
<DICH_DATA CI_END="1.2839733580037511" CI_START="0.7279873994489061" EFFECT_SIZE="0.9668073364713521" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="101" LOG_CI_END="0.10855601236834961" LOG_CI_START="-0.13787613771604043" LOG_EFFECT_SIZE="-0.014660062673845387" MODIFIED="2013-10-23 17:28:11 +0100" MODIFIED_BY="Lindsay Stead" ORDER="261" O_E="0.0" SE="0.14475546481838725" STUDY_ID="STD-Stapleton-2013" TOTAL_1="244" TOTAL_2="418" VAR="0.02095414459478735" WEIGHT="15.934795392739199"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4034436374567303" CI_END="1.3304024602700224" CI_START="1.0000205073550958" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1534425617713677" ESTIMABLE="YES" EVENTS_1="291" EVENTS_2="251" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.1239830393388732" LOG_CI_START="8.906139836181868E-6" LOG_EFFECT_SIZE="0.06199597273935468" METHOD="MH" MODIFIED="2013-11-26 15:14:56 +0000" MODIFIED_BY="Lindsay Stead" NO="6" P_CHI2="0.8453444084383606" P_Q="1.0" P_Z="0.04996709252821258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="982" TOTAL_2="977" WEIGHT="100.0" Z="1.9602455870464757">
<NAME>Bupropion for relapse prevention</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.034682368167973" CI_START="0.9323840007044027" EFFECT_SIZE="1.3773544520547945" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" LOG_CI_END="0.3084966216601877" LOG_CI_START="-0.030405187388062863" LOG_EFFECT_SIZE="0.1390457171360624" MODIFIED="2009-07-29 15:51:00 +0100" MODIFIED_BY="Lindsay Stead" ORDER="313" O_E="0.0" SE="0.19907260022595297" STUDY_ID="STD-Covey-2007" TOTAL_1="146" TOTAL_2="143" VAR="0.039629900160722084" WEIGHT="12.850890757796689"/>
<DICH_DATA CI_END="1.4383684318842844" CI_START="0.6704781214516169" EFFECT_SIZE="0.9820359281437125" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" LOG_CI_END="0.15787014295915872" LOG_CI_START="-0.17361538915892952" LOG_EFFECT_SIZE="-0.007872623099885408" MODIFIED="2009-07-29 15:51:00 +0100" MODIFIED_BY="Lindsay Stead" ORDER="314" O_E="0.0" SE="0.19471624244601282" STUDY_ID="STD-Croghan-2007" TOTAL_1="167" TOTAL_2="164" VAR="0.03791441507229444" WEIGHT="16.04267218069832"/>
<DICH_DATA CI_END="2.0135925670136983" CI_START="0.8750542097093451" EFFECT_SIZE="1.3274044795783926" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.30397159938630697" LOG_CI_START="-0.0579650415509736" LOG_EFFECT_SIZE="0.12300327891766669" MODIFIED="2013-09-09 11:03:25 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.21260337450182606" STUDY_ID="STD-Hall-2011" TOTAL_1="66" TOTAL_2="65" VAR="0.04520019484956371" WEIGHT="9.211465212974034">
<FOOTNOTE>Neither arm provided with CBT</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6079068338159226" CI_START="0.6236177471666974" EFFECT_SIZE="1.0013586956521738" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.2062608810219818" LOG_CI_START="-0.20508153397887663" LOG_EFFECT_SIZE="5.896735215525865E-4" MODIFIED="2013-09-09 11:03:27 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.24162457074929758" STUDY_ID="STD-Hall-2011" TOTAL_1="64" TOTAL_2="67" VAR="0.05838243318978231" WEIGHT="8.93232990348997">
<FOOTNOTE>Both arms provided with CBT</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5132216267374334" CI_START="0.8176249932977547" EFFECT_SIZE="1.1123164218958612" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="56" LOG_CI_END="0.17990253953691804" LOG_CI_START="-0.08744584141998209" LOG_EFFECT_SIZE="0.04622834905846798" MODIFIED="2013-09-09 11:00:46 +0100" MODIFIED_BY="Lindsay Stead" ORDER="316" O_E="0.0" SE="0.15704176236991232" STUDY_ID="STD-Hays-2001" TOTAL_1="214" TOTAL_2="215" VAR="0.024662115128248015" WEIGHT="22.206123386047746"/>
<DICH_DATA CI_END="1.551388933807766" CI_START="0.5993641687860127" EFFECT_SIZE="0.9642857142857143" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.19072068925889255" LOG_CI_START="-0.22230922362535638" LOG_EFFECT_SIZE="-0.015794267183231903" MODIFIED="2013-08-21 15:33:20 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.24261581535925036" STUDY_ID="STD-Hays-2009" TOTAL_1="56" TOTAL_2="54" VAR="0.058862433862433866" WEIGHT="8.498511707090236"/>
<DICH_DATA CI_END="2.773453343274862" CI_START="0.7701931167278759" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.4430208643094256" LOG_CI_START="-0.11340036701744113" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-07-29 15:51:00 +0100" MODIFIED_BY="Lindsay Stead" ORDER="312" O_E="0.0" SE="0.32684458561091784" STUDY_ID="STD-Hurt-2003" TOTAL_1="88" TOTAL_2="88" VAR="0.10682738314317261" WEIGHT="5.167037304906053"/>
<DICH_DATA CI_END="1.6823871786954165" CI_START="0.8361370946939441" EFFECT_SIZE="1.186046511627907" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="43" LOG_CI_END="0.22592594997602455" LOG_CI_START="-0.07772250893932484" LOG_EFFECT_SIZE="0.07410172051834987" MODIFIED="2009-07-29 15:51:00 +0100" MODIFIED_BY="Lindsay Stead" ORDER="315" O_E="0.0" SE="0.17836460785098932" STUDY_ID="STD-Killen-2006" TOTAL_1="181" TOTAL_2="181" VAR="0.0318139333338372" WEIGHT="17.090969546996945"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.151075580242141" CI_END="1.0855128230033773" CI_START="0.8548733136388345" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9633150803337103" ESTIMABLE="YES" EVENTS_1="342" EVENTS_2="658" I2="27.397893689180577" I2_Q="41.99833837152406" ID="CMP-001.07" LOG_CI_END="0.03563495807760181" LOG_CI_START="-0.0680982399667026" LOG_EFFECT_SIZE="-0.016231640944550405" METHOD="MH" MODIFIED="2013-10-23 17:55:01 +0100" MODIFIED_BY="Lindsay Stead" NO="7" P_CHI2="0.17568464154567476" P_Q="0.15960921778298454" P_Z="0.5396315195780017" Q="5.1722656140719065" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1495" TOTAL_2="2591" WEIGHT="100.0" Z="0.6133703049956487">
<NAME>Bupropion versus NRT</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favour NRT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bupropion</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.676404207206955" CI_END="1.2716612264157696" CI_START="0.8447000019463229" DF="5" EFFECT_SIZE="1.036422809681678" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="214" I2="48.327913004336715" ID="CMP-001.07.01" LOG_CI_END="0.10437142963467176" LOG_CI_START="-0.07329750481667162" LOG_EFFECT_SIZE="0.015536962409000071" MODIFIED="2013-09-26 11:52:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08494103320470414" P_Z="0.7317537422676914" STUDIES="6" TAU2="0.0" TOTAL_1="631" TOTAL_2="1003" WEIGHT="33.66375268132488" Z="0.3427935991717495">
<NAME>Patch</NAME>
<DICH_DATA CI_END="1.1471558610848298" CI_START="0.41679675135341965" EFFECT_SIZE="0.691470054446461" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="29" LOG_CI_END="0.05962242837247182" LOG_CI_START="-0.3800756747248032" LOG_EFFECT_SIZE="-0.1602266231761657" MODIFIED="2013-06-26 14:14:43 +0100" MODIFIED_BY="[Empty name]" ORDER="407" O_E="0.0" SE="0.2582808423000525" STUDY_ID="STD-Gariti-2009" TOTAL_1="133" TOTAL_2="127" VAR="0.06670899349922457" WEIGHT="7.020023471704115"/>
<DICH_DATA CI_END="2.1069888227609503" CI_START="0.27857465959384997" EFFECT_SIZE="0.7661290322580645" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.32366223175137615" LOG_CI_START="-0.5550583914981507" LOG_EFFECT_SIZE="-0.11569807987338732" ORDER="1255" O_E="0.0" SE="0.5161648438340088" STUDY_ID="STD-G_x00f3_recka-2003" TOTAL_1="31" TOTAL_2="38" VAR="0.26642614601018677" WEIGHT="1.7008454924999203"/>
<DICH_DATA CI_END="2.977679320120449" CI_START="1.1806593733061188" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="24" LOG_CI_END="0.4738779247790984" LOG_CI_START="0.07212461934837679" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2013-09-18 16:09:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1253" O_E="0.0" SE="0.2359918803209413" STUDY_ID="STD-Jorenby-1999" TOTAL_1="244" TOTAL_2="244" VAR="0.05569216757741348" WEIGHT="5.678629305604574"/>
<DICH_DATA CI_END="1.3126672723140518" CI_START="0.6536023796026147" EFFECT_SIZE="0.9262626262626262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="90" LOG_CI_END="0.11815465746023533" LOG_CI_START="-0.18468637531529297" LOG_EFFECT_SIZE="-0.03326585892752884" MODIFIED="2013-09-26 11:52:58 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.17789032173963454" STUDY_ID="STD-Piper-2009" TOTAL_1="88" TOTAL_2="262" VAR="0.03164496656863069" WEIGHT="10.70827240485434">
<FOOTNOTE>Bupropion arm divided between 3 subgroups to avoid multiple counting in overall effect</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5952546691086313" CI_START="0.5409366454477984" EFFECT_SIZE="0.9289411764705883" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="50" LOG_CI_END="0.2028300244213035" LOG_CI_START="-0.26685359652672824" LOG_EFFECT_SIZE="-0.0320117860527124" MODIFIED="2013-07-02 10:24:45 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.27589448391629423" STUDY_ID="STD-Smith-2009" TOTAL_1="85" TOTAL_2="282" VAR="0.07611776625543834" WEIGHT="5.480057799459455"/>
<DICH_DATA CI_END="1.9373350120377655" CI_START="0.5161729870086643" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.28720472722347" LOG_CI_START="-0.28720472722347" LOG_EFFECT_SIZE="0.0" ORDER="1254" O_E="0.0" SE="0.3374109569147894" STUDY_ID="STD-Uyar-2007" TOTAL_1="50" TOTAL_2="50" VAR="0.11384615384615386" WEIGHT="3.075924207202477"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18536218352657963" CI_END="1.2162746276468357" CI_START="0.6737841713155779" DF="1" EFFECT_SIZE="0.9052660338713622" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="139" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.08503164714513368" LOG_CI_START="-0.17147919577556656" LOG_EFFECT_SIZE="-0.04322377431521643" MODIFIED="2013-07-02 10:24:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6668050011082864" P_Z="0.5089113395428326" STUDIES="2" TAU2="0.0" TOTAL_1="173" TOTAL_2="521" WEIGHT="16.45598935574042" Z="0.66053380020198">
<NAME>Lozenge</NAME>
<DICH_DATA CI_END="1.350187359322208" CI_START="0.6696762104539774" EFFECT_SIZE="0.9508881922675027" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="87" LOG_CI_END="0.13039403773492958" LOG_CI_START="-0.17413512864642955" LOG_EFFECT_SIZE="-0.021870545455749946" MODIFIED="2013-06-26 14:57:44 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.17888193977609568" STUDY_ID="STD-Piper-2009" TOTAL_1="88" TOTAL_2="260" VAR="0.03199874837805872" WEIGHT="10.410820393608384"/>
<DICH_DATA CI_END="1.414345914306192" CI_START="0.48321110563091174" EFFECT_SIZE="0.8266968325791855" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="52" LOG_CI_END="0.1505556402259223" LOG_CI_START="-0.3158630928910682" LOG_EFFECT_SIZE="-0.08265372633257294" MODIFIED="2013-07-02 10:24:46 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.2739766726428851" STUDY_ID="STD-Smith-2009" TOTAL_1="85" TOTAL_2="261" VAR="0.07506321715246664" WEIGHT="6.045168962132036"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4372307900540148" CI_END="0.9761507155208777" CI_START="0.5548371599105981" DF="1" EFFECT_SIZE="0.7359379665734755" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="182" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="-0.010483123044633377" LOG_CI_START="-0.2558344599929842" LOG_EFFECT_SIZE="-0.13315879151880877" MODIFIED="2013-10-23 17:55:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5084620948555113" P_Z="0.03338265419897542" STUDIES="2" TAU2="0.0" TOTAL_1="174" TOTAL_2="546" WEIGHT="20.914002054911627" Z="2.127450690490294">
<NAME>Patch + lozenge</NAME>
<DICH_DATA CI_END="1.1145899708019877" CI_START="0.5655754566497355" EFFECT_SIZE="0.7939677145284622" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="107" LOG_CI_END="0.047115130910248895" LOG_CI_START="-0.24750944516741658" LOG_EFFECT_SIZE="-0.10019715712858385" MODIFIED="2013-09-26 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.1730639344031933" STUDY_ID="STD-Piper-2009" TOTAL_1="88" TOTAL_2="267" VAR="0.029951125391112787" WEIGHT="12.551636981589827"/>
<DICH_DATA CI_END="1.0685528174339487" CI_START="0.3939812027132227" EFFECT_SIZE="0.6488372093023256" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="75" LOG_CI_END="0.02879599374687758" LOG_CI_START="-0.4045244983588556" LOG_EFFECT_SIZE="-0.18786425230598897" MODIFIED="2013-07-02 10:24:47 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.25453460203393724" STUDY_ID="STD-Smith-2009" TOTAL_1="86" TOTAL_2="279" VAR="0.0647878636325748" WEIGHT="8.362365073321802"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24542145899920337" CI_END="1.3316678559154878" CI_START="0.8686080733585078" DF="1" EFFECT_SIZE="1.0754986985953106" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="123" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.12439591677813498" LOG_CI_START="-0.06117613836458423" LOG_EFFECT_SIZE="0.03160988920677536" MODIFIED="2013-09-16 11:30:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6203176122687402" P_Z="0.5043181385035296" STUDIES="2" TAU2="0.0" TOTAL_1="517" TOTAL_2="521" WEIGHT="28.966255908023058" Z="0.6677109261190592">
<NAME>Choice of NRT</NAME>
<DICH_DATA CI_END="1.3935610171594317" CI_START="0.8729516833353557" EFFECT_SIZE="1.102955772349851" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="101" LOG_CI_END="0.1441259890776652" LOG_CI_START="-0.05900979322631635" LOG_EFFECT_SIZE="0.04255809792567444" MODIFIED="2013-09-16 11:30:57 +0100" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.11932296406369826" STUDY_ID="STD-Stapleton-2013" TOTAL_1="409" TOTAL_2="418" VAR="0.014237969752946627" WEIGHT="23.63749475868796"/>
<DICH_DATA CI_END="1.6133231265062935" CI_START="0.5637746955427492" EFFECT_SIZE="0.9537037037037037" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.20772135933217778" LOG_CI_START="-0.24889442089573277" LOG_EFFECT_SIZE="-0.02058653078177749" MODIFIED="2013-07-02 11:31:21 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.2682183695904402" STUDY_ID="STD-Wittchen-2011" TOTAL_1="108" TOTAL_2="103" VAR="0.07194109378575399" WEIGHT="5.328761149335097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.013761057680153" CI_END="0.8278769600325544" CI_START="0.5568317964624354" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6789611291559975" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="198" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.08203420373389424" LOG_CI_START="-0.2542759734084362" LOG_EFFECT_SIZE="-0.16815508857116523" METHOD="MH" MODIFIED="2013-09-03 13:36:28 +0100" MODIFIED_BY="Lindsay Stead" NO="8" P_CHI2="0.569555500041856" P_Q="1.0" P_Z="1.2975555619767858E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="901" TOTAL_2="909" WEIGHT="99.99999999999999" Z="3.8269220995508584">
<NAME>Bupropion versus varenicline</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Varenicline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours varenicline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bupropion</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3251667123878774" CI_START="0.49267353007817255" EFFECT_SIZE="0.8080065359477124" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.12227051805822366" LOG_CI_START="-0.3074407704829496" LOG_EFFECT_SIZE="-0.09258512621236298" MODIFIED="2013-08-22 14:54:17 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.25241453799426894" STUDY_ID="STD-Cinciripini-2013" TOTAL_1="102" TOTAL_2="86" VAR="0.06371309899086025" WEIGHT="13.200658137599628"/>
<DICH_DATA CI_END="1.0099892487984776" CI_START="0.5369663480662473" EFFECT_SIZE="0.7364307425097699" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="77" LOG_CI_END="0.0043167508001214355" LOG_CI_START="-0.2700529308871936" LOG_EFFECT_SIZE="-0.13286809004353609" ORDER="1256" O_E="0.0" SE="0.16116610917495722" STUDY_ID="STD-Gonzales-2006" TOTAL_1="329" TOTAL_2="352" VAR="0.02597451474659423" WEIGHT="37.712170712502605"/>
<DICH_DATA CI_END="0.8775943876216864" CI_START="0.46180290648186434" EFFECT_SIZE="0.6366126286179584" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="79" LOG_CI_END="-0.05670616281794627" LOG_CI_START="-0.3355433380601088" LOG_EFFECT_SIZE="-0.19612475043902752" ORDER="1257" O_E="0.0" SE="0.16379033700352438" STUDY_ID="STD-Jorenby-2006" TOTAL_1="342" TOTAL_2="344" VAR="0.02682727449572809" WEIGHT="39.92740651831765"/>
<DICH_DATA CI_END="0.9773130387168238" CI_START="0.198970537655897" EFFECT_SIZE="0.4409722222222222" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.009966307097920003" LOG_CI_START="-0.701211226508628" LOG_EFFECT_SIZE="-0.355588766803274" ORDER="1258" O_E="0.0" SE="0.4060406873793857" STUDY_ID="STD-Nides-2006" TOTAL_1="128" TOTAL_2="127" VAR="0.16486903980752404" WEIGHT="9.159764631580089"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-11-26 15:15:29 +0000" MODIFIED_BY="Lindsay Stead" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="448" TOTAL_2="473" WEIGHT="0.0" Z="0.0">
<NAME>Bupropion for harm reduction</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="153" TOTAL_2="174" WEIGHT="0.0" Z="0.0">
<NAME>Reduction in cotinine &gt;50% from baseline at 1y</NAME>
<DICH_DATA CI_END="1.5789959291178153" CI_START="0.11518532712834322" EFFECT_SIZE="0.4264705882352941" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.19838101033511607" LOG_CI_START="-0.9386028399496765" LOG_EFFECT_SIZE="-0.37011091480728026" ORDER="1259" O_E="0.0" SE="0.6678699418181159" STUDY_ID="STD-Hatsukami-2004" TOTAL_1="153" TOTAL_2="174" VAR="0.44605025918413344" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="16" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="295" TOTAL_2="299" WEIGHT="0.0" Z="0.0">
<NAME>Cessation at 6m</NAME>
<DICH_DATA CI_END="2.3965354752891623" CI_START="0.6697835987318989" EFFECT_SIZE="1.2669491525423728" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.37958386212325657" LOG_CI_START="-0.17406549141461047" LOG_EFFECT_SIZE="0.10275918535432305" ORDER="1260" O_E="0.0" SE="0.32521637087664307" STUDY_ID="STD-Hatsukami-2004" TOTAL_1="295" TOTAL_2="299" VAR="0.10576568788617426" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="Lindsay Stead" NO="2">
<NAME>Nortriptyline. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="5.960793520671819" CI_END="2.782555093341034" CI_START="1.4780438363764414" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0279887586203698" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="49" I2="16.118550614776733" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.4444437719275473" LOG_CI_START="0.1696873147178569" LOG_EFFECT_SIZE="0.3070655433227021" METHOD="MH" MODIFIED="2013-11-26 15:15:49 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.3100528630971173" P_Q="1.0" P_Z="1.1820146495645537E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="480" TOTAL_2="495" WEIGHT="100.00000000000001" Z="4.380879065902395">
<NAME>Nortriptyline versus placebo</NAME>
<GROUP_LABEL_1>Nortriptyline</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.312732274924334" CI_START="1.3526266460053034" EFFECT_SIZE="3.911764705882353" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.0535675093122492" LOG_CI_START="0.13117793853741214" LOG_EFFECT_SIZE="0.5923727239248306" MODIFIED="2013-11-12 15:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1298" O_E="0.0" SE="0.5418161997751526" STUDY_ID="STD-Da-Costa-2002" TOTAL_1="68" TOTAL_2="76" VAR="0.2935647943387881" WEIGHT="7.8442226221035005"/>
<DICH_DATA CI_END="2.7695617432550126" CI_START="0.7348136384255584" EFFECT_SIZE="1.4265734265734267" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.44241105153940835" LOG_CI_START="-0.1338227916177344" LOG_EFFECT_SIZE="0.15429412996083697" MODIFIED="2013-11-12 15:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1300" O_E="0.0" SE="0.3384826118740323" STUDY_ID="STD-Haggstr_x00e4_m-2006" TOTAL_1="52" TOTAL_2="51" VAR="0.11457047854106676" WEIGHT="23.06228330016495"/>
<DICH_DATA CI_END="3.811385903376553" CI_START="1.0707958485160807" EFFECT_SIZE="2.0202020202020203" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.5810829233778229" LOG_CI_START="0.029706678755039847" LOG_EFFECT_SIZE="0.3053948010664313" MODIFIED="2013-11-12 15:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1296" O_E="0.0" SE="0.3238811354478521" STUDY_ID="STD-Hall-1998" TOTAL_1="99" TOTAL_2="100" VAR="0.10489898989898991" WEIGHT="24.791731680617982"/>
<DICH_DATA CI_END="3.304208763118388" CI_START="0.4119325407958018" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5190674786623094" LOG_CI_START="-0.38517389940108293" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-11-12 15:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1299" O_E="0.0" SE="0.5311558615414471" STUDY_ID="STD-Hall-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.28212654924983693" WEIGHT="12.458471223340855"/>
<DICH_DATA CI_END="16.46150094598688" CI_START="1.4629678995430941" EFFECT_SIZE="4.907407407407407" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2164694312918736" LOG_CI_START="0.165234796935805" LOG_EFFECT_SIZE="0.6908521141138394" MODIFIED="2013-11-12 15:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1297" O_E="0.0" SE="0.6175004279161188" STUDY_ID="STD-Prochazka-1998" TOTAL_1="108" TOTAL_2="106" VAR="0.3813067784765898" WEIGHT="6.287452766919683"/>
<DICH_DATA CI_END="3.212299475172098" CI_START="0.9119211729686267" EFFECT_SIZE="1.7115384615384615" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.5068160267535632" LOG_CI_START="-0.04004270073333594" LOG_EFFECT_SIZE="0.2333866630101136" MODIFIED="2013-11-12 15:59:06 +0000" MODIFIED_BY="[Empty name]" ORDER="1301" O_E="0.0" SE="0.3212275235201634" STUDY_ID="STD-Wagena-2005" TOTAL_1="80" TOTAL_2="89" VAR="0.10318712186689714" WEIGHT="25.555838406853038"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.369731664438186" CI_END="1.554859031057689" CI_START="0.9440561346400442" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2115585857772155" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="97" I2="25.508381983208384" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.1916910204953431" LOG_CI_START="-0.025002181295574948" LOG_EFFECT_SIZE="0.08334441959988409" METHOD="MH" MODIFIED="2013-11-26 15:16:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2514198468114215" P_Q="1.0" P_Z="0.13163631079563015" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="809" TOTAL_2="835" WEIGHT="99.99999999999999" Z="1.5076805306128747">
<NAME>Nortriptyline and NRT versus NRT alone</NAME>
<GROUP_LABEL_1>Nortriptyline &amp; NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRT alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours nortriptyline+NRT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8665034689874955" CI_START="0.8442149512525288" EFFECT_SIZE="1.2552808988764046" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.27102880142049485" LOG_CI_START="-0.07354696065238542" LOG_EFFECT_SIZE="0.0987409203840547" MODIFIED="2013-11-12 15:59:09 +0000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.20240550831914092" STUDY_ID="STD-Aveyard-2008" TOTAL_1="445" TOTAL_2="456" VAR="0.04096798979792982" WEIGHT="41.40411860080979"/>
<DICH_DATA CI_END="1.5302868377155123" CI_START="0.24746878527519092" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.1847728428185121" LOG_CI_START="-0.6064795734482984" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2013-11-12 15:59:09 +0000" MODIFIED_BY="[Empty name]" ORDER="1304" O_E="0.0" SE="0.4647855860777537" STUDY_ID="STD-Hall-2004" TOTAL_1="39" TOTAL_2="40" VAR="0.21602564102564104" WEIGHT="10.346318614093693">
<FOOTNOTE>With brief behavioural support</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3843355634703918" CI_START="0.7535142891316746" EFFECT_SIZE="1.3403846153846153" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.37736737653297375" LOG_CI_START="-0.1229085076065533" LOG_EFFECT_SIZE="0.12722943446321022" MODIFIED="2013-11-12 15:59:09 +0000" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.29386453074912366" STUDY_ID="STD-Hall-2004" TOTAL_1="40" TOTAL_2="41" VAR="0.08635636243240263" WEIGHT="13.454471942607437">
<FOOTNOTE>With extended behavioural support</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.870339933775085" CI_START="1.039455165109177" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.6875592746048848" LOG_CI_START="0.016805761617840198" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2013-11-12 15:59:09 +0000" MODIFIED_BY="[Empty name]" ORDER="1302" O_E="0.0" SE="0.3940039338120281" STUDY_ID="STD-Prochazka-2004" TOTAL_1="79" TOTAL_2="79" VAR="0.155239099859353" WEIGHT="8.383170979624634"/>
<DICH_DATA CI_END="1.6525590512519457" CI_START="0.582736993848955" EFFECT_SIZE="0.9813293502613891" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.2181569871741157" LOG_CI_START="-0.2345274107506097" LOG_EFFECT_SIZE="-0.008185211788246992" MODIFIED="2013-11-12 15:59:09 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.26590905616489297" STUDY_ID="STD-Richmond-2013" TOTAL_1="206" TOTAL_2="219" VAR="0.07070762615050419" WEIGHT="26.411919862864433"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-11-26 16:42:36 +0000" MODIFIED_BY="Lindsay Stead" NO="3">
<NAME>Bupropion versus nortriptyline. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="0.7471053661650439" CI_END="1.8165697491597257" CI_START="0.9265821417840392" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2973823988618443" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.2592520777250963" LOG_CI_START="-0.03311607430271769" LOG_EFFECT_SIZE="0.1130680017111893" METHOD="MH" MODIFIED="2013-11-26 16:42:20 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.6882848697435395" P_Q="1.0" P_Z="0.12952946834713716" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="205" WEIGHT="99.99999999999999" Z="1.5159599951007097">
<NAME>Bupropion versus nortriptyline</NAME>
<GROUP_LABEL_1>Bupropion</GROUP_LABEL_1>
<GROUP_LABEL_2>Nortriptyline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours nortiptyline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours bupropion</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2646700299600986" CI_START="0.8036286505796986" EFFECT_SIZE="1.349056603773585" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.35500493279169165" LOG_CI_START="-0.09494458839110846" LOG_EFFECT_SIZE="0.1300301722002916" ORDER="1315" O_E="0.0" SE="0.2643025760288279" STUDY_ID="STD-Haggstr_x00e4_m-2006" TOTAL_1="53" TOTAL_2="52" VAR="0.06985585169547434" WEIGHT="36.81431481825338"/>
<DICH_DATA CI_END="4.107730172663647" CI_START="0.7154256454723362" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.613601908057677" LOG_CI_START="-0.14543549599094113" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="1314" O_E="0.0" SE="0.4458623284339052" STUDY_ID="STD-Hall-2002" TOTAL_1="73" TOTAL_2="73" VAR="0.19879321591650356" WEIGHT="15.954316858146363"/>
<DICH_DATA CI_END="1.8577399239978392" CI_START="0.6707499502510098" EFFECT_SIZE="1.1162790697674418" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.2689849144592998" LOG_CI_START="-0.17343935086729842" LOG_EFFECT_SIZE="0.04777278179600068" ORDER="1316" O_E="0.0" SE="0.25988220348827756" STUDY_ID="STD-Wagena-2005" TOTAL_1="86" TOTAL_2="80" VAR="0.0675387596899225" WEIGHT="47.23136832360024"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-11-26 16:56:19 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Bupropion and nortriptyline. Adverse events</NAME>
<OTHER_OUTCOME COLS="3" ID="CMP-004.01" MODIFIED="2013-11-26 16:56:19 +0000" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO">
<NAME>Nortriptyline vs placebo. 'No report' = no information, 'None occurred' = explicit statement</NAME>
<TR>
<TH>
<P>Serious events</P>
</TH>
<TH>
<P>Other adverse events</P>
</TH>
<TH>
<P>Withdrawal due to AE</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="186" STUDY_ID="STD-Aveyard-2008">
<TR>
<TD>
<P>2 admissions to hospital (1 intervention, 1 control) with collapse or palpitations judged possibly caused by treatment</P>
</TD>
<TD>
<P>Dry mouth (80% vs 'more than half, OR 6.67, 5.12 to 8.69), Constipation (OR 2.06, 1.66 to 2.56) and Sweating (OR 1.37, 1.11 to 1.68) significantly more common</P>
</TD>
<TD>
<P>No report</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="187" STUDY_ID="STD-Da-Costa-2002">
<TR>
<TD>
<P>None occurred</P>
</TD>
<TD>
<P>No significant differences between groups.<BR/>Dry mouth 44% vs 24%, constipation 29% vs 12%, irritation 18% vs 24%, anxiety 18% vs 28%.</P>
</TD>
<TD>
<P>No report</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="188" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<TR>
<TD>
<P>None occurred</P>
</TD>
<TD>
<P>Dry mouth (67.3% vs 31.4%) and drowsiness (19.2% vs 11.8%) significantly more common with nortriptyline<BR/>Constipation (15.4% vs 9.8%) NS</P>
</TD>
<TD>
<P>No report</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="189" STUDY_ID="STD-Hall-1998">
<TR>
<TD>
<P>None occurred</P>
</TD>
<TD>
<P>Dry mouth (78% vs 33%), lightheadedness (49% vs 22%), shaky hands (23% vs 11%) and blurry vision (16% vs 6%) were significantly more common.</P>
</TD>
<TD>
<P>4 (4%) dropouts due to side effects in drug and 1 (1%) in placebo group. Total dropout rates 30% in drug and 17% in placebo groups</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="190" STUDY_ID="STD-Hall-2002">
<TR>
<TD>
<P>None occurred</P>
</TD>
<TD>
<P>Dry mouth (72% vs 33%) and constipation ( 32% vs 14%) significantly more common with nortriptyline</P>
</TD>
<TD>
<P>No report</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="191" STUDY_ID="STD-Hall-2004">
<TR>
<TD>
<P>None occurred<BR/>
</P>
</TD>
<TD>
<P>Dry mouth (85% vs 40%), lightheadedness (44% vs 22%), shaky hands (30% vs 14%) constipation (38% vs 15%), blurry vision (23% vs 7%), difficulty urinating (13% vs 2%), all p&lt;0.01. Sexual difficulties (19% vs 2% p &lt;0.02)</P>
</TD>
<TD>
<P>4 (10%) in active brief treatment, 10 (25%) in active extended treatment, 9 (11%) in placebo stopped medication due to adverse effects (active vs placebo p=0.18, Fisher's exact test)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="192" STUDY_ID="STD-Prochazka-1998">
<TR>
<TD>
<P>None occurred</P>
</TD>
<TD>
<P>Dry mouth (64% vs 23%), dysgeusia (20% vs 8%), GI upset (41% vs 24%), drowsiness (24% vs 8%) significantly more common</P>
</TD>
<TD>
<P>10 (9%) treatment withdrawal due to adverse events in nortriptyline group, vs 3 (3%) in placebo group.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="193" STUDY_ID="STD-Prochazka-2004">
<TR>
<TD>
<P>None occurred<BR/>
</P>
</TD>
<TD>
<P>Dry mouth (38% vs 8%) &amp; sedation (20% vs 3%) significantly more common.</P>
</TD>
<TD>
<P>10 (13%) discontinued nortriptyline including 1 subject with a normal baseline ECG who developed asymptomatic prolongation of QT interval, vs 1 placebo</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:32 +0000" MODIFIED_BY="[Empty name]" ORDER="194" STUDY_ID="STD-Wagena-2005">
<TR>
<TD>
<P>One death in placebo group, previously hospitalised with dermatological reactions</P>
</TD>
<TD>
<P>Dry mouth (61% vs 20%), diarrhoea or constipation (48% vs 26%) and fatigue (20% vs 9%) significantly more common in nortriptyline group</P>
</TD>
<TD>
<P>24% discontinued nortriptyline vs 9% placebo</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-004.02" MODIFIED="2013-11-26 16:56:19 +0000" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="50" SUBGROUPS="NO">
<NAME>Bupropion versus control. 'No report' = no information, 'None occurred' = explicit statement</NAME>
<TR>
<TH>
<P>Serious events</P>
</TH>
<TH>
<P>Other adverse events</P>
</TH>
<TH>
<P>Withdrawal due to AE</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="195" STUDY_ID="STD-Ahluwalia-2002">
<TR>
<TD>
<P>No seizures occurred<BR/>No serious adverse events reported.</P>
</TD>
<TD>
<P>Insomnia (29.3 vs 20.7%) more common with bupropion.<BR/>Dry mouth (28% vs 24%)</P>
</TD>
<TD>
<P>No information</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="196" STUDY_ID="STD-Aubin-2004">
<TR>
<TD>
<P>No seizures occurred<BR/>5 bupropion and 1 placebo serious AE during treatment, 2 bupropion during f-up. 1 chest pain, tremor &amp; sweating &amp; 1 depressive syndrome after end of treatment considered possibly due to bupropion.</P>
</TD>
<TD>
<P>61% on bupropion and 45% on placebo experienced at least one AE<BR/>Sleep disorder 33% bupropion vs 19% placebo</P>
</TD>
<TD>
<P>10% bupropion &amp; 5% placebo withdrew due to AEs</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="197" STUDY_ID="STD-Cinciripini-2013">
<TR>
<TD>
<P>No seizures occurred</P>
<P>3 SAEs (within 30 days of treatment) in bupropion group: bilateral mammoplasty, facial paralysis and syncope. 2 SAEs in placebo group: diabetes mellitus and chest pain.</P>
<P/>
</TD>
<TD>
<P>Significantly higher rates of influenza (7.8% vs 1.9%), nausea (16.7% vs 7.5%) and insomnia (31.4% vs 19.8%) in bupropion than placebo group. Significantly less diarrhoea in intervention than control group (11.3 vs 3.9%). No other significant differences detected.</P>
</TD>
<TD>
<P>2% bupropion and 1% placebo withdrew due to AEs</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="198" STUDY_ID="STD-Collins-2004">
<TR>
<TD>
<P>Not reported in paper</P>
</TD>
<TD>
<P>Not reported in paper</P>
</TD>
<TD>
<P>Not reported in paper</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="199" STUDY_ID="STD-Covey-2007">
<TR>
<TD>
<P>One seizure during open label phase (before randomization to relapse prevention)</P>
</TD>
<TD>
<P>'The number of reported side effects (e.g. nervousness,<BR/>constipation, insomnia, stomach-ache, depressed<BR/>mood) was low (mean = 0.43, SD = 0.91), and did not<BR/>vary by treatment group (P = 0.69)'</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="200" STUDY_ID="STD-Cox-2012">
<TR>
<TD>
<P>None occurred in first 3 weeks of treatment (not reported beyond that)</P>
</TD>
<TD>
<P>Type of AE not reported. All AEs in first week of treatment 8.9% bupropion and 28.5% placebo group.</P>
</TD>
<TD>
<P>Not reported in paper</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="201" STUDY_ID="STD-Dalsgar_x00f0_-2004">
<TR>
<TD>
<P>No seizures occurred<BR/>No serious adverse event during treatment phase. 3 events during follow-up not considered to be drug related including 1 death in bupropion group,</P>
</TD>
<TD>
<P>Insomnia (28% vs 18%), dizziness (8% vs 1%) and skin problems (15% vs 7%) significantly more common with bupropion. Major depression more common in placebo (1% vs 5%),</P>
</TD>
<TD>
<P>12% bupropion &amp; 8% placebo withdrew due to adverse event.<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="202" STUDY_ID="STD-Eisenberg-2013">
<TR>
<TD>
<P>No seizures occurred. Over the course of 12 months, 17.7% bupropion and 18.5% placebo experienced SAE. No SAEs considered related to treatment.</P>
</TD>
<TD>
<P>Over course of study treatment, no significant difference in AEs. Most common were insomnia (22.3% bupropion vs 18.2% placebo), dry mouth (13.3% bupropion vs 9.1% placebo), and dizziness (8.0% bupropion vs 8.6% placebo).</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="203" STUDY_ID="STD-Evins-2001">
<TR>
<TD>
<P>No seizures occurred</P>
</TD>
<TD>
<P>No information (only 19 participants)</P>
</TD>
<TD>
<P>No information</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="204" STUDY_ID="STD-Evins-2005">
<TR>
<TD>
<P>Not reported in abstract</P>
</TD>
<TD>
<P>Not reported in abstract</P>
</TD>
<TD>
<P>Not reported in abstract</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="205" STUDY_ID="STD-Ferry-1992">
<TR>
<TD>
<P>No seizures occurred (data from FDA submission)</P>
</TD>
<TD>
<P>No information from abstract</P>
</TD>
<TD>
<P>No information from abstract</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="206" STUDY_ID="STD-Ferry-1994">
<TR>
<TD>
<P>No seizures occurred (data from FDA submission)</P>
</TD>
<TD>
<P>No information from abstract</P>
</TD>
<TD>
<P>3% bupropion &amp; 3% placebo withdrew due to adverse experience (data from FDA submission)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="207" STUDY_ID="STD-Fossati-2007">
<TR>
<TD>
<P>No seizures occurred<BR/>8 serious adverse events in bupropion group, of which 1 thought to be medication related (suspected cholangitis) </P>
</TD>
<TD>
<P>Dry mouth (6.3% vs 2.1%), Insomnia (17.3% vs 6.2%), and constipation (11.0% vs 3.6%) significantly more common on bupropion</P>
</TD>
<TD>
<P>~14% bupropion &amp; 7% placebo withdrew due to AEs</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="208" STUDY_ID="STD-George-2002">
<TR>
<TD>
<P>No seizures occurred</P>
</TD>
<TD>
<P>Dry mouth (62.5% vs 25.0%) , headache (56.3% vs 37.5%), insomnia (43.8% vs 27.8%), memory problems (50.0% vs 31.3%), blurred vision (50.0% vs 25.0%, irregular heartbeat (37.5% vs 12.5%), nausea/vomiting (43.8% vs 18.8%) diarrhoea (50.0% vs 25.0%), anxiety/agitation (50.0% vs 25.0%), tremor (31.3% vs 12.5%)</P>
</TD>
<TD>
<P>2 bupropion &amp; 5 placebo withdrew during treatment, no reasons given</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="209" STUDY_ID="STD-George-2008">
<TR>
<TD>
<P>No seizures occurred. Three serious adverse events (SAEs) involved psychotic decompensation, 2 placebo, 1 bupropion. All deemed unrelated to study medications</P>
</TD>
<TD>
<P>There were significant (<I>p </I>&lt;.05) group differences on concentration, jitteriness, lightheadedness, muscle stiffness, and frequent nocturnal awakening</P>
</TD>
<TD>
<P>No information on AE related withdrawals</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="210" STUDY_ID="STD-Gonzales-2001">
<TR>
<TD>
<P>No seizures occurred. One serious adverse event (rash with pruritus and edema) in the bupropion group was assessed as being due to study medication</P>
</TD>
<TD>
<P>No significant differences between bupropion &amp; placebo. 72% on bupropion reported adverse event vs 58% placebo. Most common adverse events insomnia (24% vs 11%), viral infections (13% vs 19%) dry mouth (13% vs 9%), headache (8% vs 13%),</P>
</TD>
<TD>
<P>30 people discontinued medication due to adverse event, 11 (5%) placebo, 19 (8%) bupropion. For patients on bupropion most common events were anxiety (4), dry mouth (3) and rash (3)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="211" STUDY_ID="STD-Gonzales-2006">
<TR>
<TD>
<P>1 seizure after 20 days of bupropion. No other serious events assessed as due to medication</P>
</TD>
<TD>
<P>Dry mouth (8.8% vs 5.5%, NS), nausea (12.5% vs 8.4%, NS), insomnia (21.9% vs 12.8%)</P>
</TD>
<TD>
<P>9.0% placebo, 15.2% bupropion discontinued medication</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="212" STUDY_ID="STD-Grant-2007">
<TR>
<TD>
<P>No seizures occurred</P>
</TD>
<TD>
<P>Insomnia (37% vs 7%)</P>
</TD>
<TD>
<P>10 (33%) discontinued bupropion vs 3 (11%) placebo</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="213" STUDY_ID="STD-Haggstr_x00e4_m-2006">
<TR>
<TD>
<P>No seizures or other serious adverse events occurred</P>
</TD>
<TD>
<P>Insomnia (50.9% vs 17.6%), dry mouth (50.9% vs 31.4%), diarrhoea (11.0% vs 3.9%)</P>
</TD>
<TD>
<P>No report</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="214" STUDY_ID="STD-Hall-2002">
<TR>
<TD>
<P>No seizures occurred</P>
</TD>
<TD>
<P>No significant differences between bupropion &amp; placebo</P>
</TD>
<TD>
<P>No report</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="215" STUDY_ID="STD-Hatsukami-2004">
<TR>
<TD>
<P>No seizures occurred. 8 serious AEs in bupropion, 3 placebo. One case of chest pain thought to be treatment related.</P>
</TD>
<TD>
<P>No details</P>
</TD>
<TD>
<P>60 people discontinued medication due to adverse events, 22 (7%) placebo, 38 (13%) bupropion.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="216" STUDY_ID="STD-Hays-2001">
<TR>
<TD>
<P>No seizures occurred. No serious adverse events assessed as being caused by study medication</P>
</TD>
<TD>
<P>No significant differences between bupropion and placebo. Most common adverse events during 45 week double blind medication phase insomnia (10% vs 7%) and headache (24% vs 17%) also rhinitis, influenza URI and accidental injury.</P>
</TD>
<TD>
<P>41 people discontinued medication due to adverse events, 17 (8%) placebo, 24 (11%) bupropion.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="217" STUDY_ID="STD-Hertzberg-2001">
<TR>
<TD>
<P>No seizures occurred. One patient receiving bupropion suffered ataxia, headache and jitteriness.</P>
</TD>
<TD>
<P>No details</P>
</TD>
<TD>
<P>One bupropion (ataxia, headache and jitteriness)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="218" STUDY_ID="STD-Holt-2005">
<TR>
<TD>
<P>No seizures or serious adverse events</P>
</TD>
<TD>
<P>Insomnia 26% vs 9%</P>
</TD>
<TD>
<P>Three discontinued bupropion due to a rash.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="219" STUDY_ID="STD-Hurt-1997">
<TR>
<TD>
<P>No seizures occurred. One of three serious adverse events could have been associated with bupropion; extreme irritability restlessness, anger, anxiety and craving in a man who stopped smoking.</P>
</TD>
<TD>
<P>Bupropion 300mg was associated with significantly more insomnia (34.6% vs 20.9%) and dry mouth (12.8% vs 4.6%) than placebo.</P>
</TD>
<TD>
<P>37 people discontinued medication due to adverse events; 6 (5%) placebo; 9 (6%) 100mg; 7 (5%) 150mg; 13 (8%) 300mg. Tremor, headaches, rash and urticaria were the most common reasons for stopping treatment.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="220" STUDY_ID="STD-Hurt-2003">
<TR>
<TD>
<P>No seizures occurred</P>
</TD>
<TD>
<P>No significant differences.<BR/>Anxiety (16% vs 9%) and nervousness (13% vs 6%) more common in bupropion group. Insomnia less common (10% vs 17%).</P>
</TD>
<TD>
<P>Not stated.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="221" STUDY_ID="STD-Jorenby-1999">
<TR>
<TD>
<P>No seizures occurred. Three serious adverse events were attributed to bupropion, all consisted of rash and pruritus, one with shortness of breath and chest tightness. All had full resolution of symptoms</P>
</TD>
<TD>
<P>Bupropion was associated with more insomnia (42.4% vs 19.5%) and dry mouth (10.7% vs 4.4%) than placebo.</P>
</TD>
<TD>
<P>79 people discontinued medication due to adverse events; 6 (3.8%) placebo; 16 (6.6%) patch; 29 (11.9%) bupropion and 28 (11.4%) combined treatment group. 20% dropped out of study, and 35% were lost to follow-up at 12 months.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="222" STUDY_ID="STD-Jorenby-2006">
<TR>
<TD>
<P>No seizures occurred<BR/>1 serious adverse event attributed to bupropion; angioedema.</P>
</TD>
<TD>
<P>Bupropion was associated with more insomnia (21.2% vs 12.4%), sleep disorder (6.8% vs 2.6%), constipation (6.5% vs 1.5%), dry mouth (7.6% vs 3.2%).</P>
</TD>
<TD>
<P>16 (4.7%) bupropion vs 13 (3.8%) placebo discontinued study due to AEs. 12.6% vs 7.3% discontinued medication.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="223" STUDY_ID="STD-Killen-2004">
<TR>
<TD>
<P>No seizures occurred.<BR/>No adverse effects judged to be severe by study physician</P>
</TD>
<TD>
<P>22 (21%) reported severe AEs in bupropion &amp; patch group vs 25 (23%) in placebo &amp; patch.<BR/>24 (23%) vs 35 (32%) reported moderate AEs</P>
</TD>
<TD>
<P>None reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="224" STUDY_ID="STD-Killen-2006">
<TR>
<TD>
<P>1 seizure during open-label phase<BR/>2 other serious adverse events during open label phase (oedema, depression) and 2 during extended treatment (diagnosis of hyperthyroidism in bupropion group, onset of immune thrombocytopenia purpura in placebo group).</P>
</TD>
<TD>
<P>During open-label phase 53% reported insomnia, 47% dry mouth, 44% vivid dreams, 23% nausea, 22% headache, 17% racing heart rate, 12% skin rash and 7% irregular heart rate.</P>
</TD>
<TD>
<P>30 (8%) discontinued medication during open-label phase. 1 bupropion and 2 placebo discontinued during extended treatment phase.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="225" STUDY_ID="STD-Levine-2010">
<TR>
<TD>
<P>"No serious events were associated with medication use." No further information reported.</P>
</TD>
<TD>
<P>"Overall, bupropion was well tolerated." No further detail provided.</P>
</TD>
<TD>
<P>"Reasons for medication discontinuation did not differ between bupropion and placebo, with the exception of allergic reaction (5.64% vs 0.65% in bupropion vs placebo, p = 0.02). No further detail provided.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="226" STUDY_ID="STD-Muramoto-2007">
<TR>
<TD>
<P>No seizures occurred. 1 hospitalisation (150 mg/d group) for deliberate ingestion of Datura innoxia for recreational purposes. 1 hospitalisation (150 mg/d group) for intentional overdose of study medication, other drugs &amp; alcohol.<BR/>
</P>
</TD>
<TD>
<P>Headache and cough were commonest reported AEs. No others significantly different.</P>
</TD>
<TD>
<P>Eight subjects discontinued medication<BR/>early because of the following adverse events: feeling depressed, irritable, or angry; sleep disturbance; headache; urticaria; anxiety; heart palpitations; suicide attempt; anticholinergic crisis related to recreational drug use; and pregnancy.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="227" STUDY_ID="STD-Nides-2006">
<TR>
<TD>
<P>Two seizures, 2 other serious AEs in bupropion (persistent intermittent bloody diarrhoea, syncope) all considered to be possibly related to bupropion</P>
</TD>
<TD>
<P>90% of bupropion and 88% on placebo experienced at least one AE.<BR/>Insomnia 45% bupropion vs 22% placebo, constipation 14% bupropion vs 4% placebo, dry mouth 12% bupropion vs 6% placebo.</P>
</TD>
<TD>
<P>16% bupropion &amp; 10% placebo discontinued medication</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="228" STUDY_ID="STD-Piper-2007">
<TR>
<TD>
<P>No report of seizures</P>
</TD>
<TD>
<P>4.7% of adverse events was insomnia, not reported by condition</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="229" STUDY_ID="STD-Piper-2009">
<TR>
<TD>
<P>1 seizure in bupropion group, but other SAEs not reported</P>
</TD>
<TD>
<P>In bupropion vs placebo, more diarrhea (1.5% vs 1.1%), vomiting (1.9% vs 1.1%), dry mouth (3.8% vs 1.0%), and sleep disturbance and abnormal dreams (16.8% vs 5.6%). In all other AEs, same or more occurred in placebo arm.</P>
</TD>
<TD>
<P>2 in bupropion group withdrew because of events related to medication (1 interaction related to other antidepressants; 1 heartburn). 1 placebo withdrew because of "negative experience" whilst on medication.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="230" STUDY_ID="STD-Planer-2011">
<TR>
<TD>
<P>Over course of one year, 3% bupropion and 1% placebo MI, 3% bupropion and 7% placebo ACS.</P>
</TD>
<TD>
<P>No significant differences in any AEs over one year except for increased rate of dizziness in bupropion users (14% bupropion vs 1.4% placebo)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="231" STUDY_ID="STD-Rigotti-2006">
<TR>
<TD>
<P>No report of seizures. Two deaths in placebo group.<BR/>Non cardiac serious adverse events; 37% bupropion vs 31% placebo, ns<BR/>Rate of new cardiovascular events did not differ significantly at 3 months or 1 year. After 30 days off drug more bupropion group sustained a cardiovascular event, borderline significance after adjustment for cardiac risk factors.</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Withdrawals not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="232" STUDY_ID="STD-Rovina-2009">
<TR>
<TD>
<P>No seizures in either two arms included in this analysis. 0.9% tachycardia in bupropion arm vs 0 in control arm during 19 weeks of treatment.</P>
</TD>
<TD>
<P>Higher rates in bupropion than in control arm of: insomnia (15.8% vs 3.2%), dry mouth (12.9% vs 0), dizziness (8.8% vs 0), constipation (5.5% vs 1.2%), headache (5.8% vs 4.5%), anxiety (4.8% vs 3.7%), nausea (5% vs 0), concentration issues (4.2% vs 1.2%), allergic reaction (5.8% vs 0), sadness (2.6% vs 0.4%), and sleepiness (1.4% vs 0).</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="233" STUDY_ID="STD-Simon-2004">
<TR>
<TD>
<P>No report of seizures or other serious AE</P>
</TD>
<TD>
<P>Frequency of insomnia and abnormal dreams similar in both groups. Dry mouth 22% bupropion vs 8% placebo, gastrointestinal upset 9% bupropion vs 1% placebo</P>
</TD>
<TD>
<P>Withdrawals not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="234" STUDY_ID="STD-Simon-2009">
<TR>
<TD>
<P>No seizures occurred. 1 death in each group, causes not given (hospital population)</P>
</TD>
<TD>
<P>11 (26%) bupropion vs 4 (9%) in the placebo reported any AEs. Hyperactivity and insomnia reported solely in bupropion group </P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="235" STUDY_ID="STD-SMK20001">
<TR>
<TD>
<P>No seizures or deaths occurred. 7 patients (bupropion 4, placebo 3) experienced a serious AE, none considered related to medication.</P>
</TD>
<TD>
<P>Overall rate of reporting of adverse events 90% vs 83%. Sleep disorders 46% vs 27%</P>
</TD>
<TD>
<P>7% vs 1% withdrew due to AEs</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="236" STUDY_ID="STD-Stapleton-2013">
<TR>
<TD>
<P>No seizures occurred. 4 patients receiving bupropion had an SAE whilst on treatment (2 allergic reactions resulting in anaphylaxis, 1 transient suicidal thoughts, 1 severe chest pain). No SAEs occured in group receiving NRT only.</P>
</TD>
<TD>
<P>Higher rates of some adverse events in participants receiving bupropion compared to those receiving NRT only: disturbed sleep, dry mouth, headache, nausea, dizziness, low mood/depression, anxiety/panic, chest pain, disorientation, loss of appetite.</P>
</TD>
<TD>
<P>20% of abstinent participants allocated to bupropion only had switched to NRT. No further detail reported on withdrawal due to AEs.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="237" STUDY_ID="STD-Swan-2003">
<TR>
<TD>
<P>No seizures or deaths occurred. No serious AEs reported</P>
</TD>
<TD>
<P>Higher dose associated with more difficulty sleeping (48% vs 41%), difficulty concentrating (35% vs 28%), gastrointestinal problems (27% vs 20%) and shakiness/tremor (24% vs 17%) than lower dose.</P>
</TD>
<TD>
<P>26% discontinued medication in 150 mg group and 31% in 300 mg group</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="238" STUDY_ID="STD-Tashkin-2001">
<TR>
<TD>
<P>No seizures occurred. <BR/>6 patients (placebo 5, bupropion 1) experienced a serious adverse event. One event (transient ischaemic attack) in placebo group thought to be related to study treatment.</P>
</TD>
<TD>
<P>Bupropion associated with more insomnia (24% vs 12%). Rates for headache (6% vs 6%) and dry mouth (6% vs 5%) similar in 2 groups.</P>
</TD>
<TD>
<P>27 people discontinued medication, bupropion 14 (7%), placebo 13 (6.5%). Commonest reasons in bupropion group were anxiety (5), insomnia (4)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="239" STUDY_ID="STD-Tonnesen-2003">
<TR>
<TD>
<P>No seizures occurred<BR/>7 patients (bupropion 6, placebo 1) experienced serious AEs within a week of ending treatment. A reasonable possibility that SAEs in 3 bupropion patients related to study medication (fainting due to insomnia, urticaria/angioedema (2). In addition one bupropion patient delivered twin girls 4 weeks after treatment termination, one still born.</P>
</TD>
<TD>
<P>Bupropion associated with more insomnia (24% vs 15%), dry mouth (13% vs 5%) headache (13% vs 10%) sleep disorder (10% vs 7%), constipation (6% vs 1%) and dizziness (7% vs 4%)</P>
</TD>
<TD>
<P>8% on bupropion and 6% on placebo withdrew due to adverse events.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="240" STUDY_ID="STD-Tonstad-2003">
<TR>
<TD>
<P>No seizures occurred.<BR/>Five serious adverse events during treatment, all on bupropion. Only 1 (lupus disseminatus) considered related to medication. None led to medication discontinuation. Three SAEs within a week of treatment, none related to bupropion use.<BR/>36 patients (Bupropion 24, placebo 14) reported cardiovascular adverse events.<BR/>4 deaths (2, 2) during follow-up phase, none related to study medication.</P>
</TD>
<TD>
<P>Bupropion associated with more insomnia (24% vs 12%), dry mouth (18% vs 10%), nausea (13% vs 6%), dizziness (8% vs 5%). 11% in each group reported headache.<BR/>No evidence of any effect on vital signs in CVD patients.</P>
</TD>
<TD>
<P>5% on bupropion and 6% on placebo withdrew due to adverse events.</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="241" STUDY_ID="STD-Uyar-2007">
<TR>
<TD>
<P>No seizures occurred</P>
</TD>
<TD>
<P>56% on bupropion reported dry mouth, 44% headache, 40% insomnia. Sleep disturbance rates significantly higher than control (38% vs 9.6%).</P>
</TD>
<TD>
<P>4 (8%) discontinued bupropion due to adverse effects</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="242" STUDY_ID="STD-Wagena-2005">
<TR>
<TD>
<P>No seizures occurred<BR/>One death in placebo group, previously hospitalised with dermatological reactions</P>
</TD>
<TD>
<P>No significant differences between bupropion &amp; placebo. Insomnia 34% vs 24%, Dry mouth 28% vs 20%, diarrhoea or constipation 34% vs 26%</P>
</TD>
<TD>
<P>15% on bupropion and 9% on placebo discontinued medication</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="243" STUDY_ID="STD-Wittchen-2011">
<TR>
<TD>
<P>None occurred</P>
</TD>
<TD>
<P>Insomnia (7%) and dry mouth (7%) most frequently reported in bupropion group, rates not given for control group</P>
</TD>
<TD>
<P>7 on bupropion discontinued due to adverse effects (11 in NRT group, 0 in control group)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-11-26 16:44:21 +0000" MODIFIED_BY="[Empty name]" ORDER="244" STUDY_ID="STD-Zellweger-2005">
<TR>
<TD>
<P>Two seizures occurred in bupropion group. One patient had a possible familial predisposition and the other was sleep deprived. 1 patient on placebo suffered a transient ischemic attack and 1 a pulmonary sequestration</P>
</TD>
<TD>
<P>Bupropion associated with more insomnia (39% vs 22%). Similar rates of dry mouth (12% vs 10%), agitation (10% vs 11%), nausea (10% vs 7%).</P>
</TD>
<TD>
<P>9% on bupropion and 5% on placebo withdrew due to adverse events, most commonly due to nervous system events in both groups.</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-12-04 10:03:59 +0000" MODIFIED_BY="Lindsay Stead" NO="5">
<NAME>Selective Serotonin Reuptake Inhibitors (SSRIs) versus placebo. Abstinence at 6m or greater follow-up.</NAME>
<DICH_OUTCOME CHI2="1.2258548910556206" CI_END="1.2245984256265792" CI_START="0.7067422358723328" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9303093191907018" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.08799369676055961" LOG_CI_START="-0.1507389538838255" LOG_EFFECT_SIZE="-0.03137262856163296" METHOD="MH" MODIFIED="2013-11-26 15:17:01 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.7468102287013136" P_Q="0.6961248906709503" P_Z="0.6064619076265936" Q="0.7244527282502997" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="998" TOTAL_2="596" WEIGHT="100.0" Z="0.5151303930583611">
<NAME>SSRI versus placebo/control</NAME>
<GROUP_LABEL_1>SSRI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5010056417846165" CI_END="1.3037118760011712" CI_START="0.6473613525164981" DF="1" EFFECT_SIZE="0.9186798590041796" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="48" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.11518162169583138" LOG_CI_START="-0.18885323154732972" LOG_EFFECT_SIZE="-0.03683580492574915" MODIFIED="2013-11-12 15:50:55 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.47905863811971117" P_Z="0.6348405520229341" STUDIES="2" TAU2="0.0" TOTAL_1="780" TOTAL_2="456" WEIGHT="64.35263860519791" Z="0.47492483329383184">
<NAME>Fluoxetine</NAME>
<DICH_DATA CI_END="1.466903866220089" CI_START="0.6607104917729718" EFFECT_SIZE="0.9844789356984479" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="33" LOG_CI_END="0.1664016532174009" LOG_CI_START="-0.17998879674408236" LOG_EFFECT_SIZE="-0.006793571763340703" ORDER="1317" O_E="0.0" SE="0.20347146496775625" STUDY_ID="STD-Niaura-2002" TOTAL_1="656" TOTAL_2="333" VAR="0.04140063705612486" WEIGHT="47.880409914478996"/>
<DICH_DATA CI_END="1.5199960992883417" CI_START="0.3481186024370103" EFFECT_SIZE="0.7274193548387097" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.18184247343179727" LOG_CI_START="-0.4582727686723839" LOG_EFFECT_SIZE="-0.13821514762029333" MODIFIED="2009-07-30 12:08:25 +0100" MODIFIED_BY="Lindsay Stead" ORDER="1318" O_E="0.0" SE="0.3760068618335473" STUDY_ID="STD-Spring-2007" TOTAL_1="124" TOTAL_2="123" VAR="0.14138116014591234" WEIGHT="16.47222869071891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8185465711235484" CI_START="0.6404019082804802" DF="0" EFFECT_SIZE="1.0791666666666666" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="16" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.25972442737202994" LOG_CI_START="-0.19354738263273838" LOG_EFFECT_SIZE="0.03308852236964578" MODIFIED="2013-11-12 15:53:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7747617240282578" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="74" WEIGHT="23.436869162486005" Z="0.2861519764287633">
<NAME>Paroxetine</NAME>
<DICH_DATA CI_END="1.8185465711235484" CI_START="0.6404019082804802" EFFECT_SIZE="1.0791666666666666" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="16" LOG_CI_END="0.25972442737202994" LOG_CI_START="-0.19354738263273838" LOG_EFFECT_SIZE="0.03308852236964578" MODIFIED="2013-11-12 15:51:33 +0000" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.26625410492844687" STUDY_ID="STD-Killen-2000" TOTAL_1="150" TOTAL_2="74" VAR="0.07089124839124838" WEIGHT="23.436869162486005"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6439444161698633" CI_START="0.3030941261108229" DF="0" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.21588712940913835" LOG_CI_START="-0.5184224800704365" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-11-12 15:53:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4193758297508047" STUDIES="1" TAU2="0.0" TOTAL_1="68" TOTAL_2="66" WEIGHT="12.210492232316092" Z="0.8075046052666888">
<NAME>Sertraline</NAME>
<DICH_DATA CI_END="1.643944416169863" CI_START="0.3030941261108229" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2158871294091383" LOG_CI_START="-0.5184224800704365" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2013-11-12 15:52:04 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.4313370994994919" STUDY_ID="STD-Covey-2002" TOTAL_1="68" TOTAL_2="66" VAR="0.18605169340463457" WEIGHT="12.210492232316092"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2913731993149677" CI_END="1.0284692323998754" CI_START="0.47603266680291834" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6997034739259647" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" I2="0.0" I2_Q="100.0" ID="CMP-005.02" LOG_CI_END="0.012191303907432427" LOG_CI_START="-0.3223632436545912" LOG_EFFECT_SIZE="-0.15508596987357937" METHOD="MH" MODIFIED="2013-11-26 15:17:44 +0000" MODIFIED_BY="Lindsay Stead" NO="2" P_CHI2="0.5141757109529067" P_Q="0.0" P_Z="0.06919870830034162" Q="7.979053721668723E-32" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="294" TOTAL_2="172" WEIGHT="99.99999999999997" Z="1.8171202135778906">
<NAME>SSRI and NRT versus NRT alone</NAME>
<GROUP_LABEL_1>SSRI &amp; NRT</GROUP_LABEL_1>
<GROUP_LABEL_2>NRT alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours NRT alone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSRI+NRT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2913731993149677" CI_END="1.0284692323998754" CI_START="0.47603266680291834" DF="3" EFFECT_SIZE="0.6997034739259647" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.012191303907432427" LOG_CI_START="-0.3223632436545912" LOG_EFFECT_SIZE="-0.15508596987357937" MODIFIED="2013-11-12 15:53:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5141757109529067" P_Z="0.06919870830034162" STUDIES="3" TAU2="0.0" TOTAL_1="294" TOTAL_2="172" WEIGHT="99.99999999999997" Z="1.8171202135778906">
<NAME>Fluoxetine</NAME>
<DICH_DATA CI_END="1.8956951269065825" CI_START="0.42992552150478014" EFFECT_SIZE="0.9027777777777778" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.2777684936832173" LOG_CI_START="-0.36660677326004304" LOG_EFFECT_SIZE="-0.04441913978841288" MODIFIED="2013-11-12 15:53:11 +0000" MODIFIED_BY="[Empty name]" ORDER="1319" O_E="0.0" SE="0.37850922151148547" STUDY_ID="STD-Blondal-1999" TOTAL_1="48" TOTAL_2="52" VAR="0.14326923076923076" WEIGHT="24.14814714698436"/>
<DICH_DATA CI_END="1.2717002225510234" CI_START="0.2911159822946977" EFFECT_SIZE="0.6084507042253521" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.10438474729061445" LOG_CI_START="-0.5359339510989409" LOG_EFFECT_SIZE="-0.21577460190416323" MODIFIED="2013-11-12 15:53:11 +0000" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.3761263730627009" STUDY_ID="STD-Brown-2013" TOTAL_1="71" TOTAL_2="36" VAR="0.14147104851330206" WEIGHT="27.818640437368405">
<FOOTNOTE>This intervention arm received 16 weeks of treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.994956887768144" CI_START="0.19798853281080103" EFFECT_SIZE="0.4438356164383562" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="-0.00219573715381361" LOG_CI_START="-0.7033599626738738" LOG_EFFECT_SIZE="-0.35277784991384376" MODIFIED="2013-11-12 15:53:11 +0000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.4118673368893764" STUDY_ID="STD-Brown-2013" TOTAL_1="73" TOTAL_2="36" VAR="0.16963470319634705" WEIGHT="28.07745192612542">
<FOOTNOTE>This intervention arm received 10 weeks of treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.179951769661833" CI_START="0.4063452967706436" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.338446885163579" LOG_CI_START="-0.3911047626082773" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2013-11-12 15:53:11 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.42854224924008777" STUDY_ID="STD-Saules-2004" TOTAL_1="102" TOTAL_2="48" VAR="0.1836484593837535" WEIGHT="19.955760489521797"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-11-26 16:56:10 +0000" MODIFIED_BY="Lindsay Stead" NO="6">
<NAME>Monoamine oxidase inhibitors (MAOIs) versus placebo. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="5.521039363697452" CI_END="1.7895473178051096" CI_START="0.9335657635261685" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2925401765952709" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="54" I2="9.437341945493946" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.2527431861515447" LOG_CI_START="-0.02985508346686382" LOG_EFFECT_SIZE="0.11144405134234042" METHOD="MH" MODIFIED="2013-11-26 15:27:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3556444535571115" P_Q="0.6273746416923014" P_Z="0.12214240643308778" Q="0.23563782068451775" RANDOM="NO" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="413" TOTAL_2="414" WEIGHT="100.0" Z="1.5458433430407077">
<NAME>MAOIs versus placebo</NAME>
<GROUP_LABEL_1>MAOI</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.67851607487937" CI_START="0.6712999766306634" DF="0" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.5656726582217022" LOG_CI_START="-0.17308336793376583" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2013-11-20 17:20:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.297614391312501" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="12.956330344219536" Z="1.0415629009279528">
<NAME>Moclobemide</NAME>
<DICH_DATA CI_END="3.67851607487937" CI_START="0.6712999766306634" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5656726582217022" LOG_CI_START="-0.17308336793376583" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2013-11-14 13:57:39 +0000" MODIFIED_BY="[Empty name]" ORDER="1324" O_E="0.0" SE="0.43394894666502914" STUDY_ID="STD-Berlin-1995" TOTAL_1="44" TOTAL_2="44" VAR="0.1883116883116883" WEIGHT="12.956330344219536"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.220549965695702" CI_END="1.77963687856753" CI_START="0.8794328402123193" DF="4" EFFECT_SIZE="1.2510280231334665" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="47" I2="23.37972002405783" ID="CMP-006.01.02" LOG_CI_END="0.2503313968469835" LOG_CI_START="-0.055797320776016734" LOG_EFFECT_SIZE="0.09726703803548337" MODIFIED="2013-11-20 18:22:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2654070506191656" P_Z="0.21295228152093892" STUDIES="5" TAU2="0.0" TOTAL_1="369" TOTAL_2="370" WEIGHT="87.04366965578046" Z="1.2454884527835082">
<NAME>Selegiline</NAME>
<DICH_DATA CI_END="32.72441962136761" CI_START="0.48893151307571864" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.514871952931805" LOG_CI_START="-0.31075197027588036" LOG_EFFECT_SIZE="0.6020599913279624" MODIFIED="2013-11-20 18:22:26 +0000" MODIFIED_BY="[Empty name]" ORDER="615" O_E="0.0" SE="1.0723805294763609" STUDY_ID="STD-George-2003" TOTAL_1="20" TOTAL_2="20" VAR="1.15" WEIGHT="1.850904334888505"/>
<DICH_DATA CI_END="5.321514603496023" CI_START="0.9164188157836288" EFFECT_SIZE="2.2083333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7260352582955838" LOG_CI_START="-0.03790600251721765" LOG_EFFECT_SIZE="0.3440646278891831" MODIFIED="2013-11-20 18:22:25 +0000" MODIFIED_BY="[Empty name]" ORDER="616" O_E="0.0" SE="0.44874287817166897" STUDY_ID="STD-Biberman-2003" TOTAL_1="56" TOTAL_2="53" VAR="0.20137017070979335" WEIGHT="11.411079936193353"/>
<DICH_DATA CI_END="4.049439139543791" CI_START="0.650794238538077" EFFECT_SIZE="1.6233766233766234" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6073948761853639" LOG_CI_START="-0.18655630051421482" LOG_EFFECT_SIZE="0.21041928783557454" MODIFIED="2013-11-14 13:57:23 +0000" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.46637085131504136" STUDY_ID="STD-Kahn-2012" TOTAL_1="121" TOTAL_2="125" VAR="0.2175017709563164" WEIGHT="12.745658306102143"/>
<DICH_DATA CI_END="1.9670289137573325" CI_START="0.27485993503452205" EFFECT_SIZE="0.7352941176470589" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2938107437490116" LOG_CI_START="-0.5608885604894466" LOG_EFFECT_SIZE="-0.13353890837021748" MODIFIED="2013-08-20 13:10:36 +0100" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.5020546021394603" STUDY_ID="STD-Weinberger-2010" TOTAL_1="51" TOTAL_2="50" VAR="0.2520588235294117" WEIGHT="14.953840963059605"/>
<DICH_DATA CI_END="1.5966256707692406" CI_START="0.5867975327741648" EFFECT_SIZE="0.9679338842975207" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.2032031076381528" LOG_CI_START="-0.2315117208424196" LOG_EFFECT_SIZE="-0.014154306602133423" MODIFIED="2013-08-29 18:09:31 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.2553536421225942" STUDY_ID="STD-Killen-2010" TOTAL_1="121" TOTAL_2="122" VAR="0.0652054825452739" WEIGHT="46.08218611553686"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2013-11-26 16:56:08 +0000" MODIFIED_BY="Lindsay Stead" NO="7">
<NAME>Venlafaxine versus placebo. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-11-26 16:43:06 +0000" MODIFIED_BY="Lindsay Stead" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="71" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Venlafaxine versus placebo</NAME>
<GROUP_LABEL_1>Venlaxafine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3204588124286825" CI_START="0.6449417873922918" EFFECT_SIZE="1.2233400402414487" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.36557386420357496" LOG_CI_START="-0.19047948312476937" LOG_EFFECT_SIZE="0.08754719053940282" MODIFIED="2009-07-30 14:52:16 +0100" MODIFIED_BY="Lindsay Stead" ORDER="209" O_E="0.0" SE="0.32662848872913064" STUDY_ID="STD-Cinciripini-2005" TOTAL_1="71" TOTAL_2="76" VAR="0.1066861696494758" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2013-11-26 16:56:05 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>St John's wort versus placebo. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="1.4160625794435049" CI_END="2.5263442448881084" CI_START="0.25857189311148066" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8082336382828992" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="29.38165201759744" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.4024925281152057" LOG_CI_START="-0.5874186849080557" LOG_EFFECT_SIZE="-0.09246307839642497" METHOD="MH" MODIFIED="2013-11-26 16:43:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2340528088802455" P_Q="1.0" P_Z="0.7142587156623204" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="111" WEIGHT="100.0" Z="0.36614254121483114">
<NAME>St John's wort versus placebo</NAME>
<GROUP_LABEL_1>St John's Wort</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours St John's Wort</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9491950383813619" CI_START="0.1318964196980899" EFFECT_SIZE="0.5070422535211268" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2898552972268343" LOG_CI_START="-0.8797669931304104" LOG_EFFECT_SIZE="-0.29495584795178803" MODIFIED="2013-08-14 15:39:41 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.6870419230795582" STUDY_ID="STD-Parsons-2009" TOTAL_1="71" TOTAL_2="72" VAR="0.4720266040688576" WEIGHT="89.93666432090077"/>
<DICH_DATA CI_END="66.1246811677714" CI_START="0.18525609172949106" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8203635910181177" LOG_CI_START="-0.7322275023175662" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2013-08-29 17:33:27 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="1.4994046437550757" STUDY_ID="STD-Sood-2010" TOTAL_1="79" TOTAL_2="39" VAR="2.2482142857142855" WEIGHT="10.063335679099225"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-11-26 16:56:02 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>SAMe versus placebo. Abstinence at 6m or greater follow-up</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-11-26 16:43:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="80" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>SAMe versus placebo</NAME>
<GROUP_LABEL_1>SAMe</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SAMe</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0675908702901866" CI_START="0.23699079302436094" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.31546460581750124" LOG_CI_START="-0.6252685257889876" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2013-08-21 10:27:50 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.5525912982097554" STUDY_ID="STD-Sood-2012" TOTAL_1="80" TOTAL_2="40" VAR="0.3053571428571428" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-03 10:08:43 +0000" MODIFIED_BY="Lindsay Stead">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-12-03 10:08:43 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADOCAMAAADbsfL2AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-11-26 15:13:25 +0000" MODIFIED_BY="Lindsay Stead" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Bupropion. Abstinence at 6m or greater follow-up, outcome: 1.1 Bupropion versus placebo/control. Subgroups by length of follow-up.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvgAAAPwCAMAAABz2PoIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-11-26 17:06:58 +0000" MODIFIED_BY="Lindsay Stead" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Nortriptyline versus placebo, long-term abstinence</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvIAAADgCAMAAABWxHLHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Bupropion AEs.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2013-10-07 13:30:53 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIy
MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAKQAsQDASIA
AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA
AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3
ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm
p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA
AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx
BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK
U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+iii
gAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5zV9bvLLW9P0yxsILme8jlkDT3JhVAm3PRGz
nd+ldHXIeJvDlxq+t6ZfR2Gm38FpHMkltfuVVi+3BH7txxg9qQD9L8Y2F7bRNcl7a5kE58obpFIh
Yh2VwMEccdM+lTS+NdAiEe++fElul1lbeVgsL/ddiF+Vfc4x3xXNr4M1mBbWSCWyMqLeR+Q0riK3
SfG1YztJYLjphfwqsvh/XY76fSYILcrJ4fgsJbmXeIgw3KxRtp3EZzt46jJFAHZHxPpQ1K4sRdMZ
rZA85WCQxxKV3hmkC7FBXnJNV/8AhL9AFnLevetHDGYy/mQSIwD8I20qGKnPDYx78VnjwZK1t4hs
3ukW31OCCGCQZZ08uIJlgcdxng/lWT4j8Pa5PYTalPDA9+Vs7WO3st8y7UmDs7ZUHqTxjgDqafWw
dLnVDxRZTzWqW0yMZro2rJMskUiPsLY2FM5wM/NtGO/qReK9EmE0qXxCQRPMzGFwHjU4ZkJX94AR
1XP61jSeD9SvtW/tG7ktYpZr8XE0UUjMqRiBolCkqNzc5OQKqnwZq9xpcNjPNaAWGmz2No8bv++M
i7Q8g2/JgAcDdyT6UugdTrtJ1/TtaaZLC4aRodpdWieMgMMqcMBkEcgjg1s1y+g6DdaXrN7dzPE0
c9rawqEJJDRKwbOR05GK6imxC0UUUDEriz40u0W6u5NJhGm22pHT5ZluyZQd4Tf5fl4xkjjdmu0r
jdI8HwQXV7c6mDPJJqUt7Ai3MpiUE5UmPITcPXB+tJbh0JLTxjZfY3uLxZICLieJY4o5J2KxMVZ8
IpIHQnjAz1q7deKtFtEheW8YpNALlWjheQCI4xI21TsXnq2B19DXMT+DNZe2Nv5ljcW7y3jPazTS
CLMr7o5CApDsoP3SMA8gg81c0zwzrmhG1msf7Omuf7MisplnlkCI8ecOuFJYHccr8vTrzTWwM3Zf
EulRaiti14PPZkT5UZkDOMqrOBtVj2BIJyPUVT0XxrY6ncPazK1tdfa5raNCGZJDGT0faF3EDO3O
azLnwbdvrlzO4guLS6uorqRnu7iPYygZAhQhGOVBDM3Gec45ZbeDdWdo7O8ks1sI9Tn1ASQyMZTv
37U2lQP4sk59sd6QHRad4g0zVblrezut8mCy5jdBIoO0sjMAHAPGVyOnrW/XE6J4Z1KyvdI+3y2v
k6PbSW1u0DMWnDYG5wQNuFUcAtyetdtTYhaKKKBhRRRQAUUUUAFFFFABRRRQAVzur63eWWt6fpdj
ZQXM95HLIGmuTCqBNvojZzu/SuirlNe8KQ+INb06e7ht5rCCCeKWOXlsuFCleOCMHnII7UgItN8Z
W975D3IhtFaO4eUNKzbfJbaxU7NrL3ySp9j2W98a6fFpU95Zb7h4HhV4JUeBwJWCq2HXOOcg4wcd
azbDwlq0CadDcy6fLHY2VzZLvVmWRHK+WWTC9lwwz+JzVZ/BesT6Je6f58VrBKtskNqt/PPHD5bh
mZGddyZHAUDHA5piOzg1S1vTcPauZRbyNFIdjAb16gEjBweMjPPFYOl+MLq9TRZrvS7e3ttXZlga
K8MjqQpb5lMa4Hy9QTjir/h/RrrRbK505pllsklY2RLlnWNudj5HZicHJ4xXO6T4CutDfRbuxNjD
fwW72uoOqnEqNkh1+Xl1OOuMjgnFIZtP4x0ZbS6nimuZjb2zXW1bWRTLGONyFlAdc45BI7k45p1p
4ysZrdrm4ZbWBLOK7fzBIHUOSANpQZ5GBgkt2HIzzln4J1cTTSXX2HzpdJnsJbkTySyzyPjErsyg
n0xk4A44wBYbwVq9wvmzS2MNxFaWkcKrI8imW3csNx2qQrDHTkZPXHLBnX6dq1nq0byWkjMI3Mci
PG0bow7MjAMp6HkdxWxXM6DpV1bXuqajemJbrUJ1doYWLpGqqFUBiBuPGScD07V01AgooooGFFFF
ABRRRQAUUUUAFFFFABRRRQAlZWs6idJ0W91EReb9lgeby923dtBOM4OOlatY2vWE2qeHtQsIGRZr
m3kiRnJCgspAzjPHNJ7aAt9TD/4TK7tCBqVhaW+/T3v4mjvHlUKuMh/3QZfvDkBuhrUPinSY76Oz
ku9s7GNTiKQxq7jKqZNu0EjoCQenFc1P4CubaO+i0hbCCLUdK+yXUZBUCdVwrrhTwcnPT15NWLnw
vqh1aO5tJLW0YtbmS6t7maKQrH1V4h8kuRkAnbwcY45YjV0zxRb38xt2jMFw15PbRRLukLiI4Lkh
flHTrxyBmm6l4jvrbXbjTrLTraf7PZC8kluLswjaSwwMRt/d7kVmaR4Ov9G8QNq0V3GzT3dwbmIy
MUa3kbcm0Y4dWwffJ5qXxB4Lh8R6xf3F4sDQzaettA5GZIZQ7NvHHA5HQ88ilrZD0uy6njTRzpln
eXUssAuLdLhl8iSQQo3ALsqkKM5GWwDio5vGFrFqOo2QhdWsZYInlnSRI3aQgcFUb1GM/e+nzVja
14O8Ra1YGG7k0yeR7GOACSaQR20yk7pI0CYJYYGeCuSBkcGzqHhPVbi+1NomshBezWU4ZpXDIYCm
5duw5BAODn0GO9VpcXQ6GHxFpk2ptp0d1uufMaLlHCNIoyyByNpYDqoORzxwa364Wz8LX0d1Z2sk
1v8A2bZajJqEUyM3nOW3EIy4wAC7fMGOQBwM13VIfUWiiigAooooAKKKKACiiigAooooAKKKKACu
Z8QeIJdLv7CwtLOK5vL0SGJZrnyEbYAdoba2WORgY/EV01cr4o0q81u1Fp9g0u9tGVt8V6zxsj4+
V0dQ2MZPYH3FJgiKXxfb2WqtYahbXVo0Vh9tuHaJnWId1ygIOOeQcZGBknAvy+KdJiWd3vMLbxxS
y/u3yFk+5gY5J9Bk+1c5c+DtXnUxyXsNyZtDOmT3E0jbxJktvA2ncCSByQe/NMHg3WplvZp5LGO4
YWLW6Ryu6brcnh2KA4b2HGfblgbOk+MLTVL2eBg1swvJLWAOrZlKIHYnKjYQCflbng/hoNr+mHRl
1j7UBp5TzBMVYZBOBgYzkngDGTniuM13QdXh0DUBsVtWvdWW7tBZI8qx7giEM20BRt35ZsA/jgdN
rGgNc+G7XS7GRFksmhkt/MB2ExEFQ2OQDtxkdKOn3B1HyeLNGhs1upLmRUa4FrsNvL5glIyEMe3e
CQOARzx6iptb8QxaR4ek1jyZJIwE2pIDCcswUbtwygyRnIyPSsR/Cuo3WoJqc8lpHcyatBezQpIz
IkccZQKrbRuY5zkgfpXS6vBdXGmyw2cdnLK+FMV4paKRf4lOOmRnnB+hpPYOpTt9fZIrYavbpZT3
Vz5Fssc3npOcZVlZQOCAT8wXpWdceN9OhvtPjjWSa0vI53+0RxyMymI7SBGFLHnPPYDPSs6HwZqd
nb2z262kZtdU+2wWH2mQwRJsIKK5TIySW+7jJxRp/hTXtLOkTQPpk1xZR3iyJJI6oxmk3DB2E8d+
PbvmgDfvfGug2MMU09/mKSFbgPFFJIojJwGYqp2gngZxk8VO3iXSV1G4sHuHE9qoe4xBIUhUrvBd
9u1RjnJIrgNW8M3+iaXNpGnq97Ne6bDayEW0xCurk5VlQpg7iPmZdvB56V1V14VnvX8UrNcRxxax
HEkTJlmj2R7SWHA6+h6elP0DqXI/F+iSWT3X2x0iRowwkgkRv3hwh2soba2eGxj34p114p0a3dhL
dtuW6NntWCRiZgu7YAFJJwe3XpWDqHg7WNZiubq7ksYb8wW0EMUMrtEwikEhLMVBG45GNpx6mq15
oOvWV7Z3P2a3nuZ9fa+2Ql3iiQw7cO2zI5GN2O4OO1AHcadqVpqdmt3ZTCWBiVztKkEHBBBAIIPY
jNatc94Z0ifR9PmS6dGubm5lupRExKKzsTtXIHAGOwroKBDJH2Rs2M7RnFclpPim4u9ETXtSs7ax
0x4vM8xLl5pF5xygiHHvk4rrJV3xOo6kEVw3hrwhLpuknS7/AEfR08y2e3nvrWUmaYH1BiX/ANCP
Sl3GdBceI9Ms5J4prp/MhkSJkSF3Yu43KqhQS5xzhc4HWq0/jHRLe3tbh71jHcxvJF5cEjlgn38q
qkjb3BAIwfQ1hDwXqJ0qyea4hm1aC9N1MUuJYFmBTywBIo3qdgXkDqCOhqWLwhcxiyaP7JGY4L1Z
kWaVx5k4GMM+5m6ck4z1A5xTA1U8X6b/AGwLHdL5X2D7ebsxt5Qj6g7sYxjJzwO3XgX9L17T9ZaV
LKd2kiCs8ckLxOAwyrbXAOD2PQ1zlp4V1O1ls/8AkHzRjQ00ydZi7KHXJyFwN6k8YJU4q94V0LUd
ImuDcyLDaGGKKGyivJbmOMrnLKZQCoOQNoyOOtAjr+1cpba9rM3iWTRpNKsUMMSTySrfu37tmI4H
kjLfKeMge9dX2rmzoc7+KNQ1BmjFtd2MdqNpO8EFyTjGMfMO9IfQhk8X6KLW8uIriWcW0Lz7UgfM
qKcExkgBwDwWUkDuQKE8Y6SmnW13dyT2/nQJO6m2lbyVY4BchPlGcgFsA4yOKx4/BmpzWUNld3Fo
iWGnXFhayQsxM3mLsDyAgbcADgFuSeeKpar4I17VdMFpMdNkH2CK2iSW5lZLaRCcyIuzBLDA3YBX
JAyOrA7TT9Z/tLUNVtBD5f8AZ86w79+7zMorZxjj72O9TazqJ0nRbzUBF5v2WB5vL3bd20E4zg46
VQ0DSLnT7/V7i4aErezpJGsbE7QI1Qg5A7qfWrmvWE2q+HtQsIGRZrm2kiRnJCgspAzjPHNKW2gR
31KVprlytpb3Wq29rZR3bRJb+TcPOWd+it+7Xb2GeRUlx4p0e1VmkunO2WSIrHBI7bo/v4VVJKr3
bGB61k23hi4Xw7daYdK0nTpWhjMdxZSFt8ycq7jykxhgD1PU1Tn8F3qR6XNA0Ut3DBNHdJ9smtVk
eVt7MHjG7G/PynqD2xTYlsdBeeMdB0+REn1AYaFLgNHE8i+U5wrllUgKT3J7j1FVh4w0xNV1a1uI
7iCPTRH5kzwvtct2XC89VAHVs8AgZrHvfAt7JY3lraNZRpLpEVjGu6QKrrIWPXcdvPHJNW7/AMLX
9zfeIf3Om3FpqiQFUumk4aNQu0hQMZ5IcNlTj5TQM6bTNWstWikkspWcRuY5FeNo3jYdmVgGB+oq
zdNcpbu1rFFLOB8iSyGNT9WCsR+RrF8NabqGlw3iahctJ50++GE3Ulz5CbQNokkAZuQT04zXS0ME
chpXiqa60+81LVLW00+wtZZInlW6aVi6Ps+75a8E9MEk8DHNOvPG2n2kNpJGtzObi8WzKLbyB4nP
J3oV3A45C4ye3HNVD4Tvm8Nz2AntxdDUnv4D8xjJ87zFVuMj0OOnvUM/hbVri5fU82Y1BtUhvmt/
OfygkSFAofZkk5znb7dqS6Abg8T6Wbw2UcztcZkVAYZFSRkBLKshXYSMHIB4wfSregar/bmg2OqG
HyftUQk8vfu257ZwM/lXGp4P1g+ILXUbp7GZoLm4ka6kmkaaSORWCJgrhAmfugkdTx367wzptxo3
huw025aNpraBY2aMkqSPTIFNbCe43VtabTNS0m2a23xX87QGbfjym2Fl4xznBHUVif8ACdE6ff3I
0wmWC5iht4vP4uFkfYjg7eM4Y4wenWtbxTpF3q+jiPT5YYr+CaOe2kmzsV1YHnHOMZH41kN4Oul1
TQXilgFlZRQrdIS26RoQ3lleOfmck5I/GkvMbNlfE2mSai9lHdbrhS6jMbiNmQZZVk27WYdwCSOe
ODVBvHGiwabbXl5dCMy263LeRHLKqITgEkICATwNwXJ7Vm2Pgm6tdRAcQS2sVzNcwzSXlwWBfcQB
CCI1ILEFucjtzXP6l4d1bSdIl0q2h+13N7pcFnKI7ed1R0Y4KuI9mDk53Mu3rz0oQdTt4/GNgviG
80i6DW7wzxQRSbXZZWkQMASFwh5wATzireheIbfXmvvssFzELS5a3PnRMm4jqeR6546jjOM4rFu/
COoXGpXdyslsEm1SzvFBZshIlUMD8vXg4/mK0/D2kXukTatHP5DQ3V9JdwvG5LYc5KspUAY46E59
qYjpaxPE2tSaBokuoR2ounR0RYjJ5e4s4UfNg46+lblc94r0q41rQnsrYxrKZonzKSFwsisegPYG
kMzk8aeZrOh2CadldTgSV5TN/qSyuwXG35vuMOorYvdXNr4h07SRbhvtkU0nm78bNm3jGOc7vUdK
5238IahBrFpeefbmO2vpJF2sdwg2OqAZXG4Fzx096t3nhJtQ13S7jUZk1W0tUnEi6hFGzEuF24VY
wuBtPXnmmBq+H9YOuaabwweRiaWLZv3fccrnOB1xmqVtr99eazqNtFp9sLXT5RFLPJdsHOUD5CCM
juB96q3hvTNT8PGz0ny7VrFjdSyNErfu8ybo1BwAOGPGO3HAqax8LpBres6lcW9nJcXcoa2m2Zki
XyghG4jI5B6HoaX+QuvzHweMtI+wRXN1dxxM9ot4QiyMpjLBcqSgLfMQMYzyOKtv4j0qDU1sJboi
4ZkjI8p9quwyqs+Nqseykg8jjkVybeCNXk0/RYnuLJZtEtlNoeXWS4DAkvleEwoHHPOewq1ceDry
bW7m5kW3ktby6iu5A97cL5TKBkCJNqvyoIZiMdwcU+odDWk8W2J8QWGkWgNw1xPLBJJhlWNo0LHB
K4c5GDg8Z5q94h1b+xtKkuzCZ23pFHGG27ndgqgnBwMnk4PHY1zln4W1ex1XT2VrFrGwvLq5jcu5
lcTK+AV24GC2ODyPTHOncwalrng7yby0sjqE8KtJBOsixbsg44O9fY9QfpS6D6lW98bLYafLJc2l
vFfQ36WMkT3e2FWYBg/mlfu7DnO3PBGKfN4z+z3mmwXFtatHdp5kk9teebGiFsKynYN4456Y96hs
PDGoaVbyz28Omz3s1+LtobuWSVYwF2/JMwL78DO8qepGO9TWXhIR6dDBdw2ctw13JcSPsz5CyNue
OIkZwfunpkEn2ph0Okt7vzdOS8lQwBo/MZWOSgxnn3xWJp3iHUdRhgv49GUaXcI0kc32oeaqgEqz
xlQAGx/CzEZGR1wzwv4auNK0/UbW9likW7lJxESQwK4LnIHzN1PX6ml0nS9f0/TrTSGbT2sbWIw/
aS7tLKgGEGzaAh6ZO5unTnhPyBGroGq/25oNlqZh8n7VEJPL3btue2cDP5Vr1h+GNMn0Xw3Yabcm
NpraBY2aMkqSPTIFblN2voJXtqFFFFAwooooAKKKKAENcRH49d7bXJP7Kw+mziGJPtH/AB8ZlaPO
dvy8r7125rz+PwXqSXLMZ7Xy5bq5mlUM2SrNvi/h6huv9aWtxqxvr4jLeCf+Ej+ygD7F9r+z+Z/s
7tu7H64/CiDxCZ9Y0/T/ALNt+2WLXnmCTOzBUbcY5+919ulZS+FdRPhBNJ/tNlmXTTZmBdn2dn2F
dxYx+ZjJ7EdOlRHwrPoVzFqui2WmxT22lSQNHHCR50/ylSQgBYfKffmm7cz7E9F3N3XtbuNJl02C
1s4ria+ufs6CWcxKp2s2SQrH+H071BL4jg0+e4j1U29sba3jnn8p5Jdm9iv/ADzHy5HX65A61Hr2
gyeIDohure1eK1uRPdQzjcrDy2BAGCDyR1qlqfhjUHvtUk002UMN5p8VhGj5AiUM247QpB+VuB69
eKWozWk8R6TFDNKbosIrn7KQkTuzS/3EABLn/dzjB9DUN54v0i20yK+S585Zo5JIESJyW2D5twCk
oB0JYDb3rD/4Qq+t9NsrC3lgkh0u9aWyH2iS3aSJgQVd41yrAsfmXOe45NKvg7UrRbeewGnrcm3u
YLiJ5pmjHnENvDNuZiCOc43c/doYI63RdROraLZ6g0XlfaoEm8vdu27lBxnAz1rFsvF32rVIo3sv
Ksbi7msoLjzsu0sec7k2/Kp2tghj0GQM1N4dttU077LpV1HCbWz06BBNGGy0oBVhk4BHyg8Dvz2r
Ii8HXH/CTrqE0dnDBBdS3UZt5ZT5rMu0boWOxDzlmU/NgcDmm99NhLbUksfHpv8ASr3U4bWweCAN
thTUN0+d+xN6bMIG65ycDsa29E1z+3IFkW3MQEYMvz5CuSRtBwM9M544I45rMsfDd5NqVpPqlppc
NtaWstqtvZKTHOshGdyMoCqAPu5bknn1rx+D7mHX9Lv4vssMVuWaVI8r5ZO75IxjG0qVQ9OEFC6A
+pr3et3Q1eXS9MsI7u6ggE83nXBhRQxIVQQrZY4PGAOOtSWOty3WuTaZNYNbyRWcVy2+UMQXLAoQ
uRxt6gnNQXOl6pZeIrnVtJWzma7t0hmhupWiAZCdjgqrZ4YgjA7c07TtJv4fElxql5LbP51jDAfJ
DL+8VmLEKc4X5hjk0kNnTUUUUwCiiigAooooAKKKKACiiigDnv8AhBPCH/QqaH/4Lof/AIms288M
+BLC5tre68P6DFLdPshVtPi+Y5A/u8Dcyrk8bnRerKD2dcB4i0PXfEWsahNp81taCyt0t7Jr61ds
3G5LgyRsrgbNyWwyyyDdCw243BwDe/4QTwh/0Kmh/wDguh/+Jqla+EvBV/C0tt4a0aSNZZISf7Oi
GHjdo3HK9mVh+HFYNxJeXMlwV0bVkbVNa0zUkRrUjyYB9jDNIfuqytE6smS4xuxsy1LoOmyx+ILZ
49Jvra/XWdQmurqaFgslmz3OwLIePLMjRMIsglh5mzB3kA3bfwb4SuLaOdfC+jhJEDqJNLjjYAjP
KsgKn2IBHeodQ8MeCtKt1nu/DWkDe+yNItJSWSRsE4REQsxwCcAHAUnoCa5SHw9cyeGLiebTbo6h
aeEbFLINE+6K8RLk/IvadGKYIG9N3GNxz6H4g1htD0s3Udjd3spcJHDbQSSkse7bFYqg6lsHAHAY
4UgHPTaZ8PYba1uP+Ec0yVZ93lx2+i+dN8pw+YkjLrtbCtlRtYhTgnFJdaf8PbMwmTQdEeKWITiW
DS0mjSJvuyyOiFY4zgkO5CkKxz8pw2xC6PPoWpGLUbm0SyvYrm4XTZxK9zNNDIztbhTIgdo5m+7t
HAGAVzkHStS0/wAL3Wk3FhdNd3/hW00qBYYWmX7SiTqyO6ArGAZU+ZyF5JzgHAB0Vz4Z8D2V/ZWN
xoWgx3V+7pbQnT4t0pRS7YAXoFHJ6cgdSM6n/CCeEP8AoVND/wDBdD/8TWBq+l66/wAQdG1QWNtc
2cd6scEouH3W0P2acSFk8shSzOcsHw+yBSARur0CgDnv+EE8If8AQqaH/wCC6H/4mj/hBPCH/Qqa
H/4Lof8A4muhooA57/hBPCH/AEKmh/8Aguh/+Jo/4QTwh/0Kmh/+C6H/AOJroaKAOe/4QTwh/wBC
pof/AILof/iaP+EE8If9Cpof/guh/wDia6GigDnv+EE8If8AQqaH/wCC6H/4mj/hBPCH/QqaH/4L
of8A4muhooA57/hBPCH/AEKmh/8Aguh/+Jo/4QTwh/0Kmh/+C6H/AOJroaKAOe/4QTwh/wBCpof/
AILof/iaxdI0fwJrlv8AadO8L6c0BRHEk2h+QsisMqUMkahxjnK57eorpNcs11LQdTsJI55I7m2l
haOBlEjBkIIQt8obnjdxnrxWT4Y3f2jqH2T+1f7I8qHyf7S+0eZ9ozJ5uPtH7zbt8j/YznHO6gC5
/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8TXQ0UAcLp+jfD/U7hobTw/o7Ps8xC+kL
GsyZALxMyASpyvzIWHzLz8wy0aP8Pmg1CePQtBeOxn+yzlNOjfbNhf3YATLPl1XauSWO373FPWXU
tS8ST3+mwXa3EWnXESJqts0UVpcMYdkasqjzUdo2LsrSgeWNrKGG7F0zRdXsNI1q0l0zYsGs6feb
4pnuHuFi+yvNLnykMrERsxKgs7lxjIG4A39P8MeCtVt2ntPDWkHY+yRJdJSKSNsA4dHQMpwQcEDI
YHoQa0/+EE8If9Cpof8A4Lof/iah8NiSW51y/MNxFb32oLNbieFonZFt4IySjgMvzxuPmAzjI4IJ
6egDnv8AhBPCH/QqaH/4Lof/AImj/hBPCH/QqaH/AOC6H/4muhooA57/AIQTwh/0Kmh/+C6H/wCJ
qpceD/Blrby3M/hzQoYIlLySPYwqqKBkkkrgAAZzXWVSngjnjCTRJKgdZArqGAZWDKee4YAg9iAa
AOd07wt4K1PTbW/tvDOiyW11Ek0L/wBmxruRgCpwVyOCOtXv+EE8If8AQqaH/wCC6H/4mm+DYJbX
wT4ft54nhmi063SSOQFWRhEoIIPIIPGK6OgDk7jwf4MtbeW5n8OaFDBEpeSR7GFVRQMkklcAADOa
ovovgJNHtNVHh3R3tLxUe28rSVkkmDruGyNYy7HblsBcgAk4AOOtngjnjCTRJKgdZArqGAZWDKee
4YAg9iAa4Q6Zcp4H8EieHUbeOxWBr4WsTm4iX7JJEyhFBkBLOqHYNyhiQV27gAaFxo/w9t9Ck1uf
Q9Ch0+JC0k0mmxrswdpUqU3Bw3y7Mbt3y4zxWv8A8IJ4Q/6FTQ//AAXQ/wDxNcZ4m0nxHq/w+eJb
b7ZCkV+/2a6lkW4kT94tpldjmRhGytsfa/mLGSwYNn0S3W6MERuFSOcqDIkbl1VscgMQCRnvgZ9B
QBnf8IJ4Q/6FTQ//AAXQ/wDxNH/CCeEP+hU0P/wXQ/8AxNdDRQBxsHhvwNd6rd6dB4f0GS8s0je5
hXT4iYhJu2bvlwCQpOOuMHoRmvqGjfD/AEy4WG78P6Or7PMcppCyLCmSA8rKhEScN8zlR8rc/Kca
mn2X2Txpqkkdp5FvLYWu11TajyeddvJg9C2XDHv8+T1rn/EsV7JrF3qVgdYSa70iBdJW2hlVXu0a
dk8/C5QKZY/lmKxne24HadoBcuNJ+HttfS2txoegQyRIWkeTTo1iTCbypkKbA4T59md2z5sbeauW
/g3wlcW0c6+F9HCSIHUSaXHGwBGeVZAVPsQCO9ZXjbw3cXhZ9JgnuL64lN4baTH2UyxRbC0mcZ81
AlsYzIFKSs207WNdD4ZuL65tLg3cl3NAtwVtbi8t/Inmi2IS0ke1NpEhkUfIuVVTg53EAX/hBPCH
/QqaH/4Lof8A4mj/AIQTwh/0Kmh/+C6H/wCJroaKAOL1Dwx4L0m3We78M6QA77ESLSUlkkbBOERE
LMcAnABwFJ6AmprDwp4M1G1S5tfDeiSQPkA/2bEpBBwyspXKsCCCpAIIIIBFaXiDWG0PSzdR2N3e
ylwkcNtBJKSx7tsViqDqWwcAcBjhTQ0pJbbwvHa6XJJLqMtvPPHNe2c1uktyWJd5UIBjDSuW2ccE
7QQOACpBoXgG5i1GaLRPDxh0+R4buT7DCEhdFDOGYrj5Qwz6cg8ggT6f4X8Fanptrf23hnRJLe5i
SaF/7NjXcjAFTgrkcEdapeBtFvbBNcsdU0yBIRfwzRu0pnM8iwQZlLNEm9t6BzJjJkL8Ark7Pg2C
W18E+H7eeJ4ZotOt0kjkBVkYRKCCDyCDxigDnUh+G8lnbXi+HtKNvcxCdZP7EOI4iSBLL+6/dRna
xDvtUhWIJAJrSv8Awx4K0m3We78M6QA77ESLSUlkkbBOERELMcAnABwFJ6AmuUs7e4bwQbeOzu5n
1bwfZWFkYrd5FacRTgq7KCIh++j+Zyq8nn5Wx6BrWutpFnPPFZX15JHKsCQwWkz7nYAgkqjHywDl
nUNjBABYbSAYE2mfD2G2tbj/AIRzTJVn3eXHb6L503ynD5iSMuu1sK2VG1iFOCcVo2/g/wAGXVvF
cweHNCmglUPHIljCyupGQQQuCCDnNYbWwtbbQ7mGfWYY1gu1uNStNMkNy9xLLG75t3jcokjrI5/d
4UqgVlBw3ReG5FttG07RZYUtdQs9NtWntIyzLAGUoFDEnI3RuPvE/LyeQSAZUOjeALnVDp0fh7SD
NvaNWOkKIndc7kSUpsdxtbKqxI2PkfK2F0/Rvh/qdw0Np4f0dn2eYhfSFjWZMgF4mZAJU5X5kLD5
l5+YZsjUI9T8aQQS2upRwaY8vkGXTp1jmuChUyiXYECKhlQZbDmQnHyozZnhkz2n/CP+fZ3sf9h6
BLZ3+60lG2b/AEb5Y/l/ff6mTmPcOBz8y5AL9z4Z8D2V/ZWNxoWgx3V+7pbQnT4t0pRS7YAXoFHJ
6cgdSMwPpngEXk1qvh3S2ki3jKaJuSRkBLpG4j2ySDa2UQlvkYYypxHq+l66/wAQdG1QWNtc2cd6
scEouH3W0P2acSFk8shSzOcsHw+yBSARupum2V4nii0iaG+/0fVLy5ktZLcra28bi42zxzbRvkfz
EynmOB5z/IuweWAaeneFvBWp6ba39t4Z0WS2uokmhf8As2NdyMAVOCuRwR1q9/wgnhD/AKFTQ/8A
wXQ//E0vgT/knvhr/sFWv/opa6CgDnv+EE8If9Cpof8A4Lof/iaP+EE8If8AQqaH/wCC6H/4muho
oA57/hBPCH/QqaH/AOC6H/4mj/hBPCH/AEKmh/8Aguh/+JroaKAOe/4QTwh/0Kmh/wDguh/+Jo/4
QTwh/wBCpof/AILof/ia6GigDnv+EE8If9Cpof8A4Lof/iaP+EE8If8AQqaH/wCC6H/4muhooA57
/hBPCH/QqaH/AOC6H/4mj/hBPCH/AEKmh/8Aguh/+Jroay7/AEfTNVMf9o6fa3nlg+X9ogWTZnGc
bgcZwPyoApf8IJ4Q/wChU0P/AMF0P/xNH/CCeEP+hU0P/wAF0P8A8TU3/CIeGv8AoXNI/wDAKP8A
+Jo/4RDw1/0Lmkf+AUf/AMTQBD/wgnhD/oVND/8ABdD/APE1j6T4N8NTarryS+GtHZIb5UiVrKIh
F+zQNgfLwNzMcepJ71vf8Ih4a/6FzSP/AACj/wDiaxNJ8LeHpdU11JNC0x1iv0SMNZxkIv2aBsDj
gZJP1J9aANX/AIQXwh/0Kmh/+C6H/wCJo/4QXwgP+ZV0P/wXQ/8AxNTf8Ih4a/6FzSP/AACj/wDi
apX3gPwpqNm9rceH9PEb4yYYBE/BzwyYYdOxo0An/wCEE8If9Cpof/guh/8AiaP+EE8If9Crof8A
4Lof/iagtvBXhe2tkgj8PaYUjQKpe1R2wBgZYgkn3JJq7/wiHhr/AKFzSP8AwCj/APiaT30Ah/4Q
Twh/0Kmh/wDguh/+Jo/4QTwh/wBCpof/AILof/iam/4RDw1/0Lmkf+AUf/xNH/CIeGv+hc0j/wAA
o/8A4mmBD/wgnhD/AKFTQ/8AwXQ//E0f8IJ4Q/6FTQ//AAXQ/wDxNTf8Ih4a/wChc0j/AMAo/wD4
mj/hEPDX/QuaR/4BR/8AxNAEP/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/AMTV6x06x0yE
w6fZ29pCzbjHbxLGpbpnAA54H5Vp0Ac9/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8
TXQ0UAc9/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8TXQ0UAc9/wAIJ4Q/6FTQ/wDw
XQ//ABNFdDRQAVjalrFppTRC6M7SyklIra2kuJGAxltkas20ZUFsYBZQTyM7Ncndu2i+JbrVLuG5
ktLyzt7ZWtLaS4ZJInmYhkjUsAwmGCAR8rAkEruANiG9huDAYG86K4jM0UsSl43T5ed4G3ncCOeR
kjODjUrzfxRp1/dWFw0OkSW8kvh7WF+zW6+ZiWV4GVWKDBlf5iQM5bdgtjcZNT0SSzuNXtNOsLga
Y0WmTTxorOLnF1Ibst1M0jQqof7zuNoO7IBAO0aZUuEgYSb3RmBEbFcAgHLYwD8wwCcnnGcHAsyv
cPAok3oisSY2C4JIGGxgn5TkA5HGcZGeE8RabJPpLrpmlX0VqfDmrwwQNE25S7QeWgXkpuAJSPgq
o27V2lQzxPpI086lHbWN0bRl0WNPJkZHmf8AtCVnCylgTKS4JYuDlwxYE5oA9CMyxPEjCQtI+wFY
2YA7S3zEDCjAPJwM4HUgFlxOsFvJcMJCkaF2EcbSMQBnhVBLH2AJPauK0zT5F1LTZbHT5rbSBrrz
WkP2VoFgg/s50Y+UQDEpn39QuWbPO8E4qeHbqz8E29vZaXdJcXXhC7jvVETmSW58qARJJnkuuZVR
T90blUADFAHpGoalbaVbrPdvIA77I44onlkkbBOERAWY4BOADgKT0BNVZvEmlQ29rciaeZZ93lx2
9rLNN8pw+YkUuu1sK2VG1iFOCcVJ4g1htD0s3Udjd3spcJHDbQSSkse7bFYqg6lsHAHAY4U83Yhd
Hn0LUjFqNzaJZXsVzcLps4le5mmhkZ2twpkQO0czfd2jgDAK5AOpbXNMWbTYRfQM+p5+xBH3eeAh
csuOq7Rnd05HPIzDNr2nQap/Z0lxIJt6xswgkMSO2NqPKBsRzlcKzAnemB8y55/TdEuLGw8CJLYF
b2z8mG8dEDGMR2NwmGdc/KHcgc4y/HXm34ikmvdRsbCG31EyxXttL5P2Um1uI1ljcyNMFwhjCuyq
XQlkwVdWUMAdlRRRQAUUUUAFFFFABRRRQBRubiG1tpbieZIYIlLySOwVUUDJJJ4AA5zVTTdYtNVa
UWpnWWIgvFc20lvIoOcNskVW2nDANjBKsAeDi3cSPFbySJDJO6KWWKPaGcgfdG4gZPTkge4rB8PF
7rX9X1ELfSWs8UCR3F7bNbyAq8zGEIyIfLQOpDFSSZGBdtuFAOsooooAxoNb0y5h1GaO+haHTpHh
u5C+EhdFDOGY8fKGGfTkHkECCHxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFYVxol
03h7x1plhY+X9qLw2MKoI0cfYII1CZwu3cpX0G0jtVmLVRDqet+I00/U5bNbC1gjj+wTLPNLG9wz
KkTqHPEsfzY28nn5WwAb2n6lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cz4VbzrS6vH
WYXV3cvPdGa2mg+chQqqsqIWVI1jjDhRu2ZIDFq6agAooooAKzr69g062e6uZPLhTGSFLEknAVVH
LMSQAoBJJAAJNaNZOqX66VY3F+9td3IhTcILSBppZD2VVHJJOPYdSQMmgA0/UrbVbdp7R5CEfZJH
LE8UkbYBw6OAynBBwQMhgehBrWrmfCredaXV46zC6u7l57ozW00HzkKFVVlRCypGscYcKN2zJAYt
XTUAUbm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1RfXrAaRaasJ5JLS8RHtvKhkkkmDruGyNVLsduW
wFyACTgA4vzwRzxhJoklQOsgV1DAMrBlPPcMAQexANcZZ21xp/hXwNc3FndhdMWB7yJLd3liH2KW
L/VqC5IeRQQASMkngEgA6CbxJpUNva3ImnmWfd5cdvayzTfKcPmJFLrtbCtlRtYhTgnFaVtcQ3Vt
FcQTJNBKoeORGDK6kZBBHBBHOa8+GmzRSaVeahFrMFgz6qz/AGCKbzmFxdpNCriIGaMFFLHG0gqF
YjJU91of9o/2Bpn9r/8AIT+yxfbPu/67YN/3fl+9npx6UAatFFFAGFDr2nT6p/Z0dxIZt7RqxgkE
TuudyJKRsdxhsqrEjY+R8rYXUPEOm6XOsF3cyK+zzHKQSSLChJAeVlBEScN8zlR8rc/KcZQ1CPU/
GkEEtrqUcGmPL5Bl06dY5rgoVMol2BAioZUGWw5kJx8qM0PjG6e+0GWwtoNVL31oxt40s2Md2WRh
9nmO0tApyu4t5RAbhxtbaAbU+v6Ta30lnNepDJEhaR3BWJMJvKmQjYHCDfszu2fNjbzV63nWe3ju
FEgSRA6iSNo2AIzyrAFT7EAjvXF+NvDdxeFn0mCe4vriU3htpMfZTLFFsLSZxnzUCWxjMgUpKzbT
tY10Phm4vrm0uDdyXc0C3BW1uLy38ieaLYhLSR7U2kSGRR8i5VVODncQDoqKKKACsm+1W10qO3e+
uo4RPcR2sIbrJK7bVRR1JJ/IAk8Amtaua8VWH2qztpYrPzrmO/strpHudI/tkDyYI5C4QMe3yZPS
gDT1G+t9O0y6vrqTy7a2ieaZ9pbaigljgcngHpVH/hJdOGn/AGx/t0cbS+SkcthcJNI+N2EiKCR+
Mn5VPCseinEXiKK11DS7iyuotQeKJ7e4k+xK6yYWYOCjDkkGPJCHzMfdG5kzzNxaXVzaWkudaXSL
TWTLC5Sd7xbU2bRtwwNxzPI65xvVW3KVUKwAOpsrzRdL8NNfWSw2mk2sUkzLBbmNYVXcZAYwMqwI
bcuNwYEEZ4py+JNLN5DbNNOssvljc9pKqRs4BRJHK7Y5DuXCOQ3zqMZYZw9U+1/8Kh8QfbfP3fYN
Q8n7RnzPI/e+Rv3fNu8ry87/AJ8/e+bNN1C3uW1LVdPWzujPfa5YX8DrbuYjBF9k8xmlA2IR5Evy
swY7RgHcuQDpdS1i00pohdGdpZSSkVtbSXEjAYy2yNWbaMqC2MAsoJ5Gc/UPE2i6RnUZlnaOW1WZ
r610+aeNoBuZSZo0Zdoy7YJ4DE9+YPEmvTW2miKyh1ET3bSW8dzDp804tSuVMzKqMSAeVGMOduDt
JdXmxikm8NabZWs0WjWkRuwJIn27YkVIYXVxkNmVZBu+YNb9M8qAdbWHp/iHTdUnaC0uZGfZ5iF4
JI1mQEAvEzACVOV+ZCw+ZefmGbcF9b3V1dwwyb5LWUQzjaRscorgc9fldTx6/WuK8OWtzY6tZO41
FtP0bSJ7PypdOeJoVDQbF43faJSsThmiLIdi7VXcN4B2R1SyGsppJuY/t727XQgHLeUrBS59BuYA
Z684zg4r3+p6V9pm0i9dZ55LOS5kshEZme3BCsSgBJBLbQMZbkAHBqrPZbfHVjdQ2hWNrC88+ZI8
AyF7QLuYfxFY8DPOE9BWLZaXrkHxOXUryytZILi3vUN3HcO3lw77cQx4MWFOEzs3kFnncEfdIB1m
kTWU+jWM+mhF06WCN7URx7FERUFMLgbRtxxgYrUrn/An/JPfDX/YKtf/AEUtdBQAUUUUAFFFFABR
RRQAUUUUAFFFc/eeE/Duo3kl3f6Bpd3cyY3zT2cbu2BgZYgk8AD8KAOgornv+EE8If8AQqaH/wCC
6H/4mj/hBPCH/QqaH/4Lof8A4mgDoaxdF/5C3iP/ALCKf+ktvUH/AAgnhD/oVND/APBdD/8AE1ja
R4M8LS6rrqSeGtHdYr9EjDWERCL9mgbA+XgZJP1J9aAO5pa5KX4deD5LmC4bw1pYeDdtVLdVQ7hg
7kA2v7bgcdsVc/4QTwh/0Kuh/wDguh/+JpO3QDoaK57/AIQTwh/0Kmh/+C6H/wCJo/4QTwh/0Kmh
/wDguh/+JpgdDRXPf8IJ4Q/6FTQ//BdD/wDE0f8ACCeEP+hU0P8A8F0P/wATQB0NFFFABRRRQAUU
UUAFFFFABRRRQAVzuoeJdO0/UTYTi+kuFiWZktdPuLnajFgpJjRgMlG4P9010VcddagukeN9RuLm
21EwT6bZxxSWunT3ClkluSwzGjAEB14P94UAdHbXEN1bRXEEyTQSqHjkRgyupGQQRwQRzmmpfW76
jLYrJm4iijmkTaflRy4U56cmN/y9xXC6no92mkWNvdaLBdma7vbkRXVkb9InmnaWOJoVkVBIVkI8
5m2R7HG7EmTSFhr1z4fdpba7N3JoeirctcwPKZNk8rXKOmQ0p2Ft8edzBtvVhkA9Xrmo9f0LU0mE
s8bQQJ9qD3UDRxOkbBvOjeQBZEU7G3oSBlDnlSafg+zax0q7JGy3kui9vEmnNYRRpsRSI4HZmRd6
ux3bcszNjBDHJv2l8XW/iPyLHUY7ttIubHT7e6sZrfIcEO5kkRUzIwiwpJKrGD8pZ1UA6eHxJpU1
vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFP/4STSvsH27zrnHm+R5H2WX7R5mN2zyNvmbt
vz4252fN93muZ1KOfWNQ1HVrO0vvsq/2V/rbOWGRvs148022J1DtiNlIwp3HhckEVcg1SbSbbXdb
j0zUbiO/1JGs4RZTCRx9ngi3OgQyRoGjfJKZwuQGyoYA6axvYNRtkuraTzIXzglSpBBwVZTyrAgg
qQCCCCARWjXP+GoooNBtFjlnkZt8kss9q9s8szOzSyGJwCm5y7YxgbuOMV0FABRRRQAUUUUAFFFF
ABRRRQAUUUUAUbm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1U03WLTVWlFqZ1liILxXNtJbyKDnDbJ
FVtpwwDYwSrAHg4j8V2dxqPhLWbC0j8y5urGeGJOBudo2CjJ4HJHWqGjSvqHibUtWhgu47SSztLZ
GubWS3ZpI3uGcBJFVsASpzjByQCSDgA6yiiigCjc3ENrbS3E8yQwRKXkkdgqooGSSTwABzmqmm6x
aaq0otTOssRBeK5tpLeRQc4bZIqttOGAbGCVYA8HFu4keK3kkSGSd0UssUe0M5A+6NxAyenJA9xX
Fm31LVj4in0h7sPeQW8EN3qMcljKg8yUyRJ+7DKESTMchjY735Z9uFAOq0vVLPVrFL7Tblbu1d3V
Jo+VYoxRsHuNynkcHqMitiuR8C2l5p/h6Szu9Ng0/wAu/vPJt4WJRYzcSMuAUTC8nbgYKhTxnA66
gAooooAKo3NxDa20txPMkMESl5JHYKqKBkkk8AAc5q9VKeCOeMJNEkqB1kCuoYBlYMp57hgCD2IB
oAi06+t9R0y1vrWTzLa5iSaF9pXcjAFTg8jgjrWlXOeDYJbXwT4ft54nhmi063SSOQFWRhEoIIPI
IPGK6OgArJ1DUrbSrdZ7t5AHfZHHFE8skjYJwiICzHAJwAcBSegJrWrI1i9ay05nKX2x8xtNZQed
JBkHDhAGLYOBwrckEjaGIAGz+IdKtdAfW5r1IdOiQtJK4K7MHaVKkbg4b5dmN275cZ4rZrynXtD1
7UPh3JbQaek8GzUbmW3nd457hnaUwSGMIwZyHMpiITEvl42bdo9Gt1ujBEbhUjnKgyJG5dVbHIDE
AkZ74GfQUAaFFFFAGXBqlnd6rd6dBcpJeWaRvcxLyYhJu2buwJCk464wehGa+oeIdN0udYLu5kV9
nmOUgkkWFCSA8rKCIk4b5nKj5W5+U4q6fZfZPGmqSR2nkW8tha7XVNqPJ5128mD0LZcMe/z5PWud
8Ww3N9c3720OohNS0mOC3ihtHK3z5m/cXOUJgQeYg3ZhP718v8vyAHVz6/pNrfSWc16kMkSFpHcF
Ykwm8qZCNgcIN+zO7Z82NvNXredZ7eO4USBJEDqJI2jYAjPKsAVPsQCO9cX428N3F4WfSYJ7i+uJ
TeG2kx9lMsUWwtJnGfNQJbGMyBSkrNtO1jXQ+Gbi+ubS4N3JdzQLcFbW4vLfyJ5otiEtJHtTaRIZ
FHyLlVU4OdxAOiooooAKxtS1i00pohdGdpZSSkVtbSXEjAYy2yNWbaMqC2MAsoJ5GdmuT1mV9P8A
E2m6tNBdyWkdnd2ztbWslwyySPbsgKRqzYIifnGBgAkEjIBsTapZwaWuotco1myKySxnzBIGxs2b
clyxIChcliQBkkVW/wCEk0r7B9u865x5vkeR9ll+0eZjds8jb5m7b8+Nudnzfd5qn4febQvBmmWV
5ZXbXWn6bapcQwRGQr8oRtpHDldrEqhZsAYBLKDR0qeSw0nVrqVNXkivL3KXwsT9rZfIjQTPBsBB
V08sBYuioxUgs5ANy51TSrjw5dahcskulC3le582IsBGoIkV4yM5GGDIRkEEEZ4qtb67o1q9pp0H
mQoFijjQWckcUG5R5cTtsCROQUAjYq3zIMfMM4V5BNbfCDxCs8bxu9nqUoMqlXkVzM6yOp+67qwd
lwu0sRtXG0P1C3uW1LVdPWzujPfa5YX8DrbuYjBF9k8xmlA2IR5EvyswY7RgHcuQDpdS1i00pohd
GdpZSSkVtbSXEjAYy2yNWbaMqC2MAsoJ5GXNrmmLNpsIvoGfU8/Ygj7vPAQuWXHVdozu6cjnkZyN
Uu1h8Rabq8lvfNZxWt7ZyNDZTSusrSwbf3aKX2nyZCHxt4HPzLmhpuiXFjYeBElsCt7Z+TDeOiBj
GI7G4TDOuflDuQOcZfjryAdhHBDHLcOkKI0z75GVQC7bQuW9TtVRk9gB2rK0/wAS6dqGoiwgF9Hc
NE0ypdafcW25FKhiDIig4LrwP7wrRgvre6uruGGTfJayiGcbSNjlFcDnr8rqePX61k6NviOt6xeQ
TxSTXcmIzCzyLBB+6RVAG5lbY8qqB1nOAc5YAtTa9p0Gqf2dJcSCbesbMIJDEjtjajygbEc5XCsw
J3pgfMuVuNT0q7l1TS5HW7ezt1a+tFiMxEcithSgB3FlVvkwSRjj5hnmNcsLyTxBJaWZvVW61Sxv
5IfsBaOUxPBvb7SMokYjhJ8ttshdOCVZVbd0+y+yeNNUkjtPIt5bC12uqbUeTzrt5MHoWy4Y9/ny
etAGlpE1lPo1jPpoRdOlgje1EcexREVBTC4G0bccYGK1K5/wJ/yT3w1/2CrX/wBFLXQUAFFZOp6F
pGtGL+1NKsb/AMnIj+1W6S7M4zjcDjOB+Qqp/wAIJ4Q/6FTQ/wDwXQ//ABNAHQ0Vz3/CCeEP+hU0
P/wXQ/8AxNH/AAgnhD/oVND/APBdD/8AE0AdDRXPf8IJ4Q/6FTQ//BdD/wDE0f8ACCeEP+hU0P8A
8F0P/wATQB0NFc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ/wDwXQ//ABNAHQ0lc/8A8IJ4Q/6F
TQ//AAXQ/wDxNVJ/APhG4gkhbwvpCq6lSY7JEYA8cMoBB9wQRRp1A6yiuUg8A+EbeCOJfC+kMqKF
BkskdiBxyzAkn3JJNWv+EF8If9Cpon/guh/+Jo9AOhrF0X/kLeI/+win/pLb1B/wgnhD/oVND/8A
BdD/APE1jaR4M8LS6rrqSeGtHdYr9EjDWERCL9mgbA+XgZJP1J9aAO6ornv+EE8If9Cpof8A4Lof
/iaP+EE8If8AQqaH/wCC6H/4mgDoaK57/hBPCH/QqaH/AOC6H/4mj/hBPCH/AEKmh/8Aguh/+JoA
6Giue/4QTwh/0Kmh/wDguh/+JqXTfDeiaPcNcaZounWM7JsMlrapExUkEglQDjIHHsKANyiiigAo
oooAKKKKACiiigAooooAK53UPEunafqJsJxfSXCxLMyWun3FztRiwUkxowGSjcH+6a6KuOutQXSP
G+o3FzbaiYJ9Ns44pLXTp7hSyS3JYZjRgCA68H+8KAOjtriG6toriCZJoJVDxyIwZXUjIII4II5z
TUvrd9RlsVkzcRRRzSJtPyo5cKc9OTG/5e4rhdT0e7TSLG3utFguzNd3tyIrqyN+kTzTtLHE0KyK
gkKyEeczbI9jjdiTJjstO1K50aV9Th1IyyeHdJWdmgaVpJEedpUkQkGUcjzIwd7KxUcsMgHp1FeZ
xWIOgWKXOiE6NFqrPc20GmzJFcQG3cBhYtudFE5T5MHLJ5uAGyKMFlNc+FdPg/sQ3UQv9TAj1C1b
UvLl+1yBI3jEoUyH5v37vtTawLfvM0AetUV5bZ6LrF/pVxdyW99/bg8JWkNrNM7o63hS5DHcxAEw
LAFj8y7zyAxz0PhiC2i1fUpdI02XT9Ikgt1jhaxezU3AaYysImVTkq0IL7cHAGTtwADUh17Tp9U/
s6O4kM29o1YwSCJ3XO5ElI2O4w2VViRsfI+VsR2vifSboztHdbI44mnMs8bwxvEv3pY3cBZIxkEu
hKgMpz8wznjUI9T8aQQS2upRwaY8vkGXTp1jmuChUyiXYECKhlQZbDmQnHyozcyNK1LUPC9rpNvY
XS3dh4Vu9KnWaFoV+0ukCqiO4CyAmJ/mQleAc4IyAd9pusWmqtKLUzrLEQXiubaS3kUHOG2SKrbT
hgGxglWAPBwul6pZ6tYpfabcrd2ru6pNHyrFGKNg9xuU8jg9RkVzVxHqeu3ev3mixz2/2uwtLKKW
8Sayfcss5l27k3qwjlBV9hXcR12sKv8AgW0vNP8AD0lnd6bBp/l3955NvCxKLGbiRlwCiYXk7cDB
UKeM4AB11FFFABRRRQAUUUUAFFFFAFG5uIbW2luJ5khgiUvJI7BVRQMkkngADnNVNN1i01VpRamd
ZYiC8VzbSW8ig5w2yRVbacMA2MEqwB4OI/Fdncaj4S1mwtI/MubqxnhiTgbnaNgoyeByR1qho0r6
h4m1LVoYLuO0ks7S2Rrm1kt2aSN7hnASRVbAEqc4wckAkg4AOsooooA5618T6TdGdo7rZHHE05ln
jeGN4l+9LG7gLJGMgl0JUBlOfmGZbTxFpt4l1cLPJbpbJvnF7BJbNEmCd7LKFIT5W+bGPlbng4xt
L1WPUtfvNWuLPU4Fs7Z4bWGbS7lGEQcGWQExgM0hWLbGNzBYwRgs6iTw9JDrlxf6peWN3HcXDwEW
99Yyw/Z4oyWhTMiBXdX8yQlc7WfG4hUYgG/p19b6jplrfWsnmW1zEk0L7Su5GAKnB5HBHWtKuc8G
wS2vgnw/bzxPDNFp1ukkcgKsjCJQQQeQQeMV0dABRRRQAVnX17Bp1s91cyeXCmMkKWJJOAqqOWYk
gBQCSSAASa0a57xXBNPo6mGN5fIvbS5dY1LN5cVzFI5CjliFRjgZJxgAkgUAW9P1K21W3ae0eQhH
2SRyxPFJG2AcOjgMpwQcEDIYHoQa1q5jw2JJbnXL8w3EVvfags1uJ4WidkW3gjJKOAy/PG4+YDOM
jggnp6AKNzcQ2ttLcTzJDBEpeSR2CqigZJJPAAHOaozeINLt/Do8QzXqRaSbdblblwVHlsAVOCM5
ORgYySQMZq/PBHPGEmiSVA6yBXUMAysGU89wwBB7EA1xkmkzTfBmKyl053v4fD2yKFoSZUm+yFMB
cZD/ADMuBzyR3oA6jVdVtNE0641HUrlLazt03ySt0UfzJJIAA5JIAyTWxXA/ErS9W1fw5cW2n20F
1bR2ty81u0rrJJJ5RWLaoRxJgszBDtO9YiGGOeut1ujBEbhUjnKgyJG5dVbHIDEAkZ74GfQUAaFF
FFABRRRQAUUUUAFFFFABRRRQBj6pqlnpNi99qVytpao6K80nCqXYIuT2G5hyeB1OBVh763TUYrFp
MXEsUk0abT8yIUDHPTgyJ+fsaz/FUE1zpUCQxySuNRsXKxqWIVbuFmOB2CgknsATXKaho2tWl5Pp
emwTiC10HULbSLmJwpTeLYRQl8jbIrI4UnGUCHczByADtdUksorJl1EI1pO6WzrJHvVzK4jVCuDk
Mzgc8c88VNawRWltHb28KQwRIEjjRQqooGAABwAABxXnWqaNpt3Z30lh4dcaClxpci2Y0iSPMqXT
faHW3KBifJZAzBPmUbcnaQNfxzZz3l9psklvDcabHHcLNHcaVLqUfnExeWfIjYMG2iXEnRQWH8Yy
Ad9WTHqltNezW8c0jyw3H2aRVichJPKEuCcYA2MpyeMkDOTiuI1XSbqG20c3Npdapfw6bBFGt5YP
OzzoDny54pD9jnZiN8zEr/qyGPlsalt9ISDx1PLbaVJCW8RC5lnSzZEeJtNkXf5gXaw81pAeThnO
cF+QDu44IY5bh0hRGmffIyqAXbaFy3qdqqMnsAO1Xa8v8NeEbRYPC9te6PIYJNDZtSjuEcrLcKLY
RrcBuHKBpQiPkJg7QNoxna/a6zceEtNY6TPcaxHoMTQ3E9jLd3IuhGS/ltvUWsyEKxc5aQlQoZow
pAPUIL63urq7hhk3yWsohnG0jY5RXA56/K6nj1+tRRy2WtWcwUC5tXea1lSSPKsUZo5EIYcjcrD0
PuK4u4sHfxbqsqaVff2jLrNlLZXxhYxiBY7X7RsfpFlFkVidvmDCAuV2rU1DSr1oLL7XZRvp63ur
NLFeaPLqKeY94Whf7PGQ2SnmFZOgDEfxjIB6LawRWltHb28KQwRIEjjRQqooGAABwAABxWhWNodv
cWugaZbXUk8tzFaxJNJcEeY7hAGL4ZhuJznDNz3PWtmgAooooAKKKKACiiigAooooAKKKKACiiig
ArF0X/kLeI/+win/AKS29bVYui/8hbxH/wBhFP8A0lt6ANqiiigAooooAKKKKACiiigAooooAKKK
KACiiigAooooAK53UPEunafqJsJxfSXCxLMyWun3FztRiwUkxowGSjcH+6a6KvP9caa28b3dw17r
9hDJp1qiyaXphullZZbgsGPkSgFQ6nHH3u/YA7G3nWe3juFEgSRA6iSNo2AIzyrAFT7EAjvRbzrP
bx3CiQJIgdRJG0bAEZ5VgCp9iAR3rk/7KvJ/EFiiNLNpN79n1K6e4hKPJNbpt3SfKvlyM32JggCj
9xLkDkPzcPh65k8MXE82m3R1C08I2KWQaJ90V4iXJ+Re06MUwQN6buMbjkA9L1LSdO1m3SDUtPtb
2FXDqlzCsqhsEZAYEZwSM+9VbzU9N8PLa2pjkRCm2C2srSSZgiAD5Y4lJCLlRnGBuUdxXN6lYFfG
6XMVhJdXDXELI81hIXjjwqsYbxG2QxKA7GFxlz5gwRKudvxXrM+naekFpHffbLzdFFc21hLcra8c
yuqI2duRhSPmbA4G5lAJrrxPpNqYGkut8ckSziWCN5o0ib7ssjoCscZwSHchSFY5+U4km17ToNU/
s6S4kE29Y2YQSGJHbG1HlA2I5yuFZgTvTA+Zc8lrFh9m0/VrDTNOvvsup+HINN0xFtpmw6i4ASQk
ExYE0XMu3qcn5Wxc1C3uW1LVdPWzujPfa5YX8DrbuYjBF9k8xmlA2IR5EvyswY7RgHcuQDqoNUs7
vVbvToLlJLyzSN7mJeTEJN2zd2BIUnHXGD0IzqVzOn2X2Txpqkkdp5FvLYWu11TajyeddvJg9C2X
DHv8+T1rpqACiiigAooooAKKKKACiiigAooooAo3NxDa20txPMkMESl5JHYKqKBkkk8AAc5qppus
WmqtKLUzrLEQXiubaS3kUHOG2SKrbThgGxglWAPBxH4rs7jUfCWs2FpH5lzdWM8MScDc7RsFGTwO
SOtUNGlfUPE2patDBdx2klnaWyNc2sluzSRvcM4CSKrYAlTnGDkgEkHAB1lFFFABWdfXsGnWz3Vz
J5cKYyQpYkk4Cqo5ZiSAFAJJIABJrRrB8S232jQpcLOTDLDcIYYvNZWilSRWKZBdQUBZVO5lBC/M
RQBY0/UrbVbdp7R5CEfZJHLE8UkbYBw6OAynBBwQMhgehBrWrj/B0N4Bq95dtO/27UBcRyT2ptmd
RbwocRMAyKHjdVDfNtUEls7j2FABRRRQAVnX17Bp1s91cyeXCmMkKWJJOAqqOWYkgBQCSSAASa0a
57xXBNPo6mGN5fIvbS5dY1LN5cVzFI5CjliFRjgZJxgAkgUAW9P1K21W3ae0eQhH2SRyxPFJG2Ac
OjgMpwQcEDIYHoQa1q5jw2JJbnXL8w3EVvfags1uJ4WidkW3gjJKOAy/PG4+YDOMjggnp6ACiiig
DG1LWLTSmiF0Z2llJKRW1tJcSMBjLbI1ZtoyoLYwCygnkZt21xDdW0VxBMk0Eqh45EYMrqRkEEcE
Ec5rn/FCvBqOn6jFNfW8sUc1q1xa6e15tjkMbMAiZZZP3alXKsg2sGU7lB0fClncad4S0awu4/Lu
bWxghlTg7XWNQwyODyD0oA3aKKKACiiigAooooAKKKKACiiigDH1TVLPSbF77UrlbS1R0V5pOFUu
wRcnsNzDk8DqcCrD31umoxWLSYuJYpJo02n5kQoGOenBkT8/Y1n+KoJrnSoEhjklcajYuVjUsQq3
cLMcDsFBJPYAmuU1DRtatLyfS9NgnEFroOoW2kXMThSm8WwihL5G2RWRwpOMoEO5mDkAHd3l5b2M
ImuJDHG0scIJUnLyOqIOPVmUfjzWhXlWqaNpt3Z30lh4dcaClxpci2Y0iSPMqXTfaHW3KBifJZAz
BPmUbcnaQNfxzZz3l9psklvDcabHHcLNHcaVLqUfnExeWfIjYMG2iXEnRQWH8YyAd9WTHqltNezW
8c0jyw3H2aRVichJPKEuCcYA2MpyeMkDOTiuI1XSbqG20c3Npdapfw6bBFGt5YPOzzoDny54pD9j
nZiN8zEr/qyGPlsalt9ISDx1PLbaVJCW8RC5lnSzZEeJtNkXf5gXaw81pAeThnOcF+QD0iivL/DX
hG0WDwvbXujyGCTQ2bUo7hHKy3Ci2Ea3AbhygaUIj5CYO0DaMZ2v2us3HhLTWOkz3GsR6DE0NxPY
y3dyLoRkv5bb1FrMhCsXOWkJUKGaMKQD1CC+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frS2d5b30
Jmt5DJGsskJIUjDxuyOOfRlYfhxXC3Fg7+LdVlTSr7+0ZdZspbK+MLGMQLHa/aNj9IsosisTt8wY
QFyu1amoaVetBZfa7KN9PW91ZpYrzR5dRTzHvC0L/Z4yGyU8wrJ0AYj+MZAPVaKxtDt7i10DTLa6
knluYrWJJpLgjzHcIAxfDMNxOc4Zue561s0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYui/wDI
W8R/9hFP/SW3rarF0X/kLeI/+win/pLb0AbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR
QAVzuoeJdO0/UTYTi+kuFiWZktdPuLnajFgpJjRgMlG4P9010Vef6401t43u7hr3X7CGTTrVFk0v
TDdLKyy3BYMfIlAKh1OOPvd+wB2NvOs9vHcKJAkiB1EkbRsARnlWAKn2IBHei3nWe3juFEgSRA6i
SNo2AIzyrAFT7EAjvXJ/2VeT+ILFEaWbSb37PqV09xCUeSa3Tbuk+VfLkZvsTBAFH7iXIHIfm4fD
1zJ4YuJ5tNujqFp4RsUsg0T7orxEuT8i9p0Ypggb03cY3HIB6/WNqWsWmlNELoztLKSUitraS4kY
DGW2RqzbRlQWxgFlBPIzy2pWBXxulzFYSXVw1xCyPNYSF448KrGG8RtkMSgOxhcZc+YMESrnb8V6
zPp2npBaR332y83RRXNtYS3K2vHMrqiNnbkYUj5mwOBuZQCa68T6TamBpLrfHJEs4lgjeaNIm+7L
I6ArHGcEh3IUhWOflOJJte06DVP7OkuJBNvWNmEEhiR2xtR5QNiOcrhWYE70wPmXPJaxYfZtP1aw
0zTr77LqfhyDTdMRbaZsOouAEkJBMWBNFzLt6nJ+VsXNQt7ltS1XT1s7oz32uWF/A627mIwRfZPM
ZpQNiEeRL8rMGO0YB3LkA6GPxBZy61NpMX2p7uJ9kpWzmMUbbBJhpdvlg7WU43dwOprdrhbGzFj4
ngh0yPW45Gv7mXUhdGY2xhkEz5jz+45laEjy/wB5gndz5ld1QAUUUUAFFFFABRRRQAUUUUAFFFFA
BWPpeqWerWKX2m3K3dq7uqTR8qxRijYPcblPI4PUZFT3UEV3byW9xCk0EqFJI5FDK6kYIIPBBBPF
UPCsE1tpU6TRyROdRvnCyKVJVruZlOD2KkEHuCDQB0FFFFAFG5uIbW2luJ5khgiUvJI7BVRQMkkn
gADnNZ8PiTTp7S4uEF7m22+bA2n3CzgMcKwhKeYVJB+YKR8rc/KcX7idYLeS4YSFI0LsI42kYgDP
CqCWPsASe1crpWsTS2Wv+I00vUn1E24eKwns5oHEUaMYoAWQB3LmRiUDYMu3LBVJAOj0nWrPWkne
zM/+jy+TKk1vJA6PtV8FZFVvuup6d61qxtD0/wDsfRrSxMrTyQRBZZtu0zSdXkYZPzOxLEkkksSS
etbNABRRRQAVnX17Bp1s91cyeXCmMkKWJJOAqqOWYkgBQCSSAASa0aydUv10qxuL97a7uRCm4QWk
DTSyHsqqOSScew6kgZNABp+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXM+FW860urx
1mF1d3Lz3RmtpoPnIUKqrKiFlSNY4w4UbtmSAxaumoAKydQ1K20q3We7eQB32RxxRPLJI2CcIiAs
xwCcAHAUnoCa1qw/EGsNoelm6jsbu9lLhI4baCSUlj3bYrFUHUtg4A4DHCkAjm8SaVDb2tyJp5ln
3eXHb2ss03ynD5iRS67WwrZUbWIU4JxWlbXEN1bRXEEyTQSqHjkRgyupGQQRwQRzmuK+zjT7DRb6
2uNVjmEVzDPero00ju00iSTv9nxvikeRC6Eo0a8gqQUB6bwpZ3GneEtGsLuPy7m1sYIZU4O11jUM
Mjg8g9KAN2iiigDCh17Tp9U/s6O4kM29o1YwSCJ3XO5ElI2O4w2VViRsfI+VsLqHiHTdLnWC7uZF
fZ5jlIJJFhQkgPKygiJOG+Zyo+VuflOMoahHqfjSCCW11KODTHl8gy6dOsc1wUKmUS7AgRUMqDLY
cyE4+VGaHxjdPfaDLYW0Gql760Y28aWbGO7LIw+zzHaWgU5XcW8ogNw42ttANqfX9Jtb6SzmvUhk
iQtI7grEmE3lTIRsDhBv2Z3bPmxt5q9bzrPbx3CiQJIgdRJG0bAEZ5VgCp9iAR3ri/G3hu4vCz6T
BPcX1xKbw20mPsplii2FpM4z5qBLYxmQKUlZtp2sa6HwzcX1zaXBu5LuaBbgra3F5b+RPNFsQlpI
9qbSJDIo+RcqqnBzuIB0VFFFABWNqWsWmlNELoztLKSUitraS4kYDGW2RqzbRlQWxgFlBPIzs1ye
syvp/ibTdWmgu5LSOzu7Z2trWS4ZZJHt2QFI1ZsERPzjAwASCRkA15tVtLfR5dXe5Q2EdubpriP5
1MQXdvG3O4beeM57U211eyurGa/zNb20G4yvfW0lrsCjJYiVVO0D+Lp154Nc5DpY/wCFd6Zoep22
pCWxsrB7qOyDCRWiZCdjr94q0RJEZL4Hy8smYlsNZ1LRbq0sYpJ9NfUkMMOrzzxSS2axozozSI8m
GnDqRIp3RlgMKUIAOq/t3Tv7A/t37R/xLPsv2zz9jf6nZv3bcbvu84xn2qoviTSzeQ2zTTrLL5Y3
PaSqkbOAUSRyu2OQ7lwjkN86jGWGeaMN5bfAyaC/tvs9xF4bdHhJOV225A3ZAIbAGRjg5GTjJn1C
3uW1LVdPWzujPfa5YX8DrbuYjBF9k8xmlA2IR5EvyswY7RgHcuQDpdS1i00pohdGdpZSSkVtbSXE
jAYy2yNWbaMqC2MAsoJ5GY7zxNpNj9jLS3Fx9siae2+xWst15ka7cuPKVvl/eJz0+YVnapdrD4i0
3V5Le+azitb2zkaGymldZWlg2/u0UvtPkyEPjbwOfmXPNHRZ9K8P6fi31yLxKmg21nafZHla2FzC
j7Vk8o7OJHGTN+7IIwSN9AHqdYNhr9nqt9Na2f2t2geRHkazmSLdG+xwsjKEYhgRgE9D6Vdgvre6
uruGGTfJayiGcbSNjlFcDnr8rqePX61yHhm3j0W4gt9Pi8QJptjp0iXseorPKyyoYxEIw2VY7ROM
W+UPHX93QB0s3iCytdYTSnN296yo+yGymlVFdmVS7ohVASjcsR90npUTeJNLF5NbLNO0sXmDclpK
ySMgJdI3C7ZJBtbKIS3yMMZU4xL+0+y+JpptNj1pNVutQtpWbdMbN4R5KTH5f3A/dJIP3n7zcPl/
5Z1WtrC8Hi+wt4Gvvsllqt1fNBLYlERZo7jdIZ+UlzJMuxUIZVch1JUlQDstOvrfUdMtb61k8y2u
YkmhfaV3IwBU4PI4I61pVz/gT/knvhr/ALBVr/6KWugoAKKKKACiiigAorD1Lw3omsXC3Gp6Lp19
OqbBJdWqSsFBJABYE4yTx7mov+EE8If9Cpof/guh/wDiaAOhornv+EE8If8AQqaH/wCC6H/4mj/h
BPCH/QqaH/4Lof8A4mgDoaK57/hBPCH/AEKmh/8Aguh/+Jo/4QTwh/0Kmh/+C6H/AOJoA6Gkrn/+
EE8If9Cpof8A4Lof/iaoRfDfwZHqDX3/AAjWnmWRNpR4Q0QHH3Yj8ingchQevqaAOwrF0X/kLeI/
+win/pLb1B/wgnhD/oVND/8ABdD/APE1jaR4M8LS6rrqSeGtHdYr9EjDWERCL9mgbA+XgZJP1J9a
AO6ornv+EE8If9Cpof8A4Lof/iaP+EE8If8AQqaH/wCC6H/4mgDoaK57/hBPCH/QqaH/AOC6H/4m
j/hBPCH/AEKmh/8Aguh/+JoA6GisnTNC0jRTL/ZelWNh52BJ9lt0i34zjO0DOMn8zWtQAUUUUAFF
FFABRRRQAUUUUAFFFFABXO6h4l07T9RNhOL6S4WJZmS10+4udqMWCkmNGAyUbg/3TXRVyDaXez+P
Ly+W9vra2SwshiGOMx3JWW5LIzOjHgEZ2FTh/cUAdfRXmWoaVfzePJpnjxI1/ay2k66VJNMtsqw+
Yq3e8RwxkrOGjPJDPgN5gBdD4XiuH00XWmTsbjxHfzXm8PzB/p3lhvSE71+X7jeacg+YdwB6XWXB
qlnd6rd6dBcpJeWaRvcxLyYhJu2buwJCk464wehGeb8K6bNBq19BOyNBoqHSrJVJ/dRs3nbenzDy
Gsky2Tuif1LPpafZfZPGmqSR2nkW8tha7XVNqPJ5128mD0LZcMe/z5PWgCW18T6TdGdo7rZHHE05
lnjeGN4l+9LG7gLJGMgl0JUBlOfmGbGm6xaaq0otTOssRBeK5tpLeRQc4bZIqttOGAbGCVYA8HHC
WuiXF3jTpU1WXTrXQrvSTbtZC1kiV/IVEV5DsmmKxuDIjGLKKQFBy1q3tfEOpHxDeWlzJJPe2Vra
R3E9rNpoQrJN5oiVlaVCI5Ayud43txkDYoB2Wl6pZ6tYpfabcrd2ru6pNHyrFGKNg9xuU8jg9RkV
sVyPgW0vNP8AD0lnd6bBp/l3955NvCxKLGbiRlwCiYXk7cDBUKeM4HXUAFFFFABRRRQAUUUUAFFF
FABRRRQBRubiG1tpbieZIYIlLySOwVUUDJJJ4AA5zVTTdYtNVaUWpnWWIgvFc20lvIoOcNskVW2n
DANjBKsAeDiPxXZ3Go+EtZsLSPzLm6sZ4Yk4G52jYKMngckdaoaNK+oeJtS1aGC7jtJLO0tka5tZ
Ldmkje4ZwEkVWwBKnOMHJAJIOADrKKKKAKNzcQ2ttLcTzJDBEpeSR2CqigZJJPAAHOazofEulvZ6
hfPNPDFYxGa5W5tZYZI4wCd/luocqdrYIGCVYDJBqxrlmupaDqdhJHPJHc20sLRwMokYMhBCFvlD
c8buM9eK4yKyn1eXWb/VTql1ayxaeC9rYS2Ega3uJJWEUT/vtqho2JBZmLOEOQFUA7TTtTh1S3aa
CO7RFfYRdWktu2cA8LIqkjnrjHX0rWrnfCnn/Y7/AD9u/s/7V/xL/t3m+d5PlR7t3m/vf9b52N/O
MY+XbXRUAFFFFABWdfXsGnWz3VzJ5cKYyQpYkk4Cqo5ZiSAFAJJIABJrRrnvFcE0+jqYY3l8i9tL
l1jUs3lxXMUjkKOWIVGOBknGACSBQBb0/UrbVbdp7R5CEfZJHLE8UkbYBw6OAynBBwQMhgehBrWr
mPDYkludcvzDcRW99qCzW4nhaJ2RbeCMko4DL88bj5gM4yOCCenoAKydQ1K20q3We7eQB32RxxRP
LJI2CcIiAsxwCcAHAUnoCa1q5nxUHENjeQ+es9ldedFLFZtdrGTFJGS8KMJHXEhHychipPyhqAJb
rxLpkGn2t6805iu5TDAsFrLLI0gDFkMaKXDKI33AgFSpBwRWlbzrPbx3CiQJIgdRJG0bAEZ5VgCp
9iAR3rhbTSLW20vTbvWk8QsyS6iY5rJZ0kZJ7nzVMqWwWRWZVVsbQqncGCttFdpof9o/2Bpn9r/8
hP7LF9s+7/rtg3/d+X72enHpQBq0UUUAFFFFABRRRQAUUUUAFFFFAGPqmqWek2L32pXK2lqjorzS
cKpdgi5PYbmHJ4HU4FWHvrdNRisWkxcSxSTRptPzIhQMc9ODIn5+xrP8VQTXOlQJDHJK41GxcrGp
YhVu4WY4HYKCSewBNcpqGja1aXk+l6bBOILXQdQttIuYnClN4thFCXyNsisjhScZQIdzMHIAO11S
SyismXUQjWk7pbOske9XMriNUK4OQzOBzxzzxU1rBFaW0dvbwpDBEgSONFCqigYAAHAAAHFedapo
2m3dnfSWHh1xoKXGlyLZjSJI8ypdN9odbcoGJ8lkDME+ZRtydpA1/HNnPeX2mySW8Nxpscdws0dx
pUupR+cTF5Z8iNgwbaJcSdFBYfxjIB31ZMeqW017NbxzSPLDcfZpFWJyEk8oS4JxgDYynJ4yQM5O
K4jVdJuobbRzc2l1ql/DpsEUa3lg87POgOfLnikP2OdmI3zMSv8AqyGPlsalt9ISDx1PLbaVJCW8
RC5lnSzZEeJtNkXf5gXaw81pAeThnOcF+QDu44IY5bh0hRGmffIyqAXbaFy3qdqqMnsAO1Xa8v8A
DXhG0WDwvbXujyGCTQ2bUo7hHKy3Ci2Ea3AbhygaUIj5CYO0DaMZ2v2us3HhLTWOkz3GsR6DE0Nx
PYy3dyLoRkv5bb1FrMhCsXOWkJUKGaMKQD1CC+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frUUctl
rVnMFAubV3mtZUkjyrFGaORCGHI3Kw9D7iuLuLB38W6rKmlX39oy6zZS2V8YWMYgWO1+0bH6RZRZ
FYnb5gwgLldq1NQ0q9aCy+12Ub6et7qzSxXmjy6inmPeFoX+zxkNkp5hWToAxH8YyAei2sEVpbR2
9vCkMESBI40UKqKBgAAcAAAcVoVjaHb3FroGmW11JPLcxWsSTSXBHmO4QBi+GYbic5wzc9z1rZoA
KKKKACiiigAooooAKKKKACiiigAooooAKxdF/wCQt4j/AOwin/pLb1tVi6L/AMhbxH/2EU/9Jbeg
DaooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsbUtYtNKaIXRnaWUkpFbW0lxIwGMtsj
Vm2jKgtjALKCeRnZrktTaTSvEN/qMq3y21/YQWkc9jbNcSQSxvO2Sio55EwKnay5QhsZUMAb9tcQ
3VtFcQTJNBKoeORGDK6kZBBHBBHOavV5Zqmkamtlow1OCC4tR9ukuEutG/tFfNlmV4TJb220ecE8
wNIoKhi4yd4JTVtJvBpxt72zvr/U/wCwoLbSbqW2M0kOoKJQ8nmJvW3kLGAmQuBlQd52EgA9Hggj
gjKQxJEhdpCqKFBZmLMeO5Ykk9ySau153qOju9x4mvjYTyyTaraBvkZvMslS0NwqJ/ErKkisqgmT
YFIbaAMU2BnsdTj0/T5ItLj8QK89reWEl2ot/sEYQNaq29k3mIrHwY/kJVfLIUA9QubiG1tpbieZ
IYIlLySOwVUUDJJJ4AA5zWbD4k0qa3urkzTwrBt8yO4tZYZvmOExE6h23NlVwp3MCoyRiq/huN9N
8KRGdp3SLzpQos2jZYzI7IqQAuyqEKhI/vBQqkA/KOfMkuu6dqOrfYdRW9a80+d7aawmieC0guEk
EYDKBK4AnkITccybAXAQkA6v/hJNK+wfbvOuceb5HkfZZftHmY3bPI2+Zu2/PjbnZ833eaZN4k0q
G3tbkTTzLPu8uO3tZZpvlOHzEil12thWyo2sQpwTiud2z/2n/b/2O+/s/wDt/wC2/wDHnL53k/2d
9m3eRt83/W/LjbnHzY2/NVY2t1aJp95INTsInk1OT7TZWRnuUWe7EsSNEY5Nqug3HdHuUoqkqSVY
A722uIbq2iuIJkmglUPHIjBldSMggjggjnNXqwfDUFxZ+F9Itbi1jtZ4LOGOS2jYssLKgBQEliQC
MZyenU9a3qACiiigAooooAKKKKACiiigArH0vVLPVrFL7Tblbu1d3VJo+VYoxRsHuNynkcHqMip7
qCK7t5Le4hSaCVCkkcihldSMEEHgggniqHhWCa20qdJo5InOo3zhZFKkq13MynB7FSCD3BBoA6Ci
iigCjc3ENrbS3E8yQwRKXkkdgqooGSSTwABzms2HxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKr
hTuYFRkjFaNxOsFvJcMJCkaF2EcbSMQBnhVBLH2AJPauKjca7purapJa6rBevLaTJDJpsyvbRQSC
SFCrhPO2uJJHWMlvnZFZsISAddp+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXH+Dob
wDV7y7ad/t2oC4jkntTbM6i3hQ4iYBkUPG6qG+baoJLZ3HsKACiiigArOvr2DTrZ7q5k8uFMZIUs
SScBVUcsxJACgEkkAAk1o1k6pfrpVjcX7213ciFNwgtIGmlkPZVUckk49h1JAyaADT9SttVt2ntH
kIR9kkcsTxSRtgHDo4DKcEHBAyGB6EGtauZ8Kt51pdXjrMLq7uXnujNbTQfOQoVVWVELKkaxxhwo
3bMkBi1dNQAVk6hqVtpVus928gDvsjjiieWSRsE4REBZjgE4AOApPQE1rVh+INYbQ9LN1HY3d7KX
CRw20EkpLHu2xWKoOpbBwBwGOFIBHN4k0qG3tbkTTzLPu8uO3tZZpvlOHzEil12thWyo2sQpwTit
K2uIbq2iuIJkmglUPHIjBldSMggjggjnNcV9nGn2Gi31tcarHMIrmGe9XRppHdppEknf7PjfFI8i
F0JRo15BUgoD03hSzuNO8JaNYXcfl3NrYwQypwdrrGoYZHB5B6UAbtFFFAGFDr2nT6p/Z0dxIZt7
RqxgkETuudyJKRsdxhsqrEjY+R8rYnvtVtdKjt3vrqOET3EdrCG6ySu21UUdSSfyAJPAJrEGoR6n
40ggltdSjg0x5fIMunTrHNcFCplEuwIEVDKgy2HMhOPlRmzfGVjreq3Ol6lYWUF5ZQS2csEM8ksM
scpuomaRozE2MIoXd8rRq82Q2cUAdNPr+k2t9JZzXqQyRIWkdwViTCbypkI2Bwg37M7tnzY281et
51nt47hRIEkQOokjaNgCM8qwBU+xAI71xfjbw3cXhZ9JgnuL64lN4baTH2UyxRbC0mcZ81AlsYzI
FKSs207WNdD4ZuL65tLg3cl3NAtwVtbi8t/Inmi2IS0ke1NpEhkUfIuVVTg53EA6KiiigArG1LWL
TSmiF0Z2llJKRW1tJcSMBjLbI1ZtoyoLYwCygnkZ2a5PWZX0/wATabq00F3JaR2d3bO1tayXDLJI
9uyApGrNgiJ+cYGACQSMgGvNqtpb6PLq73KGwjtzdNcR/OpiC7t4253DbzxnPaqn/CS6cNP+2P8A
bo42l8lI5bC4SaR8bsJEUEj8ZPyqeFY9FOMWHSx/wrvTND1O21IS2NlYPdR2QYSK0TITsdfvFWiJ
IjJfA+XlkzVgF1EbG/8AI1SXSLDWmmt/PhnluVt2snjJKODO3+kSOPmBIBz9wAgA6s61YJok2sfa
SLCGJ5pZCjZjVM7wy43Bl2sCpG4EEEZGKgXxJpZvIbZpp1ll8sbntJVSNnAKJI5XbHIdy4RyG+dR
jLDPPX0E0Hwn8TmZHi8+31S5RZFKt5crzyISp5UlXU4OCM4IBBFP1C3uW1LVdPWzujPfa5YX8Drb
uYjBF9k8xmlA2IR5EvyswY7RgHcuQDpdS1i00pohdGdpZSSkVtbSXEjAYy2yNWbaMqC2MAsoJ5GY
7zxNpNj9jLS3Fx9siae2+xWst15ka7cuPKVvl/eJz0+YVnapdrD4i03V5Le+azitb2zkaGymldZW
lg2/u0UvtPkyEPjbwOfmXPNHRZ9K8P6fi31yLxKmg21nafZHla2FzCj7Vk8o7OJHGTN+7IIwSN9A
HqdYNhr9nqt9Na2f2t2geRHkazmSLdG+xwsjKEYhgRgE9D6Vdgvre6uruGGTfJayiGcbSNjlFcDn
r8rqePX61yHhm3j0W4gt9Pi8QJptjp0iXseorPKyyoYxEIw2VY7ROMW+UPHX93QB0c2vadBqn9nS
XEgm3rGzCCQxI7Y2o8oGxHOVwrMCd6YHzLmUa3p8t1qFnHcmW506JJrqGFGkeNXDFRtUEliFJCjL
dOORnG1nUY77xHY6LLa6ktpDcQ3M8y6dO8U8gO6KMSKhUBXCSM5YAbFX5gz7Len2X2Txpqkkdp5F
vLYWu11TajyeddvJg9C2XDHv8+T1oA1NOvrfUdMtb61k8y2uYkmhfaV3IwBU4PI4I61pVz/gT/kn
vhr/ALBVr/6KWugoAKKKKACiiigAornJ/Bvhi5uHuLjw7pE00rl5JJLGJmdickklckk96d/wgnhD
/oVND/8ABdD/APE0AdDRXPf8IJ4Q/wChU0P/AMF0P/xNH/CCeEP+hU0P/wAF0P8A8TQB0NFc9/wg
nhD/AKFTQ/8AwXQ//E0f8IJ4Q/6FTQ//AAXQ/wDxNAHQUVz/APwgvhD/AKFXQ/8AwXRf/E1m2Hw3
8HafAYYvDWnSIWLE3MInbPHRpNxA46Zx+dCsB2dYui/8hbxH/wBhFP8A0lt6g/4QTwh/0Kmh/wDg
uh/+JrG0jwZ4Wl1XXUk8NaO6xX6JGGsIiEX7NA2B8vAySfqT60Ad1RXPf8IJ4Q/6FTQ//BdD/wDE
0f8ACCeEP+hU0P8A8F0P/wATQB0NFc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ/wDwXQ//ABNA
HQ0Vl6bpOnaNbvBpun2tlCzl2S2hWJS2AMkKAM4AGfatSgAooooAKKKKACiiigAooooAKKKKACsb
UtYtNKaIXRnaWUkpFbW0lxIwGMtsjVm2jKgtjALKCeRnZrktTaTSvEN/qMq3y21/YQWkc9jbNcSQ
SxvO2Sio55EwKnay5QhsZUMAb9tcQ3VtFcQTJNBKoeORGDK6kZBBHBBHOavV5xJpT28ej/8ACTad
JqWnhL55oTYLdYnlnSSBpIYEK+aI/NDSKu3cX+b58tn3Ph3U5dG1C41Gxu7jWrXwraLbysWlYXyL
ckshBIadW24cZYb+CN5yAej39haanaPaXtrBdW0mN8M8YkRsHIyp4PIB/Cqg/s3w7pcMUUENlZLK
kMcUEO1FeWQKoCqOMu47d8muOaz0qbxZq93B4ZnXU7eO4gs/J06W0+2yPGHklN3sCoxYNGj7gR87
Bm8wYo6dp1+p1CG30zydPN3o8sCWmjyafC5W9JmkELMzBgqruZtp2opxtCsQD1qivNNH0u/j8b/a
LhPLuVv7uWaVNLkWSW3Yy+Usl4X2SxhWhIjUEqVQYHlsVteDbBrLV5o49PkQC3K3F3LYSWkxkDLg
TuWKXkrfOTMnClXIOJRQB0k2vadBqn9nSXEgm3rGzCCQxI7Y2o8oGxHOVwrMCd6YHzLkh17Tp9U/
s6O4kM29o1YwSCJ3XO5ElI2O4w2VViRsfI+VsZes6jHfeI7HRZbXUltIbiG5nmXTp3inkB3RRiRU
KgK4SRnLADYq/MGfZS0+3uV1LStPazuhPY65f387tbuIhBL9r8tllI2OT58XyqxYbjkDa2ADotP8
Q6bqk7QWlzIz7PMQvBJGsyAgF4mYASpyvzIWHzLz8wzJpeqWerWKX2m3K3dq7uqTR8qxRijYPcbl
PI4PUZFcl4X0+Wf+wbC902by9M0KXTL9Lu1ZYzK32YbAXAWVT5MnKblwBz8wz0vhWCa20qdJo5In
Oo3zhZFKkq13MynB7FSCD3BBoA6CiiigAooooAKKKKACiiigArLsdVtNSkuksrlJzZ3BtbjYchJQ
qsUz0JAYZx0OR1BFTX/2v+z7n+z/ACPt3lv9n+0Z8vzMHbv287c4zjnFcp4F0vUtJOtWl9Zpbx/b
Y3SUTtK1w32aEPIWMce8sy7mfHLtICOMkA7miiigDnrXxPpN0Z2jutkccTTmWeN4Y3iX70sbuAsk
YyCXQlQGU5+YZWHxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFZWl6rHqWv3mrXFnq
cC2ds8NrDNpdyjCIODLICYwGaQrFtjG5gsYIwWdRkXH2nxDo2qalHb6rbX8t3YSlJNPlimtbWGdJ
AqiSPbLIuJpCFV/mfYN4CbgDttP1K21W3ae0eQhH2SRyxPFJG2AcOjgMpwQcEDIYHoQa1q53wp5/
2O/z9u/s/wC1f8S/7d5vneT5Ue7d5v73/W+djfzjGPl210VABRRRQAVnX17Bp1s91cyeXCmMkKWJ
JOAqqOWYkgBQCSSAASa0aydUv10qxuL97a7uRCm4QWkDTSyHsqqOSScew6kgZNABp+pW2q27T2jy
EI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXM+FW860urx1mF1d3Lz3RmtpoPnIUKqrKiFlSNY4w4Ub
tmSAxaumoAzr69g062e6uZPLhTGSFLEknAVVHLMSQAoBJJAAJNU/+Ek0r7B9u865x5vkeR9ll+0e
Zjds8jb5m7b8+Nudnzfd5qfVL9dKsbi/e2u7kQpuEFpA00sh7KqjkknHsOpIGTXOWWrtpXh681f7
BqN3qF5elpYk0+6QmVgoQbTEH8qONY0MgT5hGTtLnaQDoJ/EOlWugPrc16kOnRIWklcFdmDtKlSN
wcN8uzG7d8uM8Vs15b4l0PUr/wCHS22lwf2hbi0vJ7yO5imtJ7q6ZX/eCBo2JzI8kgjIX5xEVYBe
fQrdbowRG4VI5yoMiRuXVWxyAxAJGe+Bn0FAGhRRRQBhQ69p0+qf2dHcSGbe0asYJBE7rnciSkbH
cYbKqxI2PkfK2J77VbXSo7d766jhE9xHawhuskrttVFHUkn8gCTwCaxBqEep+NIIJbXUo4NMeXyD
Lp06xzXBQqZRLsCBFQyoMthzITj5UZs3xlY63qtzpepWFlBeWUEtnLBDPJLDLHKbqJmkaMxNjCKF
3fK0avNkNnFAHTT6/pNrfSWc16kMkSFpHcFYkwm8qZCNgcIN+zO7Z82NvNXredZ7eO4USBJEDqJI
2jYAjPKsAVPsQCO9cX428N3F4WfSYJ7i+uJTeG2kx9lMsUWwtJnGfNQJbGMyBSkrNtO1jXQ+Gbi+
ubS4N3JdzQLcFbW4vLfyJ5otiEtJHtTaRIZFHyLlVU4OdxAOiooooAx9V1W00TTrjUdSuUtrO3Tf
JK3RR/MkkgADkkgDJNWrm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1jeNbL+0fBmtRJafaLkafc/Zk
WPe/mNC6DYMZ3EMV45+YjvVrXIo9R0i/0qaK5lW8s50K2ygMyldpCu3yK53jaGIzyegOABkPiTSp
re6uTNPCsG3zI7i1lhm+Y4TETqHbc2VXCncwKjJGKtafqVtqtu09o8hCPskjlieKSNsA4dHAZTgg
4IGQwPQg1xDW2q6gus6nL9ruhImmqJf7PktGiMFzJJI0MEgMjGNGWQbvMDvkAMP3Y6PwlDMsOqTy
fa3S5vfMiubyEwz3KiGJN8ke1NhDIyABEyqKcHO5gBJPFfh+90uN5ZHmsb638xhJZSsggbK75gUx
HEwDYaTarAMQSATWje3en6FYQKyGG3XbBb29tAzscDhI44wWOFUnCjhVJ6A153Z29w3gg28dndzP
q3g+ysLIxW7yK04inBV2UERD99H8zlV5PPytj0PVdQNva3BWPUQFfyHmtLVpHhLJkSKm0mQAlRlV
cAnkYV8AEM3iOwhtra5Vb6eG4LbTa2FxOVKnDK6ohMbA5BVgCCCMZBxf06+t9R0y1vrWTzLa5iSa
F9pXcjAFTg8jgjrXKQ2V5P4W07S3tpxHqGqytcSPGcm386W4LTJjjzlQI6EKAZyNoA8uutS+t31G
WxWTNxFFHNIm0/Kjlwpz05Mb/l7igCvaXemSaxqFjaSQG8h8qa9WIfMC64QuR/EVjHXnaF7EVHp/
iHTdUnaC0uZGfZ5iF4JI1mQEAvEzACVOV+ZCw+ZefmGaun2X2Txpqkkdp5FvLYWu11TajyeddvJg
9C2XDHv8+T1rB8Mme0/4R/z7O9j/ALD0CWzv91pKNs3+jfLH8v77/Uycx7hwOfmXIB0d34g07T9R
Flci+jkaWOESfYLgw75CqoPNCeXyWUfe6nB5qW41PSruXVNLkdbt7O3Vr60WIzERyK2FKAHcWVW+
TBJGOPmGa8lvcXnjOOSWKRLTT7MvEzKSks0zFcr2DxpEwzycXBHA+83T7L7J401SSO08i3lsLXa6
ptR5POu3kwehbLhj3+fJ60AaWkTWU+jWM+mhF06WCN7URx7FERUFMLgbRtxxgYrUrn/An/JPfDX/
AGCrX/0UtdBQAUUUUAFFFFABRRRQAUUUUAFFFFABRXP3nhPw7qN5Jd3+gaXd3MmN809nG7tgYGWI
JPAA/Ck/4QTwh/0Kmh/+C6H/AOJoA6GsXRf+Qt4j/wCwin/pLb1B/wAIJ4Q/6FTQ/wDwXQ//ABNY
2keDPC0uq66knhrR3WK/RIw1hEQi/ZoGwPl4GST9SfWgDuaQHNYH/CCeEP8AoVNE/wDBdD/8TWfa
/DvwZaXNxLH4a052nbc4mhEqqeT8ivkIOeigDp6CjS2oHY0Vz3/CCeEP+hU0P/wXQ/8AxNH/AAgn
hD/oVND/APBdD/8AE0AdDRXPf8IJ4Q/6FTQ//BdD/wDE0f8ACCeEP+hU0P8A8F0P/wATQB0NFZOm
aFpGimX+y9KsbDzsCT7LbpFvxnGdoGcZP5mtagAooooAKKKKACiiigAooooAKxtS1i00pohdGdpZ
SSkVtbSXEjAYy2yNWbaMqC2MAsoJ5GdmuS1NpNK8Q3+oyrfLbX9hBaRz2Ns1xJBLG87ZKKjnkTAq
drLlCGxlQwBv21xDdW0VxBMk0Eqh45EYMrqRkEEcEEc5q9XnEmlPbx6P/wAJNp0mpaeEvnmhNgt1
ieWdJIGkhgQr5oj80NIq7dxf5vny2fc+HdTl0bULjUbG7uNatfCtotvKxaVhfItySyEEhp1bbhxl
hv4I3nIB6vWfeXlvYwia4kMcbSxwglScvI6og49WZR+PNcG1npU3izV7uDwzOup28dxBZ+Tp0tp9
tkeMPJKbvYFRiwaNH3Aj52DN5gxR07Tr9TqENvpnk6ebvR5YEtNHk0+Fyt6TNIIWZmDBVXczbTtR
TjaFYgHrVFeaaPpd/H43+0XCeXcrf3cs0qaXIsktuxl8pZLwvsljCtCRGoJUqgwPLYra8G2DWWrz
Rx6fIgFuVuLuWwktJjIGXAncsUvJW+cmZOFKuQcSigDpJte06DVP7OkuJBNvWNmEEhiR2xtR5QNi
OcrhWYE70wPmXJDr2nT6p/Z0dxIZt7RqxgkETuudyJKRsdxhsqrEjY+R8rYy9Z1GO+8R2Oiy2upL
aQ3ENzPMunTvFPIDuijEioVAVwkjOWAGxV+YM+ylp9vcrqWlae1ndCex1y/v53a3cRCCX7X5bLKR
scnz4vlViw3HIG1sAG7a+J9JujO0d1sjjiacyzxvDG8S/eljdwFkjGQS6EqAynPzDNjTdYtNVaUW
pnWWIgvFc20lvIoOcNskVW2nDANjBKsAeDjgRpWpah4XtdJt7C6W7sPCt3pU6zQtCv2l0gVUR3AW
QExP8yErwDnBGeo8Mtcvf6g0UuqzaaYoSj6nFLHI9zmTziFlVWVSvk8KojBztA+YUAdfRRRQAUUU
UAFFFFABRRRQBRubiG1tpbieZIYIlLySOwVUUDJJJ4AA5zVTTdYtNVaUWpnWWIgvFc20lvIoOcNs
kVW2nDANjBKsAeDi3cSPFbySJDJO6KWWKPaGcgfdG4gZPTkge4rB8PF7rX9X1ELfSWs8UCR3F7bN
byAq8zGEIyIfLQOpDFSSZGBdtuFAOsooooA5618T6TdGdo7rZHHE05lnjeGN4l+9LG7gLJGMgl0J
UBlOfmGVh8SaVNb3VyZp4Vg2+ZHcWssM3zHCYidQ7bmyq4U7mBUZIxWTa3Ms/iuXVTbap9nttPnS
aO6smU2jloT5cO1R5+/y3LFTLzGu1gGAajG413TdW1SS11WC9eW0mSGTTZle2igkEkKFXCedtcSS
OsZLfOyKzYQkA67T9SttVt2ntHkIR9kkcsTxSRtgHDo4DKcEHBAyGB6EGtauP8HQ3gGr3l207/bt
QFxHJPam2Z1FvChxEwDIoeN1UN821QSWzuPYUAFFFFABWbeXqWNnJdSid44yMiGB5nOSBwiAsevY
e/StKszVryax0e9vYLWS7lt7eSWO2jzumZVJCDAJySMdD16GgBmk61Z60k72Zn/0eXyZUmt5IHR9
qvgrIqt911PTvWtWNoen/wBj6NaWJlaeSCILLNt2maTq8jDJ+Z2JYkkkliST1rZoAzr69g062e6u
ZPLhTGSFLEknAVVHLMSQAoBJJAAJNQWus2F1p818lx5Vvb7vPNyjQtBgbj5iyAMnykN8wHykHoQa
nu7o2NtJOYJ51jwWSFN77c8kL1bAycDLHGACcA8ZDpusajot+ltD9pjvNTSaZ9UL2kt9brDGGDqI
vly8YiKmJQ8SnjLbyAdRN4g0u38OjxDNepFpJt1uVuXBUeWwBU4Izk5GBjJJAxmtyvJtV0XxDffB
/SrEaZA32bRnFxYvNIsrSLb7IRs8o72GS/lkKRKseG+XJ9Jt1ujBEbhUjnKgyJG5dVbHIDEAkZ74
GfQUAaFFFFAGFDr2nT6p/Z0dxIZt7RqxgkETuudyJKRsdxhsqrEjY+R8rYXUPEOm6XOsF3cyK+zz
HKQSSLChJAeVlBEScN8zlR8rc/KcczptleJ4otImhvv9H1S8uZLWS3K2tvG4uNs8c20b5H8xMp5j
gec/yLsHlt8TGe7/AOEg8izvZP7c0CKzsNtpKd03+k/LJ8v7n/XR8ybRyeflbAB08+v6Ta30lnNe
pDJEhaR3BWJMJvKmQjYHCDfszu2fNjbzV63nWe3juFEgSRA6iSNo2AIzyrAFT7EAjvXF+NvDdxeF
n0mCe4vriU3htpMfZTLFFsLSZxnzUCWxjMgUpKzbTtY10Phm4vrm0uDdyXc0C3BW1uLy38ieaLYh
LSR7U2kSGRR8i5VVODncQDoqKKKACsbUtYtNKaIXRnaWUkpFbW0lxIwGMtsjVm2jKgtjALKCeRnZ
rk9ZlfT/ABNpurTQXclpHZ3ds7W1rJcMskj27ICkas2CIn5xgYAJBIyAb1tcQ3VtFcQTJNBKoeOR
GDK6kZBBHBBHOazT4p0b+xRrMV55+nNN5KTW8Ty7383yQEVQS+X+UbQc9Rkc1l2lhq8Xw7stBtB9
m1iHSrW3lMkjxLHlQkmyZFYCQBXwV3bW2EggjOPpujCLwrax61pd7YQ2GsXk0MOjyTbokaS4VTiN
Ul8v96QPLHK7GOFLBQDrbO80jSfDb3lrb/2dpFrFJMY/sT2/lIpZnPlFQw6Mfu89RnNIviTSzeQ2
zTTrLL5Y3PaSqkbOAUSRyu2OQ7lwjkN86jGWGcPVPtf/AAqHxB9t8/d9g1DyftGfM8j975G/d827
yvLzv+fP3vmzTdQt7ltS1XT1s7oz32uWF/A627mIwRfZPMZpQNiEeRL8rMGO0YB3LkA6i+1W10qO
3e+uo4RPcR2sIbrJK7bVRR1JJ/IAk8Amqt/rWj6TqB+1MY7iSJTNLHbPJ5cQLbWmdVIjjBMhDOQv
DnPDVU8R2y6lpttNb2cklxDqVogY27CRUW9hMuMjOz93uJ6EKG5GDVfxbqKMi6HLa6k1tfL/AKZP
b6fPcILfcA8WYkb55F3J1BUFmyCEDAHZ1l2Oq2mpSXSWVyk5s7g2txsOQkoVWKZ6EgMM46HI6gin
wX1vdXV3DDJvktZRDONpGxyiuBz1+V1PHr9axNDtl0m58SN9jkt7OO9R4I4rdsGJLO3X92ijLAFC
oCg8qQOaALd34g07T9RFlci+jkaWOESfYLgw75CqoPNCeXyWUfe6nB5plxrujXT3enT+ZMhWWORD
ZySRT7VPmRI2wpK4AcGNSzfK4x8pwSW9xeeM45JYpEtNPsy8TMpKSzTMVyvYPGkTDPJxcEcD71Ia
hHqfjSCCW11KODTHl8gy6dOsc1wUKmUS7AgRUMqDLYcyE4+VGYA3dImsp9GsZ9NCLp0sEb2ojj2K
IioKYXA2jbjjAxWpXP8AgT/knvhr/sFWv/opa6CgAooooAKKKKACiiigAorPv7C01O0e0vbWC6tp
Mb4Z4xIjYORlTweQD+FZ3/CCeEP+hU0P/wAF0P8A8TQB0NFc9/wgnhD/AKFTQ/8AwXQ//E0f8IJ4
Q/6FTQ//AAXQ/wDxNAFvUdW0/SYFuNSvrazgZtiyXEqxqWwTjLEc4B49jU9vcxXVtHPbypLDKoeO
RGDK6kZBBHUEd65y/wDhx4O1GBYZfDenxqrBs20It2zgjlo9pI56Zx+VSweAvCVvBHCvhfR2VFCg
yWUbsQOOWYEk+5JJpvlt5gdbWLov/IW8R/8AYRT/ANJbeoP+EE8If9Cpof8A4Lof/iaxtI8GeFpd
V11JPDWjusV+iRhrCIhF+zQNgfLwMkn6k+tIDuqK57/hBPCH/QqaH/4Lof8A4muhoAKKKKACiiig
AooooAKKKKACiiigAooooAKKKKACs9L63fUZbFZM3EUUc0ibT8qOXCnPTkxv+XuK0K4y50e/vPHF
/cQapqOnQnTbNBJbRQlZWEtySCZY3GVDLwuPv89RQB0dneW99CZreQyRrLJCSFIw8bsjjn0ZWH4c
VoV5bNpN4mgWdndaV/aJF/qREmoacbwO7XbmPMCtGgaRSWEzbUQAjKiSsvX7S5bwW1xrmn6ldXR8
LQLbysrmS3uVimNyzSEjyiVMW/cR5gUrhyNtAHs1FeY+JLVYtcuJ7nT7qS8fXNNa0vFRtkdp5lqp
RpchdnnCT9zkncwfZj5xbtdLjPjO4jm0r7Ss8twLqW50945fJcP/AKy63GK5hOURYcZVWjyAYTQB
2OnX1vqOmWt9ayeZbXMSTQvtK7kYAqcHkcEda0q8o8KaGYtNiuU0O7E1r4atIYLZhJZE3Q+1CZVJ
27JSzY8z7wEpIOHJMFppV7LDqtnFp0kGmzXGkPCthpUumI2Lw+dIse8urhVXc/ythFONoViAevVj
alrFppTRC6M7SyklIra2kuJGAxltkas20ZUFsYBZQTyM8lJ4e+w3Goz2OlvC9prdimniGJgtvbMb
Uz+Qo4RG3T+YUA3fNuzjjf8AFesz6dp6QWkd99svN0UVzbWEtytrxzK6ojZ25GFI+ZsDgbmUAmuv
E+k2pgaS63xyRLOJYI3mjSJvuyyOgKxxnBIdyFIVjn5TiSbXtOg1T+zpLiQTb1jZhBIYkdsbUeUD
YjnK4VmBO9MD5lzyWsWH2bT9WsNM06++y6n4cg03TEW2mbDqLgBJCQTFgTRcy7epyflbFzULe5bU
tV09bO6M99rlhfwOtu5iMEX2TzGaUDYhHkS/KzBjtGAdy5AOhh17Tp9U/s6O4kM29o1YwSCJ3XO5
ElI2O4w2VViRsfI+Vsbtee6FaX9j4gSBDqonOqX0t4kiSC1SzkeeSPYcCJmLvA2QWlG5lJCqVX0K
gAooooAKKKKACiiigCjc3ENrbS3E8yQwRKXkkdgqooGSSTwABzmqmm6xaaq0otTOssRBeK5tpLeR
Qc4bZIqttOGAbGCVYA8HEfiuzuNR8JazYWkfmXN1YzwxJwNztGwUZPA5I61Q0aV9Q8Talq0MF3Ha
SWdpbI1zayW7NJG9wzgJIqtgCVOcYOSASQcAHWUUUUAFc3beLNK1DS5NRgmuxZqiOsstjPEJQ/3P
L3oDIWOAAmSSygckZu65ZrqWg6nYSRzyR3NtLC0cDKJGDIQQhb5Q3PG7jPXisPRrprKXU7i0g1yf
R44oDGl4lw8/m7pPOKrcfvWUJ5JwMg4YIC+4EA3dP1K21W3ae0eQhH2SRyxPFJG2AcOjgMpwQcED
IYHoQa1q5XwlDMsOqTyfa3S5vfMiubyEwz3KiGJN8ke1NhDIyABEyqKcHO5uqoAKKKKACs6+vYNO
tnurmTy4UxkhSxJJwFVRyzEkAKASSQACTWjXPeK4Jp9HUwxvL5F7aXLrGpZvLiuYpHIUcsQqMcDJ
OMAEkCgC3p+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXMeGxJLc65fmG4it77UFmtx
PC0Tsi28EZJRwGX543HzAZxkcEE9PQAVmapqdtpFi97es6wI6J+7ieVizuEUBUBYkswGAD1rTrm/
FVpZXUFhNfx6o0NrdednTWkEiExSJk+V+9K/Pj93zkjPy7qALEmu6bDp9rezzSWsV3cJbwLcwSQy
SSu+xU8t1D5Jz26ZbpzW5XCS2N5d+FbCWe1mmuo9Ug+zvLGWnS0/tGN03E/OP3KRM275vky/zA13
dABRRRQAUUUUAFFFFABRRRQAUUUUAY+qapZ6TYvfalcraWqOivNJwql2CLk9huYcngdTgVYe+t01
GKxaTFxLFJNGm0/MiFAxz04Mifn7Gs/xVBNc6VAkMckrjUbFysaliFW7hZjgdgoJJ7AE1ymoaNrV
peT6XpsE4gtdB1C20i5icKU3i2EUJfI2yKyOFJxlAh3MwcgA7XVJLKKyZdRCNaTuls6yR71cyuI1
Qrg5DM4HPHPPFTWsEVpbR29vCkMESBI40UKqKBgAAcAAAcV51qmjabd2d9JYeHXGgpcaXItmNIkj
zKl032h1tygYnyWQMwT5lG3J2kDX8c2c95fabJJbw3Gmxx3CzR3GlS6lH5xMXlnyI2DBtolxJ0UF
h/GMgHfVkx6pbTXs1vHNI8sNx9mkVYnISTyhLgnGANjKcnjJAzk4riNV0m6httHNzaXWqX8OmwRR
reWDzs86A58ueKQ/Y52YjfMxK/6shj5bGpbfSEg8dTy22lSQlvEQuZZ0s2RHibTZF3+YF2sPNaQH
k4ZznBfkA7uOCGOW4dIURpn3yMqgF22hct6naqjJ7ADtV2vL/DXhG0WDwvbXujyGCTQ2bUo7hHKy
3Ci2Ea3AbhygaUIj5CYO0DaMZ2v2us3HhLTWOkz3GsR6DE0NxPYy3dyLoRkv5bb1FrMhCsXOWkJU
KGaMKQD1CC+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frUUctlrVnMFAubV3mtZUkjyrFGaORCGHI
3Kw9D7iuLuLB38W6rKmlX39oy6zZS2V8YWMYgWO1+0bH6RZRZFYnb5gwgLldq1NQ0q9aCy+12Ub6
et7qzSxXmjy6inmPeFoX+zxkNkp5hWToAxH8YyAei2sEVpbR29vCkMESBI40UKqKBgAAcAAAcVoV
jaHb3FroGmW11JPLcxWsSTSXBHmO4QBi+GYbic5wzc9z1rZoAKKKKACiiigAooooAKKKKACiiigA
ooooAKxdF/5C3iP/ALCKf+ktvW1WLov/ACFvEf8A2EU/9JbegDaooooAKKKKACiiigAooooAKKKK
ACiiigAooooAKKKKACs9L63fUZbFZM3EUUc0ibT8qOXCnPTkxv8Al7itCuMudHv7zxxf3EGqajp0
J02zQSW0UJWVhLckgmWNxlQy8Lj7/PUUAdHZ3lvfQma3kMkayyQkhSMPG7I459GVh+HFZGpr4YOt
JcanZWkup2n2XZPNaCSSLzZmSDa+0kZkDYweDycda5SbSbxNAs7O60r+0SL/AFIiTUNON4HdrtzH
mBWjQNIpLCZtqIARlRJTrOw1aewsZLu0vZLp9P8ADvnPLG5cyR3jvNuJ53KDubPIzk0AdVqcfh/S
NXg1S40yBtVlyUnt9ONxdMAoVm/do0m0AqpboNygnkAy3XifSbUwNJdb45IlnEsEbzRpE33ZZHQF
Y4zgkO5CkKxz8pxD4r1mfTtPSC0jvvtl5uiiubawluVteOZXVEbO3IwpHzNgcDcy85rFh9m0/VrD
TNOvvsup+HINN0xFtpmw6i4ASQkExYE0XMu3qcn5WwAdbNr2nQap/Z0lxIJt6xswgkMSO2NqPKBs
RzlcKzAnemB8y5Ide06fVP7OjuJDNvaNWMEgid1zuRJSNjuMNlVYkbHyPlbHPahb3LalqunrZ3Rn
vtcsL+B1t3MRgi+yeYzSgbEI8iX5WYMdowDuXN0ahHqfjSCCW11KODTHl8gy6dOsc1wUKmUS7AgR
UMqDLYcyE4+VGYA7GiiigAooooAKKKKACiiigAooooAKKKKAKNzcQ2ttLcTzJDBEpeSR2CqigZJJ
PAAHOaqabrFpqrSi1M6yxEF4rm2kt5FBzhtkiq204YBsYJVgDwcR+K7O41HwlrNhaR+Zc3VjPDEn
A3O0bBRk8DkjrVDRpX1DxNqWrQwXcdpJZ2lsjXNrJbs0kb3DOAkiq2AJU5xg5IBJBwAdZRRRQBQu
J1gt5LhhIUjQuwjjaRiAM8KoJY+wBJ7VkxeLNLnS8bzbqFrRI3lS5sZ4HxIzLHtR0DOWZSoCgkng
ckCulrldCafTvC66nd2V21zeub+6gWMtPH5rbtjA/M5iQrHjG4rEAq5wlAGpp+pW2q27T2jyEI+y
SOWJ4pI2wDh0cBlOCDggZDA9CDWtXK+EoZlh1SeT7W6XN75kVzeQmGe5UQxJvkj2psIZGQAImVRT
g53N1VABRRRQAVnX17Bp1s91cyeXCmMkKWJJOAqqOWYkgBQCSSAASa0a57xXBNPo6mGN5fIvbS5d
Y1LN5cVzFI5CjliFRjgZJxgAkgUAW9P1K21W3ae0eQhH2SRyxPFJG2AcOjgMpwQcEDIYHoQa1q5j
w2JJbnXL8w3EVvfags1uJ4WidkW3gjJKOAy/PG4+YDOMjggnp6ACsnUdTh0u3WaeO7dGfYBa2ktw
2cE8rGrEDjrjHT1rWrB8Ufa5NCureyE63N1stUlgzvt/NdYzMMc/uw5k7fc6jqACD/hK9Mexhu0k
upEneRI4orKd5iY3KSZhCGRQrDaSVABIB6jOvbXEN1bRXEEyTQSqHjkRgyupGQQRwQRzmsvWJoNL
06G1tk1Cytygjin0qyE5t9u3agjCPgFcgHYVABGVJXMnhqC4s/C+kWtxax2s8FnDHJbRsWWFlQAo
CSxIBGM5PTqetAG9RRRQAUUUUAFFFFABRRRQAUUUUAY+qapZ6TYvfalcraWqOivNJwql2CLk9huY
cngdTgVYe+t01GKxaTFxLFJNGm0/MiFAxz04Mifn7Gs/xVBNc6VAkMckrjUbFysaliFW7hZjgdgo
JJ7AE1ymoaNrVpeT6XpsE4gtdB1C20i5icKU3i2EUJfI2yKyOFJxlAh3MwcgA7u8vLexhE1xIY42
ljhBKk5eR1RBx6syj8ea0K8q1TRtNu7O+ksPDrjQUuNLkWzGkSR5lS6b7Q625QMT5LIGYJ8yjbk7
SBr+ObOe8vtNkkt4bjTY47hZo7jSpdSj84mLyz5EbBg20S4k6KCw/jGQDvqyY9Utpr2a3jmkeWG4
+zSKsTkJJ5QlwTjAGxlOTxkgZycVxGq6TdQ22jm5tLrVL+HTYIo1vLB52edAc+XPFIfsc7MRvmYl
f9WQx8tjUtvpCQeOp5bbSpIS3iIXMs6WbIjxNpsi7/MC7WHmtIDycM5zgvyAekUV5f4a8I2iweF7
a90eQwSaGzalHcI5WW4UWwjW4DcOUDShEfITB2gbRjO1+11m48Jaax0me41iPQYmhuJ7GW7uRdCM
l/LbeotZkIVi5y0hKhQzRhSAeoQX1vdXV3DDJvktZRDONpGxyiuBz1+V1PHr9aWzvLe+hM1vIZI1
lkhJCkYeN2Rxz6MrD8OK4W4sHfxbqsqaVff2jLrNlLZXxhYxiBY7X7RsfpFlFkVidvmDCAuV2rU1
DSr1oLL7XZRvp63urNLFeaPLqKeY94Whf7PGQ2SnmFZOgDEfxjIB6rRWNodvcWugaZbXUk8tzFax
JNJcEeY7hAGL4ZhuJznDNz3PWtmgAooooAKKKKACiiigAooooAKKKKACiiigArF0X/kLeI/+win/
AKS29bVYui/8hbxH/wBhFP8A0lt6ANqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz0
vrd9RlsVkzcRRRzSJtPyo5cKc9OTG/5e4rQrjLnR7+88cX9xBqmo6dCdNs0EltFCVlYS3JIJljcZ
UMvC4+/z1FAHR2d5b30Jmt5DJGsskJIUjDxuyOOfRlYfhxQl9bvqMtismbiKKOaRNp+VHLhTnpyY
3/L3FeezaTeJoFnZ3Wlf2iRf6kRJqGnG8Du125jzArRoGkUlhM21EAIyokqvZ6O7wvPqGmXw1G58
OaWbi5+wtLJLIjv56TE4MmQIhJFu3yINoBIGAD1qs9763TUYrFpMXEsUk0abT8yIUDHPTgyJ+fsa
4iyt5bSx0m8XSpIbGw1Z52FnYTQhomtJY98dmd0kQ82QKUAOSGkxhyaorpviG4WznsbS7s5wmtyy
28qbJJFe/jkW3EqttieRQQJAWwMsucBgAeq0V5bqtpO2v2E+kaF5Cx3VgIJV0uUzJab4g5SYsoto
wC8bW4UtgOxUK7MJoPDMUn2GWfTZ/Mutf1AXzsHBe0LXbojn/ngzCJtn+rYsCQdxyAd40ypcJAwk
3ujMCI2K4BAOWxgH5hgE5POM4OKU2vadBqn9nSXEgm3rGzCCQxI7Y2o8oGxHOVwrMCd6YHzLnA8P
WV3b61pfm2s8UFtFrECZiISKM30XkIOyr5aDYOm1eOBVvWdRjvvEdjostrqS2kNxDczzLp07xTyA
7ooxIqFQFcJIzlgBsVfmDPsANSHXtOn1T+zo7iQzb2jVjBIIndc7kSUjY7jDZVWJGx8j5Wwun+Id
N1SdoLS5kZ9nmIXgkjWZAQC8TMAJU5X5kLD5l5+YZ53T7e5XUtK09rO6E9jrl/fzu1u4iEEv2vy2
WUjY5PnxfKrFhuOQNrYg0G31QW+iwWlpJDqGkeHprCU30EkcC3ZFsEXcQPNTdC+WjLDA6/MuQDsb
HVbTUpLpLK5Sc2dwbW42HISUKrFM9CQGGcdDkdQRWpXDeBdL1LSTrVpfWaW8f22N0lE7StcN9mhD
yFjHHvLMu5nxy7SAjjJ7mgAooooAKKKKACiiigCjc3ENrbS3E8yQwRKXkkdgqooGSSTwABzmqmm6
xaaq0otTOssRBeK5tpLeRQc4bZIqttOGAbGCVYA8HEXiWC4vPC+r2tvax3U89nNHHbSMVWZmQgIS
CpAJOM5HXqOtZnhVJpNY1K8eXUruGS3t4kvdRtDbTOytMWj8vy4xsUOrBtnJkYbm24UA7GiiigDn
rXxPpN0Z2jutkccTTmWeN4Y3iX70sbuAskYyCXQlQGU5+YZWHxJpU1vdXJmnhWDb5kdxaywzfMcJ
iJ1DtubKrhTuYFRkjFc8zweK7jWTcWesRo2nT2NtbvYS28hic4ldZJVWPfIRFtVidojUnbudVrR2
l/qcms6rdPfXCmLTzFKulyW+yW3uJJcLbSESvGuY2Ybiz5cIc4VQDtNP1K21W3ae0eQhH2SRyxPF
JG2AcOjgMpwQcEDIYHoQa1q4/wAHQ3gGr3l207/btQFxHJPam2Z1FvChxEwDIoeN1UN821QSWzuP
YUAFFFFABWdfXsGnWz3VzJ5cKYyQpYkk4Cqo5ZiSAFAJJIABJrRrOu7o2NtJOYJ51jwWSFN77c8k
L1bAycDLHGACcAgEWn6lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cr4ShmWHVJ5Ptbp
c3vmRXN5CYZ7lRDEm+SPamwhkZAAiZVFODnc3VUAZ19ewadbPdXMnlwpjJCliSTgKqjlmJIAUAkk
gAEmqf8AwkmlfYPt3nXOPN8jyPssv2jzMbtnkbfM3bfnxtzs+b7vNT6pfrpVjcX7213ciFNwgtIG
mlkPZVUckk49h1JAya5FY3k0aPWF+2Lqa6o95NKdKuHWORoWhAMDCOWWNYmSINGASyq5HElAHR3X
iXTINPtb15pzFdymGBYLWWWRpAGLIY0UuGURvuBAKlSDgitK3nWe3juFEgSRA6iSNo2AIzyrAFT7
EAjvXC2mkWttpem3etJ4hZkl1ExzWSzpIyT3PmqZUtgsisyqrY2hVO4MFbaK7TQ/7R/sDTP7X/5C
f2WL7Z93/XbBv+78v3s9OPSgDVooooAwode06fVP7OjuJDNvaNWMEgid1zuRJSNjuMNlVYkbHyPl
bC6h4h03S51gu7mRX2eY5SCSRYUJIDysoIiThvmcqPlbn5TjJuZZr7xhpgS21L/QriQzQT2xW3iX
yplFwkoXDu29F272wshygZSVy/EsV7JrF3qVgdYSa70iBdJW2hlVXu0adk8/C5QKZY/lmKxne24H
adoB1M+v6Ta30lnNepDJEhaR3BWJMJvKmQjYHCDfszu2fNjbzV63nWe3juFEgSRA6iSNo2AIzyrA
FT7EAjvXF+NvDdxeFn0mCe4vriU3htpMfZTLFFsLSZxnzUCWxjMgUpKzbTtY10Phm4vrm0uDdyXc
0C3BW1uLy38ieaLYhLSR7U2kSGRR8i5VVODncQDoqKKKACsbUtYtNKaIXRnaWUkpFbW0lxIwGMts
jVm2jKgtjALKCeRnZrmPFesz6dp6QWkd99svN0UVzbWEtytrxzK6ojZ25GFI+ZsDgbmUA05tUs4N
LXUWuUazZFZJYz5gkDY2bNuS5YkBQuSxIAySKrf8JJpX2D7d51zjzfI8j7LL9o8zG7Z5G3zN2358
bc7Pm+7zWPrlnC/gy30zRor63is/7Pni2Wz+ZDBHPG2VEindIqRMdhDPkAFSWAJpt5cWWjai7Jrn
9nPdmOxmMEs91BCYUy5SUNM2JvMA3Kx5U48sZABuHWrBNEm1j7SRYQxPNLIUbMapneGXG4Mu1gVI
3AggjIxUC+JNLN5DbNNOssvljc9pKqRs4BRJHK7Y5DuXCOQ3zqMZYZ568gmtvhB4hWeN43ez1KUG
VSryK5mdZHU/dd1YOy4XaWI2rjaH6hb3LalqunrZ3RnvtcsL+B1t3MRgi+yeYzSgbEI8iX5WYMdo
wDuXIB02patBpJi+0x3snm52/ZLCe5xjHXykbb174zzjoaqv4q0VILa4+1uYbq3S6WVLeVljhcZW
SUhSIUIB+aTaPlb+6cRa4H1a1sdOignNvd36w3TtCwCRRFpJA6kDMcnleVz8pEoPzAgNi+LIbl7j
xLBHZ3U0msaHHYWRht3kVpwbkFXZQREP30fzOVXk8/K2AD0GsPT/ABDpuqTtBaXMjPs8xC8EkazI
CAXiZgBKnK/MhYfMvPzDNuC+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frXFeHLW5sdWsncai2n6N
pE9n5UunPE0KhoNi8bvtEpWJwzRFkOxdqruG8A6mbXtOg1T+zpLiQTb1jZhBIYkdsbUeUDYjnK4V
mBO9MD5lyxvEmli8mtlmnaWLzBuS0lZJGQEukbhdskg2tlEJb5GGMqcc7qVleP4ou4lhvv8ASNUs
7mO1jty1rcRoLfdPJNtOyRPLfCeYgPkp8jbz5miNQj1PxpBBLa6lHBpjy+QZdOnWOa4KFTKJdgQI
qGVBlsOZCcfKjMAb+nX1vqOmWt9ayeZbXMSTQvtK7kYAqcHkcEda0q5/wJ/yT3w1/wBgq1/9FLXQ
UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYui/8hbxH/wBhFP8A0lt6hvPCfh3UbyS7v9A0u7uZ
Mb5p7ON3bAwMsQSeAB+FYukeDPC0uq66knhrR3WK/RIw1hEQi/ZoGwPl4GST9SfWgDuqK57/AIQT
wh/0Kmh/+C6H/wCJo/4QTwh/0Kmh/wDguh/+JoAu6fqthq8LT6bf215Cr7Gkt5VkUNgHBKnrgjj3
FadcZYfDnwdp0Bhi8N6fIrMWJuoROwPA4aTcQOOmcfnWn/wgnhD/AKFXQ/8AwXQ//E0O19NgOhor
nv8AhBPCH/QqaH/4Lof/AImj/hBPCH/QqaH/AOC6H/4mgDoaKz7CwtNMtEtLK1gtbaPOyGCMRouT
k4UcDkk/jWhQAUUUUAFFFFABRRRQAUUUUAFZ6X1u+oy2KyZuIoo5pE2n5UcuFOenJjf8vcVoVxlz
o9/eeOL+4g1TUdOhOm2aCS2ihKysJbkkEyxuMqGXhcff56igDo7O8t76EzW8hkjWWSEkKRh43ZHH
PoysPw4oS+t31GWxWTNxFFHNIm0/Kjlwpz05Mb/l7ivNLrRr6PT9Ojv4Tc2UV3qvnnUNGk1ASSve
boZDbxbcMyeYRIF2gMQMbxTb3SrXTL0yar4bk1fUJdI02AXV1oz3pMweWOaWUxhwXVDGzLvywUKG
PBoA9NS+t31GWxWTNxFFHNIm0/Kjlwpz05Mb/l7itCvHbjQrO3jubXSNE1R4l0CC00e4exkj8u9V
7oK7KVXy5tzB/OKqE3Elk8wbtXUNKv5vHk0zx4ka/tZbSddKkmmW2VYfMVbveI4YyVnDRnkhnwG8
wAgHptUbm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1wR0KO301Li90yea2l169m1OF4HuDLb+Zd+SD
Dhi8e94nCqpALeZj7zVseDZVsvCBleG7jSG91BmikLTzKBdzfKdpcyP24LEnuc8gGnD4k0qa3urk
zTwrBt8yO4tZYZvmOExE6h23NlVwp3MCoyRin/8ACSaV9g+3edc483yPI+yy/aPMxu2eRt8zdt+f
G3Oz5vu81yhkl13TtR1b7DqK3rXmnzvbTWE0TwWkFwkgjAZQJXAE8hCbjmTYC4CEzbZ/7T/t/wCx
339n/wBv/bf+POXzvJ/s77Nu8jb5v+t+XG3OPmxt+agDpH8QaVFY2l494iQXdwlrBvBVnmZ9gj2k
bg4bIKkZXa2cbTjerz86VNJ4WtpP7PkN02trcRZhPmpby6os+SMbkGwIzA4I2/MAV49AoAKKKKAC
iiigAooooAKKKKAKNzcQ2ttLcTzJDBEpeSR2CqigZJJPAAHOaqabrFpqrSi1M6yxEF4rm2kt5FBz
htkiq204YBsYJVgDwcR+K7O41HwlrNhaR+Zc3VjPDEnA3O0bBRk8DkjrVDRpX1DxNqWrQwXcdpJZ
2lsjXNrJbs0kb3DOAkiq2AJU5xg5IBJBwAdZRRRQAVhw6/pVxo/9sW94k2n72RZ4ssJGVzHhABly
XG1QoO4kbc5Gbd1BFd28lvcQpNBKhSSORQyupGCCDwQQTxXJtY3n/CITR/ZJ/Mi197xoxGd5hTUz
MWVerfuwWAAJbjAORkA6fT9SttVt2ntHkIR9kkcsTxSRtgHDo4DKcEHBAyGB6EGtauY8NiSW51y/
MNxFb32oLNbieFonZFt4IySjgMvzxuPmAzjI4IJ6egAooooAKzr69g062e6uZPLhTGSFLEknAVVH
LMSQAoBJJAAJNaNc94rgmn0dTDG8vkXtpcusalm8uK5ikchRyxCoxwMk4wASQKALen6lbarbtPaP
IQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cx4bEktzrl+YbiK3vtQWa3E8LROyLbwRklHAZfnjcfM
BnGRwQT09ABRRRQBk6trVnoqQPeGf/SJfJiSG3knd32s+Asas33UY9O1T286z28dwokCSIHUSRtG
wBGeVYAqfYgEd6wPFFnp8l9Y3uox60ywxzQo+l/aON5jJDi3Pm8+Xx/Bwd3JStnQ/wC0f7A0z+1/
+Qn9li+2fd/12wb/ALvy/ez049KANWiiigAooooAKKKKACiiigAooooAx9U1Sz0mxe+1K5W0tUdF
eaThVLsEXJ7Dcw5PA6nAqw99bpqMVi0mLiWKSaNNp+ZEKBjnpwZE/P2NZ/iqCa50qBIY5JXGo2Ll
Y1LEKt3CzHA7BQST2AJrlNQ0bWrS8n0vTYJxBa6DqFtpFzE4UpvFsIoS+RtkVkcKTjKBDuZg5AB2
uqSWUVky6iEa0ndLZ1kj3q5lcRqhXByGZwOeOeeKmtYIrS2jt7eFIYIkCRxooVUUDAAA4AAA4rzr
VNG027s76Sw8OuNBS40uRbMaRJHmVLpvtDrblAxPksgZgnzKNuTtIGv45s57y+02SS3huNNjjuFm
juNKl1KPziYvLPkRsGDbRLiTooLD+MZAO+rJj1S2mvZreOaR5Ybj7NIqxOQknlCXBOMAbGU5PGSB
nJxXEarpN1DbaObm0utUv4dNgijW8sHnZ50Bz5c8Uh+xzsxG+ZiV/wBWQx8tjUtvpCQeOp5bbSpI
S3iIXMs6WbIjxNpsi7/MC7WHmtIDycM5zgvyAd3HBDHLcOkKI0z75GVQC7bQuW9TtVRk9gB2q7Xl
/hrwjaLB4Xtr3R5DBJobNqUdwjlZbhRbCNbgNw5QNKER8hMHaBtGM7X7XWbjwlprHSZ7jWI9BiaG
4nsZbu5F0IyX8tt6i1mQhWLnLSEqFDNGFIB6hBfW91dXcMMm+S1lEM42kbHKK4HPX5XU8ev1qKOW
y1qzmCgXNq7zWsqSR5VijNHIhDDkblYeh9xXF3Fg7+LdVlTSr7+0ZdZspbK+MLGMQLHa/aNj9Iso
sisTt8wYQFyu1amoaVetBZfa7KN9PW91ZpYrzR5dRTzHvC0L/Z4yGyU8wrJ0AYj+MZAPRbWCK0to
7e3hSGCJAkcaKFVFAwAAOAAAOK0KxtDt7i10DTLa6knluYrWJJpLgjzHcIAxfDMNxOc4Zue561s0
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYui/8AIW8R/wDYRT/0lt62qxdF/wCQt4j/AOwin/pL
b0AbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVnpfW76jLYrJm4iijmkTaflRy4U56
cmN/y9xWhXGXOj39544v7iDVNR06E6bZoJLaKErKwluSQTLG4yoZeFx9/nqKAOjs7y3voTNbyGSN
ZZISQpGHjdkcc+jKw/DiobrW9PtLqS2uJ9k0f2fcuxjjz5TFFyB/E6ke2MnA5rh7fShbw6eviLTr
vU9LiuNWEqTWDXRed7zdDK0MaHkxiUhwgUByBjeAad9oV3NpkR17S57+aCw0H7SJLc3bNJHdS/aM
YDb2CO27bklXPZuQD0HUtYtNKaIXRnaWUkpFbW0lxIwGMtsjVm2jKgtjALKCeRmvdeJ9JtTA0l1v
jkiWcSwRvNGkTfdlkdAVjjOCQ7kKQrHPynEPivWZ9O09ILSO++2Xm6KK5trCW5W145ldURs7cjCk
fM2BwNzLzmsWH2bT9WsNM06++y6n4cg03TEW2mbDqLgBJCQTFgTRcy7epyflbAB0eq3Xh3Ub1NI1
i2hvNsqZFxZGaCOVhhFaQqY0kIcAKxDHzFwPnGbNnq+mQ6h/YNnFOklptgKQ2MoghxGrhPMCeWvy
FcDd3A68Vz+oW9y2parp62d0Z77XLC/gdbdzEYIvsnmM0oGxCPIl+VmDHaMA7lzJY2YsfE8EOmR6
3HI1/cy6kLozG2MMgmfMef3HMrQkeX+8wTu58ygDuqKKKACiiigAooooAKKKKACiiigAooooAo3N
xDa20txPMkMESl5JHYKqKBkkk8AAc5qppusWmqtKLUzrLEQXiubaS3kUHOG2SKrbThgGxglWAPBx
H4rs7jUfCWs2FpH5lzdWM8MScDc7RsFGTwOSOtUNGlfUPE2patDBdx2klnaWyNc2sluzSRvcM4CS
KrYAlTnGDkgEkHAB1lFFFAFG5uIbW2luJ5khgiUvJI7BVRQMkkngADnNZsPiTSpre6uTNPCsG3zI
7i1lhm+Y4TETqHbc2VXCncwKjJGKd4lguLzwvq9rb2sd1PPZzRx20jFVmZkICEgqQCTjOR16jrXJ
vbXl5batdxLql8h/s/beX1kYLoeVctJJshEce7ylIkT92d7MVPmY2AA7TT9SttVt2ntHkIR9kkcs
TxSRtgHDo4DKcEHBAyGB6EGtauV8JQzLDqk8n2t0ub3zIrm8hMM9yohiTfJHtTYQyMgARMqinBzu
bqqACiiigArOvr2DTrZ7q5k8uFMZIUsSScBVUcsxJACgEkkAAk1o1z3iuCafR1MMby+Re2ly6xqW
by4rmKRyFHLEKjHAyTjABJAoAt6fqVtqtu09o8hCPskjlieKSNsA4dHAZTgg4IGQwPQg1rVzHhsS
S3OuX5huIre+1BZrcTwtE7ItvBGSUcBl+eNx8wGcZHBBPT0AFUbm4htbaW4nmSGCJS8kjsFVFAyS
SeAAOc1ernPE1jqWpabFZ6fFazI9whu4bmZoVlhX5im4I/DMFVlKkMhdeM5ABJN4l0tLPT75Jp5o
r6ITWy21rLNJJGQDv8tFLhRuXJIwCyg4JFaNtcQ3VtFcQTJNBKoeORGDK6kZBBHBBHOa85tNOvIN
H8HTapb6pa29ror2lzHpyztMHb7OY0fykEyZERZtuNrLtLEHD9/of9o/2Bpn9r/8hP7LF9s+7/rt
g3/d+X72enHpQBq0UUUAFFFFABRRRQAUUUUAFFFFAGPqmqWek2L32pXK2lqjorzScKpdgi5PYbmH
J4HU4FWHvrdNRisWkxcSxSTRptPzIhQMc9ODIn5+xrP8VQTXOlQJDHJK41GxcrGpYhVu4WY4HYKC
SewBNcpqGja1aXk+l6bBOILXQdQttIuYnClN4thFCXyNsisjhScZQIdzMHIAO7vLy3sYRNcSGONp
Y4QSpOXkdUQcerMo/HmtCvKtU0bTbuzvpLDw640FLjS5FsxpEkeZUum+0OtuUDE+SyBmCfMo25O0
ga/jmznvL7TZJLeG402OO4WaO40qXUo/OJi8s+RGwYNtEuJOigsP4xkA76smPVLaa9mt45pHlhuP
s0irE5CSeUJcE4wBsZTk8ZIGcnFcRquk3UNto5ubS61S/h02CKNbywednnQHPlzxSH7HOzEb5mJX
/VkMfLY1Lb6QkHjqeW20qSEt4iFzLOlmyI8TabIu/wAwLtYea0gPJwznOC/IB6RRXl/hrwjaLB4X
tr3R5DBJobNqUdwjlZbhRbCNbgNw5QNKER8hMHaBtGM7X7XWbjwlprHSZ7jWI9BiaG4nsZbu5F0I
yX8tt6i1mQhWLnLSEqFDNGFIB6hBfW91dXcMMm+S1lEM42kbHKK4HPX5XU8ev1pbO8t76EzW8hkj
WWSEkKRh43ZHHPoysPw4rhbiwd/FuqyppV9/aMus2UtlfGFjGIFjtftGx+kWUWRWJ2+YMIC5XatT
UNKvWgsvtdlG+nre6s0sV5o8uop5j3haF/s8ZDZKeYVk6AMR/GMgHqtFY2h29xa6BpltdSTy3MVr
Ek0lwR5juEAYvhmG4nOcM3Pc9a2aACiiigAooooAKKKKACiiigAooooAKKKKACsXRf8AkLeI/wDs
Ip/6S29bVYui/wDIW8R/9hFP/SW3oA2qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArP
S+t31GWxWTNxFFHNIm0/Kjlwpz05Mb/l7itCuMudHv7zxxf3EGqajp0J02zQSW0UJWVhLckgmWNx
lQy8Lj7/AD1FAHR2d5b30Jmt5DJGsskJIUjDxuyOOfRlYfhxTdRvrfTtMur66k8u2tonmmfaW2oo
JY4HJ4B6VxWj299odzpt5c2eo3YifV7YskGZZZJb1XiLBQFUOsbNvO2MZGSoIrFbwvJeeELsX+jT
z3MPg6yhtYpYGbbcrHc5CoRjzlJUDjcu/AxuOQD0nVdVtNE0641HUrlLazt03ySt0UfzJJIAA5JI
AyTSalrFppTRC6M7SyklIra2kuJGAxltkas20ZUFsYBZQTyM4/iqyt7z4d6jDYadu26ZP9htxbFX
jJt3RVSMgMjbWK7cAgEjHan+KFeDUdP1GKa+t5Yo5rVri109rzbHIY2YBEyyyfu1KuVZBtYMp3KC
AXbrxPpNqYGkut8ckSziWCN5o0ib7ssjoCscZwSHchSFY5+U4LvxBp2n6iLK5F9HI0scIk+wXBh3
yFVQeaE8vkso+91ODzXDajomqWvg+HSokvoNRvfDkGlzRxWX2hJZY45AsQlUlYfnlId5BtKsNrKV
Zh20lvcXnjOOSWKRLTT7MvEzKSks0zFcr2DxpEwzycXBHA+8AdJRRRQAUUUUAFFFFABRRRQAUUUU
AFFFFAFG5uIbW2luJ5khgiUvJI7BVRQMkkngADnNVNN1i01VpRamdZYiC8VzbSW8ig5w2yRVbacM
A2MEqwB4OLdxI8VvJIkMk7opZYo9oZyB90biBk9OSB7isHw8Xutf1fUQt9JazxQJHcXts1vICrzM
YQjIh8tA6kMVJJkYF224UA6yiiigDLsdVtNSkuksrlJzZ3BtbjYchJQqsUz0JAYZx0OR1BFZ9t4s
0rUNLk1GCa7FmqI6yy2M8QlD/c8vegMhY4ACZJLKByRnMg0NZNN8XaY1hNHZXMphhitUWMvEbGCP
EO7CDoyj+EFcHoayrq0ur2x1GPSm1saXHLp88T3aTvcpLHdeZcNGtyDI22JYiF2spIIUFiwIB22n
6lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1c74U8/wCx3+ft39n/AGr/AIl/27zfO8ny
o927zf3v+t87G/nGMfLtroqACiiigArOvr2DTrZ7q5k8uFMZIUsSScBVUcsxJACgEkkAAk1o1z3i
uCafR1MMby+Re2ly6xqWby4rmKRyFHLEKjHAyTjABJAoAt6fqVtqtu09o8hCPskjlieKSNsA4dHA
ZTgg4IGQwPQg1rVzHhsSS3OuX5huIre+1BZrcTwtE7ItvBGSUcBl+eNx8wGcZHBBPT0AUbm4htba
W4nmSGCJS8kjsFVFAySSeAAOc1Rl8QadF4fg1szyNp86wvDJHBI7OJSojwiqXJYuoxjPNX54I54w
k0SSoHWQK6hgGVgynnuGAIPYgGuLttLgf4e+ERq1tq6HT7e2eRLDzUmif7M0Z3CPEuPnIITnJGfl
DUAdHN4k06C0t7hxe5ud3lQLp9w05CnDMYQnmBQSPmKgfMvPzDOhbXEN1bRXEEyTQSqHjkRgyupG
QQRwQRzmuYt767tfDMMd62twGWWcQXlraG5nihExMAdCkj7mh25LoTwd5DkZ1/DUFxZ+F9Itbi1j
tZ4LOGOS2jYssLKgBQEliQCMZyenU9aAN6iiigDCh17Tp9U/s6O4kM29o1YwSCJ3XO5ElI2O4w2V
ViRsfI+VsLqHiHTdLnWC7uZFfZ5jlIJJFhQkgPKygiJOG+Zyo+VuflOOd0+3uV1LStPazuhPY65f
387tbuIhBL9r8tllI2OT58XyqxYbjkDa2K/iWK9k1i71KwOsJNd6RAukrbQyqr3aNOyefhcoFMsf
yzFYzvbcDtO0A6mfX9Jtb6SzmvUhkiQtI7grEmE3lTIRsDhBv2Z3bPmxt5q9bzrPbx3CiQJIgdRJ
G0bAEZ5VgCp9iAR3ri/G3hu4vCz6TBPcX1xKbw20mPsplii2FpM4z5qBLYxmQKUlZtp2sa6HwzcX
1zaXBu5LuaBbgra3F5b+RPNFsQlpI9qbSJDIo+RcqqnBzuIB0VZ19ewadbPdXMnlwpjJCliSTgKq
jlmJIAUAkkgAEmtGuU8WWdze6A62qzpJHdWsxe3QPIiR3EcjsikHcyqrELtbJGADnBANXT9SttVt
2ntHkIR9kkcsTxSRtgHDo4DKcEHBAyGB6EGq9r4m0q9M/wBnmnk8qJp1xay/v4x1eHK/vl5XmPcP
mX+8uafhqSWOG4RxqJspb0rpxvEmaUReSrN5hkHmKPNE2DLj+EDgoDieC7W8hv8ATlmhvc2Olvaz
R3NuY47GQmHEFuxVfOjPlt85aU4iT5/my4B1Gm69Y6tcXFva/a1nt0R5I7qzmt2CuWCkCRVJBKMM
jP3ahbxVpKq7LJdzMs8tuUhsZ5XZ4m2yFUVCzIrEKXAKgkDOTR4VgkTQ47y7ikiu792vZ45VIkja
U7hG5PJMalYsnHEYGAAAOb0mVtPv7TU5YLmSziuNat3e1tpLhlkk1AMgKRqzYIif5sYGMEgkZAOz
m1Szg0tdRa5RrNkVkljPmCQNjZs25LliQFC5LEgDJIqt/wAJJpX2D7d51zjzfI8j7LL9o8zG7Z5G
3zN2358bc7Pm+7zVPw+82heDNMsryyu2utP021S4hgiMhX5QjbSOHK7WJVCzYAwCWUHmZbC6lt4r
6Qaw1outm6lvFtnjvZ4DZGAu0SIHU7z5X7uNWCAOMH94QDvrG9g1G2S6tpPMhfOCVKkEHBVlPKsC
CCpAIIIIBFMOqWQ1lNJNzH9ve3a6EA5bylYKXPoNzADPXnGcHGX4fvZEsrSxv5Jxcy/aprZLhW8x
rVJsRly3IYRyQ53/AD5PzfMGp09lt8dWN1DaFY2sLzz5kjwDIXtAu5h/EVjwM84T0FAFmHXtOn1T
+zo7iQzb2jVjBIIndc7kSUjY7jDZVWJGx8j5WxZsdVtNSkuksrlJzZ3BtbjYchJQqsUz0JAYZx0O
R1BFYNzLNfeMNMCW2pf6FcSGaCe2K28S+VMouElC4d23ou3e2FkOUDKSs2h2y6Tc+JG+xyW9nHeo
8EcVu2DElnbr+7RRlgChUBQeVIHNAF+bXtOg1T+zpLiQTb1jZhBIYkdsbUeUDYjnK4VmBO9MD5ly
xvEmli8mtlmnaWLzBuS0lZJGQEukbhdskg2tlEJb5GGMqcc7qVleP4ou4lhvv9I1SzuY7WO3LWtx
Ggt908k207JE8t8J5iA+SnyNvPmaI1CPU/GkEEtrqUcGmPL5Bl06dY5rgoVMol2BAioZUGWw5kJx
8qMwBv6dfW+o6Za31rJ5ltcxJNC+0ruRgCpweRwR1rSrn/An/JPfDX/YKtf/AEUtdBQAUUUUAFFF
FABRRRQAUUUUAFFFFABRXOT+DfDFzcPcXHh3SJppXLySSWMTM7E5JJK5JJ707/hBPCH/AEKmh/8A
guh/+JoA6GsXRf8AkLeI/wDsIp/6S29Qf8IJ4Q/6FTQ//BdD/wDE1jaR4M8LS6rrqSeGtHdYr9Ej
DWERCL9mgbA+XgZJP1J9aAO6ornv+EE8If8AQqaH/wCC6H/4mj/hBPCH/QqaH/4Lof8A4mgDoaK5
7/hBPCH/AEKmh/8Aguh/+Jo/4QTwh/0Kmh/+C6H/AOJoA6CjtXJz+A/CNxBJC3hfR1V1Kkx2UaMA
eOGUAg+4IIpLT4f+DrK1S3j8MaW6IThp7ZZnOTnl3BY9e59qWnzA66iue/4QTwh/0Kmh/wDguh/+
Jo/4QTwh/wBCpof/AILof/iaYHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xN
AHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNADPEvivTvCcFjdao7Ja3V4tq
ZgeIiyOwZvb5MfjmtuKVJY1kiZXRwGVlOQQe4PeuS1b4Y+EtW+xqdD0+1S3uRO4tbWOIzAKw2MVA
O3LAkd9orprCwtNMtEtLK1gtbaPOyGCMRouTk4UcDkk/jQBoUUUUAFZ95eW9jCJriQxxtLHCCVJy
8jqiDj1ZlH481oVx2v3d1fy/2QNOuxOupWU0Eiwu8UsEc0MsjtIF2RkbJRsZtx2DAO9QQDsaK870
2wdfFFow06ePVU1S8lvr02rL5tm32jyUNxjbKo3W2IwxK7V4HlnbiroEln4Y8JJLp8f2VdNzfw32
kTal/pZSAIXgVg4dVSVQ54RRs4BUUAevVnQX1vdXV3DDJvktZRDONpGxyiuBz1+V1PHr9a891Hw5
eSafqk9xbX13qVn4XtUs55VJkN4guTvUKzKZ1YqQylmUv8rfNk2biwd/FuqyppV9/aMus2UtlfGF
jGIFjtftGx+kWUWRWJ2+YMIC5XaoB6VWXBqlnd6rd6dBcpJeWaRvcxLyYhJu2buwJCk464wehGeb
8K6bNBq19BOyNBoqHSrJVJ/dRs3nbenzDyGsky2Tuif1LPpafZfZPGmqSR2nkW8tha7XVNqPJ512
8mD0LZcMe/z5PWgCW18T6TdGdo7rZHHE05lnjeGN4l+9LG7gLJGMgl0JUBlOfmGVh8SaVNb3VyZp
4Vg2+ZHcWssM3zHCYidQ7bmyq4U7mBUZIxXF2uiXF3jTpU1WXTrXQrvSTbtZC1kiV/IVEV5DsmmK
xuDIjGLKKQFBy1qO0v8AU5NZ1W6e+uFMWnmKVdLkt9ktvcSS4W2kIleNcxsw3Fny4Q5wqgHaafqV
tqtu09o8hCPskjlieKSNsA4dHAZTgg4IGQwPQg1rVx/g6G8A1e8u2nf7dqAuI5J7U2zOot4UOImA
ZFDxuqhvm2qCS2dx7CgAooooAKKKKACiiigAooooAKy7HVbTUpLpLK5Sc2dwbW42HISUKrFM9CQG
GcdDkdQRU1/9r/s+5/s/yPt3lv8AZ/tGfL8zB279vO3OM45xXKeBdL1LSTrVpfWaW8f22N0lE7St
cN9mhDyFjHHvLMu5nxy7SAjjJAO5ooooAw9P8Q6bqk7QWlzIz7PMQvBJGsyAgF4mYASpyvzIWHzL
z8wzYsdVtNSkuksrlJzZ3BtbjYchJQqsUz0JAYZx0OR1BFczZahca7rOo39naXVvewWUtvpkeo2F
zBGp3AtI7lFBEjLD8gJYJGCMFnVc7QtD8RWeheJ9LgtYLS5mu4hDcG+k3TbreBJpRMIVPmEBmEoU
/vS2V+X5gDs9L1Sz1axS+025W7tXd1SaPlWKMUbB7jcp5HB6jIrYrkfAtpeaf4eks7vTYNP8u/vP
Jt4WJRYzcSMuAUTC8nbgYKhTxnA66gAooooAKzr69g062e6uZPLhTGSFLEknAVVHLMSQAoBJJAAJ
NaNc94rgmn0dTDG8vkXtpcusalm8uK5ikchRyxCoxwMk4wASQKALen6lbarbtPaPIQj7JI5Ynikj
bAOHRwGU4IOCBkMD0INa1cx4bEktzrl+YbiK3vtQWa3E8LROyLbwRklHAZfnjcfMBnGRwQT09AFG
5uIbW2luJ5khgiUvJI7BVRQMkkngADnNUX16wGkWmrCeSS0vER7byoZJJJg67hsjVS7HblsBcgAk
4AOL88Ec8YSaJJUDrIFdQwDKwZTz3DAEHsQDXCHTLlPA/gkTw6jbx2KwNfC1ic3ES/ZJImUIoMgJ
Z1Q7BuUMSCu3cADqJvEmlQ29rciaeZZ93lx29rLNN8pw+YkUuu1sK2VG1iFOCcVpW1xDdW0VxBMk
0Eqh45EYMrqRkEEcEEc5rjLSW90670XVdRttRktYrfULZGW2luJ1jkuImtg6KrSZMMXJYZBGHIY8
9J4Us7jTvCWjWF3H5dza2MEMqcHa6xqGGRweQelAG7RRRQBhQ69p0+qf2dHcSGbe0asYJBE7rnci
SkbHcYbKqxI2PkfK2Gax4msNDDtqCXqRpEZnlisZ5o0QZyWeNGVcYJOTwOawdPt7ldS0rT2s7oT2
OuX9/O7W7iIQS/a/LZZSNjk+fF8qsWG45A2tjWvhJqmr6FGkNwLAb9RlaSFlViiqsUTowG1t0wlG
7kNB0yMqAW59f0m1vpLOa9SGSJC0juCsSYTeVMhGwOEG/Znds+bG3mr1vOs9vHcKJAkiB1EkbRsA
RnlWAKn2IBHeuL8beG7i8LPpME9xfXEpvDbSY+ymWKLYWkzjPmoEtjGZApSVm2naxrofDNxfXNpc
G7ku5oFuCtrcXlv5E80WxCWkj2ptIkMij5FyqqcHO4gHRVm6jfW+naZdX11J5dtbRPNM+0ttRQSx
wOTwD0rSrn/E8Fte6JJDdpeyQCaGZxYkiYeXKkmVx83G3JCfPgHb82KALWnanDqlu00Ed2iK+wi6
tJbds4B4WRVJHPXGOvpUOn+IdN1SdoLS5kZ9nmIXgkjWZAQC8TMAJU5X5kLD5l5+YZo+GpJY4bhH
GomylvSunG8SZpRF5Ks3mGQeYo80TYMuP4QOCgOD4c0meTV7K1nju59M0/SJ9Na3vtPMKxozQBI2
LZW4crE4d4yYztXAXdlgDsNL1Sz1axS+025W7tXd1SaPlWKMUbB7jcp5HB6jIrMt9e8Pacty1lDI
hlvZ1mSz02VnmnRgs0mxELOA2FaQArnA3ZwKt+FYJrbSp0mjkic6jfOFkUqSrXczKcHsVIIPcEGu
Y0mVtPv7TU5YLmSziuNat3e1tpLhlkk1AMgKRqzYIif5sYGMEgkZAOzm1Szg0tdRa5RrNkVkljPm
CQNjZs25LliQFC5LEgDJIqt/wkmlfYPt3nXOPN8jyPssv2jzMbtnkbfM3bfnxtzs+b7vNU/D7zaF
4M0yyvLK7a60/TbVLiGCIyFflCNtI4crtYlULNgDAJZQc2w1KfQ9G1XUmstU1BrrUF+zPJYyC4us
wxJ5k0aR5iVSjKSIl+SMEK7MC4B0tnLZakIdTtwkp2PHHKUw6AsN6HI3KdyAMpwQUwRkU46pZDWU
0k3Mf297droQDlvKVgpc+g3MAM9ecZwcZfh6e0ttM0/TUuZ2u54prlmntJLd53Eg8+UxuAU3SS7t
vH3/AJeBTp7Lb46sbqG0KxtYXnnzJHgGQvaBdzD+IrHgZ5wnoKALMOvadPqn9nR3Ehm3tGrGCQRO
653IkpGx3GGyqsSNj5HythdP8Q6bqk7QWlzIz7PMQvBJGsyAgF4mYASpyvzIWHzLz8wzzun29yup
aVp7Wd0J7HXL+/ndrdxEIJftflsspGxyfPi+VWLDccgbWxX8OWtzY6tZO41FtP0bSJ7PypdOeJoV
DQbF43faJSsThmiLIdi7VXcN4B2R1SyGsppJuY/t727XQgHLeUrBS59BuYAZ684zg4r3Gp6Vdy6p
pcjrdvZ26tfWixGYiORWwpQA7iyq3yYJIxx8wzVnstvjqxuobQrG1heefMkeAZC9oF3MP4iseBnn
Cego0+y+yeNNUkjtPIt5bC12uqbUeTzrt5MHoWy4Y9/nyetAGlpE1lPo1jPpoRdOlgje1EcexREV
BTC4G0bccYGK1K5/wJ/yT3w1/wBgq1/9FLXQUAFFFFABRRRQAUUUUAFFFFABRRWddQRXdvJb3EKT
QSoUkjkUMrqRggg8EEE8UAaNFc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ/wDwXQ//ABNAHQ1i
6L/yFvEf/YRT/wBJbeoP+EE8If8AQqaH/wCC6H/4msbSPBnhaXVddSTw1o7rFfokYawiIRfs0DYH
y8DJJ+pPrQB3VFc9/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8TQB0NFc9/wAIJ4Q/
6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8TQB0FLXJS/DrwfJcwXDeGtLDwbtqpbqqHcMHcgG1
/bcDjtirn/CCeEP+hV0P/wAF0P8A8TSdugHQ0Vz3/CCeEP8AoVND/wDBdD/8TR/wgnhD/oVND/8A
BdD/APE0wOhornv+EE8If9Cpof8A4Lof/iaP+EE8If8AQqaH/wCC6H/4mgDoaK57/hBPCH/QqaH/
AOC6H/4mj/hBPCH/AEKmh/8Aguh/+JoAZ4l8V6d4TgsbrVHZLW6vFtTMDxEWR2DN7fJj8c1txSpL
GskTK6OAyspyCD3B71yWrfDHwlq32NToen2qW9yJ3FraxxGYBWGxioB25YEjvtFdNYWFpplolpZW
sFrbR52QwRiNFycnCjgckn8aANCiiigArPvLy3sYRNcSGONpY4QSpOXkdUQcerMo/HmtCuO1+7ur
+X+yBp12J11KymgkWF3ilgjmhlkdpAuyMjZKNjNuOwYB3qCAdjRXnem2Dr4otGGnTx6qmqXkt9em
1ZfNs2+0eShuMbZVG62xGGJXavA8s7cVdAks/DHhJJdPj+yrpub+G+0ibUv9LKQBC8CsHDqqSqHP
CKNnAKigD16s6C+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frXnuo+HLyTT9UnuLa+u9Ss/C9qlnP
KpMhvEFyd6hWZTOrFSGUsyl/lb5smzcWDv4t1WVNKvv7Rl1mylsr4wsYxAsdr9o2P0iyiyKxO3zB
hAXK7VAO9ggjgjKQxJEhdpCqKFBZmLMeO5Ykk9ySaz4de06fVP7OjuJDNvaNWMEgid1zuRJSNjuM
NlVYkbHyPlbGJ4V02aDVr6CdkaDRUOlWSqT+6jZvO29PmHkNZJlsndE/qWecahHqfjSCCW11KODT
Hl8gy6dOsc1wUKmUS7AgRUMqDLYcyE4+VGYA0LXxPpN0Z2jutkccTTmWeN4Y3iX70sbuAskYyCXQ
lQGU5+YZWHxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFcQNK1LUPC9rpNvYXS3dh4
Vu9KnWaFoV+0ukCqiO4CyAmJ/mQleAc4IzoazBc63Jq2pafBqENuU0pVlazeKdTb3ck0rJFKm5iq
MrD5GDHgBiCKAOx0/UrbVbdp7R5CEfZJHLE8UkbYBw6OAynBBwQMhgehBrWrnfCnn/Y7/P27+z/t
X/Ev+3eb53k+VHu3eb+9/wBb52N/OMY+XbXRUAFFFFABRRRQAUUUUAFFFFAFG5uIbW2luJ5khgiU
vJI7BVRQMkkngADnNVNN1i01VpRamdZYiC8VzbSW8ig5w2yRVbacMA2MEqwB4OI/Fdncaj4S1mwt
I/MubqxnhiTgbnaNgoyeByR1rN8Mtcvf6g0UuqzaaYoSj6nFLHI9zmTziFlVWVSvk8KojBztA+YU
AdfRRRQBh6f4h03VJ2gtLmRn2eYheCSNZkBALxMwAlTlfmQsPmXn5hlg8QaY0WoTx3qyRWNx9lnK
Avtmwv7sADLPl1XauSWO373FYqy6lqXiSe/02C7W4i064iRNVtmiitLhjDsjVlUeajtGxdlaUDyx
tZQw3VPCkN/4T03xLJqOkzlIruOWMWZku57t/s0Ksw/dJ5jMwyXxy7SbsbSxAOu0/UrbVbdp7R5C
EfZJHLE8UkbYBw6OAynBBwQMhgehBrWrmfCredaXV46zC6u7l57ozW00HzkKFVVlRCypGscYcKN2
zJAYtXTUAFFFFABWbqN9b6dpl1fXUnl21tE80z7S21FBLHA5PAPStKuf8TwW17okkN2l7JAJoZnF
iSJh5cqSZXHzcbckJ8+AdvzYoAtadqcOqW7TQR3aIr7CLq0lt2zgHhZFUkc9cY6+la1c74U8/wCx
3+ft39n/AGr/AIl/27zfO8nyo927zf3v+t87G/nGMfLtroqAM6+vYNOtnurmTy4UxkhSxJJwFVRy
zEkAKASSQACTUFrrNhdafNfJceVb2+7zzco0LQYG4+YsgDJ8pDfMB8pB6EGp7u6NjbSTmCedY8Fk
hTe+3PJC9WwMnAyxxgAnAPGQ6brGo6LfpbQ/aY7zU0mmfVC9pLfW6wxhg6iL5cvGIipiUPEp4y28
gHUHxBpi6Xp+ovfIlpqTwx2bsCDM02PLAUjOTkHGOBknABxuV51ZaZeN8OfC8V1phTU7b+zIyqoX
kijW5t2fOVDL8sas4xgFeSdua9FoAKKKKAMKPxBZy61NpMX2p7uJ9kpWzmMUbbBJhpdvlg7WU43d
wOppdQ8Q6bpc6wXdzIr7PMcpBJIsKEkB5WUERJw3zOVHytz8pxg2NmLHxPBDpketxyNf3MupC6Mx
tjDIJnzHn9xzK0JHl/vME7ufMqj4wt7nULfUBpg1KOXWNJFoFGnPJ5xAlMce7/l2O6YhzMoG1htK
FWZQDq59f0m1vpLOa9SGSJC0juCsSYTeVMhGwOEG/Znds+bG3mr1vOs9vHcKJAkiB1EkbRsARnlW
AKn2IBHeuL8beG7i8LPpME9xfXEpvDbSY+ymWKLYWkzjPmoEtjGZApSVm2naxrofDNxfXNpcG7ku
5oFuCtrcXlv5E80WxCWkj2ptIkMij5FyqqcHO4gHRUUUUAFZN9qtrpUdu99dRwie4jtYQ3WSV22q
ijqST+QBJ4BNa1c14qsPtVnbSxWfnXMd/ZbXSPc6R/bIHkwRyFwgY9vkyelAGpfXsGnWz3VzJ5cK
YyQpYkk4Cqo5ZiSAFAJJIABJrJtNX0CxsJb2ziNus923nQxWUiXElww3NugCeYZCoDnK52fN93mr
ep6tHpltd3Bt765a2iWQxWtq8rybiQFTAwzZHTPy5BbAOa5eAOYNO1t7e+eRNakvdRK6fcK67rWW
FAkTRrJIqB4I9yp820sQPnwAdWdasE0SbWPtJFhDE80shRsxqmd4Zcbgy7WBUjcCCCMjFQL4k0s3
kNs006yy+WNz2kqpGzgFEkcrtjkO5cI5DfOoxlhnnr6CaD4T+JzMjxefb6pcosilW8uV55EJU8qS
rqcHBGcEAgin6hb3LalqunrZ3RnvtcsL+B1t3MRgi+yeYzSgbEI8iX5WYMdowDuXIB0Op6lpulXF
vNdRySXTI6QiC1kuJ9mVL4WNWcJkR7jjGdmeSKhv/Fel6Xbi6uZbt7Rrf7SLq1sZ7iHysE7zJGjI
BgZ69OehFJrWqGK1YBtYtkld4xd2Ng00kTI+MeWY3OGw2G2FSBncNyZzbLT7w2/hHS7nT/ssVnar
c3cUeZIUkhiREgJJOcPL5iksxzbgjJ+YAHbVh6f4h03VJ2gtLmRn2eYheCSNZkBALxMwAlTlfmQs
PmXn5hm3BfW91dXcMMm+S1lEM42kbHKK4HPX5XU8ev1rmrW5ln8Vy6qbbVPs9tp86TR3Vkym0ctC
fLh2qPP3+W5YqZeY12sAwDAGzNr2nQap/Z0lxIJt6xswgkMSO2NqPKBsRzlcKzAnemB8y5guNd0a
6e706fzJkKyxyIbOSSKfap8yJG2FJXADgxqWb5XGPlOMHUrK8fxRdxLDff6Rqlncx2sduWtbiNBb
7p5Jtp2SJ5b4TzEB8lPkbefMNNsrxPFFpE0N9/o+qXlzJayW5W1t43Fxtnjm2jfI/mJlPMcDzn+R
dg8sA67SJrKfRrGfTQi6dLBG9qI49iiIqCmFwNo244wMVqVz/gT/AJJ74a/7BVr/AOilroKACiii
gAooooAKKKKACiiigAooooAKK5+88J+HdRvJLu/0DS7u5kxvmns43dsDAyxBJ4AH4Un/AAgnhD/o
VND/APBdD/8AE0AdDXI2urafpF94gn1K+trOFtTRFkuZljUt9kgOMseuAePY1d/4QTwh/wBCrof/
AILof/ia5q3+HfhLVr3W7a60CzWOHUU8v7PH5BUfZoTtBj2nblmOOmTnrRG19dgPRqK57/hBPCH/
AEKmh/8Aguh/+Jo/4QTwh/0Kmh/+C6H/AOJoA6Giue/4QTwh/wBCpof/AILof/iat6ZoWkaKZf7L
0qxsPOwJPstukW/GcZ2gZxk/maANaiiigAooooAKKKKACiiigAooooAKKKKACs9L63fUZbFZM3EU
Uc0ibT8qOXCnPTkxv+XuK0K4XVNG1LUfFepmIJ9ibT7NWgnjYRXjLNckwvIOibW+YAH76ZDLujkA
N4eINOezF3HcSfZ3aJI5vIk2SGWXyo9jbcMGbGCMjDK33WBNyzvLe+hM1vIZI1lkhJCkYeN2Rxz6
MrD8OK4vUorzUdVuryLTb2NZP7EGyWAhlaLUJWlHGQdg5JUlduGBKkE52oaVetBZfa7KN9PW91Zp
YrzR5dRTzHvC0L/Z4yGyU8wrJ0AYj+MZAPVaydQ1K20q3We7eQB32RxxRPLJI2CcIiAsxwCcAHAU
noCa4LUfDl5Jp+qT3FtfXepWfhe1SznlUmQ3iC5O9QrMpnVipDKWZS/yt82T2/iDWG0PSzdR2N3e
ylwkcNtBJKSx7tsViqDqWwcAcBjhSAV11/R7Kwhlt/MK3DyOkVpZSySs28mUtFGhdSHYhyVG12w2
GOKfdeJ9JtTA0l1vjkiWcSwRvNGkTfdlkdAVjjOCQ7kKQrHPynGBYhdHn0LUjFqNzaJZXsVzcLps
4le5mmhkZ2twpkQO0czfd2jgDAK5yDpWpaf4XutJuLC6a7v/AAraaVAsMLTL9pRJ1ZHdAVjAMqfM
5C8k5wDgA7qbXtOg1T+zpLiQTb1jZhBIYkdsbUeUDYjnK4VmBO9MD5lzu153cWuoWvizUZLf+1Be
XWqWk9qsSSfZTbeXbx3Duyjy9xSOUbZWyNilAGYFvRKACiiigAooooAKKKKACiiigAooooAKy7HV
bTUpLpLK5Sc2dwbW42HISUKrFM9CQGGcdDkdQRU1/wDa/wCz7n+z/I+3eW/2f7Rny/Mwdu/bztzj
OOcVyngXS9S0k61aX1mlvH9tjdJRO0rXDfZoQ8hYxx7yzLuZ8cu0gI4yQDuaKKKAMaDW9MuYdRmj
voWh06R4buQvhIXRQzhmPHyhhn05B5BAZaeItNvEurhZ5LdLZN84vYJLZokwTvZZQpCfK3zYx8rc
8HGH/ZEy6L41sLPS0ZLh2isrRlMUUy/YIEVAQVwm5SmQRjBGRjibw7afbNS1G6n+3ahbNFarHdat
ZfZ5mkiklfZ5ZjjG1CyOr7M7nb5jtAUA6DTr631HTLW+tZPMtrmJJoX2ldyMAVODyOCOtaVc54Ng
ltfBPh+3nieGaLTrdJI5AVZGESggg8gg8Yro6ACiiigAqjc3ENrbS3E8yQwRKXkkdgqooGSSTwAB
zmr1Up4I54wk0SSoHWQK6hgGVgynnuGAIPYgGgCLTr631HTLW+tZPMtrmJJoX2ldyMAVODyOCOta
Vc54NgltfBPh+3nieGaLTrdJI5AVZGESggg8gg8Yro6AKNzcQ2ttLcTzJDBEpeSR2CqigZJJPAAH
Oaovr1gNItNWE8klpeIj23lQySSTB13DZGql2O3LYC5ABJwAcX54I54wk0SSoHWQK6hgGVgynnuG
AIPYgGuISyvLfwH4ODwX1tJYxW5uZbe3Mlzaf6I8ZKxbW3NuYRkFGwHY4GNygHTP4g0qKxtLx7xE
gu7hLWDeCrPMz7BHtI3Bw2QVIyu1s42nG9Xn40mZvCdizafI14NXilR3hPnGF9SjlaRhjKF1VZXX
ChTn5VC7V9AoAKKKKAMuDVLO71W706C5SS8s0je5iXkxCTds3dgSFJx1xg9CM19Q8Q6bpc6wXdzI
r7PMcpBJIsKEkB5WUERJw3zOVHytz8pxV0+y+yeNNUkjtPIt5bC12uqbUeTzrt5MHoWy4Y9/nyet
UPFesRXdnb6QbLVDaajEHupo9MuZAtsSN8RCRllkkXcmDtKAsxIIUMAbE+v6Ta30lnNepDJEhaR3
BWJMJvKmQjYHCDfszu2fNjbzV63nWe3juFEgSRA6iSNo2AIzyrAFT7EAjvXF+NvDdxeFn0mCe4vr
iU3htpMfZTLFFsLSZxnzUCWxjMgUpKzbTtY10Phm4vrm0uDdyXc0C3BW1uLy38ieaLYhLSR7U2kS
GRR8i5VVODncQDoqKKKAKNzcQ2ttLcTzJDBEpeSR2CqigZJJPAAHOagh1W0uNHi1dLlBYSW4uluJ
PkURFd287sbRt55xjvVHxNY6lqWmxWenxWsyPcIbuG5maFZYV+YpuCPwzBVZSpDIXXjORhWllqVx
8HotCkspI9Un8PvBHb4bAYQhFVmZVCOdy5VsYO7GQpNAHQQ+JNKmt7q5M08KwbfMjuLWWGb5jhMR
OodtzZVcKdzAqMkYq1p+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDXJalHPrGoajq1naX
32Vf7K/1tnLDI32a8eabbE6h2xGykYU7jwuSCK3PDYkludcvzDcRW99qCzW4nhaJ2RbeCMko4DL8
8bj5gM4yOCCQCOTxX4fvdLjeWR5rG+t/MYSWUrIIGyu+YFMRxMA2Gk2qwDEEgE1tf6Jpdh/ywtLG
1i9o44Y1H4BVAH0AFeZWdvcN4INvHZ3cz6t4PsrCyMVu8itOIpwVdlBEQ/fR/M5VeTz8rY7XxFb6
hrGm/Y9OihlVbuMXkV28kCTRAByiuI3DKx2K3ysrKZF4PQAtT+J9Mt9M07UvOnkttS2/ZTBayzPL
uQyDCIpb7isenGOa0LedZ7eO4USBJEDqJI2jYAjPKsAVPsQCO9cFp2mxReF/CM+vWWtwXFnpX2Xb
pj3OY9yxfLIIAJgxEQOMbFIYEk7Cer8P3VxJaWdjqkhOtw6fbTX6YHyu4YE5X5eXjk+76ehFABa6
xpTavNZwNtnllbfILZ1jnlRdrKJduySRVTBUMWAjYEfIcPsNfs9VvprWz+1u0DyI8jWcyRbo32OF
kZQjEMCMAnofSsu5lmvvGGmBLbUv9CuJDNBPbFbeJfKmUXCShcO7b0XbvbCyHKBlJWj4Zt49FuIL
fT4vECabY6dIl7HqKzyssqGMRCMNlWO0TjFvlDx1/d0AdRdana2d9Y2Nzdol1fO6WsJ+9KUUu2AO
wUcnpyB1IzHf6npX2mbSL11nnks5LmSyERmZ7cEKxKAEkEttAxluQAcGub1fS9df4g6Nqgsba5s4
71Y4JRcPutofs04kLJ5ZClmc5YPh9kCkAjdRZaXrkHxOXUryytZILi3vUN3HcO3lw77cQx4MWFOE
zs3kFnncEfdIB1mkTWU+jWM+mhF06WCN7URx7FERUFMLgbRtxxgYrUrn/An/ACT3w1/2CrX/ANFL
XQUAFFFFABRRRQAUUUUAFFFFABRRRQAUVnXUEV3byW9xCk0EqFJI5FDK6kYIIPBBBPFZ/wDwgnhD
/oVND/8ABdD/APE0AdDWLov/ACFvEf8A2EU/9JbeoP8AhBPCH/QqaH/4Lof/AImsbSPBnhaXVddS
Tw1o7rFfokYawiIRfs0DYHy8DJJ+pPrQB3VFc9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD
/wDE0AdDSVz/APwgnhD/AKFTQ/8AwXQ//E1Qi+G/gyPUGvv+Ea08yyJtKPCGiA4+7EfkU8DkKD19
TQB2FFc9/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8TQB0NFc9/wAIJ4Q/6FTQ/wDw
XQ//ABNH/CCeEP8AoVND/wDBdD/8TQB0NFc9/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDB
dD/8TQB0NFZ9rBFaW0dvbwpDBEgSONFCqigYAAHAAAHFaFABRRRQAUUUUAFZY1SyOsvpIuY/t6W6
3RgPDeUzFQ49RuUg46cZxkZ1K8z8W6NrF14nvb7SknhuDY21ql1EHVv3v22LAdRnakktvK/91Yw2
CVUEA7TS9Us9WsUvtNuVu7V3dUmj5VijFGwe43KeRweoyKj1DxDpulzrBd3Mivs8xykEkiwoSQHl
ZQREnDfM5UfK3PynHG22jLaW9hBdaHdyaZBcaskFpbQMDHO15utmQLjyj5Yk2TZVUDffXcM74nfQ
ta1gz2N9c/2ndpc2n2S2aUPiCKIxswG2Nt0WcyFUw6ndw+0A6+s+8vLexhE1xIY42ljhBKk5eR1R
Bx6syj8ea898c6fff2csdhocIu7fS8WX2axkvPJlUNlLZg0a2zR4UiQqGkygVS0YWpNe8N2l1J4i
v7/RnvHGt2Lx77V7gm3VbMSmKPByCqyK5QZYJg52gAA76zvLe+hM1vIZI1lkhJCkYeN2Rxz6MrD8
OK0K80t/C0cptTPps+6/1rVIdQchw7Wcn2zCFuqwsfKYAYUsysPmOTteCY76e3utU1WZLjUJHWxe
ZBjItgYn4AAwbj7S4OM7ZFzjAVQDQtfE+k3RnaO62RxxNOZZ43hjeJfvSxu4CyRjIJdCVAZTn5hl
YfEmlTW91cmaeFYNvmR3FrLDN8xwmInUO25squFO5gVGSMVzF+0vi638R+RY6jHdtpFzY6fb3VjN
b5Dgh3MkiKmZGEWFJJVYwflLOqyalHPrGoajq1naX32Vf7K/1tnLDI32a8eabbE6h2xGykYU7jwu
SCKAOm/4STSvsH27zrnHm+R5H2WX7R5mN2zyNvmbtvz4252fN93mrljewajbJdW0nmQvnBKlSCDg
qynlWBBBUgEEEEAiuJube5ne51eODUbe0l1wXSXEVo5uoIhYrB5iQMhYkyKY8NG3ysWAAw46LwnB
NbaBGs8bo73FxKDKpV5Fed3WR1P3XdWDsuF2liNq42gA6WiiigAooooAKKKKACiiigCjc3ENrbS3
E8yQwRKXkkdgqooGSSTwABzmqmm6xaaq0otTOssRBeK5tpLeRQc4bZIqttOGAbGCVYA8HEfiuzuN
R8JazYWkfmXN1YzwxJwNztGwUZPA5I61Q0aV9Q8Talq0MF3HaSWdpbI1zayW7NJG9wzgJIqtgCVO
cYOSASQcAHWUUUUAY0Gt6Zcw6jNHfQtDp0jw3chfCQuihnDMePlDDPpyDyCBBD4k0qa3urkzTwrB
t8yO4tZYZvmOExE6h23NlVwp3MCoyRisK40S6bw9460ywsfL+1F4bGFUEaOPsEEahM4XbuUr6DaR
2pl5GdYu9Z1SG11FLUQaeIXaxkSTzre4lmJ8mQI7ou6MkLyw3KhLcAA6rT9SttVt2ntHkIR9kkcs
TxSRtgHDo4DKcEHBAyGB6EGtauP8HQ3gGr3l207/AG7UBcRyT2ptmdRbwocRMAyKHjdVDfNtUEls
7j2FABRRRQAVnX17Bp1s91cyeXCmMkKWJJOAqqOWYkgBQCSSAASa0aydUv10qxuL97a7uRCm4QWk
DTSyHsqqOSScew6kgZNABp+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXM+FW860urx
1mF1d3Lz3RmtpoPnIUKqrKiFlSNY4w4UbtmSAxaumoAo3NxDa20txPMkMESl5JHYKqKBkkk8AAc5
qi+vWA0i01YTySWl4iPbeVDJJJMHXcNkaqXY7ctgLkAEnABxfngjnjCTRJKgdZArqGAZWDKee4YA
g9iAa5XTr648OfDbQGl02+nuo7C1g+yRW0rusnlqD5gRGZFXB3HaSMcAthSAb0/iHSrXQH1ua9SH
TokLSSuCuzB2lSpG4OG+XZjdu+XGeK2a8t8S6HqV/wDDpbbS4P7QtxaXk95HcxTWk91dMr/vBA0b
E5keSQRkL84iKsAvPoVut0YIjcKkc5UGRI3LqrY5AYgEjPfAz6CgDQooooAwode06fVP7OjuJDNv
aNWMEgid1zuRJSNjuMNlVYkbHyPlbC6h4h03S51gu7mRX2eY5SCSRYUJIDysoIiThvmcqPlbn5Tj
KGoR6n40ggltdSjg0x5fIMunTrHNcFCplEuwIEVDKgy2HMhOPlRmyPFsNzfXN+9tDqITUtJjgt4o
bRyt8+Zv3FzlCYEHmIN2YT+9fL/L8gB1c+v6Ta30lnNepDJEhaR3BWJMJvKmQjYHCDfszu2fNjbz
V63nWe3juFEgSRA6iSNo2AIzyrAFT7EAjvXF+NvDdxeFn0mCe4vriU3htpMfZTLFFsLSZxnzUCWx
jMgUpKzbTtY10Phm4vrm0uDdyXc0C3BW1uLy38ieaLYhLSR7U2kSGRR8i5VVODncQDoqKKKACsbU
tYtNKaIXRnaWUkpFbW0lxIwGMtsjVm2jKgtjALKCeRnZrk9ZlfT/ABNpurTQXclpHZ3ds7W1rJcM
skj27ICkas2CIn5xgYAJBIyAbE2qWcGlrqLXKNZsisksZ8wSBsbNm3JcsSAoXJYkAZJFVv8AhJNK
+wfbvOuceb5HkfZZftHmY3bPI2+Zu2/PjbnZ833eazdJuJPDngjT7a+s72S60zSrYTW1rbtM7OE2
bEKgq7blI4PHBOAQah0q9EGhXt9LHqoub65ke8nt9OmEkDsgVCkUkYZ1RFijDLGdxXcyj58AGnZX
mi6X4aa+slhtNJtYpJmWC3Mawqu4yAxgZVgQ25cbgwIIzxTl8SaWbyG2aadZZfLG57SVUjZwCiSO
V2xyHcuEchvnUYywzz15BNbfCDxCs8bxu9nqUoMqlXkVzM6yOp+67qwdlwu0sRtXG0P1C3uW1LVd
PWzujPfa5YX8DrbuYjBF9k8xmlA2IR5EvyswY7RgHcuQDpdS1i00pohdGdpZSSkVtbSXEjAYy2yN
WbaMqC2MAsoJ5GYTqekR39g0d1am71ddloyYZrlERpBgjqiqWOeg3+rDNDVLtYfEWm6vJb3zWcVr
e2cjQ2U0rrK0sG392il9p8mQh8beBz8y5oabolxY2HgRJbAre2fkw3jogYxiOxuEwzrn5Q7kDnGX
468gHe1lwapZ3eq3enQXKSXlmkb3MS8mISbtm7sCQpOOuMHoRl8F9b3V1dwwyb5LWUQzjaRscorg
c9fldTx6/WuN8K2et6R4i1u91nT4F86wgnubq1kluDPKJbhiEHlBmwrbQmWZEWFfmzwAdNNr2nQa
p/Z0lxIJt6xswgkMSO2NqPKBsRzlcKzAnemB8y5guNd0a6e706fzJkKyxyIbOSSKfap8yJG2FJXA
DgxqWb5XGPlOOfuLXULXxZqMlv8A2oLy61S0ntViST7Kbby7eO4d2UeXuKRyjbK2RsUoAzAs7TbK
8TxRaRNDff6Pql5cyWsluVtbeNxcbZ45to3yP5iZTzHA85/kXYPLAOu0iayn0axn00IunSwRvaiO
PYoiKgphcDaNuOMDFalc/wCBP+Se+Gv+wVa/+ilrQv7C01O0e0vbWC6tpMb4Z4xIjYORlTweQD+F
AGhRXPf8IJ4Q/wChU0P/AMF0P/xNH/CCeEP+hU0P/wAF0P8A8TQB0NFc9/wgnhD/AKFTQ/8AwXQ/
/E0f8IJ4Q/6FTQ//AAXQ/wDxNAHQ0Vz3/CCeEP8AoVND/wDBdD/8TR/wgnhD/oVND/8ABdD/APE0
AdDRXPf8IJ4Q/wChU0P/AMF0P/xNH/CCeEP+hU0P/wAF0P8A8TQB0GcUVx198N/B2oQCGXw1p8ah
twNtCIGzz1aPaSOemcflWj/wgvhD/oVdD/8ABdF/8TQ7AdDRXPf8IJ4Q/wChU0P/AMF0P/xNH/CC
eEP+hU0P/wAF0P8A8TQB0NYui/8AIW8R/wDYRT/0lt6g/wCEE8If9Cpof/guh/8AiaxtI8GeFpdV
11JPDWjusV+iRhrCIhF+zQNgfLwMkn6k+tAHdUVz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8
F0P/AMTQB0NFc9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABWWNUsjrL6SLmP7elut0YDw3lMxUOPUblIOOnGcZGdSvM/FujaxdeJ72+0pJ4
bg2NtapdRB1b979tiwHUZ2pJLbyv/dWMNglVBAO00vVLPVrFL7Tblbu1d3VJo+VYoxRsHuNynkcH
qMitivMLfR7azg06LVdCkm0KC41VRZDTnuI0drzdbsIERiB5Ql2vtwA2MjeM17nw7qcujahcajY3
dxrVr4VtFt5WLSsL5FuSWQgkNOrbcOMsN/BG85APV6z7O8t76EzW8hkjWWSEkKRh43ZHHPoysPw4
rjNWivI9Q1GzGm30z3mu6dfRywwFo1gQ2atIz/dGGhcFclwPm27MsMJtAENvBAmjwQaZBqGqC4t7
jQJryFpWuVNu4gj2lv3IIWUZVVymRnFAHsFZ9rBFaW0dvbwpDBEgSONFCqigYAAHAAAHFebeLNO1
ZNBtYU0+e81W30ZFt7yexe8uWuFRt5jZZdltMuFcybmMhKhd5jAOtq0V5HqGo2Y02+me813Tr6OW
GAtGsCGzVpGf7ow0LgrkuB823ZlgAeh1hQ69p0+qf2dHcSGbe0asYJBE7rnciSkbHcYbKqxI2Pkf
K2MLwnZzW+pXEtzY3cEbpIulrICyQ2fms2z7oMLksv7shcRrAvLRPiyNQj1PxpBBLa6lHBpjy+QZ
dOnWOa4KFTKJdgQIqGVBlsOZCcfKjMAaFr4n0m6M7R3WyOOJpzLPG8MbxL96WN3AWSMZBLoSoDKc
/MMvh8SadPaXFwgvc223zYG0+4WcBjhWEJTzCpIPzBSPlbn5TjhhpWpah4XtdJt7C6W7sPCt3pU6
zQtCv2l0gVUR3AWQExP8yErwDnBGehTUZv7Q8Q+I7LTb6eGPTYI4IJraW3kuJoTcuY1R1D8iSMA7
SCWwMkEAA6DSdas9aSd7Mz/6PL5MqTW8kDo+1XwVkVW+66np3rWrG0PT/wCx9GtLEytPJBEFlm27
TNJ1eRhk/M7EsSSSSxJJ61s0AFFFFABRRRQAUUUUAUbm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1U
03WLTVWlFqZ1liILxXNtJbyKDnDbJFVtpwwDYwSrAHg4j8V2dxqPhLWbC0j8y5urGeGJOBudo2Cj
J4HJHWqGjSvqHibUtWhgu47SSztLZGubWS3ZpI3uGcBJFVsASpzjByQCSDgA6yiiigCjc3ENrbS3
E8yQwRKXkkdgqooGSSTwABzms2HxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFaNxO
sFvJcMJCkaF2EcbSMQBnhVBLH2AJPauI3y67pOraqtlqUd9NPZOYZrCaKW0toplddgdAJZU/fTYU
ON7BP3ihdwB2Gn6lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cr4ShmWHVJ5Ptbpc3vm
RXN5CYZ7lRDEm+SPamwhkZAAiZVFODnc3VUAFFFFABVG5uIbW2luJ5khgiUvJI7BVRQMkkngADnN
XqpTwRzxhJoklQOsgV1DAMrBlPPcMAQexANAEWnX1vqOmWt9ayeZbXMSTQvtK7kYAqcHkcEda0q5
zwbBLa+CfD9vPE8M0WnW6SRyAqyMIlBBB5BB4xXR0AFZOoalbaVbrPdvIA77I44onlkkbBOERAWY
4BOADgKT0BNa1YfiDWG0PSzdR2N3eylwkcNtBJKSx7tsViqDqWwcAcBjhSARzeJNKht7W5E08yz7
vLjt7WWab5Th8xIpddrYVsqNrEKcE4rStriG6toriCZJoJVDxyIwZXUjIII4II5zXFfZxp9hot9b
XGqxzCK5hnvV0aaR3aaRJJ3+z43xSPIhdCUaNeQVIKA9N4Us7jTvCWjWF3H5dza2MEMqcHa6xqGG
RweQelAG7RRRQBlwapZ3eq3enQXKSXlmkb3MS8mISbtm7sCQpOOuMHoRmnrHiaw0MO2oJepGkRme
WKxnmjRBnJZ40ZVxgk5PA5qHT7L7J401SSO08i3lsLXa6ptR5POu3kwehbLhj3+fJ602+EmqavoU
aQ3AsBv1GVpIWVWKKqxROjAbW3TCUbuQ0HTIyoBbn1/SbW+ks5r1IZIkLSO4KxJhN5UyEbA4Qb9m
d2z5sbeavW86z28dwokCSIHUSRtGwBGeVYAqfYgEd64vxt4buLws+kwT3F9cSm8NtJj7KZYothaT
OM+agS2MZkClJWbadrGuh8M3F9c2lwbuS7mgW4K2txeW/kTzRbEJaSPam0iQyKPkXKqpwc7iAdFR
RRQAVjalrFppTRC6M7SyklIra2kuJGAxltkas20ZUFsYBZQTyM7NcnrMr6f4m03VpoLuS0js7u2d
ra1kuGWSR7dkBSNWbBET84wMAEgkZANibVLODS11FrlGs2RWSWM+YJA2NmzbkuWJAULksSAMkio7
XWbC60+a+S48q3t93nm5RoWgwNx8xZAGT5SG+YD5SD0INZ3h95tC8GaZZXlldtdafptqlxDBEZCv
yhG2kcOV2sSqFmwBgEsoOJDpusajot+ltD9pjvNTSaZ9UL2kt9brDGGDqIvly8YiKmJQ8SnjLbyA
dPPqmk3XhmXVbho5dFlszcyPJEWV7cpuJKEZIK9sZ7YqC313RrV7TToPMhQLFHGgs5I4oNyjy4nb
YEicgoBGxVvmQY+YZ54w3lt8DJoL+2+z3EXht0eEk5XbbkDdkAhsAZGODkZOMmfULe5bUtV09bO6
M99rlhfwOtu5iMEX2TzGaUDYhHkS/KzBjtGAdy5AOl1LWLTSmiF0Z2llJKRW1tJcSMBjLbI1Ztoy
oLYwCygnkZc2uaYs2mwi+gZ9Tz9iCPu88BC5ZcdV2jO7pyOeRnI1S7WHxFpuryW981nFa3tnI0Nl
NK6ytLBt/dopfafJkIfG3gc/MuaGm6JcWNh4ESWwK3tn5MN46IGMYjsbhMM65+UO5A5xl+OvIB2E
cEMctw6QojTPvkZVALttC5b1O1VGT2AHaqGn+IdN1SdoLS5kZ9nmIXgkjWZAQC8TMAJU5X5kLD5l
5+YZtwX1vdXV3DDJvktZRDONpGxyiuBz1+V1PHr9a4jwlDc2NzYPcw6iU03SZILiKa0cLYvmH9xb
YQGdD5bjdmY/ukw/zfOAdodUshrKaSbmP7e9u10IBy3lKwUufQbmAGevOM4OM+413Rrp7vTp/MmQ
rLHIhs5JIp9qnzIkbYUlcAODGpZvlcY+U4bPZbfHVjdQ2hWNrC88+ZI8AyF7QLuYfxFY8DPOE9BV
QahHqfjSCCW11KODTHl8gy6dOsc1wUKmUS7AgRUMqDLYcyE4+VGYA3dImsp9GsZ9NCLp0sEb2ojj
2KIioKYXA2jbjjAxWpXP+BP+Se+Gv+wVa/8Aopa6CgAorL1LSdO1m3SDUtPtb2FXDqlzCsqhsEZA
YEZwSM+9Uv8AhBPCH/QqaH/4Lof/AImgDoaK57/hBPCH/QqaH/4Lof8A4mj/AIQTwh/0Kmh/+C6H
/wCJoA6Giue/4QTwh/0Kmh/+C6H/AOJo/wCEE8If9Cpof/guh/8AiaAOhornv+EE8If9Cpof/guh
/wDiaP8AhBPCH/QqaH/4Lof/AImgDoaK57/hBPCH/QqaH/4Lof8A4mj/AIQTwh/0Kmh/+C6H/wCJ
oA6ClrlLP4eeDrK1S3j8NaW6JnDXFssz8nPLuCx69zVr/hBPCH/Qq6H/AOC6H/4mlpcDoaxdF/5C
3iP/ALCKf+ktvUH/AAgnhD/oVND/APBdD/8AE1jaR4M8LS6rrqSeGtHdYr9EjDWERCL9mgbA+XgZ
JP1J9aYHdUVz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/AMTQB0NFc9/wgnhD/oVND/8A
BdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDRXPf8IJ4Q/6FTQ//AAXQ/wDxNS6b4b0TR7hrjTNF06xn
ZNhktbVImKkgkEqAcZA49hQBuUUUUAFFFFABRRRQAUUUUAFFFFABWWNUsjrL6SLmP7elut0YDw3l
MxUOPUblIOOnGcZGdSvM/FujaxdeJ72+0pJ4bg2NtapdRB1b979tiwHUZ2pJLbyv/dWMNglVBAO0
0vVLPVrFL7Tblbu1d3VJo+VYoxRsHuNynkcHqMitivNtIs5vD91p9wNJuxaQvrFrFb2tscgy3yvC
oUYCIyRkh22oBjLAEVB4f0S5isYrqfSrqW8tfClhDbQtK9sTOEuQ6K/AjlAYLv8AvIJDyAxyAeoU
V5DaaVeyw6rZxadJBps1xpDwrYaVLpiNi8PnSLHvLq4VV3P8rYRTjaFY7Enh77DcajPY6W8L2mt2
KaeIYmC29sxtTP5CjhEbdP5hQDd827OOAD0as3Tr631HTLW+tZPMtrmJJoX2ldyMAVODyOCOtcVa
6SkuvRJPpLtftqN6dUuZbNts9i4uBFG8xXZKmHth5e5sbRlR5Z24NrpJ/wCEStIP7CuxeHw9BBpA
OnSbrTUh53muDs/0dzI0LGVtgbAbcQuQAen6hqVtpVus928gDvsjjiieWSRsE4REBZjgE4AOApPQ
E1Vm8SaVDb2tyJp5ln3eXHb2ss03ynD5iRS67WwrZUbWIU4JxUniDWG0PSzdR2N3eylwkcNtBJKS
x7tsViqDqWwcAcBjhTzdiF0efQtSMWo3NollexXNwumziV7maaGRna3CmRA7RzN93aOAMArkA37r
xPpNqYGkut8ckSziWCN5o0ib7ssjoCscZwSHchSFY5+U4LvxBp2n6iLK5F9HI0scIk+wXBh3yFVQ
eaE8vkso+91ODzXEnStS0/wvdaTcWF013f8AhW00qBYYWmX7SiTqyO6ArGAZU+ZyF5JzgHHZyW9x
eeM45JYpEtNPsy8TMpKSzTMVyvYPGkTDPJxcEcD7wB0lFFFABRRRQAUUUUAFFFFAFG5uIbW2luJ5
khgiUvJI7BVRQMkkngADnNVNN1i01VpRamdZYiC8VzbSW8ig5w2yRVbacMA2MEqwB4OLVxOsFvJc
MJCkaF2EcbSMQBnhVBLH2AJPasDwtef2reajqcttfW9zc+UvkXdlNbmCBQ3lx5dVV23NK7Fc4Mm3
cwVSQDrqKKKAMaDW9MuYdRmjvoWh06R4buQvhIXRQzhmPHyhhn05B5BAhh8S6W9nqF8808MVjEZr
lbm1lhkjjAJ3+W6hyp2tggYJVgMkGsG40S6bw9460ywsfL+1F4bGFUEaOPsEEahM4XbuUr6DaR2q
K5tIdcu9ZvpLPWBpbW+np+6t5ba4L29xLM2xHCyYUPGcoMkZCZcYAB1mnanDqlu00Ed2iK+wi6tJ
bds4B4WRVJHPXGOvpWtXO+FPP+x3+ft39n/av+Jf9u83zvJ8qPdu8397/rfOxv5xjHy7a6KgAooo
oAKo3NxDa20txPMkMESl5JHYKqKBkkk8AAc5q9VKeCOeMJNEkqB1kCuoYBlYMp57hgCD2IBoAi06
+t9R0y1vrWTzLa5iSaF9pXcjAFTg8jgjrWlXOeDYJbXwT4ft54nhmi063SSOQFWRhEoIIPIIPGK6
OgCjc3ENrbS3E8yQwRKXkkdgqooGSSTwABzmqL69YDSLTVhPJJaXiI9t5UMkkkwddw2Rqpdjty2A
uQAScAHF+eCOeMJNEkqB1kCuoYBlYMp57hgCD2IBrjLO2uNP8K+Brm4s7sLpiwPeRJbu8sQ+xSxf
6tQXJDyKCACRkk8AkAHQTeJNKht7W5E08yz7vLjt7WWab5Th8xIpddrYVsqNrEKcE4rStriG6tor
iCZJoJVDxyIwZXUjIII4II5zXKWk82meG9k6atZfbb28uI7mysTPLEsl08sYaLY7KWR/4o/l5DbW
wDt+GoLiz8L6Ra3FrHazwWcMcltGxZYWVACgJLEgEYzk9Op60Ab1FFFAGXBqlnd6rd6dBcpJeWaR
vcxLyYhJu2buwJCk464wehGa+oeIdN0udYLu5kV9nmOUgkkWFCSA8rKCIk4b5nKj5W5+U4q6fZfZ
PGmqSR2nkW8tha7XVNqPJ5128mD0LZcMe/z5PWqHivWIruzt9INlqhtNRiD3U0emXMgW2JG+IhIy
yySLuTB2lAWYkEKGANifX9Jtb6SzmvUhkiQtI7grEmE3lTIRsDhBv2Z3bPmxt5q9bzrPbx3CiQJI
gdRJG0bAEZ5VgCp9iAR3ri/G3hu4vCz6TBPcX1xKbw20mPsplii2FpM4z5qBLYxmQKUlZtp2sa6H
wzcX1zaXBu5LuaBbgra3F5b+RPNFsQlpI9qbSJDIo+RcqqnBzuIB0VFFFAGPquq2miadcajqVylt
Z26b5JW6KP5kkkAAckkAZJq1c3ENrbS3E8yQwRKXkkdgqooGSSTwABzmsbxrZf2j4M1qJLT7RcjT
7n7Mix738xoXQbBjO4hivHPzEd6ta5FHqOkX+lTRXMq3lnOhW2UBmUrtIV2+RXO8bQxGeT0BwAMh
8SaVNb3VyZp4Vg2+ZHcWssM3zHCYidQ7bmyq4U7mBUZIxVrT9SttVt2ntHkIR9kkcsTxSRtgHDo4
DKcEHBAyGB6EGuDuLPWNYTV9QM97KH/sv9/Hpr2rx/Z7t5ZfJglVnbbGyuM79zEhc/cHYeFPP+x3
+ft39n/av+Jf9u83zvJ8qPdu8397/rfOxv5xjHy7aAK0nivw/e6XG8sjzWN9b+YwkspWQQNld8wK
YjiYBsNJtVgGIJAJrRvb3TPDOiSXN1JDY6ZZRDOF2pGg4Cqo/ABQOeABXndnb3DeCDbx2d3M+reD
7KwsjFbvIrTiKcFXZQREP30fzOVXk8/K2O18Z26ar4Q1+CGzluLuGyuUgU27FvNa3YDy8j5iVkK5
XPVl65FAGhqWsWmlNELoztLKSUitraS4kYDGW2RqzbRlQWxgFlBPIzbtriG6toriCZJoJVDxyIwZ
XUjIII4II5zXOeKkmj1jTbxJdStIY7e4ie9060NzMjM0JWPy/LkGxgjMW2cGNRuXdhrfhuRbbRtO
0WWFLXULPTbVp7SMsywBlKBQxJyN0bj7xPy8nkEgEtrrGlNq81nA22eWVt8gtnWOeVF2sol27JJF
VMFQxYCNgR8hxdsdVtNSkuksrlJzZ3BtbjYchJQqsUz0JAYZx0OR1BFYQ1CPU/GkEEtrqUcGmPL5
Bl06dY5rgoVMol2BAioZUGWw5kJx8qM0uh2y6Tc+JG+xyW9nHeo8EcVu2DElnbr+7RRlgChUBQeV
IHNAF+bXtOg1T+zpLiQTb1jZhBIYkdsbUeUDYjnK4VmBO9MD5lzBca7o1093p0/mTIVljkQ2ckkU
+1T5kSNsKSuAHBjUs3yuMfKcUfEUk17qNjYQ2+omWK9tpfJ+yk2txGssbmRpguEMYV2VS6EsmCrq
yhqen29yupaVp7Wd0J7HXL+/ndrdxEIJftflsspGxyfPi+VWLDccgbWwAdVpE1lPo1jPpoRdOlgj
e1EcexREVBTC4G0bccYGK1K5/wACf8k98Nf9gq1/9FLXQUAFFFFABRRRQAUUUUAFFFFABRXOT+Df
DFzcPcXHh3SJppXLySSWMTM7E5JJK5JJ707/AIQTwh/0Kmh/+C6H/wCJoA6Giue/4QTwh/0Kmh/+
C6H/AOJo/wCEE8If9Cpof/guh/8AiaAOhrF0X/kLeI/+win/AKS29Qf8IJ4Q/wChU0P/AMF0P/xN
Y2keDPC0uq66knhrR3WK/RIw1hEQi/ZoGwPl4GST9SfWgDuaQHNYH/CCeEP+hU0T/wAF0P8A8TWf
a/DvwZaXNxLH4a052nbc4mhEqqeT8ivkIOeigDp6CjS2oHY0Vz3/AAgnhD/oVND/APBdD/8AE0f8
IJ4Q/wChU0P/AMF0P/xNAHQ0Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNAHQ0
Vz3/AAgnhD/oVND/APBdD/8AE0f8IJ4Q/wChU0P/AMF0P/xNAHQ0Vk6ZoWkaKZf7L0qxsPOwJPst
ukW/GcZ2gZxk/ma1qACiiigAooooAKKKKACssapZHWX0kXMf29LdbowHhvKZioceo3KQcdOM4yM6
lcTqejXl74u1G9tU8u8t9PtJNPuJQRD9oVrxSrHBypWXawHIWTIw20gA6G11GC+YLavJIpeaPd5T
7Q0UnlyAsRgEMCAD97BIyATUqX1u+oy2KyZuIoo5pE2n5UcuFOenJjf8vcV56mna3cWEjWtlfWd/
NYeIBCr/ALt4pprxHhBcHarHqCGwcZBI5qOfS2kHiA+H9Hu7DT5YdNCRzWMiRSRpcytcBbclWKbC
26EBS+5sKfMDMAerVRubiG1tpbieZIYIlLySOwVUUDJJJ4AA5zXAR6Ow8IyrJDI1kdS86K2XQZFt
Vj8kJtax8wytF5m5scHzSJNuwbj1GgubTwvC89lJapCkjCCKKQnywzFSkRy6BlwVh5KAhMfLigCW
HxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFP/AOEk0r7B9u865x5vkeR9ll+0eZjd
s8jb5m7b8+Nudnzfd5rlDJLrunajq32HUVvWvNPne2msJongtILhJBGAygSuAJ5CE3HMmwFwEJm2
z/2n/b/2O+/s/wDt/wC2/wDHnL53k/2d9m3eRt83/W/LjbnHzY2/NQB0U3iTSobe1uRNPMs+7y47
e1lmm+U4fMSKXXa2FbKjaxCnBOK0ra4huraK4gmSaCVQ8ciMGV1IyCCOCCOc158NNmik0q81CLWY
LBn1Vn+wRTecwuLtJoVcRAzRgopY42kFQrEZKnutD/tH+wNM/tf/AJCf2WL7Z93/AF2wb/u/L97P
Tj0oA1aKKKACiiigAooooAKKKKACiiigArLsdVtNSkuksrlJzZ3BtbjYchJQqsUz0JAYZx0OR1BF
TX/2v+z7n+z/ACPt3lv9n+0Z8vzMHbv287c4zjnFcp4F0vUtJOtWl9Zpbx/bY3SUTtK1w32aEPIW
Mce8sy7mfHLtICOMkA7miiigDGg1vTLmHUZo76FodOkeG7kL4SF0UM4Zjx8oYZ9OQeQQIIfEmlTW
91cmaeFYNvmR3FrLDN8xwmInUO25squFO5gVGSMVT0O2XSbnxI32OS3s471Hgjit2wYks7df3aKM
sAUKgKDypA5rn7j7T4h0bVNSjt9Vtr+W7sJSkmnyxTWtrDOkgVRJHtlkXE0hCq/zPsG8BNwB22n6
lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1c74U8/7Hf5+3f2f9q/4l/27zfO8nyo927z
f3v+t87G/nGMfLtroqACiiigArOvr2DTrZ7q5k8uFMZIUsSScBVUcsxJACgEkkAAk1o1z3iuCafR
1MMby+Re2ly6xqWby4rmKRyFHLEKjHAyTjABJAoAt6fqVtqtu09o8hCPskjlieKSNsA4dHAZTgg4
IGQwPQg1rVzHhsSS3OuX5huIre+1BZrcTwtE7ItvBGSUcBl+eNx8wGcZHBBPT0AUbm4htbaW4nmS
GCJS8kjsFVFAySSeAAOc1RfXrAaRaasJ5JLS8RHtvKhkkkmDruGyNVLsduWwFyACTgA4vzwRzxhJ
oklQOsgV1DAMrBlPPcMAQexANcrp19ceHPhtoDS6bfT3UdhawfZIraV3WTy1B8wIjMirg7jtJGOA
WwpANebxJpUNva3ImnmWfd5cdvayzTfKcPmJFLrtbCtlRtYhTgnFaVtcQ3VtFcQTJNBKoeORGDK6
kZBBHBBHOa5eGePT/CdnbrJrifaN7zaha6W5m88yb5GNu0bsnmOZG5jKAZAIymdjw1BcWfhfSLW4
tY7WeCzhjkto2LLCyoAUBJYkAjGcnp1PWgDeooooAwode06fVP7OjuJDNvaNWMEgid1zuRJSNjuM
NlVYkbHyPlbC6h4h03S51gu7mRX2eY5SCSRYUJIDysoIiThvmcqPlbn5TjndPt7ldS0rT2s7oT2O
uX9/O7W7iIQS/a/LZZSNjk+fF8qsWG45A2tiv4livZNYu9SsDrCTXekQLpK20Mqq92jTsnn4XKBT
LH8sxWM723A7TtAOpn1/SbW+ks5r1IZIkLSO4KxJhN5UyEbA4Qb9md2z5sbeavW86z28dwokCSIH
USRtGwBGeVYAqfYgEd64vxt4buLws+kwT3F9cSm8NtJj7KZYothaTOM+agS2MZkClJWbadrGuh8M
3F9c2lwbuS7mgW4K2txeW/kTzRbEJaSPam0iQyKPkXKqpwc7iAdFWdfXsGnWz3VzJ5cKYyQpYkk4
Cqo5ZiSAFAJJIABJrRrmvFkE1zoEiwRu7pcW8pMSlnjVJ0dpEUfedFUuq4bcVA2tnaQC/p+pW2q2
7T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDVO38W6RPcvC0l1bOkElyxvbKe1URIVDvulRRhd655
4zVLww0sCXskwvpBfahmC6urVo5rgC3jG+VAiiLBjZBlEBCJ1LbmamlvqmkeJ5L62u92qPcWwhQK
s6wRqYESNnwMNteVc4UGc9cliAbGm6xaaq0otTOssRBeK5tpLeRQc4bZIqttOGAbGCVYA8HFVvFW
kqrssl3Myzy25SGxnldnibbIVRULMisQpcAqCQM5NZnhRb+613VtVu5Z545rW1gWSTT5LJQ8bzll
SKT95tAkQ7mLZZmweNq52kytp9/aanLBcyWcVxrVu72ttJcMskmoBkBSNWbBET/NjAxgkEjIB2el
Qadb6ZbppEVpDYFN8C2iqsRVvmyoXjBznI65zVVPFGjSaVHqkF4bizlleGFraJ5mmdWZWEaICz42
OflB+VS33Rmsm0sNXi+HdloNoPs2sQ6Va28pkkeJY8qEk2TIrASAK+Cu7a2wkEEZxrDTtRsfCunp
PpsmlpZ65eyA6ZG08lpCzXIV4ojF8wLSBAPLceW+/C9UAO8sb2DUbZLq2k8yF84JUqQQcFWU8qwI
IKkAggggEVX+26XH4j+xCSAarLa+c0ar+8aBHwCx/uhpDjPctjo1Z3haVbPT7XT7hJIry5e7u4kl
jZXmi+0E+a4xhHYTRsy4XBcgKoG1ZJ7Lb46sbqG0KxtYXnnzJHgGQvaBdzD+IrHgZ5wnoKALMOva
dPqn9nR3Ehm3tGrGCQRO653IkpGx3GGyqsSNj5HytizY6raalJdJZXKTmzuDa3Gw5CShVYpnoSAw
zjocjqCK5HQrS/sfECQIdVE51S+lvEkSQWqWcjzyR7DgRMxd4GyC0o3MpIVSq62h2y6Tc+JG+xyW
9nHeo8EcVu2DElnbr+7RRlgChUBQeVIHNAGjN4gsrXWE0pzdvesqPshsppVRXZlUu6IVQEo3LEfd
J6UlxqelXcuqaXI63b2durX1osRmIjkVsKUAO4sqt8mCSMcfMM4F/afZfE002mx60mq3WoW0rNum
Nm8I8lJj8v7gfukkH7z95uHy/wDLOtXT7L7J401SSO08i3lsLXa6ptR5POu3kwehbLhj3+fJ60Aa
WkTWU+jWM+mhF06WCN7URx7FERUFMLgbRtxxgYrUrn/An/JPfDX/AGCrX/0UtdBQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRXPf8IJ4Q/6FTQ//BdD/wDE0AdDWLov/IW8R/8AYRT/ANJbeoP+EE8If9Cp
of8A4Lof/iaxtI8GeFpdV11JPDWjusV+iRhrCIhF+zQNgfLwMkn6k+tAHdUVz3/CCeEP+hU0P/wX
Q/8AxNH/AAgnhD/oVND/APBdD/8AE0AdDRXPf8IJ4Q/6FTQ//BdD/wDE0f8ACCeEP+hU0P8A8F0P
/wATQB0NJXP/APCCeEP+hU0T/wAF0P8A8TVO4+Hvg66MfmeGNLTypFlXybZYskdm2gbl9VOVPcUl
bqB1tFc9/wAIJ4Q/6FTQ/wDwXQ//ABNH/CCeEP8AoVND/wDBdD/8TTA6Giue/wCEE8If9Cpof/gu
h/8AiaP+EE8If9Cpof8A4Lof/iaAOhornv8AhBPCH/QqaH/4Lof/AImj/hBPCH/QqaH/AOC6H/4m
gBniXxXp3hOCxutUdktbq8W1MwPERZHYM3t8mPxzW3FKksayRMro4DKynIIPcHvXJat8MfCWrfY1
Oh6fapb3IncWtrHEZgFYbGKgHblgSO+0V01hYWmmWiWllawWttHnZDBGI0XJycKOBySfxoA0KKKK
ACud1DxLp2n6ibCcX0lwsSzMlrp9xc7UYsFJMaMBko3B/umuiri9Q0jVbzxbqc1hq99pGdLtY4p4
7eKSOSQSXJ+YSI27buUkKVOG5PIIAOitNTtb+OCS1eSRJldlbynAXYwVlckfI4Y42Nhshhj5WxpV
5nPpmqSafbf2ZZ31tqD6HqqsXfa6X0skDEGTCqGaUSEMu1TjcmFxVNbO1k1HX49F0i7tbA2+lPJa
G2eISW63cxuAlufmCMgkBj2Aud+FbflgD0ee+t7W6tIZpNkl1KYYBtJ3uEZyOOnyox59PpUen6pb
anBDcWjySQTW8dzFKYnVXjkBKkEgDOBkjqMjIGRngn0LTry70yR/Dvm6J/bzfZLaXS22wW72RRv3
JTMUZuVydyqN2HPBDVc+HenvYw2//EvuLJF0HToXWW2aD9+j3PnDDAfNubJ9d4bncCQDqYde06fV
P7OjuJDNvaNWMEgid1zuRJSNjuMNlVYkbHyPlbEdr4n0m6M7R3WyOOJpzLPG8MbxL96WN3AWSMZB
LoSoDKc/MM541CPU/GkEEtrqUcGmPL5Bl06dY5rgoVMol2BAioZUGWw5kJx8qM3MjStS1Dwva6Tb
2F0t3YeFbvSp1mhaFftLpAqojuAsgJif5kJXgHOCMgHbw+JNKmt7q5M08KwbfMjuLWWGb5jhMROo
dtzZVcKdzAqMkYq1p+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDXHazBc63Jq2pafBqEN
uU0pVlazeKdTb3ck0rJFKm5iqMrD5GDHgBiCK6Xwp5/2O/z9u/s/7V/xL/t3m+d5PlR7t3m/vf8A
W+djfzjGPl20AdFRRRQAUUUUAFFFFABRRRQAUUUUAYzazpi3F/ai/hWfTokmvQzYECMGKl2PC8Ix
5PAwTwRk03WLTVWlFqZ1liILxXNtJbyKDnDbJFVtpwwDYwSrAHg44G28P+I2t/GFtdadbNeapoe1
riC4Z1uLlmusKpeNBgBwoBY7EWIZYHI6jwy1y9/qDRS6rNppihKPqcUscj3OZPOIWVVZVK+TwqiM
HO0D5hQB19FFFAGNBremXMOozR30LQ6dI8N3IXwkLooZwzHj5Qwz6cg8ggRQ+JNOntLi4QXubbb5
sDafcLOAxwrCEp5hUkH5gpHytz8pxR0O2XSbnxI32OS3s471Hgjit2wYks7df3aKMsAUKgKDypA5
qlpWsTS2Wv8AiNNL1J9RNuHisJ7OaBxFGjGKAFkAdy5kYlA2DLtywVSQDo9J1qz1pJ3szP8A6PL5
MqTW8kDo+1XwVkVW+66np3rWrG0PT/7H0a0sTK08kEQWWbbtM0nV5GGT8zsSxJJJLEknrWzQAUUU
UAUbm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1mw+JNKmt7q5M08KwbfMjuLWWGb5jhMROodtzZVcK
dzAqMkYrSuJHit5JEhkndFLLFHtDOQPujcQMnpyQPcVw91Dc6kNbv7eDUbiGR7BkuLqzeGeIRXLS
OscRRC4hVhImUYuxKky42AA7DT9SttVt2ntHkIR9kkcsTxSRtgHDo4DKcEHBAyGB6EGtauV8JQzL
Dqk8n2t0ub3zIrm8hMM9yohiTfJHtTYQyMgARMqinBzubqqAKNzcQ2ttLcTzJDBEpeSR2CqigZJJ
PAAHOaovr1gNItNWE8klpeIj23lQySSTB13DZGql2O3LYC5ABJwAcX54I54wk0SSoHWQK6hgGVgy
nnuGAIPYgGuV06+uPDnw20BpdNvp7qOwtYPskVtK7rJ5ag+YERmRVwdx2kjHALYUgGtN4jsIba2u
VW+nhuC202thcTlSpwyuqITGwOQVYAggjGQcX9OvrfUdMtb61k8y2uYkmhfaV3IwBU4PI4I61zK2
LT+FNI0mBbqeO+vR9uuZrOSAvhnnnaSFwCqTOjRlThcT8ZGFPcUAFY91qdrZ31jY3N2iXV87pawn
70pRS7YA7BRyenIHUjOxXn+r6Xrr/EHRtUFjbXNnHerHBKLh91tD9mnEhZPLIUsznLB8PsgUgEbq
AOsOqWQ1lNJNzH9ve3a6EA5bylYKXPoNzADPXnGcHFPWPE1hoYdtQS9SNIjM8sVjPNGiDOSzxoyr
jBJyeBzXP2Wl65B8Tl1K8srWSC4t71Ddx3Dt5cO+3EMeDFhThM7N5BZ53BH3TsXwk1TV9CjSG4Fg
N+oytJCyqxRVWKJ0YDa26YSjdyGg6ZGVALc+v6Ta30lnNepDJEhaR3BWJMJvKmQjYHCDfszu2fNj
bzV63nWe3juFEgSRA6iSNo2AIzyrAFT7EAjvXF+NvDdxeFn0mCe4vriU3htpMfZTLFFsLSZxnzUC
WxjMgUpKzbTtY10Phm4vrm0uDdyXc0C3BW1uLy38ieaLYhLSR7U2kSGRR8i5VVODncQDoqKKKACs
m+1W10qO3e+uo4RPcR2sIbrJK7bVRR1JJ/IAk8Amtaua8VWH2qztpYrPzrmO/strpHudI/tkDyYI
5C4QMe3yZPSgDUvr2DTrZ7q5k8uFMZIUsSScBVUcsxJACgEkkAAk1kwax4c07RtR1hTBp1lHK018
z2xt3EpwSZIyofzGyhGRubcuM5Gbep6tHpltd3Bt765a2iWQxWtq8rybiQFTAwzZHTPy5BbAOa5i
5shq/wAO/EU4s55tUuYrucrJYzRuJ2tzGixLIisdsRSIOqjftJxlmFAHY6jfW+naZdX11J5dtbRP
NM+0ttRQSxwOTwD0qiviTSzeQ2zTTrLL5Y3PaSqkbOAUSRyu2OQ7lwjkN86jGWGTx3/yT3xL/wBg
q6/9FNWDqFvctqWq6etndGe+1ywv4HW3cxGCL7J5jNKBsQjyJflZgx2jAO5cgHQ6nqWm6VcW811H
JJdMjpCILWS4n2ZUvhY1ZwmRHuOMZ2Z5IovPE2k2P2MtLcXH2yJp7b7Fay3XmRrty48pW+X94nPT
5hWP4heVtU02/jfVLS3iiurd7ywsWmnRy8WI/KMcn7tvLZt+z/lmmHAbD4txpEun6NbPHY6xZ+I/
7Dt7WyisZJmtI7iJX2RtsZlIV3AJnJQqRyf3lAHp9ZdjqtpqUl0llcpObO4NrcbDkJKFVimehIDD
OOhyOoIp8F9b3V1dwwyb5LWUQzjaRscorgc9fldTx6/WsTQ7ZdJufEjfY5LezjvUeCOK3bBiSzt1
/dooywBQqAoPKkDmgC3d+INO0/URZXIvo5GljhEn2C4MO+QqqDzQnl8llH3upweaZca7o1093p0/
mTIVljkQ2ckkU+1T5kSNsKSuAHBjUs3yuMfKcElvcXnjOOSWKRLTT7MvEzKSks0zFcr2DxpEwzyc
XBHA+9SGoR6n40ggltdSjg0x5fIMunTrHNcFCplEuwIEVDKgy2HMhOPlRmAN3SJrKfRrGfTQi6dL
BG9qI49iiIqCmFwNo244wMVqVz/gT/knvhr/ALBVr/6KWugoAKKKKACiiigAooooAKKKKACiiigA
ooooAaTXjPiT4sHwV4017Sxov2zfcxT+b9q8vGbeEYxsP931716vfWFpqdq9pe2sFzbSY3wzxh0b
ByMqeDyAfwrw3xJ8JNQ8QeMdam8PjSLCxgmjhW3O6IK3kRMcKiEAHfn65rqwUaDqv2/w289/kTPm
t7p6f4A8aHxzok2p/YPsXlXLW/l+d5mcKrZztH97p7V2deX+Afhda6Fok9t4l03RdSvXuWkSY24m
2xlVAXLoCOQxx05r1CsK6pqpJU/hvoON7ai0UUVAwooooAKKKKACiiigAooooAKKKKACiiigArD1
HX7HS7pbeb7XLKU3tHa2c1yyKSQCwiRioJDYLYztbGcHG5XG6/8A6L4ha58/XNO821ij+16XZ/bP
tG15D5bp5Evl7N+Q3y7vNI52cAG8JLHVrZ4cJdWs8CuSY98E0UgIGGxscEA5AJ4IzwwyabpOnaNb
vBpun2tlCzl2S2hWJS2AMkKAM4AGfauFu9H1K5gMNzpUlq8lloEc0NirIkLJeO0yRMh+URqc5Vvl
GDnvViTw99huNRnsdLeF7TW7FNPEMTBbe2Y2pn8hRwiNun8woBu+bdnHAB6NRXnem2Dr4otGGnTx
6qmqXkt9em1ZfNs2+0eShuMbZVG62xGGJXavA8s7U8G6M+j/APCMFLGe2aXQm/tFijbmnX7N5ayk
87lBlCK33V3KoAGKAOom17ToNU/s6S4kE29Y2YQSGJHbG1HlA2I5yuFZgTvTA+ZckOvadPqn9nR3
Ehm3tGrGCQRO653IkpGx3GGyqsSNj5HytjL1nUY77xHY6LLa6ktpDcQ3M8y6dO8U8gO6KMSKhUBX
CSM5YAbFX5gz7KWn29yupaVp7Wd0J7HXL+/ndrdxEIJftflsspGxyfPi+VWLDccgbWwAbtr4n0m6
M7R3WyOOJpzLPG8MbxL96WN3AWSMZBLoSoDKc/MM2NN1i01VpRamdZYiC8VzbSW8ig5w2yRVbacM
A2MEqwB4OOK07SZtQ0fTdIuLDUQLDw1c6VfosJhbzXW3XZE8oCSE+VJhlJTgEnBGdjwot/da7q2q
3cs88c1rawLJJp8lkoeN5yypFJ+82gSIdzFsszYPG1QDtqKKKACiiigAooooAKKKKACiiigCjc3E
NrbS3E8yQwRKXkkdgqooGSSTwABzmqmm6xaaq0otTOssRBeK5tpLeRQc4bZIqttOGAbGCVYA8HEf
iuzuNR8JazYWkfmXN1YzwxJwNztGwUZPA5I61Q0aV9Q8Talq0MF3HaSWdpbI1zayW7NJG9wzgJIq
tgCVOcYOSASQcAHWUUUUAFY0Gt6Zcw6jNHfQtDp0jw3chfCQuihnDMePlDDPpyDyCBbv/tf9n3P9
n+R9u8t/s/2jPl+Zg7d+3nbnGcc4rkfA2i3tgmuWOqaZAkIv4Zo3aUzmeRYIMylmiTe29A5kxkyF
+AVyQDqtOvrfUdMtb61k8y2uYkmhfaV3IwBU4PI4I61pVzng2CW18E+H7eeJ4ZotOt0kjkBVkYRK
CCDyCDxiujoAKKKKACs6+vYNOtnurmTy4UxkhSxJJwFVRyzEkAKASSQACTWjXPeK4Jp9HUwxvL5F
7aXLrGpZvLiuYpHIUcsQqMcDJOMAEkCgC3p+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CD
WtXMeGxJLc65fmG4it77UFmtxPC0Tsi28EZJRwGX543HzAZxkcEE9PQAVRubiG1tpbieZIYIlLyS
OwVUUDJJJ4AA5zV6uc8TWOpalpsVnp8VrMj3CG7huZmhWWFfmKbgj8MwVWUqQyF14zkAEk3iXS0s
9PvkmnmivohNbLbWss0kkZAO/wAtFLhRuXJIwCyg4JFaNtcQ3VtFcQTJNBKoeORGDK6kZBBHBBHO
a4qy1DU9D+Gnh6xayvrbVJ7CO2V7exmuvsW2MDzZFWMkMBg+WRy5252hnHW6TBb2uk2FvYxyQ2cV
vGlvHIrqyRhQFBD/ADAgYGG59eaANaiiigAooooAKKKKACiiigAooooAx9U1Sz0mxe+1K5W0tUdF
eaThVLsEXJ7Dcw5PA6nAqw99bpqMVi0mLiWKSaNNp+ZEKBjnpwZE/P2NZ/iqCa50qBIY5JXGo2Ll
Y1LEKt3CzHA7BQST2AJrlNQ0bWrS8n0vTYJxBa6DqFtpFzE4UpvFsIoS+RtkVkcKTjKBDuZg5AB2
uqSWUVky6iEa0ndLZ1kj3q5lcRqhXByGZwOeOeeKmtYIrS2jt7eFIYIkCRxooVUUDAAA4AAA4rzr
VNG027s76Sw8OuNBS40uRbMaRJHmVLpvtDrblAxPksgZgnzKNuTtIGv45s57y+02SS3huNNjjuFm
juNKl1KPziYvLPkRsGDbRLiTooLD+MZAO+rJj1S2mvZreOaR5Ybj7NIqxOQknlCXBOMAbGU5PGSB
nJxXEarpN1DbaObm0utUv4dNgijW8sHnZ50Bz5c8Uh+xzsxG+ZiV/wBWQx8tjUtvpCQeOp5bbSpI
S3iIXMs6WbIjxNpsi7/MC7WHmtIDycM5zgvyAd3HBDHLcOkKI0z75GVQC7bQuW9TtVRk9gB2q7Xl
/hrwjaLB4Xtr3R5DBJobNqUdwjlZbhRbCNbgNw5QNKER8hMHaBtGM7X7XWbjwlprHSZ7jWI9BiaG
4nsZbu5F0IyX8tt6i1mQhWLnLSEqFDNGFIB6hBfW91dXcMMm+S1lEM42kbHKK4HPX5XU8ev1qKOW
y1qzmCgXNq7zWsqSR5VijNHIhDDkblYeh9xXF3Fg7+LdVlTSr7+0ZdZspbK+MLGMQLHa/aNj9Iso
sisTt8wYQFyu1amoaVetBZfa7KN9PW91ZpYrzR5dRTzHvC0L/Z4yGyU8wrJ0AYj+MZAPRbWCK0to
7e3hSGCJAkcaKFVFAwAAOAAAOK0KxtDt7i10DTLa6knluYrWJJpLgjzHcIAxfDMNxOc4Zue561s0
AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYui/8AIW8R/wDYRT/0lt62qxdF/wCQt4j/AOwin/pL
b0AbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVh6jr9jpd0tvN9rllKb2jtbOa5ZFJ
IBYRIxUEhsFsZ2tjODjcrjdf/wBF8Qtc+frmnebaxR/a9Ls/tn2ja8h8t08iXy9m/Ib5d3mkc7OA
DYttb028vxZW2oQTXTWiXqIjZ3wOSFkU9GXIPIzjIz1GW6b4g0zVjbiwvo7kXKTvA0YJWRYZFjkI
bGCAzKM985GRzXAalomvzTw3VpYHTdRXRrKyb7EjIkDypeRNHGyZxHHLLbyMATtWINyVXN3T/D2p
faLCysFk0m2jTW4y62zKscb30bRIu0rsDKAQVIJQNsKnDqAdsmq2bx3VyLtEt7R3SeZztjQoMv8A
MeCF5BIOAVYHlSBXh8SaVNb3VyZp4Vg2+ZHcWssM3zHCYidQ7bmyq4U7mBUZIxT9Nu1g0p1l02Sw
+wJ5T20MTOqhFBAh2r+8TbjbtGexVWBUcoZJdd07UdW+w6it615p87201hNE8FpBcJIIwGUCVwBP
IQm45k2AuAhIB1f/AAkmlfYPt3nXOPN8jyPssv2jzMbtnkbfM3bfnxtzs+b7vNI/iDSorG0vHvES
C7uEtYN4Ks8zPsEe0jcHDZBUjK7Wzjacc3tn/tP+3/sd9/Z/9v8A23/jzl87yf7O+zbvI2+b/rfl
xtzj5sbfmpx0qaTwtbSf2fIbptbW4izCfNS3l1RZ8kY3INgRmBwRt+YArwAegUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAVg6Pr9hrtutzp32poCiOrzWc0CurDKlDIqhxjnK57eoqfXLNdS0HU7CSOeS
O5tpYWjgZRIwZCCELfKG543cZ68Vk+GN39o6h9k/tX+yPKh8n+0vtHmfaMyebj7R+827fI/2M5xz
uoA62iiigDLsdVtNSkuksrlJzZ3BtbjYchJQqsUz0JAYZx0OR1BFVB4g0xotQnjvVkisbj7LOUBf
bNhf3YAGWfLqu1cksdv3uKoaTYXliPFEemWsFtIbpf7PSaMpB8tlbonC/wDLMMpU7f7pA6Vm+D7P
UfDtp4gW+0pxHHexOGtpWuZbj/R4FllyY4zIcguzKCzP5gClgNwB1Wn6lbarbtPaPIQj7JI5Ynik
jbAOHRwGU4IOCBkMD0INa1cr4ShmWHVJ5Ptbpc3vmRXN5CYZ7lRDEm+SPamwhkZAAiZVFODnc3VU
AFFFFABRRWBr8GpXmh31rpjpHeTIIld5mh2qSA5V1DFH2ltrbThtpII4oAn0vVLPVrFL7Tblbu1d
3VJo+VYoxRsHuNynkcHqMitiuR8C2l5p/h6Szu9Ng0/y7+88m3hYlFjNxIy4BRMLyduBgqFPGcDr
qAKNzcQ2ttLcTzJDBEpeSR2CqigZJJPAAHOagh1W0uNHi1dLlBYSW4uluJPkURFd287sbRt55xjv
VieCOeMJNEkqB1kCuoYBlYMp57hgCD2IBrj7fS9Xk+G/hvTbe2h3pa2i31teyvb7o0jBaIkI+Msq
q6spBQuvGcgA3pvEulpZ6ffJNPNFfRCa2W2tZZpJIyAd/lopcKNy5JGAWUHBIrRtriG6toriCZJo
JVDxyIwZXUjIII4II5zXIaNc3mm/Drw/Z38OrabcGwhiaawtDdSW7Iq4VozEzBmUHOYyqkMN2dpb
f8NQXFn4X0i1uLWO1ngs4Y5LaNiywsqAFASWJAIxnJ6dT1oA3qKKKAMs6pZDWU0k3Mf297droQDl
vKVgpc+g3MAM9ecZwcU9Y8TWGhh21BL1I0iMzyxWM80aIM5LPGjKuMEnJ4HNc/ZaXrkHxOXUryyt
ZILi3vUN3HcO3lw77cQx4MWFOEzs3kFnncEfdOxfCTVNX0KNIbgWA36jK0kLKrFFVYonRgNrbphK
N3IaDpkZUAtz6/pNrfSWc16kMkSFpHcFYkwm8qZCNgcIN+zO7Z82NvNXredZ7eO4USBJEDqJI2jY
AjPKsAVPsQCO9cX428N3F4WfSYJ7i+uJTeG2kx9lMsUWwtJnGfNQJbGMyBSkrNtO1jXQ+Gbi+ubS
4N3JdzQLcFbW4vLfyJ5otiEtJHtTaRIZFHyLlVU4OdxAOiooooAKyb7VbXSo7d766jhE9xHawhus
krttVFHUkn8gCTwCa1q5rxVYfarO2lis/OuY7+y2uke50j+2QPJgjkLhAx7fJk9KANS+vYNOtnur
mTy4UxkhSxJJwFVRyzEkAKASSQACTVFvE2lppUmqNLOsEcqQSIbWUTJI7KqoYdvmBiXTA25IZT0I
NP1PVo9Mtru4NvfXLW0SyGK1tXleTcSAqYGGbI6Z+XILYBzXMLZ2GoaNHqWpxa2039qPe3TWVvdW
8iSGFokAXakzRpG0ce6NQWKhmAHmYAOnOtWcWizatLJPBZRRvNI09tJE6ImdxMbKHHQnpz26io18
SaWbyG2aadZZfLG57SVUjZwCiSOV2xyHcuEchvnUYywzh6p9r/4VD4g+2+fu+wah5P2jPmeR+98j
fu+bd5Xl53/Pn73zZpuoW9y2parp62d0Z77XLC/gdbdzEYIvsnmM0oGxCPIl+VmDHaMA7lyAdLqW
sWmlNELoztLKSUitraS4kYDGW2RqzbRlQWxgFlBPIytzrmnWlrZ3c17ALe+lihtZFfcJ3lIEYTH3
s5zx2yegJqnrWqGK1YBtYtkld4xd2Ng00kTI+MeWY3OGw2G2FSBncNyZ4/VtB8R/2T4Z8rSLFotN
i05VshcyD7NcCeHzDjZJuVVQKJN2URpid+aAPVKy4NUs7vVbvToLlJLyzSN7mJeTEJN2zd2BIUnH
XGD0Iy+C+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frXG+FbPW9I8Ra3e6zp8C+dYQT3N1ayS3Bnl
EtwxCDygzYVtoTLMiLCvzZ4AOom8QWVrrCaU5u3vWVH2Q2U0qorsyqXdEKoCUbliPuk9KibxJpYv
JrZZp2li8wbktJWSRkBLpG4XbJINrZRCW+RhjKnGJf2n2XxNNNpsetJqt1qFtKzbpjZvCPJSY/L+
4H7pJB+8/ebh8v8AyzqDQrS/sfECQIdVE51S+lvEkSQWqWcjzyR7DgRMxd4GyC0o3MpIVSqgHYad
fW+o6Za31rJ5ltcxJNC+0ruRgCpweRwR1rSrn/An/JPfDX/YKtf/AEUtdBQAUUUUAFFFFABRRRQA
UUUUAFFFFABRXPf8IJ4Q/wChU0P/AMF0P/xNH/CCeEP+hU0P/wAF0P8A8TQB0NctZ39pplz4mu72
5htbePUY9808gRFzbW4GSeByQKsf8IJ4Q/6FTRP/AAXQ/wDxNc3aeAvCupXPiGzuPDmmiNb9EQxW
6xMi/Z4GwrJhlG4k4BGcn1NCtfXYDtre5hurWOe3lSWGVQ8ckbBldSMggjqCO9X65KDwD4St4I4l
8L6QyooQGSyjdiBxyzAkn3JJNXP+EE8If9Crof8A4Lof/iaHa+gHQ0Vz3/CCeEP+hU0P/wAF0P8A
8TTYPBvhi2uEuLfw7pEM0Th45I7GJWRgcgghcgg96AOjooooAKKKKACiiigAooooAKKKKACiiigA
rnL/AMU6Zpd+tpeDURO7hEEWmXMqyNtL4VkjKsdoJwCcbT6Gujrn9bgln1jw60cUjrDqLySsqkhF
+yXC5J7DcyjPqQO9AGjbzrPbx3CiQJIgdRJG0bAEZ5VgCp9iAR3q/XmniO2v38YwXFppH79NQssX
a2Ek032bzIhI6XO8LDHy6NCqkkb3I2yMwt6ZYtb+NXlTT3lle4nM1zLYSRTxxsGILXYby7iLJRUh
xlVMZIBhOADq/wC3dO/sD+3ftH/Es+y/bPP2N/qdm/dtxu+7zjGfarJmWJ4kYSFpH2ArGzAHaW+Y
gYUYB5OBnA6kA+Wp4durPwTb29lpd0lxdeELuO9UROZJbnyoBEkmeS65lVFP3RuVQAMVuw6fqMfi
HTTfwSXN/FrBkmv44GWOW3NnciPAywjRGdo9m4nPznmbLAHoNYU2vadBqn9nSXEgm3rGzCCQxI7Y
2o8oGxHOVwrMCd6YHzLnl/BujPo//CMFLGe2aXQm/tFijbmnX7N5ayk87lBlCK33V3KoAGK1NZ1G
O+8R2Oiy2upLaQ3ENzPMunTvFPIDuijEioVAVwkjOWAGxV+YM+wA1Ide06fVP7OjuJDNvaNWMEgi
d1zuRJSNjuMNlVYkbHyPlbEdr4n0m6M7R3WyOOJpzLPG8MbxL96WN3AWSMZBLoSoDKc/MM4Wn29y
upaVp7Wd0J7HXL+/ndrdxEIJftflsspGxyfPi+VWLDccgbWxD4divIV0BRpt6ZdE0CWyu43gMWZz
9mwkbSbUkz5MnzKxTgZYBgSAdXpusWmqtKLUzrLEQXiubaS3kUHOG2SKrbThgGxglWAPBxs1yfh4
vda/q+ohb6S1nigSO4vbZreQFXmYwhGRD5aB1IYqSTIwLttwvWUAFFFFABRRRQAUUUUAFFFFABWP
peqWerWKX2m3K3dq7uqTR8qxRijYPcblPI4PUZFT3UEV3byW9xCk0EqFJI5FDK6kYIIPBBBPFUPC
sE1tpU6TRyROdRvnCyKVJVruZlOD2KkEHuCDQB0FFFFAHPWvifSboztHdbI44mnMs8bwxvEv3pY3
cBZIxkEuhKgMpz8wysPiTSpre6uTNPCsG3zI7i1lhm+Y4TETqHbc2VXCncwKjJGK5i/aXxdb+I/I
sdRju20i5sdPt7qxmt8hwQ7mSRFTMjCLCkkqsYPylnVTWYLnW5NW1LT4NQhtymlKsrWbxTqbe7km
lZIpU3MVRlYfIwY8AMQRQB2On6lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1c74U8/7H
f5+3f2f9q/4l/wBu83zvJ8qPdu8397/rfOxv5xjHy7a6KgAooooAKzdRvrfTtMur66k8u2tonmmf
aW2ooJY4HJ4B6VpVz/ieC2vdEkhu0vZIBNDM4sSRMPLlSTK4+bjbkhPnwDt+bFAFrTtTh1S3aaCO
7RFfYRdWktu2cA8LIqkjnrjHX0rWrnfCnn/Y7/P27+z/ALV/xL/t3m+d5PlR7t3m/vf9b52N/OMY
+XbXRUAZ19ewadbPdXMnlwpjJCliSTgKqjlmJIAUAkkgAEmqf/CSaV9g+3edc483yPI+yy/aPMxu
2eRt8zdt+fG3Oz5vu81Pql+ulWNxfvbXdyIU3CC0gaaWQ9lVRySTj2HUkDJrkYA5g07W3t755E1q
S91Erp9wrrutZYUCRNGskioHgj3KnzbSxA+fAB0d14l0yDT7W9eacxXcphgWC1llkaQBiyGNFLhl
Eb7gQCpUg4IrSt51nt47hRIEkQOokjaNgCM8qwBU+xAI71wsWlWcdpZX+rW2vxjz9SeE6f8AaFZU
uLrzk8xYP3wLIFOCMLgh8NtFdpof9o/2Bpn9r/8AIT+yxfbPu/67YN/3fl+9npx6UAatFFFAGFH4
gs5dam0mL7U93E+yUrZzGKNtgkw0u3ywdrKcbu4HU0uoeIdN0udYLu5kV9nmOUgkkWFCSA8rKCIk
4b5nKj5W5+U4wbGzFj4ngh0yPW45Gv7mXUhdGY2xhkEz5jz+45laEjy/3mCd3PmVR8YW9zqFvqA0
walHLrGki0CjTnk84gSmOPd/y7HdMQ5mUDaw2lCrMoB1c+v6Ta30lnNepDJEhaR3BWJMJvKmQjYH
CDfszu2fNjbzV63nWe3juFEgSRA6iSNo2AIzyrAFT7EAjvXF+NvDdxeFn0mCe4vriU3htpMfZTLF
FsLSZxnzUCWxjMgUpKzbTtY10Phm4vrm0uDdyXc0C3BW1uLy38ieaLYhLSR7U2kSGRR8i5VVODnc
QDoqKKKACsbUtYtNKaIXRnaWUkpFbW0lxIwGMtsjVm2jKgtjALKCeRnZrk9ZlfT/ABNpurTQXclp
HZ3ds7W1rJcMskj27ICkas2CIn5xgYAJBIyAbE2qWcGlrqLXKNZsisksZ8wSBsbNm3JcsSAoXJYk
AZJFVv8AhJNK+wfbvOuceb5HkfZZftHmY3bPI2+Zu2/PjbnZ833eazdJuJPDngjT7a+s72S60zSr
YTW1rbtM7OE2bEKgq7blI4PHBOAQayoA5g07W3t755E1qS91Erp9wrrutZYUCRNGskioHgj3Knzb
SxA+fAB1NzqmlXHhy61C5ZJdKFvK9z5sRYCNQRIrxkZyMMGQjIIIIzxVa313RrV7TToPMhQLFHGg
s5I4oNyjy4nbYEicgoBGxVvmQY+YZwr6CaD4T+JzMjxefb6pcosilW8uV55EJU8qSrqcHBGcEAgi
n6hb3LalqunrZ3RnvtcsL+B1t3MRgi+yeYzSgbEI8iX5WYMdowDuXIB0upaxaaU0QujO0spJSK2t
pLiRgMZbZGrNtGVBbGAWUE8jNe68T6TamBpLrfHJEs4lgjeaNIm+7LI6ArHGcEh3IUhWOflOKWqX
aw+ItN1eS3vms4rW9s5GhsppXWVpYNv7tFL7T5MhD428Dn5lzizPJY+DtB8K39lqKeZp0EOovb2E
1ykcSqqyw7oUYF3AZOCNoLPkEIGAO7jghjluHSFEaZ98jKoBdtoXLep2qoyewA7VBY6raalJdJZX
KTmzuDa3Gw5CShVYpnoSAwzjocjqCKfBfW91dXcMMm+S1lEM42kbHKK4HPX5XU8ev1rE0O2XSbnx
I32OS3s471Hgjit2wYks7df3aKMsAUKgKDypA5oAvza9p0Gqf2dJcSCbesbMIJDEjtjajygbEc5X
CswJ3pgfMuYLjXdGunu9On8yZCssciGzkkin2qfMiRthSVwA4Malm+Vxj5Tjn7i11C18WajJb/2o
Ly61S0ntViST7Kbby7eO4d2UeXuKRyjbK2RsUoAzAsW1heDxfYW8DX32Sy1W6vmglsSiIs0dxukM
/KS5kmXYqEMquQ6kqSoB2GkTWU+jWM+mhF06WCN7URx7FERUFMLgbRtxxgYrUrn/AAJ/yT3w1/2C
rX/0UtdBQAUUUUAFFc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ/wDwXQ//ABNAHQ0Vz3/CCeEP
+hU0P/wXQ/8AxNH/AAgnhD/oVND/APBdD/8AE0AdDRXPf8IJ4Q/6FTQ//BdD/wDE0f8ACCeEP+hU
0P8A8F0P/wATQBdj1bT5dTl02O/tnv4l3y2qzKZUXjkrnIHzL+Y9a1K46H4beDY9Re+HhrTjLIu1
kaENEBx0iPyKeByFB6+prQ/4QTwh/wBCpof/AILof/iabt0A6Giue/4QTwh/0Kmh/wDguh/+Jo/4
QTwh/wBCpof/AILof/iaQHQ1i6L/AMhbxH/2EU/9JbeoP+EE8If9Cpof/guh/wDiaxtI8GeFpdV1
1JPDWjusV+iRhrCIhF+zQNgfLwMkn6k+tAHdUVz3/CCeEP8AoVND/wDBdD/8TXQ0AFFFFABRRRQA
UUUUAFFFFABRRRQAUUUUAFFFFABXOX/inTNLv1tLwaiJ3cIgi0y5lWRtpfCskZVjtBOATjafQ10d
c/rcEs+seHWjikdYdReSVlUkIv2S4XJPYbmUZ9SB3oA0bedZ7eO4USBJEDqJI2jYAjPKsAVPsQCO
9X6871KwdvFF2x06eTVX1Szlsb0WrN5Vmv2fzkFxjbEp23OYywLbm4PmDc7SdFey1DS9QjsJ47yb
XtQ+1zFG3/ZmN2yKSfuwlvKYLwpYq2NzZIB6FRXk+neHtS07wzp0Ok2N3bajdeFbhJ3BaORrwJbi
ESOxBDqTIEDEbBuC4AwLOnaQf7F1vyYXjsZUtgLex0GSxhLI7NITbSSb5gylBIAB5kahFLNwAD0+
ivM4rEHQLFLnRCdGi1VnubaDTZkiuIDbuAwsW3Oiicp8mDlk83ADZD9N8OLqN/osWp6ZJLpsdvqj
RwTxN5SRPdwtbRvGeABFgrG4+XYPlBTgA7i+vYNOtnurmTy4UxkhSxJJwFVRyzEkAKASSQACTVP/
AISTSvsH27zrnHm+R5H2WX7R5mN2zyNvmbtvz4252fN93ms/SdQudL8BaXfanb6lc3cOnQG4gSB5
bqSXy1yu37xcsec9DkkgAmsiAOYNO1t7e+eRNakvdRK6fcK67rWWFAkTRrJIqB4I9yp820sQPnwA
dJN4k0qG3tbkTTzLPu8uO3tZZpvlOHzEil12thWyo2sQpwTikuvE+k2pgaS63xyRLOJYI3mjSJvu
yyOgKxxnBIdyFIVjn5TjndNjn0fUNO1a8tL77K39q/6qzlmkX7TeJNDuiRS65jVicqNp4bBIFRXt
vfW3w807w5LZ6iNQOkRW/lQW/nQ3EohMbW0sihvLQttDPuj4bKyDDEAHpFFFFABRRRQAUUUUAFFF
FAFC4nWC3kuGEhSNC7CONpGIAzwqglj7AEntVHTdesdWuLi3tftaz26I8kd1ZzW7BXLBSBIqkglG
GRn7tbtc54VgkTQ47y7ikiu792vZ45VIkjaU7hG5PJMalYsnHEYGAAAADo6KKKAMC28TaZdT3iLL
Okdn5vn3E1rLHAvlMUk/fOojO0g5wx6H0NLD4k06e0uLhBe5ttvmwNp9ws4DHCsISnmFSQfmCkfK
3PynHO+GbePRbiC30+LxAmm2OnSJex6is8rLKhjEQjDZVjtE4xb5Q8df3dT6VrE0tlr/AIjTS9Sf
UTbh4rCezmgcRRoxigBZAHcuZGJQNgy7csFUkA6PSdas9aSd7Mz/AOjy+TKk1vJA6PtV8FZFVvuu
p6d61qxtD0/+x9GtLEytPJBEFlm27TNJ1eRhk/M7EsSSSSxJJ61s0AFFFFABVG5uIbW2luJ5khgi
UvJI7BVRQMkkngADnNXqpTwRzxhJoklQOsgV1DAMrBlPPcMAQexANAEWnX1vqOmWt9ayeZbXMSTQ
vtK7kYAqcHkcEda0q5zwbBLa+CfD9vPE8M0WnW6SRyAqyMIlBBB5BB4xXR0AUbm4htbaW4nmSGCJ
S8kjsFVFAySSeAAOc1RfXrAaRaasJ5JLS8RHtvKhkkkmDruGyNVLsduWwFyACTgA4vzwRzxhJokl
QOsgV1DAMrBlPPcMAQexANcQlleW/gPwcHgvraSxitzcy29uZLm0/wBEeMlYtrbm3MIyCjYDscDG
5QDpJvEmlQ29rciaeZZ93lx29rLNN8pw+YkUuu1sK2VG1iFOCcVpW1xDdW0VxBMk0Eqh45EYMrqR
kEEcEEc5ridMWfR7jSdUu7O9NssWpRs0VpLLMzT3UcsbyRIpZWkRGdvlVVY7cJwtdP4Us7jTvCWj
WF3H5dza2MEMqcHa6xqGGRweQelAG7RRRQBlwapZ3eq3enQXKSXlmkb3MS8mISbtm7sCQpOOuMHo
RmvqHiHTdLnWC7uZFfZ5jlIJJFhQkgPKygiJOG+Zyo+VuflOKun2X2Txpqkkdp5FvLYWu11Tajye
ddvJg9C2XDHv8+T1rnfFsNzfXN+9tDqITUtJjgt4obRyt8+Zv3FzlCYEHmIN2YT+9fL/AC/IAdXP
r+k2t9JZzXqQyRIWkdwViTCbypkI2Bwg37M7tnzY281et51nt47hRIEkQOokjaNgCM8qwBU+xAI7
1xfjbw3cXhZ9JgnuL64lN4baTH2UyxRbC0mcZ81AlsYzIFKSs207WNdD4ZuL65tLg3cl3NAtwVtb
i8t/Inmi2IS0ke1NpEhkUfIuVVTg53EA6KiiigDJ1DUrbSrdZ7t5AHfZHHFE8skjYJwiICzHAJwA
cBSegJp0OqWc+ltqK3KLZqjM8sh8sRhc79+7BQqQQwbBUgg4INV/EGsNoelm6jsbu9lLhI4baCSU
lj3bYrFUHUtg4A4DHCmp4fkj0/w9bRwx3t3M0U1w5e0e2e4m37pWKy7RGzyOxCsVHPHyjIAJ4fEm
lTW91cmaeFYNvmR3FrLDN8xwmInUO25squFO5gVGSMVa0/UrbVbdp7R5CEfZJHLE8UkbYBw6OAyn
BBwQMhgehBrk5IJNTk1zUETVJYD9ilguLiwaOZJIbh5hGICsbSQx5RuBvcO6h2YALpeDobwDV7y7
ad/t2oC4jkntTbM6i3hQ4iYBkUPG6qG+baoJLZ3EAlk8V+H73S43lkeaxvrfzGEllKyCBsrvmBTE
cTANhpNqsAxBIBNaN7d6foVhArIYbddsFvb20DOxwOEjjjBY4VScKOFUnoDXndnb3DeCDbx2d3M+
reD7KwsjFbvIrTiKcFXZQREP30fzOVXk8/K2PQ9V1A29rcFY9RAV/Iea0tWkeEsmRIqbSZACVGVV
wCeRhXwARTeJNKht7W5E08yz7vLjt7WWab5Th8xIpddrYVsqNrEKcE4rStriG6toriCZJoJVDxyI
wZXUjIII4II5zXE6Ys+j3Gk6pd2d6bZYtSjZorSWWZmnuo5Y3kiRSytIiM7fKqqx24Tha3vCh/s7
QNJ0G5+TU7DS7T7VB18vKFB8w+U/NE44J+77jIBetLvTJNY1CxtJIDeQ+VNerEPmBdcIXI/iKxjr
ztC9iKj0/wAQ6bqk7QWlzIz7PMQvBJGsyAgF4mYASpyvzIWHzLz8wzV0+y+yeNNUkjtPIt5bC12u
qbUeTzrt5MHoWy4Y9/nyetc/4ctbmx1aydxqLafo2kT2flS6c8TQqGg2Lxu+0SlYnDNEWQ7F2qu4
bwDqZte06DVP7OkuJBNvWNmEEhiR2xtR5QNiOcrhWYE70wPmXMFxrujXT3enT+ZMhWWORDZySRT7
VPmRI2wpK4AcGNSzfK4x8pxR8RSTXuo2NhDb6iZYr22l8n7KTa3EayxuZGmC4QxhXZVLoSyYKurK
Gp6fb3K6lpWntZ3Qnsdcv7+d2t3EQgl+1+WyykbHJ8+L5VYsNxyBtbAB1WkTWU+jWM+mhF06WCN7
URx7FERUFMLgbRtxxgYrUrn/AAJ/yT3w1/2CrX/0UtdBQAUUUUAFFFFABRRRQAUUUUAFFFZepaTp
2s26Qalp9rewq4dUuYVlUNgjIDAjOCRn3oA1KK57/hBPCH/QqaH/AOC6H/4mj/hBPCH/AEKmh/8A
guh/+JoA6GsXRf8AkLeI/wDsIp/6S29Qf8IJ4Q/6FTQ//BdD/wDE1jaR4M8LS6rrqSeGtHdYr9Ej
DWERCL9mgbA+XgZJP1J9aAO6pK5//hBPCH/Qq6H/AOC6H/4mqV38PvB17avbyeGdLRHIy1vbLC4w
c8OgDDp2PtS0uB11Fc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ/wDwXQ//ABNMDoaK57/hBPCH
/QqaH/4Lof8A4mj/AIQTwh/0Kmh/+C6H/wCJoA6Giue/4QTwh/0Kmh/+C6H/AOJo/wCEE8If9Cpo
f/guh/8AiaAOhorPsLC00y0S0srWC1to87IYIxGi5OThRwOST+NaFABRRRQAUUUUAFFFFABXOX/i
nTNLv1tLwaiJ3cIgi0y5lWRtpfCskZVjtBOATjafQ10dc/rcEs+seHWjikdYdReSVlUkIv2S4XJP
YbmUZ9SB3oA0bedZ7eO4USBJEDqJI2jYAjPKsAVPsQCO9X6871KwdvFF2x06eTVX1Szlsb0WrN5V
mv2fzkFxjbEp23OYywLbm4PmDc7SdFey1DS9QjsJ47ybXtQ+1zFG3/ZmN2yKSfuwlvKYLwpYq2Nz
ZIB2Go31vp2mXV9dSeXbW0TzTPtLbUUEscDk8A9K0q8hfQnk8PeJLGPRJLh30i4V5H02S3uJLhQD
GJiSyXk5YFhNHkKysQf3oq5qtpO2v2E+kaF5Cx3VgIJV0uUzJab4g5SYsotowC8bW4UtgOxUK7MA
D0Ge+t7W6tIZpNkl1KYYBtJ3uEZyOOnyox59PpVTUPEOm6XOsF3cyK+zzHKQSSLChJAeVlBEScN8
zlR8rc/Kccjb2Dp4t0qV9Kvv7Ri1m9lvb4QsIzA0d19n3v0lwjRqpG7yxlCULbW1/FuooyLoctrq
TW18v+mT2+nz3CC33APFmJG+eRdydQVBZsghAwBrTa9p0Gqf2dJcSCbesbMIJDEjtjajygbEc5XC
swJ3pgfMuSHXtOn1T+zo7iQzb2jVjBIIndc7kSUjY7jDZVWJGx8j5Wxz2oW9y2parp62d0Z77XLC
/gdbdzEYIvsnmM0oGxCPIl+VmDHaMA7lyafb3K6lpWntZ3Qnsdcv7+d2t3EQgl+1+WyykbHJ8+L5
VYsNxyBtbAB0Wn+IdN1SdoLS5kZ9nmIXgkjWZAQC8TMAJU5X5kLD5l5+YZ3K47T5JdS8YLfLBqQS
KylilS+tzCLORmh/dxNtAlD+W5Zg0oBjXayhvm7GgAooooAKKKKACiiigAooooAKwdH1+w123W50
77U0BRHV5rOaBXVhlShkVQ4xzlc9vUVPrlmupaDqdhJHPJHc20sLRwMokYMhBCFvlDc8buM9eKyf
DG7+0dQ+yf2r/ZHlQ+T/AGl9o8z7RmTzcfaP3m3b5H+xnOOd1AHW0UUUAYen+IdN1SdoLS5kZ9nm
IXgkjWZAQC8TMAJU5X5kLD5l5+YZIdf0q40f+2Le8SbT97Is8WWEjK5jwgAy5LjaoUHcSNucjOJb
L/bHiszTWN9LafYJra5g1K08tLYu0IMKHaFmV9jliDKvyLtZVb5rmhvLpfh26luLK7YrqV9IYo4i
ZDG15KQ4Xqw2tuwMlh90MSAQDV0/UrbVbdp7R5CEfZJHLE8UkbYBw6OAynBBwQMhgehBrWrlfCUM
yw6pPJ9rdLm98yK5vITDPcqIYk3yR7U2EMjIAETKopwc7m6qgAooooAKzr69g062e6uZPLhTGSFL
EknAVVHLMSQAoBJJAAJNaNc94rgmn0dTDG8vkXtpcusalm8uK5ikchRyxCoxwMk4wASQKALen6lb
arbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cx4bEktzrl+YbiK3vtQWa3E8LROyLbwRklHA
ZfnjcfMBnGRwQT09AGdfXsGnWz3VzJ5cKYyQpYkk4Cqo5ZiSAFAJJIABJrOfxJo0Oh3Wrz3n2ezt
ci4aeJ4nhIwdrRuA4Y7lIUjLblwDuGdG7ujY20k5gnnWPBZIU3vtzyQvVsDJwMscYAJwDxNxps17
4G8WubS7vZ7hbmSxnurQpdXDGzWHeYtqlHzviAVEyqg4O4swB12paxaaU0QujO0spJSK2tpLiRgM
ZbZGrNtGVBbGAWUE8jNu2uIbq2iuIJkmglUPHIjBldSMggjggjnNZuvXzWdqqFtTtxNkC702z+0v
EwIIBQJIfmG7nYVGDkglcu8NQXFn4X0i1uLWO1ngs4Y5LaNiywsqAFASWJAIxnJ6dT1oA3qKKKAM
KHXtOn1T+zo7iQzb2jVjBIIndc7kSUjY7jDZVWJGx8j5WwuoeIdN0udYLu5kV9nmOUgkkWFCSA8r
KCIk4b5nKj5W5+U453T7e5XUtK09rO6E9jrl/fzu1u4iEEv2vy2WUjY5PnxfKrFhuOQNrYr+JYr2
TWLvUrA6wk13pEC6SttDKqvdo07J5+FygUyx/LMVjO9twO07QDqZ9f0m1vpLOa9SGSJC0juCsSYT
eVMhGwOEG/Znds+bG3mr1vOs9vHcKJAkiB1EkbRsARnlWAKn2IBHeuL8beG7i8LPpME9xfXEpvDb
SY+ymWKLYWkzjPmoEtjGZApSVm2naxrofDNxfXNpcG7ku5oFuCtrcXlv5E80WxCWkj2ptIkMij5F
yqqcHO4gHRVi22r6Xf6U2r21/DJpy+Zm634jAjZldtx42gq3zdMDIOOas3UEV3byW9xCk0EqFJI5
FDK6kYIIPBBBPFZnh2x/4k08N9a/8xW8nWOeP/p9lkjcA/8AAWU/QjtQBpadfW+o6Za31rJ5ltcx
JNC+0ruRgCpweRwR1qha+J9JujO0d1sjjiacyzxvDG8S/eljdwFkjGQS6EqAynPzDMXhIvYeDPDd
ncwTxXH2C3haNoWzG6wgkPx8mNpHzY5wOpAPHDStS1Dwva6Tb2F0t3YeFbvSp1mhaFftLpAqojuA
sgJif5kJXgHOCMgHfabrFpqrSi1M6yxEF4rm2kt5FBzhtkiq204YBsYJVgDwcVW8VaSquyyXczLP
LblIbGeV2eJtshVFQsyKxClwCoJAzk1W0aV9Q8Talq0MF3HaSWdpbI1zayW7NJG9wzgJIqtgCVOc
YOSASQcYmkytp9/aanLBcyWcVxrVu72ttJcMskmoBkBSNWbBET/NjAxgkEjIB1VvPpOj6HFPZC1t
9JVQ8Is4x5bBzlfLVB8xdmGAoJYsMZJqJ/EmjQ6HdavPefZ7O1yLhp4nieEjB2tG4DhjuUhSMtuX
AO4ZwJNMvk+G2k6Q0V1DqGn2+mSXHkReY0QiliZzGcMkjqInO1dxOF+U7lBZeWM+oeBfFES2t9cQ
rFc/2Ol5HK9zta0CHAlHm7jI06jd82GwPlK0AeiVjfbdLj8R/YhJANVltfOaNV/eNAj4BY/3Q0hx
nuWx0arL31umoxWLSYuJYpJo02n5kQoGOenBkT8/Y1kz2W3x1Y3UNoVjawvPPmSPAMhe0C7mH8RW
PAzzhPQUAWYde06fVP7OjuJDNvaNWMEgid1zuRJSNjuMNlVYkbHyPlbC6f4h03VJ2gtLmRn2eYhe
CSNZkBALxMwAlTlfmQsPmXn5hnl7awvB4vsLeBr77JZardXzQS2JREWaO43SGflJcyTLsVCGVXId
SVJWPwlDc2NzYPcw6iU03SZILiKa0cLYvmH9xbYQGdD5bjdmY/ukw/zfOAdXNr2nQap/Z0lxIJt6
xswgkMSO2NqPKBsRzlcKzAnemB8y5guNd0a6e706fzJkKyxyIbOSSKfap8yJG2FJXADgxqWb5XGP
lOMXULe5bUtV09bO6M99rlhfwOtu5iMEX2TzGaUDYhHkS/KzBjtGAdy5htrC8Hi+wt4Gvvsllqt1
fNBLYlERZo7jdIZ+UlzJMuxUIZVch1JUlQDsNImsp9GsZ9NCLp0sEb2ojj2KIioKYXA2jbjjAxWp
XP8AgT/knvhr/sFWv/opa6CgAooooAKKKKACiiigAooooAKKKKACiis+/sLTU7R7S9tYLq2kxvhn
jEiNg5GVPB5AP4UAaFYui/8AIW8R/wDYRT/0lt6g/wCEE8If9Cpof/guh/8AiaxtI8GeFpdV11JP
DWjusV+iRhrCIhF+zQNgfLwMkn6k+tAHdUVz3/CCeEP+hU0P/wAF0P8A8TR/wgnhD/oVND/8F0P/
AMTQB0NFc9/wgnhD/oVND/8ABdD/APE0f8IJ4Q/6FTQ//BdD/wDE0AdDRXPf8IJ4Q/6FTQ//AAXQ
/wDxNH/CCeEP+hU0P/wXQ/8AxNAHQ0Vyf/CvfCH2/wC1/wDCM6V5nl+Vs+zL5eM5z5eNm7/axuxx
nFW/+EE8If8AQqaJ/wCC6H/4mloB0NFc9/wgnhD/AKFTQ/8AwXQ//E0f8IJ4Q/6FTQ//AAXQ/wDx
NMDoaK57/hBPCH/QqaH/AOC6H/4mj/hBPCH/AEKmh/8Aguh/+JoAZ4l8V6d4TgsbrVHZLW6vFtTM
DxEWR2DN7fJj8c1txSpLGskTK6OAyspyCD3B71yWrfDHwlq32NToen2qW9yJ3FraxxGYBWGxioB2
5YEjvtFdNYWFpplolpZWsFrbR52QwRiNFycnCjgckn8aANCiiigArPS+t31GWxWTNxFFHNIm0/Kj
lwpz05Mb/l7itCuTu3bRfEt1ql3DcyWl5Z29srWltJcMkkTzMQyRqWAYTDBAI+VgSCV3AG5Z3lvf
Qma3kMkayyQkhSMPG7I459GVh+HFaFeY3GgX1v8AY7Z1SAeIri5tL6B2yzRPcyXYjYjIUi3a8jJQ
/fkXBIAdZIrS/X4iWVzFpXkKb+4W9njsZPMMRhm8vzLtnxLG5EbBFUrGQiEqUUMAd5c3ENrbS3E8
yQwRKXkkdgqooGSSTwABzms2HxJpU1vdXJmnhWDb5kdxaywzfMcJiJ1DtubKrhTuYFRkjFUPBdhF
ovgPSw9pPBMljDNdoY3eYyCJdwK8uWG0KF6gKqgYAFYxkl13TtR1b7DqK3rXmnzvbTWE0TwWkFwk
gjAZQJXAE8hCbjmTYC4CEgHV/wDCSaV9g+3edc483yPI+yy/aPMxu2eRt8zdt+fG3Oz5vu81HN4j
sIba2uVW+nhuC202thcTlSpwyuqITGwOQVYAggjGQcc9tn/tP+3/ALHff2f/AG/9t/485fO8n+zv
s27yNvm/635cbc4+bG35qmhsrufw7aadJa3CQ6prVxNOWjPyWrXE1yBKhHCyIqxMrYx52GGcqQDq
tOvrfUdMtb61k8y2uYkmhfaV3IwBU4PI4I61pUUUAFFFFABRRRQAUUUUAFFFFABRRRQBRubiG1tp
bieZIYIlLySOwVUUDJJJ4AA5zVTTdYtNVaUWpnWWIgvFc20lvIoOcNskVW2nDANjBKsAeDiPxXZ3
Go+EtZsLSPzLm6sZ4Yk4G52jYKMngckdaoaNK+oeJtS1aGC7jtJLO0tka5tZLdmkje4ZwEkVWwBK
nOMHJAJIOADrKKKKACubtvFmlahpcmowTXYs1RHWWWxniEof7nl70BkLHAATJJZQOSM3dcs11LQd
TsJI55I7m2lhaOBlEjBkIIQt8obnjdxnrxXHvBcT2l8dOi1iXR4bjTrlFv1uWn8yK68y4KLP+9YC
JIiAMgkEKCxYUAdjp+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXMeGxJLc65fmG4it
77UFmtxPC0Tsi28EZJRwGX543HzAZxkcEE9PQAUUUUAFZ19ewadbPdXMnlwpjJCliSTgKqjlmJIA
UAkkgAEmtGue8VwTT6OphjeXyL20uXWNSzeXFcxSOQo5YhUY4GScYAJIFAFvT9SttVt2ntHkIR9k
kcsTxSRtgHDo4DKcEHBAyGB6EGtauY8NiSW51y/MNxFb32oLNbieFonZFt4IySjgMvzxuPmAzjI4
IJ6egArJ1DUrbSrdZ7t5AHfZHHFE8skjYJwiICzHAJwAcBSegJrWrI1i9ay05nKX2x8xtNZQedJB
kHDhAGLYOBwrckEjaGIAIH8QaVFY2l494iQXdwlrBvBVnmZ9gj2kbg4bIKkZXa2cbTjerz8aTM3h
OxZtPka8GrxSo7wnzjC+pRytIwxlC6qsrrhQpz8qhdq+gUAFFFFABRRRQAUUUUAFFFFABRRRQBj6
pqlnpNi99qVytpao6K80nCqXYIuT2G5hyeB1OBSQDS9N1E6fbQw21ze+beMkMIXzipQSSMQMFsum
SeTnvg4g8VQTXOlQJDHJK41GxcrGpYhVu4WY4HYKCSewBNcpqGja1aXk+l6bBOILXQdQttIuYnCl
N4thFCXyNsisjhScZQIdzMHIAO7vLy3sYRNcSGONpY4QSpOXkdUQcerMo/HmtCvKtU0bTbuzvpLD
w640FLjS5FsxpEkeZUum+0OtuUDE+SyBmCfMo25O0ga/jmznvL7TZJLeG402OO4WaO40qXUo/OJi
8s+RGwYNtEuJOigsP4xkA7BoI2u0uPKQzojIkhUblViCwB6gEqpI77R6VXj1S2mvZreOaR5Ybj7N
IqxOQknlCXBOMAbGU5PGSBnJxXEarpN1DbaObm0utUv4dNgijW8sHnZ50Bz5c8Uh+xzsxG+ZiV/1
ZDHy2NS2+kJB46nlttKkhLeIhcyzpZsiPE2myLv8wLtYea0gPJwznOC/IB6RRXl/hrwjaLB4Xtr3
R5DBJobNqUdwjlZbhRbCNbgNw5QNKER8hMHaBtGM7X7XWbjwlprHSZ7jWI9BiaG4nsZbu5F0IyX8
tt6i1mQhWLnLSEqFDNGFIB6hBfW91dXcMMm+S1lEM42kbHKK4HPX5XU8ev1qKOWy1qzmCgXNq7zW
sqSR5VijNHIhDDkblYeh9xXF3Fg7+LdVlTSr7+0ZdZspbK+MLGMQLHa/aNj9IsosisTt8wYQFyu1
amoaVetBZfa7KN9PW91ZpYrzR5dRTzHvC0L/AGeMhslPMKydAGI/jGQD0W1gitLaO3t4UhgiQJHG
ihVRQMAADgAADitCsbQ7e4tdA0y2upJ5bmK1iSaS4I8x3CAMXwzDcTnOGbnuetbNABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABWLov8AyFvEf/YRT/0lt62qxdF/5C3iP/sIp/6S29AG1RRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY8utafBHfSPcYWylWC4wjEiRlRlRQBl2YSR4C5JLADJ4
rYritS0u8uPGsASPOl3JgvLlVBCNJbGTBYgcSF3syOcstswPChWANxL3TZ9RsjHLBNc3FrJNaSou
/dBmPeVccbSWiPXng8442a81t9Dv7Cz16J7D7RbQRW2m28OyRla2imlkU7Rhp40guI1ZAcytFLGc
5y1DT9PuhYldR0qRtEh1oySWUWlPHC9obMbCloDI2wzsrleSHyzKrKwUA9Zorx9NPnuNF0l5LLdp
sV1qyTW+oaZLq+2Y3h8vfHG5YyBVlHm5YD5hn5xm7qPhy8k0/VJ7i2vrvUrPwvapZzyqTIbxBcne
oVmUzqxUhlLMpf5W+bJAPU6xtS1i00pohdGdpZSSkVtbSXEjAYy2yNWbaMqC2MAsoJ5GeN8R21+/
jGC4tNI/fpqFli7Wwkmm+zeZEJHS53hYY+XRoVUkje5G2RmHSeK9Zn07T0gtI777Zeboorm2sJbl
bXjmV1RGztyMKR8zYHA3MoBNdeJ9JtTA0l1vjkiWcSwRvNGkTfdlkdAVjjOCQ7kKQrHPynEk2vad
Bqn9nSXEgm3rGzCCQxI7Y2o8oGxHOVwrMCd6YHzLnktYsPs2n6tYaZp199l1Pw5BpumIttM2HUXA
CSEgmLAmi5l29Tk/K2LmoW9y2parp62d0Z77XLC/gdbdzEYIvsnmM0oGxCPIl+VmDHaMA7lyAdDH
4gs5dam0mL7U93E+yUrZzGKNtgkw0u3ywdrKcbu4HU1u1wtjZix8TwQ6ZHrccjX9zLqQujMbYwyC
Z8x5/ccytCR5f7zBO7nzK7qgAooooAKKKKACiiigAooooAo3NxDa20txPMkMESl5JHYKqKBkkk8A
Ac5qppusWmqtKLUzrLEQXiubaS3kUHOG2SKrbThgGxglWAPBxH4rs7jUfCWs2FpH5lzdWM8MScDc
7RsFGTwOSOtUNGlfUPE2patDBdx2klnaWyNc2sluzSRvcM4CSKrYAlTnGDkgEkHAB1lFFFAFG5uI
bW2luJ5khgiUvJI7BVRQMkkngADnNZsPiTSpre6uTNPCsG3zI7i1lhm+Y4TETqHbc2VXCncwKjJG
Kd4lguLzwvq9rb2sd1PPZzRx20jFVmZkICEgqQCTjOR16jrXHXFjfajZ6tc282sXKB9NYX91ZeTd
4gumlkVITEgYRoQ6/uiWZ2XL4CqAdzp+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXO
+FPP+x3+ft39n/av+Jf9u83zvJ8qPdu8397/AK3zsb+cYx8u2uioAKKKKACs6+vYNOtnurmTy4Ux
khSxJJwFVRyzEkAKASSQACTWjXPeK4Jp9HUwxvL5F7aXLrGpZvLiuYpHIUcsQqMcDJOMAEkCgC3p
+pW2q27T2jyEI+ySOWJ4pI2wDh0cBlOCDggZDA9CDWtXMeGxJLc65fmG4it77UFmtxPC0Tsi28EZ
JRwGX543HzAZxkcEE9PQAVk6hqVtpVus928gDvsjjiieWSRsE4REBZjgE4AOApPQE1rVyvi2GZod
Lnj+1olte+ZLc2cJmntlMMqb449r7yWdUIKPhXY4GNygFqbxJpUNva3ImnmWfd5cdvayzTfKcPmJ
FLrtbCtlRtYhTgnFaVtcQ3VtFcQTJNBKoeORGDK6kZBBHBBHOa4aO2utP07S78/2lZz7r6M3EWmv
dO0M9wJN7RL80czhEkBKeWh3q0YyqDqvClncad4S0awu4/LubWxghlTg7XWNQwyODyD0oA3aKKKA
CiiigAooooAKKKKACiiigDH1TVLPSbF77UrlbS1R0V5pOFUuwRcnsNzDk8DqcCrD31umoxWLSYuJ
YpJo02n5kQoGOenBkT8/Y1n+KoJrnSoEhjklcajYuVjUsQq3cLMcDsFBJPYAmuU1DRtatLyfS9Ng
nEFroOoW2kXMThSm8WwihL5G2RWRwpOMoEO5mDkAHd3l5b2MImuJDHG0scIJUnLyOqIOPVmUfjzW
hXlWqaNpt3Z30lh4dcaClxpci2Y0iSPMqXTfaHW3KBifJZAzBPmUbcnaQNfxzZz3l9psklvDcabH
HcLNHcaVLqUfnExeWfIjYMG2iXEnRQWH8YyAd9WTHqltNezW8c0jyw3H2aRVichJPKEuCcYA2Mpy
eMkDOTiuI1XSbqG20c3Npdapfw6bBFGt5YPOzzoDny54pD9jnZiN8zEr/qyGPlsalt9ISDx1PLba
VJCW8RC5lnSzZEeJtNkXf5gXaw81pAeThnOcF+QD0iivL/DXhG0WDwvbXujyGCTQ2bUo7hHKy3Ci
2Ea3AbhygaUIj5CYO0DaMZ2v2us3HhLTWOkz3GsR6DE0NxPYy3dyLoRkv5bb1FrMhCsXOWkJUKGa
MKQD1CC+t7q6u4YZN8lrKIZxtI2OUVwOevyup49frS2d5b30Jmt5DJGsskJIUjDxuyOOfRlYfhxX
C3Fg7+LdVlTSr7+0ZdZspbK+MLGMQLHa/aNj9IsosisTt8wYQFyu1amoaVetBZfa7KN9PW91ZpYr
zR5dRTzHvC0L/Z4yGyU8wrJ0AYj+MZAPVaKxtDt7i10DTLa6knluYrWJJpLgjzHcIAxfDMNxOc4Z
ue561s0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYui/wDIW8R/9hFP/SW3rarF0X/kLeI/+win
/pLb0AbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVjy61p8Ed9I9xhbKVYLjCMSJGV
GVFAGXZhJHgLkksAMnitiuK1LS7y48awBI86XcmC8uVUEI0lsZMFiBxIXezI5yy2zA8KFYA3m1rT
kks40uPON5F59uYEaUSR7o13goCNuZY+emDnoCRSuJPD3iMw6feW9rqAZ53jhubbzF3W8ghlOGXA
Ks+33zxkVykWg6laJexC2kaG1vdKsrVURj/o8F8ZkKnHzIkE0aluTuikznG45UXhlbaWcaRoMlnq
fka9b21xDp7QFJ2mU2xEu0BR5RIR9wXGVB6igD04y2emjT7MKlukz/ZbSGOPC5WNnCAAYUBI29Bx
j0rWrz6XSNN1KLQrax0S7t9IGqvJJbvbyQR7Psk4J8o4McTOQpVlUOS2VYSZbJv9LvTaabFdWStp
dtPqUX2e70iXUYk/0ofZttvGQygRK4R8bVT5RjeKAPV6ydQ1K20q3We7eQB32RxxRPLJI2CcIiAs
xwCcAHAUnoCa4LUfDl5Jp+qT3FtfXepWfhe1SznlUmQ3iC5O9QrMpnVipDKWZS/yt82T2/iDWG0P
SzdR2N3eylwkcNtBJKSx7tsViqDqWwcAcBjhSARzeJNKht7W5E08yz7vLjt7WWab5Th8xIpddrYV
sqNrEKcE4qy2uaYs2mwi+gZ9Tz9iCPu88BC5ZcdV2jO7pyOeRnlrELo8+hakYtRubRLK9iubhdNn
Er3M00MjO1uFMiB2jmb7u0cAYBXL9N0S4sbDwIktgVvbPyYbx0QMYxHY3CYZ1z8odyBzjL8deQDq
TqlkNZTSTcx/b3t2uhAOW8pWClz6DcwAz15xnBxqVzM9lt8dWN1DaFY2sLzz5kjwDIXtAu5h/EVj
wM84T0FdNQAUUUUAFFFFABRRRQAUUUUAUbm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1U03WLTVWlF
qZ1liILxXNtJbyKDnDbJFVtpwwDYwSrAHg4j8V2dxqPhLWbC0j8y5urGeGJOBudo2CjJ4HJHWqGj
SvqHibUtWhgu47SSztLZGubWS3ZpI3uGcBJFVsASpzjByQCSDgA6yiiigDGg1vTLmHUZo76FodOk
eG7kL4SF0UM4Zjx8oYZ9OQeQQIIfEmlTW91cmaeFYNvmR3FrLDN8xwmInUO25squFO5gVGSMVhXG
iXTeHvHWmWFj5f2ovDYwqgjRx9ggjUJnC7dylfQbSO1Qams+sXGrapaWd6LZotNjVpbSWKZWgupJ
ZHjidQzNGjq6/Kysw24flaAOu0/UrbVbdp7R5CEfZJHLE8UkbYBw6OAynBBwQMhgehBrWrlfCUMy
w6pPJ9rdLm98yK5vITDPcqIYk3yR7U2EMjIAETKopwc7m6qgAooooAKzr69g062e6uZPLhTGSFLE
knAVVHLMSQAoBJJAAJNaNc94rgmn0dTDG8vkXtpcusalm8uK5ikchRyxCoxwMk4wASQKALen6lba
rbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cx4bEktzrl+YbiK3vtQWa3E8LROyLbwRklHAZ
fnjcfMBnGRwQT09AFG5uIbW2luJ5khgiUvJI7BVRQMkkngADnNZz+ILBdJttUjN3cWl2iPC9rZTT
Myuu5SURSwGO5Ax061pTwRzxhJoklQOsgV1DAMrBlPPcMAQexANclaW+pW/wq0zT4IruC/l06zsS
Y1ZZbVpFjiaXA5Bj3FyOPuHkdQAbDeLNKXTLXURLdNBc3D2sKJYztK0qb96+UE3gjypM5Xjaa07e
dZ7eO4USBJEDqJI2jYAjPKsAVPsQCO9c7r+l6TDLpU1zbavFBZ28ttANIEyrGGMR2Mtt+8xiMYwN
g2nODsrc0P8AtH+wNM/tf/kJ/ZYvtn3f9dsG/wC78v3s9OPSgDVooooAKKKKACiiigAooooAKKKK
AMfVNUs9JsXvtSuVtLVHRXmk4VS7BFyew3MOTwOpwKsPfW6ajFYtJi4likmjTafmRCgY56cGRPz9
jWf4qgmudKgSGOSVxqNi5WNSxCrdwsxwOwUEk9gCa5TUNG1q0vJ9L02CcQWug6hbaRcxOFKbxbCK
EvkbZFZHCk4ygQ7mYOQAd3eXlvYwia4kMcbSxwglScvI6og49WZR+PNaFeVapo2m3dnfSWHh1xoK
XGlyLZjSJI8ypdN9odbcoGJ8lkDME+ZRtydpA1/HNnPeX2mySW8Nxpscdws0dxpUupR+cTF5Z8iN
gwbaJcSdFBYfxjIB31ZMeqW017NbxzSPLDcfZpFWJyEk8oS4JxgDYynJ4yQM5OK4jVdJuobbRzc2
l1ql/DpsEUa3lg87POgOfLnikP2OdmI3zMSv+rIY+WxqW30hIPHU8ttpUkJbxELmWdLNkR4m02Rd
/mBdrDzWkB5OGc5wX5APSKK8v8NeEbRYPC9te6PIYJNDZtSjuEcrLcKLYRrcBuHKBpQiPkJg7QNo
xna/a6zceEtNY6TPcaxHoMTQ3E9jLd3IuhGS/ltvUWsyEKxc5aQlQoZowpAPUIL63urq7hhk3yWs
ohnG0jY5RXA56/K6nj1+tLZ3lvfQma3kMkayyQkhSMPG7I459GVh+HFcLcWDv4t1WVNKvv7Rl1my
lsr4wsYxAsdr9o2P0iyiyKxO3zBhAXK7VqahpV60Fl9rso309b3VmlivNHl1FPMe8LQv9njIbJTz
CsnQBiP4xkA9VorG0O3uLXQNMtrqSeW5itYkmkuCPMdwgDF8Mw3E5zhm57nrWzQAUUUUAFFFFABR
RRQAUUUUAFFFFABRRRQAVi6L/wAhbxH/ANhFP/SW3rarF0X/AJC3iP8A7CKf+ktvQBtUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXP6x4msNDDtqCXqRpEZnlisZ5o0QZyWeNGVcYJOTwO
a6CuL1/V4pPEEGm3Vpqh0612XUzwaXczLNOrq8Kq8cbAqpUu2MfMIxkjzFoA6W3nWe3juFEgSRA6
iSNo2AIzyrAFT7EAjvUFrren3d1HbW8++aT7RtXYwz5Eoil5I/hdgPfORkc1w9xYXt/42a9EUiGW
9tLixmbRpXuEtQkJdBcl1W3QlZg0TANhn+VjIAWtoOpX7rDBbSQ3IXWpLeadGVIbg6jFNbOxweNy
K4GCGCngjNAHqFFeb6fpetX2rWst5HKtjqlwur3EUsRRozEz+Ukny/JKFNgNoOD9mlznnzMjQtD1
2LSNRWDzIda/sOeCfyNOeyaW+ZU2vJcvJi4lDK+JUBX5nYsu8bgD1+ivJZbCOefxHD4e0uaytmtd
Lf7PLZuqNCLqczbbbKt5ZQSBogFMnz4B8wM1qy8Pm6t9Jt57V5dOfXHm8iPTZLGCKH7FKhUQFyyR
NJkMH2h2kbKlXBYA7fUtYtNKaIXRnaWUkpFbW0lxIwGMtsjVm2jKgtjALKCeRmvdeJ9JtTA0l1vj
kiWcSwRvNGkTfdlkdAVjjOCQ7kKQrHPynEPivWZ9O09ILSO++2Xm6KK5trCW5W145ldURs7cjCkf
M2BwNzLzmsWH2bT9WsNM06++y6n4cg03TEW2mbDqLgBJCQTFgTRcy7epyflbAB1s2vadBqn9nSXE
gm3rGzCCQxI7Y2o8oGxHOVwrMCd6YHzLkj8QWcutTaTF9qe7ifZKVs5jFG2wSYaXb5YO1lON3cDq
a57ULe5bUtV09bO6M99rlhfwOtu5iMEX2TzGaUDYhHkS/KzBjtGAdy5ksbMWPieCHTI9bjka/uZd
SF0ZjbGGQTPmPP7jmVoSPL/eYJ3c+ZQB3VFFFABRRRQAUUUUAFFFFAFG5uIbW2luJ5khgiUvJI7B
VRQMkkngADnNVNN1i01VpRamdZYiC8VzbSW8ig5w2yRVbacMA2MEqwB4OLVxOsFvJcMJCkaF2Ecb
SMQBnhVBLH2AJPasDwtef2reajqcttfW9zc+UvkXdlNbmCBQ3lx5dVV23NK7Fc4Mm3cwVSQDrqKK
KAMC28TaZdT3iLLOkdn5vn3E1rLHAvlMUk/fOojO0g5wx6H0NPtPEWm3iXVws8lulsm+cXsEls0S
YJ3ssoUhPlb5sY+VueDjil0Sb+wNQ0LQLfW/s/8AYF1ZzQao8v8Ax87ESBUaU+X084Ewny+mTjZX
S6YkWs+JNS1M2U5sHtbKGP7baPCTNDLPISElUN8vmRkNjGehypwAbWnX1vqOmWt9ayeZbXMSTQvt
K7kYAqcHkcEda0q5zwbBLa+CfD9vPE8M0WnW6SRyAqyMIlBBB5BB4xXR0AFFFFABWdfXsGnWz3Vz
J5cKYyQpYkk4Cqo5ZiSAFAJJIABJrRrJ1S/XSrG4v3tru5EKbhBaQNNLIeyqo5JJx7DqSBk0AGn6
lbarbtPaPIQj7JI5YnikjbAOHRwGU4IOCBkMD0INa1cz4VbzrS6vHWYXV3cvPdGa2mg+chQqqsqI
WVI1jjDhRu2ZIDFq6agCjc3ENrbS3E8yQwRKXkkdgqooGSSTwABzmqL69YDSLTVhPJJaXiI9t5UM
kkkwddw2Rqpdjty2AuQAScAHF+eCOeMJNEkqB1kCuoYBlYMp57hgCD2IBrhDplyngfwSJ4dRt47F
YGvhaxObiJfskkTKEUGQEs6odg3KGJBXbuAB1E3iTSobe1uRNPMs+7y47e1lmm+U4fMSKXXa2FbK
jaxCnBOK0ra4huraK4gmSaCVQ8ciMGV1IyCCOCCOc15/JaXLPot5qp1z7DFFfwbrVJ2uWje4ja1W
TygZ1/dRBi3ytlAHOWKt3Oh/2j/YGmf2v/yE/ssX2z7v+u2Df935fvZ6celAGrRRRQBhQ69p0+qf
2dHcSGbe0asYJBE7rnciSkbHcYbKqxI2PkfK2DUtesdJuLe3uvtbT3CO8cdrZzXDFUKhiRGrEAF1
GTj71ZVzLNfeMNMCW2pf6FcSGaCe2K28S+VMouElC4d23ou3e2FkOUDKStHxNAk13Pqunxa+us3W
nImnNAs6QmVTI0QlRcBSGkG4XACYOO0mADo59f0m1vpLOa9SGSJC0juCsSYTeVMhGwOEG/Znds+b
G3mr1vOs9vHcKJAkiB1EkbRsARnlWAKn2IBHeuL8beG7i8LPpME9xfXEpvDbSY+ymWKLYWkzjPmo
EtjGZApSVm2naxrofDNxfXNpcG7ku5oFuCtrcXlv5E80WxCWkj2ptIkMij5FyqqcHO4gHRUUUUAF
Y2paxaaU0QujO0spJSK2tpLiRgMZbZGrNtGVBbGAWUE8jOzXJ6zK+n+JtN1aaC7ktI7O7tna2tZL
hlkke3ZAUjVmwRE/OMDABIJGQDYm1Szg0tdRa5RrNkVkljPmCQNjZs25LliQFC5LEgDJIqt/wkml
fYPt3nXOPN8jyPssv2jzMbtnkbfM3bfnxtzs+b7vNU/D7zaF4M0yyvLK7a60/TbVLiGCIyFflCNt
I4crtYlULNgDAJZQaOlTyWGk6tdSpq8kV5e5S+FiftbL5EaCZ4NgIKunlgLF0VGKkFnIBvHWrBNE
m1j7SRYQxPNLIUbMapneGXG4Mu1gVI3AggjIxUC+JNLN5DbNNOssvljc9pKqRs4BRJHK7Y5DuXCO
Q3zqMZYZ568gmtvhB4hWeN43ez1KUGVSryK5mdZHU/dd1YOy4XaWI2rjaH6hb3LalqunrZ3Rnvtc
sL+B1t3MRgi+yeYzSgbEI8iX5WYMdowDuXIB0upaxaaU0QujO0spJSK2tpLiRgMZbZGrNtGVBbGA
WUE8jMd54m0mx+xlpbi4+2RNPbfYrWW68yNduXHlK3y/vE56fMKztUu1h8Rabq8lvfNZxWt7ZyND
ZTSusrSwbf3aKX2nyZCHxt4HPzLnmjos+leH9Pxb65F4lTQbaztPsjytbC5hR9qyeUdnEjjJm/dk
EYJG+gD1OsPT/EOm6pO0FpcyM+zzELwSRrMgIBeJmAEqcr8yFh8y8/MM24L63urq7hhk3yWsohnG
0jY5RXA56/K6nj1+tc3peqx6lr95q1xZ6nAtnbPDawzaXcowiDgyyAmMBmkKxbYxuYLGCMFnUAGx
Nr2nQap/Z0lxIJt6xswgkMSO2NqPKBsRzlcKzAnemB8y5Y3iTSxeTWyzTtLF5g3JaSskjICXSNwu
2SQbWyiEt8jDGVOM3xFJNe6jY2ENvqJlivbaXyfspNrcRrLG5kaYLhDGFdlUuhLJgq6soYuZZr7x
hpgS21L/AEK4kM0E9sVt4l8qZRcJKFw7tvRdu9sLIcoGUlQDoNOvrfUdMtb61k8y2uYkmhfaV3Iw
BU4PI4I61pVz/gT/AJJ74a/7BVr/AOilroKACiiigAooooAKK5yfwb4Yubh7i48O6RNNK5eSSSxi
ZnYnJJJXJJPenf8ACCeEP+hU0P8A8F0P/wATQB0NFc9/wgnhD/oVND/8F0P/AMTR/wAIJ4Q/6FTQ
/wDwXQ//ABNAHQ1nX19aaZaPd3tzDbW8eN808gRFycDJPA5IH41n/wDCCeEP+hU0T/wXQ/8AxNVL
z4eeDry1e3fw1pcaPjLQWywuMHPDoAw6djQrX12A3be5hurWOe3lSWGVQ8ckbBldSMggjqCO9X65
KDwD4St4I4l8L6QyooQGSyjdiBxyzAkn3JJNXP8AhBPCH/Qq6H/4Lof/AImh2voB0NYui/8AIW8R
/wDYRT/0lt6g/wCEE8If9Cpof/guh/8AiaxtI8GeFpdV11JPDWjusV+iRhrCIhF+zQNgfLwMkn6k
+tAHdUVz3/CCeEP+hU0P/wAF0P8A8TTYPBvhi2uEuLfw7pEM0Th45I7GJWRgcgghcgg96AOjoooo
AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArOuoIru3kt7iFJoJUKSRyKGV1IwQQeCC
CeK0aKAMvTdJ07Rrd4NN0+1soWcuyW0KxKWwBkhQBnAAz7VqUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAZ11BFd28lvcQpNBKhSSORQyupGCCDwQQTxS2sEVpbR29vCkMESBI40UKqKBgAAcA
AAcVoUUAFFFFAFKOCGOW4dIURpn3yMqgF22hct6naqjJ7ADtV2iigArOuoIru3kt7iFJoJUKSRyK
GV1IwQQeCCCeK0aKAM+1gitLaO3t4UhgiQJHGihVRQMAADgAADitCiigAooooAKKKKACiiigAooo
oAKKKKACiiigArF0X/kLeI/+win/AKS29bVYui/8hbxH/wBhFP8A0lt6ANqiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAK5fWtd1XStQsbaDS7S4S9m8iKR71oyG2ljuURNgfKehNdRXP63p
M+o3uizRPGqWV558u8kErsZcLgdcsPSkAP4k0+G9Swu7hYr35FlVFd443cfKpk2hQT2DYJ445qnY
+M9NvIbqSSO7hWC8azRWtZWeVwP4VCkk8NwMkAZOKz9R8K6hc3epWsctr/Z2pXkN3LKzMJoim3Kq
uMNnYuDuGMng4pknhXW1+0wxvZy2kmqyXzQPcyRrdRuD+7kwhwAccfMG7j1YGzb+KLS+1bTrWyXz
7e+gmmW4yV2+WyqVKkZzknrjGKran4tWwn1OOO0ef7CYId3mbQ88pwqdDgAFSW5+90OKoeGfB9/o
tzpTzyWRSzju0cQFufNkDLgEdAAR/jT5tDvJrzxTYrawSpfvBdQNdrJ5T/KFZSy4KsCmRg5GQaOw
dWSXvjZdP06WS5tLeK+hv0sJInu9sKswDB/NK/d2HOdueCMVJN4z+z3mmwXFtatHdp5kk9teebGi
FsKynYN4456Y96hsPDGoaVbyz28Omz3s1+LtobuWSVYwF2/JMwL78DO8qepGO9TWXhIR6dDBdw2c
tw13JcSPsz5CyNueOIkZwfunpkEn2oDodJb3fm6cl5KhgDR+YysclBjPPvisTTvEOo6jDBfx6Mo0
u4RpI5vtQ81VAJVnjKgANj+FmIyMjrhnhfw1caVp+o2t7LFIt3KTiIkhgVwXOQPmbqev1NLpOl6/
p+nWmkM2ntY2sRh+0l3aWVAMINm0BD0ydzdOnPCfkCH6F4p/tmWyjey+zm9sFvYSZN4PzYdeg5XK
H33dsV1NcFoGhXtjrOhwXCHbpGltFJMm7y3kkYDapIG7AQk+mRXe1TEr9QooopDCiiigAooooAKK
KKACiiigArktM8WNq2v3um28VgEtJ3hcPfYuG2gZZYtnK5OMlh0NdbXHt4f1O51a0aWPS7a0s72S
8jltFZZJSykAMmMAncdzbjux0GeF1DoO0/xHf3OqXlhcaIY54Lfz/LhuklIJJCxyHAVHYYIG4jHf
iobnxlPp1vqS6jpaxXtnFDL5MN15iN5rbVBcqNpDdeDxyM09NJ8QT6v/AGtdHTFvbazlt7cQvJ5c
7MwIaTK5VRtHygt1PNZ8HhjWj4evrKc2keoXbrNcXaXbyfbHB+ZJP3a7Iyo24GcA9DzlgdDoWtPr
C3iTWwt7mzuWtpUSTzELAA5VsDIww6gc10Fcz4X0i50mK8E628KT3Bkhs7Vi0NsuANqEqvUgscKB
kmumoEFFFFAwooooAKQkKCSeKWsvVdOXV9LudPknngjuEMbyQMFcA9cEg/SkwMDTvFc2sx6w2laa
101lKkcC+eE+0BgDvywwq9++RyOuKLbxnLPp1vJHpqNd3N+1jAq3OYJSMkyLLtyUwDztzkYx3qPS
/DWs6Fc6xcWN/FO1yYvs0d2q7CqKqnf5aLtOAQNuRjkgmov+ER1Pzv7TD2Y1H+1Pt4thI3kAeX5Z
Tft3ZI+bdt69u9MCe48YXSeH11SDS4mSMyrd+derEkDxkqUDbSXLMMLhecjOM10tlcm8sYLhoZID
LGrmKUYdMjO1h2I6GubtNH1zTdFFpZjTLh7hp5LyOd5FXfKxYbGCnKjOMFeR3Fb2h6Z/Y+hWOmmY
zfZYVi8wjG7AxnHb6UIRU8Ra7F4d0l7+WC5uX5WOCBCzO2C3boAFJJPQA/Ss2TxdM9lo7WWnCa71
K0a88mS48tY0VQx+facnLADjnviui1a1e/0e9tIiqyTwPGpboCykDP51yp8L6raW2hS2TWUl7p+n
NYypNIyRsGRRuVgpPDL0I5B7Uu4yS48dxiFbmxsTcW6WCajdM83lmOJjjCjadzcMcZA4681q6zrf
9mR2H2W3W6uL+dYbdGk8tSSCxZmwcAKCehNc9L4Gvra0Nlp89q8Nzpcem3Lzsysm0n94gAO7IZvl
JHQc1o6jour3UtpNEbAnTLxJbGNmdfMi8vayyNg7W5JBAI4HFDEQR+PY2uNPiexEYmZ0umM2fs7K
5Q4+X5xuU8/Lxg+1dZZztc2cM7xGIyIH8tjkrnnB965uy8JqmkW1vdw2ct2bqS4nm2bvLEjl3WMk
ZweE7ZGT7VP4Q8P3ehW96l3NFIZ5/MUREkHjBc5A+Zup6/U01sPqdVRRRQAlcpdeLIbfxhZeHo7K
eV5y4kuSCscbCPftBI+dsYyB0DD6V1dc1q2j3V/4h0HUomiEWnvM0qsx3MHj2jaMYPPrijqAviTW
bvRbIXMNpFcRIrPPLNdiBIwBwOjEsx4AA69xWfqHjSSyyYtKkZYLJL+9WeXyngjY42hcHc4wxIyB
x15q3dx+KJbWSNY9GlMhmR43aVB5ZyIzuw3OPvDbg9iKxJvA1/b2hsrG6t5ornS49NuZbhmRkCE/
vEAB3cMRtJGMDmkgOj1zXJdNXTPslrHdSahcrbxiSYxKMqWDEhW/u+lU7HxVFf8Ai6fw/FZ3AWGB
5TdSAqrsrhGVAR8wBJG71U/Wm+K4ntz4deG3uZobPUUeTyIXmZUEbjJCAnuO1W5NGu28aJraPD5C
6a1qEYndvLhgcY6ceuaFuHQqa54tbSb25ghsBcpZWou7x2m8vZGWwNg2ne2AxxwOOvNNuPF6xarL
HHZCTT7e4gtZ7ozbWV5QCu1NvzKNyZO4deAcVR1Pw1rl+1zM/wDZwn1PT0sr/azqsRDH54/lJbhj
wxXoOafP4OvGv7mGCS2Gl3d5bXcjs7CaMxBcoF24bdsXkkYyeDQvP+tQfkddeXMdlaTXU7FYoUMj
sAThQMngcnpWT4X8SnxPa3s62E9l9mumt/Ln4kOApywx8p+bpz061b0ia+ntZW1GFY5BcSogjVlD
RhiFOG55GP6cVlaZo2saPHqzW72LTXuqG6TeXKiFtoYHAHz4DY7ZxQtw6DLPxemoa5NZW9vbvbxS
Sxu4vU89fL6uYSM7C2QCCT3wKhs/Gtze26SLpkMbXVo97Yh7s4ljRgGDkJ8jYIOBuHbNNtfCN5b6
vbDdaLp1pfz30UiljM5kU/uyuMAAsedxyAOBVO18Lz6O0+pXcEUfkWc1vDDp5nnDmRs5WNgTGBx8
i5HJOeKOgdTsND1M6zodlqZh8n7VCsvl7t23IzjOBmtWuf8AB8M1t4P0iCeJ4po7SNXjkUqykKMg
g9DXQ03voJbBRRRQMKKKKACiiigAooooAKKKKACiiigArxL4gfEb/hDpvEWl6Y+dau71WV8f8e8Z
tYBv924IA9snpz7bXiHxB+HP/CYzeItU0xf+J1aXqqqZ4uIxbQHZ7MMkg++D14ALfwm+LCeIkh0L
XplTVkG2CdjgXQ9D/t/z+teyV438JvhOnh1Idd16FX1ZxuggYZFqPU/7f8vrXslABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQAVzl/4p0zS79bS8Goid3CIItMuZVkbaXwrJGVY7QTgE42n0NdHX
P63BLPrHh1o4pHWHUXklZVJCL9kuFyT2G5lGfUgd6ANG3nWe3juFEgSRA6iSNo2AIzyrAFT7EAjv
SWd5b30Jmt5DJGsskJIUjDxuyOOfRlYfhxXF6lYO3ii7Y6dPJqr6pZy2N6LVm8qzX7P5yC4xtiU7
bnMZYFtzcHzBuyRosdvo62Fv4YhKJqmofu7jSHuIS5nPkgQbo0O6IqFnZtkaoU3DccAHpSX1u+oy
2CyZuIoo5pE2n5UcuFOenJjf8vcVoVw/gu3v1nin1KO6E8nh/S0lkuFbc0ym4MgYtyXBYFgeRuGe
tYtp4dmv/FFzBqMGTNdXwvDHpcsck9nJ5yxpJe+YFkj2PFhEBZSqDA8slQD1KivKLzSNcutIhv8A
Vo0uLlr2K3vxNp73SSW8EEkeWtU2mVGumklTAziSNzgJhdDTfDK3t3oEGq2Ml5YxWeosUntGhhAe
4gaGNoSzBUCfcjckqI1+VWTCgHbpfW76jLYrJm4iijmkTaflRy4U56cmN/y9xWhXktno7vC8+oaZ
fDUbnw5pZuLn7C0sksiO/npMTgyZAiEkW7fIg2gEgY7HwXCYNKmRbBLSATnyRHayWkci7VyyW0hL
QDduG3+IqX/joA6miiigAooooAKKKKACiiigArLg1Szu9Vu9OguUkvLNI3uYl5MQk3bN3YEhScdc
YPQjOpXM6fZfZPGmqSR2nkW8tha7XVNqPJ5128mD0LZcMe/z5PWgDSsdVtNSkuksrlJzZ3BtbjYc
hJQqsUz0JAYZx0OR1BFFjqtpqUl0llcpObO4NrcbDkJKFVimehIDDOOhyOoIrF0mwvLEeKI9MtYL
aQ3S/wBnpNGUg+Wyt0Thf+WYZSp2/wB0gdKqeBdL1LSTrVpfWaW8f22N0lE7StcN9mhDyFjHHvLM
u5nxy7SAjjJAO5ooooAKKKKACiiigAooooAo3NxDa20txPMkMESl5JHYKqKBkkk8AAc5rNh8SaVN
b3VyZp4Vg2+ZHcWssM3zHCYidQ7bmyq4U7mBUZIxTvEsFxeeF9Xtbe1jup57OaOO2kYqszMhAQkF
SAScZyOvUda5P7Ld3aaheRjVL+JJNMk+1X1kYLl1guzLKixCOPcqIdw2x7mLsoLEBVAO00/UrbVb
dp7R5CEfZJHLE8UkbYBw6OAynBBwQMhgehBrWrmPDYkludcvzDcRW99qCzW4nhaJ2RbeCMko4DL8
8bj5gM4yOCCenoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoo
ooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsXRf+Qt4j/7CKf+ktvW1WLov/IW8R/9hFP/
AElt6ANqiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz0vrd9RlsVkzcRRRzSJtPyo5c
Kc9OTG/5e4rQrjLnR7+88cX9xBqmo6dCdNs0EltFCVlYS3JIJljcZUMvC4+/z1FAHR2d5b30Jmt5
DJGsskJIUjDxuyOOfRlYfhxQl9bvqMtismbiKKOaRNp+VHLhTnpyY3/L3FeaXWjX0en6dHfwm5so
rvVfPOoaNJqAkle83QyG3i24Zk8wiQLtAYgY3ikudCurc3arZTyanJo+lrcX09iZWnWK4b7WspRi
JWMYTfEJC0igKN2BQB65RXl9l4fN1b6Tbz2ry6c+uPN5EemyWMEUP2KVCogLlkiaTIYPtDtI2VKu
C1zTbB18UWjDTp49VTVLyW+vTasvm2bfaPJQ3GNsqjdbYjDErtXgeWdoB6JRXj1np14ixWdhp99a
eIG8MX0NxM2YPP1D/RgzqxI3Sb8Ezjh8r87bfluW2hyzaTfxW9vItnPeaYvkWOkTaWilLtWlkWNn
Mm/YVLSAKMIuGJU7QD1WsrUNUttMgmuLt5I4IbeS5llETsqRxgFiSARnByB1ODgHBxw+raLc21pd
2VrYImj2+tq/2VtNe6t/sxsl+7bRkGRPtDZwvR8ufusap6noN5c+F/s8tjNeL/YOriJDYmMKzzQy
W6JEWcx4Cjy0J3KEAwpUgAHrNZ19ewadbPdXMnlwpjJCliSTgKqjlmJIAUAkkgAEmuH07TbUa3ca
e9qn/CO6fbyalb6eLR8ot0mwL5W3eTlb/MRHAmQAHACdL4hgnaXSNRSGSSPTr03M8cQLSGMwSxEo
o5Ygyhto5IU4BbCkAsQ69pktgLxbiRYhcR2rCWKSORJZHVER42AdSS6feA4YN0OauXd7FaRLJIJ2
U7uIYHlPCsx4QE9FOPU4AySAeY1xD4j0qWSDTLqKKa906MTmOSC6ljS7RnO3CyRogLEMSD99gAMM
1NdFkj1mOxhsLi20qHX3MKWyNDHDA2lsGaMpjYpld/mXHzsedxoA63Sdas9aSd7Mz/6PL5MqTW8k
Do+1XwVkVW+66np3rWrlY/CtponhaXR9BtJFg3747dtTuIApLAnbMu54xwTheCSc/eJqXw1peoad
Jc/bbfyFk2bP+J1c6hnG7P8Ar1GzqPu9e/QUAWIde06fVP7OjuJDNvaNWMEgid1zuRJSNjuMNlVY
kbHyPlbC6f4h03VJ2gtLmRn2eYheCSNZkBALxMwAlTlfmQsPmXn5hnKGoR6n40ggltdSjg0x5fIM
unTrHNcFCplEuwIEVDKgy2HMhOPlRmzPDJntP+Ef8+zvY/7D0CWzv91pKNs3+jfLH8v77/Uycx7h
wOfmXIB1l1qdrZ31jY3N2iXV87pawn70pRS7YA7BRyenIHUjMh1SyGsppJuY/t727XQgHLeUrBS5
9BuYAZ684zg45PV9L11/iDo2qCxtrmzjvVjglFw+62h+zTiQsnlkKWZzlg+H2QKQCN1FlpeuQfE5
dSvLK1kguLe9Q3cdw7eXDvtxDHgxYU4TOzeQWedwR90gHoFYV1r2nWyXJknkL21wLV4ooJJJDKY1
kCoiqWc7GDfKDgZJ+6cU9dmXXPB0V1pwe6s7h7S5ZUjYma0MsbyjZjcwaLeCmCWBK4JOK5XS/D9v
Pr1pcp4emitYvEZntxdWpzDB/ZoCsu7Jjj8xI9q8bCqLhSoUAHqdZOoalbaVbrPdvIA77I44onlk
kbBOERAWY4BOADgKT0BNYGtaHqt5q88ttZebE+3a3/CT31pnCgH91EhRfwPPU8k1s+INYbQ9LN1H
Y3d7KXCRw20EkpLHu2xWKoOpbBwBwGOFIA1/EGlRWNpePeIkF3cJawbwVZ5mfYI9pG4OGyCpGV2t
nG040Lm4htbaW4nmSGCJS8kjsFVFAySSeAAOc1x76VG3hHSntYJ7q7XULSSS4lsnhmdmvYpbiQxu
N0as6tIV4UAAjgCtrxnx4YuJJB/osUsE15nkG1SZGnDD+JfKEmV53DIwc4IA1vGWjpPLE8l8nk7P
NkbT7kRwbkWQebIY9seEdWbcRtB+bGDXTVwq+H59S1jxOl5f6jbabeXqo9miRCK7iNpAr/M0ZfBw
yEo4xtOMEE1q+JdL1DUZLb7Fb+ese/f/AMTq50/GduP9Qp39D97p26mgDXubiG1tpbieZIYIlLyS
OwVUUDJJJ4AA5zVTTdYtNVaUWpnWWIgvFc20lvIoOcNskVW2nDANjBKsAeDjK1HSr64+Hep6SlsR
fz6fcwxw/bpLrLurhR50wVmzkfexjp0FGl3azeItS1eO3vls5bWys42msponaVZZ937t1D7R50ZL
428nn5WwAbR1SyGsppJuY/t727XQgHLeUrBS59BuYAZ684zg4zo/FGiyiWYXbrFGnm+bJbyojx7g
DKjMoEkQ3KTIpKKGDEgEGsSy0vXIPicupXllayQXFveobuO4dvLh324hjwYsKcJnZvILPO4I+6c/
S7ZLKeOTUzdnQ9G0O6sp4r7TmiWCHMGFbO4XDlIpA7RlozsXCruG8A9Qrnm8WaRFLFG0t2RLcfZV
lWxnaIS+cYNjSBNinzFK8kdj0IJh8M7oLCysdQGdfg0qz/tBnG+Q5DgbpOd/zrN3POT/ABc5mjeE
7G7lg1XUbS6XUbDUtQe0Y3E0Xlq93MwIQMFIdSMkj5lIByMUAd1WTqGpW2lW6z3byAO+yOOKJ5ZJ
GwThEQFmOATgA4Ck9ATWBrWh6reavPLbWXmxPt2t/wAJPfWmcKAf3USFF/A89TyTV7xIJIrnQ78Q
3EtvY6g01wIIWldUa3njBCICzfPIg+UHGcngEgAll8UaNBaW1xLeYhn3bT5TkoEOJGkXGY1Q8Ozg
BDwxBrQtb2G++0Nbu0iwytC7BTt3r94A9GwflOM4YMp5UgcZLoJn8KT3U1lfNdPLqHlWkX7t7u3u
rlnEDhlJiWQGLc2FePkkphqteC4db066XSb5554LeKZbmWS28pPMEoEMkb4/eNMhklkO+Qh+pQna
QDu6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsibU/K8Q2ulGHP2m2nu
fN3fd8p4V24xznzs5zxt9+NeuO8VaXpc+s6bqOt2lreWFvb3FuttNaG6kkmkaFlMcQVixCxSE4GQ
MnpkgA7GiuNi8NeBp9MOpDQNBWzVGZ5pNPijEYXO/fuUFCpBDBsFSCDgg1XtdH+H95Fczr4d0e3S
2TfOL3R1tmiTBO9llRSE+Vvmxj5W54OADuqK5DTvC3grU9Ntb+28M6LJbXUSTQv/AGbGu5GAKnBX
I4I61e/4QTwh/wBCpof/AILof/iaAOhornv+EE8If9Cpof8A4Lof/iaydS0DwTpfkrdeF9KaSXJS
K20cXEjAYy2yONm2jKgtjALKCeRkA6CHU/N8Q3WlCHH2a2gufN3fe815l24xxjyc5zzu9udeuEi8
F+Ek1G71t9J8PHRJbCBoXFvF5abDM7y527QpR4/mB5C88AVc07wt4K1PTbW/tvDOiyW11Ek0L/2b
Gu5GAKnBXI4I60AdfRXPf8IJ4Q/6FTQ//BdD/wDE0f8ACCeEP+hU0P8A8F0P/wATQB0NFc9/wgnh
D/oVND/8F0P/AMTR/wAIJ4Q/6FTQ/wDwXQ//ABNAHQ1g6DJv1nxQuPuami/X/Q7Y/wBaZ/wgnhD/
AKFTQ/8AwXQ//E1gaH4S8I3eoeIDFo3h+8jj1LylVLKNhblbeENFyuAQ24kLkAsc/NuAAPQKK57/
AIQTwh/0Kmh/+C6H/wCJo/4QTwh/0Kmh/wDguh/+JoA6Giue/wCEE8If9Cpof/guh/8AiaP+EE8I
f9Cpof8A4Lof/iaAOhornv8AhBPCH/QqaH/4Lof/AImsy98NeBtLjt3v/D/h+EXFxHawhtPizJK7
bVVRtyST+QBJ4BNAG7o+pnVLaS58nytl1c223duz5Mzxbs4HXZnHbOOeta9eaweG/Bnh+NrPWdD0
iS4a4nuTImliZYIJJ5GjMriMiJAny5fao8tsHCkjqf8AhBPCH/QqaH/4Lof/AImgDoaK57/hBPCH
/QqaH/4Lof8A4mj/AIQTwh/0Kmh/+C6H/wCJoA6GiuK1Xw14I0TTbjUtT0DQbazt03yTNp8WFH/f
OSScAAckkAZJpupaB4J0vyVuvC+lNJLkpFbaOLiRgMZbZHGzbRlQWxgFlBPIyAdvWRo+pnVLaS58
nytl1c223duz5Mzxbs4HXZnHbOOetcxdaf8AD2zMJk0HRHiliE4lg0tJo0ib7ssjohWOM4JDuQpC
sc/KcbnhvRjoemNp4SGONbu5eKOAYRI5J5JEUDAxhWUYHAxxQB0VFFFABXOX/inTNLv1tLwaiJ3c
Igi0y5lWRtpfCskZVjtBOATjafQ10dc/rcEs+seHWjikdYdReSVlUkIv2S4XJPYbmUZ9SB3oA0be
dZ7eO4USBJEDqJI2jYAjPKsAVPsQCO9X68y1DSr+bx5NM8eJGv7WW0nXSpJpltlWHzFW73iOGMlZ
w0Z5IZ8BvMANq10uM+M7iObSvtKzy3AupbnT3jl8lw/+sutxiuYTlEWHGVVo8gGE0AdUNasH0SHW
PtJNhNEk0UgRsyK+NgVcbizblAUDcSQAMnFWredZ7eO4USBJEDqJI2jYAjPKsAVPsQCO9cJbaHb3
nwm8OafJoe8wS6cZbSexKsjieMTsY2XI4Mu5scqzHJByZtNsHXxRaMNOnj1VNUvJb69Nqy+bZt9o
8lDcY2yqN1tiMMSu1eB5Z2gHXaZoWkaKZf7L0qxsPOwJPstukW/GcZ2gZxk/ma1q4LR9FvLH4QpY
6bbT22szaMMAuY5vtRtwoyzHKsCFUZI2hVAwFAFIafFHPfan4d0eezsNP+yXdvbR6e9qXmjaYXXl
wMqlpHt5BGGK4YlQGBTKgHpVFeRap4b1W3kgtbgLJPJp6CK4i0qS9ZNQeSZ7iW3cOi2rl5EYO+1f
udBGcbt1pREvi2/bTJLme4vYY4/MWRla38i18xljBBkTKsXjTmXyvLOcAAA62SaxsbmFGCRT6hcb
FKx8zSiItyQOvlxHk9lA9BS6dfW+o6Za31rJ5ltcxJNC+0ruRgCpweRwR1rg/DtjqSXOniTTpLe1
g195IEisGtYY4DpzgOkRZvKRpGPBOd7ncFYlRcNjqR+EOkWMVvJHdR2VgtxDLAzkRoYvOR4gQzjY
HDRjlhlepxQB1moalbaVbrPdvIA77I44onlkkbBOERAWY4BOADgKT0BNP07VLXVoDc2TySQB9qyN
E6LJwDuQsAHQggh1yp7E159Z+F7e9TRhdaXBd2g1mWSOJ9HNtBbwGydSFgkZmjjMyKx3bd0hzjlW
OUPDl9Houi2gsfsudBtYrXGjSXM1venzDM0TK6LazbmiJkkKgsFJPyHAB7TWbp19b6jplrfWsnmW
1zEk0L7Su5GAKnB5HBHWuci023n8Y6omp6TPcy3EuILhoi0QsjbIjRu5+UxmUS/uSSdzB9mPnDvh
9bWlp4S0i3i0+Szu49Nt0uRJZPA24bsgllGT5nmtjn7+7o4JANCXxXpcWpx6fMNRSeW4+zRbtMuQ
jyc8LJ5e0jCsdwOMAnOBmujrhtL1m2vvEkl9eWWsxSh2s9PSTSbtFjhYpvd2Me0F3QHJbCosfCHf
mTWtD1W81eeW2svNifbtb/hJ760zhQD+6iQov4HnqeSaAN3VdVtNE0641HUrlLazt03ySt0UfzJJ
IAA5JIAyTVq5uIbW2luJ5khgiUvJI7BVRQMkkngADnNY3jWy/tHwZrUSWn2i5Gn3P2ZFj3v5jQug
2DGdxDFeOfmI71a1yKPUdIv9KmiuZVvLOdCtsoDMpXaQrt8iud42hiM8noDgAgtde0ePRrmaHzLO
y0yDfLBLZy27QQqpwREyBtmEYDC4O0gcgir2nanDqlu00Ed2iK+wi6tJbds4B4WRVJHPXGOvpXFx
WU+ry6zf6qdUurWWLTwXtbCWwkDW9xJKwiif99tUNGxILMxZwhyAq9R4U8/7Hf5+3f2f9q/4l/27
zfO8nyo927zf3v8ArfOxv5xjHy7aAEufFWkWlyLdpLuaRnlRVtbGe4yYigkx5aNkKzqpPQNleoIG
lY3sGo2yXVtJ5kL5wSpUgg4Ksp5VgQQVIBBBBAIrg9F0u9vl8L+Re31hNa6XewahdWscbH7WJbdZ
ldpEdSzSpKS3VipYEjJPUPoj23huTTbISTys5kYveyWjSyPJ5kjmWFdyEszNhVA524CngA6WsKHX
tOn1T+zo7iQzb2jVjBIIndc7kSUjY7jDZVWJGx8j5WxX8NaXqGnSXP2238hZNmz/AInVzqGcbs/6
9Rs6j7vXv0FY2n29yupaVp7Wd0J7HXL+/ndrdxEIJftflsspGxyfPi+VWLDccgbWwAbt1rGk6F5F
hIfs8cUSkJBbO0dtEOFaQopWGP5Thn2rhG5+U4mm8QWVrrCaU5u3vWVH2Q2U0qorsyqXdEKoCUbl
iPuk9K5bxMZ7v/hIPIs72T+3NAis7DbaSndN/pPyyfL+5/10fMm0cnn5WxZv7T7L4mmm02PWk1W6
1C2lZt0xs3hHkpMfl/cD90kg/efvNw+X/lnQB1VjewajbJdW0nmQvnBKlSCDgqynlWBBBUgEEEEA
itGua8N8z67NF/x4yapJ9mA4UbUjSbC/w/v0nJ4GW3NzuyeloAKpTwRzxhJoklQOsgV1DAMrBlPP
cMAQexANXaKAKKwRrdvceUgndFR5Ao3MqklQT1IBZiB23H1q9RRQAUUUUAFFFFABRRRQAUUUUAFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy/iMPHPoV/5FxLb2OoNNceRE0rqjW88YIR
AWb55EHyg4znoCRLpmratqcjSpp1klitxLCZGvW8zCOyE7PKx1Xpu/GpIvFGk3ErRx3Tg5G1ngkV
ZAWCBkYqA67mUblJHI55oDY542N5c+ANY0qO3n+26lFqktvE8RXcs00rRhi2BGzCVDtchhzkDa2N
TTEi1nxJqWpmynNg9rZQxm9tHhJmhlnkJCSqG+XzIyGxjPQ5U4v33iDTbGRkmmlLJL5Rjhgklbdt
Dn5UUkgKQSegzzUkmt6bHHcytdqY7e3W6kdQWAibdhgQOQdrdM9KAKng6CW38D+H7eWKSGaLTrdJ
I5FKsjCJQQQeQQe1dJWFJr+mxT3ULTSl7XHnbbeRgpO3auQuCx3LhRknPAqfT9Rg1GAzWpcqGKFX
jaNlYdQysAyn6juD3oA1q5PWZX0/xNpurTQXclpHZ3ds7W1rJcMskj27ICkas2CIn5xgYAJBIzcX
xNpci3LLcOVtlLyMYJACgOCykrh1BHLLkCi58UaTaOqyXMjO7yIixW8khcx437QqnO3POPQ+hwAQ
eG7B7bwto2j6lbf6TZWFp5sUkW5FkRRjDcqzK8eflJIwp4yCZPBsEtr4J8P288TwzRadbpJHICrI
wiUEEHkEHjFTXHiDS7U2xkuspcoJI3ijaRQhIAdmUEKvI+ZsD34plz4isYbmS1jk3XEMsUMu6OQI
hdlAG8IV3fOCB39hkgA6Ciudl8VaPFcNC11KrrI0Py20pBkXOY1IXDPxwoyT2BzUkniXS4tPhvTP
KYpiyoEt5Gkyud2UClhtwc5HHegDdpawLjxPpdnOIprsljEs2YoXkVY2Jw5ZQQF4PzHAqKHxVZm4
1GOdLiL7FdC2GLeV2mYoG+RQmWP3uFzwN3QigDpK5nw7YfYL/wAQRJafZrY38f2dFj2IY1tLZBsH
TaCpXjj5SO1T22vQXmpWttaqZIriCaYSHKlTG6IVKkZBy5yDgjbjFb1AC0lc9pmrarqcjSpp1kli
txLCZGvW8zCOyE7PKx1Xpu/GnReKNInlZEunByNrPbyKsgLBAyMVAddzKNykjkc80Ab9LWFfeINN
sZGSaaUskvlGOGCSVt20OflRSSApBJ6DPNSSa3pscdzK12pjt7dbqR1BYCJt2GBA5B2t0z0oA2a5
nxTYfabG2litPOuo7+y2uke50j+2QPJg9QuEDHt8mT0qzJr+mxT3ULTSl7XHnbbeRgpO3auQuCx3
LhRknPAqzZajb6nbmW0ZyqsUYPG0bqw6hlYBlP1HcGgDk/FsN09x4lgjs7qZ9X0SOwsjDbvIrTg3
IKuygiMfvo/mcqvJ5+VsegVzyeJtJcXDi6YLAhkLNBIquoOCYyVxIM4GUz1HqKH8TaWlpFctPKFk
mMCIbeXzfMAJ2GPbvDYGcEc8eooA6GiuWPjDTYLy3j/em0ltJrprnyZMRiMgEMNvB+9nOCCACMsK
tSeJdKiSBpZZkWZS67raUbUBxvf5fkXP8TYHfNAFfxpZf2j4L1qJLX7RcjT7n7Mix738xoXQbBjO
4hivHPzEd6i1mV9P8Tabq00F3JaR2d3bO1tayXDLJI9uyApGrNgiJ+cYGACQSM6+n3/2261GDytn
2O4EG7dnf+7R89OPv4x7Vq0AeUHStS0/wvdaTcWF013f+FbTSoFhhaZftKJOrI7oCsYBlT5nIXkn
OAcer0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUo4
IY5bh0hRGmffIyqAXbaFy3qdqqMnsAO1XaKKACiiigAooooAz7WCK0to7e3hSGCJAkcaKFVFAwAA
OAAAOK0KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooA5bQ/Ddpp7yXUllZf2i9xPJ9qSEGTa8jMAWwD91gD+VZ0PhjVbi8aTUp433Wc1tJML2
WQyM5QiRYyoSLlM7V46cnFdzRQBx1vousWKWN5EbK51VVnF0JJXjicylWJUhWPylFABHT0qvc+FN
Tg064sNPks5UudKjsJJbh2jKMgfDBVUgg7+mRjHeu6pKAWhy8ujXf2bWUEdrOb26SaOOV3UbVSNS
CyjKNlCQwzg4NXNDs7yysnivpdzNIWRPtDz+UvHy+Y4DPyCckcZx0ArdpKBHBaf4VvtMR441t98V
s9rbTS3txNlWIyxjb5I/lUEqoIJAGVFKui6rpGo6NbafbW1zFZQXUcLzMyII2MW0Oyodr9R0O4Ke
mTjvKKBnA3fg+5nS2SLyp1Nklncb7ye3UAEndtiP7wHe3yMR0HIya1p/D1y4vwjwgT6pbXiZY8JH
5OQeOv7tsfUc11NFAHORaLco1tlov3Wpy3jYJ+43mYHTr84/Wsi58MXxEU0JjknjubtwgvprUFJp
N4O+MbsjC/LjByeeAa7mloA42Twtcrp2p2cD26rcaTFYQjc+FZBIOc7iF+cY5J60+60fWUl1IWck
HlXV2k+0XLwPInlCNkLqhMeCqsGXJPTiuupaAON0XQL7TLqzlneEiFLtWAmeVv30yyL8zDLYwQSe
Tx612PaloouBy2h+G7TT3kupLKy/tF7ieT7UkIMm15GYAtgH7rAH8qzofDGq3F40mpTxvus5raSY
XsshkZyhEixlQkXKZ2rx05OK7migDjrfRdYsUsbyI2VzqqrOLoSSvHE5lKsSpCsflKKACOnpVe58
KanBp1xYafJZypc6VHYSS3DtGUZA+GCqpBB39MjGO9d1SUAtDmJdGuxb6ygitpze3STRxyu6jaqR
ryyjKNlCQwzg4NW9FsLyz0+WG+lLNJIxSP7Q9x5SkAbfMcBn5yckcZx0FblFAHHpomtDRI9KY2Cw
2SRC1kV3LTvE6shcbQIwdmCBv+9wRjmWDRL99Ut9RuTbRzG/N1NFE5ZUX7OYQFYqCx6EkgdSOwz1
dFFwOFu/DOpyWckML2paWDUIWLyMoUXEnmIRhTnGACOOvBOOb+raLqF1NdfYzbGPULIWVwZ3YGEA
th0AUhuJG+U7eg5611dFHSwXMbR9Ml0+51N3ZGS5uVljweQoijTnjrlDW1RRQAUUUUAFFFFAH//Z
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-12-04 10:07:38 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-12-04 10:06:52 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-12-04 10:06:52 +0000" MODIFIED_BY="Lindsay Stead" NO="1">
<TITLE MODIFIED="2013-12-04 09:50:30 +0000" MODIFIED_BY="Lindsay Stead">Specialised Register search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-04 10:06:52 +0000" MODIFIED_BY="Lindsay Stead">
<P>Searched using CRS (Cochrane Register of Studies) software</P>
<P>#1 (bupropion or zyban):TI,AB,MH,EMT,KY,XKY</P>
<P>#2 nortriptyline:TI,AB,MH,EMT,KY,XKY</P>
<P>#3 (monoamine oxidase inhib*):TI,AB,MH,EMT,KY,XKY</P>
<P>#4 (moclobemide or selegiline or lazabemide):TI,AB,MH,EMT,KY,XKY</P>
<P>#5 (SSRI* or (selective serotonin re?uptake inhibitor*)):TI,AB,MH,EMT,KY,XKY</P>
<P>#6 (fluoxetine or sertraline or paroxetine or zimelidine):TI,AB,MH,EMT,KY,XKY</P>
<P>#7 (doxepin or imipramine or tryptophan or venlafaxine):TI,AB,MH,EMT,KY,XKY</P>
<P>#8 ((john?s wort) or hypericum):TI,AB,MH,EMT,KY,XKY</P>
<P>#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8</P>
<P>(MH, EMT, KY and XKY are keyword fields)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-12-04 09:50:35 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-06-22 09:45:18 +0100" MODIFIED_BY="[Empty name]">Suspected adverse events from national reporting schemes</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-22 09:44:56 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="7">
<TR>
<TH>
<P>Country</P>
</TH>
<TH>
<P>No. of reports</P>
</TH>
<TH>
<P>No. of users</P>
</TH>
<TH>
<P>Rate of reports</P>
</TH>
<TH>
<P>Events reported</P>
</TH>
<TH>
<P>Source/ date</P>
</TH>
</TR>
<TR>
<TD>
<P>UK (safety notice 2002)</P>
</TD>
<TD>
<P>7,630<BR/>24 July 2002</P>
</TD>
<TD>
<P>540,000 patients (31 March 2002)</P>
</TD>
<TD>
<P>14/1000</P>
</TD>
<TD>
<P>Commonest:<BR/>Urticaria/rashes/pruritus (2357, 31% of total reports)<BR/>Insomnia (994, 13%)<BR/>Headache (779, 10%)<BR/>Dizziness (747, 10%)<BR/>Seizures: 184 (2.4% of reports, est rate 0.3/1000)<BR/>Deaths: 60</P>
</TD>
<TD>
<P>Medicines Control Agency<BR/>26 July 2002 http://www.mca.gov.uk/ourwork/<BR/>monitorsafequalmed/<BR/>safetymessages/zyban26702.pdf</P>
</TD>
</TR>
<TR>
<TD>
<P>UK (MHRA routine data on suspected adverse drug reactions). Includes reports summarised in UK safety notice 2002</P>
</TD>
<TD>
<P>8,452 (18,319 reactions) to May 2004</P>
</TD>
<TD>
<P>Estimated approximately 1,000,000 community prescriptions dispensed in UK 2000-April 2004, based on England data of 762,200 for 2000-2003. Average prescription was a 4 week course.<BR/>
</P>
</TD>
<TD>
<P>approx 8/1000 prescriptions</P>
</TD>
<TD>
<P>By organ class:<BR/>-General disorders: 4127<BR/>Includes insomnia (1030), dizziness (805), chest pain (384)<BR/>-Skin &amp; subcutaneous tissue disorders: 3728<BR/>Includes pruritus (421), rashes (1094), urticaria (1104), angioedema (481)<BR/>-Psychiatric disorders: 2417<BR/>Includes affective disorders (627), suicidal ideation/ suicide/parasuicide (87)<BR/>-Neurological disorders: 2338<BR/>Includes convulsions &amp; epilepsy (212)<BR/>-Gastrointestinal disturbances: 2176<BR/>Includes nausea / vomiting (775)<BR/>-Deaths: 70, includes 4 suicides<BR/>
</P>
</TD>
<TD>
<P>Medicine and Healthcare products Regulatory Agency (MHRA) Adverse Drug Reactions Information Service. Data provided April 2004.<BR/>Prescription data from DoH Prescription Cost Analysis (www.publications.doh.gov.uk/prescriptionstatistics/index.htm)</P>
</TD>
</TR>
<TR>
<TD>
<P>Canada (safety notice 2001)</P>
</TD>
<TD>
<P>1,127<BR/>28 May 2001</P>
</TD>
<TD>
<P>1,245,000 Zyban, 699,000 Wellbutrin<BR/>(April 30 2001)</P>
</TD>
<TD>
<P>0.6/1000</P>
</TD>
<TD>
<P>Full list not given<BR/>Serious: 682<BR/>Seizures: 172 (Zyban 120, Wellbutrin 46 bupropion 6) (15% of reports, est rate 0.1/1000 for Zyban<BR/>Deaths: 19<BR/>Serum sickness: 37</P>
</TD>
<TD>
<P>Canadian Adverse Reaction Monitoring Programme (CADRMP)GSK/ Health Canada 'Dear Doctor' letter 3 July 2001<BR/>http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/zyban_e.html</P>
</TD>
</TR>
<TR>
<TD>
<P>Australia (safety alert 2001)</P>
</TD>
<TD>
<P>1,237<BR/>August 2001</P>
</TD>
<TD>
<P>Not given</P>
</TD>
<TD>
<P>not available</P>
</TD>
<TD>
<P>Full list not given<BR/>skin reactions (499 reports), psychiatric disturbances (427), nervous system (406, includes convulsions/twitching 74), gastrointestinal tract (258), facial/angioedema (89), serum sickness (63)<BR/>Deaths: 18</P>
</TD>
<TD>
<P>Therapeutic Goods Administration (TGA) alert 31 August 2001<BR/>http://www.health.gov.au/tga/ docs/html/zyban.htm</P>
</TD>
</TR>
<TR>
<TD>
<P>Australia<BR/>(routine data)</P>
</TD>
<TD>
<P>1,672 (4,390 reactions)<BR/>to March 2004</P>
</TD>
<TD>
<P>Approx 534,000 prescriptions 2000-March 2004, mainly 30 pill/2 week</P>
</TD>
<TD>
<P>approx 3/1,000 prescriptions</P>
</TD>
<TD>
<P>Deaths: 31<BR/>Skin &amp; subcutaneous tissue: 930. Includes urticaria (366), pruritus (90), rash (164), oedema (160)<BR/>Nervous system: 792. Includes convulsions (105), Psychiatric disorders: 992. Includes suicide/self-injurious ideation (32), depression (13)<BR/>Gastointestinal disorders: 440. Includes nausea/ vomiting (221)</P>
</TD>
<TD>
<P>TGA data supplied 31 March 2004</P>
</TD>
</TR>
<TR>
<TD>
<P>France<BR/>(analysis of pharmacovigilance database &amp; GSK reports)</P>
</TD>
<TD>
<P>1682 of which 475 classified as serious, September 2001 to September 2004</P>
</TD>
<TD>
<P>698,000 patients treated</P>
</TD>
<TD>
<P>approx 2.4/1,0000 people</P>
</TD>
<TD>
<P>Deaths: 21 (including 3 suicides)<BR/>Neuropsychiatric: 62, includes suicide attempts (21), suicidal ideation (19), seizures: (75, incidence 0.01%).<BR/>Skin &amp; subcutaneous tissue: 148, includes angiodema (50), serum sickness like reaction (40), urticaria (27).</P>
<P>11 intentional overdose including 2 deaths</P>
</TD>
<TD>
<P>
<LINK REF="REF-Beyens-2008" TYPE="REFERENCE">Beyens 2008</LINK>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>